fbpx

“I love my mum, sharing her story is special to me.”Ali

When my mum (Deb) was first diagnosed with cancer back in 2019 she went into Chemo that week, it was pretty intense and she fought so hard. Mum married my stepdad, Rob, in November in a small courthouse ceremony with just myself, my brother, Gio, my sister, Lily and Rob’s daughter, Rhani.

Pictured here: Deb (Ali’s mum), and her Step-dad, Rob.

Mum lived down in Denmark, so for every treatment she would stay with me for the week and my step-dad would drive her up and back. After about one year of chemo, Mum was still as outgoing and vibrant as ever, she still worked and made time for her friends and family, all while going through the pain of the treatment and the emotional pain of losing what she considered her “femininity”.

Pictured here: Lily – Ali’s sister, Ali’s mum – Deb and Ali.

There were many phone calls and discussions between us where she felt ugly without her hair and her eyelashes and yet through it all she maintained her kind personality.

Mum started treatment through a research trial around July 2020, it had an intense effect on her body and eventually, in November 2020, she passed away after a week in the hospital. Her funeral was attended by over 500 people as well as those who watched online. It was an awful but beautiful experience to get that time with my mother and have the chance to say goodbye.

Pictured here: Ali’s mum, Deb

“After Mum was gone, I found it hard to focus on anything. So when the opportunity came up to do the ACRF Hair Dare, it was honestly a lifesaver.”

At first, I thought to raise $1000 but my community is so supportive and so strong that I made that within 2 hours of posting the link, so I changed it to $5000 and after I shaved my head I had made well over that amount.

Pictured here: Gio (Ali’s brother), Lily (Ali’s sister) and Ali (Left to Right)

I held the Hair Dare on Mum’s birthday, May 1st at her beautiful home. It was attended by friends and family and it was a wonderful afternoon. I know Mum felt like she had lost her femininity in losing her hair, but for me, it had to opposite effect, I suppose because for me it was a choice.

Mum was never more beautiful than when she was fighting for her life and although she’s now gone, she will never be forgotten.

Ali

Graeme Phillips Memorial Ride

Every year, Jess Phillips, her family and the community hold a very special horse ride to remember Jess’s much-loved father, Graeme and to raise vital funds for cancer research. Graeme passed away on the 27th May, 2011 at just 49, from kidney cancer. 

The Graeme Phillips Memorial Ride is held on the family-run horse, sheep and cattle property called Yarrabin, in the picturesque O’Connell Valley NSW. The ride brings together not only the local community but people from all over NSW that knew and loved Graeme. The ride is held to honour him and the many loved ones who have been lost to this devastating disease and to support those going through treatment. 

“When Dad passed away, it was left to Mum to raise the four of us kids. I’m the eldest and then the boys are Harry, Jack and Will,” Jess explained. “Not a day goes past that he isn’t in our hearts.” 

This year, the community chose to wear colours to represent a cancer that particularly touched their hearts, either through a friend, family member or their own experience. 

The colours that can be seen in the team photo represent: 

  • Dark Blue for prostate cancer 
  • Light Blue for blood cancer 
  • Purple for brain cancer 
  • Teal for ovarian cancer 
  • Pink for breast cancer 
  • Red for kidney cancer

Cancer does not discriminate and touches so many of us and ongoing research is needed. 

The Graeme Phillips Memorial Ride in 2021 raised over $7,000 and will fund innovative research that will bring us closer to a world without cancer.  

A heartfelt thank you to all involved for your ongoing support of vital cancer research.

To learn the many ways you can support ACRF, go to acrf.com.au/get-involved.

New Drug Combination Found to be Effective Against High-Risk Leukaemia

Australian scientists have found what could prove to be a new and effective way to treat a particularly aggressive blood cancer in children.

Acute lymphoblastic leukaemia, or ALL, is the most common cancer diagnosed in children. Despite dramatic improvements in the survival of children with ALL over past several decades, children who develop ‘high risk’ ALL – subtypes that grow aggressively and are often resistant to standard treatments – often relapse, and many of these children die from their disease.

One common type of high-risk ALL for which new therapies are urgently needed is ‘Philadelphia chromosome-like ALL’ (Ph–like ALL), named for its similarity to another type, Ph–positive ALL. Shared genetic characteristics of these two types of high-risk ALL have led scientists to hypothesise that they may respond to similar treatments; specifically, a newer class of drugs known as kinase inhibitors.

However, experiments have shown that cases of Ph–like ALL that contain a genetic mutation known as CRLF2r – about half of all cases of this subtype – respond poorly to kinase inhibitors when used as a single agent. Scientists have since been investigating whether kinase inhibitors are more effective when used in combination with other agents.

In new research published this week in the international journal Leukemia, scientists at Children’s Cancer Institute tested more than 5000 drugs in combination with the kinase inhibitor, ruxolitinib, finding that ruxolitinib worked synergistically with several types of commonly used anticancer drugs, the most effective being glucocorticoids, topoisomerase I and II inhibitors, microtubule targeting agents, and antimetabolites.

“New therapies are urgently needed for high-risk ALL,” said lead researcher Professor Richard Lock, Head of the Blood Cancers Theme at Children’s Cancer Institute. “We are very encouraged by our results, which suggest we could be on the way to developing a more effective way to treat this cancer in some children.”

Based on their in vitro findings, the researchers then carried out in vivo testing in living models of disease known as ‘patient-derived xenograft models’ (PDXs) or ‘avatars’: mice specially bred to grow leukaemia cells taken from individual patients with CRLF2r Ph-like ALL. Results showed that the addition of ruxolitinib to a common treatment regimen called VXL (consisting of vincristine, dexamethasone, and L-asparaginase) enhanced treatment efficacy in two out of three avatars, achieving long-term suppression of leukaemia growth in one of these.

“The enhanced effect of treatment when ruxolitinib was added, and the variety of drug classes found to synergize with ruxolitinib in our laboratory, suggest promising potential for kinase inhibitors in the treatment of Ph-like ALL,” said Professor Lock. “We hope this leads to improved treatment options for children with this leukaemia in the near future.”

About Children’s Cancer Institute

Originally founded by two fathers of children with cancer in 1976, Children’s Cancer Institute is the only independent medical research institute in Australia wholly dedicated to research into the causes, prevention and cure of childhood cancer. More than 40 years on, our vision remains unchanged – to save the lives of all children with cancer and to eliminate their suffering. The Institute has grown to now employ nearly 300 researchers, operational staff and students, and has established a national and international reputation for scientific excellence. Our focus is on translational research, and we have an integrated team of laboratory researchers and clinician scientists who work together in partnership to discover new treatments which can be progressed from the lab bench to the beds of children on wards in our hospitals as quickly as possible. These new treatments are specifically targeting childhood cancers, so we can develop safer and more effective drugs and drug combinations that will minimize side-effects and ultimately give children with cancer the best chance of a cure with the highest possible quality of life.

This story originally appeared on the Children’s Cancer Institute website.

ACRF have awarded four grants to the Children’s Cancer Institute for a total of $8.6M. If you would like to financially support cancer research, please go to acrf.com.au/donate.

How to Help Cancer Research

With over 200 known types of cancer, reaching a world without cancer is not a small task but at Australian Cancer Research Foundation (ACRF), we believe it is possible.

That is why we continuously fund the technology, equipment and infrastructure needed to develop better prevention, earlier detection and more effective treatment across all cancer types.

The good news is, you don’t have to be a scientist to advance cancer research, there are many ways you can help. Read on to learn how you can help cancer research.

What is cancer research?

There are four types and four areas of cancer research.

Types of cancer research include:

  • Basic research  – research into the biological mechanisms related to cancer, as well as the variations impacted by both ethnical or racial diversity and environmental exposures.
  • Clinical research – determines the safety and efficacy of medications, devices and diagnostics for use in humans.
  • Population and prevention research – explores the key causes of cancer, cancer trends and factors that impact the numbers and outcomes of cancer diagnosis and care.
  • Translational research  – takes results from both basic and clinical research and moves them into everyday clinician care for patients.

Areas of cancer research include:

  • Prevention – actions taken to reduce and lower the risks associated with getting cancer. Includes research into environmental, lifestyle, medicines and substances, and vaccines that can have both a positive and negative impact on your likelihood of developing cancer.
  • Detection – improving the modes and methods for discovery of different cancer types. This is focused on the detection of cancer cells at the earliest possible point, which is when the disease is easiest to treat.
  • Treatment  – developing new and improving existing cancer treatment methods (across all types of therapies), with a focus on higher efficacy and reduction of side-effects or negative impacts.
  • Survivorship  – cancer survivorship looks at the overall health and wellbeing of people living with and beyond cancer. Survivorship research covers factors from the moment of diagnosis through treatment and life beyond treatment. This could include management of chronic illness, end-of-life care, and follow-up care.

Research with the aim of developing new and improved cancer therapies would start with researchers exploring why a body’s natural system is not able to prevent the growth of cancerous cells. Our bodies all have an inbuilt defence mechanism that repairs damage to our cell DNA or forces the cell to die, if the damage is too great. Researchers work to discover what function within an individual cell’s DNA is under or overachieving to allow cancer cells to form, grow and multiply.

Once the why is understood, researchers look for ways to rectify these failures of the body’s defence system. This is not an easy task as there are many variables. While healthy cells replicate themselves exactly, each division of a cancer cell brings about new changes. This means that a treatment may not work on all cells within the same cancer.

However, cancer researchers are committed, they are creative, they are patient and they are resilient, and breakthroughs are made. These breakthroughs often lead to potential treatments.

Once a potential treatment has been developed a clinical trial is performed with the help of people with cancer, who volunteer to trial the new treatment.

If the clinical trial results prove that the new treatment is safe and effective, it may become part of the standard treatment regime for people with cancer.

6 ways to help cancer research

  1. Donate to cancer research: If a tax deductible, simple giving option is the best option for you to help cancer research, you can donate here.
  2. Participate in a sports event: Local marathons and community fun runs are not only a great way to get fit, but they provide supporters with a challenge through which they can raise funds for breakthrough cancer research. This year, with many running events cancelled due to COVID-19, we are asking that as cancer researchers continue working to improve the lives of Australians impacted by cancer, that you continue to run in support. If your favourite event has been cancelled, we would love for you to RUN REGARDLESS any time from 1 July to 31 October 2021.
  3. Shave or colour for cancer research: Do something brave. Stand in solidarity with those diagnosed with this devastating disease and shave, cut or colour for research into all types of cancer.
  4. Host a Cuppa for Cancer event: If you’re looking for a great way to combine a gathering of friends or colleagues with cancer awareness and fundraising, then hosting a Cuppa for Cancer could be just what you’re after.
  5. Create your own event: Bring your creative event ideas to life and help ACRF Outsmart Cancer – all cancers – for all Australians. The choice is yours whether you’re organising a backyard BBQ or a special event, hosting a DIY fundraiser is the perfect way to raise vital funds for improved prevention, earlier detection and more effective treatments for all types of cancer.
  6. Check out our A-Z list of fundraising ideas: If you are ready to get involved in a fundraising event, but you’re not exactly sure how you’d like to go about doing so, check out our A-Z list of charity fundraising ideas that will inspire you to put the ‘fun’ in ‘charity fundraising’.

How can I donate to cancer research?

There are many ways that you can donate to charity to help put an end to cancer. Many of our supporters choose to host events, or take on challenging feats – but for others, a simple giving option works best.

To learn more about the ways you can get involved with ACRF go to acrf.com.au/get-involved.

ACRF’s contributions to cancer research

Since 1984, thanks to our generous supporters, we’ve awarded 78 grants totalling over $165 million to 42 research institutions who have developed some of the most incredible and ground-breaking advancements in cancer research and treatment including:

  • Cervical Cancer Vaccine: ACRF supporters enabled the seed funding for Professor Ian Frazer’s development of a cervical cancer vaccine. Thanks to a national immunisation program, Australia is set to be the first country to effectively eliminate the disease.
  • The Pill That Melts Cancer: ACRF supporters enabled landmark research resulting in the discovery of the potent anti-cancer drug, Venetoclax.
  • Personalised Cancer Treatment: ACRF supporters enabled an ambitious project that aims to provide each cancer patient a personalized treatment plan within 36 hours of diagnosis.
  • Zero Childhood Cancer: Thanks to ACRF supporters, we became one of the founding partners of an initiative to tackle the most difficult cases of infant, childhood and adolescent cancer in Australia. Clinical trials are currently underway nationally and results are looking positive.

Donate to ACRF and help fund ground-breaking cancer research

At ACRF, our mission is to reach a world without cancer. All donations go towards helping cancer researchers improve the prevention, diagnosis and treatment of all types of cancer. 

If you would like to make a donation, the giving options are listed below:

  • Become a regular giver: Regular giving is one of the most powerful ways you can support cancer research. Monthly donations help ACRF plan for the future and make more significant long-term impacts for people diagnosed with cancer.
  • Make a general donation: Together we unite with a shared vision of a future where the next generation will no longer experience the pain and heartache of cancer.
  • Donate in memory: Donating in memory of a loved one is a valuable way to celebrate their life while contributing to cancer research. We can support you to arrange charity donations at the funeral, or to make private memorial donations.
  • Donate in celebration: Donate to charity in celebration of a birthday, wedding or other occasion. By giving a gift to cancer research in lieu of traditional presents, you will be adding something special to an already momentous occasion.

Because of the generosity of people like you, we’ve helped the discovery and creation of large machines and small vaccines. Discoveries that help doctors diagnose cancer quickly and personalise treatments making them more effective.

At ACRF, we believe that together we can reach a world without cancer.

Charitable donations and tax deductions: How does giving money to charity reduce tax?

Every donation to Australian Cancer Research Foundation (ACRF) contributes to life-saving cancer research and donations of $2 and over are tax-deductible.

With the end of the financial year approaching, we thought we’d take the opportunity to explain how your gift to charities such as ACRF will reduce the amount of tax you need to pay. 

What is a tax deductible donation? 

A tax deductible gift or donation will reduce your taxable income and therefore the amount of tax you need to pay. 

A donation you make to charity is only tax deductible if the organisation is an ATO endorsed deductible gift recipient (DGR). ACRF is a DGR and also has the registered charity tick from the Australian Charities and Not-for-Profits Commission (ACNC). This means that ACRF complies with the transparency and accountability standards of the ACNC Charity Register.

To claim a tax deduction for a gift or donation, it must also meet the below conditions:

  • It must be made to a DGR organisation.
  • It must truly be a gift or donation – that is, you are voluntarily transferring money or property without receiving, or expecting to receive, any material benefit or advantage in return. A material benefit is an item that has a monetary value such as a raffle ticket, fundraising chocolates or fundraising dinner ticket.
  • The gift or donation must be of money or property. This can include financial assets such as shares.
  • The gift or donation must comply with any relevant gift conditions. For some DGRs, the income tax law adds extra conditions affecting types of deductible gifts they can receive.

For full information on charity donation tax deductions, please visit the ATO website – Gifts and Donations or speak with your financial adviser or accountant.

Tax benefits: How a charitable donation can reduce your tax 

When you file your tax return, it includes the total of how much you earned in a given year from everything that earned you money — everything you earned from work, selling investments and more.

This is your gross income. From this amount, you are able to deduct some things, including charitable donations, to organisations such as ours.

A reduced taxable income means that the tax you need to pay will also be reduced. This will result in a higher refund on tax paid throughout the year or a reduced ATO debt.

NB: To claim a tax deduction, you must have a record of your donation, such as a receipt.

Why should you give to charity in order to reduce your tax? 

In addition to reducing your taxable income, your donation will help a charity fulfil its purpose. At ACRF, our purpose is to equip cancer researchers with the tools they need to improve the prevention, detection and treatment of all cancer types

Giving to charity makes you feel good, every little bit counts, so you know your donation will make a difference. 

Giving to charity can inspire those around you to also give, meaning more donations and an even bigger impact. It could even bring about a family-wide effort to back a cause that has special significance to you as a group. 

Related reading: Does donating to cancer research help? 

How tax deductible donations help fund ground-breaking cancer research

Every tax-deductible donation helps ACRF fund the technology, equipment and infrastructure Australian researchers need to continuously explore new and improved ways to prevent, detect and treat all types of cancer.

Since 1984, donations to ACRF have enabled us to award over $165 million to cancer research initiatives. Some of the most ground-breaking advancements in cancer research and treatment have been made as a result of this funding – helping each individual diagnosed with this complex and disruptive disease. 

If you make a tax deductible donation to ACRF today you will:

  • Help researchers learn how to interrupt the nutrition of cancer cells, leaving healthy cells unharmed. 
  • Help develop treatments for tumours containing more than one cancer mutation.
  • Help fund equipment for a national program to improve outcomes for blood cancer patients.
  • Help determine the molecular structure of proteins in seconds for new cancer drug development.

Boost your tax return this year and make a tax-deductible donation to ACRF 

All donations of $2 or more to ACRF, at any time of the year, are tax deductible but there has never been a better time to give than now.

Our tax time appeal runs to 30 June, with 100% of your donation going towards vital cancer research. Help us reach a world without cancer, donate here.

Are Charity Donations Tax Deductible?

Donating to charity is a great way to contribute to a cause you feel passionate about whilst boosting your tax return.

Charity donations are tax deductible, however you should be aware of what constitutes a tax deductible donation so you can claim it correctly on your tax return. 

What is a tax-deductible donation?

A tax deductible gift or donation will reduce your taxable income, resulting in a higher refund on tax paid throughout the year or a reduced ATO debt when you complete your tax return.

Every donation you make to charity is only tax deductible if the organisation is an ATO endorsed deductible gift recipient (DGR). Australian Cancer Research Foundation (ACRF) is a DGR organisation and also has the registered charity tick from the Australian Charities and Not-for-profits Commission (ACNC). This means that ACRF complies with the transparency and accountability standards of the ACNC Charity Register.

To claim a tax deduction for a gift or donation, it must also meet the below conditions:

  • It must be made to a DGR organisation.
  • It must truly be a gift or donation – that is, you are voluntarily transferring money or property without receiving, or expecting to receive, any material benefit or advantage in return. A material benefit is an item that has a monetary value such as a raffle ticket, fundraising chocolate or fundraising dinner ticket.
  • The gift or donation must be of money or property. This can include financial assets such as shares.
  • The gift or donation must comply with any relevant gift conditions. For some DGRs, the income tax law adds extra conditions affecting types of deductible gifts they can receive.

To claim a tax deduction, you must have a record of your donation, such as a receipt. ACRF provides prompt receipting for all donations.

For full information on charity donation tax deductions, please visit the ATO website – Gifts and Donations or speak with your financial adviser or accountant.

Are charity donations tax deductible?

A tax deductible donation is an amount of $2 or more that you donate to an organisation endorsed as a Deductible Gift Recipient (DGR). It must be a genuine gift – meaning you cannot receive any benefit from the donation. Funds that are donated in exchange for benefits such as raffle tickets, fundraising chocolates, or fundraising dinner tickets, however genuine, are not tax deductible. However, pins, tokens, wristbands and stickers are deemed by the ATO as having no material value and are used by the DGR as marketing and promotional material.

All donations of $2 or more to ACRF are tax deductible.

Are donations to charity auctions tax deductible?

Donations to charity auctions are tax deductible if:

  • There is a transfer of money or property and the organisation is a DGR.
  • The transfer is made voluntarily.
  • The donor does not expect anything in return for the gift.
  • The donor does not materially benefit from the gift.

Are overseas charity donations tax deductible?

All Australian charities that operate overseas must be registered with the Australian Charities and Not-for-Profit Commission (ACNC) who have set standards that govern how a registered charity must manage its activities and resources outside Australia. This in addition to the ATO’s, Overseas Aid Gift Deduction Scheme (OAGDS) enables Australian organisations to issue tax deductible receipts for donations to their overseas aid activities. These activities must be to support aid activities in countries that are declared as ‘developing’ by the Minister for Foreign Affairs.

Donations to overseas charities not registered in Australia, are not tax deductible.

Are corporate donations to charity tax deductible?

Corporate donations to DGRs are tax deductible. Businesses can claim the same benefits from donating that individuals do. Just like an individual donation, a corporate donation must be $2 or more in value to be tax deductible. Learn more about ACRF’s Corporate Giving partnerships.

Make a tax-deductible donation to ACRF today

All donations of $2 or more to ACRF, at any time of the year, are tax deductible but there has never been a better time to give than now.

Our tax appeal is currently underway and until 30 June 2022, 100% of every donation is going directly to vital cancer research. That means your tax-deductible donation can have an even bigger impact. Donate to our tax appeal today.

Related reading: Does donating to cancer research help?

New Cellular Atlas Maps Out Healthy and Cancerous Breast Tissue

WEHI researchers have documented the diversity of cells in the human breast, explaining the relationship between healthy breast cells and breast cancer cells.
The diversity of cells in the human breast has been documented in a new ‘RNA atlas’.

The research, which relied on expertise spanning from breast cancer biology through to bioinformatics, measured gene expression in single cells taken from healthy women and cancerous breast tissue, including tissue carrying a faulty BRCA1 gene. This enabled the researchers to create an ‘RNA atlas’ that details the different cells found in these tissues.

The atlas, which was described in EMBO Journal, will enable researchers to better understand the different cell types that constitute breast tissue and how these change during the development of cancer.

The research was undertaken by a team including Dr Bhupinder Pal, Dr Yunshun Chen and Dr François Vaillant, and led by Professor Jane Visvader, Professor Gordon Smyth and Professor Geoff Lindeman.

At a glance

  • A multidisciplinary team used single-cell transcriptomics to generate an RNA atlas that documents gene expression in different cells in healthy, pre-cancerous and cancerous human breast tissue.
  • The atlas reveals the changes that occur within the breast during key events, including cancer development and menopause.
  • The atlas is freely available to researchers around the world and is anticipated to be an important resource for breast cancer research.

Understanding single cells

Lead researchers (from left) Dr François Vaillant, Dr Yunshun Chen, Professor Gordon Smyth, Professor Jane Visvader and Dr Bhupinder Pal.

The human breast is a complex tissue, comprising a wide range of cells including cells specialised for milk production and release, as well as fat cells and immune cells, Professor Visvader said.

“Different types of breast cancer arise from distinct precursor cells. However, breast cancer development can be impacted by other cells within the breast,” she said. “This atlas provides a high-resolution view into the various cell types that make up breast tissue in different states and a blueprint for studying changes that lead to breast cancer.”

Dr Pal, who is now a laboratory head at the Olivia Newton John Cancer Research Institute, said ‘single-cell’ technologies enabled the research team to isolate more than 340,000 individual cells from breast tissues donated by women and men and to measure the expression of different genes in these cells.

“Our studies included healthy, pre-cancerous and cancerous tissue, enabling us to study the differences between these tissues,” he said.

A diverse and changing landscape

The research revealed a wide variety of cell types are present in the human breast, Dr Chen said.

“Complex bioinformatic analysis was crucial for documenting the complex cellular landscape. For example, we found that the composition of a particular subset of cells in the breast was altered by menopause – a period of significant hormonal change within the body,” he said.

The research also revealed many changes that occur within breast cancers, said Dr Vaillant.

“All the breast cancer types we studied displayed considerable diversity in their tumour cells, as well as in other cells found within the tumour. In particular, hormone-responsive cancers contained fewer dividing cells of a specific immune type, which could explain why many of these tumours are less responsive to anti-cancer immunotherapies.”

A multidisciplinary effort

Single-cell RNA sequencing is a new technology that has revolutionised how researchers can study complex tissues such as the breast said Professor Smyth, joint head of WEHI’s Bioinformatics division.

“Bioinformatics was critical for obtaining a global view of the diverse populations of cells within the different breast tissues we studied,” he said. “Computational methods enabled the team to detect patterns and differences in gene expression in the different cells within the breast at unprecedented resolution.”

Professor Visvader said the RNA atlas was the most comprehensive to-date for the human breast, and provided a framework for understanding the different cell types it can contain.

“This will be an invaluable resource for breast cancer researchers around the world. Our research also has important implications for not only understanding how breast cancers arise but also how cells in the surrounding environment contribute to their development, spread and response to treatment.”

The research team would like to acknowledge the important role that tissue donors, the Victorian Cancer Biobank and kConFab played in this study.

The research was supported by the National Health and Medical Research Council, the Victorian Government, the National Breast Cancer Foundation, the Australian Cancer Research Foundation, Ian Potter Foundation, the Michael Heine Family Foundation, and the Qualtrough Cancer Research Fund.

The original news article was posted on the WEHI website.

ACRF has awarded $10m in grants to WEHI for cancer research. Our esteemed Medical Research Advisory Committee ensures that only the most promising cancer research initiatives in Australia receive our funding. If you would like to financially contribute, please go to acrf.com.au/donate

Honouring the Three Most Important Men in My Life

ACRF donor Linda Boettcher has left a bequest in her Will to honour the three most important men in her life.

Her brother, her husband and her father.

“My brother Ian passed from Leukaemia in 1979, aged just 20 years old. He was a fun loving, cheeky, healthy young man who rode motorbikes and lived life at full tilt.  

“After my brother died, Dad’s employer, Philips, made a generous donation to ACRF. Dad was so impressed with ACRF he joined the ACRF board of trustees.

“Dad quickly immersed himself in ACRF. He loved that ACRF specifically funded research equipment and technology. No charity in Australia, then or now, provides this sort of funding for cancer,” Linda said.

In 1984 Linda met and fell in love with a 6’5” Scotsman (also named Ian) who later became her husband. 

“My husband Ian, and my brother Ian would have got on like a house on fire. They both had a wicked sense of humour. Ian and I had 25 wonderful years together, spanning Scotland, the US, and finally Australia. Ian loved Australia so much, he quickly became a proud citizen.”

But just when life was at its best, cancer returned to upend Linda’s life again.

“In August 2007, Ian was diagnosed with a Glioblastoma Multiform (GBM), a brain cancer.

“Three months after Ian’s diagnosis, my beloved Dad, John was also diagnosed with cancer.

“Illness can have a strange effect on people. Ian and I were always very close, but his diagnosis brought us even closer. As Dad and Ian were both going through cancer treatments simultaneously, they had shared experiences and were a great support to each another.

“Tragically Ian left us in July 2010.

“Dad was always a very active, healthy and fit person. He exercised daily and his diagnosis of liver and bowel cancer didn’t slow him down. He kept up his strict regime of diet, exercise and daily stretching. He was an inspiration to us all.

“He received his OAM in 2003 for his service to community groups and industry associations and was an ACRF Trustee for 28 years – a wonderful heritage. We are so proud of him.

“Dad was then, and is now, an inspiration. When he passed in September 2012, he left a big hole in the lives of my mother and my two sisters.

“Today I consider myself part of the greater ACRF family. My Mum and my sisters and I attend ACRF events and keep up to date with the ground-breaking research ACRF supporters help make possible.

“When it came time to update my Will, there was not a question in my mind about leaving a bequest to ACRF. Cancer has touched my life so deeply and I know the impact ACRF funding has on advancing research outcomes.

“My bequest to ACRF honours my brother, my husband and my father. Despite having this horrible disease in common, all three of them were full of life, had a great sense of humour and kept a positive attitude throughout their illnesses. I am so very proud to have been part of their lives.

“And I know my bequest couldn’t go to better cause or organisation.”

– Linda Bottecher

If you would like more information on leaving a bequest to ACRF, please go to https://www.acrf.com.au/get-involved/leave-a-gift-in-your-will/

ACRF-Funded Equipment Crucial to Immunotherapy Trial for Children

In 2017, ACRF awarded the QIMR Berghofer Medical Research Institute a grant totalling $1.75M. The funds were used to expand their existing cell manufacturing facility and buy new equipment needed to produce cellular immunotherapies.

In January 2021, the institute announced the trial of a new cellular immunotherapy (T-Cell therapy) aimed at preventing dangerous side effects for children who undergo stem cell transplants.

The head of QIMR Berghofer’s Centre for Immunotherapy and Vaccine Development, Professor Rajiv Khanna AO, confirmed that sterility testing equipment and a large capacity control-rate freezer, purchased thanks to ACRF funding, are crucial to the trial.

“Quality testing and long-term storage of T-Cell therapies are critical steps in our ability to offer a high-quality, safe therapy to each child enrolled in our clinical trial,” he said.

Professor Khanna explained the need for T-Cell therapies, how they are made and the role of ACRF-funded equipment in this process.

“Before a patient receives a stem cell transplant, certain immune cells – including killer T Cells – are removed from the donor’s cells. This lowers the risk of potentially fatal complications like graft-versus-host disease, where the donor’s immune cells attack the recipient’s tissues. However, this necessary step leaves transplant patients at high risk of developing viral infections because they do not have the disease-fighting cells to control infection.

“By taking white blood cells from the same donor and training them in the laboratory to recognise and destroy cells infected with the four most common viruses that affect these patients, we hope to effectively prevent complications arising,”

The T-Cell therapies (also referred to as “living drugs”) must undergo stringent quality control testing and be stored at an ultralow temperature (-190°C), before being administered. This is where ACRF funded equipment plays a crucial role.

According to Professor Khanna, “A crucial aspect in the successful manufacture of T-Cell therapies is quality control. Each product must undergo this testing to ensure it is free from microbial contamination and safe for patient use … our T-Cell therapy manufacturing process is critically dependent on our ability to store large batches of it for future infusion into patients.”

Automated sterility testing equipment, purchased with the ACRF grant awarded in 2017, has accelerated the quality control process. Professor Khanna said that sterility testing, utilising this equipment, is completed in five days instead of the traditional 14, allowing for faster release of the T-Cell therapy. This equates to patients, who may be critically ill, having access to the treatment sooner. In addition, Mycoplasma testing software, also purchased with ACRF funding, is being utilised in the quality control process.

The institute also purchased a large capacity control-rate freezer with the same grant which, as reported by Professor Khanna, enables high-quality, long-term storage and recovery of T-Cells before infusion.

Professor Khanna said, “Without ACRF funding we would not have been able to purchase this critical equipment and offer T-Cell therapies to our patients.”

Each child enrolled in the trial, receives fortnightly T-Cell therapy infusions once their stem cell transplant has engrafted (a 2-to-4-week process), with the aim to boost their immune system before they show any sign of viral complications.

ACRF are proud to have funded equipment that is crucial to the manufacture of an immunotherapy treatment, working towards improved treatment and outcomes for children who receive stem cell transplants.

Breakthroughs like this are made possible by the generous support of people like you. If you would like to financially support cancer research please go to acrf.com.au/donate

View the 2017 ACRF Centre for Advanced Cellular Immunotherapy Research grant details here.

First Sino-Australian Oncology Research Alliance Established

The clinical research cooperation platform is currently undertaking clinical trials for acupuncture aimed at cancer-related pain.

In 2017, Liverpool Hospital Cancer Services was awarded a $2M ACRF grant to go towards providing a facility for the first cancer wellness centre in South-West Sydney – The ACRF OASIS Centre.

The centre will focus on gathering scientific evidence on the use of a wide range of treatments including massage, acupuncture, exercise, Chinese medicine and diet in improving short and long-term treatment and quality of life outcomes for people impacted by cancer.

Last year, the ACRF OASIS Research Advisory group developed a strategic plan and continue to provide oversight to existing research projects.

Patient Reported Outcomes (PROs) continue to be their main research focus as a platform to build infrastructure, which will improve the quality and efficiency of clinical care outcomes.

A notable update is the establishment of the first Sino-Australian Oncology Research Alliance, in collaboration with the Chinese Medicine Centre at Western Sydney University. The clinical research cooperation platform is currently undertaking clinical trials for acupuncture aimed at cancer-related pain, with Chinese herbal medicine trials currently in analysis stages.

Meanwhile, detailed design work continues for the ACRF OASIS Centre as part of the Liverpool Health and Academic precinct redevelopment project. Researchers have been part of the user group to develop the project and have now signed off on the facility design.

If you would like to financially support cancer research please go to acrf.com.au/donate

View the 2017 ACRF OASIS Centre Research grant details here.

ACRF: Backing the Brightest Minds with the Boldest Ideas

As an ACRF supporter you would often hear us talking about the pioneering research your donations are enabling. As we head into May 2021, we thought it would be good to share with you the process we go through each year to select and fund these breakthrough research programs.

In March our grant selection process gets underway and by May we have received a number of applications for funding. As always, these applications are from research institutes across Australia seeking funding to enable, accelerate or expand cancer research initiatives.

To ensure ACRF funding can have the largest impact, our focus is always on the technology, equipment and infrastructure these research programs need. We often hear from scientists that technology is the most important thing needed to innovate and drive science forward. So, this area of funding continues to be our focus.

To guarantee the best and most promising projects receive funding each application is rigorously reviewed and assessed by ACRF’s volunteer Medical Research Advisory Committee (MRAC). A group of talented individuals who themselves are driving forces behind some of the best institutes and research programs across the country.

We are often asked what it takes for an idea to get funding from ACRF. We are always looking out for the big ideas, the ones that aren’t going to just take a step forward but propel us towards a world without cancer. But, these ideas need more than just guts. They have to be backed by brilliant science and thinking, they need to be feasible and they need to be sustainable beyond ACRF’s contribution.

To showcase the type of bold thinking ACRF supports we’d like to share one of our 2020 grant recipients with you. This grant, awarded to the University of Queensland’s Centre for Advanced Imaging to establish the ACRF Facility for Targeted Radiometals in Cancer (AFTRiC), aims to unlock the cancer curing potential of targeted alpha therapy.

An Australian-first facility, with a focus on alpha therapies (a type of precision medicine which has the potential to be more effective in killing cancer without damaging healthy tissue), AFTRiC met ACRF requirements to be considered for a major capital grant.

Research at the facility will focus on discovering better ways of specifically targeting and delivering therapeutic payloads to cancer cells, measuring their effects on tissue and translating them into clinical use.

ACRF funding will be used for the purchase of critical equipment needed to complete the research pathway from synthesis of novel agents to the development of new cancer therapies.

Professor David Reutens, Director of The University of Queensland’s Centre for Advanced Imaging, said “ACRF funding provides critical equipment to complete the research pathway from synthesis of novel agents through to clinical studies and patient therapy, enabling researchers to unlock the cancer-curing potential of targeted alpha therapy. The new facility will complement the nation’s most comprehensive suite of preclinical and clinical imaging research instruments at the Centre for Advanced Imaging allowing us to fast-track the development of new cancer therapies.”

We are looking forward to seeing the exciting new ideas that will be seeking funding from ACRF this year and we look forward to sharing updates on grants with you later in 2021.

Bowel Cancer Awareness Month

June is Bowel Cancer Awareness month here in Australia. We would like to take the opportunity to share information with you about bowel cancer in the hope that by raising awareness we can continue to reduce the number of people impacted by this type of cancer.

What is Bowel Cancer Awareness Month

Bowel Cancer Awareness Month raises awareness for bowel cancer, also known as colorectal cancer. Bowel Cancer Awareness month is an opportunity to learn more about this type of cancer and to share information including stories of those impacted by bowel cancer. It is also a time to support organisations, such as ACRF, working to equip researchers with the tools they need to improve the prevention, diagnosis and treatment of all types of cancer.

When is Bowel Cancer Awareness Month held?

 The month of June is Bowel Cancer Awareness month here in Australia.

Why do we commemorate Bowel Cancer Awareness Month

In Australia, bowel cancer is estimated to be the second most diagnosed type of cancer for both men and women and the third most common cause of death from cancer. It was estimated that over 15,000 Australians would be diagnosed with bowel cancer in 2020.

What is Bowel Cancer?

Bowel cancer is caused by the mutation of genes that cause cells in the large intestine to reproduce abnormally and form polyps. Most bowel polyps are not cancerous, but some polyps may become cancerous if left to grow into tumours. Bowel cancer is also referred to as colon cancer or rectal cancer, depending on where it is found in the intestine. 

Bowel cancer most commonly develops in the lower part of the descending colon, the sigmoid colon or rectum. More than 95 per cent of colorectal cancers are adenocarcinomas, cancers that start in cells forming the mucus-making glands that lubricate the colon and rectum. Other rare types include squamous cell cancers, Gastrointestinal stromal tumours, carcinoid tumours, sarcomas and lymphomas.

Anyone can acquire it, but people over the age of 50 are at higher risk. That is why through its National Bowel Cancer Screening Program, the Australian government urges everyone aged 50 to 74 to undergo a free test which can be done at home.

What colour ribbon is for bowel cancer?

The ribbon for bowel cancer (known as colorectal cancer there) is blue. In Australia, a green ribbon with a red apple on it – an abstract representation of the human bowel, is sometimes used.

How you can help spread awareness about Bowel Cancer

Getting involved in Bowel Cancer Awareness Month gives everyone the opportunity to make a difference. You can:

  • Wear a ribbon and encourage conversations about bowel cancer.
  • Talk to family and friends about the realities of bowel cancer, clearing up myths along the way.
  • Get tested regularly and encourage others to get tested too.
  • Post and share information about bowel cancer on social media.
  • Support research into improving the prevention, diagnosis and treatment of all types of cancer, including bowel cancer.

There are many ways to support the work of ACRF and together, with everyone’s input, we will achieve our goal to outsmart cancer. For more information on how you can support bowel cancer research, learn how you can get involved with ACRF.

ACRF’s commitment to Bowel Cancer research

ACRF has partnered with several research institutes on initiatives to develop better prevention, earlier detection and more effective treatments for bowel cancer. Some of these research initiatives include:

  • ACRF Centre for Integrated Cancer Systems Biology in South Australia. This state-of-the-art facility is utilising next generation technologies to transform patient outcomes through the delivery of targeted and personalised cancer therapy for a number of types of cancer including bowel cancer.
  •  ACRF Breakthrough Technologies Laboratory to advance new treatments for many of Australia’s most common, and most deadly cancers, including bowel cancer.
  • ACRF Centre for Therapeutic Target Discovery, potentially forming a scientific cornerstone of the first comprehensive cancer centre established in Australia. The centre created an innovative Australian-first collaborative and integrated cancer research centre, where clinicians, diagnosing and treating cancer patients, work closely with scientists researching the disease.

Natalie’s Story

“Trying to work out what our lives would look like without my Dad in it broke me to my absolute core,” said Natalie who lost her beloved dad just seven months after he was diagnosed with cancer.

Natalie shared her story with us, explaining why she chose to take on the ACRF Hair Dare in support of cancer research. 

“Hundreds of men and women are diagnosed with cancer every year and it isn’t contingent upon age, gender or health. Some of the healthiest people I know have been diagnosed and several have passed from cancer. 

“I know this first-hand because my father was diagnosed with cancer in March 2018, and only seven months later passed away. He was an incredibly strong and healthy man with an amazing work ethic. He never took a sick day and would give any ‘young’ man a run for his money. 

“As a young woman with a small child, having to explain to my son why he won’t be able to see his ‘GanGan’ again was devastating. Trying to work out what our lives would look like without Dad in it broke me to my absolute core. 

“Witnessing Dad lose weight, become sick and tired every day was completely heartbreaking for both him and us. Cancer affects everyone around the person receiving treatment, not just the patient themselves. 

“Dad had so many more wonderful years left and he should be here now with us all, living his beautiful life. He should have been here to watch his grandson play his first game of football, he should have been here to witness his firstborn get married and he should have been here to enjoy what this wonderful world has to offer. 

“We now live our lives every day in honour of him and his spirit lives through all of us. 

“That is why I took on the Hair Dare for cancer research. I raised $624 and know that every single bit counts.”

ACRF would like to thank Natalie for sharing her story and for raising an incredible $624 for cancer research.

If you’ve been inspired by Natalie’s story and would like to take on the ACRF Hair dare in support of cancer research, click here.

What Embyro Development Can Teach Us About Fighting Cancer

Human development is one of the most elegant biological phenomena where rapid but controlled cellular growth leads to a healthy human life. On the other hand, cancer is an uncontrolled growth of cells often resulting in insurmountable pain and death.

There are some uncanny resemblances between embryo development and cancer, and studying these similarities at a cellular level excites our newly appointed Women’s Cancer Senior Fellow at the Harry Perkins Institute, Dr Ankur Sharma, who is also Head of the newly established Oncofetal Ecosystem Laboratory.

Over the past five years Dr Sharma has been using technologies, particularly single cell analysis techniques, to develop a method of predicting the similarities between cancer and early development with a goal to predict which patients are likely to develop cancer and which cancers they are likely to have.

His work started by studying liver cancer and looking at why it develops. During this study he stumbled upon a very interesting finding: in cancer, some of the cells which are part of the cancer supporting system are also found in foetal tissue.

“We see very interesting similarities between foetal-liver development and liver cancer. The similarities occur as if cancer remembers the early blue-prints of life,” he says.

“If you go back and match the cell types present during foetal-liver development with the cell types of cancerous adult liver we find lots of shared cell types. Importantly, in both, the immune system is kept at bay. Now we are working on methods to revert these programs and thereby empower the immune system to fight cancer,” he says.

Currently Dr Sharma is particularly interested in analysing women’s cancers, such as endometrial tumours which also arise from highly regenerative cells, in this case in the linings of the uterus. Almost 1 in 9 women is affected by endometriosis. It is a disease that hampers reproductive life and some (~3%) may develop cancer in their lifetime. However, it remains to be investigated whether we can predict risk of cancer in these patients.

“We think this can be achieved by examining historic patient biopsies held in tissue banks or archives of patients who have endometriosis and then comparing the samples of those whose endometriosis resulted in cancer to those who did not, to see if there is a difference.

“After predicting which patients may develop cancer, the next challenge is to find ‘the right drug for the right patient’ by understanding why some patients respond to treatments and others do not.

“I am driven to overcome the emotional toll of enduring treatment, which at times is ineffective and expensive. Our aim is to find ‘the right drug for the right patient’ for ultimate benefit of patients, families and society,” he says.

This article originally appeared on the Harry Perkins Institute of Medical Research’s website. ACRF has awarded $5.35m in grants to the Harry Perkins Institute of Medical Research for cancer research. Our esteemed Medical Research Advisory Committee ensures that only the most promising cancer research initiatives in Australia receive our funding. If you would like to financially contribute, please go to acrf.com.au/donate

Gene Discovery Suggests New Treatment Approach for Liver Cancer

In a comprehensive analysis of human gene activation data, researchers from the Centenary Institute have discovered that the dipeptidyl peptidase-4 (DPP4) gene family is strongly implicated in the development of human hepatocellular carcinoma (HCC), the most common type of primary liver cancer.

Reported in the journal ‘Cancers’, the research suggests that the DPP4 gene family and the four enzymes that it contains should be further studied to support potential new therapeutic approaches to fighting tumours found in the liver.

“In this study we interrogated a number of publicly accessible human gene databases including The Cancer Genome Atlas to identify cancers associated with the DPP4 gene family,” said Dr Hui Emma Zhang, researcher in the Centenary Institute’s Liver Enzymes in Metabolism and Inflammation Program and co-senior author on the paper.

“We were focused on the four enzymes of the DPP4 gene family– DPP4, DPP8, DPP9 and fibroblast activation protein (FAP). The role of the DPP9 enzyme was of particular interest as it hadn’t been studied previously with regard to liver cancer in humans,” Dr Zhang said.

Results from the data mining and subsequent analysis undertaken by the research team were revealing.

An association between high levels of the DPP9 enzyme and uterine and lung cancer was found suggesting that further investigatory work in both areas was required.

Elevated levels of DPP9, DPP4, FAP and DPP8 enzymes were also discovered in liver tumours and critically, were associated with poor survival rates in HCC patients.

“Our analysis indicates that high levels of all enzymes of the DPP4 family occur in liver cancers, which encourages us to target these enzymes as a possible new therapeutic approach to tackling the disease,” said Dr Zhang.

“With liver cancer incidence and mortality rates in Australia rapidly increasing new treatment options are urgently required both to improve and to save people’s lives.”

Over 2,000 Australians die each year from liver cancer. The five year survival rate for liver cancer is below 20%.

This article originally appeared on the Centenary Institute’s website. ACRF has awarded $7.5m in grants to the Centenary Institute for cancer research. Our esteemed Medical Research Advisory Committee ensures that only the most promising cancer research initiatives in Australia receive our funding. If you would like to financially contribute, please go to acrf.com.au/donate

Melanoma Cancer Awareness Month

This Melanoma Awareness month, we’d like to take the opportunity to highlight how you can help in the prevention and early detection of melanoma and how you can support vital research focused on the early detection and better treatment of melanoma.  

At Australian Cancer Research Foundation (ACRF) we award grants for innovative cancer research initiatives that lead to breakthroughs and discoveries that help each individual diagnosed with this complex and disruptive disease. In fact, an ACRF funded initiative is set to establish one of the largest melanoma surveillance and early detection programs in the world. Read more about the project here.

When is Melanoma Cancer Awareness Month? 

May is Melanoma Awareness Month.  This month is commemorated across Australia and the world each year. 

Why is Melanoma Awareness month so important? 

Melanoma is the most dangerous form of skin cancer because if it isn’t detected early, it can spread to other organs. For that reason, early diagnosis is key to survival. While an individual with Stage 1 melanoma has a 99% chance of surviving longer than 5 years, that figure drops dramatically if the cancer spreads. Individuals with Stage 4 melanoma have just a 20% chance of surviving longer than 5 years.

Australia has one of the highest rates of melanoma in the world and is often referred to as ‘Australia’s national cancer’.

Melanoma is the third most diagnosed cancer in Australian men and women and the most common cancer affecting 15 to 39-year-old Australians.

In fact, more than 1600 Australians die each year from this devastating disease, which is mostly preventable and highly treatable if detected early.

Melanoma Cancer Awareness Month is so important to commemorate in Australia due to it’s high rates within our country. This month aims to raise awareness about melanoma to encourage more people to get regular checks as well as raising much needed funds to help improve the prevention, diagnosis and treatment of melanoma.

What colour represents melanoma awareness month?

Melanoma awareness is represented by the colour black.

To help raise awareness throughout the month of May, you can wear the colour black to show your support and encourage conversations to start with your family, friends or colleagues about melanoma.

What colour ribbon is for melanoma cancer? 

The melanoma awareness ribbon is black.

Instead of wearing black clothes, you can choose to wear a black ribbon to support Melanoma Cancer Awareness Month.

How can you raise awareness for Melanoma Cancer this March

There are many ways you can support those diagnosed with melanoma. Support each individual by:

  • Wearing a black ribbon and encouraging conversations about melanoma.
  • Shaving to raise funds for cancer research.
  • Participating in the many fun runs or run your own race.
  • Protecting your skin from the sun and encouraging others to do the same.
  • Getting regular skin checks and encouraging others to do the same.
  • Sharing this page to raise awareness of melanoma and the risks.
  • Donating to cancer research.

There are many ways to support the work of ACRF and together, with everyone’s input, we will achieve our goal to outsmart cancer. Learn how you can get involved with ACRF and support research into all types of cancer, including melanoma.

ACRF’s contribution to melanoma research

ACRF is committed to improving the prevention, detection and treatments of melanoma.

ACRF has provided funding to several research institutes for research programs to develop earlier detection and more effective treatments for melanoma.

In 2018, ACRF awarded almost $10m to establish the ACRF Australian Centre of Excellence in Melanoma Imaging and Diagnosis. A diagnostic centre set to revolutionise the early detection of melanoma. The rollout (later this year) of 15, three-dimensional whole body imaging systems across Queensland, New South Wales and Victoria will significantly enhance the capability and capacity of clinicians and researchers to detect and understand melanoma.

The 3D imaging system takes a total body image in milliseconds, giving dermatologists the ability to detect skin cancers in a patient even from the other side of the country, through a telemedicine network. This will greatly reduce appointment times and healthcare costs, as melanoma is often referred to as Australia’s ‘national cancer’.

In 2011, ACRF awarded $5M to establish the ACRF Melanoma Research Laboratories. This grant was used as seed-funding for the construction of two world-class melanoma research laboratories. 

Click here to read more about this grant.

‘Catch-22’ Scenario Good News for Some Cancer Patients

Image above: (from left to right) Bachelor of Science student Gavin Turrell, UQ Research Fellow Dr Meihua Yu, Dr Janin Chandra, Professor Ian Frazer, and UQ Research Fellow Dr Ahmed Mehdi.

Traits that allow cancer cells to escape the body’s natural defence system and develop into tumours are actually a good indicator to a patient’s survival prognosis, according to University of Queensland researchers.

UQ Diamantina Institute researcher Dr Janin Chandra described the discovery as a “catch-22 situation” and good news for patients with either cervical or head and neck cancer who have immune inhibitory traits present in their tumours.

“Our natural defence system is programmed to pick up abnormal cancerous cells and destroy them before they can grow into a tumour mass and spread through our bodies,” Dr Chandra said.

“However, the tumour can grow by developing cunning strategies to either escape our natural defence system, or to actively block it.

“We call these strategies immune inhibition, and until recently we thought this trait was a bad thing.

“Our recent research has shown that tumours of patients with either cervical cancer or head and neck cancer which had many immune inhibition traits, had the best five-year survival prognosis compared to patients with tumours without the traits.”

The data also showed that tumours with immune inhibition traits also had high levels of defence system activity, which fight against cancer.

Dr Chandra said researchers now had a better understanding that having immune inhibition traits in the tumour was actually not bad, and in fact was a sign of immune activation.

People who lack this immune activity inside the tumour, regardless if ‘good’ or ‘bad’ immune activity, have a worse prognosis.

She said this knowledge had important implications in designing future therapies for cancer.

“On average only 20 percent of patients respond to new immune-targeted drugs, so we are organising a clinical research study to develop predictors of response to these drugs,” Dr Chandra said.

“You need to give patients that aren’t responding to treatment an alternative, so our research is geared to identify new targets that could be used for patients who don’t have any natural defence cells in their tumours.”

Image above: (from left to right) Bachelor of Science student Gavin Turrell, UQ Research Fellow Dr Meihua Yu, Dr Janin Chandra, Professor Ian Frazer, and UQ Research Fellow Dr Ahmed Mehdi.

The research paper – Immune-inhibitory gene expression is positively correlated with overall immune activity and predicts increased survival probability of cervical cancer patients – is published in Frontiers in Molecular Biosciences Molecular Diagnostics and Therapeutics (DOI: 10.3389/fmolb.2021.622643).

This story originally appeared on the UQ Diamantina Institute website.

ACRF has awarded five grants to the UQ Diamantina Institute, including the initial seed funding for the development of a vaccine to prevent cervical cancer.

Dual drug approach to treat deadly melanoma

Research from the Centenary Institute has found that a new dual drug approach could offer up a highly effective treatment strategy for melanoma, the most serious form of skin cancer responsible for more than 1,700 deaths each year in Australia.

Reported in the ‘Journal of Investigative Dermatology’ the findings have the potential to benefit melanoma patients who do not respond favourably to current therapeutic treatments.

In the study, the research team found that the combined use of inhibitors targeting two specific proteins markedly reduced the growth of melanoma both in cellular experiments as well in models with mice. The two proteins targeted were the bromodomain and extra-terminal domain (BET) family of proteins and cyclin-dependent kinase 9 (CDK9). High expression of BET and CDK9 proteins are associated with an adverse prognosis in melanoma patients and also regulate melanoma cellular activity.

According to Dr Abdullah Al Emran (pictured) , researcher in the Melanoma Oncology and Immunology Program at the Centenary Institute and lead author of the study, a key finding from the study was that the combination BET and CDK9 inhibitor treatment demonstrated significantly increased melanoma killing benefits when compared to use of the same inhibitor drugs when tested alone.

“Co-targeting BET and CDK9 proteins with inhibitors killed high numbers of melanoma cells regardless of type or status including melanomas exhibiting both BRAF and NRAS genetic mutations. The inhibitors worked by disrupting separate signalling pathways found within the melanoma cells–those responsible for cell communication and growth and this may explain the effectiveness we saw,” he said.

“We also found molecular gene signatures suggesting biomarkers of which melanoma patients were most likely to respond to this BET and CDK9 inhibitor treatment,” he added.

Dr Jessamy Tiffen, Head of the Centenary Institute’s Melanoma Epigenetics Laboratory and senior author on the research paper believes that use of combination drug treatments may offer up a new strategic approach in the fight against the often fatal skin cancer.

“Over half of all melanoma patients do not respond to current therapies and new treatment approaches are urgently required. We’ve now seen that drugs working in combination are able to produce a synergistic effect when it comes to the killing of melanoma cells. This strategy could lead to higher survival rates for patients and as a result we will be further exploring this exciting avenue of research,” she said.

This article originally appeared on the Centenary Institute Website.

In 2016, ACRF awarded at $2.5M grant to Centenary Institute for the establishment of the ACRF Tumour Metabolism Laboratory.

If you would like to financially support the work of ACRF please go to acrf.com.au/donate.

The ACRF Accelerate program

This week Australian Cancer Research Foundation has launched an exciting new initiative. The ACRF Accelerate program has been designed in line with our mission to reach a world without cancer. The program provides prospective donors with a unique philanthropic opportunity to evaluate and contribute towards promising cancer research projects. 

Survival rates from cancer are increasing thanks to decades of research, but around 396 Australians are still diagnosed with cancer every day. The Accelerate program connects generous donors who want to solve the problem of cancer with projects that have the ability to do just that.  

Tom Dery AO, ACRF’s Chair said: 

A year ago, we could never have imagined the world as it is today. From the devastation of fires and floods, through to a complete transformation in the way we connect, work, access healthcare, and travel. 

While the pandemic has highlighted the critical need for medical research into vaccine development, there also remains an ongoing need for investment in cancer research. That priority remains unchanged, and ever present.  

Despite improvements in patient outcomes, cancer continues to impact far too many lives. With vast economic pressures transforming the research funding environment, the work of Australian Cancer Research Foundation and the life-changing ACRF Accelerate program remains more vital than ever. 

Over the past 12 months, we’ve been inspired by the many generous Australians dedicated to supporting globally significant cancer research through our Accelerate program. We’re proud to say that groundbreaking, world-leading discoveries are happening right here in our own backyard because of their donations. 

As leaders in philanthropic investment, ACRF is committed to the rigour, review and assessment of the projects presented in the ACRF Accelerate program, providing you with confidence that every donation will result in real, measurable impacts for those living with cancer. 

On behalf of the ACRF board, I’m proud and excited about the potential opportunity this year’s ACRF Accelerate program presents to donors and researchers committed to changing the human and social impact of cancer in Australia. 

We invite you explore these innovative projects and consider a meaningful contribution towards their success. Find out more here: acrf.com.au/philanthropy

What is National Colorectal Cancer Awareness Month?

March is National Colorectal Cancer Awareness month. We’d like to take the opportunity to share information with you about colorectal cancer (or bowel cancer) in the hope that by raising awareness we can continue to reduce the number of people impacted by this type of cancer.

What is Colorectal Cancer Awareness month?

National Colorectal Cancer Month raises awareness for colorectal cancer, commonly known as bowel cancer. Colorectal Cancer Awareness month is an opportunity to learn more about this type of cancer and to share information including stories of those impacted by colorectal cancer. It’s also a time to support organisations, such as ACRF, working to equip researchers with the tools they need to improve the prevention, diagnosis and treatment of all types of cancer.

What is Colorectal Cancer?

Colorectal cancer is caused by the mutation of genes that cause cells in the large intestine to reproduce abnormally and form polyps. Most bowel polyps are not cancerous, but some polyps may become cancerous if left to grow into tumours. Colorectal cancer is also referred to as colon cancer or rectal cancer, depending on where it is found in the intestine. 

Colorectal cancer most commonly develops in the lower part of the descending colon, the sigmoid colon or rectum. More than 95 per cent of colorectal cancers are adenocarcinomas, cancers that start in cells forming the mucus-making glands that lubricate the colon and rectum. Other rare types include squamous cell cancers, Gastrointestinal stromal tumours, carcinoid tumours, sarcomas and lymphomas.

Colorectal Cancer facts In Australia

Colorectal Cancer is estimated to be the second most diagnosed type of cancer for both men and women and the third most common cause of death from cancer. It was estimated that over 15,000 Australians would be diagnosed with colorectal cancer in 2020.

When is Colorectal Cancer Awareness month?

March is National Colorectal Cancer Awareness month in the US and in Australia, June is Bowel Cancer Awareness Month.

How to create colorectal cancer awareness

Getting involved in Colorectal Cancer Awareness Month gives everyone the opportunity to make a difference. You can:

  • Wear a blue ribbon and encourage conversations about colorectal cancer.
  • Talk to family and friends about the realities of colorectal cancer, clearing up myths along the way.
  • Get tested regularly and encourage others to get tested too.
  • Post and share information about colorectal cancer on social media.
  • Support research into improving the prevention, diagnosis and treatment of all types of cancer, including colorectal cancer.

There are many ways to support the work of ACRF and together, with everyone’s input, we will achieve our goal to outsmart cancer. For more information on how you can support colorectal cancer research, learn how you can get involved with ACRF.

What is the Colorectal cancer awareness colour?

Blue is the colour for colorectal cancer awareness. Supporters are encouraged to wear blue clothes and/or blue ribbons to help spread awareness.

ACRF’s contribution to Colorectal cancer research

ACRF has partnered with several research institutes on initiatives to develop better prevention, earlier detection and more effective treatments for colorectal cancer. Some of these research initiatives include:

  • ACRF Centre for Integrated Cancer Systems Biology in South Australia. This state-of-the-art facility is utilising next generation technologies to transform patient outcomes through the delivery of targeted and personalised cancer therapy for a number of types of cancer including colorectal cancer.
  •  ACRF Breakthrough Technologies Laboratory to advance new treatments for many of Australia’s most common, and most deadly cancers, including colorectal cancer.
  • ACRF Centre for Therapeutic Target Discovery, potentially forming a scientific cornerstone of the first comprehensive cancer centre established in Australia. The centre created an innovative Australian-first collaborative and integrated cancer research centre, where clinicians, diagnosing and treating cancer patients, work closely with scientists researching the disease.

Spencer’s Story

This Colorectal Cancer awareness month we’d like to shout out to the heroes that continue to ensure ACRF can fund pioneering research to improve patient outcomes.

Loyal ACRF supporter Spencer Hird has supported bold cancer research by putting rubber to the road. He’s run Sydney’s City2Surf 47 times – even participating in the event virtually during COVID.

Sadly, Mr Hird lost his wife Heather in 1994 to bowel cancer. “I started fundraising soon after her passing and my focus has always been to give to cancer research. I am always impressed when I hear of improvements to treatments and diagnosis. It is so good to feel I might have contributed to that” says Mr Hird.

Thank you for your continued support Mr Hird.

Find out how you can support bold cancer research at acrf.com.au/get-involved

Steve’s Story

About 17 years ago, I shaved my head, moustache – and my legs! – to support a friend of mine, who sadly died from breast cancer. 

Around the same time, I had a spot removed from my back which turned out to be a stage 3 melanoma, so I had a large section removed from my back. I thought I was all good until 2017, when I found out that I had a secondary brain tumour. It was removed by the wonderful team at the Royal Brisbane Hospital. 

I was lucky enough to be one of the first people to trial immunotherapy for a year and had my thyroid removed late December 2019. I was in remission and going well until early February 2021, when I found out I had another brain tumour. This one had grown fast – from nothing in November 2020 to 20mm in February 2021. 

I will be undergoing a new treatment at the Princess Alexandra Hospital, called a Gamma Knife, which will shrink and kill the tumour. I will then undergo more immunotherapy to get rid of a couple of small tumours near my spine. 

Then I will be as good as new! Anything I can do to raise money to help is only a small thing compared to those who have done much more before me. Their support has allowed me to get the best and latest treatment to help me live a bit longer. 

I shaved my head and my moe for ACRF through the Hair Dare and raised $650. My youngest son Michael has taken on the dare too and I’m very proud of him. 

To learn more about how to shave, cut or colour for cancer research, head to shave.acrf.com.au

Terence’s Story

In late 2015 doctors found a mass growing in my brain after a routine check-up. After monitoring it for a few years, in late 2019 my neurosurgeon discovered that the mass was growing. Two thousand and twenty sucked for a lot of people but throwing in brain surgery and six months of chemo, all while a global pandemic was raging, wasn’t how I had pictured my wedding year!

I married my wife, Alyce, in February before my surgery – just before the lockdowns, so a win for us, I guess.  The year ended much better as we welcomed our son, Ryan, two weeks after chemo ended. He’s our number two, Emily, our daughter, is four. I take my hat off to Alyce for putting up with (I mean, supporting) me through treatment all the while going through pregnancy! Now THERE’S an inspiring story, but not mine…

One day during treatment, I got talking to an older lady who has been battling cancer for years and I was in awe of her positive attitude and bubbly personality. One thing she said that resonated with me was, “My dear, chemo is just the beginning… This journey living with cancer isn’t a sprint, as they say, it’s a marathon. The real challenges are up here,” as she pointed to her head.

So, that night, I decided that 12 months after I completed chemo, I was going to run a marathon. I completed chemo on 18 September 2020. The Blackmores Sydney Running Festival marathon is on the 19 September 2021. Fate perhaps? I’ve never been much of a runner, but why let fear stop me from doing something scary or different? I can’t change the fact that I have brain cancer. What I can change is the way I feel about it and to show those around me that cancer isn’t the GAME OVER moment some people fear it is. Why waste what life we have left in fear of things that could open our eyes to the world?

I’m running this marathon for me and all brain cancer warriors out there and also the people who dedicate their lives to overcoming all forms of cancer.

There are many ways to support the work of ACRF and together, with everyone’s input, we will achieve our goal to outsmart cancer. To find out more head to acrf.com.au/get-involved

Key Steps Discovered in Production of Critical Immune Cell

WEHI researchers have uncovered a process cells use to fight off infection and cancer that could pave the way for precision cancer immunotherapy treatment. 

Through gaining a better understanding of how this process works, researchers hope to be able to determine a way of tailoring immunotherapy to better fight cancer.

Led by Dr Dawn Lin and Dr Shalin Naik and published in Nature Cell Biology, the research provides new insight into the way cells adapt to fight infection.

Dr Shalin Naik and Dr Dawn Lin

This research lays the foundation for future studies into the body’s response to environmental stressors, such as injury, infection or cancer, at a single cell level.

At a glance

  • WEHI researchers have studied dendritic cells, a crucial component of the immune system, to gain a deeper understanding of how the body produces these cells to fight cancer and infection
  • The study found how the Flt3L hormone increased dendritic cells numbers
  • Researchers will now apply this knowledge to improving immunotherapy techniques to create more personalised treatments

Flt3L hormone plays vital role in fighting off infection

Dendritic cells are immune cells that activate ‘killer’ T cells, which are vital for clearing viral infections, such as COVID-19, but also for triggering a response to cancers such as melanoma and bowel cancer.

The Flt3L hormone can increase dendritic cell numbers, helping the immune system to fight off cancer and infection.

Dr Naik and his team studied developing immune cells at a single cell level to gain a deeper understanding of how the body uses these cells to trigger immune responses.

“There is one type of dendritic cell that the body uses to fight some infections and cancer. The Flt3L hormone increases numbers of this particular dendritic cell.”   

“We know quite well how the dendritic cell fights the cancer, but we don’t know how the Flt3L hormone increases the numbers of those dendritic cells,” he said  

Single-cell barcoding provides vital clues to how dendritic cells function

Researchers used a single-cell ‘barcoding’ technique to uncover what happened when dendritic cells multiplied.

“By using cellular barcoding – where we insert short synthetic DNA sequences, we call barcodes inside cells – we were able to determine which cells produced dendritic cells in pre-clinical models,” Dr Naik said.

“As a result of this research, we now better understand the actions of the Flt3L hormone that is currently used in cancer immunotherapy trials, and how it naturally helps the body fight cancer and infection. This is a first step to design better precision immunotherapy treatments for cancer.” 

Using single cell technology to improve immunotherapy treatment

This research answers a 50-year-long question as to what causes a stem cell to react in response to immense stress, such as infection or inflammation.

“We have known that the Flt3L hormone increases the number of dendritic cells for decades but now there is a focus on applying this knowledge to cancer immunotherapy and potentially to infection immunotherapy as well,” Dr Naik said.   

“The next stage in our research is to create ‘dendritic cell factories’ using our new knowledge, to produce millions to billions of these infection fighting cells and then use those in immunotherapy treatments.”

“These findings are a vital first step to improving immunotherapy treatments for patients, to help them better fight cancer and infection.”

WEHI authors

Dawn Lin, Luyi Tian, Sara Tomei, Daniela Amann-Zalcenstein, Tracey Baldwin, Tom Weber, Jaring Schreuder, Olivia Stonehouse, Samir Taoudi, Matthew Richie, Philip Hodgkin, Ashley Ng, Stephen Nutt, Shalin Naik.

This article originally appeared on the WEHI website. ACRF has awarded $10m in grants to WEHI for cancer research.

Our esteemed Medical Research Advisory Committee ensures that only the most promising cancer research initiatives in Australia receive our funding. If you would like to financially contribute, please go to acrf.com.au/donate

Microscopic behaviour of developing breast cells uncovered

An improved high-tech fluorescence microscopy technique is allowing researchers to film cells inside the breast as never seen before.

This new protocol provides detailed instructions on how to capture hi-res movies of cell movement, division and cooperation, in hard-to-reach regions of breast tissue.

The technology – called multiphoton microscopy – uses infrared lasers to illuminate fluorescently labelled breast cells without harming them, so that elusive cell behaviours can be observed within living tissue.

With the new method, WEHI researchers have revealed how breast cells rearrange, interact and sense their environment as the breast grows during development and recedes after lactation.

Cell imaging within living tissue has been achieved in many organs but the breast has remained especially challenging. So far, this new method has revealed exciting and unexpected details of breast biology and will help teams worldwide to advance research on breast development and cancer.

At a glance

An improved imaging protocol is allowing researchers to film cells as never seen before.

This new application of high-tech microscopy has enabled the imaging of stem cells as they guide breast development, and immune cells as they monitor the breast ducts to keep them healthy.

By imaging living, moving cells in their natural setting, researchers can better understand how our bodies function in real-time at the microscopic scale.


Understanding cell function

The protocol was developed by researcher Dr Caleb Dawson, in a team led by Professor Jane Visvader and Dr Anne Rios, in collaboration with Dr Scott Mueller from the Doherty Institute, and published in Nature Protocols today.

Dr Dawson said the filming technique unlocked a variety of applications to better understand how cells function, interact and develop.

“One of the most valuable things we have been able to film with the technique are the terminal end buds (TEBs) in breast tissue,” he said.

“These are club-like structures at the tips of the mammary ducts that grow during puberty to produce the branched tree structure of breast tissue. The unique cells inside the TEBs have never been filmed like this before so it was fascinating to watch this process for the first time.”

“We have watched a cell behaviour inside the TEB that was hypothesised in the 1980s but was never proven, and which has implications for breast stem cell function.”


Previously, TEBs had been studied by dissociating the individual cells and filming them outside the breast or by taking still images. With these approaches it is difficult to know how the cells actually behave and interact in living tissue.

“By filming the moving cells inside intact breast tissue in laboratory models, we are able to grasp a better understanding of how the cells behave and cooperate to help the breast to form and function properly.”

Dr Dawson said that he was grateful for the brilliant team and the cutting-edge technology provided by the Center for Dynamic Imaging at WEHI that made this work possible.

“When we embarked on our mission to film these processes, I had little knowledge of the effort it would require. With the vision of leading breast researchers Professor Visvader, Dr Rios and Professor Geoff Lindeman, alongside the live imaging expertise of Dr Mueller, and the microscopes available, we were able to achieve something that very few labs in the world have accomplished,” he said.

Opening the doors to new research opportunities

Dr Dawson said the filming technique could be applied to a host of research endeavours.

“Our approach enables us to image up to six fluorescent colours at the same time, which allows us to see how more cell types interact,” he said.

“We can image different stages of breast development, immune cells, lymph nodes and hair follicles and watch how individually-labelled cells function.”

“This means we can create beautiful images with extremely fine details about the cell shapes to get a better understanding of how cells interact and change over time. This opens up many new research opportunities and we are only just starting to see the potential of what this could be used for.”

Dr Dawson said he hoped the imaging protocol would make this type of imaging more widely accessible to researchers.

“There are very few research institutions doing this really high-end imaging, so it is great that we have this capacity in Melbourne and can share it with research teams worldwide.”

The original news article was posted on the WEHI website. Video courtesy of WEHI.

ACRF has awarded $10m in grants to WEHI for cancer research. Our esteemed Medical Research Advisory Committee ensures that only the most promising cancer research initiatives in Australia receive our funding. If you would like to financially contribute, please go to acrf.com.au/donate

Meet Leo.

In his first year of life, Leo was diagnosed with stage three kidney cancer.

Donate now

“When our son, Leo, was seven months old we noticed he was frequently sick. Following a very high temperature that would not break, Leo’s abdomen began to swell. When the doctor saw Leo’s stomach his eyes widened with panic. My partner, Dave, and I knew we were in serious trouble.

My name is Susan, and I am mother to two-year old Leo. Last year, our young family was nearly torn apart by kidney cancer.

I’ll never forget the night Leo’s doctor told us to rush him to the emergency room.

An ultrasound revealed an unknown 14 cm mass growing in the right side of Leo’s abdomen. Our son was getting more ill by the day, he would cry in pain all through the night. His fever was now constant and the lump in his abdomen was larger than ever before.

Before our son had even turned one, he was taken away from us to undergo extremely dangerous surgery to remove his entire right kidney.

For seven hours and 45 minutes, we reeled with anxiety and fear. I would sit, I would stand, I would cry, I would stare, and I would pace back and forth. It was excruciating.

As we walked into the PICU where Leo was recovering, nothing could have prepared us for the sight of our baby after his surgery. He was bruised and there were tubes everywhere. He had a huge gash across his tiny belly and was struggling to breathe.

When we got the tumour pathology results, the oncologist couldn’t hide his concern and before he could even speak I knew it was bad news.

 I was cold with fear as he told us Leo had been diagnosed with stage three Wilms tumour, a type of kidney cancer.

Leo underwent eight months of debilitating chemotherapy and radiation treatment. He was too young to communicate to him what was happening. All we could do was to try and make each hospital experience as fun as possible for him. We’d take toys and snacks and pretend to be happy. As soon as I would leave the room, the floodgates would open. It was heartbreaking to see our son suffer.

Finally, we reached the end of the treatment regime and Leo was given a full body scan.

To our sheer joy and relief, Leo was pronounced cancer-free and in remission. We couldn’t believe that we were lucky enough to come out of this the way we did.

The feeling of happiness we experienced was mixed with other emotions: fear, survivor’s guilt, and re-adjustment into our ‘new normal’ life. But with this came the acknowledgement that the only thing to do is to live each day and live it well –
and it is like learning to live again.

We know there are many Australian families who will not be as lucky as we are this Christmas, and it is our hope that together with fellow ACRF supporters we can help fund cancer research to outsmart cancer for future generations.

Please donate this Christmas to give the gift of life-saving cancer research and help more Aussie kids like our Leo.

If you donate before 31 December, 100% of your donation will go directly towards cancer research equipment and infrastructure to make breakthroughs possible.”

– Susan, ACRF supporter

Donate now

Stopping cancer’s clock

Cancer Scientists at Harry Perkins Institute of Medical Research in Western Australia, the Children’s Medical Research Institute in Sydney and the Max Planck Institute for Biology of Ageing in Cologne, Germany, have developed a way to wrap artificial proteins around the ends of chromosomes to effectively block the uncontrolled growth that occurs with most cancers.

Associate Professor Oliver Rackham’s team at the Perkins has engineered proteins that effectively clamp tightly around the end of the single stranded DNA in the chromosome.

“These proteins lock down the DNA so telomerase can’t touch it.”

Professor Rackham says that about 90% of cancer cells have the telomerase enzyme, when they shouldn’t and that cancer cells grow uncontrollably whereas normal cells limit their growth.

“A normal cell grows for just the right amount of time that is required for us to develop and maintain our bodies.”

“They control their growth with a molecular counting mechanism that tells the cell how old it is. This occurs on the ends of our chromosomes which have little caps on them. Each time the cell divides a little bit at the cap of the chromosome disappears. Once the caps shrink to a certain length the cell knows that it has divided too many times and it will then stop growing or die.

“However, cancer cells subvert the counting mechanism that shrinks the ends of our chromosomes so cancer cells keep replicating indefinitely.”

“The way cancer cells avoid this control mechanism is by producing an enzyme called telomerase which we need when we are babies and growing very fast but which we stop producing when we stop rapidly growing,” he said.

The enzyme extends the ends of the single strands of the DNA, or the caps in cancer cells, which effectively sends the message ‘we’re going to live forever’. So the chromosome thinks it’s a brand new chromosome.

New proteins to target DNA

“Our laboratory designed proteins that, for the first time, can actually recognise the single stranded DNA and bind it. We can basically program these proteins to target them.

“Previously scientists haven’t been able to target the single stranded DNA. The beauty of this new technology is that we have developed proteins that can actually recognise the DNA and bind to it.”

The research has been published in the journal Nature Communications.

The Australian Cancer Research Foundation has supported cancer research at Harry Perkins Institute of Medical Research by providing $5.3 million and the Children’s Medical Research Institute  by $15.2 million towards cutting edge research technology.

Roland’s story – in honour of Men’s Cancer Month

“When I was 34 years old, I thought I was invincible. I was a new dad to two young daughters, Jade and Amber. From the minute they were born, I was totally in love with my babies. I wanted to spend every moment with them, but I was also determined to provide for their future.

I burnt the candle at both ends.

It was 1988 and I had started my first bakery business. It became an immediate success, and after the first year I had twenty employees and working 18-hour days was typical. I was living on coffee and adrenaline.

For a few months, I had been ignoring the pain in my stomach. Then, one day I was rushed to hospital with a large swelling beneath my ribcage. I vividly remember the moment the doctors told me they had discovered a 20cm tumour wrapped around my intestines.

It was Burkitts Lymphoma, and I was told I had less than three months to live.

I remember looking at Jade and Amber’s uncomprehending faces at the end of the hospital bed and in that moment I decided there was no way that I wasn’t going to be around to raise my girls.

At first, I was offered very limited hope so I desperately sought a second opinion. I met with a young oncologist who was a big believer in cancer research. He suggested I try a chemo regime called MACOP-B that was very new at the time. It gave immediate results and I went through further treatment which included radiation and an autologous bone marrow transplant.

Amber and Jade were a huge part of my recovery – they were my life force

Twenty-nine years after I was first diagnosed with cancer, I can look back and count my blessings.

I recall there were times when frightening thoughts would cross my mind. In the wake of such a grim cancer diagnosis and treatment, I worried that I would miss my daughters’ precious childhood moments, and that I would never get to walk them down the aisle. Through the toughest times, the thought of another man stepping in to take my place as their father if I wasn’t around, was always a reliable motivator!

Six months later, my treatment was officially over. Shortly after I was told I had a high chance of leukaemia due to the high doses of chemo, and for the first few years I lived in the shadow of a relapse.

There has always been a 5cm mass present in my stomach, which is likely to be just scar tissue. I think of it as my talisman – it’s there to remind me to value each day, and keep me balanced in my approach to life and business. I am thankful that the only side effect of the innovative treatment was that my hair never grew back after the chemo. At least I didn’t have to go grey and I saved on shampoo!

I have been given this time to raise Jade and Amber, and their little sister Ava. Every day that I get to watch them fly is a miracle to me. I know that I am one of the truly lucky ones. Stories like mine are often too few and far between.

Everyday men are lost to cancer, and many others must live with the debilitating effects of painful treatment

This is why it is so important to continue to support cancer research into improved ways to prevent, detect and treat cancer.

When Jade told me she was taking action to support the Australian Cancer Research Foundation, I was so proud of her. I was thankful to be at her side as she shaved her head. A flood of memories poured in and I took the opportunity to phone and thank the doctor who helped me all those years ago.

ACRF supporters like you make life-saving discoveries possible. I know this because cancer research saved my life, and it will continue to save others, now and in the future.

Since my diagnosis, I have been in awe of all those new, more targeted treatments that provide better outcomes for all types of cancer.

And, there is still so much more we can do.

Cancer is smart, but when we join together, we are smarter

Each day I marvel at my extraordinary good fortune to have survived. When you donate to ACRF, you give more Australian men like me a better chance at survival.

Please make a donation this Men’s Cancer Month as an investment in the health of those you hold dear. Families like mine can’t thank you enough for your support of cancer research.”

Sincerely, Roland
Jade’s dad, cancer survivor and ACRF supporter

 

DONATE NOW

Team behind new cancer treatment wins Clunies Ross Award

A team of cancer researchers at the Walter and Eliza Hall Institute (WEHI) has been recognised for their role in the development of a new anti-cancer medicine. The team received the 2018 Clunies Ross Knowledge Commercialisation Award from the Australian Academy of Technology and Engineering (ATSE).

Professors David Huang and Andrew Roberts and Associate Professors Peter Czabotar, Guillaume Lessene received the award for their roles in the development of the anti-cancer agent venetoclax, which involved a collaboration with the companies Genentech, a member of the Roche Group, and AbbVie.

Venetoclax (marketed as VENCLEXTA® and VENCLYXTO®) is a medicine that is now approved for clinical use in Australia, North America and Europe for the treatment of people with certain advanced forms of chronic lymphocytic leukaemia (CLL). CLL the most common type of leukaemia diagnosed in Australia.

Translating research discoveries to a treatment

The development of venetoclax has its foundation in a research discovery at the Institute in the 1980s, that a protein called BCL-2 can make cancer cells immortal by preventing a form of programmed cell death called apoptosis.

Professor David Huang, whose research has investigated cell death since the 1990s, said the team had a long-term goal of developing a new anti-cancer treatment that killed cancer cells by inhibiting BCL-2.

“Venetoclax was the first drug of this kind to be approved for regular use in the clinic,” he said.

“It has been thrilling to work with our team and our industry partners to see the translation of our laboratory research to clinical benefit. We are honoured to receive the Clunies Ross Award from ATSE.”

Clinical trials of venetoclax demonstrated its benefit as a treatment for people with certain forms of CLL who had no other treatment options, said Professor Andrew Roberts, who is the Head of Clinical Translation at WEHI, a clinical haematologist at the Royal Melbourne Hospital and the Peter Mac, and also holds theMetcalf Chair of Leukaemia Research at the University of Melbourne and Victorian Comprehensive Cancer Centre.

“It was exciting and rewarding to be part of the journey that saw a fundamental research discovery developed to benefit patients,” Professor Roberts said.

“The initial clinical trials of venetoclax took place at sites including the Royal Melbourne Hospital and the Peter Mac, which meant that Australian patients were the first in the world to benefit from Australian innovation.”

The power of collaboration

The research fields of structural biology and medicinal chemistry were crucial for the development of venetoclax. Associate Professor Peter Czabotar led research that revealed three-dimensional structures of target proteins. These provided ‘blue-prints’ for developing venetoclax through the team’s collaboration with AbbVie and Genentech.

“Our research benefited from the depth of structural biology expertise in the Institute, and from our access to the Australian Synchrotron,” Associate Professor Czabotar said.

“By visualising detailed structures of BCL-2 family proteins, we could see how medicines could be developed that were highly specific for BCL-2.”

The early work to develop drug-like molecules that specifically blocked BCL-2 family proteins was led by Associate Professor Guillaume Lessene.

“These proteins presented technical challenges that needed to be overcome in our quest for inhibitory molecules,” Associate Professor Lessene said.

“The depth of expertise in medicinal chemistry at the Institute was critical for the project to reach the point at which we could secure industry collaborations to progress the research further.”

Walter and Eliza Hall Institute director Professor Doug Hilton AO said the story of venetoclax was an important example of Australian science having a global impact.

“Venetoclax is a great demonstration of the power of collaboration,” he said. “David, Andrew, Peter and Guillaume led the team that brought together skills in cancer research, structural biology, medicinal chemistry and clinical translation that, when combined with the strengths of our commercial partners AbbVie and Genentech, enabled us to see a laboratory discovery translated into a new medicine.”

“I hope the recognition the Clunies Ross Knowledge Commercialisation Award provides to this team will inspire other Australian researchers to pursue similar journeys.”

The Walter and Eliza Hall Institute acknowledges the contributions of its funding partners to its cell death research, including the Australian Cancer Research Foundation, the Australian Government, Cancer Council Victoria, the Leukaemia Foundation of Australia, the Leukaemia and Lymphoma Society, and the Victorian Government.

This story was originally posted on the WEHI website.

ACRF has supported WEHI Institute by providing three grants, totalling AUD 5.5 million towards cutting-edge cancer research equipment and technology.

The strength of a mother’s love: Tax time campaign 2018

Donate now

“You always knew exactly where my mum was. Before you even saw her – you heard her big, infectious laugh. It was her trademark.

Last year, I watched helplessly as cancer took her away from us. Within weeks of her liver cancer diagnosis, she was gone.

Losing her has been the single most devastating event that I have ever experienced. I couldn’t stand by and let cancer continue to affect our loved ones in such a cruel way.

Remembering my mother lost to cancer

My mum saw the good in people and gave her love freely and openly, and that has left a lasting impression upon all who knew her.

No matter who you were, my mum was always there with a heartfelt smile and her unique way of making the worries of your day disappear.

She had so much zest for life, and it makes me so proud to know that’s how she is remembered, warm and bright.

I was fortunate to have known my mum very well. I’m an only child, and throughout my 39 years, I shared a wonderful relationship with both of my parents. The three of us supported each other through everything. My parents sacrificed so much for me, especially Mum, who was undoubtedly the most selfless person you would ever meet.

As a reminder of my mother’s legacy of happiness, joy and love I had the soundwave of her trademark laugh tattooed on my inner bicep to represent strength. It is my first and only tattoo and is my way of keeping her close to my heart, and under my wing.

How Scott supported cancer research

Soon after Mum passed away, I decided to take action to help Australian researchers find better ways to prevent, detect and treat all cancers. I’m determined to do everything I can, to stop others from feeling the unbearable pain and heartache caused by cancer.

My mum loved me like no other, but she wasn’t that keen on my long beard – she said it hid my face. I decided that I would shave it off for cancer research. With the help of my friends and family we raised over $12,000.

I was blown away by the result – it showed me that, “a snowflake is frail, but if enough of them stick together, they can stop traffic”.

To honour my mum, I hope that I can help others live a long and fulfilling life. Cancer affects us all but I know that together we will outsmart it.”
– Scott, ACRF supporter

Make a tax-deductible donation to ACRF and help fund ground-breaking cancer research

A tax deductible donation to ACRF will help us achieve our mission of outsmarting cancer by providing world-class scientists with the equipment they need to improve prevention, diagnosis and treatment of all types of cancer.

Learn more about how tax deductible donations work and how they can boost your tax return here.

Donate now

Prostate cancer patients to benefit from targeted radiation delivery

Some men with aggressive prostate cancer will benefit from targeted radiation therapy. The new therapy, utilising radioactive material sourced from Australia’s Lucas Heights nuclear reactor, has produced dramatic responses in some men with aggressive prostate cancer and who have failed current therapies.

The treatment, LuPSMA (Lutetium-177 PSMA-617), involves a radioactive molecule that is purpose made to bind to prostate cancer cells, enabling the targeted delivery of radiation to kill these tumours.

LuPSMA was also seen to reduce bone pain and improve quality of life in the proof-of-concept clinical trial which involved 30 patients – a world-first on this scale. Results of the Peter Mac-sponsored Phase II, single-arm study have been published online by Lancet Oncology.

Professor Michael Hofman, who led the trial at Peter Mac, said the responses were remarkable and supported starting a larger, randomised and multi-site trial of LuPSMA.

“Our small proof-of-concept trial shows that LuPSMA is highly active in men with aggressive prostate cancers, and it can trigger striking responses in some men,” said Prof Hofman.

“That LuPSMA was able to achieve this in men who have exhausted conventional treatment options is remarkable, and we now look forward with great interest and optimism to results of our Australia-wide TheraP trial now underway.”

The TheraP trial (ANZUP 1603) – which commenced once the positive results of Peter Mac’s proof-of-concept trial were known – is a partnership between ANZUP Cancer Trials Group Limited (ANZUP) and Prostate Cancer Foundation of Australia (PCFA).

The primary goal of Peter Mac’s proof-of-concept trial was whether LuPSMA could reduce PSA (Prostate Specific Antigen) levels by more than 50%. PSA is a blood biomarker for prostate cancer, so lowering PSA levels in men with advanced disease indicates a reduction in cancer activity.

After LuPSMA, all but one of the men saw a decline in PSA levels. More than half (57%, 17 of 30) showed at least a halving of their PSA levels – meeting the goal. Notably, in six of the men (20%) exceptional responses were seen with PSA levels becoming close to undetectable. Full body scans also confirmed dramatic changes in men before and after receiving LuPSMA (see below).

“Some men also reported LuPSMA gave them rapid relief from otherwise severe bone pain and they had more energy for daily tasks and to enjoy their family time,” Prof Hofman said, noting the treatment was well tolerated with no immediate adverse effects and no treatment-related deaths.

LuPSMA is a personalised treatment using a concept called “theranostics”. This combines a diagnostic test and targeted therapy. First patients undergo a PSMA PET scan to see if the tumours “light up” reflecting adequate expression of the target. Only if suitable do they proceed with treatment. Peter Mac has a long history of expertise in theranostic therapies which enabled the team to perform this world-first study.

Recruitment for the larger ANZUP/PCFA TheraP trial (ANZUP 1603) is underway with trial sites now open in Victoria, NSW and Queensland and soon to open in WA and SA.

ANZUP Chair, Professor Ian Davis, says ANZUP was delighted to work with Prof Hofman to launch this important study in partnership with PCFA and: “Clinical trials like this are the only way we can find out how well new treatments work, whether they are safe, and whether they should become the new gold standard for treatment in the future.”

The news was first published on the Peter Mac Website. Image courtesy of Peter Mac, from left to right: Shaun Jenkinson (ANSTO), AProf Anthony Lowe (PCFA), AProf Michael Hofman (Study Chair) and Marg McJannett (ANZUP) at the Lucas Heights reactor.

The Australian Cancer Research Foundation has supported Peter MacCallum Cancer Centre by providing four grants, totalling AUD $7million, towards cutting edge cancer research equipment and technology.

Two clinical trials demonstrate effectiveness of venetoclax

Venetoclax, a breakthrough cancer treatment, is driving a major shift in the management of a range of blood cancers, with two new clinical trials of chemotherapy-free combinations demonstrating dramatic benefits for patients with hard-to-treat leukaemia and lymphomas.

Results of two new venetoclax trials – the MURANO Study involving patients with Chronic Lymphocytic Leukaemia (CLL) and AIM Study in Mantle-Cell Lymphoma (MCL) – were recently published in the New England Journal of Medicine.

Both trials, involving patients whose blood cancer had relapsed or was resistant to conventional treatment, used venetoclax in combination with another targeted drug. These treatment combinations resulted in high rates of patients with no detectable cancer.

“That venetoclax is able to produce such dramatic results in this hard-to-treat patient group is remarkable, and has led to much excitement among blood cancer clinicians globally and the research community particularly in Melbourne where this drug was pioneered,” said Professor John Seymour, Director of Haematology at Peter Mac and RMH.

“The data shows venetoclax should replace chemotherapy altogether in patients with advanced forms of CLL – a practice-changing result which will rapidly translate into the standard of care globally.”

The MURANO study, led by Prof Seymour, involved 389 patients across 109 international trial sites and compared venetoclax plus rituximab to standard immuno-chemotherapy (bendamustine plus rituximab).

Venetoclax treatment was found to more than double the likelihood that CLL patients would live for two years without their cancer recurring (84.9% vs 36.3%), and the proportion of patients who had very few or no detectable leukemia cells in their blood was 83.5%, compared with 23.1% of patients who received standard immune-chemotherapy treatment.

The AIM study, led by Peter Mac’s A/Professor Constantine Tam and trialled at both Peter Mac and RMH, involved 24 patients with MCL. They were treated with venetoclax plus ibrutinib – two drugs expected to have an improved synergistic effect. This was the first ever trial of this scientifically-designed chemotherapy-free combination. Most (71%) patients went on to show no detectable cancer, and 78% of these patients remained cancer free for at least 15 months.

“This was in patients who we expected to have a poor outcome on conventional therapy, and in which treatment with either ibrutinib or venetoclax alone was expected to see only 21% of patients show a complete response,” said A/Prof Tam.

“These very promising results have triggered additional and larger studies to better understand the synergistic benefits of the venetoclax-ibrutinib treatment combination in MCL patients.”
CLL is the most common form of leukaemia in Australia, with around 1000 people diagnosed with the cancer every year. MCL is an uncommon sub-type of lymphoma which is considered incurable in most patients with conventional chemotherapy treatments.

“The development of venetoclax – from basic science through to international clinical trials with practice-changing results – provides a strong example of how Australian cancer researchers and clinicians can lead the world,” said Professor Andrew Roberts, a clinical haematologist at RMH and Peter Mac, researcher at the Walter and Eliza Hall Institute and University of Melbourne, and co-designer of the AIM study.

“Venetoclax selectively targets BCL-2, essentially causing cancerous cells to simply melt away, in many instances.”
The rapidity of this “melting away” can also be problematic for patients leading to the side-effect of tumour lysis syndrome. This affected six patients in the MURANO Study and two in the AIM Study, but was managed safely in all cases.

Venetoclax is a targeted drug in tablet form that was developed based on scientific discoveries made at the Walter and Eliza Hall Institute of Medical Research. Thanks to the generosity of ACRF supporters, ACRF contributed significantly to the success of the early phases of research into venotoclax.

This news was first posted on the Peter Mac website. Image of Professor Seymour provided by Peter Mac.

Cancer killing clue could lead to safer and more powerful immunotherapies

cancer research scientist
Dr Misty Jenkins from WEHI Institute.

 

New research could help to safely adapt a new immunotherapy – currently only effective in blood cancers – for the treatment of solid cancers, such as notoriously hard-to-treat brain tumours.

The study, led by Dr Misty Jenkins from the Walter and Eliza Hall Institute, explains the crucial mechanisms by which CAR-T cell therapy is able to rapidly target and kill cancer cells, and why it may cause serious side effects.

CAR-T cell therapy is an innovative form of immunotherapy that uses synthetically engineered T cells to redirect the patient’s own immune system to fight their cancer. Approved by the US Food and Drug Administration (FDA) in 2017, it has been successfully used to treat blood cancers such as childhood leukaemia and some lymphomas.

Unfortunately, CAR-T cell therapy has had mixed results in solid cancers, often causing significant side effects such as ‘cytokine storms’ – a potentially fatal inflammatory response that can lead to organ failure in some patients.

Dr Jenkins led the study, working with collaborators Mr Alex Davenport, Associate Professor Phillip Darcy and Associate Professor Paul Neeson from the Peter Mac. It was published today in the journal Proceedings of the National Academy of Sciences.

Dr Jenkins said the new research revealed for the first time how CAR-T cells interacted with cancer cells.

“We found that CAR-T cell receptors have the ability to rapidly identify and bind to tumour cells that would otherwise remain undetected in the immune system, and promptly kill them.

“We have previously shown a correlation between cytokine production and the length of time the immune cells were latched onto the cancer cells. The longer the cells were in contact, the more cytokines were produced, causing ever increasing degrees of damage from inflammation,” she said.

Dr Jenkins said a deep understanding of the biological factors contributing to the success and side effects of CAR-T cells would help to inform a better design and safer delivery methods for the personalised therapy.

“Our research is teaching us how to make CAR-T cells even more efficient, and without the toxic side effects, so that we can safely extend the therapy to cover a broader range of cancers,” she said.

Dr Jenkins said her research focused on how CAR-T cell therapy could successfully be used to treat brain cancer. Brain cancer has some of the poorest survival rates of any cancer in the world and desperately requires new treatment approaches.

“The brain is an incredibly delicate and challenging environment to work within,” Dr Jenkins said.

“Brain tumours are often resistant to traditional treatments, such as chemotherapy; and surgically removing tumours can come with a lot of collateral damage.

“Finding an optimum design for CAR-T cell therapy where we can kill tumour cells with limited invasion, inflammation and side effects could significantly improve the treatment of brain cancer.

“Answering fundamental biological questions about how immune cells and cancer cells function and interact, as we have done in this study, is invaluable in the quest to find formidable treatments for fatal cancers,” she said.

In 2017 Dr Jenkins received a Carrie’s Beanies 4 Brain Cancer Foundation grant and a Financial Market’s Foundation for Children Grant to continue her work to develop CAR-T cell therapies and other forms of immunotherapy for treating children with brain cancer.

The PNAS study was funded by the Australian National Health and Medical Research Council, the Fight Cancer Foundation and the Victorian Government.

Australian Cancer Research Foundation has proudly supported Walter and Eliza Hall Institute of Medical Research since 2001 in their cancer research efforts, providing a total of $5.5 million to date.

This research article was originally published on the Walter and Eliza Hall Institute of Medical Research.

Can our genes help predict how women respond to ovarian cancer treatment?

Ovarian cancerNew research has shown that the genes we inherit can have a significant impact on how the body processes chemotherapy drugs, which may lead to different clinical outcomes for ovarian cancer patients.

Research has identified gene variants that play a significant role in how women with ovarian cancer process chemotherapy.

The research showed that the genes we inherit can have a significant impact on how the body processes chemotherapy drugs, which may lead to different clinical outcomes for ovarian cancer patients.

Lead researcher, Professor Anna deFazio from the Westmead Institute for Medical Research and Westmead Hospital, said this discovery may help doctors predict which patients will respond positively to chemotherapy.

“Chemotherapy and surgery are the standard treatment for women with ovarian cancer, but each patient responds differently.

“We wanted to know why some women respond very positively to treatment, while others suffer serious side effects, and some have a poor response,” Professor deFazio said.

“We set out to understand which genetic factors influence how a patient processes chemotherapy.

“Our research showed that a gene called ABCC2 plays a critical role in eliminating chemotherapy from the body,” she explained.

ABCC2 is a drug transporter, which means it pumps a variety of different substances out of cells.

“We found that variants of this gene are associated with high rates of drug elimination, which means they pump chemotherapy drugs out of the body quickly and may cause the treatment to be less effective.

“This may explain why chemotherapy is an effective treatment for some women, but not for others,” she said.

Professor deFazio said these latest research findings are an important step towards delivering better outcomes for patients.

“Now that we are beginning to understand the role of the ABCC2 gene, and other novel gene variants that were identified in this research, we can work towards developing personalised cancer treatment for patients,” Professor deFazio concluded.

Ovarian cancer is the most lethal gynaecological cancer and ranks as the sixth most common cause of cancer-related death in women in the Western world.

Professor Anna deFazio, and Associate Professor Stuart Macgregor and Professor Georgia Chenevix-Trench at the QIMR Berghofer Medical Research Institute led this research and it was part of a PhD project undertaken by Dr Bo Gao, now a Medical Oncologist at Westmead and Blacktown Hospitals.

Australian Cancer Research Foundation is a proud supporter of Westmead Institute and has provided them with $7 million towards their cancer research efforts.

This article was originally published on the Westmead Institute website.

The full paper is available online at Nature Scientific Reports.

Researchers build tiny DNA nanorobots to block cancer growth

Cancer research scientist
Professor Greg Anderson. Image supplied by QIMR Berghofer Medical Research Institute.

 

Scientists have successfully designed tiny nanorobots made of DNA and protein that can be targeted directly at tumours to stop them from growing.

The study was led by researchers at the National Centre for Nanoscience and Technology in Beijing and the University of Chinese Academy of Sciences and involved Professor Greg Anderson, head of the Chronic Disorders Research Program at QIMR Berghofer Medical Research Institute.

It has been published in Nature Biotechnology today.

Professor Anderson said the nanorobots were made using a technique called “DNA origami”, where specially constructed sheets of DNA were folded up and bound together to form a tube-like structure.

He said the group embedded the blood-clotting agent thrombin within the nanorobots.

“Thrombin is a naturally-occurring protein that causes blood clots to form,” Professor Anderson said.

“This ability can be harnessed to kill tumour cells by developing a system where the thrombin only causes clots in the blood vessels that are feeding the tumour, and not elsewhere in the body.

“When that happens, the tumour cells no longer receive essential nutrients and they die.”

Professor Anderson said the nanorobots were designed so that thrombin was released only after it was “unlocked” by a particular protein found within the blood vessels of tumours.

“The nanorobot keeps the clotting agent disguised until it reaches the place where we want it to act. In this case, that’s the tumour,” he said.

“That’s why this is such a clever delivery method.”

Professor Anderson said it was a highly-innovative example of nanotechnology being used to target tumours.

“This approach is novel in the way the team has combined a number of existing but different elements of nanotechnology to enable the controlled and targeted delivery of the blood-clotting agent,” he said.

“It shows just what is possible with contemporary biomedical technology and hints at what may be the future of intelligent drug delivery.

“Methods like this could potentially be used to deliver a wide range of drugs, and even multiple drugs at once.

“There are really limitless combinations of technologies and drugs that could be tried.

“The applications of the technology are certainly not restricted to tumour development, either.”

The targeted nanorobots also proved highly effective at reducing the growth and spread of tumours with characteristics of breast cancer and melanoma in mice.

Professor Anderson said although the treatment was successful in laboratory tests, it was still some time before the strategy would be tested in humans.

“It is an extremely exciting first step, but more work needs to be done,” he said.

“The term ‘cancer’ covers a broad range of diseases and different types of cancer require different treatments, or combination of treatments.

“Nevertheless, the use of the DNA origami approach potentially provides a new tool that could be used to help achieve the ultimate goal of eradicating primary tumours and their metastases.”

Australian Cancer Research Foundation has proudly supported QIMR Medical Research Institute since 2002 and has provided a total of $8.4m towards their cancer research efforts.

This article was originally published on the QIMR website.

Four ways precision medicine is making a difference

All human characteristics are profoundly influenced by genetic factors, including susceptibility to infectious and complex diseases such as tuberculosis and cancer. Until now it has been virtually impossible to target medicine to a specific individual’s genetic makeup, and medicine has been aimed at the average.

But now “precision medicine” is allowing us to analyse a person’s genetic makeup and target treatments based on their specific needs. A report released this week by the Australian Council of Learned Academies, The Future of Precision Medicine in Australia, notes the cost of sequencing individual genomes has plummeted from more than US$1 billion to US$1,000 over the past 15 years, and continues to fall.

Here are four areas in which precision medicine is making a difference in health care, and some of the ways we hope it will improve health care in the future.

1. Diagnosing and preventing genetic disease

The precision medicine revolution is transforming the diagnosis and prevention of genetic disease. Tragically, at least 2% of all children are afflicted by a severe developmental or intellectual disability, which can result from damage to any one of thousands of genes that encode the proteins we need to function.

Genome sequencing can now identify 40-60% of the affected genes, giving parents and doctors the answers they need to improve treatment.

This information also improves the confidence of parents to have more children, as the problem can be avoided by IVF. For these reasons, the UK National Health Service has recently announced genome sequencing will be used to determine the cause in cases of severe unexplained disability. Hopefully Australia will soon follow suit.

This is just the beginning. The use of genome sequencing for preconception screening of prospective parents is just around the corner, and has the potential to reduce the incidence of genetic disability in our community.


2. Cancer diagnosis and treatment

Cancer is caused by a wide range of cell mutations, but traditional tests do not make clear which of these is driving a particular cancer.

Identification of these mutations has led to the development of effective drugs such as Imatinib, with many more in late stage development. But these are expensive and can be applied only if the precise target is known.

Countries such as the United States, United Kingdom and France are trialling sequencing the cancer’s DNA in order to better target treatment. Unpublished, emerging evidence indicates a substantial improvement in survival, but surprisingly, an overall reduction in costs. This appears to be due to fewer episodes of patients requiring acute care.

Some of the outcomes of genomically-informed cancer treatment are spectacular. I am aware of two children locally with lethal cancers, one of whom was close to death, who have been apparently cured as a result of prescribing the correct drug (which had never before been indicated in the cancers concerned) following genome analysis.

We can also increasingly predict an individual’s risk of getting cancer by analysing genes known to be involved in cancer. A recent study using MRIs of people judged at high risk of cancer because of an inherited mutation in a cancer-causing gene showed 10% already had tumours that weren’t yet causing symptoms. These could then be readily removed.

3. The suitability of medicines

A high proportion of hospital admissions in Australia and other countries are due to toxic reactions to prescribed medications. And many medications are useless in some people.

The main reason for this is we have different forms of the liver enzymes that clear chemicals from our bloodstream, which in turn affects their concentration and how long they last. By necessity, prescriptions are directed at the average.

There are also rare gene mutations that make some medications lethal for some people. Genome analysis can predict and avoid many of these adverse reactions or unproductive prescriptions, saving enormous amounts of money and making medication more personal and precise.

4. Population health data

Given the benefits of genome sequencing for individual health, it’s assumed most people will consent, and have the results incorporated into their personal medical records. Amalgamation of this information with clinical records will provide rich data that can be mined for biomedical discovery, as well as for better management of medical systems and resource allocation.

Personal wearable and implantable devices that can monitor physiological responses (sleep, blood sugar, blood pressure, medication compliance, etc.) will contribute the other half of the personal picture by providing real-time information to assist diagnosis, helping people find the best strategies for improving their health.

The ConversationMedicine will become one of the most data-intensive industries on the planet, changing from the art of crisis management to the science of good health. This will have a transformative effect on health, both individually and systemically, with enormous implications for national economies.

John Stanley Mattick, Executive Director, Garvan Institute of Medical Research, Garvan Institute

Australian Cancer Research Foundation has provided Garvan Institute with $6.1 million towards world-class cancer research projects.

This article was originally published on The Conversation. Read the original article.

Carrie’s birthday bash fundraiser

Charity fundraising eventMy recent 40th birthday celebration with 100 nearest and dearest friends and family was held in memory of my loved friend Anna. On the night, we raised just over $7,000 for ACRF by participating in the Birthday Donations In lieu of Gifts program.

Never comfortable being the centre of attention, I had no intention of having a birthday party. Turning 40 is something of a milestone birthday but all I had in mind was dinner out with my mother, husband and our three young children. Then Anna lost her battle with bladder cancer, suddenly and unexpectedly, which of course had a profound effect on her family, my family, and our mutual friends. So I decided to throw a party to both celebrate life and fundraise in Anna’s memory. I wanted to make a difference, however big or small, to cancer research and awareness. Anna would have loved the big party idea because she had been thinking of ways to help raise bladder cancer awareness when she was going through treatment. Anna didn’t have her chance at raising funds for cancer research but I could do it for her.

The list of my friends and family who have either been affected by cancer or lost their battle to cancer goes on and on. Closest to home was my dad who died of bladder cancer when he was only 56 years old. Losing dad was, without a doubt, the worst day for my mum, my younger brother and me. All of us still miss Dad so much and not a day goes by without thinking of him. He was a wonderful father and husband and an inspiration to us. I am so sorry that he can’t be here with us today.

It is hugely important to me to support the work of the Australian Cancer Research Foundation because my mother has had a few run-ins with breast cancer over the years. If it wasn’t for the research, I doubt that Mum would still be with us today; she has now beaten the cancer twice. Mum is an amazing and strong woman and I’m very proud of her. Both my mother and father are the type of parents any kid would dream of, and I have been so fortunate to have them in my life.

I genuinely hope that raising money can help save the lives of others affected by cancer, and ensure that other young families will live a full life together. I was comfortable asking for donations rather than gifts for my birthday, and it certainly helped that ACRF is a genuine foundation with a long history of funding ground-breaking cancer research. It was also easier for me to push people to “dig deep” knowing that all of the money donated is tax deductible. I would encourage anyone thinking about fundraising to just go ahead and get started. If you don’t ask, you won’t receive, and every dollar counts!

It was a great feeling on my birthday to receive such wonderfully generous support from friends and family. Knowing that we can somehow make a difference to ensuring that cancer research continues is the best gift.

 

Share your story

Brighid gets a buzz cut

Headshave eventMy aunt passed away a few years ago to cancer and that really opened my eyes to the struggle that cancer patients go through. Despite so many advances in diagnosis and treatment over the years, there is still not a lot of hope for a cure for some types of cancer. I decided to support cancer research because it is the only way to find those breakthroughs that will end all cancers.

I am nearly 16 now, in grade 10 at high school, love playing volleyball with the Dragons, and spending time with my friends. When looking at ways to raise money, I decided on getting a buzz cut. It was a simple way to fundraise, and I really liked that my hair would be donated to make a wig for a child going through cancer treatment.

Choosing which is the best cancer organisation to support can be confusing. I came across ACRF during an internet search, liked what they’re doing to fund research into all types of cancer, and found it very easy and efficient to create my own personal fundraising page on their website.

Thanks to my generous friends, family and with my own donation, it was awesome to exceed my goal of raising at least $2,000. I’d say to anyone who wants to fundraise to just reach out to as many people as you can, in every way that you can. Raising money and awareness for cancer research is something we can all support.

 

Share your story

Josh completes Honolulu marathon 2017

charity fun run

In December 2015, Joshua Toth, his wife Jane and son Charlie were overjoyed to welcome baby Luke into their family. However, at ten weeks old, Luke was diagnosed with a rare and aggressive Rhabdoid tumour. Despite the best efforts of a team of doctors and nurses at Westmead Children’s Hospital, Luke passed away at six months of age.

“Never in a million years did I think our family would experience what we have in the past two years. Not a day goes by that we don’t wish it was possible to see Luke again. Losing a child to cancer also has us constantly thinking of ways to ensure that no other family has to endure what we’ve been through. For the past two years, Jane and I have been drawn to organisations that dedicate their time, money and effort towards research that will hopefully lead to all forms of cancer becoming a curable disease in the near future. In 2016, our family and friends raised a reasonable amount of money for Children’s Cancer Institute of Australia.

I happened across the ACRF running fundraising site in January 2017 while doing some web searches on various organisations that support cancer research. I was inspired by ACRF’s mission to end cancer and one phone call to them was all it took for me to decide to fundraise for ACRF as part of my participation in Honolulu Marathon 2017. Taking on what is described as 26.2 miles in paradise was going to be challenging as my only other distance running experience had been a 10km run in Homebush almost ten years ago. Although I would be 40 by the time the Honolulu marathon got underway in December, it seemed like do it now or never, in my head anyway. Joining in the race with me was my younger brother Brad who has been through a similarly tragic time when his son passed away very soon after birth. We gave the run everything we had on the day and finished within a few minutes of each other in our respective age groups.

It is estimated that over 134,000 Australians will be diagnosed in 2018 with some form of cancer and one out of every two people will be directed affected by cancer. We have made so much progress against other diseases, it’s hard to believe there is still no cure for this insidious disease, especially childhood cancer. I am grateful there are organisations like ACRF that dedicate themselves to cancer research, and thankful that I can contribute to raising awareness and facilitating that research.”

 

Share your story

New HPV vaccine boosts teens’ protection from HPV and cervical cancer

As 12 and 13-year-old boys and girls start a new school year, they will have access to the new, improved vaccine to protect against the human papillomavirus (HPV), which causes cervical cancer in women.

While the previous Gardasil vaccine protected against 70% of cervical cancers, the updated Gardasil 9 version will protect against up to 93% of these. And compared to the three doses required with the previous regimen, only two are needed now.

In Australia, around 900 new cases are diagnosed and around 250 women die from the disease each year. But cervical cancer rates have halved in the past 30 years due to the high quality national Pap cytology screening program.

Prevention against cervical cancer is the main aim of the Gardasil 9 vaccine. But HPV is also linked to a large proportion of anal, vaginal and head and neck cancers, and the vaccine offers protection for these too.


What is HPV?

Genital HPV is a common group of viruses, mainly transmitted through sexual contact, including contact of genital skin to genital skin. Most people are infected with HPV shortly after the onset of sexual activity and most clear the infection on their own.

But for a small number of those infected, the HPV becomes persistent. A proportion of these people will go on to develop abnormal cells that are the precursor to cervical cancer. HPV is the cause of nearly all cervical cancers. But the virus is also linked to 90% of anal cancers, 65% of vaginal cancers, 50% of vulva cancers and 35% of penile cancers and 60% of oropharyngeal cancers (cancers of the back of the throat, including the base of the tongue and tonsils).

The Australian government was one of the first to introduce a free Gardasil vaccine to all female students aged 12 to 13 years in 2007 (with a catch up to the end of 2009 for those up to 26 years of age). This protected against four different strains of HPV. Two of those strains (HPV 16 and 18) cause about 70% of cervical cancers; the other two cause the majority of genital warts (HPV 6 and 11). 

Australia was also one of the first countries to adopt a school-based, gender-neutral vaccine program in 2013, by introducing free, ongoing vaccinations to young boys 12 to 13 years of age.

What does Gardasil 9 offer?

The new Gardasil 9 vaccine, available from this week, targets nine strains, seven of which cause around 93% of all cervical cancers (in addition to HPV 6/11 so protects against 90% of genital warts). It includes protection for the five next most common cancer-causing HPVs globally (HPV 31/33/45/52/58).

The new vaccine has been tested in global clinical trials involving more than 14,000 women in 18 countries, aged 16 to 26 years. They received either the new Gardasil 9 vaccine or the original Gardasil vaccine. Published in the New England Journal of Medicine and the Lancet, the study looked at the rate of pre-cancerous cell changes in women six years later.

It found the new vaccine was far more effective, targeting an extra five of the most common cancer-causing strains of HPV and potentially preventing 23% more cervical cancers. Thus infection with the new types was markedly reduced too. With a reduction in infection, there is a reduction in the diseases that the HPV can cause.

The common side effects with Gardasil 9 in the clinical trial were the same as with the older Gardasil vaccine. These were pain at the injection site, local swelling in the arm at the injection site and redness. There were no differences between the serious adverse events between the two vaccines.

Who should get the new vaccine?

Australia was one of the first countries to adopt an HPV vaccination program and has one of the highest coverage rates, with around 79% of girls and 73% of boys having received the Gardasil vaccine.

Those who have already had the original vaccine have excellent protection from HPV, so we are not recommending they should go back for the new vaccine.

The new vaccine is free to 12- to 13-year-olds as part of the National Immunisation Program. It’s also available at a cost to adults and has been shown effective in protecting against HPV in people up to the age of 45 years.

Those who have not been infected by the strains of HPV gain the most benefit from the vaccine. However, the vaccine boosts the immune response in sexually active individuals who have been infected previously with any of these HPV strains targeted by the vaccine, should they come into contact with the virus again.

Regular screening important

It’s important women continue to have regular screening to avoid abnormal cells developing into cervical cancer, even if they have had the vaccine. In December 2017, Australia’s screening program changed. The Pap test was replaced by a cervical swab testing for HPV DNA. This is a more sensitive test to detect underlying cellular abnormalities than the Pap test.

A five year study involving 5,000 women found the new HPV test was far more effective in detecting high grade pre-cancerous changes to the cervix compared to the traditional Pap test. It has the potential to prevent 30% more cervical cancers.

Women will now have their first test at age 25 instead of 18. After their first HPV test, women will be tested every five years instead of every two years. They will be tested up to age 74, and, in an important development, self-collection will be an option for some women who may have difficulty with a vaginal test.

We are already seeing the benefit of the original Gardasil vaccine on rates of HPV. With high coverage of the new Gardasil 9 vaccine, and adoption of the new HPV screening test it is predicted we will see a rapid decline in the cervical cancer rate in Australia in the coming years.


Suzanne Marie Garland, Professor, Melbourne University, The Royal Women’s Hospital

This article was originally published on The Conversation. Read the original article.

Thanks to the generous donations from our supporters, ACRF has been able to award grants to ground-breaking Australian cancer research projects such as the development of the Gardasil cervical cancer vaccine. In 1999, we awarded a $1 million grant to Professor Ian Frazer and the Diamantina Institute in Queensland to support research into the development of the vaccine.

Melanoma is in the eye of the beholder

University of Queensland researchers have found that freckles and moles appearing on the iris indicate a high risk of melanoma, particularly in people under 40 years of age.

Dermatology Research Centre’s Associate Professor Rick Sturm said the presence of pigmented lesions was an effective predictor of the risk of melanoma that complemented traditional factors.

“We found the presence of three or more iris pigmented lesions was associated with a 45 percent increased risk of melanoma,” Dr Sturm said.

“This association was particularly strong in people under 40.

“The presence of iris freckling and naevi (moles), provides additional information about an individual’s melanoma risk over and above factors like blue eyes, red hair, fair skin and the number of moles on the skin.”

The study, involving Professor H. Peter Soyer and Dr Antonia Laino, involved 1117 participants of European background living in South-East Queensland.

Dr Laino said the results showed that participants with pigmented lesions were 1.45 times more likely to develop melanoma.

“This association was particularly strong in people under 40, suggesting a genetic susceptibility,” she said.

“It also suggests the potential use of these lesions as a marker for melanoma risk in younger patients (1.8 times more at risk).

“Melanoma is the most common cancer in Australians aged 15 to 39.

“Despite many new advances in treatments, long term prognosis remains poor, therefore early detection is still key in reducing the burden of the disease.

“It’s very easy to look for iris pigmented lesions, and we hope that these findings will help doctors identify those people who may be at increased risk of melanoma and need a skin check.”

“These lesions should be used as markers for melanoma risk in younger patients.”

The UQ Diamantina Institute study is published in the British Journal of Dermatology.

ACRF has provided The University of Queensland with $19.2 million in funding for cancer research.

This article was originally published on The University of Queensland’s website.

Countrywide delivers for ACRF

Workplace giving

 

Countrywide Food Service Distributors, Australia’s largest group of independently owned wholesale distributors of goods to a variety of foodservice establishments and outlets, is no stranger to helping charities. Countrywide initially began to support a charity after one of its distributors introduced a silent auction at the company’s National Awards Night. Since that evening, Countrywide has established partnerships with numerous selected charities where they can work together on a longer-term basis.

Most recently, Countrywide was seeking a new charity partner for the 2017/2018 period. When developing a shortlist, they looked for: a charity that had national coverage so that each one of the Countrywide 115 distributors/members could get involved, a charity receiving little or no government assistance, and a charity which Countrywide distributors and suppliers could collectively engage with. As everyone has been touched by cancer in some way, Countrywide was confident that a cancer charity would be the best fit. Countrywide recognised ACRF’s uniqueness in their funding of research for all types of cancer and their mission to end cancer through providing equipment needed to improve prevention, diagnosis and treatment of the disease.

Michelle Wearing, Countrywide Marketing Manager said, “The funding that ACRF is able to provide for grants enables some amazing research to take place. When you hear about the positive results that have been achieved from those research projects and how those results are then implemented to improve patient well-being along with preventing cancer in the first place, it is incredibly exciting.”

Countrywide also values the positive impact that fundraising has on their staff. The company has already held a number of events to raise money for ACRF through staff donations. Those events included a multi-cultural lunch where enthusiastic staff members brought in a national dish to share. It was a lunchtime that celebrated the company’s diversity and enhanced its culture. In addition, Countrywide stakeholders are eager to get involved and support ACRF at the company’s next silent auction.

“Working with ACRF really fits with Countrywide’s Mission, Vision and Values and we look forward to raising more funds for ACRF to continue their great work in cancer research.”

Share your story

Image: Countrywide presented Australian Cancer Research Foundation with $90,000 in donations.

A new blood test can detect eight different cancers in their early stages

Researchers have developed a blood test that can detect the presence of eight common cancers. Called CancerSEEK, the blood test detects tiny amounts of DNA and proteins released into the blood stream from cancer cells. This can then indicate the presence of ovarian, liver, stomach, pancreatic, oesophageal, bowel, lung or breast cancers.

Known as a liquid biopsy, the test is distinctly different to a standard biopsy, where a needle is put into a solid tumour to confirm a cancer diagnosis. CancerSEEK, is also far less invasive. It can be performed without even knowing a cancer is present, and therefore allow for early diagnosis and more chance of a cure.


The test has been shown to reliably detect early stage and curable cancers. It has also been found to rarely be positive in people who don’t have cancer. This prevents significant anxiety and further invasive tests for those who don’t need them.

Several cancers can be screened for at once, and the test can be performed at the same time as routine blood tests, such as a cholesterol check. But the test is still some years away from being used in the clinic.

How the test works

Often long before causing any symptoms, even very small tumours will begin to release minute amounts of mutated DNA and abnormal proteins into blood. While DNA and proteins are also released from normal cells, the DNA and proteins from cancer cells are unique, containing multiple changes not present in normal cells.

The newly developed blood-based cancer DNA test is exquisitely sensitive, accurately detecting one mutated fragment of DNA among 10,000 normal DNA fragments, literally “finding the needle in the haystack”.

We used CancerSEEK in just over 1,000 people with different types of early stage cancers. It was shown to accurately detect the cancer, including in 70% or more of pancreas, ovary, liver, stomach and esophageal cancers. For each of these tumour types there are currently no screening tests available – blood based or otherwise.

Along with cancer detection, the blood test accurately predicted what type of cancer it was in 83% of cases.

Published in the journal Science, the research was led by a team from John Hopkins University, with collaboration from Australian scientists at the Walter and Eliza Hall Institute.

Why it’s important

Steady progress continues to be made in the treatment of advanced cancers, including major gains in life expectancy. But this can come at significant physical and financial cost. Early diagnosis remains the key to avoiding the potentially devastating impact of many cancer treatments and to reducing cancer deaths.

However, where there are proven screening tests that lead to earlier diagnosis and better outcomes, such as colonoscopy screening for bowel cancer, these are typically unpleasant. They also have associated risks, only screen for one cancer at a time and population uptake is often poor. And for many major tumour types there are currently no effective screening tests.


There are characteristic patterns of mutations and altered proteins that differ among cancer types. So CancerSEEK can not only detect that there is a cancer somewhere in the body but can also suggest where to start looking.

For example, if the pattern suggests a bowel cancer, then a colonoscopy is a logical next step. When blood samples were taken from over 800 apparently healthy controls, less than 1% scored a positive test. This means the test is rarely positive for people who don’t have cancer, thereby reducing the problem of overdiagnosis.

Overall, these results appear to be in stark contrast to previously developed blood-based tests for cancer screening. Currently the only widely used one of is the prostate specific antigen (PSA) test for prostate cancer. This has multiple limitations and some would argue the jury is still out on whether PSA based testing does more good than harm.


What next?

The ConversationLarge trials are now underway in the US, with CancerSEEK testing being offered to thousands of healthy people. Cancer incidence and outcomes in these people will be compared to a control group who do not have testing. Study results will be available in the next three to five years.

Peter Gibbs, Professor and Laboratory Head, Walter and Eliza Hall Institute

This article was originally published on The Conversation. Read the original article.

 

Australian Cancer Research Foundation supports The Walter and Eliza Hall Institute and has provided their researchers with $5.5 million in funding towards cancer research.

 

Image: Peter Gibbs, Walter and Eliza Hall Institute

Breast cancer linked to chronic disease later in life

Women who receive hormonal therapy for breast cancer are at increased risk of developing chronic conditions later in life, according to new research published in the Medical Journal of Australia.

Researchers from Flinders University and the University of South Australia found that rates of depression, osteoporosis, diabetes, cardiovascular conditions, chronic pain and gastric disorders were higher among breast cancer survivors who had received hormonal cancer treatment than among those without breast cancer.

Hormonal therapy, also known as endocrine therapy, is currently used to reduce the risk of cancer recurrence for 70% of breast cancers in Australia.

It is typically administered after surgery or a course of chemotherapy, and/or radiation.

“Knowing that hormonal therapy may predispose women to develop chronic illnesses gives us the chance to develop effective, long-term models of care for these patients,” says Flinders University Professor and co-researcher of the study, Bogda Koczwara.

“Developing the strategies and tools to manage co-existing chronic conditions after breast cancer should now be an essential part of every patient’s overall treatment plan.”

The study compared the health of two groups of women over a ten-year period, the first group comprising women who were receiving hormonal therapy for breast cancer and the second group comprising women of a similar age who did not have breast cancer.

The emergence of chronic disease and the frequency with which it developed was mapped in both groups.

“Our study clearly found that chronic illnesses developed more frequently in women with breast cancer than in those without breast cancer,” Professor Koczwara says.

“We also found that the risk for developing chronic illnesses among women with breast cancer was greatest during their first year of hormonal therapy.

“Some of this risk may be attributable to hormonal therapy, and some of it may be the effect of the cancer itself or its earlier treatment.

“Hormonal therapy is still a very important treatment option for women with hormone responsive cancer, but we need to manage its subsequent impact on long-term health in a more informed and impactful way,” says Professor Koczwara.

The study was the first of its kind in Australia to comprehensively examine the relationship between breast cancer treatment and the development of successive chronic disease using the analysis of prescribing patterns.

“The good news is that most women diagnosed with breast cancer in Australia can be cured and we now have a way of using routine data to monitor the risk of chronic disease after cancer,” Professor Koczwara says.

“The next step is to prevent these conditions from developing through healthy lifestyle habits, exercise, diet and other strategies.”

Professor Koczwara is supported by the National Breast Cancer Foundation and is located at the Flinders Centre for Innovation in Cancer.

Her co-researchers on this study include Huah Shin Ng, David Roder, Theo Niyonsenga and Agnes Vitry from the University of South Australia.

The full findings of the study can now be read in the published paper: Ng HS, Koczwara B, Roder DM, Niyonsenga T and Vitry AI. ‘Comorbidities in Australian women with hormone-dependent breast cancer: a population-based analysis’, Medical Journal of Australia, 15 January 2018, vol. 208, no. 1, pp 24-28, doi: 10.5694/mja17.00006.

This article was originally published on the Flinders University website.

Australian Cancer Research Foundation has provided Flinders University with $1 million in funding towards cancer research.

Image: The Cardrona Bra Fence in Central Otago, New Zealand. Photo: Michael Whitney, Flickr Creative Commons.

Three charts on: brain cancer in Australia

While survival rates for most cancers continue to improve in Australia, brain cancers aren’t seeing the same success. Australians diagnosed with brain cancer had around a 25% chance of surviving for five years from 2009 to 2013. This was compared to a survival rate of 68% for all cancers combined in the same period.

Brain and central nervous system cancers (CNS) can be either malignant or benign, but unlike benign tumours in other tissues, all brain and CNS tumours are associated with significant sickness and death.

Survival rates

It is estimated that 2,076 new cases of brain and other CNS cancers will be diagnosed in Australia in 2017. Around 1,500 people will die from this disease.

While the survival rate is 25% for brain cancer in general, for certain brain cancers it’s much worse. For instance, glioblastoma, the most common form of brain cancer in adults, has a five year survival rate of 4.6%.

So why hasn’t there been an improvement in survival in the last 30 years for patients with brain tumours? A frequent problem is that it’s hard for drugs to actually get to the tumour. The brain has a unique defence, termed the “blood-brain barrier”, that limits the passage of drugs from the bloodstream into the brain.

 

Indeed, most chemotherapies are stopped from getting to the brain by the blood-brain barrier. Those that do, such as temozolomide used to treat brain tumours including glioblastoma, unfortunately have limited efficacy, and only improve survival by several months at best. There is clearly a desperate need to identify new drug targets and more effective therapies for brain tumour treatment.

Incidence rates

Incidence rates for brain and CNS cancers have stayed steady for some decades but the sickness and death that comes with the disease continues to affect many Australian lives. A recent report from the Australian Institute of Health and Welfare shows that the incidence of many cancers has increased over time.

In many cases this is due to our ageing population, as cancer is more common in older age. But other lifestyle factors also play a role. For example obesity, type two diabetes and alcohol consumption are three major risk factors for liver cancer, rates of which have increased.

The incidence of some other cancers has decreased though. In the case of lung cancer, this is likely due to a decrease in smoking. While the introduction of a vaccine for the human papillomavirus (HPV) (which is responsible for most cases of cervical cancer) would explain the drop in cervical cancer rates.

In comparison, the overall incidence of brain cancer has remained stable over the last 30 years, probably because there are no known lifestyle or environmental factors that contribute to these cancers. While we don’t know what causes brain and CNS tumours, there is evidence to suggest genetics and high levels of radiation may play a role.

Childhood brain cancer

While many cancers almost exclusively present in older people, this is not the case with brain tumours, as these kill more people under 40 than any other cancer.

Perhaps of most concern is that brain tumours disproportionately affect children, killing more children (aged 1-14 years old) in Australia than any other disease. They are only third to land transport accidents and congenital and associated abnormalities as causes of child death in Australia.

The prognosis for children with brain cancers, the most common being medulloblastoma, is much better than in adults though. Around 70% of these patients will have curable disease.

But, undergoing life-saving treatment such as surgery, chemotherapy and radiation comes at a long-term cost for these children, as these therapies themselves are associated with detrimental effects on childhood development. These can potentially result in neurological defects, learning difficulties, growth abnormalities and mental health issues.


The ConversationThe Australian government recently announced a A$100 million dollar medical research fund committed to doubling the survival rates and improving the quality of life of patients with brain cancer over the next ten years. It is hoped with this substantial investment, progress will be made to eventually defeat brain cancer.

Melinda Tea, Research Associate, Centre for Cancer Biology, University of South Australia and Stuart Pitson, NHMRC Senior Research Fellow, Centre for Cancer Biology, University of South Australia

This article was originally published on The Conversation. Read the original article.

Tony turns on the Christmas lights again for ACRF

Christmas charity fundraising

Prior to settling in Australia, Christmas for our family in the UK was always celebrated in cold and wintery weather. Decorating our house in Lake Macquarie with outdoor lights really began as a way to feel more festive in a warm climate. We started 12 years ago and, over time, it has developed into quite a hobby. My wife and I have three adult sons and ever since our eldest, Adrian, joined in with the decorating, each year’s display has become bigger and better.

This Christmas will be the second year that we’ve raised money for ACRF with donations from anyone who comes to see our lights. When both my wife and I first decided to support a cancer organisation, and after doing some research on the internet, we quickly agreed that ACRF was the one for us. We liked what they were accomplishing. Most people have a family member or friend or acquaintance who has faced cancer. A lot has been done through research to advance treatments, but there is still a long way to go to eradicate or minimise cancer and its devastating effects. My mother died of liver cancer and my family is predisposed to developing bowel cancer so I am acutely aware of what might happen to us in the future.

Setting up each year’s Christmas display does take time, a lot of time. I’m a civil engineer by profession, so you can imagine the amount of planning and structuring that goes into the entire process. It has taken 186 hours this year to set up, working most Saturdays and Sundays in November. As the front lawn is used for six weeks with part of the display and the grass has to be kept short, half-way through we remove all the lights, mow the lawn and then set up again. It takes four hours to accomplish that 15 minutes of mowing!

The complexity of the display has evolved over the years. Five years ago, we started to include computer controlled lights that flash on and off in time with music. More recently, we introduced special RGB lights so we can change every bulb to any colour we like, and then my sons presented me with a snow machine which we use on weekends during the display. The kids love it! This year’s innovation is projections of Santa in the windows waving and getting presents ready. Once the Christmas season is finished, we spend many more hours taking down the display, cleaning and testing all the lights and then carefully packing everything away. We usually don’t complete the task until early February.

In 2017 we had a good-sized flow of people who viewed the lights and who also made a donation. We successfully raised $2,800 for ACRF, and we want to match or exceed that amount this year. The reality is that cancer can affect anyone at any time so everyone should try to do their bit to help. So please come by, see the lights and help support cancer research.

 

Share your story

Study reveals a role for micro-RNAS in cancer cell survival

A collaboration between the Garvan Institute of Medical Research and Peter Mac has shed light on how cancer cells can precisely control their behaviour through the action of tiny micro-RNAs. They found these small molecules can make a very big impact on whether a cancer cell lives or dies.

Published in the journal Nucleic Acids Research, the study led by Dr Iva Nikolic at Peter Mac and A/Prof Alex Swarbrick at the Garvan has identified which micro-RNAs (miRNAs) are important in determining whether a cancer cell survives.

miRNAs are small strands of genetic material that have the power to control what signals get turned on and off inside a cell. Through this activity miRNAs can control how a cancer cell behaves, from how they divide to how they spread through the body, and even how they respond to treatments.

There are thousands of different miRNAs in every cell, but until now it has been difficult to assess which of these are important in cancer.

“Most other studies into miRNAs in cancer have looked simply at how many miRNA molecules are in a cell, but not at what they are doing,” says the study’s lead author, Dr Iva Nikolic, senior postdoctoral research fellow at the Victorian Centre for Functional Genomics (VCFG) at Peter Mac.

Dr Nikolic, who was at the time a visiting scientist at Peter Mac from A/Prof Alex Swarbrick’s laboratory at the Garvan, conducted her research largely within the VCFG using high-throughput technologies headed by A/Prof Kaylene Simpson.

“In our study we used techniques that allowed us to either mimic or stop the action of individual miRNAs inside cancer cells and looked to see whether the cells survived or died,” explains Dr Nikolic.

miRNAs are powerful molecules inside a cell with the ability to regulate the expression of not just one, but many different downstream genes.

“By targeting single miRNAs we were able to study the function of whole gene networks and determine their importance in cancer cell function.”

Another unique feature of the study was its assessment of many different cell lines representing diverse cancer types, allowing scientists to draw closer connections between gene expression and cell behaviours that has not been possible in smaller studies.

“We studied the action of each miRNA in the contexts of different cancer types and found quite big differences. For example, miRNAs in breast cancer cells act in different ways to miRNAs in prostate or brain cancer cells.”

“Therefore, miRNA-dependent regulation of cancer is likely determined by the cell type from which the cancer was originally derived. This will help us think about better treatments tailored for cancer type,” says Dr Nikolic.

The study authors also developed a web-based portal that will help cancer researchers from all over the world predict direct targets of individual miRNAs within cancer cells. This may aid the identification of new targets for anti-cancer therapies.

“It was an important aim of the study to create a resource for other scientists to be able to learn from our research. We hope this will help to find new insights into how cancers work and drive new discoveries.”

ACRF has provided $7 million in cancer research funding to Peter Mac and $6.1 million to Garvin Institute.

This article was originally published on the Peter Mac website.

Image: Dr Iva Nikolic and a research colleague from the Victorian Centre for Functional Genomics (VCFG) at Peter Mac.

Missing DNA fragments hold clue to predicting childhood leukaemia relapse

Australian cancer researche
Image courtesy of the Children’s Cancer Institute.

Australian researchers have developed a new risk scoring system for children with leukaemia based on missing DNA fragments or ‘microdeletions’.

The risk score will allow doctors to better predict the chance of relapse of a subgroup of kids currently hidden in a lower risk group. The finding was published today in the British Journal of Haematology.

The international study, led by Australian researchers at Children’s Cancer Institute, discovered that searching for specific gene microdeletions found only in leukaemia, when combined with two other test results, provides doctors with a more accurate way to categorise patient risk than the current approach.

The study tested 475 patients from 6 different children’s hospitals in Australia and New Zealand enrolled on a clinical trial sponsored by ANZCHOG, the Australian and New Zealand Children’s Haematology and Oncology Group.

The patients were all children with non-high-risk B-cell precursor acute lymphoblastic leukaemia (BCP-ALL), a subtype of acute lymphoblastic leukaemia (ALL), the most common childhood cancer with survival rates typically near 90%. Most children with ALL have B-cell precursor acute lymphoblastic leukaemia.

Study leader, Associate Professor Rosemary Sutton, said the most intensive treatment for BCP-ALL patients was usually given to the 11% or so of children in the high-risk category to limit side effects for kids who don’t need it.

“Children in the standard and medium risk category in the study were given less intensive treatment than high-risk patients. But about one in six of them relapsed. Obviously, some children needed more intensive treatment than previously thought – but which ones?” she said.

A/Prof Sutton said she and her collaborators developed a new kind of risk score which builds on a bone marrow test, the minimal residual disease or MRD test developed at Children’s Cancer Institute, which gives doctors early warning that treatment may not be working.

The MRD test is so sensitive it can detect just one cancer cell in a million bone marrow cells surviving cancer treatment. The test was a huge boon for some children with leukaemia on this same trial, since it alerted doctors that they had a very high risk of relapsing.  Consequently, they were treated very intensively with chemotherapy and bone marrow transplants, and the survival rate of this subgroup doubled. But MRD alone is not enough.

“For the standard to medium risk group, we needed more information to get a better handle on the biology of the child’s cancer to better determine their risk”, said A/Prof Sutton.

“So, we supplemented MRD results with two other pieces of patient information, the presence or absence of specific gene microdeletions and a score called the NCI (National Cancer Institute) risk, based on age and white blood cell count.

“We tested for microdeletions in 9 genes involved in leukaemia and found that two of the genes, IKZF1 (called ‘Ikaros’) and P2RY8-CRLF2, were important predictors of relapse,” she said.

These measures were combined to calculate a risk score for each patient of ‘0’ (no risk factors), to ‘2+’ (several). The study found that children with a ‘2+’ score were most likely to relapse or die within 7 years after treatment started, while those with a ‘0’ score least likely.

The same microdeletions were found to be important for predicting relapse in a cohort of Dutch children with leukaemia and the new scoring system was validated by researchers in The Netherlands.

If the new risk score system is adopted in future, doctors could give children with a ‘2+’ risk more intensive treatment with the aim of improving their survival.

Dr Toby Trahair, paper co-author and oncologist at Kids’ Cancer Centre at Sydney Children’s Hospital, Randwick said the scoring system could make a big difference to the success of childhood leukaemia treatment.

“We are always trying to improve how we diagnose and treat children with this most common childhood cancer. This risk score will mean doctors can fine tune a child’s risk category and so fine tune their treatment.

“It will mean more kids can conquer this horrible disease, which only 50 years ago had survival rates of close to zero” he said.

The study included researchers from Children’s Cancer Institute, UNSW, The Children’s Hospital at Westmead, Women’s and Children’s Hospital in Adelaide, John Hunter Hospital in Newcastle and Sydney Children’s Hospital, Randwick as well as researchers in The Netherlands and Germany.

ACRF is a proud supporter of the Children’s Cancer Institute and has provided $5.2 million in funding towards their cancer research.

This story was originally published on Children’s Cancer Institute’s website.

Researchers show aspirin added to cancer drug improves effectiveness

Adding aspirin to some existing cancer drugs could increase their effectiveness against a group of tumours resistant to treatment, new research has shown.

University of Queensland scientists are hoping clinical trials could soon be underway for people with lung, pancreatic and colorectal cancers that have not responded to other therapies.

UQ Diamantina Institute researcher Associate Professor Helmut Schaider said cancers driven by mutations in a group of genes, known as RAS, had a low response to treatments with currently no drug directly targeting them.

The group of tumours includes some pancreatic, lung and colorectal cancers with very low survival rates, as well as a small percentage of melanomas.

“We found the addition of aspirin to a cancer inhibitor drug, Sorafenib, strongly enhanced its effectiveness against mouse models of lung cancer and melanoma with RAS mutations,” Dr Schaider said.

“In a multicentre phase three trial for non-small cell lung cancer, Sorafenib alone showed a marginal improvement for patients.

“Our research suggests its combination with aspirin could benefit patients with RAS mutations who don’t otherwise respond to other treatments.”

Dr Schaider said the drug combination could potentially reduce the dose of Sorafenib required, improving quality of life for patients by reducing adverse impacts that can lead some patients to stop treatment.

“By combining it with a relatively high dose of aspirin, two molecular processes are activated and together they work to kill RAS mutant cancer cells.

“This dual activation also might prevent the tumours acquiring resistance to the treatment, which can happen when the inhibitor drug is given alone.”

Dr Schaider said adverse effects of aspirin also needed to be considered, but the doses required would be most likely clinically manageable for patients who have no remaining treatment options.

“A clinical trial of the combination could proceed relatively quickly, potentially piggy-backing on other testing already underway.”

Dr Schaider, based at the Translational Research Institute, said the dual therapy approach could improve the length of time cancer patients have without their disease progressing.

“We believe adding aspirin could also potentially prevent relapse of tumours in patients.”

The research involved Princess Alexandra Hospital oncologist Dr Victoria Atkinson along with scientists from UQ’s Dermatology Research Centre, Mater Research Institute-UQ, and The Wistar Institute in Philadelphia.

Investigations are already underway into combining aspirin with other cancer-inhibiting drugs.

The research is published in Clinical Cancer Research.

ACRF has supported UQ Diamantina Institute since 1999 and has provided $6.2 million in funding towards their cancer research efforts.

Edward is a fundraiser at age 2

charity fundraising eventWe, Jayne and Onan, are the proud and happy parents of a beautiful son, Edward. Originally from the UK and Turkey, we have made Sydney our home for almost 10 years. We work hard during the week in marketing and finance and enjoy taking Edward to the beach on the weekends.

When Edward recently celebrated his second birthday, we organised a party with a theme of his favourite things – trucks and construction. Of course, there was also food, balloons, playtime, laughter, singing, and a special birthday cake. What was unusual for a toddler’s birthday party was our request that everyone make a donation to ACRF rather than bring birthday presents for Edward. Our son is fortunate to already have an abundance of toys, and we thought it would be a special gift for him to contribute to the important cause of cancer research.

Cancer affects so many people, and we’ve experienced one of our nearest and dearest suffer from cancer. Onan’s father sadly passed away from lung cancer three years ago.
We decided to fundraise for ACRF as we’re particularly interested in how they have contributed to impactful projects such as providing the seed funding for the world’s first HPV vaccine. We are impressed that projects which receive funding undergo strong scrutiny by a panel of eminent doctors and scientists.

We are extremely happy to have made Edward’s birthday party into a uniquely meaningful occasion. Friends and family who attended were all very positive about our fundraising efforts and made generous donations. Edward had a wonderful day and we look forward to sharing the story him when he is older.

 

Share your story

Tiffany becomes an ACRF regular giver

Regular givingIf I had a personality label, it would read highly motivated and very energetic! I am 47 years old and my husband and I are the parents of two beautiful teenagers. I also work in the busy role of General Manager for a land survey practice. Life often gets absurdly hectic with juggling all of our schedules, but we are a happy and healthy family.

Having previously worked with a medical research institute as the finance manager left me with a good understanding of how much medical research relies on funding support. I chose to become a regular ACRF giver because I particularly like how ACRF funds cancer research of all types.

Sadly, cancer touches all of us at some point. The first time I encountered the disease was with my grandfather. The memory of going to see him during his last few days remains vivid. Although told that he might not remember me, his face lit up when I walked into the room and greeted him. I burst into tears and cried; it was the last time that I saw him.

The next cancer encounter was with my gorgeous father. Some 10 years ago he was diagnosed with non-Hodgkin’s lymphoma, and I will always remember how upset we were at the possibility of losing him. Dad recovered fully from that cancer, only to suffer squamous cell carcinoma a couple of years ago. The wound healing process after radiotherapy was long and painful but thankfully he pulled through again. I dread the thought that Dad might face another round of cancer at some point in time.

In more recent times my sister-in-law, Deb, was diagnosed with breast and secondary cancer, and my brother in law is currently receiving treatment for lung cancer. My understanding of his cancer is that it can be managed, but not cured. Deb and Trevor are beautiful people and it’s a long road ahead for them both.

Finally, during the past few weeks, the wife of one of my work colleagues was diagnosed with both breast and lung cancer. They are devastated and trying to come to terms with what their future holds.
There are only so many hugs and good wishes you can send when someone you know is confronted with the distressing news of cancer. I want to honour them all by giving back and taking a positive step toward helping to find a cure.

I would encourage anyone thinking about becoming a regular giver to not hesitate. If you can afford to give even a small amount, it will help and is definitely worthwhile. Continued cancer research is the only way of finding a cure, and to give hope to the many patients and their families suffering from the disease.

 

Share your story

Latest genomic technology to analyse tumours in Perth

(From left to right) The Honourable Linda Dessau AC, Professor Alistair Forrest and Mr Tom Dery AO, ACRF Chair.

 

The Harry Perkins Institute of Medical Research wins $1.75m grant to establish ACRF Centre for Advanced Cancer Genomics

The $1.75M grant awarded by the Australian Cancer Research Fund (ACRF) will fund three pieces of equipment, including a high throughput next generation DNA sequencer and equipment to isolate single cells from a patient’s tumour.

The equipment will make it possible to analyse thousands of cells from hundreds of tumours and examine billions of genetic sequences to determine the genetic make-up of each tumour and provide new insights into how cancer cells evolve and interact with normal cells.

It will be housed at the world-class single-cell sequencing facility being led by The University of Western Australia’s Professor Forrest at the Harry Perkins Institute of Medical Research in Nedlands.

Single cell analysis of cancer tumours, to see which genes are turned on and off in thousands of cells within a patient’s tumour, is the next wave in cancer research, providing hope to patients that researchers will be able to identify new drugs to combat cancer, better predict a tumour’s response to drugs and develop innovative ways to kill cancer cells.

A consortium of cancer researchers and clinicians across Perth led by Professor Alistair Forrest who heads up the Systems Biology and Genomics Laboratory at the Harry Perkins Institute of Medical Research was recently awarded $3.75M from the Cancer Research Trust to build a comprehensive atlas of the cell types that make up cancer tumours.

“The new equipment funded by the ACRF will make it quicker and less costly to generate large amounts of sequence data, which means the tumours of more patients will be able to be analysed.

“The low survival rates for some cancers, such as mesothelioma, ovarian and pancreatic cancers, highlight the need for these new approaches to understand and target cancer better.

“This new equipment is essential to building an in depth atlas of the cell types in tumours.

“Using advanced single cell profiling technologies, we will survey the cell types, the genes turned on and off in each cell and mutations contained in each patient’s tumour.

“Studying tumours at the single cell level provides opportunities to identify novel biomarkers, predict response rates to drugs and provide a better understanding of cancer which ultimately will lead to new treatments,” Professor Forrest said.

“These technologies are the next wave of genomics and we have a once in a decade opportunity to establish them and remain at the leading edge,” he said.

The Australian Cancer Research Fund (ACRF) has awarded four grants across Australia to research it considers has the greatest potential to change treatment outcomes for all Australian cancer patients.

Australian Cancer Research Foundation Chief Executive, Professor Ian Brown said it was important to invest in technology that will help build in-depth knowledge of cancer cells and their environment.

“The new ACRF Centre for Advanced Cancer Genomics at the Harry Perkins Institute of Medical Research will provide new insights into how cancer cells evolve and interact with normal cells, leading to new cancer treatments that will benefit all Australian cancer patients.”

“Thanks to the generosity of our many supporters from around Australia we are able to award high-impact grants, allowing Australia’s best scientists to embark on ground-breaking research projects.

“These cancer research initiatives are directed at all types of cancer and speed up discoveries, ultimately working to save lives by saving time,” says Professor Brown.

Chief investigators on the ACRF grant were: Prof Alistair Forrest, Prof Ryan Lister, and Prof Peter Leedman from the Harry Perkins Institute of Medical Research; Assoc Prof Timo Lassmann, Prof Ursula Kees, and Professor Terrance Johns from Telethon Kids Institute, Prof Christobel Saunders, Prof Camile Farah, Prof Wendy Erber, Prof Bruce Robinson, Prof Anna Nowak, Adj Prof Richard Lake, Prof Michael Millward and Assoc Prof Benhur Amanuel from The University of Western Australia and Prof Mel Ziman, from, Edith Cowan University.

Recognising the importance of next generation sequencing in Perth, co-funding for the sequencer has also been provided by The University of Western Australia, Curtin, Murdoch, ECU, and CSIRO.
The grant presentation will be made by the Governor General at a ceremony at Government House in Victoria at 6pm EST on 29 November.

New cancer imaging centre to shine a light on the life of a tumour

ONJCRI 2017
(From left to right) The Honourable Linda Dessau AC, Governor of Victoria, Professor Matthias Ernst and Mr Tom Dery AO, ACRF Chair.

A $2 million grant from the Australian Cancer Research Foundation (ACRF), announced today, will fund a state-of-the-art imaging centre to understand how and why tumours corrupt the normal cells of their immediate environment.

The grant enables the Olivia Newton-John Cancer Research Institute (ONJCRI) and Latrobe Institute of Molecular Science (LIMS) to extend its ground-breaking work on the interaction between individual tumour cells and normal cells, and accelerate the speed with which results in the laboratory can be translated into treatments for cancer patients.

‘Cellular interactions are crucial for tumours – they drive the growth of tumours and their spread to metastatic sites; these interactions are also often responsible for tumours becoming resistant to targeted therapy,’ Professor Matthias Ernst, Scientific Director of ONJCRI, said. ‘This new centre will literally shine a light on what happens in the micro-environment around a tumour, giving us the information we need to develop effective, targeted anti-cancer therapies.’

‘We know that tumour cells coerce and corrupt their environment to their advantage. If we understand the interactions and mechanisms they use to do this, we will better understand how to counter them.’

Professor Ernst, who is also the Head of the School of Cancer Medicine at La Trobe University, welcomed the generous support of the ACRF.

‘Australia is blessed with world-class cancer research and is playing a lead in the development of anti-tumour treatment, including those that harness the power of the body’s own immune system. We all recognise that our research achievements have to stay abreast of the rising rates of cancer, and the new ACRF Centre for Imaging the Tumour Environment will facilitate that.’

‘The ACRF Centre for Imaging the Tumour Microenvironment will offer cutting edge capabilities for researchers both at the ONJCRI and at LIMS who are studying the interactions between cancer cells. The collaborative opportunities that will arise from the centre will also greatly benefit advances in cancer research,’ said Professor Andrew Hill, Head of La Trobe University’s Institute for Molecular Sciences.

‘The ACRF Centre for Imaging the Tumour Environment will provide new insights into how the micro-environment impacts tumour growth, leading to new targeted and immune based cancer treatments that will benefit all Australian cancer patients,’ ACRF Chief Executive, Professor Ian Brown, said.

‘Thanks to the generosity of our many supporters from around Australia we are able to award high-impact grants, allowing Australia’s best scientists to embark on ground-breaking research projects. These cancer research initiatives cover all types of cancer and speed up discoveries, ultimately working to save lives by saving time,’ says Professor Brown.

Each year ACRF challenges the Australian cancer research community to propose projects that are bold and have the potential to make a significant impact on cancer prevention, detection and treatment.

In 2017, thirteen projects were submitted from across the country and evaluated by ACRF’s esteemed Medical Research Advisory Committee. The Committee recommended four grants to the ACRF Board for projects that have the greatest potential to change treatment outcomes for all Australian cancer patients.

Australian Cancer Research Foundation awards $7.5 million to accelerate cancer research across Australia

grants announcement

SYDNEY, NSW — The Australian Cancer Research Foundation (ACRF) has announced $7.5 million in cancer research funding today cutting-edge research technology and infrastructure to speed up discoveries in prevention, diagnosis and treatment of cancer.

Professor Ian Brown, CEO of Australian Cancer Research Foundation, emphasised the importance of the community’s support.

“Thanks to the generosity of our many supporters from around Australia we can award high-impact grants, allowing Australia’s best scientists to embark on revolutionary research projects. These cancer research initiatives investigate all types of cancer and act as a catalyst to speed up discoveries which are ultimately working to save lives by saving time”.

“Every year ACRF encourages the Australian cancer research community to propose projects that are innovative and have great potential to make a significant impact on cancer prevention, detection and treatment. “Thirteen projects were submitted from across the country and assessed by ACRF’s eminent Medical Research Advisory Committee who were impressed by the quality and vision of the applications,” said Professor Brown.

The recipients of the annual ACRF grants in 2017 are:

ACRF Centre for Imaging the Tumour Environment – $2 million for new imaging technology which will help develop new therapies by examining tumours within the patient’s body as well as individual cells in a tumour.

Olivia Newton-John Cancer Research Institute and La Trobe University, VIC

ACRF Centre for Advanced Cancer Genomics – $1.75 million for equipment that will help build in-depth knowledge of all cell types that make up a tumour. This will provide new insights into how cancer cells evolve and interact with normal cells, leading to new treatments.

Harry Perkins Institute of Medical Research, WA

ACRF Centre for Advanced Cellular Immunotherapy – $1.75 million for the development of manufacturing and monitoring facilities that will support new immunotherapy clinical trials.

QIMR Berghofer Medical Research Institute, QLD

ACRF Oasis Research Centre – $2 million for a new facility that supports research into improving long-term health outcomes of cancer patients and survivors.

South Western Sydney Local Health District, NSW

Since 1984, ACRF has awarded $136.8 million in grants to Australian cancer research institutes, hospitals and universities across the country to fund the technologies, infrastructure and equipment.

Funding from ACRF has helped get some of the most successful cancer research projects get off the ground, including the early support of the research that led to the cervical cancer vaccine.

ACRF is dedicated to funding research in Australia that has the power to make substantial breakthroughs in cancer prevention, diagnosis and treatment for all types of cancer across Australia.

$2 million grant brings Liverpool cancer Wellness Centre one step closer

(From left to right() Mr Anthony Howard QC, The Honourable Linda Dessau AC, Governor of Victoria, Professor Geoff Delaney and Mr Tom Dery AO, ACRF Chair.

 

Liverpool Hospital Cancer Services has been awarded a $2 million Australian Cancer Research Foundation (ACRF) grant to go towards providing a facility for the first cancer Wellness Centre in south-west Sydney.

Liverpool’s Director of Cancer Services, Professor Geoff Delaney, said the grant was a huge step forward for the innovative Oncology Alliance for the Science of Integrated Survivorship (the ACRF OASIS Centre).

“We are extremely excited, it has taken a lot of effort from the initial idea six or seven years ago and this is good recognition for the treatments and the effort all the staff have put in in this area,” he said.

The centre will work in partnership with universities and research institutes including the University of NSW, Western Sydney University, the Ingham Institute and the National Institute of Complementary Medicine.

“The centre will focus on gathering scientific evidence on the use of a wide range of treatments including massage, acupuncture, exercise, Chinese medicine and diet in improving short and long-term treatment and quality of life outcomes for cancer patients,” Professor Delaney said.

The ACRF OASIS Centre will be the only centre in Sydney collecting data for research and evidence purposes in order to further improve the care that can be provided to future cancer patients.

“UNSW Medicine welcomes this generous grant from the Australian Cancer Research Foundation towards an important initiative for the people of south-west Sydney,” said UNSW Acting Dean of Medicine Professor Anthony Kelleher.

“A Wellness Centre would not only benefit cancer patients in the care they receive, and help improve their quality of life; it would also advance our scientific understanding of new approaches to cancer treatment and aligns perfectly with our thematic approach to research and education. It will further strengthen our links and commitment to the south west.”

ACRF Chief Executive, Professor Ian Brown, said the ACRF was excited to seed fund the development of the facility.

“Research into improving long term health outcomes of cancer patients will benefit all Australian cancer patients,” he said.

“Many times patients are left weakened due to the debilitating impact of their treatment and research into reducing adverse effects of treatment will be welcomed by all.

“ACRF is pleased to support the development and delivery of evidence based models of care, which will significantly improve quality of life for cancer patients.

“Thanks to the generosity of many of our supporters from around Australia we are able to award high-impact grants, allowing Australia’s best scientists to embark on ground-breaking research projects.”

The ACRF OASIS Centre is still about $1.1million from being able to begin construction of the building.

Professor Delaney said he was confident they would be able to attract the remaining funding, and he welcomed anyone who was interested in being involved in funding the centre and helping to significantly further cancer care research.

Each year ACRF challenges the Australian cancer research community to propose projects that are bold and have the potential to make a significant impact on cancer prevention, detection and treatment.

In 2017, 13 projects were submitted from across the country and evaluated by ACRF’s eminent Medical Research Advisory Committee. The Committee recommended four grants to the ACRF Board for projects that have the greatest potential to change treatment outcomes for all Australian cancer patients.

 

ACRF grant to transform Queensland into global immunotherapy hub

QIMR Berghofer grant
(From left to right) Mr Anthony Howard QC, The Honourable Linda Dessau AC, Governor of Victoria and Professor Frank Gannon.

 

Brisbane will continue to produce new and world-leading cancer immunotherapy treatments, thanks to a $1.75 million grant from the Australian Cancer Research Foundation (ACRF).

The funding was announced at a ceremony in Melbourne this evening. It will allow QIMR Berghofer Medical Research Institute to establish the ACRF Centre for Advanced Cellular Immunotherapy and to expand its capacity to develop, trial and produce immunotherapies to treat cancers, including those treated with bone marrow transplants.

In the last decade, immunotherapy has emerged as the “fourth pillar” of cancer treatment, along with surgery, chemotherapy and radiotherapy. It works by “training” the immune system to recognise and destroy cancer cells. The field has given hope to thousands of cancer patients by successfully treating aggressive cancers like melanoma that do not respond to chemotherapy.

The ACRF funding will be used to expand QIMR Berghofer’s existing cell manufacturing facility, Q-Gen Cell Therapeutics, and to buy new equipment needed to produce cellular immunotherapies. In recognition, a new facility named the “ACRF Centre for Advanced Cellular Immunotherapy” will be established within QIMR Berghofer.

QIMR Berghofer’s Director and CEO, Professor Frank Gannon, has thanked the ACRF for its invaluable support.

“QIMR Berghofer is already at the global forefront of research into cancer immunotherapy. We are currently trialling some of the most exciting new treatments in Australia. But because of that success, demands on our facilities are growing,” Professor Gannon said.

“This extremely generous contribution will allow us to scale up production of clinical-grade immunotherapies for patients treated within clinical trials.

“But the ACRF’s support won’t only benefit QIMR Berghofer. Research organisations from across Australia and the world will be able to have clinical-grade treatments produced at our regulatory-approved facility, meaning this funding will help to advance the field of immunotherapy globally.”

ACRF Chief Executive, Professor Ian Brown, said the Australian Cancer Research Foundation was pleased to invest in the development of novel immunotherapies that would benefit all cancer patients.

“The new ACRF Centre for Advanced Cellular Immunotherapy at QIMR Berghofer will provide leadership in the development and manufacture of clinical agents for use in immunotherapy clinical trials,” Professor Brown said.

“We are excited to participate in a project that holds a promise to significantly advance the development of cancer treatment as well as improving treatment outcomes for all types of cancer.

“Thanks to the generosity of our many supporters from around Australia we are able to award high-impact grants, allowing Australia’s best scientists to embark on ground-breaking research projects. These cancer research initiatives will help to speed up discoveries that will ultimately work to save lives by saving time.”

The grant is one of four awarded by the ACRF’s Medical Research Advisory Committee Australia-wide. Funding is awarded to projects that have the potential to make a significant impact on the prevention, detection and treatment of cancer.

Stress suppresses response to cancer treatments

New research shows that chronic stress suppresses the immune system’s response to cancer, reducing the effectiveness of immunotherapy treatments.

University of Queensland scientists say they are investigating dual therapies for patients to reduce stress signalling and improve their response to treatments.

UQ Diamantina Institute researcher Dr Stephen Mattarollo said lymphoma progressed more rapidly in mouse models when stress pathways were induced to reflect chronic psychological stress.

“When we used immunotherapies on these mice they were not able to respond as effectively as those which had not been stressed,” Dr Mattarollo said.

“This is because the stress led to poor function against the cancer by T-cells, which are very important in the immune system’s control and surveillance of tumours and are a major target in many immunotherapy treatments.”

Dr Mattarollo said increased anxiety was natural with a cancer diagnosis, and it should be managed to ensure the best possible outcome for patients.

“Absolutely there is now pre-clinical evidence to suggest that treatments and lifestyle interventions to manage or reduce stress levels will improve the chances of these patients responding to therapies,” he said.

“This applies particularly to immunotherapies, but many conventional therapies such as chemotherapy also rely on components of the immune system for their effectiveness.

“It is quite possible that by increasing the immune function in patients they will also respond better to some other therapies.”

PhD candidate Michael Nissen said as immunotherapies became more widely available, it was important to build on the knowledge of factors which influence their effectiveness.

“The more we know, the better chance we have of designing them effectively and efficiently to work in cancer patients,” Mr Nissen said.

Dr Mattarollo said the lab was hoping to combine immunotherapy treatments with commonly used blood pressure drugs that block the effects of stress hormones.

“We hope this will reduce the stress-induced neural signalling and improve immune function,” Dr Mattarollo said.

“We are about to test this combination in animal models.”

Dr Mattarollo said psychoneuroimmunology – or the interaction between the mind, the nervous system and the immune system – is a rapidly growing discipline and is becoming an increasing focus of the lab’s cancer research.

The research has been published in Cancer Immunology Research.

The original news article was posted on Diamantina Institute’s website.

The Australian Cancer Research Foundation has supported cancer research at Diamantina Institute by providing three grants, totalling AUD$ 6.2 million, for the purchase of cutting edge research equipment and technology.

New institute to revolutionise cancer imaging and targeted radiotherapy

The ACRF Image X Institute, a world-leading centre for medical innovation, launches today at its University of Sydney headquarters.

The work of the Institute will focus on creating new medical devices for cancer imaging and targeted radiotherapy. The Institute will provide a site and forum where academia, medicine, industry and government can advance the science and clinical practice of cancer treatment.

The ACRF Image X Institute will be led by Professors Paul Keall (University of Sydney), Michael Barton (Ingham Institute), and Associate Professor Michael Jackson (Prince of Wales Hospital), with a team of world renowned researchers and collaborators.

The Institute is funded by $2.5 million from the Australian Cancer Research Foundation and a further $25 million in research support.

There are three main research nodes in New South Wales including the University of Sydney’s Charles Perkins Centre; Liverpool Hospital’s Ingham Institute for Applied Medical Research; and Prince of Wales Hospital’s Nelune Comprehensive Cancer Centre.

“Our mission is to create, share and apply scientific knowledge to improve human health,” said Institute Director Professor Paul Keall, from Sydney Medical School at the University of Sydney.

“We will revolutionise medical imaging, transform functionally targeted radiotherapy and enable global access to radiotherapy.

“With world class expertise in bench-to-bedside translational research, an entrepreneurial focus and cross-disciplinary collaborations, the Institute will attract top tier researchers with a track record of pioneering technology.”

The $2.5 million funding from the Australian Cancer Research Foundation is supporting three unique cancer imaging and targeted radiotherapy devices. These include an MRI-Linac, a real-time cancer imaging and targeted therapy system; the Nano-X, a smarter, smaller cancer radiotherapy system and a robotic imaging machine to advance patient connected imaging. These devices will increase cure rates and reduce the human and economic costs of treatment-related side effects.

“The ACRF Image X Institute has the potential to make significant advances in the delivery of radiation therapy worldwide,” said Professor Ian Brown CEO, Australian Cancer Research Foundation.

“Improvements in treatment accuracy will minimise harmful side effects and lead to improved patient outcomes. The development of new hardware will reduce the cost of equipment, giving more people, also in underserviced areas, access to treatment.

“ACRF is dedicated to funding innovative research in the pursuit of ways to prevent or more effectively treat cancer. The ACRF Image X Institute will have a worldwide impact and ACRF is proud to stimulate major advancements in radiotherapy.”

The Institute currently has 270 papers published in top international journals, with six clinical world-firsts in research discoveries and technology, and 13 clinical trials taking place in Australian hospitals. There have been 25 commercial R&D projects, with 25 issued and filed patents, eight licenses issued and three spin-off companies.

Image: Courtesy of ACRF Image X Institute, University of Sydney

Two team up and go bald at fundraiser

Headshave fundraiserPenny and Emma created Team Park Balding to participate in Head Shave for Cancer Research and to support ACRF. Both women have a background in science and grasp the importance and impact of scientific research. They chose to raise money for ACRF because of the organisation’s funding of research into all cancers.

“We didn’t want to be exclusive in terms of the type of cancer when we were fundraising as all cancers are impactful and distressful to humanity.”

Penny: Cancer is such a tricky disease to treat and cure. By doing this event for ACRF I hope to contribute to the research that will make life easier for cancer patients and their families. As a scientist in the biomedical field, I am passionate about unravelling the complexities of diseases and using science to improve lives. By facing the challenge head-on with passionate and diligent science, hopefully, we can eventually leave harsh treatments behind and find a cure.

Emma: At some point in life we will all be affected in some way by cancer and yet it is so easy to feel alone or that you stand out during that battle. Penny and I have both seen how devastating cancer is in society and how it impacts on people’s lives. Losing people prematurely to this disease has been a motivator to take action to help further cancer research.

“We both chose to do the shave partly because it’s been shown to be a really successful way of fundraising. We also felt that it was a great call to arms to jump on board as it’s a big commitment and personal change for us to make which showed everyone how seriously we felt about fundraising for cancer.”

Emma: Shaving my head is my way of showing support in the visual sense. Being bald has become a societal flag for a cancer patient and that makes a person’s private battle very public. I hope to show my solidarity with patients with this disease and reduce any feelings of isolation associated with hair loss.

Penny: Hair loss brings with it a unique vulnerability as people often use hair as an expression of vanity or as a shield from the outside world. By removing my hair, I want to show anyone who is dealing with this disease that they don’t have to stand out on their own. I also want to symbolise the cutting back of obstacles and barriers that can obscure our clear view and understanding of cancer, which is what more and more research funding will be able to do for the reality of cancer in the future.

“We wish for a future where a cancer diagnosis is not fatal. The only way we’re going to make it to that end is if we do some really solid research into various cancers and make sure early diagnosis is more prevalent and therapies are more effective at reducing and removing cancer from the body.”

Team Park Balding had a big turn-out of friends, families, kids and dogs at their Sunday afternoon barbeque and fundraising party at Jell’s Park, Melbourne. Over $5,700 in donations was collected at the event for ACRF and cancer research.

“We are proud of what we’ve been able to achieve together and so glad that we undertook this event as a team. It was something really worthwhile to put our energy into. Raising funds was tangible, and there was our sense of accomplishment and pride to actually go through with the head shave.”

Share your story

New study aims to deliver better outcomes for triple negative breast cancer patients

New research at the Westmead Institute aims to develop a targeted treatment for triple negative breast cancer patients.

Triple-negative breast cancer accounts for approximately 15 percent of all breast cancers but, unlike more common types of breast cancer, it does not have a targeted or effective treatment leading to poor outcomes for patients.

Lead researcher, Dr Dinny Graham from the Breast Cancer Research Group, said she hopes this study will uncover the receptors present in triple negative breast cancer so that a targeted treatment can be developed.

“We want to be able to develop personalised tests for patients suffering from triple negative breast cancer, but we need to know which receptors to target first,” Dr Graham said.

The most common form of breast cancer is estrogen receptor positive (ER+). The standard care treatment for ER+ patients targets the estrogen receptor and is highly effective.

However, ER+, triple negative breast cancer lacks estrogen receptors and therefore that treatment is not as effective.

The estrogen receptor is just one of a family of 48 different human nuclear receptors that are important to many aspects of human health.

Dr Graham has found that a number of these receptors could perform a similar role as estrogen receptors in diagnosing and treating triple negative breast cancer.

Her team is now testing which nuclear receptors act as biomarkers that may present an opportunity for targeted therapeutic treatments.

“Receptors are recognised as excellent biomarkers and as potential drug targets.

“A number of drugs, targeting a range of receptors are already approved for other clinical applications. We have evidence that some of these might be repurposed to treat triple negative breast cancer.

“This research could mean reduced mortality rates and reduced side effects of untargeted chemotherapy,” she concluded.

This study aims to close the existing knowledge gap and deliver new insights into treating patients with triple negative breast cancer.

Dr Dinny Graham is scientific lead of the Translational Breast Cancer Genomics Group at the Westmead Institute for Medical Research.

Facts:

1 in 8 women will be diagnosed with breast cancer in their lifetime.
144 Australian men are diagnosed with breast cancer each year.
More than 3,000 Australians will die from breast cancer this year.

This research news was originally posted on The Westmead Institute’s website.

ACRF has provided Westmead Institute with $7m in funding towards cancer research.

 

Karen’s Story

 

My name is Karen and I am a high school teacher, a farmer’s wife and the mother of two boisterous girls aged six and four. We live on our family farm near the rural village of Caragabal in Central NSW.

Like you, I am an ACRF supporter, and I am dedicated to raising funds for cancer research to ensure that all families will get to spend Christmas together for years to come.

And, as ACRF supporters, we know all too well that cancer affects all Australians, from the country to the city, to the coast, from my small village to your community.

Cancer is not new to our family. My dad died of cancer almost 20 years ago, and now I am a cancer survivor myself.

Last year, I was diagnosed with aggressive triple negative breast cancer at 35 years of age. I underwent a double mastectomy, chemotherapy, node dissection and radiation treatment.

Thanks to these and other breakthroughs in cancer research, there is no longer any evidence of breast cancer in my body.

And, thanks to all these advances, I have been left with hope.

Hope that the cancer never comes back. Hope that my daughters will never be directly affected by it. Hope that I will be around to help them through puberty, weddings and babies. And, hope that I will live long enough to enjoy retirement with my husband.

After my personal experience with cancer, I urgently wanted to do my bit to help Australian cancer researchers to find ways to beat all types of cancer.

Although cancer treatments are improving, and major research breakthroughs are getting closer, I know that dedicated efforts will require more funding.

When you make a donation to ACRF today, you give Australia’s best researchers access to the equipment they need to end cancer. By funding new technology, we are helping scientists to uncover information that will lead to better cancer treatment and prevention sooner.

We can all do our part to bring hope to all Australians – together we can help put an end to all types of cancer.
With more funds, researchers and scientists can help realise the hopes and dreams of so many Australian families like mine and yours. Thank you for joining me.   

Karen – ACRF supporter and cancer survivor

Please donate by 31 December to equip Australia’s best researchers with the tools they need to end all cancers.

 

Brain cancer in Australia

File 20171110 29341 7bkchy.jpg?ixlib=rb 1.1
All brain tumours are associated with significant sickness and death, even if they are benign.
from shutterstock.com

Authors Melinda Tea, University of South Australia and Stuart Pitson, University of South Australia

While survival rates for most cancers continue to improve in Australia, brain cancers aren’t seeing the same success. Australians diagnosed with brain cancer had around a 25% chance of surviving for five years from 2009 to 2013. This was compared to a survival rate of 68% for all cancers combined in the same period.

Brain and central nervous system cancers (CNS) can be either malignant or benign, but unlike benign tumours in other tissues, all brain and CNS tumours are associated with significant sickness and death.

Survival rates

It is estimated that 2,076 new cases of brain and other CNS cancers will be diagnosed in Australia in 2017. Around 1,500 people will die from this disease.

While the survival rate is 25% for brain cancer in general, for certain brain cancers it’s much worse. For instance, glioblastoma, the most common form of brain cancer in adults, has a five year survival rate of 4.6%.

So why hasn’t there been an improvement in survival in the last 30 years for patients with brain tumours? A frequent problem is that it’s hard for drugs to actually get to the tumour. The brain has a unique defence, termed the “blood-brain barrier”, that limits the passage of drugs from the bloodstream into the brain.


Indeed, most chemotherapies are stopped from getting to the brain by the blood-brain barrier. Those that do, such as temozolomide used to treat brain tumours including glioblastoma, unfortunately have limited efficacy, and only improve survival by several months at best. There is clearly a desperate need to identify new drug targets and more effective therapies for brain tumour treatment.

Incidence rates

Incidence rates for brain and CNS cancers have stayed steady for some decades but the sickness and death that comes with the disease continues to affect many Australian lives. A recent report from the Australian Institute of Health and Welfare shows that the incidence of many cancers has increased over time.

CC BY-ND

In many cases this is due to our ageing population, as cancer is more common in older age. But other lifestyle factors also play a role. For example obesity, type two diabetes and alcohol consumption are three major risk factors for liver cancer, rates of which have increased.


The incidence of some other cancers has decreased though. In the case of lung cancer, this is likely due to a decrease in smoking. While the introduction of a vaccine for the human papillomavirus (HPV) (which is responsible for most cases of cervical cancer) would explain the drop in cervical cancer rates.

In comparison, the overall incidence of brain cancer has remained stable over the last 30 years, probably because there are no known lifestyle or environmental factors that contribute to these cancers. While we don’t know what causes brain and CNS tumours, there is evidence to suggest genetics and high levels of radiation may play a role.

Childhood brain cancer

While many cancers almost exclusively present in older people, this is not the case with brain tumours, as these kill more people under 40 than any other cancer.

Perhaps of most concern is that brain tumours disproportionately affect children, killing more children (aged 1-14 years old) in Australia than any other disease. They are only third to land transport accidents and congenital and associated abnormalities as causes of child death in Australia.

The prognosis for children with brain cancers, the most common being medulloblastoma, is much better than in adults though. Around 70% of these patients will have curable disease.

But, undergoing life-saving treatment such as surgery, chemotherapy and radiation comes at a long-term cost for these children, as these therapies themselves are associated with detrimental effects on childhood development. These can potentially result in neurological defects, learning difficulties, growth abnormalities and mental health issues.

The ConversationThe Australian government recently announced a A$100 million dollar medical research fund committed to doubling the survival rates and improving the quality of life of patients with brain cancer over the next ten years. It is hoped with this substantial investment, progress will be made to eventually defeat brain cancer.

 

Melinda Tea, Research Associate, Centre for Cancer Biology, University of South Australia and Stuart Pitson, NHMRC Senior Research Fellow, Centre for Cancer Biology, University of South Australia

This article was originally published on The Conversation. Read the original article.

Kelly’s second fundraiser is a roaring success

I started working in aged care 12 years ago and during that time I saw many people and their families suffer from cancer. Then a few years ago my Nan was diagnosed with acute myeloid leukaemia and she passed rather quickly. All these sad events reinforced my desire to assist ACRF by fundraising. I believe it’s important to support cancer research, not only in hope of a cure one day, but for the advances in treatments, including less side effects, to aid in a better quality of life.

Since giving up my nursing career, I’ve been working in massage therapy and now thoroughly enjoy helping clients with reducing stress and promoting a sense of health and well-being. Running my own small business also gives me the important flexibility of spending more time with our young two children, Lucy and Connor. Outside of family commitments and fundraising, I try to slot in time with my horses too.

For my second ACRF fundraiser, I chose to host a dinner and murder mystery party; it’s something different and so much fun! The event was sold out a couple of months before the event date and there was a waiting list of others who wanted to attend. The party gave everyone the chance to dress up, enjoy a delicious three-course meal and dance the night away with new friends. A personal highlight of the evening was when my very poised six-year-old daughter welcomed everyone to the party.

The feedback from guests was really positive, and there were several requests for me to host another party next year! It is gratifying to raise $5,600 for ACRF, and I thank everyone for their support and generosity.

I would say to anyone thinking about organising an event to just have a go and do something that is fun. Every cent collected for cancer research does count.

Share your story

 

charity fundraising event

Pancreatic cancer patients to benefit from breast cancer drug

Pancreatic cancer research discovery

A newly approved breast cancer drug could be highly effective against some forms of pancreatic cancer, including metastatic cancer. The study also revealed a new straightforward way to test which patients might respond positively to treatment.

Dr Marina Pajic, leader of the Personalised Cancer Therapeutics Group at the Garvan Institute of Medical Research, said the test was designed to meet an urgent need for new, targeted therapies for pancreatic cancer.

“We know that the underlying drivers of pancreatic cancer at the molecular level differ from person to person. Despite this, there are currently few treatments that directly target the molecular drivers of an individual’s pancreatic cancer, but only a one-size-fits-all combination chemotherapy approach – and the fact is that this simply isn’t effective for most patients,” said Dr Pajic.

The researchers examined over 550 tumour biopsies from pancreatic cancer patients. In about two-thirds of those tumours, they found, a cellular pathway known as the ‘Cdk4/6 pathway’ was switched on, driving tumour cells to grow and divide.

“This was an important clue for us and we started to look in depth at how best to block the Cdk4/6 pathway. We know that the drug palbociclib switches off the Cdk4/6 protein, so we reasoned that palbociclib might halt the growth of the many pancreatic cancers where this pathway is on.”

Biomarker helps predict which patients will benefit

The researchers also showed that the RB protein – another protein in the Cdk4/6 pathway – was present in high levels in Cdk4/6 “ON” tumours and so could act as a biomarker of the tumour subtype.

“Having a good biomarker is essential for personalised medicine, because it gives us a way to predict who is likely to respond to treatment,” said Dr Angela Chou a pathologist and researcher at Garvan and St Vincent’s Hospital, Sydney.

Dr Chou also said that RB levels help to identify and treat metastatic tumours.

“Excitingly, data from our patient samples shows us that, if a primary tumour has high RB levels, then it’s likely that the metastatic tumours will also. This means there’s a possibility that both primary and metastatic tumours could be targeted in the same patient in the future,” added Dr Chou.

More information on the potential of palbociclib as a targeted therapy to treat pancreatic cancer could be coming soon.

“Therapies that target the Cdk4/6 pathway are already in clinical trials for pancreatic cancer here in Australia – and we’d love to see testing for tumour RB levels in those trials to learn more about its power to predict treatment success in people,” Dr Chou concluded.

Currently, five-year survival rates after pancreatic cancer diagnosis stand at just 7% – a figure that has scarcely improved in the last four decades. Most pancreatic cancers are diagnosed after the tumour has spread beyond the pancreas, making treatment even more challenging.

The findings have been published this week online in the journal Gut.

The research news was originally posted on Garvan’s website.

ACRF has proudly provided Garvan Institute with $6.1m towards cancer research since 2003.

 

Hannah cuts her hair for charity

cancer fundraising eventWe are the very proud parents of Hannah. Our 7-year-old daughter has a sweet and sensitive nature and is generous of heart. Hannah was born deaf in one ear but that has not slowed her down in the least. She attends a mainstream school, is now in grade 2 at St. Peter’s Primary School, and this year was asked to be part of their advanced reading programme.

Not long ago, Hannah heard from her good friend and classmate about children with cancer and how these children lose their hair from chemo treatments. Hannah spent about a week pondering this information and asked a lot of questions which I answered the best that I could. Hannah sometimes seems wise beyond her years and is very empathetic for such a young girl.

When Hannah came to her Dad and me about cutting her hair off and donating it to a charity to raise money for cancer patients, we were shocked. However, there are times as a parent when you need to accept your child’s good-hearted intentions, despite your own feelings, and this was one of those times.

My mother Brenda, who is a professional hairdresser, was happy to help with her granddaughter’s request. On Sunday, October 22, Hannah’s lovely long brown hair was shortened by nine inches. Yes, I cried and Hannah cried because I was crying! Then Hannah hugged me and we smiled away the tears.

Because Hannah wants to turn her hair into a wig for one child with cancer and wants to raise awareness of cancer, we decided to select two charities: Pantene and Australian Cancer Research Foundation.

We learn every day from our selfless daughter and hope that others will as well. A world free of cancer can happen one little step – like Hannah’s – at a time.

Share your story

 

Nigel will bare his chest for ACRF

charity fundraising event

I’m a huge believer in the phrase “no pain, no gain”! Given this, and with some encouragement from my wife and friends, I have agreed to have my chest waxed to raise funds for cancer research in memory of my Mum.

In April 2016, my Mum passed away back home in Northern Ireland as the result of a short illness from bowel cancer. My brother who is also in Northern Ireland recently organised a whisky tasting event to collect donations for Marie Curie, which is one of the organisations that assisted with Mum’s care. He was successful in raising almost $7,000 so I took inspiration from that and decided to do something in Perth, where I work as an environmental advisor. Because the Marie Curie charity isn’t set up in Australia, I chose to support ACRF for their commitment to funding cancer research.

Unfortunately, my family has been hit a few times by the devastating effects of cancer so it doesn’t take any other incentive for me to back cancer research. I also feel that it’s important to champion the research discoveries made with any type of cancer. It is a powerful motivator and people sometimes need a bit of hope, inspiration and confidence to help financially support this vital work.

I am pretty certain Mum wouldn’t be in favour of the whole chest waxing malarkey which will happen on what would have been her 67th birthday – 2 December. Yet again, she might approve on this occasion as the funds raised are going to an organisation that is striving to end this horrible disease.

Share your story

Collaboration leads to search for new cancer treatments

Melbourne researchers have produced the first three-dimensional (3D) map of a molecular ‘scaffold’ called SgK223, known to play a critical role in the development and spread of aggressive breast, colon and pancreatic cancers.

Armed with the map, the research team is looking at ways of targeting parts of the scaffold molecule critical for its function. They hope the research will lead to novel strategies to target cancer.

The research was the result of a long-standing collaboration between Walter and Eliza Hall Institute researchers Dr Onisha Patel and Dr Isabelle Lucet and Monash University’s Biomedicine Research Institute researcher Professor Roger Daly, with important inputs from Dr Michael Griffin at Bio21 Institute, University of Melbourne, and Dr Santosh Panjikar at the Australian Synchrotron.

Dr Lucet said SgK223 was a member of a family of proteins called pseudokinases and had been classified for a long time as a ‘dead enzyme’.

“SgK223 doesn’t have the measurable activity that we see with other types of enzymes, and this meant it was largely ignored. However in the past decade, we’ve come to understand that this ‘dead enzyme’ plays an active and important role in cell signalling,” Dr Lucet said.

SgK223 is unique among pseudokinases because it acts as a molecular scaffold, facilitating the assembly of vital signalling molecules whose activities control the normal functions of a cell, such as cell shape and migration.

“Because of its primary role in facilitating the assembly of signalling molecules, high levels of SgK223 can jeopardise the normal functions of a cell and contribute to changes that lead to cancer,” Dr Lucet said.

“High levels of SgK223 have been found in some aggressive subtypes of breast, colon and pancreatic cancers, suggesting that SgK223 could be a potential target for novel anti-cancer therapies.”

Dr Patel said facilities at the Australian Synchrotron enabled the team to get an unprecedented view of SgK223.

“Because molecular scaffolds such as SgK223 are structurally quite large, we focused on a critical part of the protein and produced a 3D map using facilities at the Australian Synchrotron. With this map, we have now identified several regions of SgK223 that are essential for its ability to assemble signalling molecules,” Dr Patel said.

“Solving the 3D map of SgK223 is a critical step in the effort to discover how this molecular scaffold functions, and future research will verify whether targeting SgK223 could have an impact in treating cancers.”

Professor Daly said the 3D map would enable researchers to investigate how targeting SgK223 impacts cancer cells.

“With this 3D map, we can now start to look at how inhibiting the function of SgK223 by targeting particular regions of the scaffold affects cell growth and spread in cancers where it is present at high levels, such as triple negative breast cancers,” Professor Daly said.

World-class facilities at the Australian Synchrotron in Melbourne were instrumental in the discovery, Dr Lucet said. “The Australian Synchrotron is the only facility in the Southern Hemisphere that has the specialised technology required to provide us with detailed knowledge essential for seeing molecules at an atomic level. This is essential if we wish to discover and develop drugs that target and interfere with molecules that drive cancer and other diseases,” Dr Lucet said.

The research was recently published in Nature Communications.

This news was originally published on the WEHI website.

ACRF has supported cancer research at the at the Australian Synchrotron with a $2 million grant and Walter Hall and Eliza Institute by providing them with three grants totalling $5.5 million.

Grace does the cut for ACRF

cancer fundraising headshave

If asked to describe myself, I would say: determined, compassionate, disciplined, and aspiring to develop a career in the field of mental health. I study a Bachelor of Psychological Science (Honours) at the University of Queensland, just handed in my one-year research thesis, and will be graduating from my undergraduate degree in December 2017. I recently submitted my Masters of Clinical Psychology and PhD applications and now wait to hear back with the outcome.

There is also the sporty side of me. I am very lucky to have represented Australia multiple times in Taekwondo at world championships.

I decided to fundraise for ACRF because too many people around me in the past 12 months have been diagnosed or affected by cancer. I struggled with not being able to do anything to help them so gathering donations for ACRF and cancer research was the perfect way for me to do just that.

After looking at ways to raise money, I decided on a salon event where 15 inches of my hair were cut off. The funds collected went to ACRF and my hair to Variety the Children’s Charity, which makes specialised wigs for children who can’t grow their own hair because of medical conditions such as cancer or alopecia. As a budding developmental psychologist, I recognise the impact that physical differences can have on children while they’re growing up.

We all know that cancer is a horrible condition that doesn’t discriminate who it affects. It impacts a person in so many ways. I believe in the values of ACRF, and what they can do for cancer research. Continued vital research is the only way that we can beat this monster disease.

Share your story

Breast cancer pioneers win Victoria prize for Science and Innovation

Breast cancer researchers Professors Jane Visvader and Geoff Lindeman, who jointly lead the Walter and Eliza Hall Institute’s ACRF Stem Cells and Cancer division, have been awarded the 2017 Victoria Prize for Science and Innovation in the Life Sciences.

The $50,000 prize celebrates the researchers’ two-decade commitment to cancer research, involving landmark discoveries in how breast cancers arise and could be prevented and treated.

Institute director Professor Doug Hilton said the scientists were pioneers in their field and responsible for advancing research throughout many years of dedicated work.

“Geoff and Jane, along with their teams, have made crucial discoveries describing both healthy breast development and how errors within this process can lead to cancer,” Professor Hilton said.

“Most recently, their efforts were instrumental in discovering that a new class of anti-cancer drugs, when combined with existing drugs, could potentially supercharge treatment for some of the most aggressive types of breast cancer.

“The researchers also identified the cells that give rise to breast cancer in women who carry a faulty BRCA1 gene and that an existing medication for osteoporosis could provide these patients with a non-surgical option for cancer prevention.

“Their dedication to breast cancer research since 1997 is now benefiting women in Victoria through early phase clinical trials,” he said.

Professor Visvader acknowledged the importance of team-work. “Geoff and I really have been very fortunate to work with exceptionally talented teams of scientists and collaborators. This award reflects their hard work and commitment,” she said.

Professor Lindeman, also a medical oncologist at the Royal Melbourne Hospital and Peter Mac, said that sustained State Government support had helped to progress fundamental discoveries from the laboratory through to the clinic.

“Victorian Government support has over the course of our careers helped to advance basic research from the bench to the bedside,” Professor Lindeman said.

“Jane and I are passionate about developing more effective targeted therapies for the treatment and prevention of breast cancer. We are humbled to receive this award, which highlights the importance of long-term investment in basic and translational research to improve the lives of people affected by cancer,” he said.

Professors Visvader and Lindeman’s research is supported by Australian Cancer Research Foundation and others.

This news was originally published on the WEHI website.

ACRF has supported cancer research at the Walter Hall and Eliza Institute by providing them with three grants totalling $5.5 million.

World’s biggest genetics study of breast cancer unearths 72 new genetic markers

breast cancer 72 new genetic markers

The world’s biggest ever genetic study of breast cancer has discovered 72 new genetic variants that put women at higher risk of the disease.

Researchers from QIMR Berghofer Medical Research Institute co-led the major international collaboration, which collated and analysed data from 275,000 women across the globe.

The findings were today published in the journals Nature and Nature Genetics.

The coordinator of QIMR Berghofer’s Genetics and Computational Biology Department, Professor Georgia Chenevix-Trench, said the study found 65 genetic variants that predispose women to the overall risk of breast cancer.

She said a further seven genetic variants were discovered that predispose women specifically to oestrogen-receptor negative breast cancer, which often leads to poorer health outcomes because it does not respond to drugs like tamoxifen.

The discovery was made possible through collaboration between the Breast Cancer Association Consortium (BCAC) and the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), which is led by Professor Chenevix-Trench.

“This work helps us to understand why some women are more at risk of developing breast cancer than others and what genetic markers we should be looking for in order to assess that risk,” Professor Chenevix-Trench said.

“We know that breast cancer is caused by complex interactions between these genetic variants and our environment, but these newly discovered markers bring the number of known variants associated with breast cancer to around 180.

“Our hope is that in future we will be able to test for these genetic variants in order to inform preventative approaches and treatment for women who may be at a higher risk of breast cancer.”

Professor Chenevix-Trench said the inherited component of breast cancer risk was due to a combination of rare variants in genes such as BRCA1 and BRCA2 that indicate a high risk of the disease, and genetic variants that confer only a small risk, as identified in the latest research.

QIMR Berghofer senior researcher Dr Jonathan Beesley said that one of the main findings in the Nature paper was that scientists can now predict which neighbouring genes the risk variants might act on.

He worked alongside colleagues at QIMR Berghofer, including Functional Cancer Genomics specialists Associate Professor Stacey Edwards and Associate Professor Juliet French, to conduct lab tests that confirmed some of these predictions.

“We were able to show for the first time that these risk genes are often the same ones that are mutated during the development of breast tumours, which tells us much more than we knew previously about the genetic mechanisms that may cause breast cancer,” Dr Beesley said.

“We think that this ability to pinpoint the genes associated with risk of breast cancer will eventually enable us to develop more effective screening interventions and even risk-reduction medications and treatments.”

Around 70 percent of all breast cancer is oestrogen-receptor positive, which means the cancer responds to the hormone oestrogen and helps the tumour to grow.

A smaller number of breast cancer cases are oestrogen-receptor negative, so they do not respond to oestrogen but respond to other mechanisms.

Professor Chenevix-Trench said a greater understanding of a woman’s risk of developing breast cancer may help to change the age at which that woman is offered mammogram screening.

“Many women are offered mammogram screening when they are middle-aged, but if we know a woman has genetic markers that place her at higher risk of breast cancer, we can recommend more intensive screening at a younger age,” she said.

The studies involved collaborators from 300 different institutions, including the University of Cambridge, University Laval in Quebec and Harvard TH Chan School of Public Health.

This news was originally published on the QIMR Berghofer website.

ACRF has supported cancer research at QIMR Berghofer Medical Cancer Research Institute since 2002 when they were awarded the first of three grants totalling $6.7 million.

In full swing for the 2018 marathon

I’m Hannah, born in the UK, now an Australian citizen, and living near Canberra with my partner Trent and our rescue-shelter dog Odin. My current job brought me to Australia; I work as a Textile Conservator at the National Gallery of Australia in Canberra. Art conservation is quite a unique profession that requires skills which ordinarily don’t go hand-in-hand: art and science.

Running in the London Virgin Money Marathon has been on my bucket list for a while. In 2016 I ran the Canberra Times Fun Run for ACRF, and then became interested in other sporting and fitness events where ACRF needed fundraisers. I find that being part of a wider fundraising group gives a real sense of achievement and meeting fundraising goals becomes less daunting.

I have a personal reason for wanting to raise money for cancer research. My family and I lost our much-loved and long-time friend Barry to cancer this year. As a teenager and university student in the UK, I earned extra money for school expenses by working in a restaurant with my mother’s best friend Sally and her husband, Barry. I had the dream job of making desserts, and Barry and I had all kinds of funny conversations while working together in the kitchen. Like many teenagers I also went through a tough phase with my parents and was quite rebellious. Barry and Sally would always drop me off at home after work shifts; they became my surrogate parents during that time. I will never forget the love, support and kindness they showed me.

The indiscriminate nature of cancer is heartbreaking. Of all the people in the world, Barry and Sally have been two of the most emotionally generous people you could ever wish to meet. Having spent their lives imagining they would grow old together, they have been ripped apart. Although our family is heartbroken, Barry’s death has brought us closer together and we are more appreciative and caring of one another than before.

As someone who works in the science field, I am always interested in new scientific developments. I want to raise funds to enable continued research and scientific breakthroughs as well as help people improve their chances of survival and limit the side effects of cancer treatments. Although it could be some time before cancer is eradicated, tangible progress is happening now. I recently visited the ACRF funded John Curtain School of Medical Research where pioneering researchers such as Prof. Ross Hannan and his team are making solid advances in cancer medicine and treatments. This is where I wanted my fundraising dollars to go.

My London 2018 fundraising campaign has come with its share of doubts. Will I make my fundraising goal? Will I be able to run the entire distance? Will people be interested or care about what I am doing? So far, I have been thrilled by the response to my fundraising efforts from so many generous people. The ACRF team is also fantastic with their continued support and encouragement.

Running in the 2018 London Marathon will not be for Barry alone. It will also be for my friends and colleagues who no longer have mothers, fathers, brothers and sisters because of cancer. Those gaps can never be filled.

 

Support HannahShare your story

Improving outcomes for patients with a common type of blood cancer

Australian cancer research
Peter Mac’s Director of Haematology, Professor John Seymour

Using a second generation immunotherapy drug for the long-term management of a common type of blood cancer has been shown to give patients more durable control of their cancer. A clinical trial has shown patients who took the antibody drug Obinutuzumab together with and after their chemotherapy had a 34% reduced risk of their disease getting worse, over three years.

This was compared to our current standard therapy which instead uses the first generation version of a similar antibody drug Rituximab in the same manner.

The trial involved more than 1,200 patients – many treated at Peter Mac or Monash Health – with follicular lymphoma and a paper reporting the outcome is published online today by the New England Journal of Medicine.

“We know standard treatment with chemotherapy and an antibody can suppress cancer activity for several years but, for many patients, effectiveness will wane and a relapse will occur,” says co-researcher and Peter Mac’s Director of Haematology, Professor John Seymour.

“Broadly we are looking for ways to improve and extend the durability of this response and, in this clinical trial, we’ve identified a drug that does this and is already available and funded in Australia for a related disease, chronic lymphocytic leukaemia.”

Obinutuzumab is already used to treat other types of blood cancer and, in follicular lymphoma and other non-Hodgkins lymphomas, it is used as a second-line treatment in cases where patients no longer respond to Rituximab.

The trial data supports Obinutuzumab’s use as the first-line treatment in follicular lymphoma.

Patients in the trial were split into two groups who received chemotherapy with an antibody drug and then ongoing antibody drug; either Rituximab (standard therapy) or Obinutuzumab. At follow-up three years later:

  • Progression-free survival was 73.3% in the standard therapy group, compared to 80% in the Obinutuzumab group.
  • The proportion of patients alive was 92.1% for standard therapy (46 deaths) compared to 94% in the Obinutuzumab group (35 deaths).
  • There were more high-grade adverse events in the Obinutuzumab group, but a similar frequency of fatal adverse events in each group.
  • The overall relative reduction of risk of cancer progression, or death, in the Obinutuzumab group was 34%.
  • Both Obinutuzumab and Rituximab are anti-CD20 monoclonal antibody drugs, an emerging new class of targeted immunotherapy drugs.

“This is a cancer we cannot yet cure but newly emerging immunotherapy drugs, used in conjunction with conventional chemotherapy, are giving us powerful new tools to extend patient lives,” says Prof Stephen Opat, from Monash Health, and who was also on the international clinical trial research team.

“This clinical trial data supports the use of Obinutuzumab as the first-line treatment in the immuno-chemotherapy and maintenance setting for previously untreated follicular lymphoma, as it would give patients a significant improvement in progression-free survival.”

The trial also involved researchers from the UK, Japan, Germany, Canada, Prague, Czech Republic and Switzerland.

This news was originally published on the Peter Mac website.

ACRF has supported cancer research at the Peter MacCallum Cancer Centre by providing three grants, totaling $7 million, towards cutting-edge cancer research equipment and technology.

Ashleigh’s Story

Donate now

 

My name is Ashleigh. I support the Australian Cancer Research Foundation and I am committed to doing what I can to end cancer.

In June 2015, I was 25 years old. I had just graduated from university and started my first full-time role as a lawyer. Everything seemed to be going according to plan…

Then one night, on a weekend away with my girlfriends, I felt a strange sensation in my throat and said so out loud. It was at that point one of my friends noticed that there was a visible lump on the side of my neck. I had no idea where it came from, or what it was, but I was pretty quick to assure her that it was nothing. Thankfully, she didn’t back down and made sure I went to the medical centre the next day.

One week later, the biopsy results arrived. The lump was cancerous and I was diagnosed with thyroid cancer.

For someone who had always planned their day down to the nth degree, my diagnosis came as a stark reminder that no one can ever really know what is around the corner for them. My diagnosis came at a time where everything in my life seemed to have finally clicked into the place that I had meticulously carved out. But, what I hadn’t planned for was processing a cancer diagnosis at 25.

I very quickly realised that cancer isn’t one of those things that you can predict and it isn’t something that you can immediately control. It doesn’t follow a script and it certainly doesn’t come with a manual. But what you can control, is the way you respond to it.

I also realised that many thousands of other Australian women face this life-altering reality every year and I was determined to change this

Thanks to the support of people like you and I, the survival rates for many types of cancer, including thyroid cancer, has increased by more than 20% over the past 30 years. That’s an incredible statistic – but it is also a fact. Cancer research breakthroughs are now happening at a faster rate than ever before because of our ongoing community support and advancements in scientific technology.

With this in mind, I wanted to do everything I could to help bring an end to all cancers. I approached the Australian Cancer Research Foundation with a small idea and it grew into something much, much bigger.

With their support and much planning, I hosted a charity black tie gala event called ‘Dinner for a Difference’ that raised over $26,000 for cancer research in June 2016.

By funding cancer research, we will get closer to a breakthrough that will change the way we think about cancer and the many lives that it continues to affect

When you donate to the Australian Cancer Research Foundation today, you give Australian cancer researchers access to the advanced technology they need to find better methods of prevention, detection and treatment for all the types of cancer that affect women.

None of us can know exactly what is around the next corner. But we can all take action today to help ready ourselves for whatever it is that we may find.

So, please join me in supporting the Australian Cancer Research Foundation, and a community that believes ending cancer is possible – because it absolutely is.

Please donate by 31 October to equip Australia’s best researchers with the tools they need to end all cancers that affect women.

DONATE NOW

Daniella’s tea for tomorrow and ACRF

High tea for cancer research

It was my love of the magical world of tea that prompted me to start my own business, Amity Created. Tea has this amazing ability to create a sense of calm and peace in almost any situation. That same sense of calm and peace also reminds me of spending time with my beloved Nonna (grandmother).

Last year I held my first Tea for Tomorrow event in support of my grandmother who was in the midst of a long battle with cancer. In the spirit of Amity Created and my obsession with anything tea related, it made sense to host a high tea. From our pretty teacups and delicious teas to the beautiful cakes; everyone who attended was really spoilt on the day. The response from the public was overwhelming; people attended from interstate and we raised just over $2,000.

Tea for Tomorrow has now become a new tradition. This year’s event, held again in Sydney, also quickly sold out. We more than doubled our fundraising amount to $5000, and we doubled the number of sponsors, all of whom were amazingly generous. Yet again, we had people fly in from Queensland and Melbourne to attend. Everyone came with their own story of how cancer had impacted their lives in some way. It was a very empowering and inspiring feeling to be surrounded by these wonderful people. Although my Noona has passed away, I like to think she was with us at this year’s event, saluting with a cup of tea!

ACRF and its staff have been a wonderful support to me over the past few years. I am appreciative of their help in organising my first event to the very kind words they sent to my family when we were experiencing the grief that comes with losing someone we cherished.

When it comes to fundraising, I chose to support ACRF because of their sole focus on cancer research. There is nothing more gut-wrenching than hearing the news that a loved one has been diagnosed with cancer. Until research leads to a cure for all types of cancer, it is vitally important to continue fundraising and raising awareness. I encourage anyone else who is thinking of fundraising and who genuinely wants to make a difference to act without delay. Without the support of the wider community, cancer research won’t continue at its current pace and every step forward leads to progress.

 

2017 Amity Created Sponsors: Almond Breeze Australia, Tea at Henry’s, Zen Green Tea, The Love Letter Collective, La Vita E Dolce Biscotti, Glow by Beca, Healing Hands Message Therapy, Wanderluxe and Co, The Tea Nomad, The Rabbit Hole Organic Tea Bar, Vellaris Boutique, Soul and Ark, Just Glow, Loho Stationary, Frank Trimarchi – Photography, Tulloch Wines

 

Share your story

How we can overcome the lack of treatment options for rare cancers

Colman Taylor, University of Sydney and John Zalcberg, Monash University

Rare cancers are just that: rare. This means research into each of these particular types of rare cancers is limited, and so are the treatment options. As a consequence, patients diagnosed with rare cancers face significant challenges.

In November 2016, the Australian Senate established a select committee to examine funding for research into cancers with low survival rates. More recently, the health minister announced A$13 million from the Medical Research Future Fund will be used for clinical trials to help achieve better health outcomes for people with rare or uncommon cancers.

The minister also commissioned new work on evaluating cancer medicines that treat multiple tumours and have a specific genetic feature (biological marker). This could improve access to therapies that might benefit some patients with rare cancers.

These recent steps are in recognition of the significant challenges associated with undertaking research into rare cancers. By their nature, rare cancers include small and variable patient populations making gold-standard randomised trials challenging or even impossible.


Read more: Unfair if rare: should the PBS change the way it lists cancer drugs?


The lack of evidence resulting from few or no randomised trials creates challenges for registering and reimbursing new medicines. This ultimately leads to a lack of subsidised medicines for these patients. As a result, the improvements seen in patient outcomes related to new therapies for more common cancers like lung cancer, melanoma and bowel cancer over the last two decades do not extend to rare or less common cancers.

What is a rare cancer?

The definition of a rare cancer is debatable. The RARECARE collaboration in Europe uses an operational definition of fewer than six cases per year per 100,000 population. In Australia, the medicines regulator, the Therapeutic Goods Administration (TGA), has recently updated the eligibility criteria for medicines treating rare diseases to fewer than five cases of the disease in a population of 10,000 people.

Historically cancers were categorised by the anatomical location, such as the breast or kidney. But with the discovery of new biological markers, common cancers can be grouped into smaller, more homogeneous and genetically similar subsets. So the number of rare cancers will continue to grow as medical technology advances.

Why don’t they have many available medications?

The lack of government-approved and subsidised medicines to treat rare cancers primarily stems from the lack of evidence supporting their use. Submissions to the current inquiry also cited problems such as a lack of research funding; the need for international collaboration; lack of investment by industry; attracting sufficient interest of researchers and recruiting sufficient patients.

It’s hard to recruit enough patients for research studies.
from www.shutterstock.com

Even if patients can be identified and recruited to a trial, it’s difficult to generate meaningful data from so few patients.

The lack of evidence presents challenges for new medicines trying to meet registration and reimbursement criteria in Australia. To be registered through the TGA, a new medicine must have demonstrated efficacy and safety.

In order for new medicines to be listed on the Pharmaceutical Benefits Scheme (PBS), it must have a demonstrated benefit over standard treatment, as well as being considered an efficient use of tax payer dollars.

New medicines for rare cancers are often expensive, especially when randomised trials are not possible.

What can we do to improve this situation?

With the changing nature of medicine and research, new opportunities are emerging to address the current inequity. The shift to treating patients based on the genetic profile of their tumour rather than the location of the cancer has increased treatment options for rare cancer patients.


Read more: How cancer doctors use personalised medicine to target variations unique to each tumour


To harness the benefits, changes are required with input from multiple stakeholders, including government, industry, clinicians, researchers and patients.

Better access to new medicines ultimately starts with better research. To achieve this, experts have called for additional targeted funding, innovative trial designs, and better partnerships between industry and researchers.

There is also the opportunity to collect better “real world” data via platforms such as the My Health Record, which could supplement existing research and allow performance monitoring of recently approved new medicines.

Organisations such as Rare Cancers Australia and the Cancer Drugs Alliance are liaising with government regarding changes that could improve access to novel medicines for patients with rare cancers. This includes greater input from patients and more flexibility in the way we evaluate medicines for public reimbursement.

The ConversationIt should also be recognised the problems faced in providing innovative treatments to patients with rare cancer extends to rare diseases in general. With modern medicine providing the potential to improve outcomes for patients with rare cancers as well as other serious chronic diseases, we need to have a broader conversation about what we can afford and what we are willing to pay for new medicines.

Colman Taylor, Post-doctoral Research Fellow, The George Institute; Conjoint Senior Lecturer, UNSW; Owner and Director, Health Technology Analysts, University of Sydney and John Zalcberg, Head, Cancer Research Program, Monash University

This article was originally published on The Conversation. Read the original article.

Jess shaves her head for cancer research

My name is Jess and when I was 14 years old, my mum was diagnosed and successfully treated for breast cancer. Eleven years later, Mum was diagnosed with metastatic (secondary) breast cancer, which really took her by surprise, being unaware that this could occur after being in the clear for so long. Mum is such a strong and brave woman, and someone that I look up to. I am determined to fight this battle with her, every step of the way, and getting behind cancer research is one way I can help to make a difference.

In taking on a fundraiser event, I decided to shave my head for donations. I haven’t had short hair since primary school so it was very long! I knew it would be a nerve-racking event but would also be my special way of supporting Mum as she is going through cancer treatment and experiencing hair loss. After doing some research on how my hair could be used, I decided to donate it for children who also experience hair loss. Hopefully, it will make a great wig for someone!

The whole experience of fundraising for ACRF was extremely rewarding, and the amount of support and love received from so many was overwhelming. Taking on my own fundraiser event has also inspired others to do the same. For example, a friend of mine is now hosting her own head shave fundraiser. The most important step in planning for a fundraiser is making sure you give yourself enough time to brainstorm ideas, including with others who have hosted similar events. If I didn’t have the support from friends, family, work colleagues, ACRF and local businesses, my event would not have been possible.

So many lives continued to be affected by cancer and when you see the suffering of others, especially those close to you, it encourages you to want to strive toward making a difference and support cancer research.

Share your story

Janet gets clipped at fundraising event

I am 65 years old and ready for retirement this year. I’ve been working since age 15 so it’s time! My current employer is Bunnings, and the company team was great in supporting my fundraising efforts this year.

My motivation for raising money for cancer research is one that’s close to home. Two young members of my family have been diagnosed with cancer since 2015. When my sister’s daughter, Kylie, was discovered to have ovarian cancer, the cancer was already advanced and classified as terminal; her prognosis was 12 months, at best. Kylie went ahead with her 30th birthday celebrations in February 2016 just prior to having chemotherapy treatment and surgery to remove as much of the cancer as possible and to improve her level of comfort. After several weeks of recovery in hospital, she returned home and then passed away two weeks later while sleeping next to her beloved husband. My niece had known about her cancer for less than six months.

The family is also supporting my brother’s daughter, Leanne, while she fights bowel cancer. Her outlook is encouraging, having reacted really well to chemotherapy treatment. There were shadows on her lungs and liver where the cancer spread, but surgery has successfully removed lung tumours destroyed by the chemotherapy. We are hopeful it will be the same outcome with her liver. Leanne is 35 years old with a wonderful husband and two young children.

When I decided to go ahead with fundraising, I was very overdue for a haircut so shaving my head seemed the best way to go. Bunnings let me use their public BBQ area for the event. Several of my co-workers gave up their rostered day off and along with my family cooked and served the BBQ, sold at the cake stall and mixed with the Bunnings customers who stopped to see what was going on. The amount of donated jams, pickles, relish, cakes and biscuits was astounding and well received by the customers, making over $600 in that area alone. The Bunnings Manager, Damian, cut my hair the same way he does his own – short and with clippers. The whole day was really great, a wonderful atmosphere, fantastic customer attendance and successful with approximately $2700 raised altogether.

Fundraising for cancer research is something we can all do – there is strength in numbers. Being able to do something that will assist in the discovery of a cancer cure is well worth while.

Share your story

Brent in endurance competition for ACRF

I’ve been involved in Surf Life Saving since age eight and played sport my whole life so it was a natural to get involved in Coolangatta Gold, the ultimate endurance race in surf sports. I have competed numerous times, three years taking out the 30-39 age group, and runner-up twice. This year’s Coolangatta Gold for me will be unique in two ways. I plan to push the boundaries a little further by taking part in both the 21 km course and 41.8 km course, and I’ll be fundraising for ACRF. My goal is to raise $10,000 and generous donations have already pushed that goal over the half-way mark.

I have known many people over the years who have been affected by cancer; most recently a good mate’s daughter had a tough fight with cancer. Myself and others felt helpless, so I had been wondering just how I could support my friend and others. I believe that kind of support is best represented by ACRF and their ongoing cancer research. Research not only assists in treatment advances; it will ultimately result in a cure for all cancers.

I’m sure there are people who think it’s crazy to take on two races in the same weekend and in reality that is probably true. Thankfully, my wife, family, friends, coaches and colleagues have been truly supportive, which helps me to forget about the cold mornings paddling in winter, being tired and having sore muscles. I don’t believe anyone has done both courses on the same weekend so this is my chance of pushing myself to achieve it.

My two-year-old daughter won’t remember her Dad’s efforts in this year’s competition, but I do hope she has the opportunity to remember a long lifetime – free of cancer.

 

Share your storySupport Brent

 

Girls with curls fundraise for cancer research

We are four aqua aerobic friends, the Curly Girls. Sadly, cancer has impacted all of us in some way – family members, colleagues and friends. If we are to lessen cancer’s grip on us, it means continued research and the cost of that is enormous, well beyond government funding and grants. We wanted to help out and decided to fundraise for ACRF by holding a head shave event. The Curly Girls would become the Baldy Babes!

In planning our event, we decided to think big and involve the whole community of Sussex Inlet. We canvassed local shops and businesses seeking donations of raffle prizes and BBQ supplies and lined up volunteers to help out on the day. The event was held for three hours on a Saturday to coincide with our local market that is always popular and draws extra people into town. There was a coin toss, golf putting competition, door prizes, wig library demo, raffle draw, and entertainment by local musicians. Everyone in the community was enormously supportive and our head shave day raised over $11,000. There are many memorable highlights: the buzz on the day, the personal stories shared by raffle ticket purchasers and the hugs that followed, the generosity of anonymous donors, the many friends and people in the community who gave their time, money and support without hesitation, and of course the excitement of having raised such a sizeable amount of money.

We love our new less hair look and some of us are thinking how easy care it is. Our friends, family, and people on the street are having fun sharing comments as our hair slowly grows back.

We’re proud of our fundraising achievement, and we had a great time doing it. To anyone else planning a similar event, our advice would be to give yourself time to plan – we took 10 weeks – and don’t be afraid to ask others for help. Plan to print and sell raffle tickets, plan an event schedule for the day, do a test run, and then plan some more. After all, you want the best opportunity possible to raise funds on the day.
Kerrie, Kim, Denise & Pam

 

Share your story

Scott is shaving his beard for cancer research

Australia cancer researchMy mother was Dawn by name and Dawn by nature. She shone every day and had an amazing ability to turn our world into a brighter place. Losing her this year was the single most devastating thing to happen in my life.

I am 37, an only child, and fortunate to have always enjoyed a wonderful relationship with my parents. The three of us have done everything together, including working in the marketing and creative agency that I started in 2000.

Mum was a remarkably selfless person. She saw the good in everyone and everything, giving her love freely and openly. Mum battled rheumatoid arthritis for over 50 years and to also be diagnosed with cancer was doubly harsh, but she remained resolutely strong.

Because Mum never really liked my beard, and certainly wouldn’t as long as it is now, it’s a gesture to her and to honour the way she approached life that I’ve decided to shave it off and fundraise for cancer research. Even before Mum knew she was ill, I had thought about fundraising but didn’t act on it. My advice now to anyone, who wants to fundraise, is to stop just thinking about it and get started! You will be amazed by the support you’ll receive from people when you put it out there.

My fundraising goal is $10,000, and I’m working hard to achieve that amount – and more – for the researchers determined to find the answer to cancer. While my Mum initially contracted breast cancer, she passed away from secondary cancer to the liver. Finding the answers to one type of cancer will help to unlock the key to another. It’s vitally important to continue supporting research into this horrible disease so that a cure will be discovered.

There are a lot of people who can’t wait to see my beard of three years gone, or who are just curious about what my chin looks like these days! Even those who don’t want me to shave it off totally understand the cause and support me because they know how special Mum will always be for me.

Support ScottShare your story

New drug to supercharge immune cells in the fight against cancer

Australia Cancer Research
The vascular team at the Harry Perkins Institute, Image courtesy of the Harry Perkins Institute of Medical Research.

A new cancer treatment with the dual ability to normalise tumour blood vessels and boost the body’s immune system, has been developed by researchers from the Harry Perkins Institute of Medical Research and The University of Western Australia.

Many tumours can become resistant to the body’s immune system by creating a barrier of tangled blood vessels that feed the tumour while locking out immune cells that would attack cancer cells.

Professor Ruth Ganss, head of the Perkins Cancer and Cell Biology Division, said the new treatment worked by generating more “normal” blood vessels and lymph-node-like structures within the cancer, which together enabled immune cells to better reach the cancer core.

“Lymph nodes, a vital component of our immune system, normally only exist outside of the cancer and work to filter cancer cells and generate white blood cells that fight infection,” Professor Ganss said.

“Our drug strengthens the immune response against tumours by inducing these lymph-node-structures together with normalised blood vessels, producing immune cells that infiltrate deep into the cancer. There are currently no single treatments available which can produce these two features in cancers.”

“Our research shows that once our drug has triggered the lymph-node-structures within the cancer, current immunotherapies that have been approved for clinical use, can work more effectively,” Professor Ganss said.
“We’ve tested our treatment on pancreas and lung cancer models, which are particularly difficult to treat, and have had very promising results.”

“We envision that a combination of our drug and existing immunotherapies, will greatly enhance the outcomes for patients in the future.”

Perkins Director, Professor Peter Leedman, said the treatment was a novel approach to overcome the challenge that occurs when tumours become resistant to the body’s immune system.

“Immunotherapy is an exciting new area of research, whereby the immune system is amplified to support the body’s natural defenses to help fight cancer,” Professor Leedman said.

“Professor Ganss and her team are building on this groundbreaking work, to develop combination therapies that could deliver the best outcomes for patients.”

The research was published in the journal Nature Immunology.

This news was originally published on the Harry Perkins Institute of Medical Research website.

ACRF has supported cancer research at Harry Perkins Institute of Medical Research by providing two grants, totalling $3.6 million, towards cutting-edge cancer research equipment and technology.

QLD jewellers do charity run for ACRF

Charity fundraising event

Original story written by Talia Paz for Jeweller Magazine

Two Queensland jewellers have completed the Sydney Running Festival in an effort to raise money for the Australian Cancer Research Foundation (ACRF) and pay tribute to a sales representative who passed away earlier this year.

House of Harvey jewellery store owners, Alannah and Bob Harvey, participated in the running event on Sunday 17 September and have so far raised $2,750 for ACRF in 2017.

The Ingham-based retailer has supported the cancer research foundation for many years; however, Alannah said the 2017 fundraising efforts were in honour of Mike Griese, a sales rep for Ikecho Pearls, Jewellery Centre, Imajpack and AM Imports who lost his battle with cancer in March.

“We have always supported cancer research; having lost family, and with a team member’s survival from cervical cancer, it is the best ‘fit’ for our store,” Alannah explained.

“After Mike Griese lost his battle, we felt compelled in 2017 to honour him, another life cut too short,” she added.

Alannah said the Sydney Running Festival was an ideal way to generate industry support for the retailer’s charity efforts and increase customer relationships.

“It’s a high-profile event with many spectators and national media coverage, and therefore is a great platform for ACRF to create awareness, recruit participants for vital funding for cancer research and showcase achievements,” she explained.

“It also gives us a fundraising platform for our clients – who support us each and every year – to regularly see just how a little effort can achieve great results.”

Industry support

Alannah said her store’s ACRF fundraising initiatives would continue through to Christmas, noting that several suppliers including the Jewellery Centre and Adina Watches had also supported the business’ efforts.

She stated that there were additional industry benefits to promoting charitable causes.

“We believe today perhaps more than ever, the public seeks businesses that have a social conscience,” Alannah explained.

“The opportunities are there for all of us in retail to contribute to society by simply being a little creative every time we run a promotion, and it is our philosophy that most of the public appreciate that a business is constantly working to assist ‘something’; they feel apart of it, and they get a bonus in return.”

ACRF was established in 1984 and aims to end cancer by providing scientists with the equipment required to improve prevention, diagnosis and treatment.

Founded in 2001, the Sydney Running Festival is conducted by non-profit organisation Athletics Australia.

The event supports numerous national-based charities and has raised more than $16.9 million since its inception.

Share your story

Melbourne teenager makes generous donation to ACRF

Hello, my name is Ben. I am 13, attend McKinnon Secondary College, like hanging out with my friends, watching classic films – my favourite is No Country for Old Men – and listening to music.

I also had my Bar Mitzvah celebration this year, which is quite an important occasion. It’s traditional for family members and friends attending the ceremony to give gifts, and I ended up receiving a generous amount of money. At first I really couldn’t think of what to do with all of it. Sure, I could have bought some expensive clothes and other stuff which I probably don’t need, but then I got to thinking about one of my favourite musicians, George Harrison, who died of cancer. That’s when I decided to make a donation towards cancer research.

I read somewhere that 8.2 million people die of cancer related deaths each year, and like everyone, I want to see that number at zero. I know that ACRF is funding cancer research and researchers are getting closer every day to finding the cure for many cancers, so my donation will hopefully help make that happen a little faster.

To anyone thinking of fundraising or making a donation to cancer research, I have to say, 100% you should do it. If you can donate to research, you are pretty much closer to helping save people’s lives.

Surprise discovery to help those with prostate cancer

Cancer researcher Dr Katherine Morel Flinders University
Dr Katherine Morel, image courtesy of the Flinders Foundation

 

A surprise discovery by researchers at Flinders Centre for Innovation in Cancer is giving hope for men with the most aggressive and incurable form of prostate cancer.

Two years ago, a Flinders University research team led by Professor Pam Sykes started investigating how parthenolide – a naturally occurring anti-inflammatory compound found in feverfew daisies – could aid radiotherapy by attacking tumours while also protecting nearby heathy cells, potentially increasing survival rates while also helping to eliminate the nasty and debilitating side effects of radiotherapy.

Further research has demonstrating that Parthenolide may also have the ability to prevent aggressive and incurable metastatic prostate cancer.

“When we started this research, we were really just focusing on using parthenolide in radiotherapy, but this side-project looking at slowing down tumour progression evolved and has been a bit of a surprise,” says Flinders Centre for Innovation in Cancer (FCIC) postdoctoral researcher Dr Katherine Morel from the Flinders University College of Medicine and Public Health.

“Many men with localised prostate cancer can live for a long time, but when the cancer becomes metastatic – meaning it spreads from the prostate to other parts of the body – unfortunately it’s incurable,” she says.

Part-funded by Flinders Foundation, preliminary results of the latest research have shown slower tumour growth and a reduction in metastatic tumours when treated with dimethylaminoparthenolide (DMAPT), a water-soluble version of parthenolide.

“When combined with radiotherapy, the drug induces greater cancer killing, particularly targeting high-grade tumours which tend to metastasise,” Ms Morel says.

“If we could give it to men with early stage prostate cancer, or men who may be more susceptible to prostate cancer, then it may have the potential to reduce the severity of the cancer or even reduce metastasis all together.”

The latest research holds great hope for the thousands of men who will be diagnosed in future.

“Science is long-haul and it can take time to see results – the work that’s now emerged on metastatic tumours has far and away exceeded what we expected to find.”

Dr Morel has been collaborating with Professor Christopher Sweeney from Dana-Farber Cancer Institute at Harvard Medical School in Boston, who is currently testing parthenolide in leukaemia clinical trials.

Prostate cancer is the most commonly diagnosed cancer in Australian men.

While significant improvements have been made in prostate cancer therapy, there is still a need for novel treatment options, particularly for preventing and treating metastatic prostate cancer which has a very poor prognosis, and for protecting from unwanted debilitating side effects of radiotherapy due to damage done to healthy tissues near the prostate.

“When delivered prior to radiation, DMAPT was able to reduce cell death in healthy cells during radiotherapy while also increasing prostate cancer killing particularly in more advanced regions of prostate cancer, providing the potential to increase cure rates,” she says.

“Analysis of the prostate tumours identified important molecules involved in the mechanism of parthenolide protection, which support the potentially broader application of DMAPT for a number of different cancer types.”

The research was published earlier this year in the journal Radiation Research.

This news was originally published on the Flinders University website.

ACRF has supported cancer research at Flinders University by providing a $1 million grant towards cutting edge cancer research equipment and technology.

Stef is losing her locks to fundraise for research

Australia cancer research

I admit to being completely obsessed with my hair – it’s my crown and a huge expression of my personality. I also love unicorns and unicorn coloured things, which explains why my hair is dyed in ever-changing bright colours. Despite the hair fascination, I decided to shave it off when a really close friend of mine was recently diagnosed with brain cancer and started chemotherapy. If she was going to lose her hair during treatments, mine could go as well. I didn’t want her going through the experience alone.

I was apprehensive about my decision but any doubts vanished after one of my lovely work colleagues shared her hair loss experience while receiving cancer treatment. She was on a weekend away with her husband for his birthday when all of her hair fell out. I could only imagine how confronting and distressing that would have been for her. While I can choose to lose my hair, and when, she couldn’t.

Like so many others, my family and friends have been affected by cancer; we’ve lost one of my aunties and my Noona to cancer and my best friend’s mother and sister have both died of cancer. Fundraising for ACRF and cancer research is my way of giving back to a community that dedicates so much time and effort into finding a cure for all forms of this horrible disease.

I have been really thrilled by the big-hearted support and encouragement received from my co-workers, local businesses, ACRF, and my family and friends. Since starting my fundraising page, I have received several generous donations, including from people who have never met me. And, retailer Peter Alexander sent a plush stuffed unicorn for my unicorn themed party on the night of the big shave – just one week before my 26th birthday.

The world needs more doers. I’m really stoked that I’m making a difference and hopefully taking ACRF one step closer to finding an end to all cancers.

Zero Childhood Cancer national clinical trial launched

Personalised treatment for childhood cancers in Australia is a step closer thanks to the Zero Childhood Cancer program’s national clinical trial launched today.

ACRF is one of the founding funders of the Zero Childhood Cancer Project, a $1.5 million grant was awarded to the project in 2014.

The trial will see scientists from thirteen leading Australian and international research institutes and doctors from all eight of Australia’s kids’ cancer centres will work together to identify and recommend new treatment options. These will be specifically tailored to suit the individual cancers of children with the highest risk of treatment failure or relapse.

The Zero Childhood Cancer program recognises that each child’s cancer is unique, so they respond differently to anti-cancer treatment. Detailed laboratory analysis of tumour samples will help identify the drugs most likely to kill each child’s specific cancer.

Pilot study paves way for national launch

The national clinical trial builds on a successful NSW pilot study of nearly 60 children begun in late 2015 for children with the most aggressive cancers whose chance of survival on standard treatments was less than 30%.

The pilot study proved the program’s feasibility, successfully putting in place the complex logistics and laboratory testing needed to analyse patient tumours and get meaningful results back to doctors in real-time.

The clinical trial expands the program to give hope to families across the country and will enrol more than 400 Australian children over the next three years, bringing the most advanced diagnostic technologies close to home.

Professor Michelle Haber AM, Executive Director of Children’s Cancer Institute and Research Lead for Zero Childhood Cancer, said the pilot study showed the urgent need for personalised medicine.

“Originally this pilot study was planned for 12 young patients. However nearly 60 children have been enrolled in the program due to the high demand by clinicians and parents.

What’s next?

Professor Haber said personalised treatment gives kids with the most aggressive cancers the best chance of surviving their disease because it is based on reliable scientific information, such as individual genetic mutations, unique to that child’s cancer.

“Using the latest molecular profiling techniques and laboratory testing of patient cancer cells with anti-cancer drugs, Zero Childhood Cancer will give the most detailed diagnosis possible in Australia to date for children with the most aggressive cancers. It is one of the most complex and comprehensive personalised medicine programs in the world,” she said.

Another benefit of personalised medicine is the potential to refine or change an individual child’s cancer subtype. Cancer diagnoses may be changed once detailed genetic and other molecular tests are done, opening up new treatment options. Several children on the pilot study had changed diagnoses as a result of detailed testing.

A/Professor Tracey O’Brien, Director of the Kids Cancer Centre at Sydney Children’s Hospital, Randwick, said targeted therapies such as those identified through Zero Childhood Cancer will allow a much more sophisticated approach.

“The information we gather will benefit children on the program first and foremost but will also be incorporated into future front-line treatments. The knowledge gained is likely to unlock further scientific discoveries that will also ultimately benefit future patients.  Most of all, it will bring us a step closer to our vision of one day curing all children of cancer.”

The Zero Childhood Cancer initiative will be led by Children’s Cancer Institute and The Kids Cancer Centre at Sydney Children’s Hospital Randwick, part of The Sydney Children’s Hospitals Network. Participating hospitals and research centres in this collaborative national project include a number of previous ACRF grant recipients:

NSW

  • Children’s Cancer Institute (Program research leaders)
  • Sydney Children’s Hospital, Randwick (Program clinical leaders)
  • The Children’s Hospital at Westmead
  • John Hunter Children’s Hospital
  • Kids Research Institute, Westmead
  • Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research
  • The ACRF International Centre for the Proteome of Cancer (ProCan), Children’s Medical Research Institute, Westmead

QLD

  • Lady Cilento Children’s Hospital
  • University of Queensland Diamantina Institute

SA

  • Women’s and Children’s Hospital
  • South Australian Health and Medical Research Institute
  • Centre for Cancer Biology

VIC

  • Royal Children’s Hospital, Melbourne
  • Monash Children’s Hospital
  • Peter MacCallum Cancer Centre, Melbourne
  • Murdoch Children’s Research Institute

WA

  • Princess Margaret Hospital (moving to Perth Children’s Hospital)
  • Telethon Kids Cancer Centre, Telethon Kids Institute

Any interested parents of children with cancer should contact their child’s paediatric oncologist in the first instance.

Children's cancer

Image: Minister Greg Hunt MP with a young cancer patient and their family. Photo courtesy of Sydney Children’s Hospital, Randwick.

New bioinformatics tool to improve the early detection of cancer

Matcol is a bioinformatics tool which helps determine protein and DNA co-localisations visualised using fluorescence microscopy. Co-localization is the observation of the spatial overlap between two or more different fluorescent labels and their biological interaction –  this process allows cancer researchers to see whether a protein of interest is in proximity to cancer marker proteins.

Previously, most scientists used image analysis software to manually perform co-localization identification.Yet the challenge with manual co-localization quantification is that it’s subjective, prone to human error, and takes longer to perform.

Dr Khushi told the Daily Telegraph, “Single image analysis takes up many hours and scientists are required to study a large cohort of images.”

This pioneering development can replace manual co-localisation counting, and be applied to a wide range of biological areas including cancer detection.

MatCol automates this quantification task and can quantify hundreds of images automatically within a few minutes,” Dr Khushi said.

With MatCol’s automation and more streamlined processing, scientists can identify cancer in its early stages—allowing for early medical intervention and the potential to save lives.

This news was first published on CMRI’s website.

In 2015, ACRF  awarded one of the largest private grants for medical research equipment in Australian history – $10 million – for six cutting-edge machines to establish The ACRF International Centre for the Proteome of Cancer (ProCanTM) at Children’s Medical Research Institute (CMRI) in Westmead. The Centre was officially opened in September 2016.

Image: Dr Dr Matloob Khushi, image supplied by CMRIDr Matloob Khushi, postdoctoral researcher at Children’s Medical Research Institute, has developed a new bioinformatics tool to improve early detection of cancer.

Cell surface receptors guide immune cell attacks

Researchers at Walter and Eliza Hall Institute (WEHI) have discovered how immune cells use a unique set of assembly instructions to ‘mix and match’ how they respond to, and kill, tumour and diseased cells.

Cell surface receptors form groups that the body assembles using different molecular combinations, much like logo blocks. These combinations guide how the immune cell acts when it makes contact with a cancerous cell, an infection, or other external signals.

The new research identifies the features that allow these pieces to assemble in specific combinations. Understanding how these groups assemble naturally could pave the way for future improvements in immunotherapy, such as engineering cancer-specific immune killers.

How do cell surface receptors work?

Cell surface receptor groups consist of an external receptor that binds to signalling molecules, an internal molecule that instructs the cell how to respond, and a cell membrane-embedded portion that anchors and links the other two segments.

In the past, these cell membrane-embedded sections of the receptor were largely ignored, partly because they are so difficult to work with, said Associate Professor Matthew Call at WEHI.

Associate Professor Call said the team discovered an entirely new set of assembly instructions used by molecular sensors embedded in the thin fatty cell membrane to build receptor complexes in response to different stimuli.

“Effectively, these membrane-bound sensors determine ‘who’ the immune cell talks to. This is really important in the promising field of cancer immunotherapy, because it could help us better engineer cells to specifically talk to – and destroy – cancer cells,” Associate Professor Matthew Call said.

The new findings

The researchers began by studying the receptors on natural killer (NK) cells, but found that the same assembly instructions were used in a host of immune cells that “run around and eat and blow up” cancerous and other diseased cells, Dr Melissa Call at WEHI said.

“One subset of these receptors, called Fc receptors, were the focus of this research. We were particularly looking at the subset of Fc receptors found on natural killer (NK) cells – immune cells that poison tumour and virus-infected cells that have been ‘marked’ by antibodies,” Dr Melissa Call said.

She said the study showed that different subsets of Fc receptors used completely different assembly instructions compared to other, similar receptors.

“Over the past decade or so, this has become really important therapeutically because of a new field of cancer immunotherapy called chimeric antigenic receptor therapy, or CART,” Dr Melissa Call said.

“The idea of CART is that you create specially engineered receptors in immune cells that are highly specific for an individual cancer. Understanding in depth how these receptors are assembled naturally is vital for us to understand how best to design them ourselves for cancer therapy, to look at improved ways of stimulating the immune response to cancer.”

The finding were published in the journal Proceedings of the National Academy of Sciences.

The news was first published on the institute’s website.

ACRF has supported WEHI by providing three grants, totalling AUD 5.5 million towards cutting edge cancer research equipment and technology.

Image: ‘T-cell receptors interact with MHC class II antigen complexes’ from istockphoto for illustrative purposes only.

Samantha is taking part in Blackmores Sydney Running Festival 2017

Australia cancer research

Honestly, I have never been interested in running a marathon but after the recent loss of two very special people, I wanted to do something to raise money for cancer research.

My god-daughter Jessica passed away at age four last year, after months of treatment for neuroblastoma. My Grandad Graham also died, and very suddenly, with lung cancer being a contributing factor. Both of them lived in the UK, which was my home before moving to Australia three years ago to take a job in the banking industry.

The impact of cancer is huge. I see how my friend Nicki struggles every day, having lost her daughter, and my own family was shattered by the death of my Grandad.

I cherish memories of Jessica and it’s sad to know that Aunty Sammie, as she called me, will never be able to build the relationship I really wanted to have with my only god-daughter.

My grandfather and I were very close and there are so many wonderful memories of times we spent together. He was a very patient man which was undoubtedly tested while teaching me how to drive a car, and he was an enthusiastic football fan, convincing me to support his favourite association club.

When thinking about the many options for fundraising, nothing stood out that would challenge me to push out of my comfort zone. At the same time, I also wanted to highlight the importance of on-going fundraising for cancer research. One of my work colleagues suggested running in a marathon – a suggestion that I entertained for about five minutes before dismissing it as too hard. It took me about a week to come to the conclusion that any pain that I would encounter in distance running would only be a shadow to what Jessica felt on a daily basis while trying to beat cancer.

I started off unable to run 5 km and now my longest distance has been 35 km. It’s thrilling to come so far in so little time.

I chose to support ACRF at the Blackmores running festival after learning that ACRF have a panel of medical advisors that ensure funding is provided to the most promising research initiatives. Those researchers need funding to work out the combined clues that will eventually end this disease.

I am probably a bit addicted to running now. It’s not just the mental and physical challenges, it also really shows how much you want to raise money to support this cause. Memories of Jessica and my Grandad will be with me every running step of the big race on 17 September.

Share your story

Potential treatment for brain cancer as drug shrinks tumours

An international team of researchers has found a drug previously approved to treat breast cancer could also be used to shrink medulloblastoma, the most common malignant brain tumour found in children.

The discovery, made by The University of Queensland’s Institute for Molecular Bioscience and the Fred Hutchinson Cancer Research Center in Seattle, has led to a clinical trial using the drug palbociclib to treat children with medulloblastoma.

Professor Brandon Wainwright from University of Queensland said brain tumours were the most common cause of cancer death in infants, children and adolescents. And, even survivors can end up with significant long-term side effects from existing treatments.

“Clearly, we need new therapies that increase survival of young patients and reduce the side effects they suffer, such as delays in brain development, growth problems and increased risk of other cancers,” Professor Wainwright said.

Genetic code leads to remarkable discovery

Fellow UQ researcher Dr Laura Genovesi examined the genetic code of medulloblastoma to predict whether these tumours may respond to already-approved drugs.

“This analysis led us to believe that palbociclib, an oral drug approved in 2015 for the treatment of breast cancer, would be effective against medulloblastoma,” Dr Genovesi said.

“We expected that palbociclib would arrest the growth of medulloblastoma, but we were stunned to find that it went a step further and actually shrank the tumours to a size where survival is possible.”

“The finding is remarkable since the tumours were very advanced and were treated for only a short period of time and we did not use any other therapy such as chemotherapy in combination.

“Some tumours recurred once treatment with palbociclib stopped, probably due to resistant cells within the tumour.

“It means that palbociclib, or drugs like it, could be used against medulloblastoma in combination with other drugs to treat resistant cells.

“If the clinical trial is successful, it would represent a major step forward to taking this research from the genome to the clinic.”

The study is published in the journal Clinical Cancer Research.

The research was supported by many American and Australian organisations. The news was first published on the UQ website.

ACRF has supported cancer research at IMB by providing four grants, totalling AUD $7.1 million, for the purchase of cutting edge research equipment and technology.

Image: Courtesy of IMB UQ

Cooper Rice-Brading

Australia cancer research

Sarcoma claims the lives of two in five people with this cancer. Hope lies in research, which will aim to significantly increase the prospects of survival for adolescents and young adults.

Eighteen-year-old Cooper, will leave the Sydney Grammar School gates for one final time on Friday 1 September 2017, but not as an HSC student with his life ahead of him, but instead, surrounded by many family and friends, who are left broken hearted at his passing. He lost a protracted battle with osteosarcoma on Thursday, 24 August 2017, in the arms of his loving family, and life will never be the same for those left devastated by his passing.

As were Cooper’s wishes, his family, Mitchell, Colin and Tania will continue the meaningful work of their son Cooper, through the Cooper Rice-Brading Foundation, for sarcoma research. Cooper identified the need for critical research for this cancer, very early in his treatment regime. He spent the past eighteen months passionately telling his story, in order to raise awareness and funding, so other adolescents did not have to suffer his plight.

In lieu of floral tributes, the family have asked if you may consider donating to the Australian Cancer Research Fund (ACRF), to facilitate the critical research required to prevent another adolescent needlessly losing their life to sarcoma.

 

Donate now

Zoë’s Story

 

My name is Zoë and I’m writing to you because I believe in a world without cancer is possible. But it will not be possible without your help.

To me, actions speak volumes. There are times when cancer can make us feel powerless, but I’ve chosen to take action.

I wanted to share my story with you, because like me, I know that you want to see an end to all cancers. In December 2013, my father Ron was diagnosed with Burkitt lymphoma. I don’t remember a lot about the moment we found out, except that I was with my parents in the oncologist’s office and he told us it was rare. When you stop and think, you realise not a single person goes through life without being impacted by cancer – either through a friend, family member or by experiencing it themselves.

So I am asking you to please help me fund the technology researchers need to stop this suffering.

My dad did everything he could to beat his cancer over the next three years. It was hard work and he had set backs – including a heart failure, multiple infections and countless trips to the ER. And to his dismay, his golf game got much worse. But the treatment was working and his tumour went from 119mm to nothing. We had been celebrating a year of remission for my dad when I got married in July 2016. He was in good spirits.

But we all know that with cancer things change quickly and without notice.

The day after my wedding, dad told me he had relapsed. The cancer was in a new spot and it was aggressive. He had known for two weeks – in fact he found out on my birthday. My father loved his family so much so that when faced with heartbreaking news that required unrelenting support towards him, he buried it, gave me away, delivered a beautiful speech and danced and mingled the night away. When he told me, I cried. I sobbed actually. It turns out you can never feel comfortable about defeating cancer. It is a beast and it’s not polite about when or where it will occur. It is the worst house guest and it is never, ever invited. Once I finished crying, my thoughts went to my parents who had to stump up and do this again. My dad had good days, bad days and damn ugly days. There were days when he wanted to eat super foods, drink super drinks and exercise. And there were days when he just wanted to hide, when he was angry and absolutely deflated, when no one could say anything to make it better. He lived as best he could, inside hospital walls and even with a drip attached to him.

My mother (pictured above with my dad and their granddaughter) had one of the hardest jobs of any of us. They had been married for 48 years, they were best friends. But you cannot deny that cancer changes a relationship; they became comrades, standing side by side every day.

What I would love is for us, as a community, to remember that everyday there are people and families around us who are struggling with this.

Cancer changes the way people interact with you. It makes people uncomfortable – cancer patients look different and they look unwell. Friends can go missing for a period of time too. When times are hardest, it is the patient in the middle of it with their family, and a small handful of friends, who stand on the edges for support. Sometimes you don’t know what support you need, sometimes you just need someone to hold you up.

In September 2016, my father died. It is hard. There is no amount of time between dad’s death that will make it easier or less present for me.

That person has gone and naturally there is a huge hole in my life. I will always miss him. Every memory of my dad is clearer than it was when he was alive. Everything that I knew he loved is even more present in my days. There is no getting over it, there is simply taking steps forward knowing I have his spirit with me. I think we need to support each other in this community in whatever way we can. Together we can make life better for those who are living with cancer.

If you feel like I do, and you want to make sure that no one else has to experience the pain and heartache of cancer in the future, join me to give Australia’s best researchers the tools they need to end cancer.

The sum of what you give doesn’t matter, what matters is the sum of people who give. Together we can change the future. We can create a world without cancer.

Please donate by September 30th. Your donation will go directly to cancer research.

Study confirms: Over 90 per cent of cervical cancers are preventable by vaccination

Up to 93 per cent of cervical cancers in Australia could be prevented by a new HPV vaccination, and researchers hope one day vaccination will almost entirely eradicate the disease.

In the largest study of its kind, researchers in Melbourne have taken an in-depth look at a large number of cervical cancer samples to determine the types of human papillomavirus (HPV) that cause cancer in Australian women.

The results show that 77 per cent of cervical cancers in Australian women carry the HPV types 16 and 18, which the current quadrivalent HPV vaccine (Gardasil) protects against. This is higher than the international prevalence of 71 per cent.

The study further identified that 16 per cent of Australian cancers contain the next five most common cancer-causing types globally (types 31, 33. 45, 52 and 58), which a new HPV vaccine would protect against. The new vaccine is currently under consideration for use in the Australian National HPV Vaccination Program.

HPV is a group of viruses mainly transmitted through sexual contact and most people are infected with HPV shortly after the onset of sexual activity. A small number of those infected will go onto to develop abnormal cells that are the precursor to cervical cancer.

Published in the International Journal of Cancer, the collaborative study was led by the Royal Women’s Hospital and Victorian Cytology Service (VCS), in partnership with expert cancer pathology laboratories in Victoria, New South Wales and Queensland.

Lead author Associate Professor Julia Brotherton, Medical Director of Australia’s National HPV Vaccination Program Register at VCS, said the findings were “great news for our daughters and all young Australian women”.

“This study highlights that the new HPV vaccine yet to be released in Australia could prevent over 90 per cent of cervical cancers, which is an incredibly exciting prospect,” Prof Brotherton said.

Director of the Royal Women’s Hospital Centre for Infectious Diseases and study senior author Professor Suzanne Garland said the research confirmed that girls who are vaccinated against HPV with the new vaccine should have a very high level of protection against cervical cancer, and that one day this could potentially mean women need to screen less often.

“The new vaccine still protects against genital warts but is expanded to cover the seven most common viral types that cause cervical cancer. I do believe that if we continue with this high coverage of vaccination, we could almost wipe out cervical cancer in women,” she said.

The outcome of a Pharmaceutical Benefits Advisory Committee (PBAC) review of the new vaccine is scheduled for release mid-August. If recommended, the vaccine could become part of the National HPV Vaccination Program as early as next year.

The study Looking beyond human papillomavirus (HPV) genotype 16 and 18: defining HPV genotype distribution in cervical cancers in Australia prior to vaccination was jointly authored by Prof Brotherton and the Women’s Dr Sepehr Tabrizi.

This news article was first posted on The Royal Women’s Hospital Victoria website.

Will attempts to break Guinness World Record at Blackmores Running Festival

Australia cancer researchWill Bond took on the 2017 City2Surf, running 14km in a full Chinese Lion Dance costume raising over $5,000 for cancer research.

Now, Will is taking on a whole new challenge by pushing limits and competing for a Guinness World Record at the Blackmores Sydney Running Festival this 17 September 2017.

“I am running the Sydney Blackmores Marathon on the 17 September 2017, and as a mark of respect and memory to my Kung Fu Sifu (at Jow Ga Kung Fu Academy Australia) who recently passed away from cancer, I will set the world record for FASTEST MARATHON RUN IN A KUNG FU UNIFORM!!”

Will is running this in the official Jow Ga Kung Fu Academy uniform, including black Jow Ga tunic, full length black Kung Fu pants, a black belt, and black Kung Fu training shoes. Note: these shoes are not made for running! They are very thin, canvas shoes. Will, we bow down to you!

“Sifu Randy Sullivan Bennett was (and always will be) an amazing person who brought so much energy and vibrancy into the world. He was a teacher, mentor, Kung Fu Master, and good friend… Every time I practice Kung Fu I will feel his energy there watching over us all (and silently correcting our forms)!

I want to be able to do anything I possibly can to help the fight against cancer, and to help people who have cancer in any possible way!”

 

Marking the anniversary of world’s first HPV vaccine

Article by Professor Ian Frazer

Eleven years ago, on 29 August 2006, the first Human Papillomavirus (HPV) immunisation was administered in Australia. The opportunity to develop the vaccine resulted from the discovery of a linkage between HPV and cervical cancer, and an insightful funding body, the Australian Cancer Research Foundation.

Looking back – how did we get here? 

Human Papillomavirus and cervical cancer

In the early 1980s a research group headed by Harald Zur Hausen at the German Cancer Research institute discovered that cervical cancer was associated with infection with Human Papillomavirus (HPV). This discovery was later recognised by being awarded the Nobel Prize in Physiology or Medicine in 2008.

Subsequent careful epidemiological studies by many groups showed not only that all cervical cancer could be attributed to infection with this virus, but also that a limited subset of about 10 of the many different papillomaviruses, termed “high risk” were the culprits.

Two HPV types (HPV16 and HPV18) were responsible for about 70% of the cervical cancer burden worldwide, and also contributed to the risk of other cancers relating to the anus and genitals, and some cancers of the mouth and throat. These studies also showed that cancer was a rare consequence of persistence of infection, that infections are largely without symptoms, generally transmitted sexually, and very common.

Vaccine development

These observations initiated a search by many research groups for vaccines to prevent HPV infection. Initial seed funding from the Australian Cancer Research Foundation helped to enable our research team at the Diamantina Institute in Queensland to achieve a breakthrough discovery and to attract more funding.

Professor Ian Frazer
Professor Ian Frazer at Diamantina Institute.

By mid-90s a technology for making a mimic of the virus, termed a virus like particle, had been shown to induce virus neutralising antibodies in animals, and was therefore a likely candidate for a vaccine.

Vaccine manufacturing companies subsequently developed methods for large scale production of the virus like particles. Early in the following decade, there were large scale clinical trials, that showed that vaccines based on these particles were safe and effective at preventing infection, and the subsequent development of cervical pre-cancer. By June 2006 the first vaccines were licensed for use, and deployment started in August 2006.

Dramatic reduction in presence of HPV

Over the past decade, HPV vaccine programs have been rolled out in many countries around the world. Australia was one of the first to adopt universal immunisation of school girls and young women, and also one of the first to add immunisation of school boys to the vaccine program. The vaccine used in Australia prevents infection with the two papillomaviruses most commonly responsible for cancer together with the two papillomaviruses that cause genital warts.

Over the past decade there has also been a dramatic reduction (over 80%) in new presentations with genital warts amongst young women and men. There has been a corresponding reduction in the presence of HPV in the cervix of young women undergoing pap smear screening for cervical cancer. These results have been achieved through immunisation of about 70% of the eligible females.

Young girl at an immunisation clinic.

Recently, similar results have been demonstrated in immunised women in the USA, where immunisation rates are much lower. Currently vaccines are licensed for use in every country of the world that regulates vaccines. Canada, Mexico, Brazil, and most European countries now have some form of universal immunisation program, and China has recently licenced the vaccine with the intent to introduce universal immunisation, while funding from the Gates Foundation and the WHO have enabled limited demonstration and pilot programs of HPV immunisation in many countries with developing and emerging economies, including India, Bhutan, Thailand, Mexico, Kenya, Vietnam, Fiji and Vanuatu. The majority of the more than 250,000 annual deaths from cervical cancer occur in these developing economies.

Immunisation is most commonly offered to 10-12 year old girls, prior to the onset of sexual activity. Although there have been some attempts to discredit the safety, the utility, or the moral justification of the vaccine programs, they have generally proven safe and well accepted. Over 150 million doses of vaccine have been delivered worldwide to date.

Looking forward – the next decade

Vaccine delivery in the developing world

One future challenge is to develop effective means of delivering universal vaccination in the countries of the developing world, where cervical cancer incidence is high and where strategies for prevention of cervical cancer are non-existent or ineffective.

Universal vaccination delivery remains a challenge in developing countries.

Barriers to all universal immunisation programs include vaccine cost, development of infrastructure for vaccine delivery and education to raise vaccine awareness, and the HPV vaccine is no different.

The relatively high cost of the vaccine itself in the developed world, which pays for the 15 year development program, has been sharply reduced by the manufacturing companies for the developing world. A further subsidised cost is available to those countries with with annual GDP of less than US$1580 per person. Nevertheless this vaccine is expensive in comparison with others.

Further, there are few countries that routinely deliver public health measures, including immunisation, to teenage and pre-teen girls, further hindering effective delivery. Considerable education about safety, efficacy, and purpose is necessary to ensure community acceptance of universal immunisation.

New vaccine technologies

The current two virus type (Cervarix, GSK – HPV16, HPV18) and four virus type (Gardasil, Merck HPV 16 , HPV 18, HPV 6 and HPV11) have proven equally effective in preventing cervical HPV infections. Gardasil also protects against genital warts. A new virus like particle vaccine (Gardasil-9) includes seven of the most common cervical cancer HPV types plus HPV6 and 11. This is now being made available and is likely to replace the others, at least in the developed world.

Alternative and potentially cheaper vaccine products, some with broader coverage against HPV types are being developed. These are made in bacteria rather than yeast or insect cells and, if effective, may replace the current technologies. However, these are still in early development and it is unlikely that they will have much impact within the next 10 years.

Alternative and potentially cheaper vaccine products, some with broader coverage against HPV types are being developed.

Better vaccine delivery

Over the past ten years, the original vaccine delivery schedule of three doses over six months has been shown effective in extensive clinical trials at an individual and population level. However, data from subsequent trials suggests that two vaccine doses delivered over the same period gives comparable immune responses in younger people and two doses may therefore be as effective in preventing infection.

Data on the duration and individual and population efficacy of two dose regimens will need to be gathered over the next decade. Ideally, the HPV vaccine might be given with other routine childhood vaccines to preschool children, perhaps topped up with a single booster shot in adolescence. Studies are underway to determine whether this strategy for delivery will prove effective.

New targets for prevention

Use of the current vaccines may turn out to prevent other cancers caused by HPV infection. There is particular interest in head and neck cancers, where a formal clinical trial is unlikely because of the long lag time between infection and disease.

One area of particular research interest is whether immunisation against HPV might prevent reinfection after successful treatment for HPV associated disease, and therefore avoid the need for ongoing surveillance in women treated for the infection.

The current vaccines do not cure people already infected with HPV. Mostly, current infections cure themselves, but if they don’t, then the vaccines do not diminish the future risk of cancer.

Therapeutic vaccines that might cure people of cancer or at least of persisting infection are therefore under development, with a number of strategies showing some evidence of efficacy. However, none have proven 100% effective and all are still at the stage of early phase clinical trials.

Observations from over the past ten years are that the HPV vaccines, if delivered effectively to the majority of 10-12 year old girls in the developing world from today forward, should lead to the global elimination of new cervical and other HPV associated cancers by 2050.

Article author, Professor Ian Frazer is the Chair of the Medical Research Advisory Committee at the Australian Cancer Research Foundation.

Speaking with: Professor Peter Koopman on CRISPR and the power of genome editing

Editing DNA has the potential to treat disease by repairing or removing defective genes.
Kyle Lawson/flickr, CC BY-NC-ND
 

Listen

Speaking with: Professor Peter Koopman on CRISPR and the power of genome editing

CRISPR, or clustered regularly interspaced short palindromic repeats, is a technology that is able to alter DNA.

While this sounds like the realms of science fiction, right now scientists are investigating its potential to eliminate genetic diseases in humans by repairing or replacing defective genes.

The University of Melbourne’s William Isdale spoke with Professor Peter Koopman from the University of Queensland about his research into CRISPR and the possibilities it could offer to future generations, as well as those suffering from genetic conditions right now.


Subscribe to The Conversation’s Speaking With podcasts on iTunes, or follow on Tunein Radio.

Additional Audio

Music

William Isdale, Research Assistant, Melbourne Law School, University of Melbourne

This article was originally published on The Conversation. Read the original article.

Karen organises a clearing sale for cancer research

Karen supports cancer research in Australia

I am a high school teacher, a farmer’s wife, and the mother of two rambunctious girls aged four and six. We live on our family farm near the rural village of Caragabal, in the middle of NSW.

Unfortunately, cancer is not new in our family; my dad died of cancer almost 20 years ago, and I am a cancer survivor myself.

I was diagnosed in 2016 at age 35 with aggressive triple negative breast cancer, I underwent a double mastectomy, chemotherapy, node dissection and radiation. My outcome is there is no longer any evidence of the disease. With treatment over, hope is left. Hope that the cancer never comes back, hope that my daughters are never directly affected by it, hope that I am around to help them through puberty, weddings and babies, and hope that I live long enough to enjoy retirement with my husband.

After my personal experiences with cancer, I urgently wanted to do my bit to help cancer researchers in this country to beat this disease. Although cancer treatments are improving and major research breakthroughs are getting closer, continuing those efforts needs more money.

My first, and small, event to raise funds for cancer research was shaving my head for donations, just before starting chemo last year. The next event will be massive! On August 26 there will be a combined farming machinery clearing sale in Caragabal with buyers and sellers attending from all over the district. Our village is well known for both its strong community spirit and making any event into a social event, and the upcoming sale will be no different. There will be plenty of good company throughout the day, bar and canteen facilities on offer, and a club dinner after the sale. Because the stock and station agents are all generously donating their time, the usual commission associated with a clearing sale will instead be donated to the Australian Cancer Research Foundation. We are hoping to sell $100,000 worth of machinery.

I know that there are many worthy causes out there, and all of them are important. If you’ve chosen to raise money for cancer research, I just want to say thank you. Your hard work, and the dollars that you raise mean so much to every cancer survivor. You’re giving hope for a brighter and more certain future. If cancer research is successful in its aims, my own hopes and dreams will all be realised.

Breast cancer study reveals new treatment targets

Cancer researcher Dr French at QIMR Berghofer
Associate Professor Juliet French at QIMR Berghofer

 

Researchers at QIMR Berghofer Medical Research Institute have identified two new genes that influence the risk of breast cancer.

The study was a collaboration between Associate Professors Juliet French and Stacey Edwards.

Associate Professor French said the genes, known as CUPID1 and CUPID2, affect the way cells respond to potentially cancer-causing DNA damage.

“When damage occurs to certain parts of our DNA, it can lead to cancer developing,” Associate Professor French said.

“That’s why our bodies have well-developed ways of constantly repairing damage to our DNA. “

“We found that these two genes are involved in switching the mechanism by which cells repair DNA damage.”

“If you have these genes, your cells will repair DNA damage without causing any errors. However, if you don’t have these genes, your cells will switch to repairing DNA in a way that is prone to errors, and can actually cause more damage.”

Associate Professor French said the finding could, in future, provide a new target for treating the most common type of breast cancer, estrogen receptor positive breast cancer.

“While it’s still a long way off, we hope that in future a new treatment could be developed that could target these genes and switch them on,” she said.

“CUPID1 and CUPID2 fall within new class of genes called long non-coding RNAs.”

“Long noncoding RNAs are an under-studied class of genes that are likely to provide a wealth of opportunity for uncovering major breakthroughs for treating a range of diseases.”

The findings have been published recently in the American Journal of Human Genetics.

This post was first published on QIMR Berghofer’s website.

The Australian Cancer Research Foundation has supported cancer research at QIMR Berghofer by providing three grants, totalling AUD$ 6.65 M, for the purchase of cutting edge research equipment and technology.

New way to empower the immune system to detect and kill cancer

Cancer researchers find new immunotherapy targets An international team of scientists led by Peter MacCallum Cancer Centre has identified a new way to potentially stop cancer cells hiding from the immune system.

Their research has identified a master regulator of a protein (PD-L1), which is over-expressed by tumour cells, and which suppresses the immune response to these rogue cancer cells allowing them to proliferate.

 “For some time we’ve known that PD-L1 plays an important regulatory role for our immune system – and when it is operating normally it is a handbrake that prevents over-reactions,” said Professor Mark Dawson, Head of the Translational Haematology Program at Peter Mac.

“We’ve also know that cancers exploit this process and an over-supply of PD-L1 on the surface of tumour cells effectively shields them, stopping them from being killed off by our immune system.”

“If we had a way to control the production of PD-L1 this would be a powerful new addition to our armoury of immunotherapy agents, and that’s what the research has identified.”

New protein target for immunotherapy

The researchers found the protein CMTM6 is needed to maintain the expression of PD-L1 and in a wide variety of cancers cells they showed that as CMTM6 levels decline so does the cancer’s ability to suppress the immune response.

The discovery opens a new avenue to develop immunotherapy drugs that target CMTM6. These would use the similar pathway as emerging “anti-PD1” class of antibody therapies, which have already shown great promise for the treatment of a broad array of cancers.

“If we can develop new drugs that re-activate a patient’s immune response to their cancer, this would be a major world-wide advance,” said Professor Joe Trapani, Executive Director of Research and Head of the 70-strong Cancer Immunology Program at Peter Mac.

“Immunotherapy is the first totally new treatment for advanced cancer in over 50 years and our capacity for this exciting research project and many more is rapidly expanding.”

A paper describing this work, titled “CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity”, has been recently published in the journal Nature.

The study was funded by the National Health and Medical Research Council and other collaborators.

This post was originally published on Peter Mac’s website.

ACRF has supported cancer research at Peter Mac by providing three grants, totalling $7 million towards cutting edge research technology and equipment.

Sandra celebrates her birthday by fundraising for cancer research

Sandra raises money for Australian cancer researchThis year I decided to support a charity as part of my 65th birthday celebration. This was a heartfelt decision as I’ve survived breast cancer and my partner Terry saw his wife die of cancer 23 years ago. The birthday party was Terry’s idea and gift to me.

I love life and celebrate every day. Retirement is not for me, yet. After many years of working in adult educational management, I currently run my own consultancy business doing small projects mainly for health department agencies. Family time is also a priority – there is my partner, my two grown sons and my 2-year old grandson. I am also a passionate amateur photographer and express my creativity through this art form as often as possible.

Invitations to the celebration included the request of no presents please. Having all that I need in life, it seemed appropriate and timely to ask people to make a donation to cancer research rather than bring me presents. The request didn’t particularly surprise my family, as I’ve done overseas mission work in the past which included raising money for the mission. I knew about ACRF and its efforts in cancer research from another friend, whose wife died last year, and donations in lieu of flowers were requested then.

The theme colours used for the party were purple and orange with silver and our large outdoor area was decorated in these colours with balloons, lanterns and anything else we could find. At the party entrance there was a large purple box decorated with the silver ACRF ribbons and donation envelopes. Nearly everyone who made a donation has been affected by cancer.

It is sad how many families are dealing with this horrible disease. One of my dear friends died of breast cancer in 2014, there is my own experience and that of my partner. There are undoubtedly many cancer not-for-profit organisations deserving our support but the most important thing to me is that better methods of prevention, detection and treatment are found for the many cancers affecting us and that is the goal of ACRF through continued research.

To anyone thinking about supporting cancer research, I would say, why hesitate – just do it! Give someone a chance to live, help put an end to all cancers.

Share your story Organise your own event

 

Judy opens her home again to fundraise for cancer research

Judith supports cancer research in Australia“My name is Judith, but I am Judy to family and friends and any new acquaintances. If asked to describe myself, I would say 71 years young, an optimist, pacifist, wife, mother of two, grandmother of four, and a friend to many.

In 2013 I decided to open my home and fundraise for cancer research, because I felt, and continue to feel today, that I should do something to help end this dreadful disease. Over the years, cancer has taken the lives of so many people that I love, and currently, four of my friends are receiving cancer treatments. I also had bladder cancer in 2014, but all has been well with check-ups since the operation.

Getting ready for a fundraiser is hard work and while my husband John thinks I’m a bit crazy for doing it, he does support me in every way. I also have friends who wouldn’t undertake a similar event themselves, but they are more than willing to lend a hand each year. Believe me, they are always a tremendous help!

My home is small compared to many others, but we manage to cram a lot of people in each year (from 20 to 41). There is always coffee and cake, or sometimes soup and sandwiches, for everyone who drops by. In addition to the table of gift items for purchase which I make, there is an auction of donated items, a guessing competition, a coin toss, and plenty of lively conversation. We are sometimes a bit short on space, but no one complains and we do have a lot of fun. Every person who was at my first fundraiser has attended all of my others. It is quite a thrill to have raised over $10,000 for cancer research since 2013. 

I plan to go on supporting ACRF and their cancer research efforts for as long as possible. If we stop raising funds for research, cancer wins. We can’t allow that to happen!

Share your story Organise your own event

Tumour blood supply stopped by a modified natural compound

Researchers have discovered how a modified natural compound can disrupt the formation of blood vessel networks in neuroblastoma tumours, thus preventing tumours from laying down the vital supply lines that fuel cancer growth and spread.

The international study paves the way for less toxic treatments for neuroblastoma, a childhood cancer that has an average age of diagnosis of just one to two years old.

The discovery is based on an earlier study by Dr Orazio Vittorio of Children’s Cancer Institute (CCI). In 2012, he found that the natural polyphenol catechin slows tumour growth in the laboratory but breaks down too quickly in the body to be effective.

“We joined catechin with a sugar called dextran. We found this dextran-catechin complex is much more stable in the body and that it slows tumour growth by affecting copper levels – but we didn’t know precisely how,” Dr Vittorio said.

The new research showed that copper is needed by endothelial cells, the cells that line blood vessels, and that dextran-catechin disrupts the cells’ copper levels in several ways.

The result is clearly visible down a microscope. When human endothelial cells were cultured and treated with dextran-catechin, the normally branching networks of blood vessels failed to form properly. Likewise, in animal models, neuroblastoma tumours treated with dextran-catechin had significantly fewer blood vessels than tumours treated with saline control.

“Instead of forming a neat, branching network of blood vessels, you see a mess of cells all over the place, which means cancer cells can’t get the blood supply they need,” explained Dr Vittorio.

“This is exciting because it’s a new target for the childhood cancer neuroblastoma that appears safe and has minimal side effects”, he said.

Further laboratory research into dextran-catechin’s potential as a future treatment is underway. The study was recently published in the journal Scientific Reports.

This news article was first published on the CCI website.

ACRF has supported cancer research at CCI by awarding three research grants, in total $5.2 million, towards cutting edge research technology.

Behind the Scenes with the Department of Human Services

supporting Australian cancer research

Throughout the months of May and June, ACRF was lucky enough to have the Department of Human Services (DHS) support us as their national 2017 DHS Games charity.

On Monday 3 July, Clare Halloran from the Social Work Services Branch – a former cancer patient with Hodgkin’s lymphoma had the chance to see things

from the other side of the fence. Clare donned a lab coat during a visit to The ACRF Department of Cancer Biology and Therapeutics at the Australian National University’s The John Curtin School of Medical Research. Joined by colleague, Jackie Paul, as well as Tamara Shaw and Stephanie Luck from the communications team, Clare got the low-down on the latest research into cancer detection.

Led by Professor Ross Hannan, Centenary Chair of Cancer Research and Head of the ACRF Department of Cancer Biology and Therapeutics at the ANU, the private tour was coordinated by ACRF’s Priscilla Leong.

“What better way to learn about ACRF and the research we fund than by entering the home of top ANU scientists?” said Priscilla.

“The tour gives participants a behind-the-scenes look into discovery-based research and the development of new compounds, drugs and diagnostic approaches for cancer treatment.”

The emphasis of the School’s research is on an understanding of the fundamental principles of human life processes and the pathologies of these processes which cause human disease.

Leading cancer researcher Professor Hannan and his team at the ANU received a $2 million grant from ACRF in December 2015. The grant was used to establish the ACRF Department of Cancer Biology and Therapeutics which features a one-of-a-kind drug screening facility, commissioned to identify new combinations of the 4,500 FDA-approved drugs that can lead to new treatments and potential cures for cancer patients. As it can take 10 years and $1.2 billion to get a new drug approved, using pre-approved drugs is a much more cost-effective, ready-made and safe option.

At the conclusion of the tour, Professor Hannan praised the work undertaken in the labs.

“The work they do could not be underestimated, we are currently expanding the department with new cancer researchers and our current goal is to raise $10 million by next year,” he said.
Clare was equally effusive.

”The lab was spectacular and it was great to see research being done in the heart of the city I call home,: she said. “Of particular interest to me was getting to look through a microscope at 20-year-old Leukemia cancer cells that were donated for research studies.

“I feel very privileged; not many people get the opportunity to see the great research and equipment inside a medical research lab! I was blown away by the enthusiasm, dedication and expertise on display today. It gives me a great deal of hope for the future.”

We’d like to send out a big thanks to DHS and all their staff who supported us through the months of May and June. Through their efforts ACRF raised just over $19,000. But to keep labs like these funded—so hope can be turned into reality— ACRF continues to rely on the generosity of others.

It’s important to mention that when you donate to ACRF, your money works a couple of ways. Not only does it go towards grants to help fund vital work, it act as leverage for places like The John Curtin School of Medical Research to attract additional grants from other entities. So in effect, your donation keeps on giving.

Workplace Giving Program — the way you can continue to support ACRF

If you haven’t donated so far—or would like to send some more money our way — why not donate regularly, or as a one-off, via the Workplace Giving Program? All donations received are processed as pre-tax deductions and donations over $2 are tax deductible. Every dollar counts, so it’s worth doing.

Learn more about workplace giving Share your story

Why some moles become melanoma still a mystery

Some moles become skin cancer

Our definition of a Melanoma is a cancer that begins in the melanocytes. Most melanoma cells still make melanin, and so melanoma tumours are usually brown or black, however, some melanomas do not make melanin and can appear pink, tan, or even white.

The risk of Melanoma increases with exposure to UV radiation from the sun or other sources such as solariums, particularly with episodes of sunburn.

As stated by the Melanoma Institute of Australia, Australia has one of the highest rates of melanoma in the world and kills more young Australians (20 -39-year-olds) than any other single cancer.

Testing for two gene mutations commonly associated with melanoma would be insufficient to determine whether a mole could turn cancerous, University of Queensland research has found.

UQ Diamantina Institute’s Dr Mitchell Stark is among researchers investigating why melanomas develop from some naevi (moles).

“In Australia, about half of all melanomas develop from a naevus, but most moles will never progress to become a melanoma,” Dr Stark said.

“We are trying to determine what causes some naevi to change so that we can better predict or more accurately detect those which could become dangerous.

“This would help avoid unnecessary excisions of those lesions unlikely to pose a risk.”

Scientists from UQ’s Dermatology Research Centre analysed samples from participants in the Brisbane Naevus Morphology Study, and discovered all had one of two key mutations associated with melanoma.

“We found that 85 per cent of samples had a mutation on the gene known as BRAF, and the remaining samples had a mutation on the NRAS gene,” Dr Stark said.

“When either of these genes are mutated it activates the signalling pathway known as MAPK, which is commonly active in melanomas.

“Clearly our samples were not melanomas, so additional genomic events need to occur before a mole becomes malignant.”

Dr Stark said further research was underway to determine other genetic changes that could trigger the development of melanoma from naevi.

Studies have consistently shown the number of naevi a person has is the strongest predictor of risk for melanoma.

Dr Stark said people with a high number of moles, and other risk characteristics such as fair skin or light coloured hair or eyes, should continue to see their treating dermatologist or skin cancer physician for routine skin examination.

Dr Stark is a National Health and Medical Research Council (NHMRC) Early Career Fellow. The UQ Dermatology Research Centre is a participant in the Centre of Research Excellence for the Study of Naevi, and is based at the Translational Research Institute.

The research was published in the British Journal of Dermatology.

This news post was first published on the University of Queensland’s website.

ACRF has supported cancer research at Diamantina Institute by providing three grants, totalling AUD$ 6.2M, for the purchase of cutting edge research equipment and technology.

If you would like to donate to help fund research to prevent, detect and treat all types of cancer, including melanoma, you can donate here to help Australians affected by this devastating disease.

Whole-body MRI scan picks up early-stage hereditary cancers

A major study confirms, for the first time, that whole-body MRI detects primary cancers in people with an inherited cancer risk condition called Li-Fraumeni syndrome at an early and curable stage.

Li-Fraumeni syndrome is a rare and devastating condition caused by mutations in the TP53 gene and characterised by high cancer risk at multiple body sites.

Half of those with Li-Fraumeni syndrome will develop their first cancer by the age of 30, and almost all will have cancer in their lifetime. Despite this near-inevitability, there is no universally accepted approach to managing cancer risk in Li-Fraumeni syndrome –largely because it is difficult to justify invasive organ-by-organ screening approaches for multi-organ cancer syndromes.

To address this issue, an international consortium of researchers sought to determine whether whole-body MRI could play a role in surveillance of those with Li-Fraumeni syndrome.

The findings were clear. A previously unidentified primary cancer was detected in one in 14 adults undergoing their first whole-body MRI. In children, the detection rate was higher still: a primary cancer was identified in one in seven children. Primary cancers were detected in the bone, soft tissue, breast, brain, lung, kidney, thyroid, prostate and bowel. In all, 35 new primary cancers were detected and all were treated with curative intent.

Professor David Thomas, at Garvan Institute of Medical Research, said that the screen picks up cancers before symptoms appear and at a high rate. This makes it possible to treat those cancers before they have had a chance to spread.

Results applicable to other cancers with increased hereditary risk

Research findings also confirm that the findings using whole-body MRI compare favourably with breast MRI, which is currently approved for screening of women at increased risk of breast cancer.

“In our analysis, the detection rate of primary cancers was several-fold higher than has been reported for breast MRI in women at high risk of breast cancer (BRCA1/2 carriers) – which is typically about one cancer in every 50 women screened. And the false positive rate – the detection of lesions that turn out not to be new primary cancers – is also comparable to that observed for breast MRI in at-risk populations,” said Professor Thomas.

Dr Mandy Ballinger at Garvan said that the study is likely to herald a change in thinking around the clinical management of hereditary cancer risk.

“Typically, individuals with Li-Fraumeni syndrome have been monitored for new cancers in only those few organs where robust screening approaches exist – in breast, for instance. But in Li-Fraumeni syndrome and in other cases of high cancer risk, cancers can appear at any time, in any organ. This means that this organ-specific approach inevitably fails to pick up most cancers.”

These findings, which are set to change clinical practice in monitoring those at high genetic risk of cancer, have been recently published in the leading cancer journal JAMA Oncology.

The news article was first published on the Garvan website.

ACRF has supported cancer research at Garvan by providing three grants, totalling AUD $6.13million, towards cutting edge cancer research equipment and technology.

Image: Dr Ballinger and Prof Thomas. Image courtesy of Garvan.

Cancer immunotherapy drugs like Keytruda and Opdivo hold hope for some, but there’s still a way to go

File 20170725 7881 3ml7zo
Some people taking these drugs can see their cancer completely disappear – there’s nothing left to see on their x-rays. From www.shutterstock.com.au

 

This article was originally published on The Conversation. Read the original article.
By Craig Gedye, Oncologist and Senior Lecturer, University of Newcastle

Imagine being able to offer hope to people with cancers that were once thought untreatable. Checkpoint immune drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo) are heralding this new era in cancer treatment. Some people taking these drugs can see their cancer completely disappear; there’s nothing left to see on their x-rays.

We rightly celebrate these successes, but must face the sobering truth that only a minority of people experience these dramatic benefits. Decades of research have helped us reach this point. Now scientists and doctors from Australia and around the world are working furiously to learn more about how these immune treatments work or fail.

Who it works for now

Nivolumab and pembrolizumab are checkpoint immunotherapy antibodies. They work by blocking barriers (or “checkpoints”) created by cancer cells to protect against attack from the immune system. Remove the barrier and the immune system can destroy the cancer.

The Conversation, CC BY-ND

The most success so far for these drugs is with melanoma, which has long been known to respond to immunotherapy. In Australia, single or combination checkpoint immunotherapy substantially helps about half of people with melanoma, and will soon be available for people with kidney and lung cancers.

Trials continue in most types of cancer. Checkpoint immunotherapy has proven beneficial in patients with bladder cancer, head and neck cancer and Hodgkin lymphoma. A smaller proportion of people, typically around 20-30%, are helped in most of these cancers. These successes and failures start to show us how checkpoint immunotherapy works, and how it might work better.

Who it might help soon

Patients whose cancers are already under attack from immune cells are the people who seem most likely to be helped by checkpoint immunotherapy. But many patients’ cancers are devoid of immune cells – so removing checkpoints doesn’t help.

This is why the first strategy to improve checkpoint immunotherapy is to diversify and muster the immune system into tumours. Some checkpoint immunotherapy drugs (such as ipilimumab, brand name “Yervoy”) work this way. In effect they “vaccinate” the patient against their cancer, educating the immune system on how to fight the cancer, and recruiting immune cells to attack tumours.

A similar method uses modified viruses that infect and explode immune cells. These can be directly injected into cancers, drawing in immune cells to attack the cancer. This is the basis of the very first immune therapy for cancer, first used in 1896.

Finally, identifying the minority of people who naturally have immune-infiltrated cancers may identify those likely to benefit from checkpoint immunotherapy (such as aggressive breast cancer needing chemotherapy before surgery).


Read more: Explainer: how does Keytruda treat melanoma and why is it so costly?


We may be able to identify a few people within various types of cancer most likely to benefit from checkpoint immunotherapy. For example, while checkpoint immunotherapy doesn’t help most bowel and prostate cancer patients, a small group of people whose cancers’ DNA isn’t able to repair properly have dramatic outcomes from checkpoint immunotherapy.

This lack of efficient DNA repair is called “mismatch repair deficiency”. Mismatch repair is one of the tools cells use to repair their DNA. Loss of mismatch repair leads to aggressive cancers that don’t respond to chemotherapy, but which throw up lots of targets for the immune system.

Up to a third of uterine cancers, 15% of bowel cancers, 15% of stomach cancers and perhaps 5% each of prostate, oesophageal, cervical and ovarian cancers have mismatch repair deficiency, potentially making them treatable with checkpoint immunotherapy.

How we might improve immune therapy further

Even when fully implemented, these strategies will leave many people who won’t benefit from checkpoint immunotherapy – but a huge number of new treatments, combinations and ideas are being tested in clinical trials.

Drugs that protect immune cells from toxic chemicals released by nearby cancer cells appear very promising. A myriad of new antibodies that block other immune checkpoints are in development. And we haven’t abandoned standard cancer treatments like blood-supply blocking drugs, radiotherapy or chemotherapy; these may help immunotherapy by killing enough cancer cells to recruit immune cells into tumours.

Should everyone with cancer take checkpoint immunotherapy? These drugs are safe overall, though people with autoimmune diseases (such as rheumatoid arthritis) need to be very cautious. This is because the underlying cause of checkpoint immunotherapy side effects, an overactive immune system, is very similar to the causes of autoimmune diseases.

And there is a social challenge: cost. We are privileged to have many publicly funded PBS-reimbursed cancer treatments in Australia, but drug costs are rising sharply. One solution will be to find more ways to identify the patients most likely to benefit from these drugs, so we’re not using expensive drugs to treat people for whom they won’t have an effect.

Another, perhaps complementary, strategy would be pay-for-performance – treat everyone, but only reimburse the manufacturer if the patient is helped. This might particularly assist people with rare cancers, where clinical trials are extremely hard to perform.

The ConversationCheckpoint immunotherapy is a triumph – when it works. It’s important to temper our hopes with the knowledge that these promising drugs can’t yet help every person, with every cancer. But we’re working on it.

Targeting Cancer’s Achilles’ heel to improve breast cancer treatment

Researchers at Walter and Eliza Hall Institute (WEHI) and their collaborators have found a promising new class of anti-cancer agents that targets cancer cells’ Achilles’ heel. The new compound, MCL-1 inhibitor S63845, is one of a promising new class of drugs that triggers tumour cell death.

Combining the new anti-cancer compound S63845 with currently used cancer drugs has been now demonstrated to be more effective in killing triple negative breast cancers and HER2-positive breast cancers, suggesting it should be investigated in clinical trials.

Dr James Whittle at WEHI, who is also a medical oncologist at Peter Mac, said that S63845 targeted MCL-1, a protein that WEHI scientists have previously shown to be important for cancer cell survival.

“MCL-1 gives cancer cells a survival advantage, allowing them to resist chemotherapy or other anti-cancer therapies that would otherwise trigger cancer cell death.”

“Importantly, the combination of the MCL-1 inhibitor S63845 with standard therapies was far more effective than either treatment alone. These can be incredibly aggressive tumours, so to see a response to the combined therapy in this tumour type is very exciting.”

Professor Geoff Lindeman, also a medical oncologist at the Peter Mac and Royal Melbourne Hospital, said MCL-1 inhibitor S63845 was one of a promising new class of drugs.

“Our hope is that it will be possible to combine MCL-1 inhibitors with conventional therapies to more effectively treat certain types of breast cancer and deliver better outcomes for our patients,” Professor Lindeman said.

MCL-1 is a critical anti-cancer therapeutic target. It is found at excessive levels in triple negative and HER2-positive breast cancers, and is often associated with poor outcomes for patients.

Around one in three Australian women with breast cancer have a triple negative or HER2-positive breast cancer. Professor Lindeman said triple negative breast cancers, in particular, were in urgent need of new treatment options.

“Triple negative breast cancers have not seen the same improvement in targeted therapies, or survival, as some other types of breast cancer,” he said.

The study was published today in Science Translational Medicine.

The research was supported by the Australian Cancer Research Foundation amongst others.

The original news post was published on the WEHI website.

Focus on a single cell sees development of new cancer treatment

For over 30 years, Professors Jenny Gamble and Mathew Vadas AO at the Centenary Institute in Sydney have been working on understanding the function of a single cell, the “guardian” endothelial cell that lines our blood vessels.

Their thorough understanding of how the endothelium is critical in the control of inflammation, the body’s response against harmful stimuli, has led to the development of the new cancer treatment.

Collaboration with Danish and Australian researchers has shown that the new drug, called CD5-2, has potential to be effective and to work alongside the current immunotherapy for cancers.

CD5-2 is the first drug of its kind and works by altering the endothelial cells of the blood vessels within the tumour. This allows T cells to penetrate into the tumour and also impacts on the behaviour of these T cells by allowing them to more effectively provide their protective function of fighting and killing the cancer cells.

The new drug could be effective in some of the hardest to treat cancers with the highest mortality rates, such as pancreatic and liver cancer, although it would also be effective in other, more common cancers such as melanoma.

Essential toxicology and safety studies are currently underway and it is hoped that this new drug could be in clinical trials in the next 2-3 years.

Professor Gamble is the Head of the Vascular Biology Program and Professor Vadas is the Executive Director of the Institute. Professor Vadas has previously chaired ACRF’s Medical Research Advisory Committee and is currently a committee member.

The study has recently been published in the journal Cancer Research.

This news was first published on the Centenary Website.

ACRF has supported cancer research at the Centenary Institute by providing two cancer research grants totalling $7.5 million.

Image: Professors Vadas (left) and Gamble. Image courtesy of Centenary Institute.

Early ACRF support of anti-cancer treatment results in landmark Australian deal

WEHI researchers, image courtesy of WEHI.

The Walter and Eliza Hall Institute of Medical Research (WEHI) has made a landmark deal worth up to US$325 million from the partial sale of royalty rights in the anti-cancer treatment venetoclax. The rights have been acquired by Canada Pension Plan Investment Board and WEHI will retain partial royalties in the treatment.

Venetoclax is based on three decades of ground-breaking research into cancer cell survival, which lead to the creation of the treatment for chronic lymphocytic leukaemia in collaboration with commercial partners.

WEHI director Professor Doug Hilton AO said that many important discoveries at the Institute laid the foundation for venetoclax’s development and the philanthropic support over the past 30 years, including grants from ACRF, have been a vital part of this journey of discovery.

Professor Doug Hilton AO said the Institute’s commitment to scientific excellence, innovation and its collaborative culture underpinned the successful translation of venetoclax.

“With venetoclax, we have shown the Institute has both the scientific determination and entrepreneurial acumen to take basic research all the way to being a clinical and commercial success, alongside our partners. This need not be a one-time event. Venetoclax is proof that Australian institutions can be key players in globally significant translation.”

 “Venetoclax demonstrates what success can look like for a collaborative, entrepreneurial and innovative medical research institute and why investment in basic research is so important.”

Professor Hilton also thanked WEHI’s long term partners and supporters.

“Discoveries are always the result of collaborations and teamwork. We recognise that our supporters are vital contributors to our research teams. Thank you for standing with us. I am proud that the Institute continues to uphold its promise to make discoveries for humanity. Together we can continue this important work,” said Professor Hilton.

The income generated by the partial sale of rights will be invested back into research at WEHI to fuel more discoveries. One of the priority areas will be to accelerate drug discovery, ensuring that potential new treatments will be taken from laboratories and translated into new treatments and diagnostics.

The news was first published on the WEHI website. 

You can find out more about the development of venetoclax on the discovery timeline.

ACRF has supported WEHI by providing three grants, totalling AUD 5.5million towards cutting edge cancer research equipment and technology.

 

Hayley runs City2Surf for cancer research

funding research Australia

“From a young age I enjoyed all sports with touch football and athletics being my favourites, and someday I would like to work in the health and fitness industry. Now at age 22, and after two knee reconstructions, I feel ready to participate in a big event like City2Surf. To be honest, I am not too sure what urged me to register this year other than telling myself to do it now or probably I never would. I absolutely love my family and friends and have learned in the past few years that life is definitely too short, and we don’t know what is around the corner.

Although I am running for every person, family member or friend affected by cancer, there are three people in particular that I’ll be thinking of all along the way. There is my father, Michael Collins, who was diagnosed with Stage 1 prostate cancer in 2016, and he continues to have scans and tests; my brother-in-law, Jacob McCormick who had a benign brain tumour removed in 2016 at age 17; and Sharon McCormick, my partner’s beautiful mother, who died of cancer in 2014.

With no warning signs other than a horrible pain in her lower back, Sharon was diagnosed with cancer and then passed away four months later, just one day away from achieving her 46th birthday. The emptiness of not having Sharon in our lives is undeniably still there, and not a day goes by without thinking of her.  She was a beautiful soul and everything about her was infectious: the smile, the laugh (or snort!), the down-to-earth loving nature. Sharon was a true friend and an amazing person that I will treasure for the rest of my life.

I don’t think any of us can truly understand the pain of loss that comes with cancer until it affects you or your loved ones. Participating in City2Surf and fundraising for cancer research is my way of honouring all of my family, past and present, who have been affected by cancer.

After registering for this year’s race, I needed to decide on one cancer foundation to support. The choices seemed overwhelming but I ended up selecting the ACRF because it is the foundation that funds research on all types of cancers.

My advice to anyone else who is thinking of fundraising would be: honestly, just go for it! Whether you are sponsoring a friend or an organisation or running in the event itself, you are helping get one step closer to ending cancer, which in turn will save lives.

Every cent raised for cancer research counts. Without fundraising, we have no research and without research, there will be no breakthroughs. Together we can fund the technology and equipment that researchers need to continue progress towards ending all cancers.”

Share your story

Clinical trial to test new treatment for pancreatic cancer

A study, published in the International Journal of Cancer, forms the basis for a trial which will screen 150 to 200 pancreatic cancer patients for responsiveness to specific drugs at Monash Health in Victoria.

The multi-disciplinary team from Hudson Institute of Medical Research, Monash Health and Monash University aims to improve treatment for pancreatic cancer, one of the least survivable forms of cancer.

In this initial trial, tumour samples will be screened for genetic compatibility with drug currently used to treat colon cancer in the hope it may be effective in treating up to 10 per cent of pancreatic cancer patients.

“Pancreatic cancer has an overall five year survival rate of around five per cent, which is one of the lowest survival rates of any malignancy. While there have been marginal improvements in treatments, long-term survival rates have remained poor and stagnant over the last 30 years,” said Professor Brendan Jenkins, Research Group Head, Cancer and Immune Signalling at Hudson Institute.

Professor Jenkins and Dr Daniel Croagh, a Monash Health hepatobiliary surgeon who is leading the trial, say it may inform a fast-tracked pipeline for treatment, where biopsies are taken from patients, genetically sequenced and screened for suitability with new drugs, meaning patients could be on a clinical trial within just two weeks.

The treatment will be used to target an important receptor called the epidermal growth factor receptor in those patients whose tumours have a non-mutated version of the KRAS gene. These types of tumours make up about 10 per cent of all pancreatic cancers.

Dr Croagh and Professor Jenkins are hopeful the clinical trial will lead to more targeted treatment approaches to improve responsiveness to drugs and give patients a better chance at surviving longer.

“Pancreatic cancer is a particularly aggressive disease, and a challenging one to treat. The one-size-fits-all treatment approach in place for the last three decades needs to be altered if survival rates are to improve. While there is no silver bullet, we hope this is the beginning of a shift towards better patient outcomes,” they said.

This news post was first published on the Hudson Institute of Medical Research website.

ACRF has supported cancer research at Hudson Institute of Medical Research and Monash University by funding cutting edge research equipment and technology.

For more information on all clinical trials in Australia, please contact Australian Clinical Trials.

Gene discovery to help breast cancer patients

Breast cancer cells
Breast cancer cells: Image QIMR Berghofer

 

Cancer researchers at QIMR Berghofer have discovered a set of genes that could be used to predict the survival of breast cancer patients. The findings could in the future help to determine which patients would benefit from additional treatments. The scientists have also discovered one of the factors that can cause breast cancer to grow more aggressively.

Dr Jason Lee said G9a was a molecule that promoted tumour growth.

“When conditions are normal inside the body, a change occurs to this molecule and it breaks down, making it harmless,” Dr Lee said.

“However, we have discovered that inside a tumour, where there is very little oxygen, that change doesn’t occur to the molecule, meaning it doesn’t break down and instead starts to accumulate.

“This accumulation of the molecule G9a then makes the tumour grow more aggressively.”

Dr Lee said the team had also found that G9a silences certain genes.

“We don’t yet know what these genes control, but we found that when these genes are switched on, patients tend to have better survival rates, and when they’re switched off, patient survival tends to be worse.”

“In other words, these genes are predictors of whether patients are likely to experience a recurrence of their cancer.”

Professor Frank Gannon said when the group tested an available drug that targets G9a, they found tumour growth more than halved.

“The available drug we tested appeared to be effective in all types of breast cancer, but particularly in estrogen-receptor-positive (ER+) breast cancer, which is the most common form. While most of these patients respond well to treatment, about a quarter develop resistance to the treatment they receive.”

“We hope that in future, we will be able to test patients for the genes controlled by G9a to determine which patients are likely to experience a relapse and need further treatment.

“Only those patients could then receive the treatment, which would be more cost effective and save patients from unnecessary drugs.”

The findings have been published in the Proceedings of the National Academy of Science.

This post was originally published on the QIMR Berghofer website.

The Australian Cancer Research Foundation has supported cancer research at QIMR Berghofer by providing three grants, totalling AUD$ 6.65 M, for the purchase of cutting edge research equipment and technology.

Interleukin-2 immunotherapy improved

Researchers at the Garvan Institute of Medical Research have been exploring ways to make interleukin-2 (IL-2) immunotherapy less toxic and more effective against cancer. In doing so, the team has uncovered surprising new information about how to boost the antitumour activity of interleukin-2 molecules.

IL-2 has been in clinical use for decades, and has been called ‘the first effective cancer immunotherapy’. But, it is so toxic that it is currently only prescribed in a very limited number of late-stage cancers.

Associate Professor Daniel Christ, who led the research, said that IL-2’s potential to be a better anticancer therapy is promising.

“We are currently witnessing an explosion in new immunotherapies for cancer, such as the immune checkpoint inhibitors – and this has really reinvigorated huge interest in early immunotherapies, such as IL-2, that can support the immune system to attack cancer.”

“Importantly, we’re seeing that immunotherapies tend to work better in combination – so one reason we wanted to investigate IL-2 again was because it could be a good candidate for use in combination therapy with newer treatments.”

Modification of IL-2 cells leads to improvement

In the current study the research team set out to make a range of different versions of IL-2.

“We wanted to make two key changes to IL-2,” said Dr Rodrigo Vazquez-Lombardi, who co-led the research with A/Prof Christ and Professor Jonathan Sprent.

“We wanted to make it more powerful as an antitumour agent, and we also wanted to extend its half-life in the body – because IL-2 is removed from the blood so rapidly that this limits its use as a therapy. We reasoned that, by doing both things, we had a good chance of developing a more effective and less toxic version.”

IL-2 acts against cancer by instructing immune cells on how to behave towards a tumour. In particular, IL-2 activates ‘killer cells’, such as killer T cells and natural killer cells, stimulating them to attack tumours.

When the researchers looked more closely, they found that modifying the IL-2 molecules changed their behaviour and helped to reduce the numbers of a different class of immune cell – the regulatory T cells. These cells are a part of the immune system that suppress immune responses of other cells.

The researchers say their findings will change thinking about IL-2, and provide important guidance for the development of future IL-2-based therapies.

Prof Sprent points out, “Clinicians have become wary of IL-2 therapy for cancer because it’s a double-edged sword: the benefits of boosting killer cell function are countered by the parallel stimulation of T regulatory cells.

“Our simple trick of selectively stimulating just the killer cells and not the T regulatory cells is a real breakthrough and should restore faith in IL-2 therapy.”

Their findings were recently published in Nature Communications.

The original post was published on Garvan’s website. Image of Dr Rodrigo Vazquez-Lombardi courtesy of Garvan.

ACRF has supported cancer research at Garvan by providing three grants, totalling AUD $6.13million, towards cutting edge cancer research infrastructure, equipment and technology.

Image: Dr Rodrigo Vazquez-Lombardi

New ACRF research centre targets early detection of lung cancer

The ACRF Centre for Lung Cancer Early Detection has been officially launched today at The University of Queensland’s Thoracic Research Centre at The Prince Charles Hospital (TPCH). The centre will deliver a major new research effort focusing on detecting lung cancer sooner.

In 2015, ACRF provided $1 million grant to equip the centre with the latest technology needed to advance lung cancer diagnostics. Director, UQ Thoracic Research Centre at TPCH, Professor Kwun Fong said the centre’s focus will be on identifying better ways to screen for lung cancer and improving methods for diagnosing suspected cases.

“We will use the latest technology to identify markers for lung cancer that might be present in the breath, blood or lung fluids at a very early stage of the disease,” Professor Fong said.

“These markers could form the basis for new lung cancer tests to allow earlier diagnosis and treatment.”

Professor Fong said the centre will bring together the skills from several highly skilled researchers and scientists, including collaborators at CSIRO, who will assist by analysing breath samples.

“They will be looking for very small traces of lung cancer cells to identify the disease long before our current tests can,” Professor Fong said.

“Most importantly we will also be looking at how to take research to the clinic as quickly as possible to ensure that our patients see the benefits of earlier diagnosis.

“Due to the clinical focus of the research, the team will be able to translate findings directly into daily clinical practice.”

ACRF Chief Executive Dr Ian Brown said lung cancer remains the leading cause of death from cancer in Australia, for both men and women, with less than 15 per cent of patients surviving for five years.

“The low survival rate is mainly due to the diagnosis usually occurring at an advanced stage of the cancer, when there are few effective treatment options available.” Dr Brown said.

“Lung cancer can be more effectively treated if diagnosed in its earliest stage, and that is why ACRF felt it was vitally important to support this research.”

A robotic system for handling multiple specimens and equipment to look for genetic markers has been installed at the centre’s laboratories at The Prince Charles Hospital.

Research will be conducted over the next five years.

Health authorities estimate that more than 9000 Australians will die from lung cancer in 2017, and more than 12,400 new cases will be diagnosed this year.

William Bond running City2Surf to support cancer research

William is supporting Australian cancer research

“I am 28 years old, passionate about new challenges, and will soon take on the City2Surf running in a Lion Dance Costume! My participation in this year’s race is to honour the memory of my late Kung Fu Sifu (Grandmaster), Randy Sullivan Bennett, who passed away earlier this year from mantle cell lymphoma.

Randy was an enthusiastic martial arts teacher, a mentor, and my friend. Although I only knew him for four years, he made a huge impact on my life, my outlook, and of course my Kung Fu training. Towards the end of 2016, I successfully completed black belt testing with Randy pushing me hard, overseeing all the grading and most of my sparring sessions. He did my black belt presentation, and I made a promise to keep on training and make Grandmaster proud!

The greatest appeal of doing a fundraising activity is to be able to help people and improve things. The City2Surf is a big event, and it is a good opportunity for me to raise as much money as possible for cancer research and ACRF. It’s also where I can show respect to Randy in a meaningful way.

Sadly, cancer affects so many people with seemingly no regard to health, happiness or diet. Even Randy was not immune: he was a vegetarian, incredibly fit, good-humoured and with a positive view on life. Cancer makes me feel like there is so much we don’t know about the world and so much we can’t control, even with our own bodies. I believe that continued research is the only way forward in achieving an end to cancer, which is why I chose to raise funds for ACRF.

We can all help out with encouraging more funding for cancer research and increase awareness of how that research is resulting in more successful treatments. Ultimately, we all want to see cancer completely eliminated!” – ACRF supporter, William Bond

Share your story

 

 

Study raises hopes for new sarcoma treatment

Researchers at Monash University in Melbourne have played a critical role in an international collaboration that has identified promising therapeutic targets for a rare form of sarcoma afflicting mostly young people.

Synovial sarcoma is a subtype of soft-tissue sarcoma, a group of malignant tumours originating from connective tissue in the body. Treatment options are limited and survival is poor.

The Monash Biomedicine Discovery Institute researchers, led by Professor Roger Daly, collaborated with Dr Emmy Fleuren and other scientists from the Institute of Cancer Research in London, scientists from Radboud University Medical Centre in Nijmegen, the Netherlands, and other institutes, to investigate what drives sarcoma progression and to identify targeted therapies.

Professor Daly’s laboratory took a novel approach using a technique called mass spectrometry, which enabled the scientists to look at large numbers of proteins across cell lines derived from different types of sarcomas and identify those driving aberrant growth.

They identified two suspect proteins, called ALK and MET, in subsets of synovial sarcoma, validating their observations in preclinical models and in patient specimens.

“It’s exciting to apply a new technique which looks at proteins rather than DNA, and be able to identify novel therapeutic targets,” Professor Daly said.

“This provides a proof of principle for our approach, and means that we can now go ahead and apply this to other cancers,” he said.

Importantly, drugs are already available against the two proteins that are currently being used to treat other cancers, he said. However, clinical trials would be needed to test for their appropriateness in treating all forms of synovial sarcoma, the researchers said.

Dr Fleuren said that despite intensive treatment options including chemotherapy, radiotherapy and surgery, the prospects for synovial sarcoma patients were poor.

“This disease can have a devastating impact, particularly among young patients and in the metastatic setting,” Dr Fleuren said.

“At the moment, sarcoma patients are generally speaking treated in a one-size fits all strategy – there’s a critical need for new approaches and for developing personalised treatments with more efficacy and less side effects,” she said.

The findings were recently published in the journal Cancer Research.

Scientists involved in the international collaboration, which also included the Garvan Institute of Medical Research in Sydney and Peking University Cancer Hospital & Institute in Beijing, are expected to pursue further research and clinical trials.

Professor Daly’s laboratory is applying the novel approach to other cancers including Triple Negative Breast Cancer.

This news article was first posted on the Monash website.

In 2016, ACRF awarded Monash University a $1.2 million grant to support cancer research at the University. ACRF has also supported research at Garvan by providing three grants, in total $6.1 million, towards cutting edge cancer research technology.

Childhood cancers defy current understanding

Cancer is still surprising researchers, making the pathway to urgently-needed new treatments more difficult to predict. Researchers in Sydney have made an unexpected discovery that transforms our thinking about one of the ‘universal features’ of cancer.

A combined team of scientists from Sydney Children’s Hospitals Network (SCHN) and Children’s Medical Research Institute (CMRI) studied an aggressive category of neuroblastoma, which is the most common solid cancer of childhood.

For many years, the presence of a telomere lengthening mechanism has been considered essential for the growth of essentially all cancers. Dr Loretta Lau (SCHN) and Professor Roger Reddel (CMRI), who jointly led the research team and collaborated with Professor Michelle Haber’s team at Children’s Cancer Institute (CCI), have now shown this isn’t always the case. They found that 11% of high-risk neuroblastomas can keep growing without any method to lengthen their telomeres.

Telomeres can be found at both ends of all chromosomes, the bundles of DNA found in most cells. In normal cells, telomeres gradually become shorter, and this limits the number of times normal cells can multiply. In cancer, cancerous cells need to find a way to lengthen telomere DNA—to allow it to keep multiplying, and therefore for the cancer to keep growing.

Previously, researchers have believed that because something has gone wrong, probably during a child’s very early development, some cells have had abnormally long telomeres, so long that the cancer can keep on growing aggressively even though the cancer cells’ telomeres keep on shortening.

The new finding means that cancer biologists need to re-evaluate their understanding that the presence of a telomere lengthening process is a universal feature of cancer. Already, there is evidence from researchers in Belgium that a similar principle applies to melanomas, a common skin cancer which can also be very aggressive.

The study was recently published in Cell Reports.

In 2013, ACRF awarded CMRI $2 million in funding to develop the ACRF Telomere Analysis Centre. This funding was given to support an internationally unique consortium of telomere research groups to better understand the differences in telomere biology between normal and cancerous cells.

ACRF has supported cancer research at CMRI by awarding three research grants, in total $15.2 million, towards cutting edge research technology. ACRF has also awarded CCI three grants, in total $5.2 million.

This news post was originally published on the CMRI website.

ACRF Image-X Institute facility opened

ACRF supporting Australian cancer research projectsAn Australian first and one of four worldwide, the Ingham Institute’s MRI-Linac facility was officially opened on Monday. The facility combines an MRI scanner with a Linear Accelerator for research into cancer therapy and treatment.

Housed in the Ingham Institute’s high-tech research bunker located at Liverpool Hospital in Sydney, the new technology is set to improve the precision and accuracy of radiotherapy.

In 2014, ACRF provided a $2.5 million grant to establish the ACRF Image-X Institute. The MRI-Linac facility is a key part of the new Institute, which aims to revolutionise cancer imaging by creating new and better cancer imaging methods. The new facility pioneers the development of targeted radiotherapy where the x-ray beams are focused on the most aggressive and resistant cancers, increasing survival and reducing the chance of metastases.

Prof Ian Brown FTSE, Chief Executive, Australian Cancer Research Foundation said, “ACRF is dedicated to funding research in Australia that has the power to make significant breakthroughs in cancer diagnosis and treatment. The projects selected by ACRF for research funding are cutting edge and globally competitive.”

“Ingham’s MRI-Linac exemplifies the type of state-of-the-art technology that attracts ACRF’s support and ongoing investment in the pursuit of ways to prevent or more effectively treat cancer.”

Since its inception in 1985, ACRF has awarded more than $25 million in grants to research institutes located in Western Sydney.

Prof Michael Barton OAM, Research Director at the Ingham Institute said, “South Western Sydney is rapidly becoming the world centre of development of this pioneering cancer treatment technology; it is the next generation in cancer treatment as it will improve the effectiveness of cancer treatment for patients in our community, Australia and around the world.”

The facility was officially opened by the Hon. Craig Laundy MP, Assistant Minister for Industry, Innovation and Science and Federal Member for Reid NSW, on behalf of Minister for Health, Greg Hunt MP. The new facility has received support and funding from ACRF as well as the Federal Government.

Ann’s story: This is why cancer research is so close to my heart

Ann supports Australian cancer researchLoyal supporter, Mrs Ann Smith, is proud to be connected with ACRF and hopes that together we can put an end to the devastating effects of cancer.

I met my John in 1974 at our workplace in London. Relationships between staff were discouraged in those days so we kept it a secret until I left the company. We were both madly in love and we knew that we were meant to be together. We got married in 1975 because we couldn’t wait to start our life together.

We had an incredible holiday in Australia and we loved it so much we decided to migrate here in 1980. We found a beautiful family home where we lived happily for 36 years. We quickly made wonderful friends which I am happy to say I still have today.

John liked to stay busy and was a book-lover, so when he retired, he wrote three. He also volunteered in the book room at Lifeline, helping to cull, sort and price the books. He even organised the famous Northern Beaches Book Fairs. We travelled extensively – and celebrated our Ruby wedding anniversary by candlelit dinner at Uluru.

In 1993 I lost my dear twin sister, Rosemary, to breast cancer and it was heart-breaking, especially as she lived back in the UK. We got to share some special time together just before she died. Sadly, she left behind a husband and four small children.

When John was diagnosed with cancer in 2012, I was devastated. I couldn’t bear the thought that he would experience what Rosemary had to. John was very courageous and was determined to go through treatment. Thanks to cancer research, there were various therapies that gave us more time, but unfortunately, they couldn’t cure him. He never complained and was always positive.

In December 2016, John passed away and it is still very hard to grasp he is gone.

John left me a great legacy. He was a fabulous organiser and was famous for his Excel spreadsheets. Before he got too sick, he bought us a beautiful new home that is much smaller and suits me perfectly. When we moved in, we would sit together on the patio drinking our morning coffee, sharing the crossword. It gives me great happiness to carry on this tradition each day, although I no longer get John’s helpful clues and have to tackle the crossword alone.

John was my soulmate and my best friend. He was a true gentleman, an awesome father, grandfather, brother and a loyal friend to all. A friend of ours once called him the Rolls Royce of husbands and I couldn’t agree more.

I am very happy to help end cancer through ACRF. At John’s funeral, we arranged donations in lieu of flowers. I also donate each month via direct debit, and with my daughters’ full support I have left a gift to ACRF in my Will.” – ACRF Supporter, Ann

A world without cancer could be the legacy you leave behind to your loved ones. When you leave a gift in your will to Australian Cancer Research Foundation, you provide some of the greatest minds in the world with the vital tools they need to uncover new ways to treat and prevent over 200 types of cancer. 

Learn more about leaving a gift  Share your story

New leukaemia treatment outperforms standard chemotherapies

Researchers at ANU are working on a new treatment for an aggressive type of leukaemia that outperforms standard chemotherapies.

Lead researcher Dr Nadine Hein from The John Curtin School of Medical Research at ANU said researchers have successfully treated highly aggressive acute myeloid leukaemia (AML) in mice using the new treatment.

“Not only have we been able to reduce the number of cancer cells, we have been able to reduce the number of cancer stem cells that tend to develop or be resistant to chemotherapy and are thought to be responsible for disease relapse in patients,” Dr Hein said.

Dr Hein said researchers used a compound known as CX-5461 to target the protein-making process within the cancer cells.

“We are working towards a treatment that will improve on the current chemotherapy options and improve the patient’s prognosis,” Dr Hein said

Around 1,000 people are diagnosed with AML in Australia each year and, depending on the patient’s age, there is a high rate of mortality with only about 30 percent surviving long term.

Canberra haematologist and ANU Senior Lecturer Dr James D’Rozario said the standard approach to treating AML hasn’t changed in over 30 years.

“Novel agents such as CX-5461 with more sophisticated mechanisms of action are desperately required to improve outcomes in patients with this group of illnesses,” Dr D’Rozario said.

Professor Ross Hannan, Head of the ACRF Department of Cancer Biology and Therapeutics at JCSMR, said that based on the promising preclinical results, a Phase 1 clinical trial for the treatment of patients with blood cancer has just been completed in Australia. Results are expected to be published later this year.

“Another Phase 1/ Phase 2 clinical trial is underway in Canada for the treatment of patients with solid tumours,” Professor Hannan said.

The research has been published in the journal Blood.

ACRF has supported cancer research at The John Curtin School of Medical Research by providing two grants, totalling $3.1 million, towards cutting edge cancer research equipment and technology.

The ACRF Department of Cancer Biology and Therapeutics was officially opened in February 2017.

TAX TIME DONATIONS

As we approach June 30th, there is a lot of talk about tax deductible and tax time donations. This is because if done correctly, making a tax deductible donation can have many benefits.

Read on to learn more about tax time donations.

Why make a tax time donation?

There are a number of benefits that come with making a tax deductible donation. Not only is making a tax time donation a great way to give back to a charity you are passionate about, but it also reduces your taxable income and as a result boosts your tax return. 

All donations that are $2 or more made to ACRF before June 30th will be tax deductible.

Make a donation to an organisation with the registered charity tick

This tax time ACRF would like to remind Australians to check the Australian Charities and Not-for-profits Commission (ACNC) register and review financial documents to ensure that you are giving to transparent charities.

ACRF has received the registered charity tick. A stamp that is reflective of the standards to which ACRF proudly holds itself to. The charity tick initiative has been developed to give reassurance to donors that a charity is transparent and accountable by highlighting its presence on the ACNC Charity Register.

Where your tax deductible donation to ACRF will go

ACRF has awarded over $165M in 78 cancer research grants to 42 research institutes, universities and hospitals across Australia. Thanks to our supporters, these grants make a real impact by providing researchers across Australia access to state of the art technology which in turn speeds up research outcomes.

Throughout the year ACRF organises lab tours, openings of new facilities and the opportunity to meet the researches to allow supporters to see firsthand the impact that ACRF grants are having on research to prevent, detect and better treat cancer.

Each year we provided comprehensive details on our grant recipients and their projects. You can also read about the latest cancer research updates and outcomes of ACRF projects when they make breakthroughs.

The Australian Cancer Research Foundation is committed to funding the technology that Australian scientists need to end all types of cancer, and we want you to know where your donations go.

We are proud to make our financial reports available to you annually and reports from the last ten years are easily accessible on our website. We invite you to review them when making your decision to donate.

Make a tax deductible donation to ACRF this tax time

Donations to ACRF help support some of the most impactful breakthroughs in cancer research. Still not sure how it benefits your finances? Learn more about how your tax deductible donation can help boost your tax return.

Make your tax time donation here and 100% of your gift before June 30 will go directly to cancer research.

New treatment hope for women with triple-negative breast cancers

Researchers at Walter and Eliza Hall Institute (WEHI) and Peter MacCallum Cancer Centre in Melbourne have shown, for the first time, that combining two immunotherapy drugs could be effective in treating triple negative breast cancers arising in women with BRCA1 mutations.

The findings suggest that clinical trials of combined immunotherapy should be considered in women with these breast cancers.
Immunotherapy, a relatively new form of cancer treatment, works by boosting the body’s immune cells to attack tumours and has previously showed promising results for treating melanoma and lung cancers.

The study, led by the Walter and Eliza Hall Institute’s Dr Emma Nolan, Professor Geoff Lindeman, Dr Daniel Gray and Professor Jane Visvader, and Peter Mac’s Associate Professor Sherene Loi and Associate Professor Phillip Darcy, has been published recently in Science Translational Medicine.

Professor Lindeman, also a medical oncologist at the Royal Melbourne Hospital and Peter Mac, said triple negative breast cancers were more aggressive and more likely to recur than other breast cancers.

“Triple negative breast cancers have not seen the same improvement in targeted therapies, or survival, as some other types of breast cancer,” Professor Lindeman said.

“Our study showed that combining anti-PD1 and anti-CTLA4 immunotherapies with chemotherapy halted the growth of BRCA1-related tumours and significantly improved survival in laboratory models.”

Some cancer cells survive by hijacking and ‘switching off’ immune cells that would otherwise destroy the tumours. Anti-PD1 and anti-CTLA4 immunotherapies are so-called ‘immune checkpoint inhibitors’ that release the brakes on critical immune cells, enabling them to attack the tumour.

Dr Gray said previous research had shown that immunotherapy was particularly effective at treating tumours that had accumulated many mutations.

“BRCA1-related triple negative breast cancers have some of the most ‘chaotic’ genomes, and we see many immune cells accumulate in and around the tumour,” Dr Gray said.

“This suggests that the immune cells can readily detect that something is awry, but they aren’t able to respond properly, because they have been disabled by tumour cells.”

“We showed that a combination of anti-PD1 and anti-CTLA4 therapies restored their ability to attack and kill triple negative breast tumour cells, and very effectively control tumour growth.”

Associate Professor Loi, head of breast cancer clinical trials research at Peter Mac said work was already underway to translate these important findings from laboratory models of breast cancer into a clinical trial for women with the disease.

“Our lab-based findings provide compelling evidence to progress to a clinical trial of this combination of immunotherapy drugs, and chemotherapy, in women with BRCA1-related breast cancer,” Associate Professor Loi said.

“There is also a rationale to consider the same for BRCA2-related cancers and triple negative breast cancer more broadly.”

“Importantly, there are already a number of immunotherapy-based clinical trials underway in breast cancer and these two drugs – anti-PD1 and anti-CTLA4 – are in use for other cancers, so we would hope to begin a trial of this specific combination of immunotherapies in suitable breast cancer patients in the near future.”

This research was supported by the Australian Cancer Research Foundation amongst others. ACRF has awarded three grants towards cutting edge cancer research equipment and technology to WEHI, totalling $5.5 million. The Foundation has also supported cancer research at Peter Mac by providing three grants, totalling $7 million.

This news was first published on the WEHI website. Image of the research team courtesy of WEHI.

Image: Dr Daniel Gray, Professor Jane Visvader, Professor Geoff Lindeman, Associate Professor Sherene Loi and Associate Professor Phillip Darcy. Image courtesy of WEHI

Maddie and Tom support ACRF on their wedding day

Wedding donations to support Australian cancer research“I love picking out gifts for friends but there is nothing more special than the gift of giving, which is why Tom and I chose to support a charity on our wedding day.

It was a personal decision to select Australian Cancer Research Foundation (ACRF). We chose this charity because my mum is alive today thanks to progress in cancer research and they are an organisation that has helped seed fund a number of great advances, such as the cervical cancer vaccine.

Mum was diagnosed with breast cancer back in 2012 but luckily they caught it early and were able to treat it. Even though her cancer has been removed, I know the experience impacted Mum deeply. The realisation of what could have killed her has left its own scar. I feel so lucky that Mum is still with us today.

Our families and friends all thought it was a great idea to support cancer research with donations on our wedding day. And why not? You can spend time making homemade jam or some other craft to serve as table favours. However, most of the time they are behind or they guests just never eat them. The more we can educate people about the importance of continued cancer research, the better.” – ACRF supporters Maddie and Tom

Know a couple like Tom and Maddie?

With many modern couples accumulating their household goods before they tie the knot, wedding donations are becoming increasingly popular.

The bride and groom to be can request donations in place of traditional gifts. Or replace favours or bonbonniere the same way. All funds received by ACRF in celebration will help fund new and better treatments for cancer. Click here to learn more.

Scientists find link between smoking and skin cancer

Cancer researcher Professor Whiteman

Scientists have found the strongest evidence yet of a link between smoking and a common form of skin cancer.

The team from QIMR Berghofer Medical Research Institute studied nearly 19 thousand people and found that current smokers were significantly more likely to develop a squamous cell carcinoma (SCC) of the skin than non-smokers.

It is the most comprehensive and highest-quality study that’s been conducted into the link between smoking and skin cancer. The findings have been published in the Journal of Investigative Dermatology.

The study involved 18,828 Caucasian Queenslanders aged 40 to 69 who had never been diagnosed with a skin cancer. Ten per cent of the group were current smokers, 35 per cent were former smokers, and 55 per cent had never smoked.

Professor David Whiteman and his colleagues tracked how many common skin cancers the group developed over three years.

Squamous cell carcinoma more likely in smokers

“We found that current smokers were at significantly higher risk of SCC than former smokers or people who had never smoked,” Professor Whiteman said.

“In contrast, we found no evidence that smokers had higher risks of BCC than non-smokers.

“We also found that among the smokers and former smokers, their risk of skin cancer wasn’t affected by how long they’d smoked for, how heavily they’d smoked, or the length of time since they’d quit.

“We don’t yet understand how smoking might increase the risk of SCC, but these findings strongly suggest that by quitting, smokers are lowering their risk of SCC to the same level as someone who has never smoked. This is another good reason to quit.”

SCCs and BCCs are the most common forms of cancer worldwide. SCCs are generally more serious than BCCs.

While ultraviolet (UV) exposure is the biggest risk factor for developing these common skin cancers, these findings suggest that smoking could also play a role. A number of previous studies have examined the relationship between smoking and common skin cancers, but the findings to date have been conflicting and inconclusive.

Skin cancer on a mole
Image by Dr Richard Johns.

“Unlike previous studies, we controlled for a range of established risk factors including skin colour and history of sun exposure,” Professor Whiteman said.

“A consensus is starting to emerge that smoking has very different associations with SCCs and BCCs.

“There are several possible biological explanations as to how smoking might cause skin cancers, but none of those explains why it would apply only to SCCs and to current smokers.This is an area in which more research is needed.”

 

The study was funded by the National Health and Medical Research Council (NHMRC).

ACRF has supported cancer research at QIMR Berghofer by providing three grants, totalling AUD$ 6.65 M, for the purchase of cutting edge research equipment and technology.

This news post was first published on the QIMR Berghofer website. Image of professor Whiteman courtesy of QIMR Berghofer.

Gold standard technique for cancer research revealed by global study

Cancer research in AustraliaA research technique that is widely used to test new anti-cancer agents could be improved by adoption of a worldwide ‘gold standard’, according to a new study led by Walter and Eliza Hall Institute scientists.

In the first research of its kind, 64 academic research programs in North America, Europe, Australia and Asia were surveyed to establish how they used a technique called ‘patient derived xenografting’ to grow and study cancer samples taken from consenting patients. The method is an important way that cancer researchers can undertake laboratory experiments such as the testing of new anti-cancer agents.

Walter and Eliza Hall Institute cancer researchers Dr Kim Pham, Dr Gwo Yaw Ho and Associate Professor Clare Scott used the information from their study to develop a ‘gold standard’ for growing human cancer samples in the laboratory, considering both how the experiments are conducted as well as the governance of the use of human tissue in this system. Their research was published in a new book, Patient Derived Tumor Xenograft Models – Promise, Potential and Practice.

Dr Pham said patient derived xenografts were an important laboratory technique for studying human cancers in conditions mimicking the human body. “They are an important pre-clinical research tool that informs the future development of clinical cancer trials,” she said. “It is crucial that we have worldwide standards for patient derived xenografts to ensure research in this field can be reproduced and directly compared between laboratories.

“Our study uncovered considerable variability in how laboratories around the world undertook patient derived xenograft experiments. From this we have developed what we consider a ‘gold standard’, what would be the best practice in the area. The good news is that almost all the laboratories we surveyed had elements of best practice. The next step is for laboratories and organisations overseeing research to develop a process that ensures all laboratories work to the same gold standard,” she said.

Associate Professor Scott, who is also medical oncologist at the Peter MacCallum Cancer Centre and the Royal Women’s Hospital, said gold standard research could be achieved in some situations through research consortia bringing multiple organisations together to collaborate. “Improvements in reproducibility would enhance international collaborations, as well as accelerating preclinical research output,” she said.

“We were also able to establish guidelines for how this research can be optimally governed, particularly around questions of how permission for the use and transfer of human samples is governed. In the long term, improving this field of research will benefit people with cancer.”

Dr Ho said cancer research using patient derived xenografts was very expensive to conduct. “In Australia, despite the challenges of using this technique in a tight funding climate, we were pleased to find most research was conducted to a high standard,” he said.

“In the future, the involvement of Australian researchers in local or international research consortia could be a viable option for our researchers to continue to making important advances in preclinical cancer research.”

Dr Pham is a postdoctoral scientist at the Walter and Eliza Hall Institute. Dr Ho is a medical oncology fellow at The Royal Women’s Hospital and the Peter MacCallum Cancer Centre, and a PhD student enrolled at the Walter and Eliza Hall Institute through the University of Melbourne’s Department of Medical Biology.

This article was first published on the WEHI website.

Rachel joined #imovebeCAUSE to support cancer research

Rachel joined #imovebeCAUSE to support cancer research in AustraliaACRF supporter, Rachel is tackling 200kms this June to fundraise for ACRF – with two small kids, this is no minor task! She is supporting cancer research in memory of her mum who passed away from cancer last year.

“I decided to take on #imovebeCAUSE and fundraise for cancer research in memory of my beautiful mum. She lived with myeloma for 10 years and passed away just before Christmas last year after being in the hospital for three long months. She is my reason! I want to fundraise through this great initiative so I can help others in her situation.

My mother was my best friend and my mentor. She was the bravest, strongest and most positive woman I have ever met. We had a very close relationship and I miss her every day.

Unfortunately, cancer has impacted me and my family a lot. Both my aunt and my mum passed away from cancer. And now my father in law currently has lymphoma. Family means everything to me, and cancer has taken away too many amazing people from us.

This is why cancer research is so close to my heart. It’s critical that we help put an end to all cancers. It’s a horrible disease that takes away way too many beautiful people and breaks people’s spirit. I hope that one day the world will be free of this awful disease, thanks to the amazing researchers who are working to make new discoveries and developments all the time.

I chose to fundraise for ACRF because I know that many new treatments and positive medical developments are made possible by wonderful ACRF supporters. ACRF is focused on trying to end all cancers. It’s important to me that all cancers are researched, not only the common and well-known cancers.

I would encourage others thinking about getting involved with the #imovebeCAUSE initiative to support cancer research because every donation counts. Big or small – it is making a difference and helping lifesaving research progress. Please support those who work so hard to try and better the lives of those who are living with cancer.

I’m so grateful for all the work ACRF does. It was heartbreaking seeing mum suffer, but one day in the future, thanks to cancer research fewer people will have to suffer.” – ACRF Supporter, Rachel

Sign up today to join Rachel and get moving in June to support research into all cancers.

Support Rachel Sign up now

One step closer to early detection of lung cancer

Australian cancer researcher, Clare Weeden, from WEHI, early lung cancer detection Cancer researchers at ACRF grant recipient, Walter and Eliza Hall Institute (WEHI) in Melbourne, have made a breakthrough that could help early lung cancer detection.

They’ve discovered cells which are thought to give rise to lung squamous cell carcinoma, the second most common subtype of lung cancer. This type of cancer primarily affects smokers and ex-smokers.

The study, led by Dr Marie-Liesse Asselin-Labat and PhD student Ms Clare Weeden, aims to understand how cancer could form. Researchers used donated lung tissue to discover that, when they exposed isolated cells found in the airway of the lung to harmful chemicals, such as cigarette smoke, the cells would rapidly try to repair any damage and make errors in the process.

Dr Asselin-Labat said the team found that despite attempts to help the body repair from damage, the basal stem cell DNA repair process was faulty.

“Our team unearthed some of the first evidence that the basal stem cell DNA repair process is flawed. Pointing to the accumulation of DNA errors and genetic mutations that could eventually lead to cancer,” Dr Asselin-Labat said.

Further genetic analysis using a technique developed in the Institute’s bioinformatics department, confirmed a correlation between the genetic signatures of the lung-based basal stem cells and lung squamous cell carcinoma. This genetic data reinforces that lung basal stem cells could be the ‘seed’ from which a cancer is able to ‘grow’.

Lung cancer is the number one cause of cancer death in the world and there is a link to squamous cell carcinoma for thirty percent of these cases, says Ms Weeden.

“Lung squamous cell carcinoma is a devastating disease with a poor prognosis. This is because these types of tumours are often discovered too late, at a point where the cancer is inoperable. Therefore, having the ability to detect this cancer early could be a real game-changer,” Ms Weeden said.

“The hope going forward, is that our work will be a gateway to new, tailored prevention and treatment measures for patients with lung diseases,” Ms Weeden concluded.

Despite being the leading cause of cancer death, lung cancer research currently only receives about 5% of cancer research funding in Australia.

This article was first published by WEHI and the image of Dr Marie-Liesse Asselin-Labat and PhD student Ms Clare Weeden was provided courtesy of WEHI.

The Australian Cancer Research Foundation (ACRF) has supported WEHI by providing three grants, totalling AUD 5.5 million towards cutting edge cancer research equipment and technology. ACRF has also provided three research grants, totalling AUD $ 9 million, to the Victorian Comprehensive Cancer Centre for research into all cancers.

Kempsey Cancerian Committee’s gala dinner was a pearl of a night

Kempsey Cancerians supporting cancer research in Australia

The Kempsey Cancerians are the longest running Cancerian fundraising committee in the country and over the past 30 years, they have raised nearly $1 million to support Australian cancer research projects.

On May 20, the group hosted their 30th ‘Pearl Anniversary’ gala fundraising dinner. More than 280 people attended the dinner which was held at the Kempsey Macleay RSL and included raffles (including the very popular pearl box balloon raffle), a very entertaining auction, fantastic live music and wonderful meals by Chef Lloyd Newell.

The night was a great success and saw the committee raise over $24,000 for the Australian Cancer Research Foundation.

We would like to extend our thanks to all the committee members who helped organise this incredible event. Thank you also to the Kempsey Community for their support over the past 30 years – you are amazing.

We would also like to recognise some of the original sponsors who were there on the night – Peter and Lorraine Hadlow of Blyth and Hadlow; Paul and Lesley Cooney of Winsome Real Estate; Paul and Jan Stubbs of Sheridan & Stubbs; Patrick Sheridan; Jim and Chris Shaw of Hot n Tasty; John Scott of John Scott Promotions; Jenny Preston of GIO; David and Helen Parker; Sandra Walsh of Larry’s Pharmacy.

Our profound thanks to original Kempsey Cancerians Committee members who were also there on the evening – Helen Campbell, Brian Irvine, Darrell Crilley and original members who are still on the committee – Alison Mavin, Kay Irvine, Helen and Max Packwood for their decades of hard work and dedicated support of cancer research.

We look forward to seeing what amazing research breakthroughs will be made possible, thanks to the generosity of the people of Kempsey.

To view photos from the night visit the Kempsey Cancerian’s Facebook page here.

New cancer treatment targets from inside the cell

Laser microscopeResearchers at the Institute for Molecular Bioscience (IMB) have found a promising small molecule cancer treatment in a pre-clinical study of breast cancer.

Associate Professor Mat Francois said the team developed a new approach to drug design. The new approach targets a molecular switch that was previously considered inaccessible.

“Current cancer treatments target elements on the outside of cancer cells. This limits our ability to control specific activity happening inside the cell,” Dr Francois said.

“Our new approach to drug design allows us to cross this barrier and get inside the cell. We do this by targeting the activity of transcription factors. These operate as a molecular switchboard inside cells and bind to DNA, turning gene expression on and off as needed.”

Dr Francois said the team demonstrated it could successfully use this approach to fine tune the cellular activity responsible for cancer-induced vessel growth, a key contributor to cancer metastasis.

“The small molecule we have discovered, Sm4, has shown it can target and switch off the activity of transcription factor SOX18. This controls the development of our blood and lymphatic vessels induced by cancer growth.”

“These vessels act as an on-ramp system to carry cancer cells throughout the body. Being able to block access to these vascular highways with the flick of a molecular switch is a critical step to limit cancer metastasis.”

A collaborative effort

In a pre-clinical study of breast cancer, performed in collaboration with QIMR Berghofer Medical Research Institute, Dr Francois said the team found that mice treated with Sm4 had significantly improved survival rates.

“Our results show that targeting the transcription factor SOX18 with a small molecule compound is a promising new molecular strategy to treat cancer metastasis.”

“High levels of SOX18 have also been associated with poor prognosis for cancer in human patients so it’s exciting to know that we have identified a small molecule inhibitor that could help improve cancer treatment.”

The study appears in eLife and involved research teams from Australia, the UK, the US and China.

The original news article on the discovery can be viewed on the IMB website.

The Australian Cancer Research Foundation has supported IMB by providing four grants, totalling AUD 7.1 million, towards cutting edge cancer research equipment and technology. The Foundation has also supported cancer research at QIMR Berghofer by providing three grants that amount to AUD 6.7 million.

Dave & Tess take on Nepal Himalayas for cancer research

Hiking for Australian cancer researchers

“In October 2017, Dave and I will be spending 23 days in the Nepal Himalayas as an adventure fundraiser for ACRF. We’re doing this extended trek in memory of Dave’s dad, Len. Len sadly passed away unexpectedly last year following investigations for a pancreatic tumour.

Len was such a welcoming and caring man. He felt like a second father figure to me from early on in my relationship with Dave. For Dave, Len wasn’t just his father, he was his supporter, friend, confidant, teacher and handyman! Len’s dedication to his family was paramount. He worked hard to show this until the end.

Dave has a large family so at times it can be chaotic but Len was always the sea of calm. He was laid back, warm-hearted and known for his goofy smile. Len also had a passion for the water – lakes, seas and oceans. He was a keen sailor and loved going to the beach to watch the ripples and waves.

Since Len’s passing, we’ve been wanting to do something to help improve the detection, diagnosis and treatment of pancreatic cancer. Supporting research into this disease seemed to be the best way. Dave and I looked for an event that would challenge us physically. We both love travelling, hiking, camping, snowboarding – just about anything that gets us outdoors really so we chose to do an adventure fundraiser. During our trek through the Nepal Himalayas in October, we’ll be visiting the Mt Everest base camp, crossing three passes and ascending three peaks along the way.

Why we’re doing this for ACRF

David and I are no strangers to cancer as we are both doctors, currently working at Townsville hospital. Dave is training to be an emergency medicine specialist and I’m a general surgeon. ACRF is one of the leading organisations when it comes to contributing to cancer research, and has a reputation to match. Research is what provides medicine with the ability to understand, detect, diagnose and treat these diseases, and without that ongoing research, we can’t improve on what we already have.

Cancer highlights how unexpected life can be, how quickly things can change, and forces you realise that even those people in our lives that seem so permanent, strong and stable – like our parents – are mortal too. We miss you Len, your time with us was all too brief” – ACRF supporter Tess.

 

Tumour-trained T cells on the lookout for cancers

‘Tumour-trained’ immune cells – which have the potential to kill cancer cells – have been seen moving from one tumour to another for the first time. The new findings were uncovered by scientists at ACRF grant recipient, Garvan Institute of Medical Research.

The study has revealed that activated T cells are the main immune cell to leave tumours and that these T cells move to other tumours and lymph nodes. It, therefore, reveals how immune therapies for cancer might work and suggests new approaches to the development of anti-cancer immune therapies.

Metastatic cancer, in which cancer has spread to other sites beyond the primary tumour, is responsible for almost all cancer deaths, and treatment options remain very limited. New immune therapies that help the body’s own immune T cells to attack cancer cells within tumours are showing promise in metastatic cancer – yet little is understood about how these therapies function.

“We know that T cells and other immune cells accumulate inside tumours – but until now we’ve known very little about what happens next. How does the environment within the tumour change the cells? Do they leave the tumour? Which types of immune cells leave? Where do they go, and why?” said research leader Dr Tatyana Chtanova, head of the Innate and Tumour Immunology lab in Garvan’s Immunology Division.

Fluorescent immune cells provide clues

To watch ‘tumour-trained’ immune cells travelling through the body, Dr Chtanova and her team used an innovative ‘photoconversion’ strategy – in which all the cells in a mouse are labelled with a green fluorescent compound, and only those within a tumour (including immune cells) are turned to red by shining a bright light on the tumour.

“Before, we could only guess at which immune cells were leaving tumours,” said Dr Chtanova, “so to see these red cells moving in a sea of green, as they exited a tumour and travelled through the body, was remarkable.”

ex tumour immune cells
Ex-tumour immune cells (red) 

“We saw immune cells leaving the tumour and moving into lymph nodes – and, importantly, we could see immune cells moving out of one tumour and into another, distant tumour.”

The researchers were surprised to see that the mix of immune cells leaving tumours was sharply different to the mix of immune cells going in.

“We found, unexpectedly, that T cells were the main immune cells to exit tumours and move to lymph nodes and other tumours – even though they represent only a fraction of the immune cells that enter tumours,” Dr Chtanova said, “and some classes of T cell, such as CD8+ effector T cells which promote tumour destruction, were more likely to exit the tumour.”

“This tells us that there’s strong control over the tumour-exiting process.”

Tumour trained T cells stronger

Those T cells that had been exposed to the tumour’s ‘microenvironment’ and then exited the tumour were more activated and had a stronger cytotoxic (cell-killing) activity than those that did not enter the tumour.

“What we suspect is happening is that, within the tumour, these T cells are acquiring knowledge about the cancer that helps them to seek and destroy tumour cells.”

“It’s possible that these T cells ‘on patrol’ – which leave one tumour and move to another – are using their new-found knowledge to attack cancerous cells in the second tumour.”

The research team is now working on ways to prompt activated T cells to exit tumours in greater numbers.

“Ultimately, we’re working to understand more deeply the relationships between immune and cancer cells, so that we can design approaches to empower the immune system to destroy cancer,” Dr Chtanova concluded.

The study has recently been published in the Proceedings of the National Academy of Sciences USA.

This news article was first published on Garvan’s website. Images courtesy of Garvan.

ACRF has supported cancer research at Garvan by providing three grants, totalling AUD $6.13million, towards cutting edge cancer research equipment and technology.

New therapies in development to starve cancer cells

New cancer therapies for patients with some of the most difficult-to-treat cancers are now being developed following a major discovery by scientists in the ACRF Centenary Cancer Research Centre based at the Centenary Institute in Sydney.

These drugs block metabolic processes critical to cancer cells and are currently in the early stages of development.

Clinical trials are likely to commence within three years thanks to a recent new investment in this research, including a $2.5 M grant from the Australian Cancer Research Foundation (ACRF).

Centenary’s scientists are focused on new treatments for patients suffering with cancers associated with very low survival rates and for which limited treatment options are available. Having revealed links between cancer and its metabolism of nutrients, they have developed a novel method of starving cancer cells – but not normal cells – essentially cutting the energy supply to the diseased cell.

The study led by Associate Professor Jeff Holst, Head of Origins of Cancer Program at Centenary Institute and Sydney University, revealed an important role for a protein involved in the metabolism of certain cancer cells that is vital for helping them survive and grow.

“If we are able to specifically block the supply of nutrients to cancer cells by inhibiting the function of this protein, we can essentially ‘starve’ the cells and stop them from growing”, Associate Professor Jeff Holst said.

In collaboration with University of Sydney researchers, the team has also been able to identify molecules that block the action of the protein and these are now being developed as possible new drugs. The new therapy will focus on translating the results of Associate Professor Holst’s research into drugs for testing in clinical trials.

The discoveries leading to the development of the new treatment have been published in Oncogene, International Journal of Cancer and Journal of Pathology.

ACRF has supported cancer research at the Centenary Institute by providing two grants, totalling AUD$ 7.5 M, for the establishment of the ACRF Centenary Cancer Research Centre and purchase of cutting-edge research equipment and technology.

Image: Assistant Professor Holst, Image courtesy of the Centenary Institute.

Jane, Maxine, and Shea are skydiving for cancer research

Skydiving for cancer research“It was utterly and totally devastating when my older sister died of cervical cancer. We were born three years apart and were always exceptionally close. More often than not, people assumed we were twins, and we had no problem with that! I think she would love that I went skydiving for cancer research.

I became her full-time carer when she was diagnosed with cancer. Sadly, the recently developed cervical cancer vaccination was too late to help prevent my sister’s cancer. This is why I wanted to help researchers speed up discoveries and save lives.

Soon after my sister’s death, I decided I would fundraise for Australian Cancer Research Foundation by going skydiving. Two of my work colleagues, Shea and Jane, put their hands up to jump alongside me. Like me, they do something out of the ordinary every now and again to remind themselves that life is only lived once.

We call ourselves ‘The Gravity Girls,’ but it’s a bit of an in-joke because when we did the jump we were equally excited and petrified at the thought of leaving the plane. After we jumped, strangely enough, we actually wanted to do it again!

I will never stop missing my sister. When I did the big jump, I was thinking of her. I’m proud that I could do something for cancer research and help bring an end to all cancers. I’m confident in the progress researchers are making. I like to think that ending the threat of cancer could happen within my lifetime – what a bonus that would be!” – ACRF support, Maxine

We’d like to thank Jane, Maxine, and Shea for being brave and raising over $6K for ACRF. To show your support for ‘The Gravity Girls’ you can visit their Everyday Hero Page here.

New childhood leukaemia subtype found

Researchers at the Children’s Cancer Institute (CCI) in Sydney, together with collaborators in Prague, have found a new technique for tracking leukaemia cells containing a genetic change called BCR-ABL1.

The new DNA test has proven to be more accurate than standard Minimal Residual Disease (MRD) testing currently used for patients with BCR-ABL-positive leukaemia.

The new test has revealed a biological diversity amongst this high-risk subgroup – in about 20% of children with this gene change, their leukaemia cells resembled chronic myeloid leukaemia (CML), the most common leukaemia in adults.

This discovery is surprising but important because treatment choices for CML can differ to those for acute lymphoblastic leukaemia (ALL), the most common type of childhood cancer.

Knowing which children are part of this subgroup will allow clinicians to make better decisions about treatments to maximise effectiveness and minimise side effects. Current treatment options for BCR-ABL-positive leukaemia include drugs targeted directly at BCR-ABL1, chemotherapy and bone marrow transplantation.

A/Prof Rosemary Sutton is head of the MRD group and one of the authors. She says that while the number of children with this newly-identified type of leukaemia is low, she is enthusiastic about the implications of this study for their treatment.

“I’m most excited about our capacity to do our MRD testing in a new and different way to benefit children with BCR-ABL-positive leukaemia, particularly this CML-like subtype of ALL.

“Now that we can test for the BCR-ABL1 gene directly, it will help identify the best treatment options for children in this high-risk group,” she said.

The findings were announced in a research paper recently published online in the journal Blood.

The research was funded by grants from the National Health and Medical Research Council (NHMRC) and Cancer Council NSW.

This news was first published on the CCI website. Image: Jodie Giles (left) and Nicola Venn (right), research paper co-authors, look at DNA test results in the MRD lab, courtesy of CCI.

The Australian Cancer Research Foundation has supported cancer research at the Children’s Cancer Institute by providing three grants, totalling AUD$ 5.2 M, for the purchase of cutting-edge research equipment and technology.

Leanne’s Story


 

“I met Scott in early December 2001, when I was a 19-year-old university student. I was out with a good friend when he and I noticed each other and started talking. By the end of the night, he asked for my number and a few days later we went on our first date. I was smitten.

Just after Christmas the same year, Scott left for a two week holiday with a few of his friends. While he was away we constantly sent text messages to each other. On New Year’s Eve, I was at a party when I messaged him to say that I wished he was with me so I could kiss him at midnight. The next day, he flew home early from his holiday so we could spend time together. He later told me this was when he knew he was in love.

Every spare moment we had, we spent together.

When I had my wisdom teeth removed I stayed at my parents’ place while I was recovering, which was over two hours away. Every day, Scott would drive up in the morning to spend time with me and then drive back in the afternoon to work as a chef. It was during one of these trips that I told him I loved him for the first time. I had never told anyone I had loved them before, and I was on top of the world. Scott was welcomed as a part of my family, and I had told my friends he was the man I was going to be with for the rest of my life.

In April 2002, Scott and I moved into our first place together. He spent hours teaching me the rules of AFL and cricket, which were his favourite sports. And while I was studying for my university exams, he would make me cups of tea.

We loved going to the beach together as we enjoyed the sunshine we would imagine what our lives together would look like, talking about when we would get married, how many kids we would have and what their names would be.

Two years later, I graduated from university – an accomplishment I would have struggled to achieve without Scott’s support. As a graduation present, he took me to Melbourne for the first time. While we were there we saw his beloved Hawthorn AFL team play. We also took a trip to Wooli together, where we sat on the rocks at the river mouth for hours, just watching the water, fishing and talking. I remember him telling me how he would love to retire somewhere like that.

Around July 2004, Scott’s knee became very sore and he was struggling to stand on his feet all night at work. He had also lost 10kg which he attributed to stress.

When a lump started growing in his leg above his knee he got scared and went to his GP looking for answers.

After numerous tests, he was diagnosed with Ewing’s Sarcoma, a rare primary bone cancer that affects children and young people. They found a tumour in his leg that had already spread to his lungs. Later, the doctors told us they were unsure of how many tumours he actually had. At the age of 22, he had the fight of his life on his hands.

In late August 2004, Scott needed to have 12-18 weeks of chemotherapy. He suffered extreme pain in his leg and back throughout the treatment and often required morphine injections and oxygen to help him breathe.

There were so many things that we had to watch out for and monitor. I had to regularly check Scott’s temperature and take him to hospital immediately if it was above 38 degrees. He had to make sure to be very careful not to cut himself when he was shaving, as the chemo could stop his blood from clotting. He needed to take a number of medications at various intervals during the day so to help I wrote up a schedule of what medication had to be taken when. He would also bruise easily, have dizzy spells and get migraines. It seemed the list was never ending.

At times, it would all just get too much and he would cry for hours.

 

 

A few months later, in October 2004, things started to look up as the primary tumour in Scott’s leg was shrinking and he started feeling a little better. He even went to work for a couple of days. Our spirits were lifting and we talked more about what we would do when he went into remission.

But our hopes were quickly dashed a few weeks later when we were told the chemo wasn’t working.

The pain in his back and leg was getting worse and he found it increasingly difficult to breathe. The tumours we knew about were getting bigger and spreading.

We were told his cancer could not be cured but, hopefully, ongoing radiation treatments would shrink the tumours to give him more time – maybe a few years if we were lucky. The doctor said we would know if the treatment had worked within the next two weeks. If it didn’t, he wouldn’t have much time left.

Scott and I were devastated by this news and we wanted to get a second opinion. We couldn’t understand why nothing could be done to cure his cancer, but we vowed to not give up. We talked about things like getting married and travelling to see the world before it was too late.

On the day we had an appointment to get a second opinion, Scott was rushed to hospital with extreme back pain and a tingling sensation in his legs. MRI scans showed that tumours on his spine were pressing on his spinal cord and had cracked one of his vertebrae. He was given three high doses of radiation on his back over three consecutive days.

By the end of November, Scott was confined to his bed because he had lost all the feeling in his legs and could no longer support himself. The doctors told us the radiation had not been successful and that he would be lucky to live another week.

During Scott’s final days, I lived in the hospital with him. He spent lots of time with his friends and family during that time as well. I will never forget the memory of his young, fit and healthy friends, crying and supporting each other in the hallways of the hospital.

We celebrated our three year anniversary in the hospital.

I was in a chair beside Scott when he lowered his bed as if he was getting down on one knee, and he presented me with an engraved eternity ring, asking if he could be mine for eternity.

Scott’s tumours had continued to spread and were now visible even on his face. As the days went on, he was on so many pain medications that he rarely woke up, and on the occasions he was awake, he was hallucinating, on one occasion he believed it was our 50th wedding anniversary.

During one of our last conversations, Scott was feeling sad about his imminent passing and worried that people would forget him. I promised him I would never let that happen.

Scott continues to be my guide through life.

On the night of Christmas Eve 2004, I laid in the bed beside Scott so I could hold him all night. I guess I knew it would be for the last time.

We spent Christmas morning with family crowded around Scott’s hospital bed. I sat beside him all day, holding his hand. At around 3pm, I left the room to talk to some family members. Before leaving, I kissed him on the forehead and told him I loved him and I’d be back soon. I felt his heart beat and it was very weak.

Half an hour later, Scott passed away as an afternoon storm rolled in. We believe he chose his moment to move on, as he had hoped he would get the chance to see a storm one last time.

His family and I comforted each other as we had a drink in his honour on the balcony of the hospital and watched the storm fade away. It’s been 12 years now and every Christmas at 3.30pm I still share a drink with my family in his memory.

Saying goodbye to Scott and leaving the hospital for the last time without him was one of the hardest things I have ever had to do. He was farewelled on New Year’s Eve 2004, and is buried with a photo of us on his heart.

Leanne and her family 2017

 

I consider myself lucky to have known Scott. He was such an important part of my life and I wouldn’t be the person I am today without him.

Scott taught me what life and love are about and showed me real happiness. He encouraged me to never give up, achieve my goals and follow my dreams. Rarely does a day pass where he does not cross my mind. His memory reminds me to never take things for granted, to make the most of every day and appreciate every moment.

I have made it my life goal to continue fundraising for cancer research in his memory and ensure his legacy lives on.” – ACRF supporter, Leanne

Leanne wouldn’t be who she is without Scott, and cancer research wouldn’t be where it is without you. 

Two melanomas that aren’t linked to UV radiation

The genetic study, led by Australian researchers at Melanoma Institute Australia (MIA), QIMR Berghofer Medical Research Institute and The University of Sydney as part of the Australian Melanoma Genome Project, has found that melanomas on the hands and feet (known as acral) and internal surfaces (known as mucosal) are not linked to ultraviolet (UV) radiation. This is in contrast to melanoma of the skin, which is strongly related to UV radiation.

The research shows that acral and mucosal have different causes to skin melanoma. This has implications for preventing and treating these forms, which occur worldwide.

“This is by far the largest study to have looked at the whole genome, and it has proven these less common cases are strikingly different in terms of their causes,” said Professor Richard Scolyer, Conjoint Medical Director of MIA and a lead author.

Every year in Australia, up to 420 people are diagnosed with acral or mucosal melanomas. They affect people of all ethnic backgrounds and are the most common forms of the disease in people with very dark skin. These forms often behave more aggressively, are harder to diagnose and have a poorer outcome compared to skin melanoma.

Melanoma type helps find the right treatment

Treatment for skin melanoma has advanced rapidly in recent years, with therapies tripling the life expectancy of some advanced patients. For the first time, this research sheds light on why revolutionary treatments—many of which have been pioneered at MIA — don’t work as well for acral or mucosal melanomas.

“Acral and mucosal melanomas occur all over the world, but they have been even more challenging to treat than skin melanoma,” said Professor Nicholas Hayward, a lead author from QIMR Berghofer Medical Research Institute.

“Knowing these are really different diseases to skin melanoma is important for the development of future therapies.”

The study also found acral and mucosal melanomas have much less gene damage compared with skin melanoma and the damage ‘footprints’ did not match those of any known causes of cancer, like sun exposure. This means we must target new research to discover what is causing these cancers, and what can prevent them.

While they had fewer gene drivers that could be targeted for therapy, new ones were found. Some mucosal melanomas unexpectedly had mutations in the SF3B1 and GNAQ genes, which had previously only been connected to melanoma of the eye.

Understanding which gene mutations are driving an individual tumour is the basis of personalised cancer medicine. This is the first study to survey the entire DNA sequence of melanomas, not just the genes themselves, giving 50 times more information than in previous work. Many genes were found to have damage in their control regions, the so-called ‘dark matter’ of our genome, and these may be previously unsuspected drivers.

“This is a world-leading genetic analysis of melanoma,” said Professor Graham Mann, a lead author at MIA.

“We are working hard now to turn these discoveries about the uniqueness of acral and mucosal melanoma, and about the new control mutations, into better results for our patients.”

The research has been published in the journal Nature.

New pathway for blood cancer therapies

ACRF supports Australian cancer research at Peter MacCullum Cancer CentreCancer researchers at Peter MacCallum Cancer Centre and Monash University in Melbourne have identified how a new class of epigenetic drug engages with the immune system to kill off blood cancer cells.

The research, published in journal Cell Reports, has demonstrated the potential of combining ground-breaking epigenetic and immune-based treatments for improved results.

The experiments showed that immune-competent mice with lymphoma had a far greater response to BET-inhibitors than their immune-deficient counterparts. BET-inhibitors are a relatively new class of cancer treatment, which work to ‘switch off’ important cancer-causing genes expressed within tumour cells.

In addition to the improved response, the research showed that BET inhibitors were able to ‘switch off’ a protein called PD-L1 which is used by tumour cells to hide from the immune system.

Through this mechanism, BET-inhibitors were making tumour cells more sensitive to attack from the immune system.

The power of an activated immune system in eliminating tumour cells has been proven through successful drugs such as Keytruda and Opdivo, which also target the PD-L1 pathway.

Building on this knowledge, Melbourne researchers confirmed that the combinations of BET-inhibitors with other immune therapies work better in lymphoma than either therapy alone.

Based on laboratory research performed at Peter Mac, the Monash team is currently trialling a combination of different epigenetic drugs. They are combining Dinaciclib with the anti-PD1 therapy, Keytruda, in relapsed lymphoma, myeloma and chronic lymphocytic leukaemia. Further clinical trials for the combination therapy are likely to emerge as a result of this research.

This article was first published on the Peter Mac website, image courtesy of Peter Mac.

To date, ACRF has awarded in total $AUD 8.2 million to support cancer research at Peter MacCallum Cancer Centre and Monash University.

Shanuki says goodbye to her long hair for a great cause

Shave, cut our colour your hair to support Australian cancer research“Each year I try to give some of my time to a great cause. Last year, I volunteered as a buddy at a camp that helps kids affected by cancer. It aims to take children’s minds off of the hospitals and treatments. While I was spending time with these families, I thought a lot about what it would be like to put an end to the suffering that cancer causes. It motivated me to continue my yearly ritual so no more families would have to go through this ever again.

That same year I witnessed a wave of cancer diagnoses. Sadly, a work colleague of mine and several family friends passed away. While I consider myself lucky to have had none of my immediate family diagnosed with cancer, it seems to be happening all around me. My husband’s already lost an aunt to breast cancer and another one of his aunts was recently diagnosed.

I’m shocked by the sheer number of people affected by cancer. I feel we should all do what we can to help eradicate or at least control the effects of this disease. I believe better prevention and treatments will only come about through research which is what led me to Australian Cancer Research Foundation (ACRF).

When I went searching for more information about fundraise funds for Australian Cancer Research Foundationing cancer research discoveries I came across ACRF. I discovered that they’re a charity that supports research into all cancers and they help fund projects across Australia. After speaking with a staff member, I decided to support their efforts with my own fundraising event. I decided to donate my waist-long hair and help raise funds for Australian Cancer Research Foundation. My hair hasn’t been short since I was five years old so I was quite nervous about it.

Throughout the fundraising process, the love and support from family, friends and colleagues was amazing.

I also found that fundraising provided an opportunity for people to start a dialogue about personal experiences relating to cancer. A family friend is now looking into how she can help her daughter cut and donate her hair just like I did.

Learning how to style my new short hair is challenging but with the help of YouTube tutorials, I’m getting there. I’m actually really enjoying the change. I’ve discovered that a shower cap stays on so much better without a kilo of hair under it!” – ACRF supporter, Shanuki

Alycia’s birthday is helping Australian cancer researchers

Alycia supports Australian cancer research“For my 20th birthday, I just wanted an easy-going, simple celebration where I could spend time catching up with friends. I also wanted to use the occasion to help bring an end to cancer.

I think it’s important that we each take the time to think about how lucky we really are, and how we can each do our part to help others. I thought long and hard about how I could do something special and make a difference. I decided I would ask for donations to ACRF in lieu of gifts.

Once I chose to support cancer research as part of my birthday celebration, I spread the word weeks before the party about donations in lieu of gifts and reminded everyone quite often (which may have been annoying, but it was effective).

At my party, I had a donation station set up where people could look at ACRF pamphlets, grab a ribbon and put their contribution into a box. The support I received from everyone exceeded expectation. My friends all loved the idea and were keen to make a donation.

My family has experienced losing a loved one to cancer. My grandfather passed away from cancer when I was about 11 years old. At that age, everything seems like a blur and I didn’t fully understand what was happening when he was sick. Naively, I believed everything was going to be fine and things would soon go back to being normal. It was when he was admitted to the intensive care unit that the seriousness of his illness really hit me, and it was frightening.

I remember telling my mum that I didn’t want to see Granddad because I didn’t want to remember him like that. The hopelessness that I felt at the time was overwhelming.

Cancer is a devastating disease and until we end it together, we will continue to worry for our family, friends and ourselves. I want to help reduce this anxiety and fear by helping researchers find better methods of prevention, detection and treatment of all cancers.

I wanted to raise money for ACRF to help fund the equipment researchers to speed up discoveries. To all of those who support cancer research, you are doing a fantastic thing, together we’ll bring an to end cancer, and I think you will be so proud that you helped make it happen.” – ACRF supporter, Alycia

Immune cell discovery opens up possibility of new treatment for blood cancer

Researchers have unlocked the secrets of a little-understood immune cell, potentially paving the way for an easier way to treat and prevent graft-versus-host disease (GVHD).

GVHD occurs in up to 70 per cent of patients who receive a stem cell transplant to treat blood cancer. It is caused by donated immune cells (called T cells) attacking tissue in the recipient’s skin, gastrointestinal tract, liver or lungs. Unfortunately, a significant proportion of patients who develop acute GVHD of the gastrointestinal tract do not survive.

Regulatory T cells play vital role

QIMR Berghofer senior scientist Professor Geoff Hill, lead author Dr Ping Zhang, and their team have discovered that a type of T cell known as a type 1 regulatory T cell, or TR1 cell, plays a crucial role in fighting GVHD.

Importantly, they have also discovered the protein that causes these cells to develop, allowing them to produce TR1 cells in large numbers in the laboratory.

Professor Hill said that while conventional T cells fight disease and infection, regulatory T cells are responsible for keeping a check on immune responses and preventing them from causing harm.

“Regulatory T cells are particularly important for stem cell transplant recipients because they stop the donor cells from mounting an immune response against normal tissues,” Professor Hill said.

“There are two types of regulatory T cells: FoxP3 regulatory T cells, and TR1 cells.”

“In most cases, FoxP3 regulatory T cells are more important and exist in much higher numbers than TR1 cells. But in this study, we found that TR1 cells are very important in stem cell transplantation.”

“Patients with GVHD stop being able to make FoxP3 regulatory T cells and therefore have very low numbers of these cells. However, we found that when their levels decline, TR1 cells increase in number and become critical in stopping donor cells from attacking host tissues.”

“In other words, TR1 cells compensate when FoxP3 regulatory T cells either fail or can’t be made.”

Protein helps identify cells in patients

Dr Zhang said the researchers had also identified the particular protein that controls the development of TR1 cells.

“Knowing which protein controls the development of these cells means we can now find them easily in patients, and we’ve also been able to generate them in the laboratory,” he said.

Professor Hill said that it was also very exciting that the abundance of TR1 cells could be changed by specific signals delivered by molecules known as cytokines.

“It is probable that some of the therapies we are investigating in clinical trials induce TR1 T cells, and we are now able to examine this in our patients,” he said.

“Also, now that we understand more about how TR1 cells are produced and what they do, we hope to be able to generate them and give them to stem cell transplant patients to prevent GVHD.”

“This is already being done with FoxP3 regulatory T cells, but we think it will be easier to do with TR1 cells.”

“We hope that by giving patients infusions of these cells early on, we will eventually be able to prevent GVHD altogether.”

The findings have been published in the journal Science Immunology.

The study was funded by the National Health and Medical Research Council (NHMRC).

This news article was first posted on the QIMR Berghofer website.

For many more happily ever afters

Wedding donations to support Australian cancer research“My name is Celine and my husband’s name is Khoi and we recently got married. We had a beautiful ceremony at Mosman’s Sacred Heart Church, followed by the perfect waterfront reception on Middle Harbour – it was a wonderful day.

I first met Khoi when I was on my university placement, training to become a sonographer. We struck up a friendship which continued on well past my placement. We had been together for about seven years when Khoi proposed. It was on April Fool’s day – if you knew him you would understand that he would choose that day of all days! It was a huge surprise to me and I didn’t believe him.

We had been together for about seven years when Khoi proposed. It was on April Fool’s day – if you knew him you would understand that he would choose that day of all days! It was a huge surprise to me and I didn’t believe him.

When it came time to plan our wedding we went to a wedding expo and came across a booth set up by ACRF. I had never thought about asking for cancer research donations at our wedding. But after talking with the ACRF staff and learning about how donations help fund cancer research equipment, we felt it was important for us to contribute and it just made sense to make it part of our special day.

Supporting cancer research in Australia at your weddingWith both of us working in the medical imaging field, we meet many people with cancer. Sadly, cancer has also affected my own family. Not only have both of my grandmothers and one grandfather died from cancer, my remaining grandfather has recently overcome prostate cancer.

Our family and friends thought it was a great idea that we were supporting cancer research with donations to ACRF.

In the midst of wedding planning, it’s so easy to spend money on trivial things and lose sight of what is really important, but a contribution to research or charity will go such a long way.” – ACRF supporter, Celine

 

Learn about wedding donations Share your story

Lyss Organises Star Wars Themed Fundraising Event

Fundraising to support Australian cancer research“Cancer is not just something that happens in a galaxy far, far away. Early last year, my eight-year-old nephew was diagnosed with Langerhans Cell Histiocytosis (LCH), a rare form of cancer that affects young children. As he bravely goes through treatment for this disease, I wanted to do something on his behalf.

I often like to joke and say that my nephew is more like me than his own mother, who is my older sister. Like me, he has a love of Star Wars, superheroes and video games and has even built a basic video game himself. My nephew has been having chemotherapy for a year now and the disease is currently in remission.

Previous to my nephew’s diagnosis, no one close to our family had been affected by cancer. It was a reality check that cancer can happen to anyone. We are lucky that my nephew’s form of cancer is treatable and with a high survival rate. ACRF does a great deal of research into LCH and other childhood cancers and is one of the reasons my nephew is doing so well today.

Star Wars themed fundraiser to help end cancerWhen I decided to fundraise for the Australian Cancer Research Foundation, it was an easy decision to combine two of my favourite things: Stars Wars and selfies.

A group of nerdy volunteers and myself, dressed up as characters from the Star Wars Universe and set up a photo-booth at Wollongong Central on March 12.

For a donation, face painting, props and knick-knacks were available for anyone to dress up and snap photos with some out-of-this-galaxy characters. Twi’lek, Jedi and Droids joined forces with us to raise awareness and money for much-needed cancer research. The public response was fantastic, and we reached our fundraising goal.

The researchers, doctors, nurses and medical staff who help patients living with cancer every day are truly special. They inspire me to continue fundraising for cancer research. Together we can defeat this dark disease so more children can see the stars. May the cure be with us!” – ACRF supporter, Lyss

To organise an awesome event of your own you can visit our A-Z fundraising ideas page

Genetic links for neuroendocrine pancreatic cancer revealed

Australian cancer research discoveries, Pancreatic cancer

An Australian-led international research effort has revealed that genetic changes normally linked to breast, colon and ovarian cancers could also drive a rare form of pancreatic cancer.

Researchers found as many as one in five patients with pancreatic neuroendocrine tumours (PanNETs) had a clear genetic predisposition for their cancers, even though they had no family history of the disease.

The findings, published today in the journal Nature, offer the prospect of one day being able to identify people at risk of these cancers, as well as aggressive forms of the disease, and who might respond to current or new targeted therapies.

The breakthrough is the work of researchers at the University of Melbourne, Garvan Institute of Medical Research, QIMR Berghofer Medical Research Institute, The University of Queensland and the Children’s Medical Research Institute, as well as European and US teams.

They carried out whole genome sequencing of tumours from 100 Australian patients recruited through the Australian Pancreatic Cancer Genome Initiative (APGI).

Study co-leader Professor Sean Grimmond, the University of Melbourne’s Bertalli Chair of Cancer Medicine, said researchers were surprised to find striking similarities between the genetic drivers of PanNETs and other cancers.

“We found that the MUTYH and BRCA2 gene mutations, normally associated with colon and breast cancers, also appear to play an important role in PanNETs,” Professor Grimmond said.

“This raises exciting possibilities for how we treat this disease in the future,”

Study co-leader Dr Nicola Waddell, from QIMR Berghofer, said people without a family history of cancer could still carry a faulty gene that increases their risk of developing this tumour.

“The genetic variants we’ve identified may help to predict how aggressive each patient’s tumour is and what sort of treatment they’re likely to benefit from,” she said.

“In the future, patients at risk of this rare pancreatic cancer could be identifiable through genetic screening.”

PanNETs account for about two per cent of the 3,000 cases of pancreatic cancer diagnosed in Australia each year.

Amber Johns of the APGI at the Garvan Institute said although patients often have a better prognosis than those with more common pancreatic cancers, this group of tumours is highly unpredictable.

“Doctors currently face the challenge of being unable to tell apart patients who would benefit from early aggressive therapy from those who might be spared harsh treatment for less invasive cancers,” Ms Johns said.

She said the study data would be freely available to cancer researchers and clinicians, to build on this work.

This project is the latest Australian contribution to International Cancer Genome Consortium, a global research effort focused on mapping out the genetic landscape, causal mutations and novel therapeutic opportunities in the 50 most common cancer types across the globe.

The Australian Cancer Research Foundation supports world class Australian cancer research by funding cutting edge technology, equipment and infrastructure. To date, the Foundation has awarded in total $AUD 49.9 million to support cancer research at the University of Melbourne (VCCC), Garvan Institute of Medical Research, QIMR Berghofer Medical Research Institute, The University of Queensland and the Children’s Medical Research Institute.

This new article was first published by QIMR Berghofer, Garvan and the University of Melbourne.

Australian-first detector to accelerate cancer research

Australians with cancer will be the first to benefit from the multi-million dollar Australian Cancer Research Foundation (ACRF) Detector launched today at ANSTO’s Australian Synchrotron, fast-tracking cancer research by harnessing light a million times brighter than the sun.

Minister for Industry, Innovation and Science, Senator the Hon. Arthur Sinodinos, today unveiled the ACRF Detector, which is akin to a turbocharged camera, and will take images at a speed and accuracy currently not possible at any other Australian research facility.

The detector will enable researchers, including those working in cancer, to more than double their outputs, gaining more answers at a faster rate.

Currently, more than 60 per cent of all the research conducted on the Synchrotron’s Micro Crystallography (MX2) beamline is dedicated to cancer research, helping scientists to understand and develop new drug targets and refine treatments for a disease that is the leading cause of death around the globe.

ACRF CEO, Professor Ian Brown, said ACRF and its supporters are proud to have provided the $2 million grant that facilitated the purchase of the ACRF Detector.

“The ACRF Detector is a vital, core piece of equipment for cancer and medical research in Australia, and one that will be used by cancer researchers from all institutes, hospitals and universities,” said Professor Brown.

“It shows the three-dimensional structure of proteins, which do most of the work in cells, identifying opportunities to neutralise those involved in cancer and promoting those that may protect us from cancer.”

The Synchrotron is operated by the Australian Nuclear Science and Technology Organisation. Australian Synchrotron Director, Professor Andrew Peele, said the leaps that will be enabled by the new detector will more than double the facility’s capacity to collect data, leading to more targeted and effective treatments and, ultimately, improved patient outcomes.

“This new capability will take a beamline that was previously at full capacity – booked for use at all available hours of the day – and find it an extra gear, so it can deliver more research, and arm researchers with clear representations of protein structures,” said Professor Peele.

“There are a lot of questions that still need to be answered in the world of cancer research, and by partnering with ACRF and speeding up the throughput of important research, we are bringing more solutions closer than ever before.

“We’re essentially shifting from dial-up internet to high-speed broadband, putting our foot on the accelerator of cancer research technology, providing faster protein analysis to turbocharge cancer research and facilitate significant discoveries.”

Senator Sinodinos said the new ACRF Detector is a great example of how collaboration between research facilities, not-for-profits and government can improve outcomes for the Australian community.

“This investment in Australian research and technology has the potential to increase and quicken the rate at which research turns into practical applications for patients and the community,” Senator Sinodinos said.

“High quality research, collaboration and smart investment are needed to ensure that new research and knowledge are supported, and I am thrilled to be here today to witness exactly that, and officially reveal the ACRF detector.”

Attending the launch of the ACRF Detector with Minister Sinodinos was researcher and protein crystallographer from the University of Western Australia, Professor Charlie Bond, who has utilised the MX2 beamline for extensive protein analysis, including research into the childhood cancer neuroblastoma.

They were also joined by Lucy Jones, who is focused on driving change in survival rates through increased research into neuroblastoma, having lost her daughter Sienna to the illness in 2010.

“Losing a child to neuroblastoma has driven me to do all I can to support research in finding an effective treatment for this insidious disease and other childhood cancers, made all the more challenging due to the high cost of drug development and the rarity of most childhood cancers,” Ms Jones said.

“We must do everything we can to help researchers such as Professor Bond, and innovative technologies such as this, to help make the whole research process more efficient by reducing costs and time to clearly benefit the research of childhood cancers and other diseases, shortening the time between lab discoveries and clinical testing of new drugs,” she said.

Neuroblastoma occurs most commonly in infants and children under five years of age. It is cancer made up of cells that are found in nerve tissues called neuroblasts, commonly found in adrenal glands and along tissues around the spinal cord in the neck, chest, abdomen and pelvis.

The ACRF Detector was made possible by a $2 million grant from the ACRF, and additional contributions from Monash University, CSIRO, La Trobe University, NZ Synchrotron Group, the University of Western Australia, the Walter and Eliza Hall Institute of Medical Research, the University of Melbourne, the University of Queensland, the University of Sydney, the University of Wollongong, Victor Chang Cardiac Research Institute, the University of Adelaide, Australian National University and ANSTO.

Prue is running for cancer research

Prue is a long-time runner, training for the Australian Running Festival in Canberra and raising funds for cancer research.

“Although I have been running for about eight years now, I haven’t done a half marathon in three years – it’s been quite hard work getting my fitness back after the birth of my daughter 14 months ago. When my cross-fit coach asked me in January to set a goal, I decided it was time to take on another 21km + challenge.

I also want to use the event to fundraise for cancer research because a dear and very close friend of our family passed suddenly in 2014. It shocked us all how cruel this disease is, and how it can claim another victim in such a short time.

My friend, Sharon, was only 46, a cherished daughter, loved wife, big sister, true friend and a mother to three beautiful boys. She is truly missed every day and in so many ways.

Too many people suffer and die because of cancer. I would like to see that stop and also ensure my children do not have to lose friends and family to such an awful disease, like we have.

Pru is running for cancer research in Australia

I would like to see a future without cancer, but if cancer continues to be diagnosed, then it wouldn’t be a death sentence and treatments could be less devastating.

If anyone reading this is thinking about fundraising or donating, I would say to them, “Don’t hesitate, because every cent counts.”

If you would like to support Prue, you can learn more on her everyday hero page.

University of Queensland opens new era in cancer research

A .5 million Australian Cancer Research Foundation grant has enabled the purchase of a large-bore PET-CT scanner
The ACRF Facility’s large-bore PET-CT scanner will conduct studies in both humans and companion animals.

New cancer-fighting drugs and devices could emerge from The University of Queensland, thanks to a research program comparing cancers in pet animals and humans in a state-of-the-art imaging facility opened today.

UQ Centre for Advanced Imaging (CAI) director Professor David Reutens said the new Australian Cancer Research Foundation (ACRF) Facility for Molecular Imaging Agents in Cancer opened a new paradigm in comparative oncology.

“It will allow researchers to examine the effects of tiny doses of anti-cancer drugs in human and animal cancers,” he said.

A $2.5 million Australian Cancer Research Foundation grant has enabled the purchase of a large-bore PET-CT scanner and an upgrade of the CAI’s magnetic resonance imaging facilities.

“We are using molecular imaging to improve cancer detection, characterisation, treatment and monitoring,” he said.

Professor Reutens said the centre would run Australia’s first comparative oncology research program, studying naturally occurring cancers in companion animals such as dogs to learn more about treating cancer in humans.

“This will help develop new drugs, devices and imaging procedures for human patients,” he said.

“The new facility will enhance the success of clinical trials on human cancer therapies.”

Australian Cancer Research Foundation CEO Professor Ian Brown said the ACRF Facility for Molecular Imaging Agents in Cancer offered a new opportunity to better understand cancer in its many forms.

“It provides a chance for the development of new approaches for the prevention, detection and treatment of cancer,” he said.

“The ACRF supporters who made this grant possible know that the investment in state-of-the-art technology when placed in the hands of the best researchers will lead to the breakthroughs that we all desire.”

“Researchers in Australia are among the best in the world, and we’re delighted to be supporting the cutting-edge work of the teams working together at UQ.

“Research and innovation are our best means of finding ways to end cancer.”

Jane swims the Cole Classic for cancer research

Jane describes herself as a fairly active person with a passion for cross-country skiing and swimming. The Cole Classic is a favourite event for Jane, and this year she did the 2km swim to fundraise for cancer research in memory of her mother.

“I swim regularly – always have and love it. The regular aquatic fix keeps me healthy and sane. My two gorgeous daughters, Kate and Meg, think I am nuts to be sharing water with, and being on the menu, for sharks. Peter, my husband, is more of a runner and cyclist than a swimmer but does occasionally join me in an ocean swim.

I particularly like the vibe of the Cole Classic from Manly Beach. It is a swim that attracts lots of newbies who have never participated in an ocean swim. I grew up swimming in a pool and the Murray River and had to learn how to swim in the ocean. Anyone new to ocean swims is to be admired. They are putting themselves way out of their comfort zone, and way away from the safety of the shore! If they are also doing their bit by fundraising, that’s really commendable.

I am always reminded of cancer research whenever I think about the surgeon’s comment to my mother 38 years ago. Not long after she was diagnosed with cancer, the surgeon – a bloke with a fairly dry sense of humour – said, “Well Ann, they will have a cure for this in five years, a pity you will not be around to benefit”. That was 1978 and regrettably, neither cure, nor complete prevention, has been found.

My mother was 49 when she was diagnosed and given only three months to live. Being an incredibly determined person, Mum lived for another twelve months. Today chemotherapy is not much fun but in the 1970s the treatment was harsher. With no chance of survival, Mum chose not to subject herself (or us) to treatment. She helped my brother celebrate his 21st birthday and me, my 18th in fine fashion. I am convinced her focus was to hang around as long as possible to equip us to be capable, strong and resilient after she was no longer with us.

Not having Mum around for the last 38 years hasn’t been a picnic, but I am sure she would be proud of how we have coped and what we have achieved.

The lasting impact for me of my mother’s experience is how she behaved: her strength, her grace and calm while suffering, her focus on the positive, her ability to retain a sense of humour. These behaviours not only help you, they help others. Of course, her leaving us has been particularly tough. As too many others who have experienced loss know, every significant and happy event in your life – weddings, children being born – is tinged with a bit of grey.

An experience like this can lead you to dismal places, but focusing on the positive as my mother did has kept my life mostly bright.

I believe in what the ACRF are doing for cancer research in Australia. The ACRF fundraising team has been spectacular in their support and encouragement and certainly emboldened me to actually ask people to donate!” ACRF supporter, Jane

An enzyme with the capacity to suppress cancer growth

Abnormal cells courtesy of Centre for Cancer Biology
Abnormal mutant cells (Caspase-2 deficient) in the right panel.

 

Cancer researchers at the Centre for Cancer Biology (CCB), an alliance between the University of South Australia and SA Pathology, have discovered a new aspect of cancer biology that may help to battle the spread and growth of tumours.

The research focuses on aneuploidy cells, which are often associated with abnormal chromosome content and cell division – and how an enzyme known as caspase-2, initially discovered by the lead researcher 25 years ago, can act to prevent their growth.

The research team, led by Professor Sharad Kumar and Dr Loretta Dorstyn, have discovered that caspase-2, which is found in all mammals, has the capacity to suppress cancer growth by working to destroy aneuploid cells.

“Aneuploidy is a term that describes the abnormal chromosome content of a cell and occurs when there are failings during the normal division of a cell,” Prof Kumar said.

“Aneuploidy is a feature of the majority of human tumours and is known to lead to chromosomal instability that can promote cancer onset and progression and cause drug resistance.”

In two recent publications, the team demonstrated that cells that have a deletion in the caspase-2 gene are deficient in the cell division “checkpoints” that normally prevent damaged cells from surviving and becoming aneuploid.

Their research also shows that bone marrow cells that lack caspase-2, accumulate many of these defective, potentially cancer causing aneuploid cells with age.

“This research establishes that caspase-2 is necessary to prevent the long-term survival and uncontrolled growth of aneuploid cells that could otherwise become tumorigenic,” Prof Kumar said.

“The research has provided many clues on the molecular basis of preventing aneuploidy and tumour onset and identifies caspase-2 protein levels as a potential biomarker for cancer prognosis.”

“Understanding how cells become tumorigenic and how tumours evade normal “stop growth” and “cell death” checkpoint signals, is fundamental in cancer treatment and our search for new cancer therapies”, Dr Dorstyn said.

The research was recently published in journals Cell Death & Disease and Oncogene. The original news article was posted on the University of South Australia website. Images courtesy of CCB.

The Australian Cancer Research Foundation has supported the Centre for Cancer Biology by providing two grants, totalling AUD $5.6 million, towards cutting edge cancer research equipment and technology.

Glowing, drug-resistant leukaemia cells could help unlock new therapies

A new method for finding hidden leukaemia cells by making them glow has been investigated by ACRF grant recipient, Children’s Cancer Institute (CCI). Their method offers a more sensitive and accurate preclinical test for leukaemia drugs, increasing the chances of finding those most likely to succeed in clinical trials.

Dr Luke Jones’ research is based on making leukaemia cells glow to reveal reservoirs of the disease. In general, survival rates for childhood leukaemia are approximately 90% but some subtypes and relapsed leukaemias do not respond well to treatment.

Bioluminescence imaging can more accurately measure drugs’ effects on high-risk leukaemias that are either unresponsive to standard treatments or likely to relapse,” said Dr Jones.

“Using information from bioluminescence imaging will help make sure only future drugs with the best chance of success go on to be tested on human patients in clinical trials,” he explained.

An improved way to test treatments

Before new drugs can be given to children, their safety and effectiveness are tested in avatars that model different leukaemia subtypes.

Each drug’s effectiveness against these models is typically monitored by measuring the number of leukaemia cells in the blood. However, the blood is one of the last places leukaemia spreads to, and the first place it’s eliminated from with treatment. This means that cancer cells could be hiding away in organs like the spleen or bone marrow even if all leukaemia cells have been cleared from the blood.

Australian cancer research
Bioluminescent materials from nature can be used the lab.

Looking to find the hiding cancer cells, Dr Jones cloned the gene that makes fireflies glow into the DNA of the cancer cells. This meant that a scan could reveal any hidden reservoirs of leukaemia.

The new study is the first to compare bioluminescence imaging with traditional methods of assessing preclinical drug efficacy in an effort to increase the ability to predict clinical success.

It is also the first time bioluminescence imaging has been evaluated for its ability to track the amount of residual disease following treatment in a preclinical leukaemia model.

“Our paper shows that bioluminescence imaging gives us extra stringency,” said Dr Jones.

“It gives us more and better information to make decisions about which drugs to progress to clinical trials,” he concluded.

The results were recently published in the journal Clinical Cancer Research.

This news article was first published on the CCI website. Images of Dr Luke Jones and wells with bioluminescent materials courtesy of CCI.

The Drug Discovery Centre at CCI came about as a result of an AUD $3.1 million grant awarded by the Australian Cancer Research Foundation in 2007. A subsequent grant of AUD $1.5 million from the Foundation helped transform the facility went to the ACRF Child Cancer Personalised Medicine Centre, the operational headquarters and key testing platform of the Zero Childhood Cancer Program.

Wayne’s ‘Beat the Bastard’ bike ride for cancer research

Wayne is supporting Australian cancer research by fundraising for ACRFHaving lost both family members and close friends to cancer, Wayne Irwin is doing his bit to raise money for cancer research by organising a bike ride in November.

“I was inspired to take action when my brother Dale died from cancer last year because I lost one of my sisters to cancer a few years ago as well. Dale was not only my brother and best mate, he was and still is the finest bloke I have ever known.

He battled cancer for three years and his death affected me very badly. Although my wife, children, grandchildren and friends were all emotionally supportive, I found myself in a dark place and alienating myself from everyone. I desperately needed to redirect my anger toward something else.

Putting all my energy into organising this cancer research bike ride, which I’m calling ‘Beat the Bastard’, is the best thing I could have done. For years, I’ve been an avid motorcyclist so it seemed natural to invite others who share the riding passion to join in. It will be a great way to meet other people including anyone who has lost family and friends to cancer. It also gives people fighting the disease an opportunity to hop on their bikes, knowing that we are supporting them.

The 400-kilometre route includes Gunnedah, Narrabri, Wee Waa and Pilliga. I included Pilliga in the ride route because that’s where I grew up. Pilliga is pretty close to my heart, and my brother’s heart.

I’ve been using contacts in Gunnedah, including my sister Robyn, to get the word out about the ride. A couple of Gunnedah businesses have been absolutely awesome and I’m grateful for the kind-heartedness of people who are offering to help. The campaign is also generating a lot of interest in Brisbane and Sydney through social media. There are people I don’t know and they’re responding about the bike ride – my goal is to get at least 80 participants. The cost for the day is $50 with funds to go towards food and the Australian Cancer Research Foundation.

I honestly believe there’s going to be better treatments found for cancer, and it will happen here in Australia. ACRF has been alongside me in this fundraising effort. They’ve been exceptional in helping me out and giving me some great ideas for organising the ride.

The impact of cancer on my family has been devastating, but ironically the resolve to beat this horrible disease has brought us closer together.” – ACRF supporter, Wayne Irwin

‘Beat the Bastard’ participants will stop in Pilliga for lunch and finish up in Gunnedah for dinner. An auction and raffle will be conducted during the evening with some great prizes available.

For those who can’t take part in the ride, but would like to support it, click here.

New discovery helps target lung cancer

Australian cancer researchersCancer researchers at Peter MacCallum Cancer Centre in Melbourne have identified a potential pathway for the development of precision medicine, targeting an aggressive form of non-small cell lung cancer, one of the most common types of lung cancer.

In a world-first study published in Science Signalling this month, lead researchers Professor Ygal Haupt and Dr Cristina Gamell have zeroed in on the behaviour of a set of proteins that normally act to suppress the development of tumours.

These proteins were found to be dysfunctional in particularly aggressive cases of non-small cell lung cancer (NSCLC). NSCLC accounts for around 90% of the 10,000 cases of lung cancer diagnosed in Australia each year.

A key step during the onset of most NSCLCs is the loss of the tumour suppressor protein – p16INK4a (p16). In around a third of NSCLC cases, loss of p16 protein is caused by abnormal silencing of the p16 gene through a process called hypermethylation.

Professor Haupt and Dr Gamell’s research has uncovered the intricate chain of events that leads to a loss of function in some of the remaining two-thirds of cases.

“In human DNA, the gene responsible for p16 expression clusters with two other tumour suppressors in a region called the ‘INK4/ARF locus’. Loss of tumour suppressors from this locus is a common feature of many different types of cancer.”

“Our research discovered a distinct group of aggressive NSCLCs, in which the reduction of another protein, called E6AP, triggers an increase of a third protein called Cdc6. This process appears to reduce the expression of tumour suppressors in the INK4/ARF locus.”

“NSCLC patients whose cancers have decreased E6AP and p16, and increased Cdc6, were shown to have particularly poor survival rates.”

“With this insight, we have the opportunity to look at ways of countering the impact of Cdc6 on these cancer-fighting proteins.”

“This knowledge, coupled with the rapidly advancing field of precision medicine, defines new biomarkers and suggests a new pathway for better treatments for this devastating form of cancer in the not too distant future,” according to Professor Haupt.

The research was led by Prof. Ygal Haupt’s Tumour Suppression Laboratory in collaboration with key clinicians from St Vincent’s, the Olivia Newton-John Cancer Research Institute. The study was enabled through funding from the National Health and Medical Research Council.

The original news article was posted on the Peter Mac website.

The Australian Cancer Research Foundation has supported Peter MacCallum Cancer Centre by providing three grants, totalling AUD $7 million, towards cutting edge cancer research equipment and technology.

Ivy’s headshave for cancer research

Ivy raises funds for cancer research in Australia“Hi everyone, I’m Ivy. I’m 10 years old, and enjoy horse riding, playing with my friends, board games, basketball and being with my family. I shaved my head for cancer research in memory of my grandmother’s best friend – Granny Jenny.

Granny Jenny was like a second grandmother to me. She died last year of cancer, and it was very sad for all of us who knew and loved her. She was kind and always supportive about everything we did or wanted to do.

Deciding to do the head shave is a funny story. I was camping at a river with some friends and we’d been swimming in the river every day. My hair is really long and it was getting more and more knotted from being wet so much. When I finally took it out of the braid it was in, it was like a big tangled birds nest. At that moment, I got the idea to shave my head. Two girls in the year above me shaved their heads last year for cancer research and I’ve always thought it would be a really cool thing to do.

Ivy shaved her head to support cancer research in AustraliaLots of people asked me if I was nervous about losing my long hair but I wasn’t, I just wanted the day to hurry up! Now that it’s all shaved off, I’m also going to donate it to be made into a wig for a patient who has lost their hair from cancer treatment.

Cancer is a terrible thing. It puts people in a lot of pain. It would be really scary to have cancer and know you could die and never see your family again. I like that Australian Cancer Research Foundation is helping to find better treatments for people with cancer by giving scientists equipment and I want to support them. It’s exciting that I raised over $4500.00 for cancer research and I want to thank all the generous people who have donated.” – ACRF Supporter, Ivy Bartlett

To support Ivy, you can make a donation on her page here.

Running for cancer research in support of my mum

michael-pirone-small-for-web

“In April I will be running in the 2017 London Marathon. I am a passionate footballer, runner and now fundraiser who decided to begin this journey about a year after my Mum, Krystyna was diagnosed with lung cancer. I’m participating in this marathon, not just for Mum, but also for everyone who has ever been diagnosed with cancer.

In March 2015, my mother was diagnosed with inoperable stage IV lung cancer. A non-smoker, Mum was told it was a genetic mutation that had led to cancer. Our entire family could not have been more shocked as Mum has always been really healthy. She is 63 years old, retired and enjoying a well-earned break from working life.

Mum is one of my best friends, she has always been there for me through the tough times. She is a devoted grandmother to my two little girls. A wonderful wife to her husband, Joe, and an amazing mum to my brother Steven and I.

Shortly after her diagnosis, Mum started chemotherapy in tablet form on a daily basis. This helped, but only for the first 10-11 months, at which point, cancer fought back. In February 2016, the oncologist told Mum that she had qualified to take part in a clinical trial for a drug which has been FDA approved in the UK and US. This particular drug has stopped cancer in its tracks. Mum’s condition has improved and she continues to live an otherwise normal life. For the longer term, we are not sure what the future holds for Mum, but there is hope.

Fundraising for cancer research in Australia

130,470 new cases of cancer will be diagnosed in Australia this year, with that number set to rise to 150,000 by 2020. I feel like these numbers should speak for themselves but it seems to me that research is undervalued in our society even though it holds the key to beating this horrible disease. If it wasn’t for cancer research advancements both overseas and locally, Mum might not be here right now.

I chose to fundraise for Australian Cancer Research Foundation because I truly believe in everything they are doing to support cancer research in Australia. I am very grateful that I’ve been granted one of their charity gold spots in the London Marathon, London is somewhere I’ve always wanted to visit. My partner spent 10 years living and working there so I’ve heard so much about the city from her. I’m nervous and excited about the race but also filled with energy. I can’t wait to run for my mum, my girls, and the many people whom my family and I have loved and lost to cancer.

 

Allyson and Rob are running for cancer research

“Our dads both have cancer so my wife Allyson and I are taking on the Canberra Times Australian Running Festival in April this year to raise funds for cancer research.

My dad was diagnosed with aggressive prostate cancer a few years ago. He has been undertaking hormone treatment and while it has assisted somewhat, unfortunately, the cancer is also in his bones and has now spread to his lungs. Dad will soon be on his fourth round of chemotherapy.

Ally’s dad was diagnosed with oesophageal cancer less than 12 months ago. He underwent a major operation that removed part of his stomach, but shortly afterwards, cancer spread to his liver. He now finds it very difficult to eat and has lost a lot of weight.

We found out late last year that Ally’s dad’s liver cancer was terminal, he was only given 12 months to live. Ally’s dad was a passionate runner and completed a few marathons over his lifetime, including the Gold Coast Marathon while in his mid-60s. So Ally and I decided that we wanted to show our support of cancer research and push ourselves by giving the Canberra Running Festival a go. Ally will be running the marathon and I will be running the ultramarathon (50kms). We aren’t athletes, and won’t be there to win the race, there’s a chance we won’t finish the race, but we are going to give it a go.

Ally and I aren’t completely new to running. Over the past four or so years, we’ve done a few half marathons and two years ago I finished my first full marathon. Since completing those events, Ally gave birth to our lovely daughter Eliza. So while Ally had a very good excuse for not running, I didn’t, and the out-of-shape dad bod quickly appeared! I’m currently running most days a week now though and Ally isn’t far behind. We barely managed to complete a 10km run on the weekend so we need to quickly improve our fitness levels.

Although my dad loves sport, he is probably wondering why the hell anyone would choose to run 50kms but I know he’ll be very proud of us for our efforts.

We originally entered the Running Festival to show our support for our dads, but as their cancer treatments go on, we are quickly realising that more funds need to go toward ending cancer.

Finishing our respective runs on April 9 will be a great personal achievement for Ally and me, and our emotions will more than likely be all over the shop. If Ally’s dad has stabilised health-wise, he’ll be there at the finish line, and I will be on the phone with my dad.

Neither of us has lost anyone close to us at this point in our lives. I think we are both in agreement that we can’t imagine our lives without either of dads and Eliza loves her amazing granddads! Right now we are just focusing on creating some wonderful memories.

Whether we raise $5 or $500 for cancer research, it all adds up. The longer our fathers live with cancer, the more we dream that better methods of prevention, detection and treatment will be discovered. ACRF is one of the leading organisations when it comes to contributing to cancer research and we all need to support research to one day end this deadly disease.” – ACRF supporters, Rob & Allyson

To support Rob and Allyson, visit their everyday hero page.

Donate Join a fitness event Share your story

Cancer immunity enhanced by natural killer cells

A team of researchers from Australia and France have uncovered new insights into how to prolong the lifespan of the body’s disease-fighting natural killer (NK) cells.

The finding offers fresh clues about how best to harness NK cells to improve their disease-fighting function. This may have particular importance for cancer immunotherapy, ‘buying more time’ for NK cells to detect and destroy cancer cells.

The Melbourne team led by Dr Nick Huntington from the Walter and Eliza Hall Institute along with collaborators from Centre of Immunology in France, Professor Eric Vivier and Professor Sophie Ugolini, made the discovery by investigating factors that control NK cell function.

Dr Huntington said the research revealed that a protein called BCL-2 was particularly important for controlling the reservoir of NK cells in our body. BCL-2 is a so-called ‘pro-survival’ protein that makes normal immune cells survive for extended periods.

“We have been very interested in understanding which factors control the lifespan of NK cells,” Dr Huntington said.

“We had previously identified a protein related to BCL-2, called MCL-1, which was critically required for all NK cell survival. This new study now shows that BCL-2 “teams up” with MCL-1 and both these proteins crucially determine NK cell survival in our body, and the majority of NK cells died following a reduction in the levels of BCL-2.”

“Importantly, we were able to prevent NK cell death when BCL-2 levels were low by using a hormone-like protein or cytokine called IL-15. Boosting NK cell numbers by treating them with IL-15 may be a valuable new approach to boosting our immunity to viral infections or cancer. On the flip side, targeting this growth factor or BCL-2 could reduce NK cell numbers and offer potential therapies for immune disorders such as some types of autoimmune diseases, sepsis or graft versus host disease, a side effect of bone marrow transplants.”

The team’s research also identified that NK cells may be vulnerable to new medicines that inhibit BCL-2, which are also becoming widely tested as anti-cancer treatments.

“Our research has identified that adding cytokines could be a novel way to protect NK cells from the effect of BCL-2 inhibitors, maintaining healthy NK cell numbers in people undergoing cancer therapy,” Dr Huntington said.”

The research was published this month in The Journal of Experimental Medicine.

The original article was posted on the WEHI website. Image of Dr Huntington’s BCL2 NK cells team courtesy of WEHI.

The research at the Walter and Eliza Hall Institute of Medical Research was supported by the National Health and Medical Research Council, the Harry J. Lloyd Charitable Trust, the Cancer Research Institute, Cancer Council Victoria, the Australian Research Council, the Leukemia and Lymphoma Society (US), the Menzies Foundation and the Victorian Government.

The Australian Cancer Research Foundation has supported WEHI by providing three grants, totalling AUD 5.5million towards cutting edge cancer research equipment and technology.

New ACT drug discovery platform

img_1574Today, Australian National University (ANU), the ACT Minister for Health and Australian Cancer Research Foundation (ACRF) will launch a new robotic system to fast-track the development of new drugs to fight cancer and other diseases.

Projects using this platform will also help to screen existing drugs and novel compounds to identify if they are effective alone or in combinational therapies on cancer cells.

This initiative was made possible in part by an ACRF grant of $2 million, awarded in 2015, to provide the equipment required to screen native Australian plants for anti-cancer properties.

Professor Ian Brown, CEO of Australian Cancer Research Foundation says “ACRF is a private foundation supported by community members who are interested in advancing cancer research. It’s inspiring to see researchers at ANU push cancer research forward with this funding and turn it into tangible treatments that future patients will benefit from.”

The High-Throughput Robotic Target and Drug Discovery Screening Platform at the ACRF Department of Cancer Biology and Therapeutics is the first technology of its kind in the ACT.

The specialised robotics and precision instruments will enable researchers to test thousands of possible drug compounds against hundreds of disease cells, to find the best possible treatment for patients.

ACT Centenary Chair of Cancer Research Professor Ross Hannan said the new technology would increase research collaboration and lead to more rapid drug discoveries in the fight against cancer and many other diseases.

“This is an exciting time for research collaboration across the ACT. The multi-million dollar equipment will cut screening times from years to months,” Professor Hannan, Head of the Department of Cancer Biology and Therapeutics at ANU said.

Until now, researchers in the ACT needed to travel to Sydney or Melbourne to use similar machines. They would also need to stay for months while the testing was done.

Professor Hannan said the technology could give new hope to patients with diseases that have failed all standard therapies and who have no other options.

“We now have the potential to repurpose drugs, testing against more than 4,000 drugs in the FDA drug library have been approved for use in humans to treat disease,” he said.

Professor Hannan said that in the case of cancer, researchers will be able to take bone marrow and tumour cells, grow them in culture, and screen every known compound currently approved for use in humans against the cell lines to see if one could be used to treat the patient.

“In one to two weeks we could identify existing drugs, repurpose them for new treatments, and rapidly set up trials,” he said.
The Target and Drug Discovery Platform has been set up at JCSMR with the generous support of the Australian Cancer Research Foundation and ACT Health.

Walking El Camino de Santiago in Mike’s memory

Fundraising to support Australian cancer research

“My name is Kate Narracott. I’m 55 years old and work full time as a Travel Agent. In April 2017, I’m walking 500,000 steps across Spain, travelling along the ‘Camino de Santiago’ also known as the ‘Way of St James’.

This journey began as a means to honour a youthful promise my older brother, Mike, and I made to each other to one day share an amazing adventure together.

Our destination was unimportant, our expectations were never defined but our determination to one day have our moment in time never wavered. Sadly my brother passed away 27 years ago from cancer and I lost a man who was not only my best friend and confidante – he was my hero and my champion.

Michael was 36 years old when he died. He loved life and lived each and every day with humour, style and vitality. We were very different people, both strong in completely opposite ways but those differences cemented our respect and love for each other. When we were together, laughter filled our world. I would give anything to hear his laugh just once more.

Watching somebody you love slowly slip away from you piece by piece every day is devastating. He and I made a decision to try not to cry on the days we shared. Instead, we laughed and told stories and jokes. We ventured out when his days were good and curled up on the days that were dark. When you share this with somebody you love – the moments that matter become very clear and you realise that the little things that may have bothered you once are no longer important.

In the last few days of his life, our world became very small and each moment we had was very intense. On the day of his death, I sat on his hospital bed with him cuddled into my lap. His young body had become a skeleton and his breathing was shallow and rattly – but I held him and talked to him until he passed away quietly in my arms.

We have all been touched by the sadness of cancer, it is around us each and every day. I have lost too many family members to this disease and am watching now as more struggle to overcome and survive cancer. I am in awe of their bravery, their daily fight and their enduring hopefulness for the future.

I wanted to support cancer research by walking El Camino de Santiago because the funds we raise today might help to save the lives of my own children if cancer was to affect them in the future. For that alone, I would walk across every country. Cancer research is vital to one day making life easier for those who struggle with cancer.

So to my brother Mike, our big adventure has finally begun. My hiking boots, bamboo socks, backpack and walking poles are ready and waiting. All that remains now is for me to get whipped back into shape, and believe me I am trying. I have been training for several months, walking around 80-90 kilometres per week. I have wonderful walking buddies who are keeping me motivated. Many kilometres are walked every day, even on days when I would rather sit back with a good book and just let the world go by.

On my trip I’ll be walking 450 kilometres or approximately 500,000 steps across Spain. The walk itself will take just over 3 weeks. The journey will have many challenges, both physically and emotionally. There will be moments of great joy and peace and I am sure moments when I will be so fatigued that I will want to give up – but I won’t. I am walking with a dear friend named Karen who also lost her brother, Anthony to cancer. Both of our brothers will have birthdays while we are on the Camino de Santiago.

This walk is far more than just my own personal journey, I would like to dedicate these small steps of mine to the loved ones that I have lost to cancer and especially to my friends and family who right now bravely fight their daily battles with this disease. You are all the true heroes – your immense courage, dignity, laughter and hopefulness inspire me.

I am a person who started with a dream to raise a small amount of money for cancer research. That dream has turned into a reality and I am well on my way to reaching my goal of $10,000. I have found the support, generosity and enthusiasm of others overwhelming and emotional. To say I am appreciative of the people who are behind me is not nearly enough.

I must thank with all my heart the members of the Rotary Club of Redcliffe Sunrise. I am moved and deeply grateful for all that they do for me. They’ve walked many kilometres with me in training, they’ve helped me sell raffle tickets, they’ve contributed financially to the cause and they’ve fed and watered me when I am too tired to do it myself. Most importantly they are my friends. They have wrapped their arms around me and given unconditional support and encouragement to the crazy idea that I would walk across a country to raise money for cancer research. I am humbled by their kindness and so very proud to call them my friends.

Well, Big Brother, it has taken 27 years of waiting, but the day is nearly here. We’re finally getting our moment and our adventure.

Please join me in making each step count, together we can increase awareness about the power of cancer research and raise much-needed funds. If you would like to donate to cancer research visit my Everyday Hero page here.”

Organise an event Donate Share your story

Aggressive prostate cancer linked to faulty BRCA2 gene

New research has revealed why men with a family history of prostate cancer, and who also carry the BRCA2 gene fault, have a more aggressive form of prostate cancer.

The study, led by Monash University’s Biomedicine Discovery Institute with Peter MacCallum Cancer Centre and the Princess Margaret Cancer Centre in Toronto, Canada, revealed that the molecular profile of the prostate cancers in men with the faulty BRCA2 gene is similar to the profile seen in patients with advanced cancer. This also helps explain why BRCA2 patients tend to have poorer treatment outcomes.

Previously, a larger Victorian Cancer Agency funded program reported that men who carry the BRCA2 gene fault are at a higher risk of having a more aggressive form of prostate cancer if a cell pathology known as IDCP (intraductal carcinoma of the prostate) is present. The IDCP cell pathology predicted these men are much more likely to have a poor clinical outcome.

The new study, published last week in Nature Communications, showed that early stage untreated prostate cancers were genetically similar to cancers that are usually seen in men with more advanced cancer that has spread to other parts of the body.

This finding was in contrast to the cancers seen in men who don’t carry a BRCA2 gene fault and who rarely have cancer spread at diagnosis. The findings were confirmed when comparing data with a companion study led by the Toronto group, which looked at prostate cancer tissue samples from more than 320 patients with prostate cancer who don’t carry a BRCA2 gene fault.

Put together, these studies identified why the presence of the BRCA2 gene fault led to markedly different clinical outcomes, with the disease progressing rapidly in those with the faulty gene.

“This study shows how different these tumours are from ‘regular’ tumours and emphasises the importance of men knowing if they have a family history of prostate, breast or ovarian cancer in their family and may carry the BRCA2 gene fault,” said Professor Gail Risbridger, Director of Monash Partners Comprehensive Cancer Consortium and Monash BDI.

Associate Professor and Director of Genitourinary Oncology at the Peter MacCallum Cancer Centre, Dr Declan Murphy, highlighted possible therapeutic implications.

“We now know that the BRCA2 fault is seen in many more men presenting with advanced prostate cancer than previously realised. Also, as prostate cancer progresses, the BRCA2 fault begins to develop in prostate cancer secondaries, and drives the aggressive behaviour of the cancer.

Therefore these new findings detailing the genomic instability of BRCA2 prostate cancer are important as we may be able to target this with new therapies,” he said.

This news post was originally published by Peter MacCallum Cancer Centre.

The Australian Cancer Research Foundation has supported cancer research at the Victorian Comprehensive Cancer Centre, Peter MacCallum Cancer Centre and Monash University by providing in total AUD $17.2 million towards cutting edge cancer research technology.

ACRF qualifies for the Registered Charity Tick

ACRF supports cancer research in AustraliaIn 1984, ACRF’s founders, Sir Peter Abeles and Lady Sonia McMahon, identified a gap in scientific funding and set about trying to fill that gap. They did this by raising funds to provide large grants for cancer research equipment, technology and infrastructure in the most efficient manner possible.

Today, Australian Cancer Research Foundation are proud to receive the registered charity tick from the Australian Charities and Not-for-profits Commission (ACNC). A stamp that is reflective of the standards to which ACRF proudly holds itself to.

The charity tick initiative has been developed to give reassurance to donors that a charity is transparent and accountable by highlighting its presence on the ACNC Charity Register.

The ACNC aims to improve public understanding of the work of charities and the not-for-profit sector. As part of this work, they make available the information collected annually from the 54 000 charities operating in Australia.

As well as the Charity Register being a regulatory tool, ACNC also analyses the information and conducts research to learn more about the charitable sector and how charities contribute to the community. They publish their findings in an in-depth analysis of the financial situation of Australia’s charity sector, called the Australian Charities Report. Read the Australian Charities Report and explore the data.

ACRF has awarded $129.2 million in 65 cancer research grants to 36 research institutes, universities and hospitals across Australia. Thanks to our supporters, these grants make a real impact by providing researchers across Australia access to state of the art technology to speed up research outcomes and save lives by saving time.

If you would like to read more about ACRF and the impact it has had on cancer research over the past three decades click here.

Congratulations to Australia Day Honours winner and ACRF supporter, James Service

cancer researchThe Australian Cancer Research Foundation would like to congratulate James Service AM on his appointment as a Member of the Order of Australia.

James is a loyal supporter of ACRF through his work with the Canberra Cancerians. The Canberra Cancerians Committee is renowned as being one of the most successful fundraising groups for cancer research in Australia and enjoys a reputation of staging glamorous and much sought after events on the Canberra social calendar.

Since their formation in 1987, the Canberra Cancerians have raised $4.02 million for ACRF through balls, gala dinners and other activities such as golf events. The Australian Cancer Research Foundation is very grateful for the efforts of this incredible group of volunteer fundraisers.

James Service has been an integral part of this committee’s success. During the 15 years that he served on the committee $1.77 million was contributed to cancer research and a further $1.97 million has been raised in the past 8 years that James has been Committee President.

This magnificent effort has been due to the leadership and commitment provided by James supported by his outstanding committee. ACRF would like to extend our thanks to James for his contribution and support to our Foundation and congratulate him on this very honourable achievement.

Immunotherapy before surgery could improve cancer survival rates

Cancer research in Australia

Researchers have found that reversing the order of treatment for patients with certain cancers could dramatically improve survival rates.

Scientists at QIMR Berghofer in Brisbane conducted a study of triple negative breast cancer in mice and found that about half were cured when they received immunotherapy drugs before surgery, rather than after. When the mice received the current regimen of immunotherapy drugs after surgery, very few were cured.

Triple-negative breast cancer tends to be more aggressive than other types of breast cancer and is more likely to spread (metastasise) and recur. Based on the findings, several oncologists worldwide have started clinical trials to see if giving immunotherapy before surgery for certain cancers could produce the same results in humans.

The study was led by Dr Michele Teng and PhD student Jing Liu from QIMR Berghofer’s Cancer Immunoregulation and Immunotherapy Laboratory. It has been published in the journal Cancer Discovery.

Immunotherapy is a field that is revolutionising the treatment of some cancers. It works by activating a patient’s immune system to recognise and destroy cancer cells.

There are already immunotherapy drugs approved for use in some advanced cancers, such as melanoma and kidney cancer. Researchers are investigating whether different combinations of those drugs can improve survival even more than individual drugs and whether the drugs are effective at treating early-stage cancers.

“We wanted to find out when was the best time to schedule immunotherapy,” Dr Teng said.

“Traditionally, cancer patients have had surgery to remove the primary tumour before receiving supplementary treatments like chemotherapy or radiation to destroy any cancer cells that might have spread.”

“To our surprise, when we gave mice a combination of two immunotherapy drugs (anti-PD1 and anti-CD137) before surgery, between 40 and 60 percent were cured of triple negative breast cancer. It appears that this therapy destroyed any cancer cells that had spread to other parts of the body and stopped the cancer from returning.”

“In contrast, when mice received the drugs after surgery, between zero and 10 percent of them were cured. If these results are replicated in humans, it could lead to widespread changes in oncology practices and could greatly improve survival rates for some cancers.”

The researchers found the mice that received immunotherapy before surgery had higher levels of an immune cell known as tumour-specific T cells. These cells are responsible for recognising and destroying cancer cells.

“We think that giving immunotherapy while the primary tumour is still there provokes a better immune response by generating more tumour-specific T cells that are of better quality,” Dr Teng said.

“In other words, giving these drugs while the primary tumour is present not only increases the number of soldiers fighting the battle but also turns them from regular soldiers into SAS officers.”

“We think that these tumour-specific T cells can then travel to other sites and destroy any cancer cells that may have spread or metastasised. We also found that when immunotherapy was given before surgery, the increased numbers of tumour-specific T cells lasted for a long time, preventing a recurrence of the cancer.”

“Our next step is to try to understand in more detail why giving immunotherapy before surgery led to better survival rates in mice and whether this could also apply to other cancers.”

The study was primarily funded by the National Health and Medical Research Council.

The original news article was published on the QIMR Berghofer website. Image of Dr Teng courtesy of QIMR Berghofer.

The Australian Cancer Research Foundation has supported cancer research at QIMR Berghofer by providing three grants, totalling AUD$ 6.65M, for the purchase of cutting-edge cancer research equipment and technology.

Rosie’s story: Why I support cancer research

b846d8_067ec229e34b4b7c809d5e07242a14fe“It was 2007 and I was enjoying retirement after 30 years in nursing. But I had been experiencing stomach pain and weight loss for a few months. I’d ignored my friend’s continued pleas to see a doctor. Even though I knew there was a problem, I was in denial.

I finally had a gastroscopy procedure which confirmed I had stomach cancer. The first words that came out of my mouth were ‘How long have I got?’ and I remember feeling calm. My husband Jeff and I immediately broke the news to our children, both of whom were living overseas. Without delay, they flew home to be by my side and also support their father.

Over the next few weeks, I went through many different tests. A biopsy from my stomach showed it was a “rare lymphoid tissue lymphoma” and could be treated by antibiotics and chemotherapy. Unfortunately, a few weeks later another gastroscopy revealed the cancer was unaffected by antibiotics and it had spread through my stomach and developed into a high-grade lymphoma. The next move was a CAT scan to map out my stomach. I had to be given four minuscule tattoos as reference markers for my radiation treatment and I couldn’t wait to tell my son-in-law, who has a large tattoo on his arm, that now I had tattoos too!

It was humour that often helped me get through each day. It was a frightening time but I was so hell-bent on fighting for my survival. It’s amazing how the body and mind can cope through such a nightmare.

In early March, I started four weeks of daily radiation treatments. The treatments were successful and I was in remission until late June when I found a lump on the left side of my neck. A biopsy confirmed it was an aggressive type of cancer known as ‘diffuse large B-cell lymphoma.’ Surgery could only remove part of the node as it had adhered to my jugular vein so I began chemotherapy in August to help treat it. It was a particularly daunting time. I was nauseous, lost my sense of smell and taste and developed blisters in my mouth. I also became very forgetful, especially pots cooking on the stove. The loss of body hair made me feel very self-conscious. Thank goodness for wigs!

To deal with the side effects of my cancer treatment, I started composing music and lyrics. I never thought in my wildest dream, I would compose the story of my cancer experiences through music. It became the best medicine for me, taking me to another world where I could disassociate my cancer pain and any other discomforts from my various treatments.

After two months, the chemo treatment was finally over and I was back in remission in October 2008. I continued for another month on fortnightly MabThera IV treatment to kill off any stray cancer cells that might have been floating around my body. In March 2009 I had the best 60th birthday gift given to me, which was an offer to have my stem cells collected and stored for future use. but I hope I never have to use them!

The chemotherapy did affect my immune system badly and in 2010 I was placed on monthly IV Intragam Therapy to help rebuild it. Finally, the good news came in 2011. The oncologist informed me that I was cured, but there was a caveat – cancer may come back in about ten years. My reply was, “I’m not going to worry about the future as new and better treatments will be found.”

After experiencing cancer myself and losing friends who were not so lucky, I wanted to support cancer research. I know that researchers are working on new and improved treatments that will one day make our fear of cancer a thing of the past. After looking at various Australian cancer organisations I came across ACRF and was very impressed with how it functioned. Donations go towards grants that buy state-of-the-art diagnostic equipment for the best cancer researcher projects around the country.

I have raised money for ACRF in many different ways over the years. I’ve sold my handmade chocolates, jams and musical pattern placemats and serviettes. I’ve also hosted morning teas and organised garage sales with my husband and a few friends. One of my favourite fundraising activities so far has been creating my album ‘Chrysalis’, a musical storybook of cancer experiences. Proceeds from the sale of this CD go towards ACRF. I wanted to make a touching and uplifting album written from the heart to help others who are going through similar experiences. I want to support others who need to talk about their feelings and frustrations when going through cancer. Anyone interested is welcome to visit my website and interact with me. Hopefully, they will realise they are not alone.” – ACRF supporter, Rosie Lee

Organise an event Donate Share your story

Australian approval for drug that ‘melts’ leukaemia

researchers-at-wehi-courtesy-of-wehiA new anti-cancer drug with the power to ‘melt away’ certain advanced forms of chronic lymphocytic leukaemia (CLL) has been granted approval by the Australian Therapeutic Goods Administration (TGA), following equivalent approvals in the United States and European Union.

CLL is the most common type of leukaemia in Australia, with 1300 people diagnosed each year.

Venetoclax, to be marketed as VENCLEXTA™, has just been approved for Australian patients with relapsed or refractory CLL with 17p deletion, a mutation that makes the disease relatively resistant to standard treatment options, as well as for patients with relapsed or refractory CLL for whom no other treatment options are available.

Walter and Eliza Hall Institute of Medical Research director Professor Doug Hilton AO welcomed news of the drug’s approval, most importantly for patients with limited treatment options.

“The fact that Australians with hard-to-treat chronic lymphocytic leukaemia can now benefit from a drug like venetoclax demonstrates how critically important medical research is to the health of our community,” Professor Hilton said.

Professor Hilton applauded the team effort by Australian researchers and their international partners that preceded the approval.

“TGA approval of venetoclax is a major milestone in a journey spanning decades of powerful and innovative research by teams of leading scientists, clinicians and entrepreneurs, including more than one hundred researchers at Melbourne’s Walter and Eliza Hall Institute of Medical Research,” Professor Hilton said.

The timeline of discovery began at the Walter and Eliza Hall Institute in 1988, with the identification of BCL-2, a protein enabling cancer cells to survive.

Professor Hilton said scientists worldwide had subsequently been trying to find a way to ‘hit’ BCL-2, in order to stop cancer cell survival.

“Like a lethal arrow, venetoclax flies straight to the heart of BCL-2,” Professor Hilton said.

Venetoclax was discovered and developed with scientists from US pharmaceutical companies AbbVie and Genentech, as part of an international collaboration with the Walter and Eliza Hall Institute.

The first clinical trials for venetoclax started in Melbourne at the Institute’s Victorian Comprehensive Cancer Centre partners The Royal Melbourne Hospital and Peter MacCallum Cancer Centre and were led by Australian haematologists.

Professor Andrew Roberts, a clinical haematologist at The Royal Melbourne Hospital and cancer researcher at the Walter and Eliza Hall Institute and the University of Melbourne, said venetoclax was being combined now with other approved drugs and undergoing phase 2 and phase 3 clinical trials in other blood cancers.

“The hope is that venetoclax, potentially in combination with other approved drugs, could benefit more patients including those with other hard-to-treat types of blood cancer,” Professor Roberts said.

“Ongoing research suggests that this drug will be very active against other cancers, so this milestone may just be the beginning,” he said.

The Australian Cancer Research Foundation (ACRF) has supported cancer research at WEHI by providing three research grants, in total AUD$ 5.5M, towards cutting edge cancer research technology.

Below is a recent video of Professor Doug Hilton at ACRF’s Chariman’s Dinner. Here he talks about his experiences as a cancer researcher over the years. He discusses how some of the significant breakthroughs celebrated today, such as venetoclax, have been the result of an incredible amount of support provided by the community of ACRF supporters.

Donate now

Chris celebrates her 50th birthday while supporting cancer research

“Turning 50 was a milestone in my life. My only sadness, as that milestone approached, was that I wouldn’t get to share this special day with my parents as they had both passed away with cancer.

When the question of whether I should have a party or celebrate quietly loomed closer. I thought to myself, “In every other way I am blessed and wish for nothing else but continued health and happiness for myself and those I love, so why not party and celebrate?!” In a salute to the wonderful lives we live and as an investment in our future and those of our children, I asked for donations to cancer research instead of birthday presents.

We have all been touched by cancer in some way and we all live in fear that we or someone we love will be diagnosed with cancer. I’ve watched too many friends and family undergo invasive and debilitating treatments. The trauma associated with the cancer journey is heartbreaking. We are lucky that we have intelligent and talented scientists in Australia who devote their lives to cancer research. Every day they are working to improve methods of cancer prevention, detection and treatment. I believe we all must do what we can to support their lifesaving work.

I was very close to both my parents, mostly my mum. Mum and I did a lot of things together and she was always a great support to me, especially once I started my own family. She was a soft, kind, gentle and loving soul. Family meant everything to her and she sacrificed a lot to always be there for her children.

When my mum started getting very tired and had a lack of appetite it didn’t seem too unusual to us – after all she was 87. Then her leg began swelling a couple of months later and her doctor began investigating but still no one suspected cancer.

It wasn’t until 2.5 weeks prior to her passing that we found out she had advanced ovarian cancer and it was terminal. We never expected cancer and certainly never expected her to pass away so quickly. On 30 November 2015 Mum passed away just a few months short of her 88th birthday.

While we knew my mum had a good and long life, it still came as a huge shock. It is difficult to reconcile the passing of someone who is such a big part of your life. I miss her every day but I am trying to follow her example with my own family.

I know she would have loved my party! My birthday is on Christmas Day and she named me after Christmas – Christine Joy – so I held my party one month early with a Christmas theme.

My mum was the last of my children’s grandparents to pass away. My husband and I lost all four of our parents in three years. All four were over 80 so we were very lucky in so many ways.

My dad was the first to pass. He was diagnosed with bowel cancer when he was 87. We organised a family weekend away for my parent’s anniversary and my dad really enjoyed himself. I’m so thankful for that special time together. My dad always made the most of every moment of life. Forever the optimist, he broke the news to my brother by saying, “The bad news is that I am dying but the good news is that I am going to Heaven!” Dad was 89 years when he died.

Research really does make a difference and we all will benefit in some way. Thank you to my friends and family who donated to ACRF in lieu of gifts. My party raised $1400 for ACRF which I know will contribute to something greater and far more valuable than gifts. I believe it is a great investment in all our futures especially for those of us with children, as we all want to know that they will live longer and healthier lives and hopefully not have to suffer through terrible diseases and difficult treatments.” ACRF supporter, Chris Hizart

Celebrate a special occasion Donate Share your story

Supporting cancer research in memory of Max Walker

supporting canecr research in memory of Max Walker

“On the 28th September 2016, Australia lost a legend. Max ‘Tangles’ Walker died following a long and brave battle with multiple myeloma, a form of blood cancer.

Max was a celebrated Australian Cricketer, a former AFL player with the Melbourne Football Club and most recently, a much-loved presenter and sports commentator in the Australian media.

Max was a close friend and client of our accounting company, Findex. By all accounts, he was a great bloke. When the community loses such a person, it touches the hearts of many and makes us realise how precious life is.

Max’s dearest wish was to help anyone affected by the terrible disease that ultimately claimed his life. When it came to supporting causes that were important to him, Max always said, ‘if you can, you must.’ So we decided to organise a group-wide fundraising campaign to support cancer research in honour of him, and of every great man and woman who have lost their lives to cancer.

Our employees really wanted to give back and Findex was willing to support that culture by matching donations. Together we raised over $17,000 in just a few days.

All employees were invited to wear casual clothes on the day in exchange for a donation. Some of our offices also held a morning tea to mark the occasion and encourage donations.

Everyone was happy to get involved as cancer research is a cause close to the hearts of many of the staff. Chances are most people know someone whose life has been impacted by cancer, and even those who didn’t know Max Walker could relate to the feeling of losing someone too soon.

Every day scientists are discovering new information that could one day lead to better methods of prevention, detection and treatment. We still have a long way to go but there is hope and all of us here at Findex believe this is a crusade worthy of joining.

The employee culture of our company has traditionally been one of generosity and we are happy to harness that community spirit as a coordinated group. In 2017, we plan to continue that focus on philanthropy with the launch of the Findex Community Fund.

Thank you to everyone who helped make this fundraiser a success, and to ACRF, please keep up this very important work. You made it easy to get involved and we look forward to hearing of your newest developments!” – Claire Quince, ACRF supporter and Findex Senior Marketing Coordinator

Organise an event Donate Share your story

Derrin runs to support cancer research in memory of her dad

Derrin runs for cancer research“A year and a half ago, on the 18 June 2015, I held my beautiful Dad’s hand as mesothelioma consumed his twinkle. His love for Mum and our family, his lifetime of friendships, adventures, kindnesses and dedication had come to end. They were dark days but I knew from running City to Surf in 2014 that I could do something to help.

I had run the City2Surf as a tribute to my uncle, who died of early-onset Alzheimer’s and I just loved the challenge, comradery and community spirit of the event. I also loved the self-esteem it gave me from knowing I had run that far and raised lots of money. So when my father, Norman, died last year I knew it was the perfect, positive way for me to bring together so many people from all aspects of his life to keep him in our thoughts and reflect on what a great bloke he was.

My father was a very conscientious, hard-working, proud man with a mischievous sense of humour. He left school early but worked hard later in life to improve his qualifications and provide a role model for my brother and I. And I guess it worked because we both graduated with degrees within a year of each other.

He was very sociable and had great friends from a wide sphere of activities and experiences. Many were very close mates he’d known for years – people he’d travelled with, played squash with, or worked with since he was in his twenties.

He and my mum made a great team. They did everything together – socialising, playing golf and travelling the world – right up until about six months before he died. Although he was a retired teacher, my dad still worked up until a few weeks before he died, supervising university exams. He was a bit of a perfectionist so I thought he might have been a tricky boss but I was wrong. His colleagues came along to the funeral and couldn’t wait to share with us what a caring and fair man he was.

Dad and I were really close when I was little. He’d take me and my brother to see the Saints play and afterwards he’d take us into the Club after to see the players. He loved playing in the surf with us and he would spend hours pushing us around on a surf mat. He taught us about the rips and wave direction and how to body surf and catch waves. Some of my favourite memories are of us camping down at Wilson’s Prom and going for hikes and hearing my Dad tell jokes.

After I left university I moved to the UK to work in London, so for a long time my Dad and I had a phone and Skype relationship. I lived there for many years, during which time I met my British partner Tracy, we have now been together over 20 years.

When we had our kids – two boys, now aged 6 and 9, my Mum and Dad started visiting every year. Dad just wanted to do so much to help us out around the house. We had a lot of fun together as a family in those years.

We decided to move our family back to Australia in December 2012 and of course one of the reasons was to be closer to my Mum and Dad. It was so exciting to be just an hour’s flight away, instead of 24 hours.

But less than three months later, in the February, Dad phoned me to tell me he had mesothelioma (asbestosis) and it was terminal.

It came as such a shock and I think for a few weeks my Mum, Dad, brother and I whirled about separately in worlds of consuming bleakness. Facing up to death was terrible. We had no idea how long we had together and it was all made worse by a horrible, painful procedure Dad underwent straight after his diagnosis. We thought it was the end but gradually things got better and when he was able to take on chemotherapy, Dad coped with it with strength, dignity and humour.

The next 18 months or so were amazing. I had such respect for my Dad as he faced his illnesses positively and with so much hope. Being my organised, considerate Dad, he organised his own funeral, even down to the food and venue for the wake. And my Mum still finds little notes explaining how tools work or which appliances batteries are for.

When my Dad was in the last stage of his illness we heard on the news that there was a breakthrough with asbestosis. I can remember feeling so sad we hadn’t had the chance to fix this for Dad and give him back the life that was taken from him, all because he’d worked so hard as a carpenter when he was a young man. But I remember feeling real joy that other families would maybe not have to go through what we were going through.

Cancer research also made my dad’s chemo bearable. We had two years of good times because his doctors were able to get the drugs right and help him manage the side-effects. For my little boys, those two years are the times and memories they shared with their Pop. They are the years I re-connected with Dad after years of distance. In that time both my parents came to term with Dad’s illness in different ways but I think they managed it well and made sure they said the things that needed to be said. I don’t think I had realised how much my mum and Dad loved each other until I watched them go through that.

I know that I am stronger now and more appreciate of health and I make sure to live in the moment.

It’s been a pleasure raising money for the ACRF in my dad’s name. I chose to support cancer research through ACRF because I think this organisation does the most to eliminate cancer, pure and simple. ACRF are a small, efficient machine drilling debilitating holes into a life-shattering scourge. Their funds help passionate, dedicated researchers make discoveries that could save you or a loved one. My appreciation for every person who got behind me for my City to Surf run is deep, heartfelt and inspiring. Thank you.” ACRF supporter, Derrin Stent

Join a fitness event Donate Share your story

Australian breast cancer researchers win Ramaciotti Medal

Professor Geoff Lindeman and Professor Jane Visvader

Breast cancer researchers Professor Geoff Lindeman and Professor Jane Visvader, who jointly lead the Walter and Eliza Hall Institute’s Stem Cells and Cancer Division at the ACRF Breakthrough Technologies Laboratory, have been awarded the 2016 Ramaciotti Medal for Excellence in Biomedical Research.

Professor Lindeman and Professor Visvader have been selected for their contribution to cancer research and a series of landmark findings that have provided a new framework for understanding how breast cancers arise and how they could be prevented and treated.

Over the past decade, the researchers and their teams have identified the cells responsible for giving rise to normal breast tissue, making key discoveries in the regulation of normal breast growth and how errors within this process can lead to breast cancer.

Most recently, they identified the culprit cells that give rise to breast cancer in women who carry a faulty BRCA1 gene, and found that an existing medication for osteoporosis could provide a non-surgical option for breast cancer prevention in these women.

Mr Gary Jeffs, State Manager at Perpetual and Trustee of the Clive and Vera Ramaciotti Foundations, made the official award announcement during a ceremony at the Walter and Eliza Hall Institute.

Professor Visvader said she was honoured to receive the prestigious award.

“This medal is a testament to more than 15 years of continuous work – not just by Geoff and myself, but also our very talented teams of students, postdoctoral students, research assistants and our collaborators, who have been instrumental to the discoveries,” Professor Visvader said.

Professor Lindeman said the support of the Ramaciotti Foundations would advance efforts to translate discoveries from the laboratory into a clinical setting.

“With past Ramaciotti winners having been responsible for important contributions to the health of our communities, we feel deeply humbled and a sense of responsibility. Jane and I will continue to work with our amazing teams to progress fundamental discoveries from the bench to the bedside,” Professor Lindeman said.

Past Ramaciotti Medal winners from the include Institute director Professor Doug Hilton.

Over the years, Australian Cancer Research Foundation has supported WEHI by providing three grants totalling AUD $5.5million. These grants have been put towards cutting edge cancer research equipment and technology.

The original news article was published on the WEHI website. Image of Professor Lindeman and Professor Visvader courtesy of the WEHI.

‘Cellular CCTV’ helps solve longstanding leukaemia mystery

Cancer researchers in Australia and the UK have answered the longstanding question of how leukaemia survives chemotherapy.Cancer researchers in Australia and the United Kingdom have answered the longstanding question of how leukaemia survives chemotherapy. These findings will help develop more effective therapies for leukaemia in the future.

Leukaemia is a cancer of the blood with significantly high mortality rates. In Australia, 50% of adult leukaemia patients relapse after their initial chemotherapy treatment. Leukaemia is often resistant to subsequent treatments, allowing the cancer to spread and become fatal.

The recently published study has overturned popular theory that acute lymphoblastic leukaemia (ALL) cells resist cancer treatment by hibernating in bone marrow.

Lead researchers, Dr Edwin Hawkins at Walter and Eliza Hall Institute in Melbourne and Dr Cristina Lo Celso at London’s Imperial College, found that while chemotherapy was able to eliminate the majority of cancerous cells, the remaining treatment-resistant cells were doing the exact opposite of ‘hiding’ in order to survive.

“We realised that instead of playing ‘hide-and-seek’ with the chemotherapy, as was initially thought, the treatment-resistant ALL cells were engaging in a ‘catch-me-if–you-can’ game of ‘tag’. Right before our eyes, these cells were sprinting off in all directions: dividing, jumping in and out of blood vessels and using such ‘highways’ in the body to migrate and recolonise,” said Dr Hawkins.

To capture this remarkable action, the researchers developed a revolutionary high-resolution technique using ‘optical windows’ which, for the first time ever, enabled the cellular equivalent of ‘CCTV-like’ observation.

Dr Hawkins said previous techniques only involved analysis of static ‘snap-shots’, rather than any kind of video-based medium.

“Our new technique allows us to watch action unfolding for days, with the ability to zoom in and out on the same patch of tissue: from 3.5 x 2.5 mm, right down to a single micron – it’s incredible,” he said.

Dr Lo Celso said this dynamic new perspective would mean a shift in focus for researchers working to advance treatments for ALL.

“We now know that it is ineffective to design treatments to target the surrounding stromal cells or ‘hiding places’, because the cancer cells are not hiding,” Dr Lo Celso said.

“To beat leukaemia, we must instead develop a treatment that targets the ability of the cells themselves to ‘run’ around the body. Researchers must find a way to stop these cells in their tracks and win the game of tag,” she said.

Study co-author Dr Delfim Duarte, from Imperial College, added there was much to learn by being able to observe cancer in this new way.

“We also discovered that pain experienced by many leukaemia patients is caused by cells stripping and destroying tissue lining the bone, rather than from pressure caused by cells over-crowding in the bone – as was initially thought. We have much to gain from this dynamic information source,” Dr Duarte concluded.

The research was funded by Australia’s National Health and Medical Research Council (NHMRC), charities Bloodwise and Cancer Research UK, the European Research Council, the Human Frontier Science Program, and the European Hematology Association.

The study was recently published in the journal Nature.

The original post and video were published on the WEHI website. The image of Dr Hawkins was provided courtesy of WEHI.

The Australian Cancer Research Foundation has supported cancer research at WEHI by providing three grants, totalling AUD $5.5million, towards cutting edge equipment and technology.

Cancer treatment to benefit from nanotechnology study

Cancer research in AustraliaWhen it comes to delivering drugs, nanoparticles shaped like rods and worms are the best. For the first time, new research has identified how shape affects nanoparticles’ ability to move through intracellular barriers.

Chemists, engineers and medical researchers from University of NSW (UNSW), and the ARC Centres of Excellence in Advanced Molecular Imaging and in Convergent Bio-Nano Science and Technology at Monash University set to find out answers to two long-standing questions: how does nanoparticle shape affect the voyage through the cell and how could this information be used to design better treatment delivery?

The research team applied a new microscopy method, which allowed them to track the movement of differently shaped nanoparticles through a single cultured cancer cell. The new method produces a very high temporal and spatial resolution, allowing researchers to pinpoint where drugs were being released, and how they spread throughout the cell.

They found that the cancer drug, doxorubicin, was most effective when it could breach the strong yet porous cellular barrier protecting the nucleus – the cell’s control centre. Importantly, they discovered that a nanoparticle’s shape influenced how well the drug breached the barrier.

“We were able to show for the first time that nanoparticles shaped like rods and worms were more effective than spherical nanoparticles at traversing intracellular barriers and this enabled them to get all the way into the nucleus of the cell,” said lead author, Dr Elizabeth Hinde at UNSW.

Rod, worm or a sphere?

Polymeric nanoparticles can carry drugs to help attack and kill cancer cells, selectively deliver drugs just to where they are needed, and will play a vital role in the future of medicine.
UNSW engineers fabricated four types of nanoparticle: one shaped like a rod, one like a worm, and two that were spherical in shape. These were labelled with fluorescent tags and incubated in cancer cells. By combining a novel fluorescence microscopy approach with some statistical analysis, the team was able to create a clear picture of how each particle passed through the cell.

While the spherical particles got blocked by the nuclear envelope, the rod and worm-shaped particles were able to pass through. This provides a pathway for the development of particles that can selectively target and kill cancer cells, without hurting healthy ones.

“Cancer cells have different internal architecture than healthy cells. If we can fine-tune the dimensions of these rod-shaped nanoparticles, so they only pass through the cellular barriers in cancer cells and not healthy ones, we can reduce some of the side effects of chemotherapies,” explained Dr Hinde, an Associate Investigator at the Imaging Centre of Excellence.

The study was recently published in the journal Nature Nanotechnology.

The original news post was published on the ARC Centre of Excellence in Advanced Molecular Imaging website.

Neil’s guitar: keep the music playing for cancer research

“In 2015 my good friend Neil Kilgour passed away from cancer. Neil was a brilliant and generous person who encouraged, inspired and invested in people who he felt were talented.

Although he didn’t play an instrument himself, he was the centre point of a large group of musical friends. He loved music and had a vast collection of ’78s, principally folk music, jazz, and those genres, but he liked everything.

Every Tuesday night, up to 30 or 40 people would visit Neil and Leslie’s house to share a love of guitars. In one room there were guys playing classical guitar and in another room, there would be guys playing bluegrass… it took over the whole house. There were fiddles, banjos, mandolins and even concertinas, button accordions.

People would teach each other technical skills and Neil would also repair instruments. In the final stages of Neil’s illness, we would visit him and play music for him. These gatherings continued until his death. In 2014, prior to his diagnosis, I began building a guitar to present to Neil in gratitude for everything he had done for me.

Sadly the guitar was to be completed after Neil’s passing, but Neil and I devised a plan to keep the music playing and to raise funds for cancer research.

It was his wish that its use could generate funds for the ACRF. We hatched a plot that the guitar should be used by musicians for recording purpose – and that it should not sit in a box somewhere.

We fulfilled his wish by recording an album called ‘Neil’s Guitar’ featuring eight well-known Newcastle musicians – including Bruce Mathiske, Ian Milroy, Peter Smith, Christopher Cady, Steve Cowley, Kent Daniel and Peter Allsop.

On the album, eight different people are playing ‘Neil’s Guitar’ and the interesting thing is how different it sounds in the hands of each person, you would think they were different guitars.

The CD was launched with a special concert at Adamstown Arts in November. All proceeds from the concert and CD sales went to the Australian Cancer Research Foundation.

Special thanks to Christopher Cady for organising the recordings and Peter Allsop for planning the launch and for both of their ongoing commitment to this. The effort everyone has put in has been overwhelming and it’s turned a crazy idea into a real thing which is really inspiring.” – Jeff Mallia

 

Venetoclax could target hard to treat childhood cancers

Australian cancer researcher Professor Richard LockA newly approved adult leukaemia therapy called venetoclax could successfully target high-risk leukaemia subtypes in infants or children reveals an Australian study published last month.

The study’s lead authors are Professor Richard Lock, Head of Leukaemia Biology at Children’s Cancer Institute (CCI) and Professor David Huang at Walter and Eliza Hall Institute (WEHI).

Earlier this year, venetoclax, which was developed at Walter and Eliza Hall Institute (WEHI), showed remarkable results in clinical trials for adults with chronic lymphocytic leukaemia (CLL). Most patients with an advanced form of CLL achieved either a partial or complete response.

Venetoclax targets the cell-survival protein BCL-2. In this collaborative study, researchers at WEHI built on their many years’ of research into drugs like venetoclax and their mechanism of action. Testing on children’s cancers was done at CCI in Sydney.

While leukaemia is the most common childhood cancer and has survival rates of around 90%, some leukaemia subtypes have much lower survival rates. Although treatment with venetoclax alone was not as effective in children’s cancers as in adult CCL, venetoclax was effective against pediatric acute lymphoblastic leukemia (ALL) in combination with other treatments.

Venetoclax alone was shown to be effective in mixed lineage leukemia-rearranged ALL (MLLr-ALL), which is a sub-group with a particularly poor prognosis. With further testing, the drug could be used for targeted treatment for children and infants with these hardest-to-treat leukaemia sub-types as part of a personalised medicine approach. Data from the published study will be used to support a future clinical trial.

Professor Richard Lock, Head of Leukaemia Biology at Children’s Cancer Institute, said that although it is disappointing that venetoclax is not looking as broadly active for the most common paediatric leukaemia, ALL, the research identified paediatric ALL sub-types that could be more susceptible to the drug than others.

Professor Lock said venetoclax is likely to be most effective when used in combinations with other drugs and that further research is needed to determine which combinations work best.

This news post was originally published on the CCI website. Image of Professor Lock courtesy of CCI.

Ambre Hammond’s dedication to ending all cancers

Ambre Hammond supports cancer researchKnown as “The People’s Pianist” and one of Australia’s most passionate and hard-working musicians, Ambre Hammond has performed both solo and with orchestras throughout Switzerland, England, Italy, Spain, Poland, North and South America, New Zealand and China.

And we are so grateful that Ambre so graciously gives her time to perform at special ACRF events too. She has also donated funds to cancer research from the sale of her CD’s.

Ambre’s fifth album Akasha will be released in two weeks. She says the new album consists of 12 compositions, the style of which stems from her background in classical, but is also influenced by her great love of jazz. This album is a journey of beauty that is intended to uplift and inspire.

We spoke to Ambre about what inspired her to support cancer research.

“I’m a proud Aussie, a concert pianist, composer, full-time single mother, producer and public speaker.

My composition career began in 2011 when after the loss of a friend to cancer, which happened very suddenly. The only way I could deal with the grief was to write music. I felt some sense of peace in honouring them with a piece of beautiful music that would ensure her memory remained.

Ambre Hammond supports cancer researchIt is important to support cancer research because all of us are susceptible to being struck unexpectedly with cancer. It should be everyone’s duty and interest to help find better treatments and ultimately permanent eradication of all cancers.

I support ACRF because their work is truly extraordinary. They are an Australian charity that seeks to support researchers working to end all cancers. The $120 million+ in grants already made to research facilities has made a significant difference and will continue to do so.

I’d encourage everyone to support cancer research. You feel such a sense of joy in knowing your contribution can be so significant. Even if it means buying one less coffee a week!

I will continue to support ACRF through my music for as long as I can, and I’m excited to hear of new scientific breakthroughs and development.”

Thank you Ambre, we are so grateful for your support. If you would like to find out more information about Ambre’s new album, click here.

Revolutionary advances in microscopy provide an opportunity to break a roadblock in cancer research

Dr-Rashmi-Priya-CREDIT-UQ's-Institute-for-Molecular-Bioscience - Copy for webA $2.3M grant from Australian Cancer Research Foundation (ACRF) is being awarded to The University of Queensland’s Institute for Molecular Bioscience (IMB) today to establish the new ACRF Cancer Ultrastructure and Function Facility (CUFF).

The nation-leading facility will provide cutting-edge imaging capabilities for tracking and visualising cancer. Researchers will be able to see cancer cells grow, spread and respond to drugs in real time. This will help them learn how cancer cells behave and change, and ultimately, develop new treatments to control cancer.

“The need for this facility came from a realisation that we are at a crucial juncture in global cancer research. Despite outstanding developments in understanding the genetic changes in cancer, we still do not understand how these changes cause cancers to grow and spread,” says Professor Brandon Wainwright, Director, IMB.

The researchers at IMB are hopeful that the revolutionary new advances in microscopy will provide the opportunity to break this roadblock.

“Donations received by ACRF help to provide researchers with the most powerful tools available. The three new microscopes at IMB will allow researchers to observe the structure and function of living cancer cells in real time with unprecedented resolution, giving them the opportunity to optimally target and fine-tune cancer treatments. It is our hope that they will assist IMB in making significant contributions to the global understanding of how cancers grow and develop to improve treatments and patient outcomes,” says Professor Ian Brown, CEO of the Australian Cancer Research Foundation.

The new ACRF Cancer Ultrastructure and Function Facility represents an apex of multidisciplinary efforts. Biologists, physicians and chemists will work together to build a deeper understanding of cancer biology and pioneer new therapeutic approaches to beat the disease.

ACRF has supported cancer research at The University of Queensland’s Institute for Molecular Bioscience since 1994. Over the past 22 years, ACRF has awarded three grants totalling $4.8M to the institute for research into all types of cancer.

“ACRF is proud to continue to support the cutting-edge research being carried out at IMB. It is our mission to do everything we can to provide Australia’s best researchers with the tools they need to end cancer,” concludes Professor Brown.

Support of cancer research in Australia turns ideas into information

The new ACRF Child Cancer Personalised Medicine Centre’s specialised robots can now rapidly test hundreds of treatments for kids with high-risk cancers to guide their care..

Each year, ACRF challenges the Australian cancer research community to propose projects that are bold and have the potential to make a significant impact on cancer prevention, detection and treatment.

Eleven projects were submitted from across the country and evaluated by ACRF’s esteemed Medical Research Advisory Committee who were impressed by the quality and vision of the applications. From these, four were chosen to receive grants.

“Thanks to the generosity of our many supporters from around Australia each year we are able to award high-impact grants, allowing Australia’s best scientists to embark on ground-breaking research projects. These initiatives in cancer research cover all types of cancer and speed up discoveries, ultimately working to save lives by saving time,” said Professor Ian Brown, CEO of Australian Cancer Research Foundation.

The recipients of the annual ACRF grants in 2016 are:

  • ACRF Tumour Heterogeneity Program – $2 million to learn more about the mutation, internal variation, location and the impact of time on growth and treatment of tumours. Victorian Comprehensive Cancer Centre (VCCC), VIC
  • ACRF Tumour Metabolism Laboratory – $2.5 million to determine the differences in nutrient metabolism by cancerous and normal cells to improve cancer treatments. Centenary Institute, NSW
  • ACRF Cancer Ultrastructure and Function Facility – $2.3 million to provide microscopes that can see cancer cell behaviour and their response to drugs in order to stop the spread of cancer. Institute for Molecular Biosciences University of Queensland, QLD

Since its inception, 32 years ago, ACRF has awarded $129.1 million in grants to Australian cancer research institutes across the country to pay for infrastructure and equipment.

Funding from ACRF has helped get some of the most successful cancer research projects get off the ground, including the early support of the research that led to the cervical cancer vaccine.

ACRF is dedicated to funding research in Australia that has the power to make significant breakthroughs in cancer diagnosis and treatment and will continue to fund cutting-edge treatment until cancer no longer poses a threat to the health of Australians.

Technology boost to help address one of the biggest challenges facing cancer research today

Marija-Koljic-CREDIT-UQ's-Institute-for-Molecular-Bioscience - Copy small for webA $2M grant from Australian Cancer Research Foundation (ACRF) has been awarded to a Peter Mac-led application from members of the Victorian Comprehensive Cancer Centre (VCCC) to establish The ACRF Tumour Heterogeneity Program.

This investment will see world-leading researchers from the Peter MacCallum Cancer Centre, Walter and Eliza Hall Institute of Medical Research (WEHI) and the University of Melbourne join forces to address one of the biggest challenges facing cancer research today.

Tumour heterogeneity occurs when more than one distinct cancer mutation exists, either within one tumour or when there are variations of cancer mutations between tumour types. These mutations can evolve differently over time and cause significant challenges in designing effective treatment strategies.

The Program will work towards a better understanding of the diversity of evolutionary changes that result from tumour heterogeneity, gaining information that will be critical to the development of strategies that overcome and/or exploit this diversity and ultimately improve patient survival across many cancer types.

While cancer research efforts have reached a high level of sophistication, knowledge of the full extent of tumour heterogeneity remains limited, hindering efforts to understand patterns of tumour evolution, select effective therapies and combat treatment resistance in the clinical setting.

“New technologies now provide us with unprecedented opportunities to research and understand fundamental questions about tumour heterogeneity,” says Peter MacCallum Cancer Centre Associate Professor, Sarah Jane Dawson, who led the application on behalf of the partnership.

“With ACRF’s support, the combined power of our laboratory and translational research will deepen our understanding of tumour heterogeneity and accelerate discoveries so they can directly benefit patients with cancer sooner,” says Associate Professor Dawson.

“ACRF exists to challenge researchers and encourages them to look at new ways of working together in an effort to realise new insights and bold ideas. We are proud to continue to support the collaborative efforts of the VCCC,” says Professor Ian Brown, CEO Australian Cancer Research Foundation.

“Many of the research institutes involved in this new initiative have received grants in the past from Australian Cancer Research Foundation, including Peter MacCallum Cancer Centre, University of Melbourne and Walter Eliza Hall Institute. The Australian Cancer Research Foundation is proud to continue to support the world-class cancer research at these institutes,” says Professor Brown.

New blood cancer centre to improve patient outcomes

blood cancer, cancer research, donate to cancer,Alfred Health and Monash University are set to establish Australia’s first dedicated blood cancer research centre, thanks to a $1.2 million grant from the Australian Cancer Research Foundation (ACRF).

The ACRF Blood Cancer Therapeutics Centre, based at The Alfred, will be home to the latest technology available in blood cancer research and will enable researchers to dramatically improve outcomes for patients with blood cancer.

Each year, 11,500 Australians are diagnosed with blood cancer, including leukaemia, lymphoma and myeloma. Sadly, these debilitating diseases – which account for one in 10 cancers diagnosed nationally – claim 4000 lives every year.

Dr Andrew Wei, haematologist at The Alfred and Monash University, said the new centre will enable researchers to find out more about these cancers – including why some treatments work for some people and others don’t – and develop new ways to treat them.

“Many of our patients with various forms of blood cancer have had great success in clinical trials, which use new and unique drug combinations,” Dr Wei said.

“Utilising the most up to date technology available, this new centre will enable us to discover more effective therapies, track patient treatment responses up to 1000 times more closely, and improve therapies to get better outcomes overall for patients.

“Blood cancers are relatively neglected when it comes to research. Thanks to this grant, Monash University and The Alfred will be at the forefront of blood cancer research – it is the only way we can improve outcomes for people diagnosed with blood cancer.”

Mary McKenzie is one such patient who owes her life to the clinical trials that will now be available to more people through the new centre. Five years ago Mary was diagnosed with acute myeloid leukaemia and after several treatments failed, took part in a drug trial at the Alfred.

“My chances of survival were really low, but here I am now five years later and I’m better than I’ve been in years. The trial saved me,” she said.

“Having the opportunity to go on the trial gave me hope there was still something they could do. This opportunity should be available to everybody.”

The flagship centre will collect samples from across the country. It is one of only four projects nationally to receive an ACRF grant this year.

“This project encompasses a virtuous cycle of drug discovery, validation, personalised molecular monitoring and improvement of new treatment combinations. It is something ACRF feels has the potential to become a flagship success,” said Australian Cancer Research Foundation CEO Professor Ian Brown.

Understanding the diet of tumours to help in the development of new cancer therapies

Removing a protein and enzyme pair can improve cancer treatmentA $2.5M grant from Australian Cancer Research Foundation (ACRF) is being awarded to The Centenary Institute today to establish the new ACRF Tumour Metabolism Laboratory.

The grant is a continuation of support to help researchers better understand the way cancer cells metabolise dietary nutrients and provide critical information to the development of new cancer diagnostics and therapies.

Researchers will be focused on three fundamental and interlinked areas: nutrient uptake into tumours, sugar metabolism and fat metabolism. From this, they hope to ‘outsmart’ the cancer cells that have evolved to the point where other forms of treatment have become ineffective.

“For years cancer researchers have focused on identifying specific changes in a patient’s genes which have been associated with cancer formation and growth, and developing therapeutics to target these changes. While this information is still vital, it is becoming clear that many cancer cells are skilful at bypassing specific genetic changes and this makes many targeted therapies only briefly effective,” says Professor Philip Hogg, Head of the ACRF–Centenary Cancer Research Centre.

This reality has led to a renewed focus on a fundamental property of cancer cells that was identified some time ago: their irregular metabolism of dietary nutrients.
“Technological advances and insights into how cancer develops have unleashed new opportunities for researchers to pioneer alternative approaches to treating cancer. This project is a shining example of ACRF’s support of projects exploring new ways to beat cancer. We’re excited at the potential it holds,” says Professor Ian Brown, CEO Australian Cancer Research Foundation.

“The chief drivers of cancer, whether genetic or inflammatory, operate through altered metabolism. This research has the potential of developing therapeutics applicable to a wide range of tumours”, says Professor Mathew Vadas AO, Executive Director of the Centenary Institute.

In addition to funding from ACRF, the Cancer Institute NSW has committed to supporting Centenary Institute by providing funding for the scientists that will carry out the research.

Chief Cancer Officer and CEO of the Cancer Institute NSW, Professor David Currow, said, “The ACRF Tumour Metabolism Laboratory provides an opportunity to gain important new knowledge of changes at the molecular level of tumours. The Cancer Institute NSW is proud to be partnering with the Australian Cancer Research Foundation in this exciting new initiative. By supporting researchers working in the lab, we hope to accelerate these important discoveries.”

Research at the ACRF Tumour Metabolism Laboratory will focus on the role of nutrient metabolism particularly in endometrial, brain and triple-negative breast tumours. These cancers are among the most difficult to treat of all cancers.

Endometrial cancer is diagnosed in more than 2,200 Australian women each year, accounts for 9.4% of all new cancer cases in women and has a 5-year survival rate of only 26%.
Glioblastoma is the most common and most malignant brain tumour and in terms of years of life lost is the highest of all the malignant cancers. It is associated with a 5-year survival rate of less than 5% and a median survival rate of less than 15 months.

Triple-negative breast cancer (TNBC) is an aggressive form of cancer that accounts for 10-15% of all breast cancer cases. TNBC lacks a targeted therapy, has an increased rate of recurrence, and a lower 5-year survival rate compared to other breast cancer subtypes.

Cancer research gave Dad 13 more years to spend with our family

Jess and Phil“On April 8 I lost my dad to cancer. Just a month before, I watched as he walked up the hospital hallway by himself, achieving a goal he had been working towards with his physio team since his last surgery. It seemed impossible to most of us but he was always determined to get better.

My dad lived with cancer for 13 years. There were many years where we thought to ourselves, ‘This is it. This is the last Father’s Day, this is the last Christmas’ but he always made it through.

He had been fortunate that he qualified for many different medical trials throughout his illness. Every medication that came around, he would give it a go – no matter what. It was always something new, like a magic trick the researchers would pull out of a hat to give him more time.

I am so thankful for cancer researchers. Their dedication to progress provided some of the newer treatments that not only gave him more time but improved his quality of life.

This meant so much to him because it let him keep doing the things he loved, like travelling and spending time with his family. He was also able to keep working for the Fire Brigade. Everyone who knew my dad knew about his passion for his career, I feel like it was one of the things that kept him going.

Following in his father’s footsteps, he first began as a volunteer firefighter and worked hard to earn a full time position as a fire investigator. He worked right up until the very end.

PhilHe was such a fighter, not just as a fireman but in the way he refused to give up.

Dad endured many different cancers over the last 13 years, including bowel, lung and bone. But it was brain cancer that took him in the end. I feel it was the worst for him to go through.

My mum and I were playing all his favourite songs on his last day, dancing around his bed like mad women, he would have loved it. They say that hearing is the last thing to go, so I just know this would have made him happy.

My dad always liked to make sure he thanked people when they helped him. So I wanted to thank cancer researchers on his behalf.

I began supporting Australian Cancer Research Foundation to give other families more time with their loved ones. I know that together we can help researchers improve cancer prevention, detection and treatments for patients.

It is my hope that one day cancer won’t be on anyone’s mind at Christmas.” – ACRF supporter, Jessica Broome

Donate Share your story

New compound shows promise in treating multiple human cancers

Australian cancer researchersA collaborative team of researchers has shown that a new compound blocks a protein that is essential for the sustained growth of up to a quarter of all cancers.

The study presents a new way to efficiently kill cancerous cells and holds promise for the treatment of blood cancers such as acute myeloid leukaemia, lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast.

The new compound, S63845, targets a protein of the BCL2 family, called MCL1, which is essential for the sustained survival of cancer cells.

Associate Professor Guillaume Lessene at Walter and Eliza Hall Institute in Melbourne said the work provided the first clear preclinical evidence that inhibiting MCL1 was effective in targeting several cancer types.

“MCL1 is important for many cancers because it is a pro-survival protein that allows the cancerous cells to evade the process of programmed cell death that normally removes cancer cells from the body,” Associate Professor Lessene said.

“Extensive studies performed in a variety of cancer models have shown that S63845 potently targets cancer cells dependent on MCL1 for their survival.”

The researchers demonstrated that not only was S63845 effective against several cancer types, but that it could also be delivered at doses that were well tolerated by normal cells.

Associate Professor Lessene said the research also provided further evidence of the usefulness of a new class of anti-cancer drugs called BH3 mimetics.

“BH3 mimetics inhibit a group of proteins known as the ‘pro-survival BCL-2 proteins’,” he said.

“MCL1 is a member of this protein family, and inhibiting it activates the process of programmed cell death.”

“Walter and Eliza Hall Institute researchers revealed the role of BCL-2 in cancer more than 28 years ago and the essential role of MCL1 for the survival of malignant cells four years ago,” he concluded.

The research was supported through a research collaboration with Servier and through funding from Australian Cancer Research Foundation, the National Health and Medical Research Council of Australia, the Leukemia and Lymphoma Society (US), Cancer Council Victoria, the Kay Kendall Leukemia Fund, Victorian Cancer Agency, the Victorian Government Operational Infrastructure Scheme and the estate of Anthony Redstone.

The research was published last week online in the journal Nature.

The original news post and video were published on the WEHI website.

Kicking it for Kieran

fundraising stories, cancer charities “My name is Iain Chisholm. Over the last few months, I’ve been truly inspired and heartened (though not surprised) as I watched my community back home in the North East of England band together and support one of our own, Kieran Wrightson, as he goes through one of the toughest experiences of his life.

Kieran is a talented footballer and FA Vase winner from my hometown. He is a 25-year-old father of one, about to get married.

Earlier this year his world was turned upside down when he found a lump in one of his testicles. His doctors delivered the devastating news that it was cancerous and that it would have to be removed.

In an interview, Kieran said ‘it came completely out of the blue – I don’t drink, I don’t smoke, I’m a young fit lad who plays football. The doctors made it clear that I had a good deal. I’d caught it early and testicular cancer is one of the easiest to treat. I had it removed on May 2, which was also my birthday.’

Myself and my fellow expats in Brisbane have been touched by Kieran’s situation, particularly as we are mostly young(ish) footballers enjoying life and earning an honest living for ourselves and our loved ones. Naturally, it didn’t take much effort in getting the ‘Brisbane family’ on board to show some support.

With Kieran’s blessing, I was delighted to get my friends together and arrange a fundraiser to support cancer research in his name.

This past Saturday, we challenged ourselves to set off in the early morning on a self-guided group hike and rock climb (9km/4hours) to the summit (1.2km high) of Mount Warning for a spectacular Australian sunrise.

This was followed by a late afternoon charity football match at Bayside United which saw my team the ‘Geordie XI’ which I captain, take on ‘Mackem XI’ captained by my fellow event organiser, Ben Ryan.

We raised just over $1,000 which will be split between the Australian Cancer Research Foundation and Saras Hope based in the United Kingdom. The UK charity was selected by Kieran and our good friend Alan Dalgarno. While our Australian charity was selected by me and endorsed by Kieran unequivocally.

We’re proud to raise funds for cancer research in Kieran’s name. If you’d like to join us in supporting these two charities you can donate to our page here. #ClimbForCancer #KickAboutForKieran.” – ACRF supporter, Iain Chisholm

Thank you to Iain for supporting cancer research. If you’ve been inspired by Iain, the charity fundraising options are endless! Click here to view our A-Z of charity fundraising ideas.

Organise an event Donate Share your story

Bright mammogram spots could predict future breast cancers

Bright mammogram spots could predict future breast cancersResearchers have discovered a new way to interpret mammograms that could transform routine breast screening and save lives.

Professor John Hopper at the University of Melbourne said the new technique makes it possible to predict with 30 per cent more accuracy which women will develop breast cancer in the future.

“We’ve discovered that the best predictor of a woman developing breast cancer in the future is how much of her mammogram is covered by bright areas — even more than all the known genetic factors discovered over the past 20 years,” said Professor Hopper, Director of Research at the Centre for Epidemiology and Biostatistics.

Professor Hopper said the findings open up possibilities for personalised prevention of breast cancer through screening.

Radiologists have long known that areas of breast density, which show up as white on a mammogram, are a risk factor for breast cancer. They pay particular attention because these white areas can also hide existing cancers.

However, the research team decided to switch focus away from white areas to bright areas, which have not previously been viewed as significant.

The team, led by PhD student Tuong Linh Nguyen, studied 1300 mammograms of Australian women aged in their 20s to 70s, comparing the bright areas of 354 women with breast cancer with those of 944 women who were cancer-free.

“While the white areas are important for hiding existing breast cancers, we found that it is the bright, not white, spots that provide information about future breast cancers,” Mr Nguyen said.

“These results also apply to young women and women with a family history of breast cancer.”

mammograms can show increased risk of cancer

Professor Hopper said not all women have the same risk of breast cancer.

“Fortunately, for 50 per cent or more of women, their lifetime risk is low, at a few per cent. But for the remainder, the risk can vary greatly.

“Women at increased risk might need more or different screening, perhaps starting at a younger age, while women at low risk might not need to have as many mammograms,” he said.

Professor Hopper said his colleagues are now working on digital automation to make this technique available for screening services, and conducting more research on why brightness predicts increased risk and how these findings can be used to improve screening.

The study has been published in the International Journal of Epidemiology.

The Australian Cancer Research Foundation has supported University of Melbourne’s cancer researchers at the Victorian Comprehensive Cancer Centre with a $2 million grant to fit-out a specialised centre for translational research and personalised medicine.

Supporting Australian cancer research in memory of my grandfather

Alex Lombardo“My name is Alex Lombardo. I’m currently a Senior Analyst at Deloitte. My mum, Carmel, and I have been supporters of the Australian Cancer Research Foundation for some time.

After catching up with their CEO, Professor Ian Brown, I gained an even greater understanding of exactly how ACRF grants work to help researchers find better ways of detecting, preventing and treating all cancers. I was inspired to assist, so my mum and I hosted a high tea for cancer research in memory of my grandfather, Consolato Federico, who passed away from cancer last year.

My grandfather was one of the most amazing and giving people you could ever meet. I hope I can one day be half the man he was. He was a very important part of our lives. We always lived close to him so his positive and inspirational influence was always around us.

It had a huge impact on our family when he was diagnosed with cancer. It was extremely difficult to watch him – someone I perceived to be a superhero – go through so much pain.

My mum and I had always wanted to host a fundraising event like this because we thought it was a great way to honour my grandfather. It was important to raise money but we also wanted to increase awareness of the impact of supporting cancer research in Australia. In the end, the high tea raised $8,335.00. Thank you to our friends and family who attended on the day and to the fantastic sponsorship we received from a number of local businesses.

It is my hope that one day, instead of having to treat cancer, we will be in a situation where we can prevent most cancers from happening in the first place. I want to help prevent everybody’s loved ones from enduring unnecessary pain.

I hope that others join me in supporting cancer research, the more people, the better our impact will be!” – ACRF supporter, Alex Lombardo

Organise an event Donate Share your story

Facts and Statistics about Common Women’s Cancers: Breast, Gynaecological, Cervical and Ovarian

Australian Cancer Research Foundation, Breast Cancer, cancer charity, Cancer Research, charity foundation, Fighting cancer, Funding research, Types of cancer, women's cancer, women's cancers, Women’s Cancer Month, Women’s Cancer Facts, Breast Cancer Facts, Gynaecological Cancer, Gynaecological Cancer Facts, Cervical Cancer, Cervical Cancer Facts, Ovarian Cancer Facts, Ovarian Cancer, Awareness, Breast Cancer Awareness Month, ovarian cancer awareness month, cancer fundraising, cancer research fundraising, give to charity, cancers affecting women

Each day up to 170 women in Australia are diagnosed with cancer. With this alarming figure, ACRF is determined to make a difference in the lives of Australian women through cancer research.

To raise awareness of the cancers that affect women this month, we’ve compiled a few interesting facts and stats.

Women’s cancer facts and statistics at a glance

  • 1 in 3 women will be diagnosed with some form of cancer before the age of 85
  • There are over 200 types of cancer that can affect women
  • The most common cancers diagnosed with Australian women are: non-melanoma of the skin, breast, colorectal, leukaemia and lymphoma
  • Thanks to research, survival rates were highest for women diagnosed with thyroid cancer (97%), lip cancer (94%) and melanoma of the skin (94%)

Breast cancer facts and statistics

  • 1 in 8 women diagnosed with breast cancer before the age of 85
  • Breast cancer is the most common cancer diagnosed in Australian women
  • Thanks to research, the 5 year survival rate is just over 90%
  • Known risk factors are diet, alcohol consumption and physical inactivity
  • Breast cancer in men accounts for around 1% of all breast cancer occurrences

Gynaecological cancer facts and statistics

  • The risk of an individual being diagnosed with a gynaecological cancer by age 85 is 1 in 22.
  • Gynaecological cancers were the 3rd most commonly diagnosed cancer among females in Australia.
  • Known risk factors include age
  • The five year survival rate is 68%
  • Gynaecological cancers include malignant neoplasms of vulva, vagina, cervix, uterus, placenta and ovaries

For more information on gynaecological cancer, click here.

Cervical cancer facts and statistics

  • The risk of a woman being diagnosed with cervical cancer by the age of 85 is 1 in 162.
  • The five-year survival rate for women with cervical cancer is 72%
  • In 2009, cervical cancer was the third most commonly diagnosed gynaecological cancer in Australia
  • Since the introduction of the National Cervical Screening Program in 1991, the number of new cases of cervical cancer for women of all ages almost halved
  • In 2006, Professor Ian Frazer and his team at the University of Queensland discovered a vaccine to prevent HPV, protecting women against most types of cervical cancer

Ovarian cancer facts and statistics

  • 1 in 75 women diagnosed with ovarian cancer before the age of 85
  • Most common most common cause of gynaecological cancer death in Australia
  • More research is needed to increase the 5 year survival rate from 45%
  • Known risk factors are family history and genetic susceptibility as well as obesity and physical inactivity
  • Symptoms are often vague and can be similar to the symptoms of many other conditions

Donate or Fundraise To Support Women’s Cancer Research

By donating, fundraising for and supporting cancer research into all cancers that affect women, you are helping to fund the next big breakthrough in cancer detection and treatment.

Our Woman’s Appeal aims to raise much needed funds for research into common women’s cancers, including breast, cervical and ovarian cancer. You can make a donation today to help fund research for women with cancer.

Gypsys Gift: fighting cancer with music

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, Cancer Research Grants, cancer scientists, Challenge, charity challenge, charity foundation, donate to charity, current cancer research, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories, give to charity, regular giving, gemma ameera, jimi may, gypsys gift Gemma and her fiancé, Jimi, started the band Gypsys Gift five years ago. Since then, the duo have won an Australian Independent Music Award, achieved rotation on Foxtel’s CMC and will shortly release their highly anticipated, debut album Chapters.

Over the weekend, the band unveiled the new music video for their single, Feed the Fire, alongside a special announcement.

“We do not ask that you buy our new song – we’re doing things a little differently this time. In support of the Australian Cancer Research Foundation, we aim to create awareness of cancer research with the release of Feed the Fire. Our ONLY intention is to raise as much money as possible for cancer research. All funds raised will go directly to ACRF, and this will be an ongoing campaign for us.” said Gemma.

“The last couple of years have been both incredible and heartbreaking for Jimi and I. We have travelled the world and experienced remarkable growth, but we have also been on a tough road.

Two Christmases ago we were faced with the hard news that my Mum, Joanne, was diagnosed with Stage 4 bowel cancer.

Mum underwent multiple major surgeries to remove half her liver, gall bladder, part of the bowel and lymph nodes. She then went through six months of chemotherapy treatment as a further measure to prevent the cancer coming back.

Joanne and Gemma 2This was a whole new world for my entire family. We felt very much in the dark as we had no experience and no understanding of what anything meant. It’s safe to say the journey was hard on all of us, especially on my Mum, step-dad and two brothers who lived through this every day.

Slowly things began to feel normal again as Mum was recovering day by day. Although the physical and emotional scars of the cancer had not entirely faded, my Mum, being the warrior that she is, was soaring to better days.

Then out of the blue, while I was on my way to a songwriting session, I received a phone call that would once again change the lives of myself and family.

Mum had been re-diagnosed with terminal cancer of the liver. Hearing the news was like being in a movie. A fear that I have never felt, and didn’t quite comprehend, washed over me – I was now faced with losing my mother when she was only 48 years old.

They say, as an adult you must carry on. But this time, it’s not been the case. This is now my life. I often describe it as living in a permanent nightmarish limbo-land.

We all have our good days and our bad days, but my Mum has kept us all positive and moving forward. She has spent her entire life putting everyone else before herself, and even now, she wishes for nothing more than everyone else’s happiness.

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, Cancer Research Grants, cancer scientists, Challenge, charity challenge, charity foundation, donate to charity, current cancer research, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories, give to charity, regular giving, gemma ameera, jimi may, gypsys giftMum has been fighting cancer for a couple of years now – in true grace. Her resilience, strength and courage is unfathomable and we stand by her side while she battles through this.

This illness has turned the life of myself and my loved ones upside down, and this happens every day to families all over the world. Cancer does not discriminate; almost everyone has been touched by this illness in some way or another.

This painful journey has inspired Jimi and me to help put an end to cancer, and we will not cure cancer without research. This is why we feel so passionately about ACRF. It is my belief that they are by far one of the most compassionate and forward-thinking foundations we know.

We are determined to raise money for the research that we all so desperately need to stop this illness. Every little bit helps and I truly believe it raises the spirits of those struggling with cancer too. Great things happen when people work together.” ACRF supporters, Gemma & Jimi, Gypsys Gift.

To support Gemma and Jimi, click here.

Hiking Larapinta trail for cancer research

Dan and Ferg take on the Larapinta trail for Australian cancer research“We’re two good friends who went to university together. We have always enjoyed keeping fit, healthy and running together. In the last two years, both of our fathers were diagnosed with cancer. Due to the medical treatment and care available to them, their doctors were able to halt the disease and today they both have the all clear.

We were shocked when Chippa, Dan’s dad, was diagnosed with bowel cancer at the age of 65. He underwent extensive chemotherapy and radiation therapy after having part of his bowel removed. The bowel cancer was cleared but about a year later he was diagnosed with secondary cancer in his liver. He had 60% of his liver removed and underwent more treatment.

Ferg’s dad, Ian, was diagnosed with prostate cancer at the age of 68. He underwent hormone treatment and had his prostate removed. He is now clear of cancer. It was Ian who introduced Ferg to running when he was eight and has been the main driver behind his passion for running.

Our dads’ experiences with cancer have really taught us about both the value and fragility of life. As a boy and young man you feel like your father is invincible and then you realise he’s not. As fathers ourselves, we could easily follow in their footsteps so it makes us feel a bit vulnerable. The key lesson we’ve learnt is to do what you want to do now – don’t wait for tomorrow as there may not be one.

We are so very grateful to the cancer treatment agencies that we decided to raise funds to continue to improve cancer awareness and treatment.

In mid-August, we covered 88 km of the Larapinta Trail in the MacDonnell Ranges near Alice Springs. Larapinta is a landmark Aussie trail that gave us the chance to connect with and experience Australia as it is and was.

The trail is off-road, hot and dusty. The tough trail running took us completely out of our comfort zone but we were up for the challenge. On the second day of the trail, Dan got a knee injury which meant we had to slow down to a walk. It was a very tough day but the conversation that we had over the nine-hour journey was a true highlight. We were two good mates, just turned forty, trying to solve the problems of the world!

We believe that no one’s loved ones should die from cancer. Cancer affects so many people in Australia and worldwide. It’s a disease that is so destructive and attacks your body slowly. The more we can support research, the better chance we have to minimise the impact it has.

We chose to support ACRF because they are a foundation that is committed to treating all types of cancer and making a difference to people’s lives. Everyone has a story about cancer. We all know a loved one that has been impacted by it, we want others to get on board and help researchers find better forms of treatment.” Dan and Ferg

Share your story Fundraise for cancer research

Removing a protein and enzyme pair can improve cancer treatment

Removing a protein and enzyme pair can improve cancer treatment

Australian cancer researchers at QIMR Berghofer in Brisbane have found that removing a particular enzyme and protein from the immune system significantly reduces the spread of breast cancer and melanoma.

The enzyme and protein are related to adenosine which is an immunosuppressive molecule that promotes the growth and spread of tumours by sending a message to certain immune cells. This inhibits the immune cells’ ability to kill cancer cells.

The research team at QIMR Berghofer set out to find the best way to stop adenosine from promoting the growth and spread of cancers.

Researcher Arabella Young said they tested this by inhibiting the enzyme that makes adenosine (CD73) and the protein that receives its messages (the A2A receptor) separately and in combination.

“During our laboratory experiments, targeting the enzyme CD73 and the A2A receptor separately slowed the growth and spread of breast cancer and melanoma,” Ms Young said.

“But when we removed the function of both at the same time, it had a more powerful effect, inhibiting the growth and significantly reducing the spread of the cancers.

“In some of our experiments, removing both CD73 and the A2A receptor eliminated the melanomas altogether.”

A treatment targeting the A2A receptor is currently in clinical trials. Study leader, Professor Mark Smyth said the Institute’s collaborators at MedImmune had developed another immunotherapy treatment to block CD73 in solid tumours, which is also in clinical trials.

“Up until now, it was believed that targeting each one individually may have the same effect as targeting the two together, but our results have shown otherwise.”

“Removing the enzyme CD73 stops adenosine from being produced and inhibiting the A2A receptor stops adenosine’s message from getting through,” Professor Smyth said.

“This is the first time that anyone looked at the effect of targeting CD73 and the A2A receptor together.”

“Our findings suggest that targeting both would lead to better results for patients.

“We hope that these findings will in future lead to better treatments for a number of cancers, particularly those with high levels of CD73 and adenosine within the tumour, including triple negative breast cancer, high-grade serous ovarian cancer and melanoma.”

The study was led by QIMR Berghofer Medical Research Institute in collaboration with MedImmune. It has been published in the journal Cancer Cell.

The original news article was published on the QIMR Berghof website.

The Australian Cancer Research Foundation has supported cancer research at QIMR Berghofer by providing three grants, totalling AUD$ 6.65 M, for the purchase of cutting-edge cancer research equipment and technology.

New method to tackle hard to treat breast cancers

Supporting cancer research in AustraliaResearchers at the Harry Perkins Institute of Medical Research have developed a new method to tackle triple negative breast cancer. It is an aggressive form of cancer with few treatment options.

Triple negative breast cancer can become highly resistant to chemotherapy and patients often relapse after remission. The new study has found that chemotherapy resistance is linked to a DNA-altering protein, which is found in two places in the body, the brain and the breast. In the brain the protein works to protect neurons from damage, warding off brain cell death that could lead to Parkinson’s Disease. In breast tissue, the protein triggers cancer cell growth, spread and chemotherapy resistance.

Study leader Dr Anabel Sorolla said nanoparticles developed by her team have been shown to be more effective than those currently used to treat patients. They work by blocking the DNA-altering protein and delivering chemotherapy drugs directly to the tumour, while also making the cancer cells more susceptible to chemotherapy.

“We have found that our nanoparticles only trigger cell death in this highly aggressive form of breast cancer, not in healthy cells,” Dr Sorolla said.

The team is currently testing a targeting molecule that functions like a GPS navigator and sends the nanoparticles straight to the tumour site.

“On the whole, when we combine existing anticancer drugs with our nanoparticles we can greatly reduce the dose of chemotherapy needed, with better results and less side effects,” Dr Sorrolla concluded.

This news post was originally posted on the Harry Perkins website.

More than one in every ten breast cancers are found to be triple negative. You can find out more about all types of breast cancer and breast cancer signs and symptoms on the dedicated www.breast.cancerresearch site managed by the Australian Cancer Research Foundation (ACRF).

ACRF has supported cancer research at the Perkins by providing two grants, totalling AUD $3.6 million, towards cutting edge cancer research equipment and technology.

Fast facts about the most common men’s cancers in Australia

Supporting cancer research in Australia

There are over 200 types of cancer that can affect men. Prostate, bowel, melanoma and lung cancer are the most common types of cancers in Australian men. It is estimated that over 74,000 Australian men will be diagnosed with cancer this year.

Today is the last day of September, a month where we focus on the impact that cancer has on Australian men, their families and friends. To raise awareness of the most common cancers affecting Australian men, we’ve compiled a few interesting statistics:

Prostate cancer statistics

  • Prostate cancer is the most common cancer diagnosed in Australian men.
  • The risk of developing prostate cancer before the age of 85 is 1 in 5.
  • The five-year survival rate is 92 percent.

Bowel cancer statistics

  • In 2009, the risk of developing bowel cancer before the age of 85 was 1 in 12.
  • The five-year survival rate for bowel cancer is 66.2 percent.
  • Bowel cancer is considered one of the most treatable cancers, if detected early, however, it remains the third highest cancer killer in men.

Skin cancer and melanoma statistics

  • From 1982 to 2010 melanoma diagnoses increased by around 60%.
  • In 2011, 2087 people died from skin cancer in Australia. The majority of these deaths were due to melanoma, with 1544 deaths from melanoma that year, compared with 543 deaths from non-melanoma skin cancers.
  • More than 374,000 Australians annually are diagnosed with basal cell and squamous cell carcinoma. Melanoma incidence in Australia and New Zealand is four times higher than in Canada, UK and US.
  • Melanoma is the most common cancer in young Australians aged 15–39 years old.

Lung cancer statistics

  • In 2009, lung cancer was the 5th most commonly diagnosed cancer in Australia.
  • Lung cancer is most commonly diagnosed in people aged 65-79.
  • In 2010, lung cancer was the most common cause of cancer death for men.
  • The five-year survival rate for lung cancer is 14.1 percent.

Donate Now To Help Outsmart Men’s Cancers

These aren’t the only cancers affecting Australian men, just a few of over 200Right now, one in two men will be diagnosed with cancer before the age 85 — you can change this.

When you donate to the Australian Cancer Research Foundation (ACRF), you are providing critical support, which provides world-class scientists with equipment to pursue their research initiatives. We award grants to projects with the power to improve prevention, detection and treatment of all types of cancer.

Together we can make these statistics history and outsmart cancer for good.

Supporting Australian cancer research in honour of my dad

Wedding donations to support Australian cancer research

“Two weeks ago my father died of cancer. He had fought for 3 long years – had 18 months in remission, and then was struck down again recently with another form of cancer. In 2012 he was diagnosed with a Birkett’s Lymphoma. We got told that the lymphoma was rare, which was followed with the phrase we treat “600 to 700” a year. To a bystander that doesn’t seem rare.

The reality is, when you stop and think, you realise not a single person goes through life without being impacted by cancer – either through a friend, family or having it themselves. My husband and I also have a dear friend whose son has a rare form of cancer and needs treatments every second week. And another friend has been diagnosed with breast cancer.

I found out my father had relapsed the day after my wedding. That was 16 July 2016. He went into hospital on the 18th. He had a few trips in and out of hospital in the past few months but these times he would end up in ICU. This battle was harder. The treatment had taken its toll on other organs. My father was brave until the end. But his battle is now over and he has found his peace.

It was important to us to have an option for people to support cancer research on our wedding registry. We have everything we need. All we want for our lives and the lives of our friends and family is love, health and happiness. We can do what we can to show love and help with happiness but we need to support research into cancer to get closer to cures – the health bit. In my lifetime I would love to see an end to at least one of the major killers but my selfish reality is that I want to see all of them cured. If 600 to 700 people being affected is rare – I want it to be even rarer!

Wedding donations to support Australian cancer research

Cancer is awful and it is everywhere. There are really smart people working to end it and to help make life better for those who are suffering from it. Cancer took my father too soon, as a result it is my number one enemy. My husband, my family and I are all committed to doing what we can to support cancer research going forward.

I also want to make a special mention of the amazing nurses who cared for my father at the Mater Hospital in Brisbane. Those men and women never left him alone, they cared for him, they laughed with him, they held his hand and they gave him his dignity. They also cared for us in his final days as we sat with him. There was an unbelievable warmth in the hugs I received from those people. They have a special place in our hearts.

I have included a photo of my dad and I after he gave his speech as well as my mum, dad and I before the wedding (the supporters need to be praised too – mum deals with it 24/7 as well).” – Zoë Robinson, ACRF supporter

Thank you to Zoë for supporting cancer research in lieu of gifts on your special day. With many modern couples accumulating their house-hold goods before they tie the knot, wedding donations to cancer research are becoming an increasingly popular option for both guests and the happy couple. Whether you wish to replace traditional gifts with a wedding donation, or replace a favour in the same way, all funds received by the ACRF in celebration of your wedding will help fund new and better treatments for cancer. Click here to learn more.

Share your story

Targeting telomerase for new cancer treatments

Australian cancer researcher at Drug Discovery CentreRecent advances in drug discovery technology and molecular studies could help scientists develop a suite of potential drugs that target telomerase – the enzyme that controls the number of times a cell divides before stopping.

Dr Greg Arndt and Dr Karen MacKenzie from the Children’s Cancer Institute (CCI) say cancer researchers around the world are searching for safe, effective anti-cancer drugs that kill rapidly growing cancer cells but leave normal cells alone. MacKenzie, Senior Scientist in Personalised Medicine, says this is especially challenging for childhood cancer as children are themselves rapidly growing.

Telomerase is disrupted in cancer and makes cancer cells divide out of control. It is located at the ends of chromosomes, in the telomeres, which shorten with each cell division.

“We’ve known for more than 20 years that telomerase helps cancer cells achieve immortality, but we still don’t have a safe, effective drug on the market that inhibits it, said Dr Arndt, Manager of the ACRF Drug Discovery Centre at CCI.

In their review paper, Drs Arndt and MacKenzie distil current knowledge about telomerase and argue that, with the increased rapidity and sensitivity of today’s molecular analysis technologies, researchers should explore new approaches. They say that targeting telomerase beyond its usual role in the telomere could be the key to finding the next generation of small-molecule telomerase inhibitors.

Dr Arndt says automation of drug testing means it takes days rather than years to test thousands of chemical compounds against normal and cancer cells.

“We have technologies now that weren’t available when telomerase was first studied. These allow us to explore it in more detail than ever.

“We can bring new knowledge in cell biology and drug discovery together and speed up the search for new therapeutics”, Dr Arndt said.

Protein components of telomerase reveal new treatment targets

Looking beyond the telomere is an approach Arndt and MacKenzie have some success with. In April the researchers published in the journal Cancer Research some exciting findings showing that targeting dyskerin, one of the protein components of telomerase, rapidly kills neuroblastoma cells but in an unexpected way.

MacKenzie said neuroblastoma is a cancer responsible for 15% of Australian childhood cancer deaths.

“We found that, without dyskerin, neuroblastoma cells stopped dividing and died in days, most likely because dyskerin has roles beyond the telomere. Without dyskerin, the protein-building machinery falls apart and the cell dies – an effect that is independent of the telomere” she said.

This intriguing result could have implications in the search for drugs that target dyskerin in other adult and childhood cancers. The next step is to find chemical compounds that target the protein using drug discovery technology for potential use in personalised medicine.

The ACRF Drug Discovery Centre at Children’s Cancer Institute screens many thousands of novel chemicals to identify potential new drugs. The Centre also contains high content imaging software that analyses cell changes and 3D computer models of molecules. It was established with the help of a $3.1 million seed-funding grant from the Australian Cancer Research Foundation in 2009.

The original news was posted on the CCI website. Image of Dr Arndt courtesy of CCI.

Australian cancer researchers develop ‘smart glove’ to reduce need for follow up breast cancer surgery

Australian cancer researchers at the Harry Perkins Institute of Medical Research in Perth.

Thousands of breast cancer patients might be spared a second surgery thanks to innovative technology developed by researchers at the Harry Perkins Institute of Medical Research in Perth.

Up to one in four women undergoing surgery to remove breast cancers will have to return to the operating theatre within weeks to remove further tissue, as small traces of tumour can be left behind.

Currently, surgeons use their finger to distinguish the edge of the tumour because cancerous tissue is much harder and stiffer than normal tissue, but this method doesn’t detect tiny cancerous cells which could allow the tumour to regrow.

To solve the challenge, Perkins biomedical engineer, Dr Brendan Kennedy and his team of researchers from the Perkins and the University of Western Australia, have developed the world’s first 3D printed finger-mounted optical imaging probe – a ‘smart surgical glove’.

Dr Kennedy said the probe measures tissue stiffness at a microscopic level using high-resolution imaging, allowing surgeons to detect cancer cells that are too small to see or feel but can continue to grow if left in the breast.

Breast cancer image courtesy of Harry Perkins“The finger can only identify large tumours so the ability to detect cancer at a cellular level is key to ensuring effective removal of the tumour,” Dr Kennedy said.

“The surgeon will be able to run their gloved finger around the edge of the tumour and the super sensitive probe will project an image of what they’re touching on to a high-resolution screen for far better visibility.”

Dr Kennedy is working with surgeons and pathologists in Perth to test the first generation prototype on tissue taken from mastectomies and he believes the glove will be ready to test in surgeries by the end of 2016.

He said the ability to translate research outcomes into patient benefits was fundamental, and he hoped consultations between surgeons and scientists would allow patient outcomes to continuously improve at a faster rate.

Dr Kennedy is developing the glove in association with leading breast surgeon Professor Christobel Saunders and UWA’s Professor David Sampson.

This news article was first posted on the Harry Perkins Institute of Medical Research website. Images of Dr Kennedy and the team as well as of breast tissue courtesy of Perkins.

The Australian Cancer Research Foundation has supported cancer research at the Perkins by providing two grants, totalling AUD $3.6 million, towards cutting edge cancer research equipment and technology.

ProCan™ leads innovative approach to cancer diagnosis and treatment

Cancer researchers at ProCan

Imagine being a parent who is told ‘Your child has cancer.’ For hundreds of Australian parents every year, this is the reality. Every one of them wants to ensure, from the moment of this terrible diagnosis, that the treatment chosen by their child’s doctors will have the best possible chance of success. To this end, a world-first cancer research facility is opening right here in Australia, which aims to improve the precision of cancer diagnosis and treatment.

The ACRF International Centre for the Proteome of Human Cancer, also known as ProCanTM, officially launched at Children’s Medical Research Institute (CMRI) in Sydney today. The goal of ProCan is to transform the way in which cancer is diagnosed and treated.

ProCanTM was established with the help of the Australian Cancer Research Foundation (ACRF)’s 30th  Anniversary grant, awarded in December 2015.

Professor Ian Brown, Chief Executive, Australian Cancer Research Foundation says, “ACRF created the $10 million Anniversary grant to promote bold and significant programs that would facilitate major advances in the prevention, early detection, treatment and management of cancer. It is with great credit to CMRI that an eminent panel of international researchers and clinicians recommended their project as being the most visionary and having the greatest potential impact.”

“ProCan is very simple in concept but massive in scale,” said CMRI Director, Professor Roger Reddel, who is also co-leader of ProCan. “We believe the results of ProCan will greatly improve the speed and accuracy of cancer diagnosis and provide clinicians an enhanced capability to choose the most effective treatment option for each individual patient’s cancer and, importantly, to avoid those treatments that are likely to be unsuccessful. This will reduce treatment toxicity and improve cancer treatment outcomes in children and adults – worldwide.”

Facing cancer is all too familiar to the Catterick family from Canberra. Before he had even turned one, Josh Catterick was battling a disease no child should endure – brain cancer. At four months of age, his mother, Kylie, noticed he wasn’t feeding properly. Doctors discovered a tumour the size of a mandarin. Josh was rushed to hospital in Sydney for treatment, where Kylie was told he may not survive. “I just fell apart,” she said.

ProCan-2Doctors successfully removed the tumour, but the ordeal was far from over. As a result of the tumour, four-year-old Josh has since been diagnosed with cerebral palsy, epilepsy, global communication delay and autism. There’s also the uncertainty of what happens next.

“We are aware there’s a chance the cancer could relapse and take him. But you can’t let that run your life,” Josh’s mother, Kylie, says. “We’re excited about ProCan and want to do all we can to support it and what it could do to help other families facing cancer.”

Over the next 5-7 years, ProCan’s research team will analyse the proteome (the thousands of different proteins created by the genome) in about 70,000 samples of all types of cancer from patients around the world. The new information uncovered will be compared to existing knowledge, including which treatments were effective or ineffective for each individual cancer. The data generated will form an enormous database of information that can be accessed by scientists and clinicians worldwide to enable a better understanding of cancer and speed up the discovery of new cancer treatments.

What’s more, ProCan’s researchers will use this data to develop tools that would provide cancer clinicians, an accurate cancer diagnosis within 24 to 36 hours of analysing a tumour biopsy and also information about the available treatments that have the greatest probability of success for that individual cancer.

ProCan scientists will work in collaboration with technology experts in Zurich, as well as cancer researchers globally to progress this initiative. The specialised equipment required was funded by the Australian Cancer Research Foundation and is operated with support from Cancer Institute NSW.

ProCan recently attracted the attention of US Vice President, Joe Biden, which led to CMRI signing a landmark Memorandum of Understanding with the US National Cancer Institute as part of the Cancer Moonshot initiative. The MOU directly links ProCan with the Cancer Moonshot and will increase collaboration and flow of information between cancer researchers and research organisations, to accelerate the pace of cancer research globally.

“The agreement signed with the White House will ensure that all resources and knowledge gained from the establishment of ProCan are international in focus and affiliation. It is terrific to see ProCan attract additional attention and investment. ACRF is proud to support scientifically sound programs based on bold ideas where the availability of major pieces of state-of-the-art equipment can act as seed funding to be leveraged with the assistance of other important organisations, such as Cancer Institute NSW. This isn’t the first nor do I expect it to be the last time ACRF awards a cancer research project with a grant and witness it grow into an international collaboration,” Professor Brown concluded.

In addition to seed funding from CINSW, in July, the New South Wales Government recognised the work of ProCan and committed $6 million toward a joint proteogenomics research project on childhood and young adult cancers, with the proteomics component to be conducted at CMRI’s ProCan laboratory.

NSW Chief Cancer Officer and CEO of the Cancer Institute NSW, Professor David Currow, said, “This program of work will allow us to better characterise the nature of each cancer, which will in turn lead to more personalised treatments.”

“We’re excited by the international interest and very grateful for the New South Wales Government’s support,” said Professor Phil Robinson, co-leader of ProCan. “The project has a clear goal of using ProCan’s results to develop technologies that will greatly improve the diagnosis and personalised treatment of cancer. For me, as a scientist, what we’ll learn about cancer is equally exciting — the biology of cancer and the control pathways affected in cancer cells — which will lead us in uncharted directions, generating fresh ideas and new discoveries that could help develop new and better treatments. Cancer is just the start. The potential of this technology goes far beyond cancer – we plan to extend this research technology to the study of many other diseases.”

2016 ACRF Charity Golf Day for cancer research

2016 ACRF Charity Golf Day for cancer research

On 6 September 2016, we held our annual ACRF Charity Golf Day at the New South Wales Golf Club in La Perouse.

The NSW Golf Course, situated on the northern headland of historic Botany Bay, is flanked by the cliffs of Henry Head and the prominent headland of Cape Banks.

It has been written that golf had its origins on unique seascapes similar to that of the NSW Golf Club. A course that has been the home of the Australian Open, and counted amongst its members golfing greats such as Greg Norman.

With its undulating fairways and small greens, this course calls for great skill in shot making especially when the sea breezes blow. Lucky for our players, it was a beautifully calm day that gave everyone a chance to participate in some friendly competition for cancer research.

A mix of players with varying golf experience and backgrounds stepped out on the greens for a three-four ball Ambrose, including the Chair of ACRF’s Board Mr Tom Dery, playing with his son Robbie Dery from oOh! Media and ACRF supporters from VAMP and RMS. We even had a pro golfer in our midst, Ms. Annabel Rolley!

We also welcomed very special guests, Dr Darren Saunders and Dr Nigel Turner who are leading Australian cancer researchers at the University of New South Wales.

Congratulations to the winning team this year: Ben, Simon, Tony and Annabel. They took home the team cup, and Annabel won the trophies for longest drive and nearest to pin.

Thank you to everyone who took part. And a special thank you to our Silver Sponsor H&R Block Limited and Drinks Cart Sponsor KSP Stoneloc Flooring for their generous support.

We hope to see you all again next year! Click here to check out the photos from the day.

Robots play major role in tailoring treatment for kids’ high-risk cancers

The new ACRF Child Cancer Personalised Medicine Centre’s specialised robots can now rapidly test hundreds of treatments for kids with high-risk cancers to guide their care..Thanks to a $1.5M grant from the Australian Cancer Research Foundation (ACRF), the new ACRF Child Cancer Personalised Medicine Centre’s specialised robots can now rapidly test hundreds of treatments for kids with high-risk cancers to guide their care.

The robots work 24/7 at Children’s Cancer Institute, in one of only three drug discovery facilities in Australia. Originally designed to develop new drugs, the facility is being put to a new use in the quest to match the safest, most effective drugs to individual cancer patients’ treatment needs. By testing the efficacy of already-approved drugs and their combinations against each child’s unique cancer cells, the robots will help identify those most likely to kill their specific cancer.

The ACRF Child Cancer Personalised Medicine Centre was officially opened today by His Excellency General the Honourable Sir Peter Cosgrove AK MC (Retd), Governor-General of the Commonwealth of Australia and Patron of Children’s Cancer Institute. It houses robotics, libraries of known and clinically-approved drugs, expanded tumour bank facilities, tissue culture and a state-of-the-art laboratory information management system.

The Centre will serve as operational headquarters for the Zero Childhood Cancer program, a national initiative of Children’s Cancer Institute and the Kids Cancer Centre at Sydney Children’s Hospital Randwick. It is one of the most ambitious childhood cancer research initiatives ever undertaken in Australia, to tackle the most serious cases of infant, childhood and adolescent cancer.

Professor Michelle Haber AM, Executive Director of Children’s Cancer Institute, said the need for better treatment options is urgent.

“Every week in Australia, three children die of cancer. When standard treatments fail, these children have few options and little time.

“The ACRF Child Cancer Personalised Medicine Centre is the centrepiece of the most comprehensive program ever assembled in this country to analyse children’s cancers with a suite of tests, including several advanced gene sequencing [or genomic] tests, as well as drug sensitivity tests to better tailor treatment to the child’s individual cancer.

The new ACRF Child Cancer Personalised Medicine Centre’s specialised robots can now rapidly test hundreds of treatments for kids with high-risk cancers to guide their care.“The equipment that ACRF has provided will allow us to rapidly identify targeted treatments to recommend to clinicians in time to guide treatment decisions,” she said.

Over the next four years, the Centre will receive and process hundreds of samples of patients’ tumours from partner children’s hospitals around Australia, will analyse the samples and test them against libraries of drugs approved for a range of adult and child cancers.

The drug-screening data that the robots produce will identify the drugs and drug combinations most likely to be effective in stopping the growth of each individual patient’s cancer cells. This will form part of the reports that will go to clinicians, to guide treatment as part of the national clinical trial of the Zero Childhood Cancer Program which will open next year, led by the Kids Cancer Centre, Sydney Children’s Hospital, Randwick.

Mr Tom Dery AO, Chairman of Australian Cancer Research Foundation said that the growth of this program is a wonderful testament to the work that ACRF supports.

“We are here to challenge researchers and help push bold ideas forward. Being involved in and witnessing programs like Zero Childhood Cancer grow is exactly the sort of thing we hope for when we award funding.”

“Many of the partner research institutes involved in the national initiative have received grants from the Australian Cancer Research Foundation including Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research in NSW; The Peter MacCallum Cancer Centre in VIC; South Australian Health and Medical Research Institute in SA and the University of Queensland Diamantina Institute in QLD,” said Mr Dery.

Professor Ian Brown, CEO of Australian Cancer Research Foundation says, “By funding essential technology in cancer research, our supporters enable institutes like Children’s Cancer Institute to attract the world’s best researchers to Australia, allowing them to carry out their vision of one day curing childhood cancer.”

The grant received from ACRF is also funding expanded tumour bank facilities, improved tissue culture capability, and a state-of-the-art data management system that will link the results of the tests conducted at Children’s Cancer Institute with the clinical data from patients being treated as part of the Zero Childhood Cancer Program at paediatric oncology facilities around the country.

ACRF has supported Children’s Cancer Institute, including the Zero Childhood Cancer Program, by providing three grants, totalling $5.1million, towards cutting edge cancer research equipment and technology.

Supporting Australian cancer research in memory of Craig

Funding cancer research into all cancers that affect men/“My son, Craig, was a fit 27-year-old swim coach when he was diagnosed with a rare type of brain cancer. He had just become a husband and a father when we found out we were going to lose him.

Craig, first met his wife when they were both junior swim coaches. You could really see Craig’s passion shine through when he was coaching. He was so dedicated to his students, he loved helping them succeed.

We had all been on holiday with family in Tasmania when he realised something wasn’t right. As soon as we returned, he sought medical help.

I went in to see him first after the results came in and he broke down with the news that he had cancer. We were both devastated. He tried to hide the seriousness of his diagnosis from me, or perhaps he didn’t know.

Funding cancer research into all cancers that affect men/Craig had just become a husband and a father. His son was only 10 months old. It was hard to believe this was all happening.

The astrocytoma was found at the base of his spine and because of its location, doctors feared surgical removal would cause him to become a paraplegic so they treated it with radiation therapy.

The therapy appeared to be successful in reducing the size of the tumour and he was sent home, but in less than two months he started to experience severe headaches.

At first, the doctors thought the headaches were just a side effect of the radiation treatment but then they did a spinal tap. From this, they discovered fragments of the tumour had travelled through the fluid in the spinal column and attached themselves to his brain.

It was around Christmas time when they were ready to start further radiation treatment and we were told he would not survive. In his final week having lost his sight and the use of his arms and legs, he was still able to joke with his friends who kept him company through his final days.

Funding cancer research into all cancers that affect men/His willpower kept him alive until all his friends and family said goodbye and then he quietly slipped away whilst his young wife slept in the chair beside him.

Craig died just six months after the initial diagnosis. I was touched to see so many of his students at his funeral, it made me proud of the man he’d become. I can see so much of him in his son.”

– ACRF Supporter, Diana

Donate Share your story

 

Celebrating the 10th anniversary of the world’s first cancer vaccine

ianfrazergivesworldsfirstcervicalcancervaccineshotTen years ago, on the 29th August 2006, the very first Human Papillomavirus (HPV) vaccine was administered in Australia.

HPV vaccines protect against 70% of cervical cancers in women and 90% of all HPV-related cancers in men, which include certain types of head and neck cancers and various cancers of the genital tract.

To date, over 187 million doses of HPV vaccines have been administered across more than 130 different countries. This has helped to halve the number of new cases of cervical cancer in women.

In 1999 the Australian Cancer Research Foundation (ACRF), awarded a $1 million grant for vital equipment that would help advance Professor Ian Frazer’s research into HPV and its role in causing cervical cancer. This funding enabled Professor Frazer’s research team at the Diamantina Institute in Queensland to achieve a breakthrough discovery and attract more funding to develop the HPV vaccine.

Professor Ian Brown, CEO of Australian Cancer Research Foundation says, “Donations to the ACRF fund essential technology for cancer research. The foundation exists to challenge researchers and help push brave ideas forward.

Over the years this has enabled research teams like Professor Ian Frazer’s at the Diamantina Institute to attract the world’s best researchers to Australia and allowed them to explore novel and potentially game changing ideas. Witnessing these types of life-saving outcomes is exactly the sort of thing we hope for when we award funding.”

Australia was one of the first countries to approve the use of the vaccine for Australian boys via school-based programs, with all students aged 12-13 now receiving the vaccine under the National Immunisation Program.

“Being parents to two young boys aged nine and four, my wife and I were so heartened to read that our boys were to receive the vaccine. We thought it was such wonderful news that our kids and many others would be given such a great start in life, and hopefully be free from fear of this horrible disease.” Norman Elias, ACRF fundraiser.

The HPV vaccine was co-created by the Chairman of the Australian Cancer Research Foundation’s Medical Research Advisory Committee, Professor Ian Frazer.

Professor Frazer says, “Observations from over the past ten years are that the HPV vaccines, if delivered effectively to the majority of 10-12 year old girls in the developing world from today forward, should lead to the global elimination of new cervical and other HPV associated cancers by 2050.”

Professor Brown concludes, “It takes an immense amount of collaboration on a global scale to achieve feats such as this but it’s the people that support ACRF and foundations like it that fuel this type of positive change in the world.”

What To Get Dad: DONATE A GIFT TO CANCER RESEARCH ON FATHER’S DAY

Father-and-Daughter-picture-300x199

With Father’s Day just around the corner, we all will be thinking about what to get Dad and how to show Dad that we care. Rather than filling his cupboard with more unwanted gifts like socks, jocks and ‘World’s Greatest Dad’ mugs, why not donate in his name to cancer research?

Why Donate a Gift to Cancer Research on Father’s Day?

September is the month where we raise awareness for the most common cancers affecting Australian men. 1 in 5 men will develop prostate cancer before the age of 85, and the five year survival rate for bowel cancer in men is 66.2 percent. This means now, more than ever, we need to support researchers who are working to outsmart cancers affecting men.

It’s also the month where we celebrate one of the most important men in our lives on Father’s Day. If you’re stuck for what to buy for Dad, donations to charity are a meaningful gift, particularly if someone he knows has been affected by cancer.

When you make a donation to cancer research in place of a gift you’ll be helping speed up cancer research discoveries and bring new hope for the future. What better way to make Dad feel really special this Father’s Day than for him to know that you’ve donated in his honour to fund world-class research into ending cancer!

What can you do with Dad to Fundraise for Men’s Cancer Month?

One of the best gifts you can give to Dad is your time. Organising a fundraiser with Dad can be a great Father’s Day bonding activity. If you and Dad would like to fundraise for Men’s Cancer Month, but aren’t quite sure how to get started, then we’ve got some ideas for you to make a difference:

  • Dinner Party: Organise a dinner party where all the Dad’s in the family give up Father’s Day privileges and prepare dinner for the guests. Attendees need to make a minimum donation set by the hosts.
  • Garage Sale: Make room for new Father’s Day gifts by selling unwanted items to the community and donating the profits to cancer research.
  • Golf Tournament: Is Dad or Grandpa skilled on the green? Organise a golf tournament and ask participants for a small donation.
  • Quiz Night: If Dad isn’t so savvy with a golf club, perhaps a trivia card is more his forte. Host a trivia night and ask for a small donation from each team of players.
  • Walk to Outsmart Cancer: If you would prefer one on one time with Dad, trek to an exciting destination this Father’s Day.

Never doubt the impact even a small donation can have. You can help researchers make new ground on their projects, and improve the technology which detects, diagnoses and treats all types of cancer.

Support Cancer Research at your Father’s Day Lunch

If you and your family are throwing a party or holding a lunch for Dad this Father’s Day, why not turn the affair into a fundraising activity the whole family can participate in. It’ll make the day a fun and memorable experience for all involved.

Honour Dad, Grandpa and other men in the family with these easy to execute fundraising ideas:

  • Swear Jar: Is there a relative or two who are a little loose on the lips? For larger gatherings, use a swear jar to raise money for cancer research, and give Dad’s ears a break (assuming he’s not the culprit!).
  • Headshave: Symbolically remove your hair and encourage others in the family to do the same. This gesture makes a statement of love for someone you or Dad knows who’s been affected by cancer.
  • BBQ and Raffle: Make the event itself a charity fundraiser! Extend the invitation to your friends and neighbours and hold a raffle in support of cancer research.

Whether your donation is in lieu of a gift, or you choose to host a fundraising event, Dad will appreciate the meaningful gesture this Father’s Day.

DONATE NOW GET INVOLVED

First 3D map of cell-building protein linked to cancer

Cancer researchers at Walter and Eliza Hall Institute (WEHI) and Olivia Newton-John Cancer Research Institute in MelbourneAustralian cancer researchers at Walter and Eliza Hall Institute (WEHI) and Olivia Newton-John Cancer Research Institute in Melbourne have revealed for the first time a three-dimensional molecular ‘map’ of a protein that has been pinpointed as a driver of many types of cancers.

The unprecedented view of the protein doublecortin kinase like domain 1 (DCLK1) could provide clues to how it contributes to cancer formation and progression. This could lead to new cancer treatments in the future.

DCLK1 is a protein that assembles scaffolds within cells called microtubules. These rope-like structures give cells shape, enable movement and cell division, and are crucial in enabling the growth and spread of cancer cells. More than one in 10 stomach cancers have defective forms of DCLK1, which have also been found in kidney, rectal and pancreatic cancers.

The research team used the Australian Synchrotron to reveal the three-dimensional structure of a part of DCLK1 known as the ‘kinase domain’. They were able to pinpoint the parts of DCLK1 that can go wrong in cancer cells, providing new information about how the protein functions.

Dr Isabelle Lucet at WEHI said in healthy cells, DCLK1 can control its own function, ensuring it only assembles microtubules at the right time.

“We can think of the kinase domain of DCLK being an inbuilt controlling unit. The kinase domain sits separately from the part of the protein that assembles microtubules, and can switch microtubule assembly on or off as needed.”

“The complexity of having these two different components in one protein has, until now, hindered our understanding of how DCLK1 functions normally and what goes wrong in cancer. We decided to focus on just the regulatory kinase domain of DCLK1, because we knew that this is the part of DCLK1 that is often altered in cancers,” Dr Lucet said.

Dr Onisha Patel at WEHI said the team created a detailed map of the DCLK1 kinase domain using the Australian Synchrotron, providing new information about how the part of the protein functioned.

“By looking at the structure of the kinase domain at the atomic level, we can now understand the effect of cancer-associated mutations located in this region,” she said.

“These mutations can lead to a non-stop microtubule building by DCLK1, and consequently chaotic cell division that is a hallmark of cancer.”

“The protein structure we have generated allows us to pinpoint a crucial three-dimensional pocket within DCLK1. We hope this will provide a first step towards designing a drug that will precisely target DCLK1, and prevent it from driving cancer growth. Similar protein structures have been used to design anti-cancer agents that are now in clinical use, so we’re hopeful that our research may have similar applications into the future,” Dr Patel said.

The Australian Cancer Research Foundation has supported WEHI by providing three grants, totalling AUD $5.5million, towards cutting edge cancer research equipment and technology.

The research was recently published in the journal Structure.This news article was first published on the WEHI website. Image of the research team courtesy of WEHI.

Supporting cancer research in Australia in memory of my mother

Australian Cancer Research Foundation supporter Margaret gives moonthly donations to support cancer research in Australia“Like most families, mine too has been touched by cancer. I lost my brother-in-law when he was just 49 years old to cancer and recently lost my mother to it as well.

My mother was a very strong person. I admired how she lived her life and faced cancer. In December 1993, she was diagnosed with non-Hodgkin lymphoma. It was very aggressive so it required treatment with both chemotherapy and radiation. A doctor at the time asked her how she thought she would handle the treatment. She replied: “You don’t know what you are made of until you face something like this but I’ll give it my best shot”, and that she did.

After some setbacks, she went into remission two years later. But as many who have experienced cancer in their life know all too well, it doesn’t stop there. It means that you are now on the ‘cancer merry-go-round’ of endless check-ups, blood tests and trips to various doctors and oncologists. She did this for the next 22 years and during these years she enjoyed life to the fullest and felt very blessed.

The aggressive treatment came at a cost though and in more recent years she began to suffer the long-term effects of radiation treatment.

The diagnosis of oesophageal cancer in February 2015 was devastating but she faced it with hope and determination. Twenty radiation treatments and other surgeries were to follow. A further diagnosis in early September revealed that cancer had spread and she made the very difficult decision to not continue with treatment. She had indeed given it her best shot but sadly passed away on 15 September 2015.

From palliative care, during her final days, she began to plan her funeral – hymns, flowers and of course donations to the Australian Cancer Research Foundation (ACRF) which she had supported for many years in memory of my brother-in-law. Like many others, she wanted to help end cancer.

Australian Cancer Research Foundation supporter Margaret gives moonthly donations to support cancer research in AustraliaI am extremely grateful we had an extra 22 years with my mother. I am grateful she got to see her five children grow into adults and spend time with her nine grandchildren. I am grateful she got to see the arrival of three of her great-grandchildren. But what I would be most grateful for is a cure and that’s why I support cancer research in Australia with regular monthly donations to ACRF. They are an Australian charity that focuses on funding research with the best possible outcomes for patients.”  Regular Giver of the Month, Margaret Bible.

We would like to thank Margaret for her ongoing support of cancer research. Regular charity donations provide a stable and supportive future for Australia’s best cancer researchers. We are incredibly grateful for her support.

Learn more about becoming a regular giver.

Share your story

 

Australian cancer researchers discover fats and cholesterol are linked to aggressive cancers

Cancer researcher breakthroughs supported by Australian Charity ACRF

Research has revealed how fats – including cholesterol – could increase the progression of aggressive cancers.

Study leader, Associate Professor Michelle Hill at University of Queensland’s Diamantina Institute, said the findings offered potential new treatment strategies and targets.

“Our previous research showed a high cholesterol diet increased the spread of prostate cancer tumours to lymph nodes, lungs and bones,” Dr Hill said.

“The new study has extended the results to melanoma, breast, ovarian and kidney cancers by analysing published data sets.”

Dr Hill said cholesterol and other fats were essential components of cell membranes, and played a role in regulating processes such as cell migration and division.

“Cholesterol makes specialised membrane regions which are important regulators of cell function, and our laboratory has been investigating how these membrane regions increase cancer progression,” Dr Hill said.

“By comparing data published by other research groups using melanoma, breast and kidney cancer models, we were able to identify common mechanisms associated with increased cancer progression.

“Interestingly, the amount of cytoskeleton (cell skeleton) proteins at the cholesterol membranes are elevated in more aggressive cancers in all models.”

The cytoskeleton is a network of fibres connecting parts of the cell, which plays an important role in structural integrity.

“Some chemotherapy drugs work on breaking up the cytoskeleton, notably the taxane family of drugs including docetaxel.

“Because of its importance in all cells, targeting the cytoskeleton leads to toxicities and side effects for patients.

“If we can identify a specific cancer-associated change in cytoskeleton, then more specific therapies could be designed to kill cancer without affecting normal cells.”

Dr Hill said the group’s previous study on prostate cancer had revealed a reduction in the cytoskeleton-cholesterol membrane link when a gene that suppresses tumour growth was activated.

“When we tested a completely unrelated tumour suppressor gene in an ovarian cancer cell model, we again found a correlation between reduction of cytoskeleton-cholesterol membrane linkage and cancer properties.”

The team will now follow up on the specific molecules responsible for increasing cytoskeleton-cholesterol membrane linkage in cancer.

Dr Hill said the research reinforces the importance of cancer patients maintaining low cholesterol levels, in consultation with their clinicians. The study has been published in the Journal of Proteome Research.

The original news article was published on the University of Queensland’s website. Image of Associate Professor Hill courtesy of Diamantina Institute.

The Australian Cancer Research Foundation has supported cancer research at Diamantina Institute by providing three grants, totalling AUD $6.2 M, towards cutting edge cancer research equipment and technology.

$5M cancer research grant helps beat melanoma

WIMRThe Westmead health precinct’s world-leading expertise in the analysis and treatment of melanomahas been boosted by the new, $5 million, Australian Cancer Research Foundation (ACRF) Melanoma Laboratories at The Westmead Institute for Medical Research.

Speaking at the official opening of the laboratories in Sydney today, the Institute’s co-director of cancer research, Professor Graham Mann, said that thanks to the generosity of many Australians, melanoma researchers and clinicians working at The Westmead Institute are becoming global leaders in skin cancer research.

To date, researchers at the ACRF Melanoma Laboratories have helped discover the first gene that causes a high risk of melanoma. Professor Mann’s team then went on to discover most of the 20 gene variations identified to date that, together with sun exposure, determine melanoma risk in the community.

The ACRF-funded facilities enable data and tissue samples provided by Westmead melanoma patients to be part of the largest melanoma research biobank collections in the world, in partnership with Melanoma Institute Australia.

These tumour samples help to drive efforts to understand why treatments work or don’t work, and to provide the means for the discovery of the next generation of effective therapies.

The Westmead Institute is at the forefront of translational melanoma research and has been involved in the very first trials in the world of the new generation of mutation targeted therapy and immune checkpoint inhibitor drugs. The outcomes of these trials have brought new hope to melanoma patients in recent years.

“Translational research aims to close the gap between basic research and clinical application. In recent years ACRF has had the privilege to support this kind of visionary work that we are confident it will play a major part in facilitating a pathway from medical discovery to improved health,” said Professor Ian Brown CEO, Australian Cancer Research Foundation.

“The grant from the Australian Cancer Research Foundation allowed us to hard-wire melanoma research and its translation into clinical care at the Westmead campus. And it has created an attractive environment that continues to bring the best cancer researchers to work on melanoma at Westmead,” said Professor Mann.

Professor Mann continued that the next challenge is to identify and understand the many genetic variations of melanoma and why they result in different treatment responses in individual patients.

“We are increasingly confident that the drugs we are using now are benefiting most people, even with extensive melanoma. It’s exciting to have made this exceptional progress,” said Professor Mann.

“But we still need more options because existing treatments don’t work on everyone; and we need smarter testing so that we can quickly identify which drug is more likely to work for a particular patient. There is a way to go yet, but we are determined to make melanoma a treatable disease for everyone. State of the art labs like the ACRF Melanoma Laboratories at The Westmead Institute are what will get us there,” concluded Professor Mann.

A further practical outcome of the team’s research has been the ground breaking discovery that artificial sunbeds were boosting melanoma rates in Australia, especially in young people. As a result, the NSW Government instigated bans on the use of commercial solaria which are now replicated around Australia.

Tea is for tomorrow: Creating a better future for cancer patients one drop at a time

Australian cancer research charity fundraising

“Since a young age, I have believed in making a difference and leaving my mark on the world. While I am a teacher by trade I also indulge in my love for tea, homeware and anything floral through my side business, Amity Created. To marry my two passions, I decided to host a tea to raise funds for Australian charity.

In the past few years, I have noticed an increase in those around me being touched by cancer. A lot of my close friends and family have been affected by this disease in one way or another. My grandparents and my close friend’s relatives have all been struck in the past few years with different types of cancer. While I can’t speak on their behalf, I think it’s safe to say that the diagnosis really changed their lives.

My Nonna (grandmother) is in the midst of a long battle with cancer and unfortunately is not able to have much treatment. When she was first diagnosed I made it my main interest to align myself with the Australian Cancer Research Foundation and start raising much-needed funds.

In the spirit of Amity Created, I decided to host a beautiful fundraising event called ‘Tea is for Tomorrow’. It’s a garden tea party where attendees can expect to meet fabulous new people, indulge in delicious treats and of course drink some amazing tea. They’ll even walk away with some goodies. All this, whilst supporting the best cancer research in Australia.

I believe that without the support of the wider community, cancer research would simply not continue. It is important we band together to make sure that cancer researchers can develop effective new ways to prevent, detect and treat cancers for us and the next generation.

To me, there is nothing more gut-wrenching than hearing the news that a loved one has been affected by such an illness. Personally, it made me reflect on moments with my family – past and present. I knew I had to do something to help make a difference and ensure that future generations will not be affected in such a devastating way.

I encourage people to research the efforts of the ACRF and to acknowledge their hard work. While I was doing my research into Australian charities that support cancer research, I found ACRF and felt that their supporter’s contribution to treatments and preventions had been enormous. I wanted to be a part of that because I believe that together we can help researchers make further treatments available so fewer lives will be lost to cancer. To others thinking about supporting cancer research I would tell them to absolutely go for it! If you are not able to attend fundraisers, there are so many creative and fun ways to raise money with those around you.” ACRF supporter, Daniella Libri

Thank you to Daniella for hosting such an exciting event for cancer research. Tea is for Tomorrow was on Wetherill Park, NSW.

New drug class gives hope for better treatments for incurable myeloma

Cancer researchers have discovered that a new class of anti-cancer agents may be effective in treating multiple myeloma.Cancer researchers in Melbourne have discovered that a new class of anti-cancer agents may be effective in treating multiple myeloma.

The research revealed that the majority of myelomas rely on a protein called MCL-1 to stay alive. Potential drugs that inhibit MCL-1 are in pre-clinical development and may become a promising new treatment for multiple myeloma.

Each year more than 1,700 Australians are diagnosed with multiple myeloma, which is a cancer of immune cells called plasma cells. Currently, the treatments are only able to halt the progression of the disease and relieve symptoms, but cannot cure the disease.

Researchers at Walter and Eliza Hall Institute (WEHI), Australian Centre for Blood Diseases, Monash University and the Alfred Hospital investigated the ‘survival proteins’ that keep myeloma cells alive, allowing the cancer to persist.

The survival of many cancer types relies on a family of related survival proteins called BCL-2 family proteins, Professor David Huang at WEHI said.

“In the past decade there has been considerable interest in the using anti-cancer agents called ‘BH3-mimetics’ to kill cancer cells by blocking the BCL-2 family proteins.”

“Recent clinical trials have demonstrated that a BH3-mimetic that switches off the protein BCL-2 is an effective treatment for certain forms of leukaemia.”

“Our latest research has focused on which BH3-mimetics would be the most effective in treating multiple myeloma, a cancer for which new treatments are urgently needed,” Professor Huang said.

Dr Jianan Gong at WEHI said the team discovered that the majority of myeloma samples died when MCL-1 was switched off.

“In contrast, only around one-quarter were susceptible to inhibiting BCL-2. This finding is in keeping with earlier research at the Walter and Eliza Hall Institute that pinpointed MCL-1 as the likely protein that keeps myeloma cells alive.”

“Our research shows that switching off MCL-1 has the potential to be effective new treatment approach for the majority of patients with myeloma,” Dr Gong said.

Professor Andrew Roberts at WEHI said that there had been considerable interest in developing anti-cancer agents that target MCL-1.

“As yet, these inhibitors are still in pre-clinical development,” he said.

“Our results suggest that, once necessary laboratory testing for safety is completed, clinical trials of their effectiveness in treating patients with multiple myeloma that is no longer responding to current therapies would be well justified.”

The Australian Cancer Research Foundation has supported WEHI by providing three grants, totalling AUD $5.5million, towards cutting edge cancer research equipment and technology.

The research was published in the journal Blood. The original news article was posted on the WEHI website. Image courtesy of WEHI, (L-R) Professor David Huang, Dr Jianan Gong, Dr David Segal, Ms Yuan Yao and Professor Andrew Roberts.

Light and Love: White Empathy Candles supports cancer research

To honour her mother, Megan and Ryan from White Empathy candles donates to cancer research in Australia“Our business, White Empathy Candles, emerged out of a desire to create something in honour of my mum, Carol, who passed away last year from a very rare form of cancer, says Megan. “My husband, Ryan, and I were inspired by the incredible impact the latest medical treatments had on my mum’s battle with cancer. She was given three months to live but thanks to new treatments she stayed with us for over 15 months longer.

We were also encouraged by the hundreds of messages of ‘Light & Love’ that Mum’s family and friends posted on a blog that we created for her whilst she was sick. People often found it hard to know what to say when Mum was going through such a tough battle with cancer. The mantra of wishing her ‘Light & Love’ became an easy way for people to post their love and support when many couldn’t find the right words to show how much they cared. Together, we would often light a candle and read all the beautiful messages posted on her blog.

This is how White Empathy Candles was born. Every box has the message ‘Because sometimes words don’t seem enough, a gift for you of Light & Love’ and we make a donation towards medical research into major illnesses such as cancer. Candles are not only beautiful but as a gift, they are more enduring than flowers so we felt they were the perfect fundraising vessel to support charities focused on medical research.

Our ultimate goal for the business is to raise to $1m for charity in honour of Mum by her 10 year anniversary.

To honour her mother, Megan from White Empathy candles donates to cancer research in AustraliaMum was an incredibly generous and loving woman. She was a nurse and my father is an Orthopaedic Surgeon so we have always been a part of the medical community and very passionate about supporting it, particularly medical research. She was an incredibly devoted wife and mother, I heard so many times growing up people exclaim “your mother is amazing” and “I don’t know how she does it” and it is only now that I am a mother myself, that I understand how truly amazing she was. I could write volumes about her but she really was the epitome of ‘Light & Love’.

Mum was diagnosed with a very rare form of malignant melanocytoma, with tumours in her brain and central nervous system, primarily affecting the meninges. We had doctors from the Mayo Clinic in the US assisting with her treatment because there were very few documented cases of Mum’s cancer.

Cancer was brutal, unfair and really sad but she was incredibly stoic, brave and loving through the whole thing. She had such a strong spirit and fought hard right until the very end – we were often left in awe of her strength.

Mum ended up proving wrong the doctor’s original prognosis on three months largely because of the leading-edge medical treatments that were made available to her. We really believe these treatments, that are the product of the latest medical research, gave us the precious gift of more time.

I lost my best friend and even now, nearly a year later, it can take my breath away that she is gone. I was angry that such a beautiful, generous person had to suffer such a ruthless and relentless disease.

The most constructive way to deal with my grief, so that it doesn’t overwhelm me, is to channel it into something positive in her honour – White Empathy Candles.

This is why I am also so passionate about supporting charities such as ACRF as they provide real hope for a better future through the treatment and potential cure of cancer.

When Mum was sick we saw first-hand what leading edge treatments could do, we would not have had access to them without medical research. I also experienced the false hope that is peddled to those affected by cancer. We tried everything from magnets to alkaline water and a sugar-free diet but the reality is that cancer research is what makes the real difference.

White Empathy candles donate to cancer research in AustraliaCancer will affect every single one of us in some way, whether directly or someone we love. Cancer research and the people who devote their lives and incredible talent to this field are our modern day angels. They are our source of hope, so they deserve our support. Every little bit matters, so give now because you never know what they may save you from in the future.” – ACRF supporters Megan and Ryan O’Donnell

White Empathy Candles is Ryan and Megan’s business. It is Australian owned and operated and the candles are currently only available online. White Empathy Candles offer two beautiful candles: Passionfruit & Citron and Pomegranate & French Vanilla. Upon purchase, the buyer can select one of three charities including Australian Cancer Research Foundation. Click here to visit White Empathy Candles for more information.

Matt sheds his dreads for Australian cancer research charity

Before2When Matt Cools from Canberra approached the Australian Cancer Research Foundation to do a fundraising event, everyone here in the ACRF office was really excited because Matt had amazing hair.

He had been growing his dreadlocks for over ten years – his longest dread measured over 80cm! We couldn’t wait to see the “after” photos from the head shave event that Matt, and his wonderful wife Mel, organised last month.

Matt answered some of our questions about his event and what it was like to brave the shave:

Has anyone close to you ever been touched by cancer?
Yes, I have had close family members affected by breast cancer, stomach cancer and small intestine cancer.

Why did you want to do a head shave as part of your fundraiser?
It just seemed like the right time to cut my dreadlocks, and I was happy to do it for a good cause. But I have my wedding photos with the dreads, so that’s pretty cool.

Can you tell us about the day of the shave? 
I was feeling nervous before the shave, but I was looking forward to seeing all my friends and family that were coming along. We had about 70 people there and it was great catching up with everyone! After the auction winners had cut my dreads off it felt weird running my hands through my hair! I can now feel a breeze on the back of my head!

Why did you decide to support cancer research?
I wanted to help researchers find a cure and better options for early diagnosis.

What would you say to someone thinking about fundraising for cancer research?
It’s not that hard – all I had to do was cut off my hair! I would suggest that you make sure you have someone to help you organise the event so it isn’t too overwhelming. I would like to thank my wife, Mel, for organising the head shave event for me.

Before1 Post Dreadcut The new hubby

ACRF supporters love to brave the shave as a symbolic gesture of hope and solidarity for people with cancer. If you’re interested in fundraising for cancer research by shaving, cutting or colouring your hair, sign up here to give cancer the chop once and for all.

 

 

 

Existing treatment could halt lung cancer progression

Cancer researcher, Professor Brendan JenkinsCancer researchers at Hudson Institute of Medical Research have discovered a potential new way to halt the progress of lung cancer and emphysema, offering new hope to the 15,000 Australians who die from the diseases each year.

The researchers identified that an inflammation causing molecule, Interleukin 6 (IL-6), drives lung cancer and emphysema. They then found that an existing drug, sgp130Fc, has the ability to halt the progression.

The drug is currently in clinical trials for other diseases which develop through a similar mechanism, for example, inflammatory bowel disease. The team now believes the drug has clinical potential in lung cancer and emphysema.

“We were surprised to discover that lung cancer and emphysema are so closely linked when they are such different diseases. Emphysema is characterised by the loss of lung tissue and lung cancer by uncontrolled growth of tissue,” said Project Leader, Professor Brendan Jenkins.

Early detection may be as simple as a blood test

The team also found out that a simple blood test could detect both diseases much earlier. Professor Jenkins’ team is now working with clinical colleagues at Monash Health, led by Professor Philip Bardin, to analyse the blood samples of lung cancer and emphysema patients in the hope of developing an early detection blood test for both diseases.

“By matching blood results to the severity of the disease, we will look to confirm whether a blood test is an effective earlier test for emphysema and lung cancer,” said Professor Bardin.

“Early detection is crucial to effective management and treatment of both diseases. A blood test has the potential to vastly improve survival rates through earlier diagnosis while sgp130Fc has the ability to halt the progression of lung cancer and emphysema,” said Professor Jenkins.

Professor Jenkins is cautiously optimistic about the drug’s potential. Armed with both findings, his team will now also investigate the potential uses for sgp130Fc in the management of lung cancer and emphysema.

“Not every patient with emphysema or lung cancer is a candidate for this drug, but with clinical trials, we can identify which patients would respond to treatment and at which stage of the disease. We believe there’s a real opportunity here to target and treat patients with these lung diseases.”

The study has been published in the prestigious American Journal of Respiratory and Critical Care Medicine.

The Australian Cancer Research Foundation has supported cancer research at Hudson by providing a grant, totalling AUD $1.6 million, towards cutting edge cancer research equipment and technology.

The original post and image were published on the Hudson Institute of Medical Research website.

Sarah and Jemma run Bibbulmun for cancer research in Australia

1ACRF supporters, Jemma Read and her Aunty, Sarah Wiese have just completed the Bibbulmun track to raise money for cancer research in Australia.

In an incredible feat of endurance, commitment and focus, the women covered 1003 kilometres in just 26 days by running 25 back to back marathons. Each day they ran an average of 45km over 6-8 hours. They went up mountains, over bush terrain, and across beaches, often in unforgiving weather conditions.

“Sarah and I have a lot of things in common, but the two main things here are that we are both absolutely nuts and that we both have friends and family that have died from, or are currently fighting breast cancer,” said Jemma.

“I have wanted to run along the Bibbulmun track for a long time, so Jemma and I decided to do this together and at the same time raise some funds for an Australian charity that is focused on cancer research.

We knew it would be quite an undertaking, not only for us but also for our families and friends supporting us and coping without us while we ran. Thank you to all of those people who have helped us out. We have been incredibly lucky that we had an absolutely fabulous crew willing to back us up. They’ve helped feed us, move our gear along the track and set up camp for us every night with a lovely roasting fire to dry out by.

I felt really great during the run; it was a fairly simple routine of good food, plenty of exercise and early nights – a luxury not always easy to find in our normally busy lives.

We have come away really appreciating what a fantastic state Western Australia is to live in. We travelled through one beautiful and diverse national park after another, all linked together by the incredible, well maintained Bibbulmun Track.

2Almost without discussion, we had both decided we wanted to support the Australian Cancer Research Foundation (ACRF) because they are an Australian charity that supports cancer research into all cancers including breast cancer. For me, breast cancer is a young woman‘s disease, it’s what I’m seeing a lot of my peers suffering from whilst they’re in their prime, and they’re in the middle of raising children and building careers. It’s a very difficult time to deal with that sort of thing. And both Jemma and I have got a couple of really close family fighting it at the moment.

Thank you to everyone who supported our journey in so many ways. Thank you to our amazing support crews who looked after us so well, and to those who gave us encouragement along the way – you helped make our journey even more enjoyable and memorable. We are overwhelmed by everyone’s generous donations and are so proud to have raised over $10K for cancer research in Australia,” said Sarah.

ACRF is amazed by the effort that Jemma and Sarah put towards completing this challenge. The money they raised will help provide the best researchers in the country with the tools they need to do lifesaving cancer research.

To learn more about these inspiring women and their trip, watch the great clip below. You can also donate to their fundraising page here.

 

Romina’s dance fundraise for cancer research

photos recording studio

ACRF supporter, Romina Di Sauro is using her passion for dance to raise funds for cancer research.

“I have many years of experience in performing and teaching. I love teaching dance because I am able to express myself and share my knowledge. I’ve been running Romina’s Dance, where we teach all ages from 2-Adults, for 25 years.

To celebrate our anniversary, we’re putting on our very own junior production of Disney’s High School Musical, starring Lukas Wildrok from Justice Crew.

It will be a fantastic show – we’ve got an amazing cast of young talent. We held auditions and more than 100 kids turned up, but only 26 could be selected.

This production was my way of giving our students an opportunity to perform whilst supporting vital cancer research.

All proceeds raised from the show will be donated to the Australian Cancer Research Foundation. Cancer is a health issue close to my heart after I lost my sister cancer last year.

My sister, Daniela (pictured) was only 37 years of age when she was diagnosed with stage 4 stomach cancer. She only managed to live for 4 months after her diagnosis and left behind two young children.

danielaIt’s been extremely hard on our family. We lost her so quickly, at such a young age – it’s devastated all of us.

Whilst organising this production fundraiser, I have felt like my sister is close to me and it has helped to ease the pain a little.

There was nothing that could be done for my sister, but I hope that by supporting cancer research, I can help researchers find better methods of detection, prevention, and treatment that will help others in the future.

The High School Musical JR Production is being held at the National Theatre in Melbourne on 24 July 2016 at 2pm.” – ACRF Supporter, Romina Di Sauro

 

ACRF funded ProCan to be part of the ‘Cancer Moonshot’ initiative

ACRF Procan cancer research facility

 

ACRF International Centre for the Proteome of Human Cancer (ProCan™) at Children’s Medical Research Institute (CMRI) will be part of the ‘Cancer Moonshot’ initiative led by the United States’ Government. The ProCan™ project was included in an agreement announced yesterday by the White House, which links ProCan™ to the ‘Cancer Moonshot’ initiative led by Vice President Joe Biden.

ProCan™ was established with the help of the Australian Cancer Research Foundation’s 30th Anniversary grant, awarded in December 2015.

“The Australian Cancer Research Foundation and its supporters are very proud to have provided the $10 million grant that facilitated the purchase of the equipment essential to the initiation of this ambitious international program,” said Dr Ian Brown, Chief Executive, Australian Cancer Research Foundation.

“ProCan is designed to improve our knowledge of cancer and the treatment of patients. ProCan will be immensely strengthened by the collaboration announced by the US Vice President J Biden with United States researchers and clinicians.”

“The 30th Anniversary Grant for $10 million is something ACRF is very proud of. We knew that a grant of this magnitude would make a real difference, stimulate new ideas and bring us closer to our goal which is to end cancer,” Dr Brown continued.

Using specialised equipment ProCan will analyse about 70,000 cancer samples from all over the world during the next 5-7 years. This will provide a searchable library for researchers and clinicians to enhance our understanding of cancer. It will also provide a means of personalised, precision diagnosis and treatment, giving clinicians the tools they need to decide on the best option for each individual patient.

ProCan has also been awarded a significant grant from the NSW Government. The multi-million-dollar injection from the state government will help fund crucial ‘big data’ analysis infrastructure and expertise to enable ProCan to achieve its goals, which also include facilitating collaboration and access to research results that will boost cancer research efforts worldwide.

“ACRF stands behind ProCan because we believe it will not only advance basic research into new and better cancer treatments but soon it will also help doctors rapidly choose the best existing treatment for their patients,” said Dr Brown.

“It is terrific to see ProCan attract additional investment. ACRF grants provide funding to scientifically validated projects and have seen many projects grow as a result of an initial investment made possible by our donors. We can’t thank them enough.” Dr Brown concluded.

Epigenetics: Cancer researcher’s new tool for precision medicine

Methylation 15cm courtesy of GarvanAn international team of researchers, including Professor Susan Clark and colleagues from ACRF grant recipient, Garvan Institute of Medical Research, has shown that DNA methylation analysis is a mature technology that is now ready for clinical use. DNA methylation is a process by which methyl groups are added to DNA to modify the function of the DNA.

The study underscores the robustness of DNA methylation and other epigenetic tests and heralds an era in which epigenetics will be used in clinical diagnostics and personalised medicine.

Epigenetics refers to chemical modifications that ‘decorate’ DNA and its associated proteins. Epigenetic modifications control gene activity independently of the genetic code so that they comprise an additional layer of information and control that overlies the genome itself. DNA methylation is one form of epigenetic modification.

In many diseases, including cancer, the epigenetic control of the genome is heavily distorted. By measuring these alterations, a detailed picture of disease-specific changes emerges, which can help distinguish disease subtypes or identify suitable treatments. To date, however, little epigenetic testing has been carried out in the clinic.

“What we wanted to do in this study was to carry out a wide-ranging technology comparison – to look in detail at the many DNA methylation tests (assays) now in existence, and to compare their accuracy and robustness in a systematic fashion,” Prof Clark said.

The research was coordinated by the Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM; Vienna) and included contributions from 18 research groups across three continents.

Prof Clark’s team compared two DNA methylation tests they had previously optimised: amplicon bisulphite sequencing (AmpliconBS) and mass spectrometric analysis of DNA methylation (EpiTyper). Both assays have their roots in bisulphite-based methods developed by Prof Clark in the 1990s, which were quickly adopted as the gold standard at the time.

The study found that AmpliconBS is the best choice for assaying dozens of genomic regions in parallel, while EpiTyper provides the highest sample throughput. It concludes that, overall, DNA methylation analysis is ready for widespread use in the clinic.

The study was published coordinately with three other papers in Nature Biotechnology and Nature Communications. Conducted in the context of the European Blueprint Project and the International Human Epigenome Consortium, the four papers together mark the feasibility of epigenetic analysis for clinical diagnostics and personalised medicine, in cancer and beyond.

The original news article was published on Garvan’s website. Image of methylation courtesy of Garvan.

The Australian Cancer Research Foundation has supported cancer research at Garvan by providing three grants, totalling AUD $6.13M, towards cutting edge cancer research technology and infrastructure.

Cancer research teams across Australia apply for millions in ACRF seed funding

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, Cancer Research Grants, cancer scientists, charity foundation, current cancer research, donate to charity, Fighting cancer, Funding research, fundraising, tax time donation, tax time, June tax time appeal, immediate tax benefit, tax deductible donations, tax donation, tax-deductible donation

Thanks to the generosity of our supporters, each year ACRF proudly awards high-impact grants. These major grants help cancer research teams develop state-of-the-art facilities, and purchase advanced equipment that has the power to speed up cancer discoveries and ultimately save lives.

ACRF is excited to announce we have received 11 grant applications from research teams and collaborations across Australia. Each team is applying for seed funding between $1.5 and $5 million.

No other private research funding body in Australia provides grants as large as these which are designed to fund research into cancer prevention, diagnosis and treatment.

All applications for grants will now be considered and assessed according to the world-class standards of the ACRF’s Medical Research Advisory Committee (MRAC), a group of highly distinguished cancer scientists.

That committee, led by Professor Ian Frazer, will now go through a detailed review process of each application and will develop a short-list in coming months.

After further interviews, the MRAC will make recommendations to our Board and the final awardees will be publicly announced on 14 November this year.

To learn about the latest discoveries, read our research news.

Researchers design blood test to determine colon cancer treatment

Dr Jeanne TieFragments of cancer-related DNA circulating in the blood of patients with colorectal cancer can be used to determine whether their surgery should be followed by chemotherapy, new research has shown.

Scientists at the Walter and Eliza Hall Institute, with international partners from Ludwig Cancer Research and the Johns Hopkins Kimmel Cancer Center, have designed a blood-based screening test to determine a patient’s risk of colon cancer recurrence after surgery.

Accurate testing of this risk factor could end the arduous experience of chemotherapy following surgical tumour removal by accurately identifying those patients who don’t need the extra treatment.

Lead author of the study Dr Jeanne Tie, a clinical research fellow at the Institute, said most patients with stage 2 colon cancers would be cured of the disease after surgery alone.

She said stage 2 tumours had generally invaded through the bowel wall but did not spread to other organs and the majority of these cancers at this stage were cured by surgery alone.

“Because current methods of predicting recurrence are imprecise, doctors tend to err on the side of caution,” Dr Tie said.

The research, just published in the journal Science Translational Medicine, followed 230 stage 2 colon cancer patients in 13 hospitals in Australia over four years.

“Up to 40 percent of these patients undergo the ordeal of chemotherapy even though we know only a small fraction of them are likely to experience a cancer relapse.

“By identifying who is likely to experience a relapse we can better target post-operative chemotherapy at those who actually need it, and spare those patients who will not benefit from this additional treatment.”

Cancer cells often shed their DNA into the blood when they die. Recent technology has allowed researchers to capture and profile these fragments of DNA and understand whether chemotherapy would be beneficial.

The original post was published on the WEHI website.

The Australian Cancer Research Foundation has supported cancer research at WEHI by providing three grants, totalling AUD $5.5million, towards cutting edge cancer research equipment and technology.

Ajith’s cycle challenge for cancer research

Ajith

“My name is Ajith, I’m 54 years old and based in Melbourne. In September I’ll be taking on a solo cycle challenge to fundraise for cancer research. I’m inspired by the work of Australian Cancer Research Foundation and I want to do my part to help give scientists the equipment they need to do their lifesaving work.

I have known a few people who have been affected by cancer, two of them were very close to me. These friends lived a very healthy lifestyle – they made sure to exercise regularly, eat nutritious food and they weren’t smokers. Yet cancer still impacted these people’s lives.

These experiences with cancer have shown me just how important it is to support organisations like the ACRF so that we can gain a better understanding of cancer and develop proactive and preventative measures to avoid all types of this disease.

In a few months’ time, I’ll be travelling to Spain to cycle a historic pilgrim route called El Camino de Santiago, which is also known by the English names: Way of St. James and Road to Santiago. The trail is in Galicia in north-western Spain, where tradition has it that the remains of the Saint are buried.

For me, this is a personal challenge. The 700-kilometre trail across a mix of flat, hilly, gravel roads will take me approximately 16 days to travel if I cycle for 4-6 hours per day.

I have been cycling for 20 years and love to be outdoors in the fresh air discovering nature and taking in beautiful sights.

I am looking forward to being on this cycle tour. I really enjoy travelling. I have been to more than 70 countries in the world and I love to meet new people along the way and experience various local cuisines, and this time I’ll also be raising funds for a cause close to my heart,” ACRF supporter Ajith.

Cancer Research Breakthrough could help prevent breast cancer in high-risk women

Cancer researchers at Walter and Eliza Hall Institute have discovered that an existing medication could prevent breast cancer in women carrying a faulty BRCA1 gene.

By pinpointing the cells that give rise to breast cancers in women who have inherited a faulty version of the BRCA1 gene, researchers have identified that the drug denosumab may have the potential to prevent breast cancer from developing. If confirmed in clinical studies, this would provide a non-surgical option to prevent breast cancer in women with elevated genetic risk.

People who carry a faulty BRCA1 gene are at high risk of developing aggressive breast cancer. Currently, many women with the gene mutation choose surgical removal of their breast tissue and ovaries to reduce their chance of developing cancer.

Using samples of breast tissue donated by women carrying the faulty gene, Ms Emma Nolan, Professor Jane Visvader and Professor Geoff Lindeman were able to pinpoint the cells that give rise to breast cancer.

“Cancer precursor cells in BRCA1-mutant breast tissue had many similarities to aggressive forms of breast cancer,” said PhD student Ms Nolan.

“These cells proliferated rapidly and were susceptible to damage to their DNA – both factors that help them transition towards cancer. We were excited to discover that these pre-cancerous cells could be identified by a marker protein called RANK.”

Professor Lindeman, who is also a medical oncologist at The Royal Melbourne Hospital, said the discovery of RANK as a marker of cancer precursors was an important breakthrough because inhibitors of the RANK signalling pathway were already in clinical use.

“An inhibitor called denosumab is already used in the clinic to treat osteoporosis and breast cancer that has spread to the bone,” he said. “Which is what led us to investigate what effect RANK inhibition had on the cancer precursor cells in BRCA1-mutant breast tissue.”

The research team showed that RANK inhibition switched off cell growth in breast tissue from women with a faulty BRCA1 gene and curtailed breast cancer development in laboratory models.

“We think this strategy could delay or prevent breast cancer in women with an inherited BRCA1 gene mutation,” Professor Lindeman said. A clinical trial has already begun to investigate this further.

A concurrent study led by an Austrian group had also identified the importance of RANK. Both studies suggest that targeting RANK offers hope to women at high genetic risk for breast cancer.

Professor Visvader said the discovery had its basis in more than a decade of investigations of breast stem cell function.

“By thoroughly dissecting how normal breast tissue develops, we have been able to pinpoint the precise cells that are the culprits in cancer formation,” she said.

“It is very exciting to think that we may be on the path to the ‘holy grail’ of cancer research, devising a way to prevent this type of breast cancer in women at high genetic risk.”

The Australian Cancer Research Foundation has supported WEHI by providing three grants, totalling AUD 5.5million towards cutting edge cancer research equipment and technology.

The research was published in Nature Medicine. The original news post was published on the WEHI website.

Zero Childhood Cancer Program receives $20M funding commitment from the Federal Government

Little girl going through chemotherapy treatment from home

The ‘Zero Childhood Cancer’ Program, a personalised medicine program giving hope to children with the highest risk of treatment failure or relapse has received a $20M funding commitment from the Federal Government. The program aims to have each patient’s therapy individually and uniquely personalised based on a combination of genomic and molecular data relating to their own particular cancer.

This exciting program will produce a detailed laboratory analysis of each child’s unique cancer cells to help identify the drugs most likely to kill their specific cancer. Researchers and clinicians can then work collaboratively to identify and deliver the most effective treatment plan, specifically tailored to suit each child’s individual circumstances.

Since 2001, the Australian Cancer Research Foundation (ACRF) has proudly awarded the Children‘s Cancer Institute $5.1 million in grants to fund programs like this. This funding was provided to help researchers make breakthroughs in all childhood cancers, as well as breast, prostate, lung, colon and brain cancers.

“Seeing programs like this grow is exactly the sort of thing we hope for when we award grant funding each year. ACRF funds new, often ground-breaking programs, that are based on sound science and have significant potential. These projects are often lead by some of the best scientists and clinicians across the country and, in some cases, even the world. Collaboration is at the heart of finding the most effective methods and treatments for cancer and the Zero Childhood Cancer Program is a demonstration of how Australian researchers are creating the building blocks for this important national initiative.” ACRF CEO, Ian Brown.

The personalised medicine platform will give Australian children diagnosed with the most aggressive cancers the best chance of survival. “As the Personalised Medicine Program is implemented, and as we gather more information, we will hopefully get better and better at identifying the most effective treatment for each child’s cancer.”

From the institute’s many years of research, it became clear that a ‘one size fits all’ approach to treating children with cancer was not working, as one in five children diagnosed were still dying from their disease. “The challenge in curing every child is that each child’s cancer is unique, which means they respond differently to anti-cancer treatment.

“We see this as a key step towards our vision of one day helping to cure 100% of children with cancer. Currently, for children with the most challenging forms of cancer, there is very little hope. This program will offer them the best standard of care here in Australia.”

This new approach has the very real potential to substantially improve patient outcomes and survival rates. Professor Glenn Marshall AM, Director of the Kids Cancer Centre at Sydney Children’s Hospital, Randwick, and Head of Translational Research at Children’s Cancer Institute is very optimistic about the potential of the Personalised Medicine Program to improve treatment and minimise the side-effects and suffering caused by chemotherapy.

“Knowing which drugs will not be effective in a patient is as important as knowing which drugs will be effective. Our ward is full of children suffering as much from the side effects of treatment as they are suffering from cancer.”

“The data we will be gathering and using is exciting in two respects – we will have evidence-based treatment options in the present, and we will be building a powerful research repository for the future.”

This commitment in funding will help broaden the scope for the program so that it can become a national clinical trial involving 120 children. When fully implemented, the program will be offered to children throughout Australia who are at highest risk of relapse or treatment failure.

Today marks the closing day for Grant Applications for ACRF 2016 Grants. Each year researchers are raising the bar with bold initiatives that we can’t afford not to invest in. This is why our community of supporters are so important, they enable brilliant work that saves lives.

The original article was published on the Children’s Cancer Institute website. To read the original article, please click here.

Ashleigh’s Dinner for a Difference

DFAD“My name is Ashleigh Mills, I’m a 26-year-old living in Sydney. In June 2015, a few months after finally saying goodbye to six years of tertiary education, I started my first permanent full-time role at a legal firm – Holding Redlich. At that time, everything seemed to be going according to plan.

Then, one night on a weekend away with friends I felt a weird sensation in my throat. A friend who had heard this complaint noticed that there was a visible lump on the side of my neck. I had absolutely no idea where it came from, or what it was, but I was pretty quick to assure her that it was nothing – obviously.

I’d been to the doctor about the sensation in my throat a few times, but each time I was told that it was likely a response to stress – something that I didn’t question.

When my friends noticed a lump I assumed that it would be nothing and told them so. Thankfully, they didn’t take no for an answer and made sure I went to the medical centre the following day. One week later the biopsy results were in.

That lump turned out to be cancerous and I was diagnosed with thyroid cancer. For someone who had always planned their day down to the nth degree, the diagnosis came as a stark reminder that no-one can ever really know what life has in store around the corner.

I still can’t really comprehend everything that happened in the months following my diagnosis. But I remember that for me, one of the hardest things was learning how to deal with telling the people you care about most. In mentioning the word cancer, a subconscious fear sweeps across people’s eyes for just a moment and, as the affected person, you can’t escape how it makes you feel.

That’s the thing with cancer, it doesn’t follow a script and it certainly doesn’t come with a manual. You can’t always control it, but you can control the way you respond to it. It is easy to fear cancer but I don’t think we can afford to. We need to replace that fear with action because every moment is truly important.

By August 2015, my thyroid had been removed and I had commenced radioactive iodine therapy.

While thyroid cancer itself is often highly treatable, many cancers are not and each year too many people lose control of their lives to a disease that poses more questions than answers.

Cancer remains the second biggest killer in Australia. It is an awful and indiscriminate disease, but it is not invincible. Nor should we accept it to be.

20160618_184447With that in mind, I decided that I needed to do something in the fight to end cancer and that I needed to do it fast. I approached the Australian Cancer Research Foundation with a small idea and it grew into something much, much bigger. Then last Saturday night, after months of planning, I hosted a charity black tie gala event called Dinner for a Difference. We raised over $26,000.

Honoured premium sponsors and partners on the evening, Toy ‘R’ Us and Babies ‘R’ Us, said:  ‘The support from the attendees was overwhelming, most of the guests knew Ashleigh personally and most had a very strong connection with her. It was such an exciting night filled with great positivity and joy. The effort that was put in by Ashleigh and all those involved was outstanding and it was so great that all the hard work paid off’.

I chose to support the ACRF because I immediately felt buoyed by the focus of the organisation to end cancer – for good. While I appreciate the importance of programs that are targeted towards raising awareness of the disease and providing post-diagnosis assistance, I truly believe that the key is research.

To me, cancer research is more than important, it’s absolutely crucial. By funding cancer research, we are getting closer to a breakthrough that will change the way we think about cancer and the many lives that it continues to affect. Thanks to ACRF and its supporters, cancer researchers are being armed with the tools that they need to make breakthroughs.

Thank you to everyone who joined forces with me to support the ACRF, including all 180 guests who attended and Holding Redlich who generously signed on as a gold sponsor of the event. Thank you for believing that together we could make a difference. I am so blown away by everybody’s generosity – blown away and inspired to do more.” – ACRF supporter, Ashleigh Mills.

Cancer researchers uncover new insight into MLL translocated leukaemia

C0061986 Dr Mark Dawson's labCancer researchers at Peter MacCallum Cancer Centre in Melbourne have found a new lead that could fast-track the development of a more targeted and effective treatment for MLL Translocated Leukaemia.

More than 80% of infants diagnosed with either Acute Myeloid Leukaemia (AML) or Acute Lymphoblastic Leukaemia (ALL), and up to 10% of diagnosed adults, have a sub-type known as MLL Translocated Leukaemia.

Prognosis for MLL Translocated Leukaemia is particularly poor with only 40- 50% of diagnosed infants likely to survive, and the five-year survival rates in older adults remaining at less than 20%.

Peter Mac’s Professor Mark Dawson has studied Acute Leukaemia and this particular sub-type for a decade. He says the latest findings provide a step towards next-generation therapy for the disease, for which treatment has changed very little since the 1970s.

“Every other disease that I’ve treated in my time as a haematologist has had one if not many, new drugs come along to improve treatment but this has not been the case for AML,” Professor Dawson said.

“This is a disease where patients affected are often young and fit when first diagnosed but do not respond to conventional therapy.”

Research by Professor Dawson’s team along with international collaborators has – for the first time – explained the role played by two proteins (BRD4 and DOT1L) which are known to be key regulators of MLL Translocated Leukaemia.

His research identified a previously unknown cooperation between these proteins, showing how they depend on each other to progress the disease.

Drugs which target both of these proteins are now in separate clinical trials as potential leukaemia treatments. Professor Dawson’s research suggests a combination therapy involving drugs that target both proteins at the same time may be an effective strategy against the disease.

Professor Dawson’s findings explaining the interdependence of BRD4 and DOT1L in MLL Leukaemia has been published in the journal Nature Structural & Molecular Biology.

“We’ve always known that these leukaemias needed these regulators but what we didn’t know was why, and we didn’t know that they spoke to each other to drive the disease,” Professor Dawson said.

“The good news is we don’t have to develop new drugs in light of this research because they are already here and in clinical trials,” Professor Dawson said.

The original article was published on Peter Mac’s website. The image of Professor Dawson was provided courtesy of Peter Mac.

The Australian Cancer Research Foundation has supported Peter MacCallum Cancer Centre by providing three grants, totalling AUD $7million, towards cutting edge cancer research equipment and technology.

Zoe takes on Mt Kilimanjaro for cancer research

Cancer, types of cancer, cancer foundation, australian cancer research foundation, cancer charities, cancer charity, acrf, cancer news, cancer fundraising, cancer awareness, cancer donate, cancer donation, cancer donations, give to charity, giving to charity, cancer articles, cancer research donate, cancer research donation, donate to cancer research, cancer research funding, charities for cancer, donate to cancer, Australian cancer charities, australia cancer research, best cancer charity, cancer research fundraising, cancer charity events, cancer charity donations, donate to cancer charity, australia cancer research, cancer research fundraising, give to cancer research,“In October, I’ll be fulfilling one of my biggest dreams — climbing Mt Kilimanjaro. About six years ago I did some trekking in Nepal and Tibet, and because I’m such a beach girl I was really surprised by how much I loved being in the mountains. It gave me this unexpected sense of peace and inspired me to explore other places.

I knew that when I did finally get the chance to turn my dream into a reality, I would be fundraising for cancer along the way.

Cancer research is a cause that is very dear to my heart. I have witnessed many loved ones suffer from this disease, including my grandfather who passed away from bowel cancer 16 years ago.

My Aunty is now fighting ovarian cancer as well. After two rounds of chemotherapy, we’re hopeful that it won’t progress. Despite what she’s going through, she still carries herself with such courage and grace and inspires everyone around her.

Her son was diagnosed with leukaemia at just two years old and sadly lost his battle at seven. I was 14 at the time and I remember how brave he was, how little he complained, and how much I learned about the importance of living each day to the fullest. This is when I first realised that life is precious and not to be wasted.

You only live once so you may as well make it count, which is why I thought; why wait any longer to cross Mt Kilimanjaro off my bucket list?

I really love to travel and meet new people and see new cultures so this is the perfect opportunity. Africa is such a fascinating place to me and I’m really looking forward to being in nature, removed from all the distractions of daily life. The area looks so stunning, I’m hoping that I might get a glimpse of some of the ‘Big 5‘ in their natural habitat.

I’m sure it will be challenging but I’m passionate about breaking down the limitations of the mind and living the life of your dreams. A few years ago, I was in a serious car accident that left me with injuries and for months I was bed ridden, so ever since then I love to challenge myself physically and mentally.

Cancer, types of cancer, cancer foundation, australian cancer research foundation, cancer charities, cancer charity, acrf, cancer news, cancer fundraising, cancer awareness, cancer donate, cancer donation, cancer donations, give to charity, giving to charity, cancer articles, cancer research donate, cancer research donation, donate to cancer research, cancer research funding, charities for cancer, donate to cancer, Australian cancer charities, australia cancer research, best cancer charity, cancer research fundraising, cancer charity events, cancer charity donations, donate to cancer charity, australia cancer research, cancer research fundraising, give to cancer research,I remember trekking in Tibet, over a pass at 5500 metres and feeling so sick that I wanted to give up. But I just kept putting one foot in front of the other and telling myself “you can do this, this is nothing compared to what you’ve been through before.” The sense of accomplishment at the end of the day was like nothing else. It showed me that we can do anything we put our minds to.

I am so proud to be climbing for cancer research. With 1 in 3 people now being diagnosed with cancer, I believe anything we can do to stop cancer in its tracks is important. Having seen so many loved ones go through treatment I think the more we learn about the disease, the better treatment will become. My hope is that we can not only cure cancer but prevent it.

In honour of those who have survived, who kicked cancer in the butt, to those who are currently fighting and to those who have lost their battle, I dedicate this climb to you. I know that all of you will be with me every step of the way.” – ACRF supporter, Zoe Trenwith

Zoe is a yoga teacher and in the lead up to her climb, she will be hosting a 108 Sun Salutation Fundraising class in South Australia on June 17th. “As a yoga teacher, I knew that hosting a yoga event was one way I could do something to bring people together.” If you would like to support Zoe, or find out more about her yoga class, click here.

Promising new treatment for acute myeloid leukaemia

cancer articles, cancer research donate, cancer research donation, donate to cancer research, information about cancer, cancer research funding,Patients with acute myeloid leukaemia (AML) can look forward to the development of new therapies following a discovery by cancer researchers at Walter and Eliza Hall Institute.

While investigating ways to target particular types of AML, and hoping to increase the chance of a cure for the patient while limiting damage to healthy cells, the team discovered a new way to kill cells that are dangerously multiplying.

A process known as apoptosis (programmed cell death) is a natural and necessary response to keep the proliferation of human cells in check. Apoptosis is interrupted in cancers, including AML, leading to unchecked cell growth.

Dr. Gabriela Brumatti said traditional chemotherapies, which encourage apoptosis, have a high relapse rate. For example, within five years of completing treatment, half of AML patients suffer a relapse of their cancer, and of those who relapse, only 50 percent survive.

Her team tried a ‘blue sky’ approach, inhibiting apoptosis of AML cells in order to unleash an alternative form of cell death called necroptosis. They found that the necroptosis cell death pathway was more effective at killing AML than apoptosis.

In preclinical trials, they used a combination of drugs – birinapant, a new anti-cancer drug, and emricasan, a US Food and Drug Administration (FDA) approved inhibitor of apoptosis – to kill AML.

“It has been speculated that inducing necroptosis might be an effective way to kill cancer cells,” said Professor Silke. “Our work now demonstrates clearly it is a clinically feasible and safe approach.”

Dr. Brumatti suggested that since cancer cells often acquire resistance to traditional chemotherapy-induced apoptosis, this novel type of chemotherapy has the potential to be used to treat otherwise impossible to treat leukaemias.

These findings have just been published in the research journal Science Translational Medicine.

The Australian Cancer Research Foundation has supported WEHI by providing three grants, totalling AUD 5.5million towards cutting edge cancer research equipment and technology.

The original news post was published on the WEHI website. Images of the research team courtesy of WEHI.

Cancer researchers ‘switch on’ Natural Killer cells to fight cancer

Walter and Eliza Hall Institute (WEHI) researchers, led by Dr Sandra Nicholson and Dr Nicholas Huntington, together with colleagues from the Queensland Institute of Medical Research (QIMR), are investigating ways to ‘switch on’ our Natural Killer (NK) cells to fight cancer.

The researchers identified a protein ‘brake’ within Natural Killer cells that controls their ability to destroy their target tumour cells.

“Natural Killer cells exist to detect and then destroy any deviant cells in our bodies before those cells go on to develop into tumours or before infection spreads,” Dr Nicholson said.

“Natural Killer cells are a key part of our immune system they work by locating other cells posing a danger to health either because they are infected or because they are becoming a cancer cell,” she continued.

Our bodies are constantly and successfully fighting off the development of cells that lead to tumours – but when there is disruption to this process cancer is free to develop.

In their paper published in Nature Immunology, they showed that when the brake was removed in an experimental model, the NK cells were better able to protect the body against metastatic melanoma.

Natural Killer cells rely on a growth factor called Interleukin 15 (IL15) to activate. Dr Nicholson and Dr Huntington’s research has shown that an inhibitor protein made inside the Natural Killer cells limits the ability of the NK cell to respond to IL15 and therefore kill cancer cells.

By identifying for the first time how this protein inhibits NK cell responses, they now hope that a drug can be developed that will improve the response of NK cells to this growth factor and help patients fight cancer with their own immune system.

“This is about learning how to activate the NK cells of the individual patient and boost their immune system to tackle the disease,” Dr Huntington said.

“We are hopeful our research will lead to new immunotherapies that supercharge the body’s Natural Killer cells and maintain it in a highly active state to more efficiently and specifically fight cancer.”

The Australian Cancer Research Foundation has supported WEHI by providing three grants, totalling AUD 5.5million towards cutting edge cancer research equipment and technology.

The original news post including the YouTube video was published on WEHI website.

ACRF teams up with H&R Block to provide tax calculator that shows the true value of donations to cancer research

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, Cancer Research Grants, cancer scientists, charity foundation, current cancer research, donate to charity, Fighting cancer, Funding research, fundraising, tax time donation, tax time, June tax time appeal, immediate tax benefit, tax deductible donations, tax donation, tax-deductible donationThis tax season, the Australian Cancer Research Foundation (ACRF) has partnered with tax accountants, H&R Block to deliver an online calculator that tells individuals how much tax they will receive back from their donation, as well as exactly what their donation has the capacity to fund.

The creative concept and implementation of the calculator was all thanks to pro-bono work done by M&C Saatchi’s creative team.

“We hope that by being transparent and showing donors how much influence even a small donation can have on the work that’s being done in cancer research, it will help them understand how truly valuable their support is,” commented Professor Ian Brown, CEO of the ACRF.

Last year, donations to the ACRF went towards equipment that is being used to further develop personalised cancer treatments, detect lung cancer before it spreads, and examine native Australian plants to see if they can be used to develop new cancer treatments.

The ACRF has been a driving force behind cancer research for over 30 years. However, with success rates now less than 14 percent for applications to grants from the National Health and Medical Research Council, the organisation is keen to do all it can to increase the availability of vital funding.

Advancements in technology are allowing researchers to analyse data like never before. But such technology is difficult to get funding for. The ACRF is the only national charity in Australia whose sole purpose is to make advanced equipment and technology more accessible to Australian cancer researchers, regardless of the type of cancer they study. This is helping prevent the best and brightest scientists from moving elsewhere or changing jobs.

The support of H&R Block, as well as other corporate partners, continues to help ACRF provide the sector with the lifeline that it needs.

“At H&R Block we value the health and wellbeing of all Australians, so we’re proud to assist ACRF in its goal to deliver the highest impact in an area of vital need. Too many people are suffering from the effects of cancer, so being even a small part of the solution is both humbling and gratifying,” said Brodie Dixon, managing director of H&R Block.

New research study explains how cancer cells resist treatment

cancer research, types of cancer, funding research, fighting cancer, current cancer research, cancer scientists, cancer statistics Australia, cancer charity, charity foundation, ACRF, Australian Cancer Research Foundation, cancer fundraising, Cancer Research, cancer research fundraising, Cancer Research Grants, donate to charity, Fighting cancer, Funding research, Walter and Eliza Hall Institute, Victoria, leukaemiaCancer researchers at grant recipient, Walter and Eliza Hall Institute (WEHI) in Melbourne have worked out how a new class of anticancer drugs kill cancer cells. The finding also helps explain how cancer cells may become resistant to treatment.

Dr Zhen Xu, Professor David Huang, Dr Stefan Glaser and colleagues studied a class of anti-cancer drugs called BET inhibitors, which are considered promising new drugs for the treatment of blood cancers such as leukaemia and lymphomas.

BET inhibitors reduce tumour growth by blocking BET proteins, a family of proteins that control whether genes are switched on or off.

Although it has been known that BET inhibitors are effective at halting tumour growth, it has been unclear whether the drugs kill cancer cells outright.

The research team found that when tumours are treated with drugs, some resistant cancer cells can survive and continue to grow, leading to disease relapse. In the process, they identified potential ways in which cancer cells may develop resistance to BET inhibitors.

The experiments revealed that BET inhibitors principally act to kill cancer cells through the process of programmed cell death (apoptosis). For BET inhibitors to successfully kill lymphoma and myeloid leukaemia cells the presence of a protein called BIM, which brings on apoptosis, was critical.

“We found that when apoptosis was impaired, for instance by the loss of BIM, the BET inhibitors were no longer effective,” Dr Xu said.

“This suggests that cancer cells that acquire mutations in genes that drive apoptosis will lose sensitivity to BET inhibitors and thus will be able to survive treatment, leading to disease relapse.”

Dr Glaser said that knowing how BET inhibitors worked could help researchers develop improved strategies for using these drugs to treat cancer.

“Understanding how the drugs work gives us the opportunity to investigate new treatments, for example by using combination therapies, or altering the dosage and timing of treatment to prevent drug resistance from emerging,” Dr Glaser said.

The original news post was published on the WEHI website.

The Australian Cancer Research Foundation has supported the Walter and Eliza Hall Institute by providing three grants, totalling AUD 5.5million, towards cutting edge cancer research equipment and technology.

Stevie saddles up for cancer research

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, cancer scientists, charity foundation, donate to charity, Fighting cancer, Funding research, fundraising, Fundraising Stories, Fundraiser“Dad was a typical country guy. He was always dressed in a flannel shirt with his shoulder-length hair tied into a ponytail.

Nine years ago we lost him to lung cancer. I was just 12-years-old and my older sister was 15. Since then, my family has participated in various events to help raise funds for cancer research, including an annual charity walk.

This year, I was inspired to do something a little different. I’d recently been thinking about the loving horse my dad left to my sister and me when he passed away. I realised this beautiful horse is one of the last things I have of my dad. So I decided I would plan a Horse-riding Fundraiser to honour him and support cancer research.

His horse is named Boston and they had a really beautiful connection – my dad adored her and you could tell that she really loved him too. She would always come right over when he called her. My sister and I now look after her. She’s a very quiet and gentle horse, but she’s also the boss – and she knows it!

Our family has always had a love for horses. Both my parents rode – mum used to ride in competitions all the time, but dad did it just for the love of it. When my sister and I were growing up we loved listening to all their horse stories and going on rides with them. It was so special to have that time together and I’ll always cherish those memories.

I now have a beautiful one-year-old daughter and it saddens me to know that she’ll never get to meet her pop and that my dad will never get to meet his granddaughter. I hope that together we can make great memories of horse-riding too. Even before she could walk we would sit with her on the back of Boston and gently lead her around, she loved it.

I’ll actually be riding Boston on the day of the charity ride. Everyone is welcome to come and enjoy a day with these beautiful animals and show their support for cancer research. People are encouraged to bring their horses along. We’ll be organising market stalls and entertainment to help make the day as fun as possible.

The fundraiser will be held at Chapman Valley Horse Riding. They have generously donated the use of their 8,000 acres to the cause. It’s located in Howes Valley, which is an hour drive from Pokolbin and a two-hour drive from Sydney and Newcastle. There will also be a camping area for people to stay overnight and make a weekend of it.

The only fee for the day will be $35 per person to ride and $10 per car to camp on the grounds.

Cancer research is a cause close to my heart and being able to do this in the memory of my dad means the world to me. I’m so proud to be doing my part to help support the amazing researchers who are working to end cancer.” ACRF supporter, Stevie Lee Ackley

To register or learn more about the event, please contact Stevie directly at stevie.ackley@hotmail.com. If you can’t attend but would like to help Stevie reach her fundraising goal, click here.

More genetic risk factors for endometrial cancer uncovered

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, Cancer Research Grants, cancer scientists, Challenge, charity challenge, charity foundation, current cancer research, donate to charity, Fighting cancer, Funding research, give to charity, Types of cancer, QIMR, Endometrial Cancer, QIMR Berghofer, Queensland Institute for Medical Research

Cancer researchers at ACRF grant recipient, QIMR Berghofer Medical Research Institute, along with research teams from the University of Cambridge and Oxford University, have discovered five new gene regions that increase a woman’s risk of developing endometrial cancer.

Endometrial cancer affects the lining of the uterus. It is the sixth most commonly diagnosed cancer in Australian women, with nearly 2,500 new cases expected to be diagnosed in 2016.

The study was led by the head of the Molecular Cancer Epidemiology laboratory at QIMR Berghofer, Associate Professor Amanda Spurdle, and has been published in Nature Genetics.

Associate Professor Spurdle said the findings helped to paint a clearer picture of the genetic causes of endometrial cancer in women who do not have a strong family history of cancer.

“Up until now, we have only known about four gene regions in women in the general population that contribute to the risk of developing endometrial cancer,” Associate Professor Spurdle said.

“In this study, we have identified another five, bringing the total to nine. This finding doubles the number of risk regions we know of, and therefore significantly increases our knowledge of the genetic drivers of endometrial cancer.”

The study also looked at how the identified gene regions might be increasing the risk of other cancers, and what the implications would be for the future treatment of endometrial cancer patients.

Interestingly, several of the gene regions we identified in the study were already known to contribute to the risk of other common cancers.

“As we develop a more comprehensive view of the genetic risk factors for endometrial cancer, we can start to work out which genes could potentially be targeted with new treatments down the track,” Associate Professor Spurdle said.

“In particular, we can start looking into whether there are drugs that are already approved and available for use that can be used to target those genes. Our genetic findings may also be useful, together with our knowledge of other risk factors, to identify women at risk of endometrial cancer so they can be regularly checked and be alert to the signs and symptoms.”

The Australian Cancer Research Foundation has supported QIMR Berghofer Medical Research Institute by providing three grants, totalling AUD 6.65million, towards cutting edge cancer research equipment and technology.

The original news post was published on the QIMR Berghofer website.

Introducing our 2016 City2Surf Ambassador!

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, cancer fun run, Cancer Research, cancer research fundraising, Cancer Research Grants, cancer scientists, Challenge, charity challenge, charity foundation, City2Surf, current cancer research, donate to charity, Fighting cancer, Funding research, fun run, Fundraiser, fundraising, Fundraising Stories, give to charity, marathon, Running for Cancer Research, Sydney

We’re excited to announce our first ever Team ACRF City2Surf Ambassador, Jessica Broome.

Jess is an incredibly positive young woman with a close connection to cancer research. We are honoured to have her join us this year as our Ambassador.

The last time Jess ran with Team ACRF was in 2014. Her Dad had been diagnosed with cancer eight years earlier, and she ran in support of his journey. After crossing the finish line, having raised over $1,600 for cancer research, she celebrated with a toast to her Dad.

This year Jess will be running again.

“I’m passionate about cancer research because I lost my Dad to cancer in April this year.

A month before we lost him, I watched him walk up the hospital hallway and achieve the massive goal he had been working towards with his physio team. It seemed impossible to most of us, but he was always determined to get better.

He was a fighter, not just as a fireman, but in the way he refused to give up.

We were fortunate that he qualified for numerous medical trials which managed to get him through each year. For ten years they kept coming back with something new, like a magic trick that the researchers would pull out of a hat.

Each new trial medication that came around, he would give it a go – no matter what. There were many years where we thought to ourselves: ‘This is it. This is the last Christmas, this is the last father’s day’…but it never was.

Thanks to those trials our family was able to spend more precious time with him, which meant so much to us.

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, cancer fun run, Cancer Research, cancer research fundraising, Cancer Research Grants, cancer scientists, Challenge, charity challenge, charity foundation, City2Surf, current cancer research, donate to charity, Fighting cancer, Funding research, fun run, Fundraiser, fundraising, Fundraising Stories, give to charity, marathon, Running for Cancer Research, SydneyDad loved to travel, so we were able to get in some extra holidays together. He also had the chance to ensure his family, including his now 94-year-old Mum, would be okay. We even managed to squeeze in a few more parties with him!

Mum and I were playing all his favourite songs on his last day, one of those songs was Margaritaville by Jimmy Buffett. We were dancing around his bed like mad women.They say that hearing is the last thing to go, so I just know this would have made him happy.

He suffered many different cancers over the last ten years, but it was brain cancer that took him in the end. I feel that was the worst for him to go through. I’d really like to see a trial medication to treat this, other than steroids and pain killers. I know researchers are going to get there in time.

This is why I have decided to participate in this year’s City2Surf for cancer research. It’s a great way to support a great cause.

I’m not the best runner, but I really enjoy it. I think it will probably be quite a challenge as I haven’t been running for quite a while. My Dad was always telling me to get back into it, so now I’m doing it!

I think he would really love that I’m getting involved. He always liked to make sure he thanked people when they helped him. So this is my thank you on his behalf.

I’ll know I’ll probably cry through the finish line, but afterwards, I plan to throw one hell of a party! That’s how he would do it!” Jessica Broome ACRF City2Surf Ambassador

 

 

 

New genome sequencing technologies for childhood cancer patients

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, Cancer Research Grants, cancer scientists, charity foundation, Childrens Cancer Institute Australia, current cancer research, donate to charity, Fighting cancer, Funding research, Fundraising Stories, Garvan Institute of Medical Research, Running for Cancer Research, give to charity, Children's Cancer Institute, Zero Childhood Cancer

Australian children with high-risk cancer will have access to new genome sequencing technologies that could help guide their treatment thanks to the Lions Kids Cancer Genome Project.

The Zero Childhood Cancer Program launched in September 2015 and is currently one of the most detailed genetic and biological analyses of children’s cancer globally. The Lions Kids Cancer Genome project will serve as an important new component to the program as it expands its efforts.

Whole genome sequencing will take place following diagnosis or relapse of cancers with the poorest prognoses, such as brain tumours.

Sequencing looks at each child’s entire genome and its 20,000+ genes in order to define the genetic changes associated with a given cancer. This makes it possible to develop personalised cancer treatment by integrating genetic information with other biological and clinical data.

In addition, the study will identify genetic changes in each child’s DNA that might predispose a person to cancer, helping to build up a database of genetic risk factors that could assist with prevention and treatment strategies in the future.

At any one time in Australia, over 2,000 children, adolescents, and young adults, are on active treatment for cancer or at risk of relapse. In most cases, the treatments used are general, non-targeted, cytotoxic drugs and the side effects from treatment can be serious and lifelong.

The Zero Childhood Cancer Program is a national initiative of Children’s Cancer Institute (CCI) and The Sydney Children’s Hospitals Network, giving hope to children with the highest risk of treatment failure or relapse. Genome sequencing and analysis for the project will be carried out at Garvan Institute of Medical Research’s Kinghorn Centre for Clinical Genomics.

The Lions Kids Cancer Genome Project is supported by the Lions Club International Foundation and by the Australian Lions Childhood Cancer Research Foundation. The project will roll out through the Zero Childhood Cancer Program to children’s hospitals across Australia in 2017.

The Australian Cancer Research Foundation (ACRF) welcomes the new initiative and partnership which will contribute towards improving children’s quality of life and ending all childhood cancers.

ACRF has supported Children’s Cancer Institute, including the Zero Childhood Program, by providing three grants, totalling AUD $5.1million, towards cutting edge cancer research equipment and technology. ACRF has also supported cancer research at Garvan Institute of Medical Research, including the Kinghorn Centre for Clinical Genomics, with three grants, totalling AUD $6.13million.

The original news post was published on the CCI and Garvan websites.

A taste of hope

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, Cancer Research Grants, charity foundation, corporate giving, donate to charity, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories, give to charity, corporate donations, workplace giving, corporate charity donationsACRF corporate supporter, Bob Warner, is the owner of Betta Buy Wine. He has been funding cancer research since 2010.

“Ending cancer is one of the paramount issues in health today. Sadly, I have had many close friends who have lost their lives to this terrible disease.

Cancer can affect any one of us – children, the fit and healthy, and the aged alike. It knows no boundaries. We must help to bring it to an end.

Here at Betta Buy Wine we thought it was time to, again, support our friends at the Australian Cancer Research Foundation (ACRF) to help raise funds for vital cancer research.

When we delved into the history of fundraising we found that many wineries around the world have been involved in raising funds for an assortment of different community causes.

So we decided to source a selection of fantastic wines that are among the top boutique wineries in Australia. And to encourage people to support ACRF, we’ve discounted them. When customers purchase from this range, we will donate $25 from the sale to ACRF.

I have been supporting the ACRF for a number of years because I know that the dollars raised go to where funding is needed the most.

By supporting our wine fundraiser you will receive great value, and at the same time help end cancer. We hope everyone enjoys these magnificent wines and the goodwill feeling that goes along with supporting a worthwhile cause.

I would encourage everyone to get on board and support cancer research in any way they can, because every dollar counts.” Bob Warner, ACRF Corporate Supporter – Betta Buy Wine

Celebrating a special group of people

20150809_104807This week, Volunteering Australia are celebrating all the benefits that volunteers bring to Australia with the theme Give Happy, Live Happy. And we want to take this opportunity to thank all the ACRF volunteers who play a large part in our mission to end cancer.

“There is so much more to volunteering than simply giving your time and skills to help others,” says Brett Williamson, OAM, CEO Volunteering Australia. “This week we say thank you to the six million Australian volunteers and celebrate that they are living healthier, happier and more meaningful lives by volunteering.”

Associate Professor Dr Thomas Nielsen, University of Canberra, says “Volunteering is a core part of the community and plays a critical role in Australian society, and in Australia’s economy. Volunteers form a formidable workforce powering many essential community services and supports.”

This is certainly true at the Australian Cancer Research Foundation. Our volutneers play a vital role and so we are extremely grateful for all that they do. With their help, we can continue to reduce the impact of cancer by funding world-class cancer research.

A special thank you goes out to the individuals that give their support in our office and to the ACRF cheer squad who encourage our runners at marathon events. We are also very appreciative of the amazing Cancerian Committees who host events across the country to raise funds, and to our corporate partners who volunteer their time to and share their professional skills.

Volunteering is a positive and inspiring way to help any cause and your enthusiasm, positivity and a dedication are the only qualifications you need!

If you would like to find out more about how you can volunteer with the ACRF, click here. To register interest for ACRF volunteering opportunities please email info@acrf.com.au or call us on 1300 884 988 to see what is available.

The forever kind of friend

ACRF, Australian Cancer Research Foundation, cancer charity, Cancer Research, cancer fun run, cancer research fundraising, Cancer Research Grants, Challenge, charity challenge, charity foundation, HBF Run for a Reason, Run for a Reason, donate to charity, Fighting cancer, Funding research, Types of cancer, Running for Cancer Research, PerthACRF supporter, Brett will be participating in Perth’s Run for a Reason in memory of his best friend Steph.

“Twenty years ago, at 18 years old, Steph and I met through a friend and grew close from that day on. We were quite similar – we both loved to socialise and have fun. We were always laughing and never took life too seriously. Her quick, witty humour was my favourite part about her.

Throughout our years of friendship, I would have to say, she helped shape me into the person I am today.

Just under two years ago, Steph found out she had bowel cancer. It was devastating news but we thought, since she was young, her chances of survival would be good. They weren’t. When the tests came in we were told she had stage four cancer and it had already spread throughout her body.

Steph, being the trooper that she was, fought a hard eight months and went through 20 rounds of chemo before passing last year. And she did it all with the utmost grace, I will always admire that.

I decided to raise funds for cancer research because I felt I had to do something to help. This is the first time in my life that something like this has happened. Before Steph, I’d never lost anyone close to me.

I believe it’s so important to support cancer research. Cancer is such and cruel and unforgiving disease and until it affects you or a loved one, you don’t realise how important it is to improve early detection and treatments for patients.

This is my first running event. Since Steph’s passing, I was looking for a way to play some part in raising money for cancer research and Run for a Reason seemed like the perfect opportunity.

Thank you to all my generous friends and family who have been so keen to support me.

I hope that, by sharing this story, I can encourage others to get involved and come together to help end cancer.” – Brett Stubbs-Mills, ACRF supporter

If you would like to show your support for Brett, please click here.

Cancer research develops new drug to enhance cancer treatment

Professor Ruth Ganss courtesy of Harry Perkins Institute of Medical ResearchCancer researchers at the ACRF grant recipient, Harry Perkins Institute of Medical Research have developed a new drug that could be used to repair blood vessel defects and allow for more targeted and effective cancer treatment delivery.

Current treatments like chemotherapy and immunotherapy can struggle to enter a tumour because the blood vessels that fuel it have become malformed.

Tumours require a lot of nutrients so many times this causes blood vessels to re-direct towards the tumour, leading to abnormalities in the vessels.

The drug that was developed by Woodside Professor Ruth Ganss and her team discovered that smooth muscle cells that line blood vessels to give them shape and help them pump blood often break down in tumours.

Once the smooth muscle cells break down, the blood vessel becomes leaky, reducing blood flow and preventing chemotherapy and immune cells from travelling into the tumour.

Professor Ganss said the new drug works by repairing the smooth muscle cells and returning normal blood flow to the vessels, allowing anti-cancer drugs to reach the tumour’s core.

“To achieve greater absorption of anti-cancer drugs, the blood vessels are really key,” Professor Ganss said. “Helping stem the spread of cancer.”

Professor Ganss said the defect in smooth muscle cells lining blood vessels in cancer could also be a catalyst for the cancer to spread.

“It could be that once the smooth muscle cells break down and the blood vessels become leaky, cancer cells are able to slip out of the tumours and migrate through the bloodstream to spread to different parts of the body.”

“We are currently investigating whether our drug could help stem the spread of cancer in a patient by repairing the leaky blood vessels.”

The original news article was published on the Harry Perkins website.

The Australian Cancer Research Foundation has supported Harry Perkins Institute of Medical Research by providing two grants, totalling AUD 3.6million, towards cutting edge cancer research equipment and technology.

How will you celebrate this Mother’s Day?

Balloon_MothersDayv2Mother’s Day is fast approaching, and many of us are starting to think about meaningful Mother’s Day gifts. Wouldn’t a world without cancer be the greatest gift of all this Mother’s Day? These three gift ideas will make mum smile and fund research to end cancer.

  • Donate in lieu of a gift
    Many ACRF supporters choose to make an in-celebration donation in lieu of traditional gifts. A Mother’s Day donation is a thoughtful gift idea that will help fund world-class cancer research. And as thanks, we’ll send your mum a lovely card to acknowledge your generous contribution. Click here to make a donation.
  • Purchase an Entertainment book for her
    Get her an Entertainment Book! It’s full of deals on things you could do together. From each book purchased, 20% percent of the sale will go directly to cancer research. Click here to order.
  • Order a Mother’s Day hamper
    Treat your mum to a gorgeous charity hamper filled with luxury products. 10% of proceeds will help scientists advance research into cancer prevention, diagnosis and treatment. View the hampers here.

Your support will bring new hope to cancer patients and their families around the world. Families like Gemma’s.

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, Cancer Research Grants, cancer scientists, Challenge, charity challenge, charity foundation, donate to charity, current cancer research, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories, give to charity, regular giving, gemma ameera, jimi may, gypsys gift“For a couple of years now, my mum has been fighting cancer with unfathomable strength and courage. While our family has had both good and bad days, Mum is a true warrior and has kept us positive and moving forward, as we stand by her side. She has spent her entire life putting everyone else before herself, and even now, she wishes for nothing more than everyone else’s happiness.

This illness has turned all our lives upside down, and this happens every day to families all over the world. We are determined to help end cancer, and we cannot do this without research.”

We are very grateful to have supporters who choose to mark special occasions such as Mother’s Day by contributing to the fight against cancer. Read more on Gemma’s story here.

I’m still standing

ACRF, Australian Cancer Research Foundation, Breast Cancer, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, cancer scientists, charity foundation, donate to charity, Donations in lieu of gifts, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories, give to charity, Types of cancer, pancreatic cancer

“Ian and I will have been married for 46 years next month. We have spent very little time apart in those years. We have three adult children and four grandchildren. We both grew up in the country but spent some time in Brisbane before settling in the rural town of D’Aguilar, Queensland.

On Valentine’s Day in 2004, a year after we moved, I found a lump and was diagnosed with breast cancer.

I had to undergo a major operation and travel to the city for daily radium treatments. Not only did cancer have a physical impact on my body, but it also affected me emotionally and financially. For a number of years after, I suffered panic attacks and became a recluse which made it incredibly difficult to work. Six years after my first diagnosis the breast cancer was back.

Thankfully we managed to get through it all together. We never used to celebrate Valentine’s Day, but we do now because I am all clear and have been for six years now.

However, our fight against this disease wasn’t over. A week before Christmas in 2014, Ian went to see the doctor in severe pain and he was diagnosed with pancreatic cancer. The doctors told him that unfortunately there was nothing they could do for him and that he should go home and get his affairs in order and enjoy what time he had left.

After we had got all of our affairs in order, our son suggested we have a “wake” as Ian was always saying how unfair it was that you’re not there to party with your friends and family when you die. So we had a pre-departure wake last year. It was just what we both needed – over 120 people came and it was a fantastic day.

During the day of celebrations, Ian told everyone to save the date for an ‘I’m Still Standing’ celebration in 2016 as he would still be here. And he was right.

Because Ian was keeping well, his doctors did an endless amount of scans, blood tests, and biopsies and discovered that he had a Neuroendocrine Tumour. This is a slow-growing form of pancreatic cancer, but it is still terminal. It has been an endless roller coaster ride of emotions, with a lot of twists and turns, but we are grateful for this extra time to enjoy together.

Cancer is an insidious disease that affects so many people. In the past five years, we’ve lost two brothers-in-law, I very recently lost my brother, and now I’m losing a good friend, and my husband – all to terminal cancer.

I nearly lost Ian at Christmas this year, but the fantastic staff at the Redcliffe Oncology performed a miracle and like Ian had promised, he is still here. My darling Ian is such a fighter, so I have decided to make his “I’m Still Standing” celebration day into a fundraiser for cancer research. I wanted to make a difference and help the dedicated and hardworking researchers bring an end to cancer.

We have been very humbled by the wonderful love and support of family and friends and even strangers. While I have been organising the fundraiser I have been blown away by people’s generosity. Thank you to everyone who has kindly helped this day come together. It’s going to be a fantastic event filled with lots of music, laughter, great prizes and everyone is welcome. We’ll also hold an auction, a cut and colour for cancer and have an open mic for anyone who wants to sing on the day.

I would really encourage others to donate or fundraise for cancer research because you may one day help save someone you love!

I hope that maybe our story will give someone else some comfort in their own struggle with cancer.” ACRF supporter, Carol Robinson

 

The Governor-General and Lady Cosgrove thank ACRF supporters

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, Cancer Research Grants, charity foundation, donate to charity, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories, Canberra Cancerians, Canberra Cancerians Committee, Governor General, Sir Peter Cosgrove, University of Queensland, John Curtin School of Medical Research, Government House, Canberra Cancerians Gala Dinner, Canberra Cancerians Annual BallThe Canberra Cancerians Committee is one of the most successful fundraising groups for cancer research in Australia. To date, they have raised more than $3.2 million for the Australian Cancer Research Foundation.

Over the years, they have earned a reputation for staging some of the most sought after and glamorous events on the Canberra social calendar, which includes their prestigious annual Gala Dinner. The ACRF is very grateful for the efforts of this incredible group of volunteer fundraisers.

Last week the Governor-General and Lady Cosgrove hosted a reception to recognise the efforts of this committee and thank them for their generous contributions to cancer research over the years. Below you will find his speech.

“On behalf of Lynne and I, I welcome you to Government House. Everyone here knows what a terrible disease cancer is. It kills nearly 50,000 Australians every year.

And we all know someone, a relative or friend, whose life has been deeply affected by it. What we need to do is beat this disease. We often hear the phrase ‘imagine a world without cancer’. Well, wouldn’t that be a great thing? But imagination only goes so far.

A world without cancer can be achieved but it will be achieved through research: world-class research that helps us to better prevent and diagnose cancers and develop new treatments and cures. This is what will beat cancer. This is what will save lives.

This is what drove the ACRF’s founders, Sonia McMahon and Sir Peter Abeles, and it is what lies at the very heart of your work and the work of the Australian Cancer Research Foundation.

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, Cancer Research Grants, charity foundation, donate to charity, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories, Canberra Cancerians, Canberra Cancerians Committee, Governor General, Sir Peter Cosgrove, University of Queensland, John Curtin School of Medical Research, Government House, Canberra Cancerians Gala Dinner, Canberra Cancerians Annual BallToday is about recognising the Canberra Cancerians and the foundation they support.

It is about saying thank you. Thank you for the $121 million in grants provided by the ACRF to hospitals, universities and researchers across Australia. Thank you for helping researchers at the University of Queensland find new ways to detect lung cancer before it gets a chance to spread. Thank you for supporting the John Curtin School of Medical Research to see if our native plants may hold the answers to new cures and treatments.

I could go on and on, but in short it will suffice to say that thanks to supporters like you, the foundation has transformed the scale and scope of cancer research in this country.

So take a moment to be proud of yourselves and all that you do—because what you do is remarkable, it is making a difference and it is appreciated by so many.

You are giving back, you are saving lives and you are part of a wonderful community and a wonderful foundation that is tackling cancer—head on.

And as tough as cancer may be, we’ll beat it, you’ll beat it—because not even cancer is a match for the spirit and determination I see in this room.”- His Excellency General the Honourable Sir Peter Cosgrove AK MC (Retd)

Australian melanoma rates improve

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, Cancer Research Grants, cancer scientists, Challenge, charity challenge, charity foundation, current cancer research, donate to charity, Fighting cancer, Funding research, Fundraiser, fundraising, give to charity, Types of cancer, QIMR Berghofer, QIMR Berghofer Cancer Research Institute, QIMR Berghofer Institute of Medical Research, Skin cancer, melanoma, skin cancer research, Australian cancer research

A study found that rates of invasive melanoma, the deadliest form of skin cancer, have started to decline in Australia and are predicted to keep falling over the next 15 years.

Researchers at QIMR Berghofer Medical Research Institute have found that Australia no longer has the highest per capita rates of invasive melanoma in the world, after being overtaken by New Zealand.

Researchers compared the rates of melanoma in six populations over a 30-year period from 1982 to 2011. The six populations were Australia, New Zealand, the United Kingdom, Norway, Sweden, and the caucasian population of the United States.

The researchers found that melanoma rates in Australia increased from about 30 cases per 100,000 people in 1982 and peaked at nearly 49 cases per 100,000 people in 2005. The rates then declined to about 48 cases per 100,000 people in 2011. Invasive melanoma rates in New Zealand reached about 50 cases per 100,000 people in 2011.

Professor David Whiteman, who led the study, said Australia was the only one of the six populations where melanoma rates had begun to fall overall.

“We think the main reason for this decline is that Australia has put a huge effort into primary prevention campaigns since the 1980s,” Professor Whiteman said.

“Australians have become more ‘sun smart’ as they have become more aware of the dangers of melanoma and other skin cancers. Schools, workplaces and childcare centres have also introduced measures to decrease exposure to harmful UV radiation.”

“This has contributed to a decline in melanoma rates in people under the age of about 50.”

“Unfortunately, rates of melanoma are still increasing in people over the age of about 50. This is probably because many older people had already sustained sun damage before the prevention campaigns were introduced, and those melanomas are only appearing now, many decades after the cancer-causing exposure to sunlight occurred.”

Despite the fall in average melanoma rates per 100,000 people, the overall number of invasive melanomas diagnosed in Australia is still rising and is expected to increase from 11,162 cases per year from 2007-2011, to 12,283 cases per year from 2012-2016.

Professor Whiteman said this was due to the ageing of the Australian population, as well as overall population growth.

“Melanomas occur most commonly in older people. As Australia’s population ages, the number of melanomas diagnosed will continue to increase,” he said.

“The picture in Australia at the moment is mixed. While it’s good news that average melanoma rates have started to fall, the fact that the actual number of cases is still rising is bad news.”

The Australian Cancer Research Foundation has supported cancer research at QMRI Berghofer by providing three grants, totalling AUD 6.65million towards cutting edge cancer research equipment and technology.

Mark’s eyes are on the finish line

ACRF, Australian Cancer Research Foundation, cancer charity, Cancer Research, cancer fundraising, cancer fun run, cancer research fundraising, Cancer Research Grants, cancer scientists, Challenge, charity challenge, charity foundation, donate to charity, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories, marathon, Running for Cancer Research, Types of cancer, Kidney cancer, Australian Running Festival, Canberra Times Australian Running Festival“I am 44 years old and have lived in Australia now for over 10 years. Last year, I had a very big scare when I was diagnosed with kidney cancer and had to have my kidney removed as a result.

Discovering the cancer was completely incidental. I had no symptoms or impaired renal function. About eight months ago I was admitted to the hospital with lower bowel pain. The doctors performed a CT scan and found that I had colitis.

They also noticed something that looked like a cyst in my right kidney. They advised me to get it investigated further so a few weeks later I had another scan. The result came back as “consistent with a cystic renal cell carcinoma.” It was in the very centre of my kidney.

It was just two months from when we first saw the mass, to when I underwent surgery to remove my whole kidney. In that time the mass had doubled in size and the final pathology found that it was a grade 2 cystic renal cell carcinoma.

Whilst I have enjoyed a good recovery and my prognosis is very good, there are many people and families who are not so fortunate. We need better diagnosis and treatments to help battle this terrible illness that has struck down so many of our loved ones. To help raise funds for cancer research, I decided to run in the Australian Running Festival’s Canberra Times half marathon.

In 2015, I participated in the half marathon to prove to myself that I could still be healthy and active after a spinal fusion I’d had a few years earlier. This year I’ll be motivated to raise funds for cancer research, not only because of my own battle but for all my family and friends who have battled cancer, many of whom have sadly passed away.

I want to try for a personal best but I have had to make big changes to my training. The biggest being that that I have only had eight weeks to prepare. Prior to that, I was not allowed to do any exercise, as I had to allow the stomach muscles to completely heal. It will make this year’s half marathon very challenging for me but running is not just about the physical activity, it also takes mental endurance.

I hope that we can encourage more people to support cancer research so that the teams of scientists – the unsung heroes in this battle, can achieve breakthroughs that save lives.

Thank you to everyone who has helped and supported me over the past six months as I have recovered and to those who have so generously donated to my page.” – ACRF supporter, Mark Potten.

To support Mark’s fundraising page, click here.

Michelle faces her fears to honour her brother

MichelleACRF supporter Michelle Ross will be facing her fear to help end cancer. “Three years ago, my brother Robbie found out that he had cancer at just 27 years old. His doctors found a large tumour in his leg that had to be surgically removed. Although the surgery left him with permanent nerve damage from his ankle down, he had received the all clear.

Unfortunately, his battle was not over. Two years later he began having back troubles and a scan revealed that cancer had returned. This time, it was in his shoulders, his femurs, his lower back and his chest. He fought through a major shoulder replacement which resulted in the loss of almost all movement in his arm. This was followed by months of radiation and chemotherapy treatment.

Last year, just before Christmas, we received the good news that he was again in remission.

Watching my brother go through this had really touched my heart. It was amazing to see all the support the hard working nurses and doctors gave Robbie. So to say thank you, I decided to help raise funds for cancer research.

Robbie has been facing what would be anyone’s worst fear. In honour of his courage, I wanted to attempt to face one of my fears and jump out of a plane at 15,000 feet. I signed up to the Australian Cancer Research Foundation’s JUMP! tandem skydiving program.

Since I’ve signed up, Robbie’s health has worsened. He started having back pain again and after a recent scan, doctors found that the cancer had returned for a third time in the vertebras of his lower back and he’s had to undergo more chemotherapy.

Two weeks ago his legs gave way and he had a fall. The cancer has paralysed him from his belly button down and he can no longer walk.

My family has come together with so much strength and love to support my brother through this hard time. Robbie is now in a wheelchair full-time and my parents have moved in to care for him at his home in Sydney.

I want to help find a cure for families in the future. No one should have to go through what my brother and so many people are going through.

I am so thankful for the amazing fundraising support that I have received from my friends and even strangers. Too many people you talk to in the street, know a family member or friend going through cancer and I hope that one day we end cancer once and for all.” ACRF supporter, Michelle Ross

To support Michelle visit: https://jump.everydayhero.com/au/michelle 

New Sydney cancer research centre looks into metabolic causes of cancer

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, Cancer Research Grants, cancer scientists, Centenary Institute, charity foundation, Charles Perkins Centre, current cancer research, donate to charity, Fighting cancer, Funding research, give to charity, Phillip Hogg, Professor Philip Hogg, Sydney, Sydney Catalyst, Types of cancer, University of SydneyThe Centenary Institute, in partnership with the Australian Cancer Research Foundation (ACRF) and Sydney Catalyst, today opened the new ACRF Centenary Cancer Research Centre at the University of Sydney’s Charles Perkins Centre in Camperdown.

The new centre will focus on two key specialist areas of cancer research – understanding the inflammatory and metabolic causes of cancer and the drivers behind cancer-driven blood clotting.

By investigating these two areas, the research team hopes to unveil how changes in metabolism support cancer growth and how these changes can be controlled by new treatments and therapies.

The ACRF Centenary Cancer Research Centre will be headed by Professor Philip Hogg, a world-renowned researcher whose expertise lies in the discovery of new cancer-active drugs and therapies. The centre will host a team of over 40 dedicated cancer researchers whose capability spans fundamental research to clinical trials.

“I would like to thank ACRF and their supporters for funding the new centre. It will significantly expand the Centenary Institute’s capabilities in cancer research and accelerate the development of new treatments for cancer patients,” said Professor Hogg. “Having this new facility has also helped us attract a brilliant team that includes some of the world’s leading scientific minds.”

ACRF’s CEO, Dr Ian Brown said, “Supporters of ACRF helped lay the foundation for this centre, a centre that will help the team at Centenary reveal key information that will help inform better cancer treatments which is an exciting step forward.”

The new centre is located within the University of Sydney’s Charles Perkins Centre and is the first dedicated cancer research centre in the Royal Prince Alfred (RPA) Hospital and The University of Sydney Precinct.

The establishment has been a collaborative effort lead by the Centenary Institute and included the Australian Cancer Research Foundation, Sydney Catalyst, Sydney University, the Charles Perkins Centre, RPA Hospital and Chris O’Brien Lifehouse.

Image from left: ACRF Chairman Mr Tom S Dery AO, NSW Minister for Medical Research, The Hon. Pru Goward, MP, Centre Director Professor Philip Hogg and Executive Director Mathew Vadas AO.

Jake takes on Mt Aspiring for cancer research

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, Cancer Research Grants, cancer scientists, Challenge, charity challenge, charity foundation, corporate giving, current cancer research, donate to charity, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories, give to charity, charity adventure, trekking adventureACRF supporter, Jake Hesson, has first-hand experience of the devastating effect of cancer on families. He recently embarked on a unique fundraising challenge to raise funds for a cause close to his heart.

“Almost all of us, at some point in time, will be touched by cancer. Over the past 2 years, this disease has significantly affected a number of my family members, as well as my friends and their families. I recently lost two uncles and an aunt to cancer and now my father is also undergoing treatment for thyroid cancer.

I became inspired by the work of the Australian Cancer Research Foundation and wanted to help make a difference for families suffering from cancer. My brother is a cancer researcher so I know just how important charitable grants, like the ACRF grants, are to the scientific community.

I chose to combine my love of alpine mountaineering with fundraising and decided to take on New Zealand’s Mt Aspiring. Not only is this mountain one of the most beautiful in the world, it was also going to be a very physical challenge.

I’ve been climbing since 2012 and have done a number of trekking trips. However, I had never climbed anything as technically difficult as this and certainly nothing quite as exposed! I did the trip with just one very experienced (and very patient) guide.

The highlight of my trip was definitely the isolation, absolute silence and beauty of the mountains. One night I woke up at 3:30 am and when I stepped out of the tent I looked at the summit and the Milky Way.  It was all brighter than I had ever seen. It seemed to be coming directly from the top of the mountain.

My advice to others thinking about supporting cancer research is to just do it! It doesn’t matter how you are planning to raise funds, the important thing is to try. Every donation contributes to advancements in cancer research and the sense of achievement and pride you will feel is really worth it.

I’d like to make a special note of gratitude to my employer, QBE (Australia) and the QBE Foundation for matching the sums I raised and donating almost $3,000 directly to ACRF.” – Jake Hesson, ACRF supporter.

Thank you to Jake and QBE for their generous contributions to cancer research. Corporate Matching Schemes are a great way for you make the most of your fundraising efforts. If you have been involved in a fundraising event for ACRF, it could be worth asking your employer if they offer a Corporate Matching Scheme.

Shave to Save supports cancer research

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, Challenge, charity challenge, charity foundation, donate to charity, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories, Types of cancer, End cancer, Head shave, head shave for cancer research, shave for the cure, shave for cancer, had shave for cancer, shave for cancer researchYoung Western Australian siblings, Prem and Mansi Aghera, together with their friends, Amee Bhuva and Ravi Ghodasara, raised over $6,000 for cancer research. We spoke to Prem about their amazing ‘Shave to Save’ fundraiser.

“My sister, Mansi was affected by cancer some time ago, so cancer research is a cause close to home. Mansi wanted this fundraiser to be a tribute to those who aren’t as lucky as her and to help researchers bring an end cancer. We know first-hand how cancer affects patients and their families and we wanted to help prevent more families from going through what we had to.

Apart from raising money, we also thought it was equally important to show solidarity with current cancer patients. We know that sometimes patients who lose their hair feel embarrassed and try to cover up. We hoped that by shaving our heads and proudly strutting around with our new looks that we could encourage people going through treatment to feel confident, with or without hair.

We wanted to spread awareness of the importance of cancer research and get as many people involved as possible. By choosing to shave our head we attracted a lot of interest in our community.

The ‘Shave to Save’ fundraiser was our way of showing everyone who is battling this disease that our community is standing with them – and we were overwhelmed by the support. Honestly, I don’t know why we didn’t do this sooner! We are truly humbled by the incredible support we’ve received over the past few months and we hope we’ve made a positive impact.

We chose to support the ACRF because the main aim of the foundation is to eradicate cancer altogether, and that’s our ultimate aim too. While there is a long road ahead, we have seen the impact a small fundraiser can have.

I believe that if people unite together we will continue to get closer to a future without cancer.” – ACRF supporter, Prem Aghera

FDC conquered the Rottnest Island Swim for Cancer Research

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, Challenge, charity challenge, charity foundation, corporate giving, donate to charity, Fighting cancer, Funding research, Fundraiser, Fundraising Stories, fundraising, give to charity, Types of cancer, Rottnest Channel Swim, Rottnest Island, The Rottnest Channel SwimThank you to our corporate supporters, FDC! A team from the Western Australian construction business took on the 19km Rottnest Swim challenge late last month.

Their swimmers – Mark, Monique, Sveta and April along with support crew Ed, Jason and John were all very excited to be fundraising for a cause close to their hearts.

“A number of people in our office have recently been touched by different types of cancer. So we chose to compete in this challenge to support the Australian Cancer Research Foundation because they are committed to ending all types of cancer.

We received wonderful support from our work colleagues, friends, families and extended community. We encouraged everyone we knew to get behind our team and help us reach our target by donating their spare change or coffee money to cancer research. Together we were able to raise close to $3,000 for a charity we value so highly.

The highlights on the day were all of us working together and having a laugh, everyone was very supportive – team members and competitors alike. This made our experience very enjoyable and we have been talking about doing the race again next year.

Most of us know someone that is either fighting cancer or has been directly affected by it in one way or another. With the shocking stats out there we are proud that we could do our bit to help researchers find a cure for all cancers.” – ACRF supporter, April Moir

To support the team, visit their everyday hero page.

Photo supplied by Aussies in Action.

A motorcycle trek in memory of two great men

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, Challenge, charity challenge, charity foundation, donate to charity, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories, give to charity, leukaemia, Types of cancer, Motorcycle challengeACRF supporter, Daniel Kranz is a 36-year-old father of two. He lives with his wife, Hannah, in Tinonee. In addition to recently starting his own skateboard manufacturing business, he is also busy planning an epic postie trek to honour two special men whom he lost to cancer.

“The Jindaboonda Postie Trek is a motorcycle ride of over 3,000km to raise funds for cancer research in memory of Dennis Jeffers (Jindaboonda). Last year pancreatic cancer took this awesome husband, father, son, grandfather, uncle and mate away from us. And what’s worse is Den wasn’t the first person I’ve lost to cancer. In 2001, I lost my Grandad, Murray Kranz, to leukaemia.

Den and I were always trying to organise a ride together but unfortunately that never happened.

Losing him so suddenly left our family utterly shell-shocked. I wanted to make something positive out of something so negative and organise this epic ride to celebrate the memory of him, my Grandad and everyone else who is afflicted by cancer. And what better way to help a family heal, than to get everyone together doing something these men loved, and in the process raise funds to help fight the disease that took them away.

A love of motorcycling wasn’t the only similarity between Den and Murray. They were both devoted family men who were respected and adored by everyone that knew them. We are told time and again by numerous people how positive their impact was on the community and how dearly missed they are. They were fine examples of how to be a good human being.

Both men were also very passionate about their careers. Den was an ecologist and ‘Jindaboonda’ was the name given to him by the members of the Biripi community after he worked with them extensively, teaching them about native plant seed propagation and bush regeneration.

Murray was a mechanic and in his retirement he restored several old 40s and 50s motorcycles. I guess once motorcycling is in your blood – you’re hooked for life. Anyone who rides a motorcycle will agree with me that it’s about as close to complete freedom as you can get.

Over 20 riders have registered for the trek so far. A large crew of extended family and close friends will also be following in support vehicles. I think all those postie bikes riding in group formation through town should get quite a lot of attention for the cause!

We’ve even had a few people who obtained their licences just to take part in the trek. One such rider is Emma. She lost her mum to cancer three and half years ago, and there was no way she was missing out on doing the ride.

We chose to support the Australian Cancer Research Foundation because it was important to us that we raise funds for an organisation that contributes to the research of all forms of cancer. When we approached the ACRF, they were so helpful and assisted me to get the ball rolling. It’s been a positive experience right from the start.

We’re all working hard to fundraise as much as we can in the memory our loved ones, and in the process, we’re having an adventure and healing together.

Thank you to all the participants, to everyone who has donated and sponsored us, and to all those who have helped us out so far.” – Daniel Kranz, ACRF supporter.

To support the Jindaboonda Postie Trek, click here.

 

Entertainment Books are now available for order through ACRF

entertainment book, cancer research, deals, charity, donationsEntertainment Books are a great way to make the most of what is happening in your local community. They offer hundreds of discounts and 2-for-1 vouchers from the finest restaurants, cafés, attractions, and accommodation.

And best of all, when you order the Entertainment Book through ACRF you’ll also be investing in better cancer diagnosis, treatments and prevention methods.

From each book purchased, 20% of profits will fund world-class cancer research, helping Australia’s best scientists speed up progress in cancer research. Find out more about the work they do here.

The Entertainment Book now has two options to choose from – the traditional hard copy book and a new digital membership. Each membership gives you over $20,000 worth of valuable offers valid through to 1 June 2017.

With the digital version of the Entertainment Book, it’s even easier to find restaurants and attractions near you. The hard copy book will be available for pick up in April from the ACRF office which is conveniently located in the heart of Sydney.

“The book gave us hundreds of ideas on places to see and eat. We saved heaps on trips as well, it’s just fantastic!” Michelle E., Sydney

Place your order and help bring us closer to a world without cancer.

Melbourne researchers trial new leukaemia treatment

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, Cancer Research Grants, cancer scientists, charity challenge, charity foundation, current cancer research, donate to charity, Fighting cancer, Funding research, Peter MacCallum Cancer Centre, Walter and Eliza Hall Institute, Types of cancer, leukaemiaIn a world-first clinical trial, Melbourne medical researchers have shown that patients with an advanced form of leukaemia can achieve complete remission with a new tablet treatment.The trials were conducted at The Royal Melbourne Hospital and the Peter MacCallum Cancer Centre, in collaboration with the Walter and Eliza Hall Institute, as well as trial sites in the US.

Clinical trials of the potent new anti-cancer drug Venetoclax showed it was effective in killing cancer cells in people with advanced forms of chronic lymphocytic leukaemia (CLL) when conventional treatment options had been exhausted.

Seventy-nine percent of those involved in the trial had promising responses to the new therapy – including twenty percent who went into a complete remission. A small number of patients had such a profound response that even very sensitive tests were unable to detect any remaining leukaemia in their bodies.

CLL is one of the most common forms of leukaemia, with around 1,000 people diagnosed with this type of cancer in Australia every year. More than 350,000 people were estimated to have been diagnosed with leukaemia in 2012 worldwide, with incidence rates varying across the world.

The drug has been granted priority review status by the US Federal Drug Agency (FDA) for treating some types of CLL. The designation is granted to medicines that the FDA has determined to have the potential to provide significant improvements in the treatment, prevention or diagnosis of a disease.

Venetoclax was developed based on a landmark discovery made in the 1980s by Walter and Eliza Hall Institute scientists that a protein called BCL-2 promoted cancer cell survival. Venetoclax was co-developed for clinical use by US pharmaceutical companies AbbVie and Genentech, a member of the Roche Group, and was discovered as part of a joint research collaboration that involved Walter and Eliza Hall Institute scientists.

Professor Andrew Roberts, a clinical haematologist at The Royal Melbourne Hospital and cancer researcher at the Walter and Eliza Hall Institute, said the drug works very specifically by overcoming the action of BCL-2.

“Most trial patients responded positively to the therapy, showing substantial reductions in the number of leukaemia cells in their body. Many patients have maintained this response more than a year after their treatment began, and some patients remain in remission more than four years on,” Professor Roberts said.

“High levels of BCL-2 protect the leukaemia cells from dying, so leukaemia cells can grow and become resistant to standard treatments. Venetoclax selectively targets the interaction responsible for keeping the leukaemia cells alive and, in many cases, we’ve seen the cancerous cells simply melt away.”

Professor John Seymour, Chair of the Haematology Service at Peter MacCallum Cancer Centre says, “The fact that a targeted drug, given on its own, can produce such a profound reduction in the leukaemia burden in the patient, to the point we cannot find leukaemia cells even with our best tests, underscores what a powerful strategy targeting the BCL-2 gene is.”

These results set the foundation for building towards the dream of a cure for CLL. Phase 2 and phase 3 studies are currently being undertaken to test Venetoclax across a range of blood cancers globally, including at many sites in Australia.

The Australian Cancer Research Foundation has supported cancer research at Walter and Eliza Hall Institute and Peter MacCallum Cancer Centre by providing three major grants to both institutions, totalling AUD 12.5m.

This news was first published on the Peter MacCallum Cancer Centre website.

Cancer research uncovers promising new cancer drug

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, Cancer Research Grants, cancer scientists, charity foundation, current cancer research, donate to charity, Fighting cancer, Funding research, Walter and Eliza Hall InstituteCancer researchers at the Walter and Eliza Hall Institute in Melbourne have uncovered how nutlins, a type of small molecule inhibitor, contribute to cancer cell death. Until now, it was unknown whether nutlins were killing cancerous cells or suppressing them temporarily.

In early clinical trials for treating blood cancers, Dr Liz Valente, Dr Brandon Aubrey, Professor Andreas Strasser and team discovered that nutlins are able to stop cancer growth by activating the body’s natural cancer-suppressing mechanism. They stimulate a gene called P53 to trigger programmed cell death of blood cancer cells while avoiding some of the damaging effects of chemotherapy.

Dr Aubrey, who is also a clinical haematologist at The Royal Melbourne Hospital, said the discovery reinforced that nutlins were a promising new treatment for blood cancer. They also provided invaluable information for a more personalised approach to patient care.

“Our findings will help identify which patients are most likely to benefit from nutlins and which types of cancers are most likely to respond to nutlins as a treatment,” Dr Aubrey said.

“Understanding in detail how the drugs work will help in the design of better clinical trials and bring the world closer to more precise and personalised medical treatments for cancer.”

Professor Strasser said previous research around P53 showed that one of the properties of the gene was to protect the healthy cells in the body. The gene has been identified as a major barrier to developing cancer.

“Without the ‘help’ of P53, a damaged cell can be allowed to multiply, leading to cancer development. P53 lies dormant in many types of cancer – that do not have mutations in P53 – and the nutlins work through re-awakening its activity.”

Professor Strasser said knowing more about what nutlins were capable of was a critical step towards developing more refined treatments for cancer.

“By understanding how nutlins are killing cancer cells, we can begin to formulate their best possible use, including choosing the best partner drugs to combine the nutlins with,” Professor Strasser said.

The research has been published in the journal Cell Reports. To view the original news article was published on the WEHI website, click here.

The Australian Cancer Research Foundation has supported WEHI by providing three grants, totalling AUD 5.5million towards cutting edge cancer research equipment and technology.

What research did for breast cancer patient, Shona

ACRF, Australian Cancer Research Foundation, Breast Cancer, cancer charity, cancer fundraising, cancer fun run, Cancer Research, cancer research fundraising, Challenge, charity challenge, charity foundation, current cancer research, donate to charity, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories, Running for Cancer Research, Canberra, Canberra Times Australian Running Festival“My name is Shona. I’m a mother of two young girls, aged 6 and 10, and a police officer from Canberra. In November last year, a week after my 39th birthday, I discovered a lump in my left breast.

I had never been diligent about self-checking. I always thought I was too young to contemplate breast cancer but I had a feeling that this lump hadn’t been there before. I reluctantly went to see my GP in the hope she would tell me it was nothing to worry about – she didn’t.

She sent me in for testing and two days later I was booked in for an ultrasound and biopsy. The results came back the following day and I was diagnosed with invasive ductal carcinoma.

The next few days were all a whirlwind and it felt like my feet didn’t touch the ground. I was quickly referred to a breast cancer surgeon and put in contact with a breast care nurse at Calvary Hospital.

Within two weeks of my diagnosis, I underwent a mastectomy. I will be forever grateful that my lymph nodes were clear and I was sent home from the hospital three days later. I recovered from the operation with absolutely no complications and was able to return to work a few weeks later.

My medical team suggested that I have Oncotype DX testing to determine what treatment plan I would need. I only realised how important this testing was when the results came back and showed I wouldn’t have to undergo chemotherapy. Without the testing, my oncologist would have recommended chemotherapy. I am undergoing endocrine therapy, which is not without side effects, but thankfully they are minimal. Which means that I’ll be well enough to run in the Australian Running Festival half marathon in April to raise funds for cancer research.

I have now been given the all clear and I consider myself very lucky. Sadly I lost my grandmother to bowel cancer and two amazing women in my extended family to breast cancer. I am the first woman in my immediate family to undergo treatment for breast cancer and I never want to see my sisters or daughters go through what I had to.

I’m astounded by the overwhelming support I have received from my family, friends and especially my colleagues. I am so proud of my fellow brothers and sisters in blue, their generous donations have contributed to over 90% of my current fundraising total. We really try to support each other during the tough times – they are my extended family and I love them all.

I will carry scars into the future as a testament to my battle but I am determined to not let cancer kill me. I have two amazing and beautiful daughters that need their mum and I am supported by the most incredible man I call my husband. This has been a tough time for me and my family but I am thankful that I am one of the lucky ones.

Early detection and superb medical intervention means I will survive. I hope that by sharing my story I can make people aware of the importance of early detection and self-breast checks, and help raise funds for cancer research.” – ACRF supporter, Shona Davis.

Click here to support Shona’s Canberra Times Half Marathon.

Share your story

 

Tony Cant Real Estate – Fundraising in memory

Feb_Corporate_TonyCantHunter-based Real Estate agency Tony Cant will be supporting cancer research in honour of their founder, Ross Birrell who lost his battle with lung cancer last year.

Ross’s son, John Birrell followed in his father’s footsteps as the Principal and Sales Consultant of the agency. He has pledged to donate 5% of the commission from each house sold in March to the Australian Cancer Research Foundation.

“I lived my life to make my father proud, and I like to think I achieved that. It was great to hear him say how proud he was of his kids, his wife, and his staff.

Ross, in a nutshell, was an action man. He was an utterly selfless and giving man with an enviable spark for life. He lived by the phrase ‘actions speak louder than words’ and I like to think I can carry on that legacy. As the anniversary of his passing approached we decided to support cancer research because we wanted to prevent other families from going through the same loss.

Ross tried his hand at every career under the sun before finding his true passion in real estate. Real estate resonated with his ambitious, enthusiastic and vibrant personality and with the help of his long-term mate, Tony Cant, he was able to set up two small businesses in Thornton and Medowie.

All of our offices are doing something to get involved. We’re currently advertising our promotion in local newspapers, have distributed flyers and made letterbox drops throughout the community. We have also shared it across our social platforms, our website and on our email signatures.

It was hard to say goodbye to my dad as he was my role model and my best mate.  I am proud that the team at Tony Cant can do our part to end cancer in his memory.” – ACRF Supporter, John Birrell

To learn about different ways your workplace can get involved with ACRF, click here.

Barbas & Zacári – Your time is valuable

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, charity foundation, corporate giving, donate to charity, regular giving, Corporate donations to charity, corporate charity donation, corporate charity donations, workplace giving

ACRF corporate supporters, Tas Zacári and Emmanuel Barbas are two young entrepreneurial designers from Melbourne.

They recently established a new watch brand, Barbas & Zacári which caters to those with a passion for minimalist style and gives customers an opportunity to contribute to the fight against cancer with every purchase.

“To give back to a good cause and to do what we can to help, we decided to donate $5 (AUD) to the Australian Cancer Research Foundation for every watch sold.

We are extremely proud to be supporters of cancer research and we can’t thank our customers enough for their support thus far. We are really excited to see what we can do in 2016,” said the founders.

The brand promotes their watches alongside the hashtag #yourtimeisvaluable, to highlight the importance of cancer research and recognise that every hour we spend on this earth is valuable to each individual.

“We think it’s marvellous that designers and young entrepreneurs are doing what they can to help us fund research into the diagnosis, treatment and prevention of all types of cancers,” said ACRF’s CEO Professor Ian Brown.

Their first collection, released in December, offers five styles of contemporary and fashionable unisex watches that suit any occasion. For more information on Barbas & Zacári or to purchase one of these great time pieces, click here.

Basia and Gary’s Story

Basia&GaryFamily“I was pacing the lounge room floor feeding Grayce when I heard a car door slam out the front. Just for a second, I thought he’d come home, that he had been out for dinner with the boys, that the last six months had disappeared.

It felt nice, for one second, like it used to be. I hope there are other fleeting moments like that. Because just for a second, I was in that other life and I remembered how it felt to be happy.

I lost my husband, Gary, to oesophageal cancer 19 days after we were married. Our third child, Grayce, was born four weeks later.

Though our time together was short we managed to fit a lot of life into those years. We also had lots of quiet moments, just enjoying spending time with each other.

He was very hands-on around the house and with the children. There was nothing he loved more than to potter around on the weekends doing the jobs he had listed during the week, fixing things and finding better ways of doing things and then we would have our coffee mid-morning sitting in the backyard.

We would email each other every day at work – just a few words here and there, or an interesting article. I miss all the little things that made our lives so much fun. The touch of his skin, a thousand gestures.

Gary’s battle with cancer started on the 2nd of July and lasted for twelve and a half weeks. As the cancer ate away at Gary, I thought he looked more beautiful. His spirit, grace and dignity shone through more with each passing day.

He was the perfect patient. He never complained and would try and help me help him as much as possible, even trying to lift and move his legs with his hands, and I would tell him off each time.

That’s why we decided to call our daughter Grayce with a ‘y’ – grace for how much of it shone through him during this battle. The four letters of Gary’s name are carried on in the name of his daughter.

That was his next goal, and what he told the doctors at his last oncology appointment. He wanted to meet his daughter.

In the end I couldn’t ask it of him. I knew he could hear everything I was saying. I lay down on the bed next to him and put his right hand on top of my belly. I told him I loved him so. I said, ‘I don’t want to let you go but I have to. It’s time for you to go.’

He opened his eyes and deliberately blinked at me for the first time in hours. Then he took two more breaths and went.

I still cannot bring myself to stretch out across the whole bed. It will mean finally admitting to myself that he won’t be riding his bike home and pushing it through the open door. That he won’t be bending down to hug the kids as they come running to greet him, squealing with delight. I know those things cannot happen but I still see them. I wish them. I live them in my head.

They say memories are golden. Well maybe that’s true, but I never wanted memories, I only wanted you.” – ACRF Supporter, Basia

We can’t bring Basia’s husband back to her but we can stand beside her while she continues to battle cancer through supporting research. To help her in her mission to protect others from having to go through what she went through click below.

DONATE NOW

 

International Day of Women and Girls in Science

cancer research, women in cancer research, International Day of Women and Girls in ScienceToday is International Day of Women and Girls in Science, a day to recognise the inspirational women who are achieving incredible feats, many of which we already benefit from. From our world-class Medical Research Advisory Committee (MRAC) we would like to recognise the following women who have dedicated their careers to advancing cancer research.

Professor Michelle Haber AM, BSc (Psych) (Hons), PhD, Hon DSc UNSW: Professor Haber was appointed to the MRAC in 2012. She is the Executive Director of the Children’s Cancer Institute Australia in Sydney. Additionally she is the Conjoint Professor at the Faculty of Medicine at the University of NSW.

Professor Jennifer Stow, BSc (Hons), PhD: Professor Stow was appointed to the MRAC in 2009. She is an NHMRC Principal Research Fellow and the Deputy Director for Research and Group Leader at the Institute for Molecular Bioscience located in the University of Queensland.

Associate Professor Connie Trimble, MD: Professor Trimble was appointed to the MRAC in 2014 and is one of the first international members of our committee. Professor Trimble is the Associate Professor of Gynecology, Obstetrics and Oncology at John Hopkins School of Medicine in Baltimore, USA. She is also a Diplomat of the American Board of Pathology and the American Board of Obstetrics and Gynecology as well as a Fellow of the American Congress of Obstetricians and Gynecologists.

Professor Emma Whitelaw: Professor Whitelaw was appointed to the MRAC in 2012. She is an NHMRC Australia Fellow as well as the Director of the La Trobe Institute of Molecular Sciences.

Each of these women have done amazing work with the ACRF and is an inspiration to young women looking for mentors in leading roles. We’re extremely proud to work with these women on a regular basis and thank them all very much for their dedication to cancer research in Australia.

ADF Long Tan Youth Leadership winner pledges to shave his head

head shave, shave for cancer, ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, Cancer Research Grants, cancer scientists, charity foundation, donate to charity, current cancer research, Fighting cancer, Fundraising StoriesRiley Debney is working his way through year 11 and enjoying his hobbies – footy, basketball and photography. He also spends a great deal of time contributing to his community and helping others, which has included time volunteering in a Cambodian orphanage and now he’ll be raising funds for cancer research.

Riley first contacted the Australian Cancer Research Foundation to donate his prize money to cancer research after he became an ADF Long Tan Youth Leadership and Teamwork award winner through his school. Riley continued to build on his fundraising ideas and he’s well on his way to reaching the impressive fundraising target he set for himself. When he achieves it, he and a friend have pledged to shave their heads.

“Cancer had never really affected me until about four months ago when a relative was diagnosed with pancreatic cancer. That’s when I really started to think about how many other people in my community must be going through the same thing.

Then a young boy from my school, Rafael, sadly lost his battle a few days before Christmas. He was diagnosed with neuroblastoma when he was just four years old. His passing really encouraged me to bring my fundraising goals to life.

Our school and community had been following Rafael’s cancer journey for the past couple of years. His parents set up a Facebook account called ‘Rafael’s Warriors’ that gave us news on his progress and helped us keep connected with Rafael when he was away receiving treatment.

He truly inspired me to help out and contribute more to my community. His strength taught us all so many lessons of love, happiness and support – and that’s something I will take with me everywhere I go so that his legacy lives on.”

Riley believes it’s important to support cancer research because of the benefits that it provides to those who are affected by cancer. “It’s amazing to me that each dollar does so much to help end cancer and help save lives,” he said.

“I have got some great support behind me from my friends and family, as well as some sporting clubs that have come onboard to help me fundraise and some generous local businesses that have made donations. I’ve also been selling ribbons to help raise awareness about the importance of cancer research.

My advice to others thinking about supporting cancer research is to just go for it – there’s nothing to lose! At first, I was nervous about starting this fundraiser as I didn’t really know where to start, but this is a cause that I really believe in and I have already gained so much support from my friends and family. Within just a few friendly emails between myself and the team at ACRF, my idea had come to life and I was on my feet. Use your resources and you’ll be surprised what you too can achieve.”

To support Riley’s ACRF fundraiser click here.

Cancer research to improve radiotherapy treatment

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, Cancer Research Grants, cancer scientists, charity foundation, donate to charity, current cancer research, Fighting cancer, Fundraising StoriesThe radiotherapy research team at Ingham Institute is one of only three research teams in the world to develop a new technological concept and design to improve targeted radiotherapy.

The technology, called MRI-Linac, combines an MRI magnet with a Linac Accelerator (a radiation cancer treatment machine) to improve the accuracy and precision of radiotherapy treatment for cancer.

Radiotherapy is a mode of cancer treatment that uses a Linear Accelerator to produce X-rays that kill or damage tumours to stop them from growing. However, in doing this, the radiation process may also damage normal tissue in the way of the radiation beam during the treatment. Improving the accuracy of treatment will result in better treatment outcomes and fewer side effects for cancer patients.

Until now the MRI and the Linac have worked separately. By joining them together as the MRI-Linac, the Ingham Institute has a system that enables a real-time view of tumours that stretches way beyond basic anatomy, including the chemical structure of tumours and normal tissues. The unique design of the system gives Ingham Institute scientists and cancer researchers the ability to position the treatment or radiation beam in two different arrangements which will improve accuracy further.

“Radiation treatments for cancer must take into account changes that can occur to the location and shape of tumours, which move as a result of breathing, swallowing and other normal body changes. This is where the strength of the MRI-Linac system comes into play, as it is the only system that will enable us to target the tumour with the radiation beam much more accurately in real-time and have control over the radiation dose,” said Associate Professor Gary Liney, Senior MRI Physicist at the Ingham Institute.

In 2014, the Australian Cancer Research Foundation provided a grant of AUD 2.5 million for the creation of The ACRF Image-X Institute at the Ingham Institute. The research is in its early days and the clinical applications of the new treatment are 5-10 years away.

A little girl with big dreams

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, cancer research fundraising, charity foundation, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories, give to charity, Types of cancer

At only seven years old, Leah Paterson is one of the Australian Cancer Research Foundation’s youngest supporters. She’s been working to raise funds for cancer research in honour of her great-grandmother who is currently undergoing treatment for pancreatic cancer.

Leah has earned a place as a finalist in the Junior Miss Diamond Australia 2016 pageant. The contest encourages participants to be part of a cause that helps others and teaches them how to fundraise for charity.

As part of her quest to gain the title, Leah is required to represent her local area and choose a charity to partner with. Leah chose to support cancer research through the ACRF as her family has been touched by the horrible disease twice in the past few years.

“My great-grandmother has been going through treatment for pancreatic cancer. And my mum also lost her uncle a few years ago to the same cancer. I am raising money so researchers can help fix people like my great-grandma by finding stronger ways to fight cancer,” said Leah.

Leah is hoping to raise close to $2,000 before the pageant grand final in April. To help reach her target she been raising awareness about cancer research by doing various fundraising activities throughout her school and community.

Leah’s mother and great-grandmother are very proud of Leah’s commitment to a cause so close to their hearts. “This contest is different to typical pageant competitions, it focuses on promoting community values and helps teach children that there is so much more to beauty than physical appearance,” said Leah’s mother, Sara.

 

Fighting blood cancers with new therapies

ACRF, Australian Cancer Research Foundation, cancer charity, Cancer Research, Cancer Research Grants, cancer research fundraising, cancer scientists, charity foundation, current cancer research, Peter MacCallum Cancer Centre, Types of cancer, leukaemia, lymphoma, myeloma

Researchers at the Peter MacCallum Cancer Centre in Melbourne are pioneering the development of a new combination drug therapy to treat advanced blood cancers.

The new therapy builds on a world-first clinical trial already underway at Peter Mac, which uses the drug CX-5461 to treat patients with incurable blood cancers such as myeloma, lymphoma and leukaemia.

The new discovery, published in the journal Cancer Discovery, has shown promising results to date. The research team has found that CX-5461 could be even more effective when used in combination with another drug, Everolimus, already used to treat other cancers. The new combination has shown doubled survival times in pre-clinical laboratory models.

According to Professor Rick Pearson, Head of Peter Mac’s Cancer Signalling Laboratory, the research findings significantly enhance understanding of pre-emptive strategies to kill off cancer cells before they have the chance to become resistant to therapy.

“CX-5461 targets a particular process that is required for cancer cell survival. Our experiments show that adding Everolimus synergistically strengthens this attack, more rapidly and more effectively eradicating the killer disease.”

“We know that all cells rely on ribosomes (protein builders of the cell Ed.) which act like a factory producing the proteins essential for their growth and survival,” said Professor Pearson.

“Peter Mac researchers have previously shown that certain blood cancers are far more reliant on these proteins than normal cells and that eliminating the protein production capability of ribosomes leads to the rapid death of cancer cells while normal cells stay viable.”

“This novel therapy works to inhibit the ribosomes’ protein production capability, effectively starving the cancer cells of a key ingredient they need to survive and proliferate.”

“A further study in collaboration with scientists at Monash University shows striking effects in the targeting of late stage prostate cancer through a similar strategy indicating that this approach may be generally applicable for a range of cancer types.”

Associate Professor Simon Harrison, Consultant Haematologist at Peter Mac and Principal Investigator on the CX-5461 first-in-human trial, says this new research provides further confidence that researchers are on the right track.

“The prevalence and poor prognosis for people with advanced blood cancers demand the ongoing and intricate study of abnormal cell behaviour, which has been an indicator of cancer for over 100 years. To date, 15 patients have been treated on the first-in-human clinical study with a number of patients experiencing prolonged benefit.”

More than 12,000 Australians are diagnosed with blood cancer annually (approximately 10% of all cancers) and around 4,000 Australians will lose their lives to the disease each year.

This research is supported by the National Health and Medical Research Council; Cancer Council Victoria; the Leukemia Foundation; Prostate Cancer Foundation of Australia; Cancer Australia; Victorian Cancer Agency, Australian Cancer Research Foundation and Peter MacCallum Cancer Foundation. Collaborators include the John Curtin School of Medical Research at the Australian National University and Monash University.

The Australian Cancer Research Foundation has supported cancer research at Peter Mac by providing three major grants, totalling AUD 7 million.

The news was originally published on Peter Mac’s website.

 

 

Lee Bektash is on the fast-track to end cancer

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, charity foundation, corporate giving, donate to charity, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories

Lee Bektash is a Victorian drag racing driver for Team Mopar and he’s put his support behind the Australian Cancer Research Foundation. The Pro-Stock Star and his team donated their prize money from last week’s race at Calder Park to help fast-track better treatments and detection for cancer.

Lee achieved the top speed of the Pro Stock Race, reaching an incredible 200.65 mph (323 km/h).

“This is something that I have wanted to do for a little while. I lost my first cousin to cancer six months ago and our family had also lost another relative to cancer just last year.

Cancer affects everyone and we want to be a part of helping to find cures so that as few families as possible are affected like we have been. The cures are out there, we just need to find them!

We decided to support the Australian Cancer Research Foundation because it is a private organisation, relying on the power of the community in order to provide Australia’s best cancer research teams with the technologies and facilities they need to fast-track discoveries.

I’ve been so proud of our team’s efforts over the last few seasons, we’ve had good results because of the support we’ve received. Our weekend at Calder Park gave us a great opportunity to put some money to good use – and there is no better cause than this!

The ACRF funds and supports the analysis and testing of new treatment, diagnostic and preventative measures for all types of cancer. It keeps Australian scientists at the forefront of medical research and brings us ever closer to the cures.

This is a privilege for the Team Mopar Australia crew, we put everything into our races in the hope that we can give something back!”

A big thank you to Lee and the team for their generous support!

 

Toby’s Beard Shave for Cancer Research

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, Challenge, charity challenge, charity foundation, donate to charity, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories, Types of cancer, shave for the cure, be brave and shave, shave my hair for cancer, head shave for cancer research“My name is Toby and I’m 29. I was diagnosed with rectal cancer in October 2014. Prior to my diagnosis, I was a very active and healthy person – I enjoyed running and hitting the gym, I never smoked and drank only on occasion. There was also no history of rectal cancer in my family – so the diagnosis came as quite a shock.

Since then I have received multiple rounds of chemotherapy and radiation, as well as some major operations so doctors could remove the cancer, create a temporary ileostomy, and then reverse it.

I’m currently recovering from the reversal surgery and getting used to my new “plumbing.” I will still need to go to follow-up appointments every three months or so but fortunately I was given the all clear late last year.

A couple of months before I was diagnosed I started growing a beard. Once everybody got over the initial shock of my diagnosis, questions began turning to my beard and when I was going to shave it.

My beard had become a comfort for me through all of this, so if I was going to shave – it had to be for a good reason! I started thinking about the idea of shaving it off for charity and because I received so much support, I felt that I should do something to give back.

Cancer is too common and this has become even more obvious since I was diagnosed. Almost everyone I meet has a story of someone close to them who has been affected by cancer. I feel like I am one of the lucky ones and I wanted something good to come from my experience.

On Australia day, I’ll be holding a celebration and shaving ceremony at our local bowls club. I’ll be putting on a big barbeque to say thank you to all my friends and family who supported me and donated to my cause. I’ll also be raffling off some great prizes from generous local businesses, as well as the honour of who will get to make the first cut of the shave!

I really hope that someday, no one will have to go through what I and so many others have been through. Finding a cure or a gentler form of treatment is the ultimate goal and that is why I decided to support the Australian Cancer Research Foundation.

Every little bit helps to bring us closer to finding a cure or developing better treatments that will make it easier on those diagnosed, and their family.” – ACRF Supporter, Toby Stodart.

To support Toby’s Beard Shave for Cancer, click here.

Scanning centre to transform disease research

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, Cancer Research Grants, cancer scientists, charity foundation, current cancer research, donate to charity, Fighting cancer, Funding research, fundraising, QIMRThe diagnosis and treatment of cancers, mental health disorders and conditions such as dementia is set to reach new heights in Brisbane with the launch of a $24 million facility that combines state-of-the-art equipment with world-class research and clinical expertise.

The Herston Imaging Research Facility has officially been launched by Premier Annastacia Palaszczuk.

Facility Medical Director Dr Liz Kenny said the new centre was one of the most exciting clinical imagery ventures in the Asia Pacific.

“It will become the centre of clinical research in Queensland through the use of cutting-edge imaging equipment and will contribute to the understanding of diseases and the development of new drugs and treatment therapies,” she said.

Dr Kenny, who is also the Royal Brisbane and Women’s Hospital’s senior radiation oncologist, said the facility featured hybrid scanners which combined magnetic resonance imaging (MRI), positron emission tomography (PET) and computed tomography (CT), allowing molecular processes and anatomical images to be captured simultaneously.

“This results in a faster and more efficient process for researchers, clinicians and patients,” she said.

The facility is a collaboration between The University of Queensland, the Metro North Hospital and Health Service, the Queensland University of Technology and the QIMR Berghofer Medical Research Institute, with Siemens as an industry supporter.

University of Queensland Vice-Chancellor and President Professor Peter Hoj said the infrastructure made Queensland a better environment for the development of new patient treatments.

“It will add value to other recent partnership developments like the Queensland-Emory Drug Discovery Initiative and the Centre for Advanced Imaging, and give Queensland innovators a sharper edge in the global race for new preventions, treatments and cures,” he said.

Australian Cancer Research Foundation Chairman, Mr Tom Dery, said the facility would help Queensland’s world-class cancer scientists pursue important cancer research discoveries.

“The future of cancer prevention and treatments depends on Australia’s best researchers having access to the cutting-edge resources and technologies such as these,” he said.

QIMR Berghofer Medical Research Institute mental health and complex disorders leader Professor Michael Breakspear said the imaging facility would enable work to begin to categorise and discover different subtypes of mental health disorders.

“We’re exploring ways to diagnose mental health disorders before the symptoms appear,” he said.

“To do this, we need to develop new diagnostic tests using medical imaging technology.”

QUT Faculty of Health Assistant Dean (Research) and Institute of Health and Biomedical Innovation Deputy Director Professor Greig De Zubicaray said the scanning capability of the new facility would contribute to understanding of the function and structure of diseases such as cancer and stroke.

“With this imaging technology we can detect disease, we can monitor progress and we can see whether or not we can predict recovery,” he said.

The Herston Imaging Research Facility is on the Herston health campus, near the Royal Brisbane and Women’s Hospital and major medical research facilities.

The Global Effort to End Cancer

Barack Obama

US President Barack Obama has shared his hope that one day America will cure cancer. In his state of the union address on Wednesday, he declared, “For the loved ones we’ve all lost, for the families that we can still save – let’s make America the country that cures cancer once and for all.”

Australian Cancer Research Foundation CEO Professor Ian Brown spoke with ABC Radio National to explain why researchers believe that a cure for cancer really is on the horizon.

“There are statements being made now, that say within a generation, cancer will go from being a source of trepidation, where a sizeable number of people are lost, to one where it will become a treatable disease. And there are very good reasons why we think we’re heading in that direction.

Going back 30-40 years ago, the number of people who were passing away from cancer was quite high and since then researchers have worked to increase our knowledge of the disease substantially.

Today, about 50% of people who contract cancer will survive. But this varies between certain types of cancer. Take thyroid cancer for instance, the survival rates are much higher than they used to be, with more than 95% of people now surviving. However, in a range of other cancers, such as pancreatic cancer or mesothelioma, the survival rates have remained very low.

Over time three main ways have been established as methods to treat most cancers, those are: surgery, radiation therapy and chemotherapy. But over the last 15 years, we have come to understand more about how cancer forms and this has helped shape new treatment methods.

We now know that cancer is basically a mutational change to the genetic information that causes the cells to proliferate abnormally. These cells won’t simply die and our own internal systems aren’t able to kill the tumours. With this understanding, scientists have worked to find new ways to fight this disease.

Medicine is now becoming far more personalised. Information about each individual’s tumour is now being logged into databases. This includes data such as: what the mutation was, what doctors used to try and treat that particular tumour, and whether that treatment was successful, making it far easier for doctors treating the varying mutations that cause different cancers.

The Human Genome Project in 2002 was the first example of such a database, logging all the genetic information that we had. It cost around $3 billion and took twenty years to complete. Whereas, the equipment that we now have, can do this much faster and easier that for less than $1000.

This is why seed funding for upgrading technology and infrastructure is so important. By equipping the best researchers with the right tools, we will speed up discoveries and ultimately save lives.

Science is a collaborative enterprise. People are constantly working to add to our understanding of cancer. We know that by sharing this knowledge around the world, progress is possible. For example, after it was discovered that certain types of viruses could cause cells to become cancerous Australian scientist, Professor Ian Frazer co-developed the cervical cancer vaccine which can now prevent various forms of cancer. This vaccine has now been used in hundreds of millions of people in 120 countries around the world.

So as Obama delcared, America will continue to play an important role in curing cancer, but ending this disease will take global collaboration.”

To listen to the interview: Click here

Breakthrough in predicting the spread of cancer

ACRF, Australian Cancer Research Foundation, cancer charity, Cancer Research, Cancer Research Grants, cancer scientists, charity foundation, current cancer research, Fighting cancer, Funding research, Garvan Institute of Medical Research, Sydney, Types of cancerA team of cancer researchers from Australia and the UK have bred a biosensor mouse that has enabled them to watch as pancreatic cancer cells ‘unzip’ right before they begin to spread.

“Our biosensor mouse makes it possible to look at a primary tumour that has not yet spread: in real time, in 3D, and in a living tumour. Using state-of-the-art laser technology, we can see, at a molecular level, whether the contacts that hold tumour cells in place have started to unzip – and that’s a sign that the cancer is about to spread,” says Dr Paul Timpson of Sydney’s Garvan Institute of Medical Research.

To understand how unzipping contributes to the spread of pancreatic cancer, the researchers implanted a genetic model of invasive pancreatic cancer. Remarkably, the researchers were able to successfully rezip these cancer cells by treating them with anti-cancer therapies, stopping the spread of cancer before it had begun.

To make the biosensor, the researchers bred a mouse in which a key “zippering” protein that holds cells together – called E-cadherin – was linked to a protein from jellyfish that glows green in fluorescence microscopy. This allowed for them to pinpoint when key changes occured.

Which is incredibly important given that five-year pancreatic cancer survival rates stand at just 6.1% – a figure that has barely changed in the last 40 years. “Many patients present with pancreatic cancer at a very advanced stage, when the cancer has already spread to other tissues such as the liver,” says Dr Timpson.

“But sometimes, the cancer is detected before it has spread – and that’s the point where we have an opportunity to intervene and stop it in its tracks. If we give a drug early enough, we can rezip those cells together.”

Dr Timpson says the most exciting part of the study was the fact that the existing treatment – an anti-invasive drug called dasatinib – allowed us to stabalise the primary tumour. “We treated mice that had developed pancreatic cancer that had yet to spread with the anti-invasive drug [and] within three days of treatment, we saw cells within the tumour had re-zippered, and the tumour had stabilised.”

Similar results were achieved with a second therapy, saracatinib.

“The biosensor mouse is a powerful tool for anti-cancer drug discovery,” Dr Timpson says. “It makes it possible to evaluate the effect of new therapies on tumour spread, in real time and in a system that reflects human cancer as closely as is currently possible.”

Dr Timpson points out that this is just the beginning for the biosensor mouse. “We now have a model that is one step ahead of the invasion process in pancreatic cancer – but we are also already using this model in our laboratory for other aggressive and highly invasive cancer types, such as breast cancer.

“Ultimately, we expect to use the biosensor mouse to explore zippering and cancer spread in a wide range of tumours throughout the body.”

The Garvan Institute of Medical Research has received three ACRF cancer research grants totalling $6.13m. To read the original article, click here.

I’m a walking testimony to cancer research

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, charity foundation, donate to charity, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories, Types of cancer, cancer scientistsPamela Kirby supports cancer research because she has seen the life-saving benefits first-hand.

“My cancer journey started in September 2010. I was first diagnosed with bowel cancer and an operation was quickly scheduled for November. It was during my treatment process that I was also diagnosed with stage 1 primary lung cancer.

Within a few weeks I was back in surgery for a major lung cancer operation. That was the hardest to recover from and it was followed by four and a half months of chemotherapy treatment.

Unfortunately, the bad news continued and in 2013 three more lesions were discovered on my lung. By May 2014 I had suffered a major seizure and my doctors told me I had developed secondary brain cancer that spread from my lungs.

Cancer has been a challenge from day one, but it has been really empowering to fight this battle and I believe I am much stronger now. After five years of intensive treatment and lengthy hospital stays, the prognosis is looking good for me and I’m feeling much better.

I am so thankful for my highly skilled oncologist Dr Nick Pavalakis and his team. Using the treatment options and testing resources cancer research has made available to them, they were able to learn more about my cancer, find out which treatments would work best for me and help manage some of the unbearable side-effects.

From my experience I learned just how vital cancer research was and how significantly it impacts current patient treatments. I’m a walking testimony to the progress researchers are making.

Whilst undergoing treatment I wanted to inspire others affected by cancer and show them that they have the strength to fight through this battle too. I decided to organise a fundraising event to help contribute towards cancer research.

I held a Ladies Night Out at our local bowling club. It was a great evening of tequila tasting, 60’s music, a fashion parade, raffles, candle demonstrations and an auction. I’m really proud that we were able to raise close to $4000 for the Australian Cancer Research Foundation.

My health has greatly improved and we’re now looking forward to the future and a special holiday in Hawaii in just a few weeks. I still need to get scans every three months, which are stressful as waiting for the results is always a torment. But I believe remaining positive has really helped me on this journey and I am thankful to have been supported by my wonderful friends and family and a highly skilled medical team. Every new day I get to spend with my amazing husband Brian, our kids and grandkids is sheer joy.” – Pamela Kirby, ACRF Supporter

Share your story

Pedalling for cancer research in memory of Penny

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, cancer research fundraising, Cancer Research, Challenge, charity challenge, charity foundation, donate to charity, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories, spin challenge, cycle challenge
Kirsten, Amber, Angie and Rachel

 

In May 2015 ACRF supporter, Kirsten lost her mother, Penny, after a two-year battle with lung cancer. To honour Penny, Kirsten and her good friend Rachel began planning a garden party to support cancer research. When her friend Angie received the invitation, she put her hand up to help with the fundraising efforts.

“Kirsten absolutely adored her Mum and it has been a difficult time for her and her family. As soon as I heard about the fundraiser I wanted to do my part to help, so I decided to hold an epic 24-hour spin challenge,” said Angie.

“I got to work organising my ‘Pedalling for Penny’ event. The local community really got behind me. I received such generous support from my local 24-hour gym and many local businesses that each sponsored a one-hour block of my ride or donated their services.

From 10 am on Saturday 7th November to 10 am on Sunday 8th November I cycled continuously around the clock. In that time, I accomplished the equivalent distance of riding from the Sunshine Coast to Newcastle.

I love being active and I’m very social, so it was very mentally challenging for me to be seated in one place for such a long time – I am very thankful I had so much wonderful support around me the whole time. It melted my heart to have my husband, my sons and friends there cheering me on. And it was great to see my community come out to support me too! Other gym members and sponsors cycled alongside me for an hour and shared their stories of loved ones who had been affected by cancer. Even the police stopped by to visit and make sure I was doing okay.

It was an honour to ride for Penny and to support Kirsten and her family. Penny was the most beautiful person filled with an enormous amount of love and I felt her by my side throughout this journey.

Sadly so many people are touched by cancer, and as a registered nurse I often see the awful effect it has on patients and their families. I am so proud that I was able to do this challenge and raise funds for cancer research to help put an end to this awful disease.”

Kirsten along with her good friends Rachel and Angie have raised a total of $6,698.50 for cancer research.

To support Angie, click here.

Share your story

Young cyclist takes on Mount Kosciuszko for cancer research

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, cancer research fundraising, Cancer Research, Challenge, charity challenge, charity foundation, donate to charity, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories, Cycling Challenge, give to charity, online fundraising

ACRF supporter, Ben Coulter is a 19-year-old cycling enthusiast from Cairns. In October, he successfully rode solo and unsupported from Melbourne all the way to Sydney via Mount Kosciuszko to support cancer research.

“I wanted to give something back to the community and, because cancer impacts so many lives, I decided to raise funds for the Australian Cancer Research Foundation.

I’m very passionate about road cycling and mountain biking. I love riding because it’s such a good release. I’ve been working professionally in the biking industry for around three years now and I really enjoy it.

Over the 16-day journey, I covered around 1,700 kilometres and climbed over 24,000 vertical meters! I chose the route via Mount Kosciuszko because it was a huge challenge. It was mostly steep climbs and I thought the harder, the better, as I knew it was going to be the most rewarding for me to achieve.

In the past, I’ve completed a few other big rides including the 720 kilometre Cairns to Karumba and the 320 kilometre Cairns to Cooktown. However these rides were all supported and we rode in groups. The Sydney to Melbourne challenge was my first solo, unsupported journey and I plan on doing many more.

My favourite areas along the way were probably Corryong or Marysville in Victoria – I love the beautiful, crisp alpine environment and the scenery made for a great ride. One of the most memorable highlights from my trip included cycling the mountain ranges around the Tolmie area. It was such a great feeling making the climb to the top of the Dead Horse Gap just outside of Thredbo and cycling to the top of Mount Kosciuszko.

I would highly recommend doing a solo charity ride. If you’re thinking about taking on any charity challenge for the ACRF, my advice is to make sure you’re prepared and then give it all you’ve got! Embrace the challenge and when it gets tough, remember why you are doing it.”

Click here to support Ben.

Share your story

Australian Cancer Research Foundation gives $17 million to advance cancer research

cancer research, research institutes, anniversary grant, cancer research grants, cancer scientists, new discoveries, types of cancer, cures for cancer, treatment for cancer, fighting cancer, funding research

The Australian Cancer Research Foundation (ACRF) announced its 2015 grant recipients at an awards ceremony in Sydney last night. This included one of the largest private grants for cancer research equipment in Australian history, the $10 million ACRF 30th anniversary grant.

The anniversary grant was awarded to The Children’s Medical Research Institute based in Sydney, for the establishment of The ACRF International Centre for the Proteome of Cancer (ProCan). This facility will enable the analysis of tens of thousands of samples of all types of cancers from all over the world. It will also allow scientists in Australia to develop a library of information to advance scientific discovery and enhance clinical treatment worldwide. The end result will be rapid and more accurate development and initiation of the most appropriate cancer treatments for each individual patient.

“Our 30th-anniversary grant for $10 million is something ACRF is very excited about,” said Professor Ian Brown, CEO of ACRF. “We knew this amount of money could make a real difference, stimulate new ideas and bring us closer to ending cancer.”

“ACRF challenged the Australian cancer research community to propose projects that were bold and that would have a very significant impact on cancer prevention, detection and treatment. The response was tremendous with six very impressive projects submitted.”

Our international judges were impressed both by the quality and vision of the applications and the high standard of Australian research. CMRI was chosen after lengthy discussion to be the best of the best.”

In addition, Cancer Institute NSW will be supporting the project by funding a full time researcher at CMRI to operate the new technology.

The recipients of the annual ACRF grants in 2015 are:

  • The Australian Synchrotron ($2million) for the establishment of the ACRF Detector. The technology, which is available at only a handful of other synchrotron facilities around the world, will enable the shape and function of proteins to be analysed ten times faster, and more accurately, shortening the timeline from laboratory research to clinical trials of new cancer drugs.
  • The John Curtin School of Medical Research, ANU ($2 million) for the establishment of the new ACRF Department of Cancer Biology and Therapeutics. The department will help to understand the underlying biology of cancer and to develop new drugs to treat Australian cancer patients. Research will focus on Australia’s Chmome (whole sets of small molecule natural products) and exploring the existing collections for novel lead compounds that can be developed into drugs for cancer therapy.
  • The Centre for Cancer Biology (CCB) in South Australia ($2 million) for the establishment of the world-class ACRF Cancer Discovery Accelerator facility in Adelaide. The centre aims to significantly enhance our understanding of fundamental cancer biology and translate these findings to improve outcomes for Australian cancer patients.
  • University of Queensland, Thoracic Research Centre ($1million) for the establishment of the ACRF Centre for Lung Cancer Early Detection. The Centre will conduct research into the discovery and development of innovative methods for detecting lung cancer as early as possible. Lung cancer remains a major worldwide cause of cancer deaths, and early detection will improve treatment outcomes and survival rates.

The recipient of 30th-anniversary grant was selected by an international judging panel after a competitive application process. The four annual grant recipients were selected by the ACRF’s Medical Research Advisory Committee comprising eminent Australian and international cancer researchers and clinicians, chaired by Professor Ian Frazer.

Cancer Research Saved My Parents

ACRF, Australian Cancer Research Foundation, Breast Cancer, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, charity foundation, donate to charity, Donations in lieu of gifts, Fighting cancer, Funding research, Regular donations to charity, Regular donations, Regular charity donations, Regular giving, Monthly charity donation, monthly donation

Targeted laser treatments for breast cancer and early diagnostic tests for bowel cancer gave Christina more time with her mum and dad.

“The best gifts I’ve ever received were the cancer treatments that saved my parents. My mum was diagnosed with breast cancer when I was living interstate so when I got the phone call I was in utter shock and disbelief.

I came back to sit with her through as many of her appointments as I could because she just sort of shut off when they were going through all the different options, I think it was just too much to take in all at once. We had never been touched by cancer before, so everything we were hearing was new.

At an appointment, one of the doctors explained to us that there was a new experimental treatment available that allowed them to better target cancerous lymph nodes, which meant that she could still keep her healthy ones.

This new treatment was not only successful, it also lessened the aftermath of surgery. Some people may not know, but treatments have come a long way. This was a really eye-opening experience for me because it was the first time I could really see it first-hand.

Later that year my dad was diagnosed with bowel cancer and we actually thought it was a cruel joke because the diagnosis was now the third one to hit our family over just a few months’ time. We lost my grandpa to oesophageal cancer shortly after my mum was diagnosed with breast cancer.

I think after that we were on high alert because my dad noticed he was having symptoms and went in for testing straight away. It was because of this that they were able to catch bowel cancer early. I’m so thankful for the hard lessons we learned because I know they played a big part in saving my dad’s life.

I know there are a lot of great charities out there, but the thing with cancer research is that you never know how many lives could be saved with the next breakthrough.”

Christina Belperio – Regular Giver of the Month

Share your story

The Norman Foo Fund

HarbourBridge

In memory of his late uncle, ACRF Supporter Timothy Lim has embarked on an intense training regimen to help prepare him for the Busselton Ironman Triathlon this Sunday, December 6th.

“My uncle, Norman Foo lost his three and a half year battle with lung cancer in the early hours of July 24, 2015. He was a father, a husband, a grandfather, an academic, and a genuine human being. He was positive and brave to the end.”

In Australia, lung cancer is one of the five most commonly diagnosed cancers and causes more deaths than any other type of cancer. It only has a 5-year survival rate of about 14%.

“One of his final wishes was that we donate to charities in lieu of flowers at his funeral. Through my fundraiser, the Norman Foo Fund, I hope to raise over $10,000 to help the ACRF fund research to end cancer.”

With the help of generous family and friends, Tim has already achieved more than half of his initial fundraising target!

“Uncle Norman has always been such an inspiration to me. I have been in awe of his bravery, optimism, and ability to endure. To champion my fundraising effort, I will be attempting my first full Ironman-distance triathlon. It will consist of a 3.8km swim, followed by an 180km bike ride, and finished with a 42.2km run. This will be a true test of my physical and mental endurance.”

Tim is a 30-year-old engineer from Brisbane who considers himself pretty ordinary. “I enjoy food, frolicking in the sunshine…and not being at work.” And when he’s not working his 9-5 he’s been putting in an extraordinary effort into his fitness and training. Already this year, Tim ran 42km at the Blackmores Sydney Running Festival and completed his first triathlon in Noosa. He pushes his limits in weekly swim squad sessions and long distance cycling. With one month to go to the Busselton Ironman, he is feeling fit and strong.

To help support Tim and his Norman Foo Fundraiser, click here.

Share your story

Cancer Research Achievements Acknowledged at Clifford Awards

ACRF, Australian Cancer Research Foundation, Centre for Cancer Biology, Cancer Research, cancer scientists, charity foundation, current cancer research, Fighting cancer, Professor Inder Verma, Professor Jane Visvade, Barossa Meeting on Cell Signalling in Cancer Biology and Therapy, Clifford Prize for Cancer Research, Australian Scientists, cancer scientists Australia, cancer types, Funding research

The Clifford Prize for Cancer Research was presented to Professor Inder Verma and Professor Jane Visvader at Seventh Barossa Meeting on Cell Signalling in Cancer Biology and Therapy.

The bi-annual prize is presented by the Centre for Cancer Biology (CCB), South Australia, for outstanding international achievement in cancer research.

Professor Verma is an American Cancer Society Professor of Molecular Biology in the Laboratory of Genetics at the Salk Institute for Biological Studies. He has been responsible for many major discoveries in cancer biology over the past four decades, ranging from basic discoveries regarding transcription factors involved in cancer, laying the basis for modern molecular biology by developing the cDNA synthesis procedure using reverse transcriptase, to development of viral-based vectors for gene therapy approaches to various genetic diseases, including cancers.

Professor Verma and co-workers have ingeniously employed specific methods of mouse genetics to reveal the roles of many specific oncogenes / transcription factors in normal cellular growth, differentiation and development.

Professor Visvader is a Fellow of the Australian Academy of Science. She and her team have made major contributions to the understanding of breast cancer by isolating mammary stem cells, defining master regulators of mammary gland development and identifying genetic lesions that drive oncogenesis. Her landmark discoveries have revealed master regulators that orchestrate cell fate decisions in the mammary gland, providing an indispensable framework for understanding mammary lineage commitment and differentiation, and a basis for understanding origins of breast cancer.

The Clifford Prize for Cancer Research represents an appreciation by Australian scientists for discoveries that have combined outstanding science with significant clinical relevance.

The ACRF Cancer Genomics Facility was established at the CCB in 2009, with the assistance of a $3.5m grant from the ACRF.

Image courtesy of CCB, left to right: Professor Inder Verma, Professor Jane Visvader, Prof Sharad Kumar, Dr Leanna Read, Chief Scientist, South Australia and Prof Angel Lopez, CCB.

Fiona knows how precious time is

ACRF, Australian Cancer Research Foundation, Breast Cancer, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, charity foundation, donate to charity, Donations in lieu of gifts, Fighting cancer, Funding research, Regular donations to charity, Regular donations, Regular charity donations, Regular giving, Monthly charity donation, monthly donation

“I will forever cherish the Christmas holidays I spent with my mum and my sister. My mum Annie was sedated and on pain relief, but she smiled and was so happy when I told her that she was finally going to be a grandmother. I still remember holding her hand and the way she smiled when I told her. My father kept joking saying ‘You’re going to be Grannie Annie, Grannie Annie.’

She now has six grandsons but sadly she didn’t get the chance to meet any of them. I think my mum would have been so proud of what thoughtful caring young men they have turned out to be. They have their grandmother’s sense of compassion and mischievous sense of humour.

My mum was totally devoted to her family. She was so loving and supportive and was a fantastic role model for me and my two sisters – Andrea and Dominique. I’ve always tried to be as loving and giving as she was. I could easily talk to her about anything and she had this strength about her that I’ve always admired so much.

My family originally came from Great Britain, and so every Christmas we’d have roast turkey with stuffing, baked potatoes and veggies, plum pudding with hot custard – even if it was 38°C. I’ve continued with the turkey (I just serve it cold with salad and seafood now). But I still love my Christmas pudding served hot so that is something that will never change! Also every Christmas me and my three siblings would hang up our Christmas stockings for Santa, and every year we’d find them filled in the morning with a small present.

My husband Colyn and I carried on this tradition when we had Fraser and Lachlan – I even still try and put out their stockings though they sometimes grumble good-naturedly because they’re now teenagers.

Losing my sister to the same disease cut a wound that will never heal. My sister Dom would do anything for anyone.

Riley & mum Thornleigh - 1-2003

She was well respected and loved and this was shown in the large crowd of friends and family who attended her funeral. She was special. Dom was also quite shy and quiet like my mum. She was passionate about the environment and worked as a volunteer.

She loved being a mum – it was her greatest joy. She loved to take her boys out and would run around and play with them.”

At night it was time for bedtime stories and cuddles. Because Riley and Logan loved Thomas the Tank Engine her husband,  Ross built cubbyhouse and Dominique spent hours painting the face of Thomas the Tank Engine on the front. She would make special little carrot muffins for her boys because she knew they loved them.

She would take them to outings and loved taking them for bush walks and showing them the birds, trees and other flora and fauna. She started up a mothers group where she lived as a chance for mums and babies to play and get to know each other.

Her family miss her so very much, it was the special little things that she did for them.

Being there to cuddle them and love them when they were sad or upset. Riley and Logan’s dad and grandmother shower them with love and take them on lots of adventures and holidays but they still miss their mum.”

– Fiona Henrisson, ACRF Supporter

Join Fiona and become a cancer research supporter today

Ruth Robinson, Regular Giver of the Month

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, cancer research fundraising, charity foundation, donate to charity, Fighting cancer, Funding research, regular giving, regular charity donations, monthly donations, give to charity, charity donation, donations in memory, regular charity givers, regular donations

“My dear friend and colleague, Andrew “Sid” Sidoli had fair skin and freckles. While he loved surfing, he always tried to look after his skin by putting on sunscreen and a shirt or wetsuit but it still wasn’t enough in the end.

He was on holidays with his sister, Rebecca, when she noticed an abnormality on his back and told him he needed to get it checked.

The lesion turned out to be melanoma. But from the day of his diagnosis Andrew fought it with everything he had and remained optimistic. One day when I saw him in the corridor at work he told me ‘I’ve been given a 10% chance of survival, and while I have a 10% chance, I have hope.’

Sid was larger than life, he always had a cheeky smile on his face and everyone at work loved and respected him. He made time for everyone and was really supportive when my Mum passed away. He encouraged me, and I think most people in his life, to get our skin checked regularly.

He later became bedridden when the melanoma spread to his lungs and brain. His doctor, the well-known, Charlie Teo did everything he could for him, but at just 40 years old my beautiful friend sadly lost his battle.

Unfortunately, Sid was amongst many of my work colleagues who had been affected by various cancer types over the years. I believe the only way we will fight this dreaded disease is through research, which is why I choose to support the Australian Cancer Research Foundation.

I used to donate whenever I had spare money, which was about twice a year, but not long after Sid passed I signed up to be a regular giver. I realised that if I donated on a monthly basis it would help researcher’s fast track discoveries and ultimately save more lives. I donate just over $1 a day each month so it barely affects my daily budget.

I have seen how advancements in cancer research can really help people. My brother in law, Noel Hughes is now battling liver cancer and the oral chemotherapy tablets he takes are far less traumatic for him than those that were available years earlier.

If you can afford just $1 a day, please consider supporting the ACRF, cancer could affect anyone of us and at any time.”

– Ruth Robinson, Regular Giver of the Month

Share your story

Trekking the Larapinta Trail for Cancer Research

A few weeks ago, dedicated ACRF supporter, John Pratt returned home from an epic Larapinta Charity Challenge in the Northern Territory.

Before we got a chance to hear all about his trip, this avid trekker was back in his hiking boots, taking on a section of the Heysen Trail in South Australia for a second time – an impressive way to celebrate his recent 74th birthday.

The ACRF Larapinta charity challenge is one of the seven Great Walks of Australia. “In 2014 I completed the 1200km Heysen Trail and this opportunity to walk the Larapinta Trail seemed too good to pass up. Not only would I be supporting a cause I’ve contributed to for several years, I would get to experience hiking parts of the iconic Larapinta trail and have an opportunity to be on the summit of Mount Sonder to see the sunrise.”

Over the six-day trip, John and a group of 4 leaders and 15 other hikers covered between six and sixteen kilometres each day over a variety of terrain. They were treated to the beautiful sights of an ancient land, taking in the scenic landscapes including the vast flood plains, the razorback rocky outcrops and narrow canyons where sheltered pockets of delicate ferns and twisted gum trees grow from the dry rivers of sand.

After their long days of trekking, the group were able to relax in style in exclusive wilderness campsites. The little taste of luxury ‘glamping’ added to the trekkers enjoyment of the Larapinta Trail, offering lounge and dining facilities, hot showers, eco-toilet facilities, solar lighting, and camera battery charging ports. “The facilities at the semi-permanent campsites were good and all the food was excellent, including the lunches the leaders carried and prepared out on the Trail.“

“Everything went smoothly – it was well organised and well led. For me, the best part of the trip was experiencing highlights of the Larapinta Trail along with a selection of features near its route (like Ormiston Gorge and Pound) with a group of like-minded people who blended together very well.”

The Larapinta Trail is just one of many fundraisers John has accomplished. His advice to others considering signing up for a charity challenge is to just go for it! “Make sure you’re physically and mentally prepared as it will make the experience much more enjoyable,” says John.

John, who lost a close friend to cancer last year, has raised over $2,000 for cancer research in addition to his long-term regular giving. Click here to show your support for John.

There are many ways to get involved in an adventure charity challenge. We provide one-to-one fundraising support along the way to help you reach your fundraising target. Learn more about charity challenges and fundraising.

Share your story

Research discovery paves the way to prevention of a common childhood cancer

TeamSciTraMed

Researchers at Children’s Cancer Institute have identified a molecular ‘feedback loop’ that accelerates the development of neuroblastoma, a cancer of the nervous system in children. Fortunately, the research team has also identified an experimental drug, currently in clinical trials for adult cancer, with the potential to interrupt the loop and halt tumour progression.

Researchers showed in laboratory models of neuroblastoma that the drug could block the very start of this embryonal cancer, paving the way to possible prevention strategies in the future.

They found that a combination of the drug – known as CBL01371 – used in combination with traditional DNA damaging chemotherapy agents was much more effective than either drug alone.

Professor Michelle Haber AM, leader of the Experimental Therapeutics laboratory and Professor Glenn Marshall AM, leader of the Molecular Carcinogenesis laboratory at Children’s Cancer Institute, worked on two very different aspects of the study.

Professor Marshall’s team focused on the genetic and molecular mechanisms behind the feedback loop, and its interruption by CBL0137. Professor Haber’s team focused on the therapeutic potential of CBL0137, both as a single agent and in combination with other drugs.

“Our laboratory tests tell us that CBL0137 is likely to be very effective against the most aggressive neuroblastomas, and indeed the most aggressive forms of other childhood cancers, and that is very exciting,” said Professor Haber.

“But what is particularly exciting is that, in contrast to many other chemotherapeutic agents, CBL0137 does not damage DNA, and it is DNA damage that is responsible for the many unpleasant and serious side-effects that frequently affect children after they are cured of their cancer.”

“The drug is currently in Phase 1 clinical trials for adults, which means that safe dosage levels are being tested. Once the adult trials are completed, a Phase 1 trial for children with refractory – or relapsed – neuroblastoma, and also other aggressive childhood cancers, will open in the United States and Australia,” Professor Haber said.

Neuroblastoma is the most common solid tumour cancer of early childhood, and is generally diagnosed when the disease is advanced. Around half of all children with neuroblastoma have aggressive tumours, and fewer than half of these patients survive, even after intensive treatment.

These findings are published today in the journal Science Translational Medicine.

This news item was originally published on the Children’s Cancer Institute’s website. The original version provides more detailed scientific information on the study.

ACRF has supported cancer research at the Children’s Cancer Institute by providing three major grants, totalling AUD $5.1m.

Image courtesy of Children’s Cancer Institute. Clockwise from left to right: Professor Glenn Marshall, Dr Dan Carter, Professor Murray Norris, Professor Michelle Haber, Jayne Murray

Fighting cancer with fitness

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, cancer fun run, cancer research fundraising, charity challenge, Challenge, charity foundation, donate to charity, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories, give to charity, Types of cancer

In April, dedicated ACRF supporter, Jodie Gardiner ran in the Australian Running Festival in Canberra and raised over $2,200. Now she’s working her way through a unique fundraising challenge she set for herself called ‘Fighting Cancer with Fitness.’ Jodie hopes to complete 100 workouts before her 42nd birthday while raising funds for a cause close to her heart.

“This year I lost my step-sister, Rachael to liver cancer. My step-mum was diagnosed and is fighting lung cancer. My aunty was diagnosed and is fighting breast cancer. Last year I also lost my uncle to cancer. This is an insidious disease and I’ve had enough.

In losing my step-sister Rachael, we didn’t just lose one woman we lost several because she was the center of so many universes. We always got on like a house on fire and shared a lot of similarities in our lives – we were both public servants who also qualified as a personal trainer and we each had two sons.

Rachael was diagnosed with a rare form of liver cancer called Sarcomatoid Hepatocellular Carcinoma. After ten months of treatment, she lost her battle. She was only 36 years old, leaving behind her loving husband, Paul and their two young sons.

Rachael was a great mother, it broke her heart that she would not be there to see her children grow up. She worried that her sons wouldn’t remember her, so she asked her family to promise to help make sure they would never forget her.

Paul has been an absolute tower of strength for his sons and is making every effort to ensure they still see their grandparents and that they will always remember their mum.

I am fortunate to have some great memories of Rachael. I worked at a gym with her a few years ago. We had an absolute ball working together – we learned so much about each other and became really close.

Rachael was such a fun, energetic and vibrant woman. She had such a passion for health and exercise, and her love of fitness inspired me to get my personal training qualifications. I remember not long after Rachael was diagnosed, her sister Kylie was attempting her first 10km fun run. Rachael and her family were waiting on the sidelines to cheer Kylie on.

Suddenly, Rachael ran out from the crowd to jog alongside her sister. Rachael motivated Kylie through the final kilometres and they crossed the finish line holding hands. It was a very special moment that I’m glad I got to witness and I think it beautifully sums up what sort of a person she was.

Losing her to cancer made us all realise that life is short and it has certainly made us all stop and smell the roses a little. Everyone knows someone who has been diagnosed with some form of cancer, I’m fighting for all of them.”

Click here if you would like to support Jodie.

Share your story

Making a Difference in Michael’s Name

ACRF, Australian Cancer Research Foundation, Breast Cancer, cancer charity, Cancer Research, cancer research fundraising, charity foundation, donate to charity, Fighting cancer, Funding research, Fundraising Stories, regular giving, campaign for cancer, charity donation, give to charity, tax deductible donation, monthly donation, donations in memory, regular charity givers, memorial gifts

“My family has been touched by cancer a few times, but the two that hurt the most were the loss of my mother and then my husband.

My mother was recently retired when she told me she had found a lump in her breast. After lots of convincing, my sisters and I finally got her to visit the doctor. What she hadn’t told us was that she had first noticed the lump six months ago and by then it had grown extremely large. This was 20 years ago and there weren’t many options available to her at the time. After fighting through 15 months of gruelling treatment she sadly lost her battle with breast cancer.

Years later, Michael, my wonderful husband and the father of our four sons was diagnosed with pancreatic cancer at 54 years old. We were really shocked as he had always enjoyed good health and was not showing any symptoms other than an itchy feeling under the skin. Our doctor however, did not suspect good news and the blood test proved it.

Michael endured a lot to try and beat the cancer. He went through one and a half rounds of chemo and underwent a very high risk operation called a Whipple procedure. Thankfully he made it through but it was a long, hard road to recovery after the extensive surgery.

Thanks to the expertise of the doctors and their teams things began to look more positive, but we were only able to spend an extra 22 months with Michael before he passed away at 56 years old.

I donate in Michael’s name each month and hope that my little bit will make a difference so we can find a cure for all cancers. I chose to support the Australian Cancer Research Foundation because it’s a non-profit organisation that awards grants to the most ground-breaking research teams in Australia. I know my donations will help cancer researchers to continue fast-tracking discoveries for the future.”

– Jannelle Scerri, Regular Giver of the Month

Learn more about becoming a regular giver.

Share your story

Cancer Research to Benefit from Twitter for Cells

ACRF, Australian Cancer Research Foundation, cancer charity, Cancer Research, cancer research fundraising, Cancer Research Grants, cancer scientists, charity foundation, current cancer research, Fighting cancer, Funding research, Types of cancer, Professor Alistair Forrest, Harry Perkins Institute of Medical Research

An international team of researchers have completed a study into cell behaviour, providing insight into how different, specialised cell types communicate as a cohesive network.

The researchers have produced the first map of cell-to-cell communication which shows the division of labour between cell types and reveals the ways cells use proteins to pass hundreds of messages between each other. This will help advance cancer research in the future.

The lead author, Professor Alistair Forrest, recently joined the Harry Perkins Institute of Medical Research in WA as Laboratory Head of Systems Biology and Genomics to continue his work with a renewed focus on cancer. Professor Forrest says systems biology studies all elements (typically genes or proteins) simultaneously to see how they work together in a system (or network) instead of focusing on only one or two genes at a time.

“What we have revealed in this new research is that cells have many ways of talking to each other.” Imagine twitter for cells – hundreds of cell types telling each other what is happening via hundreds of different messages.

Professor Forrest says the work has important implications for medicine. “The proteins involved are actually well known to the general public. Insulin, human growth factor and leptin are important in diabetes, height and obesity. This type of signalling is also very important in our immune response to infectious diseases. It’s also important in cancer – in particular neuroblastoma and lung cancer.”

The researchers believe that further investigation will provide answers into what happens to this intercellular information in cancer cells and how cancer avoids the immune system. It is hoped that this research will eventually help identify new therapeutic targets to improve treatments for people battling cancer.

The original article was published on the Harry Perkins Institute of Medical Research, click here to read more.

Erin Prepares To JUMP! For Cancer Research

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, cancer research fundraising, Challenge, charity challenge, charity foundation, donate to charity, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories, Skydive, skydive for cancer, skydive for cancer research, Skydiving for charity, Erin Headington, Shellharbour

ACRF Supporter, Erin Headington has a passion for helping people and isn’t afraid of taking on a challenge. In December, shortly after she graduates university as a Registered Nurse, Erin will take the plunge and skydive for cancer research.

“I’m making the jump in honour of my cousin who was diagnosed with lymphoma in June. It was a huge shock at first as she was just 24 years old. We’re only a year and half apart and we have a very close relationship. It’s really horrible knowing she has been having a really tough time with the side-effects of chemotherapy.

Her mother, father and brother have not been coping well with the diagnoses. Their family have experienced a lot of loss in the last 3 years and are now coming to terms with my cousin fighting cancer at such a young age.

I decided to do something to support my cousin and her family so I began researching ways to help cancer patients. When I came across the ACRF I thought that raising money for cancer research would be a good way to do my part to help find a cure. I want to prevent others from enduring this devastating disease in the future.

The ACRF JUMP! skydiving challenge really appealed to me as I’ve always been a thrill-seeker at heart. It’s great to know there are so many different ways to get involved – especially since I could never picture myself running in a marathon.

I would really encourage others to find a fun and achievable challenge that suits them too. At the moment I’m very busy managing two jobs and studying full time – so if I can do it, anyone can!”

Show Erin your support. Erin will also be raising funds for the ACRF with a sausage sizzle out the front of Woolworths Shellharbour on Sunday 22 November between 10am-2pm.

 

Share your story

Breakthrough cancer research technologies to advance treatments

ACRF, Australian Cancer Research Foundation, cancer charity, Cancer Research, cancer research fundraising, Cancer Research Grants, cancer scientists, current cancer research, donate to charity, Fighting cancer, Funding research, fundraising, Walter and Eliza Hall Institute, charity foundation, Victorian Comprehensive Cancer Centre, Professor Doug Hilton, Professor Jim Bishop, ACRF Breakthrough Technologies Laboratory, CRISPR/Cas9 technology

With support from the Australian Cancer Research Foundation, the Walter and Eliza Hall Institute has today unveiled the $2.5 million ACRF Breakthrough Technologies Laboratory which will help researchers uncover new insights into how cancer develops, and how it can be more effectively treated.

This is the third ACRF grant awarded to Walter & Eliza Hall Institute of Medical Research. These grants were awarded 2001, 2010 and 2014 with a combined value of $5.5 million to help researchers make breakthroughs in genomics, as well as breast, lymphoma and lung cancers.

The ACRF Breakthrough Technologies Laboratory is Australia’s first dedicated cancer laboratory to use ‘CRISPR/Cas9’ technology to target and directly manipulate genes in cancer cells.

The facility will be used by researchers from WEHI and the Victorian Comprehensive Cancer Centre (VCCC) partners to enhance and accelerate research into many of Australia’s most common, and most deadly, cancers including cancers of the blood (leukaemia, lymphoma), breast, ovary, lung and bowel.

The director of the WEHI, Professor Doug Hilton, said the ACRF Breakthrough Technologies Laboratory would provide an enormous boost to Australia’s cancer research efforts. “It has become clear that technologies such as CRISPR/Cas9 can accelerate new breakthroughs in understanding cancer and developing new treatments.”

“The generosity of ACRF and its donors has allowed us to equip our research teams with precisely the tools they need to advance their research,” Professor Hilton said.

Mr Tom Dery, Chairman of the ACRF Board said “We are proud to enable the ground-breaking research conducted at the ACRF Breakthrough Technologies Laboratory. The facility will help to accelerate new treatments for people with cancer in Australia and worldwide.”

The contributions Australian researchers are making to improve the prevention, diagnosis and treatment of cancer are very significant. “More than 14 million people around the world were diagnosed with cancer last year, including more than 125,000 Australians,” Mr Dery said.

Professor Jim Bishop, Executive Director of the VCCC, said the ACRF Breakthrough Technologies Laboratory represented a critical addition to the Victoria’s cancer research capabilities. “The facility provides our researchers with unparalleled access to world-leading technology.”

“The strength of the VCCC lies in the close ties it fosters between the laboratory-based, clinical and other researchers in its partner organisations. This means that discoveries made in the ACRF Breakthrough Technologies Laboratory will be translated into new treatments for cancer as rapidly in Melbourne as anywhere in the world,” Professor Bishop said.

The VCCC is an alliance of ten successful Victorian organisations committed to cancer care: the Walter and Eliza Hall Institute of Medical Research, Peter MacCallum Cancer Centre, Melbourne Health (including The Royal Melbourne Hospital), The University of Melbourne, The Royal Women’s Hospital, The Royal Children’s Hospital, Western Health, St Vincent’s Hospital Melbourne Austin Health and Murdoch Children’s Research Institute.

The original article was published on the Walter and Eliza Hall Institute website, click here to view.

Remembering Rosemary

ACRF, Australian Cancer Research Foundation, Breast Cancer, cancer charity, cancer fundraising, cancer research fundraising, charity foundation, donate to charity, Fighting cancer, Funding research, regular giving, regular giver, charity donation, give to charity, tax deductible donations, regular charity donations, memorial gifts, regular charity donation, Monthly donation, monthly giver, monthly donations, campaign for cancer

“In the UK in 1998, my twin sister, Rosemary discovered a lump on her breast and was diagnosed with breast cancer at only 38 years old.

Rosemary and her husband were busy parents with four kids – two teenagers Rachel and Tommy, an 11 year old daughter, Jenny and a 9 year old son, Sam. Her illness was extremely hard on the whole family. We felt powerless as we watched her endure so much pain and distress at the thought of leaving her children.

Rosemary fought courageously and was an inspiration to her community. Her friends and neighbours rallied to support the family during their time of need. The locals made renovations to their house to make her life easier and raised money to send her on a trip to visit me in Australia. This was one of the happiest months of my life, we shared precious time reconnecting and reminiscing about our childhood.

It was heart-warming to know that so many people were offering a helping hand where they could. Wednesdays became known as ‘Rosemary Day’ in the area and each week, for three whole years, a group of ladies would take her out for the day. They would visit beautiful and interesting places and then have dinner together at their favourite restaurant.

After five years of suffering Rosemary sadly lost her battle on her daughter’s 11th birthday. It is now a bittersweet day for the family and each year on the anniversary the four children meet in the church garden to celebrate their mother. The two girls also “Run for Rosemary” in Mother’s Day fundraising marathons.

As her twin sister I feel her loss greatly, it’s very upsetting for me knowing that she did not get to see her children grow up or meet her grandchildren. I know that Rosemary would be so proud of her family and how much they have cared for each other.

Over the years, cancer has continued to touch the lives of friends and others around me. A couple of years ago my husband and I realised the importance of cancer research first hand when he was diagnosed with melanoma and took part in a research trial. He has since developed kidney cancer and is being treated with targeted immune therapy which would not have been possible a few years ago.

I often think back to the time when Rosemary developed cancer and appreciate all the progress that has been made since then. I support the ACRF with a monthly donation and have left a bequest in my will. I know my donations go towards helping the ACRF fund the necessary equipment that allows researchers to make many more life-saving discoveries. I hope that together we can spare many families the heartbreak of losing their loved ones in the future.”

ACRF Regular Giver of the Month, Ann Smith

Learn more about becoming a regular giver.
Share your story

Beneath the surface of skin cancer patients

skin cancer, research discoveries, cancer charity, donating to cancer research, charity foundation, types of cancer, fighting cancer, current cancer research, cancer scientists, give to charity, donate to charity, charity donation, online fundraising, cancer fundraising

Here at the ACRF we are proud to equip Australia’s leading cancer researchers with the resources they need to end cancer.

Recently, a team of researchers from the University of Queensland discovered a protein that helps to control an important process in cell adhesion that is disrupted when someone contracts a disease such as skin cancer.

The researchers said that the Australian Cancer Research Foundation Cancer Biology Imaging Facility at UQ’s Institute for Molecular Bioscience (IMB) played a vital role in this research.

It is currently one of the largest and most comprehensively equipped facilities in Australia for both the imaging and screening of chemical and biological libraries.

The facility was founded in 2010 with a $2.5 million ACRF grant and is home to 23 high-performance microscopes and supporting image data analysis workstations.

PhD student Rashmi Priya at IMB says that what the research has done is clarify the role of the protein myosin in tissue integrity.

“The protein Myosin is found at cell connection points and we now know that it plays a crucial role in regulating how cells stick together to form tissues in the body,” she said.

“Our research has shown that this is because myosin protects a switch that acts as a stabiliser. This switch must be very tightly controlled as it affects many processes within the body. Too much or too little of this switch, or having it in the wrong place, can lead to diseases such as skin cancer, says Priya.”

Professor Alpha Yap, who led the research team, says “The cells in all the tissues of our body die and have to be replaced as regularly as every 24 hours in the intestinal system. For this to happen, adhesion between cells must be carefully broken down and rebuilt, and we now have a better understanding of what it is that’s controlling this whole process.”

The original article was published on the Institute for Molecular Bioscience website, click here to read more.

Isabella’s Crazy Hair Day for Cancer Research

ACRF, Australian Cancer Research Foundation, cancer charity, cancer fundraising, cancer research fundraising, charity foundation, donate to charity, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories, Fundraising ideas for schools, Crazy Hair Day, School Fundraiser, Wacky Hair Day

An outstanding young student from Victoria wanted to honour her late grandfather by raising money for cancer research. Isabella is in year six and decided that the best way to make a big impact was to get her whole school involved – so she approached the vice principal about organising a crazy hair day.

“Isabella came to see me at the start of the term to share her enthusiasm for wanting to make a difference to the lives of people living with cancer. Her passion for this cause was obvious and she had really done her research,” said Vice Principal Stuart Boyle.

“As adults, we are all educators and it’s often how we respond to young people that teaches them the most. I’m truly impressed by Isabella wanting to take on the responsibility of organising a whole school fundraiser.”

Isabella was so proud to be able to do her part to end an illness that had affected her family in such a horrible way. She spent the term organising every detail of the event herself.

She put signs up around the school to promote the event, made sure it was advertised in the weekly school newsletter and spoke at her assembly about the ACRF and why she felt it was important to support cancer research.

She wanted all the students to come to school with their hair teased, coloured and gelled into fun and unique hair styles – and the crazier, the better, because she had even prepared prizes for the ‘best hair’ winners to be drawn at an assembly on the day.

Everyone was invited to participate and students brought along a gold coin donation to show their support for cancer research.

Together Isabella and her primary school were able to raise a fantastic total of $471.10. We thank Isabella for all the hard work she put into supporting the ACRF.

If Isabella’s story has inspired you to organising an event for cancer research, check out our A-Z of Fundraising Ideas.

Share your story

How you can end men’s cancers this Blue September

Blue September is a month dedicated to raising awareness of the risks that cancers pose to men. The campaign encourages men to stay diligent about their health and helps to raise funds for world-class research into the prevention, treatments and ultimately cures for some of the most common cancers affecting men.

In Australia, one in two Australian men will get cancer in their lifetime – that’s 20% more men than women who will be touched by this terrible disease. Despite this statistic, men often tend to have a bad track record when it comes to looking after their own health.

This is why we would like to invite you to join us in celebrating or remembering the men who are important to you and encourage them to start thinking about their health and family histories with cancer. There are lots of great ways you can get involved to help prevent cancer in men:

Blue September, men's cancer, prostate cancer, testicular cancer, jump for cancer research, current cancer research. fundraising for cancer research, charity fundraiser, fundraising, charity, charity challenge

Edited in September 2018: You can support our current Men’s Cancer Month campaign here.

Premier Annastacia Palaszczuk Unveils ACRF Centre for Comprehensive Biomedical Imaging at QIMR Berghofer

ACRF, Australian Cancer Research Foundation, cancer charity, Cancer Research, Cancer Research Grants, cancer scientists, current cancer research, Fighting cancer, Funding research, give to charity, QIMRX QIMR Berghofer Institute of Medical Research, QIMR Berghofer Cancer Research Institute, Annastacia Palaszczuk, Queensland, Professor Frank Gannon, Russell Caplan, QIMR Berghofer, ACRF Centre for Comprehensive Biomedical Imaging, Queensland Premier

Premier Annastacia Palaszczuk unveiled Queensland’s newest weapon in the fight against cancer this week, opening the ACRF Centre for Comprehensive Biomedical Imaging at QIMR Berghofer Medical Research Institute.

A $2.6 million grant from the Australian Cancer Research Foundation has funded the three state-of-the-art microscopes housed by the new lab – a significant and exciting advancement for the institutes researchers.

Ms Palaszczuk said the centre would allow QIMR Berghofer to unlock new techniques which would dramatically accelerate our understanding of cancer.

“To beat cancer, we need both brilliant minds and cutting edge technology – as we can see today, QIMR Berghofer has both,” Ms Palaszczuk said.

“This imaging facility will build on Queensland’s global reputation for research excellence.”

“And it builds on my government’s Advance Queensland strategy – to not only consolidate and grow our research base, but also develop investment opportunities to diversify and strengthen our economy.”

QIMR Berghofer Director and CEO Professor Frank Gannon said the new imaging equipment would allow the Institute to build on its world-leading immunotherapy program.

In recent days QIMR Berghofer has launched Phase II clinical trials of an immunotherapy treatment for nasopharyngeal carcinoma, and announced a major agreement with a global pharmaceutical company to discover cancer antibodies.

“Thanks to the generosity and vision of the ACRF we will be able to take our research to a new level of understanding and target cancer with greater accuracy as our scientists continue to deliver outcomes which have real consequences for patients,” says Professor Gannon.

The ACRF CCBI consists of three crucial pieces of imaging equipment: a multiphoton intravital microscope for imaging of live cells; a laser scanning confocal microscope for high resolution imaging of cancer at the molecular level; and a spinning disc confocal microscope for imaging signalling pathways in cancer cells.

The new equipment will also allow QIMR Berghofer scientists to study the process by which cancers metastasise, or spread, to distant tissues.

ACRF Trustee Russell Caplan said that since the ACRF was established in 1984 it has awarded more than $103.9 million to 34 research centres across Australia.

“Eleven of those grants ($23.3 million) have been distributed to research centres in Queensland and three of them have directly funded projects at QIMR Berghofer ($6.65 million).”

“These grants are awarded on the basis of research excellence and are subject to a rigorous approval process overseen by a Medical Research Advisory Committee made up of some of Australia’s most respected researchers, so it says a lot about the level of work being conducted at QIMR Berghofer,” Mr Caplan said.

To learn more about the other grants that have been awarded to leading research institutes across Australia click here.

International gene study identifies five new melanoma risk regions

ACRFX Australian Cancer Research Foundation, Cancer Research, Cancer Research Grants, cancer scientists, current cancer research, Fighting cancer, melanoma, cancer scientists Australia, QIMR Berghofer Medical Research Institute, Doctor Matthew Law, Melanoma Genetics Consortium, genome wide association study, GenoMEL, research discoveries

An international study led by QIMR Berghofer cancer researcher, Dr Matthew Law, has uncovered five new gene regions which increase a person’s risk of melanoma.

Melanoma is the third most commonly diagnosed cancer in Australia, and although there are effective treatment options available to those who detect it early, the five-year survival rate of patients with more advanced cases is only 10%.

“Each day around 30 Australians are diagnosed with melanoma, and from that more than 12 hundred a year lose their battle with the disease,” says Dr Law. “So each little piece of knowledge that we uncover is crucial as it affects the overall picture and helps us to continue to develop and improve the ways we detect and treat it.”

The study found five new regions of the genome associated with melanoma and formally confirmed two more that were suspected to be risk factors.

This research takes the total number of known melanoma gene risk regions to 20. “Most of the major gene risk regions previously identified are associated with pigmentation, or the number of moles a person has. The five new gene regions we’ve discovered are from different pathways, so it’s yet another piece to add to the melanoma puzzle.”

“Out of the new regions that were found, the most interesting biologically, was one involved with the maintenance, development and length of the telomeres. Telomeres are like shoelace caps at the end of each strand of DNA that protect our chromosomes from damage. We know that loss or damage to telomeres is a key factor in the development of cancer cells.”

Over 12 thousand melanoma samples were used for the project, making it the largest genome wide association study (GWAS) to identify variations associated with melanoma.

The international collaboration of researchers from QIMR and the Melanoma Genetics Consortium (GenoMEL) are now preparing for an even larger study which is expected to find more markers of risk.

“Our long term goal is to find drugs that modify the pathways that we’re identifying – that way we’ll be able to alter specific activity and bring it back to normal.”

“It’s very exciting to find something new about a serious condition – that’s the joy of doing this kind of research. Working in science is all about discovering new things that haven’t been seen or understood before and hopefully add a bit more knowledge to the world.”

QIMR Berghofer Medical Research Institute has received $6.65 million in grants from the ACRF which has funded technology to progress research in colon, breast, ovarian, prostate, leukaemia, lymphoma and melanoma.

The original article was published on the QIMR Berghofer Medical Research website. 

Hope from Heartache: The Dillon Family Honour Their Beloved Grandfathers

ACRF, Australian Cancer Research Foundation, Blue September, cancer charity, Cancer Research, charity foundation, donate to charity, Fighting cancer, Funding research, donations in memory, cancer donations, regular giving, regular givers, Partner in the Cure, Partners in the Cure

“Unfortunately both my husband Travis and I suddenly lost our fathers to cancer within two and a half years of each other.

Both of these wonderful men had only recently retired and were looking forward to making plans for their futures. They were in their mid-sixties and had worked hard in the agricultural industry all their lives.

The impact of losing a parent was made even worse knowing our young children would no longer get to enjoy such precious times with their adored Poppa and Grandpa.

It has now been over six years since I lost my Dad and not a day goes by where I don’t think of him. I miss him dearly, and every now and then I’ll pick up the phone to call him before remembering that it’s not possible anymore.

Following my Dad’s funeral, Travis and I wanted to do something positive to help prevent others from suffering the same devastating loss. We decided the best way to do this was to support the hard working cancer research scientists trying to find cures for this cruel disease.

As we had lost our fathers to different types of cancer – kidney and prostate, we looked for a foundation that researches cures for all cancers. We chose the ACRF as they are committed to funding research in Australia that aims to end all cancers.

We now make a contribution every month in memory of our fathers. We’re happy to do our part in the fight against cancer and hope that in the future more children will be able to grow up experiencing the joy of spending time with their grandparents.

We are proud to be ACRF supporters and every month we receive updates and eagerly read about the ground-breaking discoveries being made. We believe that without cancer research many more families will be deprived of valuable time with their loved ones.

While there is nothing that can be done in our sad situation, we take comfort in the precious memories we made with our fathers and hold out hope for families in the future.”

– Sally and Travis Dillon

Learn more about becoming a regular giver.
Share your story

 

Over $117,000 raised for cancer research at City2Surf

city2surf, fun run, cancer research, cancer charity, charity foundation, types of cancer, funding research, online fundraising, give to charity, charity volunteer, cancer fun run, charity challenge, cancer scientists, funding research, medical research

This past weekend over 80 thousand people participated in the iconic 14 kilometre City2Surf. Runners set off from Hyde Park in the heart of Sydney’s CBD and made their way through to the finish line at Bondi Beach.

This year, Team ACRF was made up of 190 incredible runners from all walks of life. Thanks to their hard work and dedication they were able to raise over $117k for cancer research.

Many of the ACRF runners have been personally affected by cancer, including Jonathan Wiener, who had an army of supporters contribute an astounding $20,000 in memory of his cousin Michelle, who lost her battle with brain cancer in February.

“I promised Michelle that I would do everything in my power to find a cure for this devastating disease and running City2Surf for cancer research is my first step in keeping that promise.”

Supporting them along the way were 35 enthusiastic volunteers who cheered on Team ACRF and doled out high-fives from the sidelines.

One of ACRF’s Corporate Champions, Deloitte, generously sponsored a fantastic beach front Marquee where ACRF runners and their families joined the Deloitte team for a congratulatory lunch on the beach.

The ACRF thanks everyone who participated in the City2Surf or who came out to support our runners on the day. We loved meeting you all and celebrating your achievement.

View the team leaderboard – click here.

Researchers Honoured at Cancer Institute NSW Awards

ACRF, Australian Cancer Research Foundation, Cancer Research, Cancer Research Grants, cancer scientists, current cancer research, Fighting cancer, Garvan Institute of Medical Research, Cancer Institute NSW, Cancer Institute MSW Awards, Sydney Children’s Hospital Network, Premier’s Awards for Outstanding Cancer Research, Dr Geffrey McCowage, Amber Johns, Professor Terry Speed

Last Friday the ACRF attended the 2015 Premier’s Awards for Outstanding Cancer Research. These awards honour the achievements of the individuals and teams that work across the cancer research sector to lessen the impact of cancer on the community through prevention, early detection, innovation, and research discoveries.

The event marked the 10th anniversary of the awards and was hosted by the Cancer Institute NSW at Doltone House, Hyde Park. Over three hundred guests from the health and medical sector attended.

The night celebrated excellence and innovation in cancer research, acknowledging the immense contributions of professionals who have dedicated their life’s work to improving the lives of people with cancer, and commending ‘rising stars’ who are embarking on brilliant new research endeavours.

Throughout the night, speeches not only discussed the scientific implications of their findings on future treatments and preventions, but recognised the real world difference cancer research is making to patients battling the disease today.

Keynote speaker Professor Terry Speed, a world-leader in statistics and bioinformatics, marvelled at the impact cancer research teams have on patients. “I severely underestimated the realism of the people in this room. It was a moment of awakening for me, when I realised that someone I knew from an institute that I worked at had made such an impact on my nephew who just had a stem cell transplant.”

Winner of the ‘Wildfire’ Highly Cited Publication Award, Ms Amber Johns, acknowledged the collaborative nature of cancer research worldwide, “it’s important to thank the dedicated scientists undertaking the research, the clinicians for everything they do for our patients and to our patients who volunteer for these studies, and allow researchers into their bedside at such a vulnerable time in their lives.”

Dr Geoffrey McCowage, a paediatric oncologist at the Sydney Children’s Hospital Network Westmead won the Excellence in Translation Cancer Research Award for his work with Gene Therapy. He shared insight on the emotional impact of working in this field. When asked whether the scientific rewards outweigh how difficult it is to work with childhood cancers, Dr McCowage responded with “Absolutely, however people often ask me if it gets any easier to deal with tragedy, and as the years go on I honestly have to say it gets harder.”

Despite the difficulties, Professor Speed revealed that in his experience he found that many researchers are motivated to continue on by a single thought: “There’s a driving force at the back of our minds – if a Eureka moment does happen, there will be an army of people who will bring this discovery from the bench to the bedside.”

The Australian Cancer Research Foundation thanks the nominees and award winners for their hard work and dedication. We know that these awards go beyond recognition of a scientists achievement, they are a celebration of the shared progress that brings us closer towards finding a cure for all cancers.

Brave ACRF supporters skydive for cancer research

ACRF, Australian Cancer Research Foundation, Blue September, cancer charity, cancer fundraising, Cancer Research, cancer research fundraising, charity challenge, Challenge, donate to charity, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories, Sky diving, Experience, Skydive

With Father’s day right around the corner, we’re looking back at some of the unique ways ACRF supporters have chosen to celebrate this special day.

Last year the ACRF held a Father’s Day jump in Wollongong where an extremely brave and inspirational team of four siblings did the jump in memory of their father.

As the year progressed we discovered how Father’s Day was just one of many reasons that our supporters chose to take on this challenge.

Susanne Richter was inspired to raise money for Cancer Research as her grandma, grandpa and dad all fought different kinds of cancer.

“My dad successfully fought prostate cancer,” says Susanne. “He is now well and enjoying his retirement but getting there has been really tough. I made the decision to jump for ACRF because there is still so much research that needs to be done to ensure that everyone’s story has a happy ending like my dad’s.”

Susanne jumped with 10 other ACRF supporters who went above and beyond, raising more than $34,000 for world-class cancer research.

“I am so happy to support such a wonderful cause and I am very proud of us and the incredible amount of money that was raised. This was definitely an experience I will never forget!”

ACRF jumper and cancer survivor, Maria De Virgilio, shared her thoughts on why she took the plunge and how she feels that she is living proof that that cancer research will save lives.

“Cancer does not have to be a death sentence, it’s an illness and it’s one we are getting better at fighting with new treatments, and support groups, and most importantly ongoing research.” She teamed up with her sister Teresa and best friend Vicky to celebrate her strength and pay tribute to her friends and family who also battled the disease.

Where as Krystyna Pollard chose to make the jump as brave gesture in support of her mother’s fight against pancreatic cancer.

“I hope that by flinging myself out of a plane I can not only raise money so someone, somewhere can perhaps find a cure for this disease, but so I can face some fear of my own and overcome it. Just like mum is,” says Krystyna.

We are inspired by each and every one of these amazing Jumpers– we cannot thank them enough for their bravery, determination and generosity.

 

A dedicated daughter and determined mum runs toward the cures for cancer

Australian Cancer Research Foundation, ACRF, cancer charity, cancer fundraising, cancer fun run, cancer research fundraising, City2Surf, Challenge, charity challenge, donate to charity, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories, Sydney, marathon, London Marathon, Carol Tannous-Sleiman

Carol Tannous-Sleiman is setting an incredible example for her three young children. Having just run in the 2015 London Marathon in memory of her father, she is already gearing up for another race and continues to raise funds for cancer research.

“The ACRF is an important charity for me and taking on fundraising challenges is something that I do on behalf of my father, my family and my children.”

In the lead up to London she raised an astonishing $11,000. “I can’t thank everyone enough, I’m very humbled that people have donated and are here to support me. Not only does it mean a lot to me, it really means a lot to the many survivors and families out there who have lost love ones to cancer.”

Her and her team of 29 staff from Greenwood Early Education Centre have been gearing up to run in this year’s City2Surf. Together they’re working with a personal trainer and planning a number of fun fundraisers in the lead up to the race, including an international party for both the kids and the parents to get involved in.

Over the years Carol has participated in many famous Marathons, including Paris, Chicago and New York. London was her twelfth Full Marathon and another to cross of the Bucket List.

“London was definitely in the top five – why not do a nice run, for a good cause, in a beautiful city like London?!”

Before having kids, Carol had never pictured herself as a runner. To keep fit she enjoyed a daily 8km walk. “Strangely enough, it was actually my busy lifestyle that provided me with the impetus to start running. With the demands of work and parenthood, I needed to find a more time efficient form of exercise. So I thought, why don’t I just run instead of walk?” Since then she’s never looked back, and has continued to move from strength to strength.

Her first real test was to run the 14km City2Surf and before long she found herself participating in 21km Half Marathons. She finally took on the full 42.2km at the Melbourne Marathon. “When you finally cross that line, it is the biggest sense of achievement. You get very tearful, it’s amazing I’m so excited to share in that moment with my team.”

Click here to show Carol your support.
Share your story

James and Kirsty have their eyes on the finish line

Fundraising Stories, ACRF, Australian Cancer Research Foundation, Blue September, cancer fundraising, Cancer Research, cancer research fundraising, Challenge, charity challenge, donate to charity, Fighting cancer, Funding research, Fundraiser, fundraising, Fundraising Stories, Running for Cancer Research, marathon, give to charity, Berlin, Berlin Marathon, James Robson, Kirsty Donovan, Sydney Half Marathon, Iron Man challenges, Iron Man, Everyday Hero, Half Marathon, SMH Half Marathon, Sydney Morning Herald Half Marathon, Berlin Marathon 2015

For us, this year is about not letting anything come between us and our dreams – this was the advice my Dad, Mick always gave me.”

This September, James Robson and fiancé Kirsty Donovan will be heading to Europe to run in the Berlin Marathon.

James has been a dedicated ACRF supporter for many years. “While my Dad was receiving chemotherapy treatment back in the UK, I felt like there wasn’t a lot I could do from 12,000 miles away, so I decided to raise as much money as possible to help eradicate this disease.”

“For years I ran in his honour. I ran Iron Man challenges, half marathons and more; running to prevent the sadness, raising money to give every step more meaning in the hopes that Dad might survive his cancer.”

“After three long years of fighting brain tumours, Dad lost his battle with the disease and passed away. I was on a plane home to him as soon as I received the phone call and was able to make it in time to say goodbye. It will be almost a year but it still feels like yesterday.”

“Now I am running in his memory. The ACRF is very close to our hearts and running to raise funds is a way for us to take on a personal challenge at the same time as hitting back at cancer.”

With the help of generous family and friends the couple have raised an astounding $25,000.

James and Kirsty continually strive to move onwards and upwards. With each event they participate in, they continue to challenge both their physical and mental endurance.

“People all over the world are fighting for their lives and they have no rest, so we’ve decided to carry on going to really make a difference and help more people.”

Already this year, they took on the Sydney Half Marathon. “Together we hope to keep going for the full 42km until we reach the Brandenburg Gate.”

We wish James and Kirsty the best of luck, and thank them for their ongoing support.

Click here to show your support for James and Kirsty.
Share your story

Kelmscott Police Officers set to scale Mt Fuji in honour of fallen friends

Fundraising News
Mt. Fuji, Japan viewed from Chureito Pagoda in the autumn.

 

This September, Western Australian Police Officers Oliver, Anita, Wendy and Tanya will be on route to Japan preparing for an experience of a lifetime. They will be hiking the country’s tallest mountain – Mount Fuji, in an effort to raise funds for cancer research and honour their fallen friends.

The past two years have been difficult ones for the Kelmscott Local Police Team. They’ve had to watch two of their brothers in blue, Larry McCarthy and Gary Husain, lose their battle with cancer.

“We’re a really close-knit crew and have been working together for a number of years. It was really difficult losing our friends. They were both really hard working and loyal men. They were always doing their best for our community.”

Experienced hiker and Senior Sergeant, Oliver Lund, will be leading the team on their ascent. And as someone who has already successfully scaled one of the world’s most challenging summits – Mt Kilimanjaro, he will be the perfect man for the job.

“We’re taking on this challenge for a number of reasons. Not only is it going to be a great team-building exercise, but it will also be a really special way to remember our friends and raise funds for a cause that has affected us so deeply. Cancer is never too far from our minds as so many families in our community are facing the disease.”

They decided that Mount Fuji would be the safest for the crew of first-time hikers, but at 3776 meters above sea level, it’s still considered one of the more challenging climbs.

“It’ll require quite a lot of strength and endurance. We like to keep fit as possible for work, and participate in regular police training days – but we’ve all really stepped it up in preparation for the climb.”

“Depending on how the weather treats us we’re planning on setting off in the evening and planning our trek so that we will finally reach the peak at dawn. Watching the sunrise from the top will be such an amazing experience.”

The team hopes to raise awareness of the ACRF Fundraising program “The more people that know about the ACRF Online Fundraising Program, the greater the impact we can have so we’re doing everything we can!”

To show your support these brave officers click here.
Share your story

Running for S.T.E.F – Elderene is on a mission to Stop Tumours Ending Friendships

Cancer Fundraising, Charity Challenge, Running for Cancer, Funding Cancer Research, Charity Foundation, Cancer Charity, London Marathon, Donate to charity, Fighting Cancer, End Cancer, Campaign for Cancer, Running for Stef, Brain Cancer, Fundraising Campaign, Cancer Campaign, running for stef, running for cancer research, marathons, fun runs, brain cancer, cancer treatments, cancer prevention

Earlier this year, Stephanie Barker was preparing to run the Mackay half marathon when she realised something wasn’t right. Just days after running 10km, she was flown to Townsville for treatment for an aggressive grade four brain tumour.

“I was totally unaware of what it was to have a tumour, or a mass, or brain cancer, I am so lucky the emergency room doctor was able to stabilise me in Mackay. Once stable, I was flown to the Townsville Hospital where I underwent major brain surgery.”

Before the surgery, Stephanie’s brain tumour was the size of an orange, which meant that she could only spend two weeks at home over Easter before heading back to Townsville to undergo six more weeks of daily radiation and chemotherapy.

It was there she met Elderene, a Senior Radiation Therapist and soon to be friend. “We were surprised to find that we have so much in common, we are both originally from Africa and had spent time living in England before getting married and making the move to sunny Queensland.”

The similarities didn’t end there – Stef and Elderene also share a passion for running. “I had been training for the Mackay run before being diagnosed but, unfortunately, doctors advised me not to run.”

“Being the character that I am, I started joking that Elderene should run in my place.” What Stef didn’t know at the time was that Elderene had actually completed 22 full marathons. “Unlike me she’s a veteran of distance – I’m in awe of her as I have to drag myself over the line in a half marathon.” Elderene assured her that 42.2km is nothing compared to having to battle a grade four brain tumour.”

A few days later, Elderene had some big news for Stef, “Elderene was bursting with excitement as she told me that she had been given a spot in the 2016 London Marathon, and that she would be running for me!”

“I am still stunned, so overwhelmed! Elderene had taken me so seriously that she is now going to travel 16,000km at her expense to run for me in the London Marathon.”

‘S.T.E.F’ became an inspiring acronym for the ‘Running for Stef’ Fundraising Campaign: Stop Tumours Ending Friendships. Elderene explained that raising money and awareness made her feel like she was playing her part.

“I want to see a cure for cancer in my lifetime and my aim is to raise $10,000 for the Australian Cancer Research Foundation for Stef and the thousands of people who are battling cancer.”

Click here to support Elderene.

Share your story

The ACRF Cancer Imaging Facility officially opens its doors today to researchers in Western Australia

Cancer charity, new cancer research facility, fighting cancer, technology, medical research, current cancer reserach, opening

Harry Perkins Institute of Medical Research is opening the doors today to the ACRF Cancer Imaging Facility, a state of the art imaging centre that has been outfitted with cutting edge technology to enable further breakthroughs in cancer research.

The facility was funded in part by the late Mr Kevin McCusker who made a generous donation to the Australian Cancer Research Foundation through his Will. Mr McCusker was a quiet and unassuming man of strong principles who made this bequest in honour of all the people he loved and lost to cancer.

As a state facility, the equipment will be made available to researchers from all over Western Australia. What this means for cancer patients is that for the first time in WA, researchers will be able to subject cancerous tumours to more intensive scrutiny, and thereby speed up the development of new therapeutic advances.

“Imaging for cancer management and diagnosis in humans is fundamental. These micro-scanners will allow Perkins researchers to image cancer progression in a range of well-developed preclinical models like never before, enabling them to monitor for the first time tumour development, angiogenesis (the process through which new blood vessels form from pre-existing vessels), metastasis (or growth) and response to treatments” says Peter Leedman, Director of the Harry Perkins Institute of Medical Research.

Harry Perkins sees ACRF is absolutely essential in filling a gap that no other foundation fills, which is providing funds for core infrastructure.

“Large cutting-edge pieces of equipment such as the ones at this new facility are remarkably difficult to get in any other way. The ACRF stands alone in this country so we are very grateful to have been able to work with them to attain this final result. It’s allowed us to take an exciting step forward in our field,” says Mr. Leedman.

The Harry Perkins Institute of Medical Research has received $3.6 million in grants from the ACRF which has funded technology to progress research in Leukaemia, breast, prostate, cervical, pancreatic, liver, brain, lung, colon as well as head and neck cancers.

The moment that changed my family forever.

regular giving, cancer research, funding cancer research, cancer charity, charity foundation, ACRF, Types of Cancer, Leukaemia, cancer scientists, regular charity donations, cancer fundraising, donate to charity, give to charity, funding breakthroughs

“Back in 1998 my husband and I were like any other typical family. We had two sons, one aged four and eight. My husband, Craig, was an electrical engineer and Officer in the Navy. He was passionate about the Navy and his job at HMAS Albatross in Nowra. Craig was looking forward to being promoted and taking the next step in his career, while I was studying adult education and both our boys were involved in many sporting activities. We were no different than any other family.

April 1998 will be a month I will never forget. Craig had been complaining of not feeling well, having a sore throat and just feeling lethargic. Within one week Craig had been admitted to the oncology section of Wollongong hospital and diagnosed with a rare form of Acute Myeloid Leukaemia. Our world tipped upside down in a moment and I was trying to explain to a four and eight year old that their father was very sick and may not live. Craig was told that the only way he could live was with a bone marrow transplant and that he didn’t have much time. The chances of survival were given at 30%.

Craig endured chemotherapy which was quickly followed by a bone marrow transplant. Fortunately for Craig his identical triplet sisters were a match and one was selected as his donor. Hurdle one was achieved. The next step was to get into Westmead Hospital for the transplant and that was hurdle two. The transplant unit only took 6 patients at a time and we had to wait. Unfortunately we didn’t have time to wait.

Eight months were spent in and out of hospital however after the transplant it was found that Craig had suffered a complication from the transplant which affected his lungs. After many years with Craig’s lung problems he eventually passed away on 8 August 2002 at 38 years of age.

Throughout all the treatments and hospital visits there was one thing that Craig was passionate about and that was raising funds to find a cure for leukaemia, particularly in children. Craig felt that if he found the treatments hard to cope with, then small children with any type of cancer would be in a worse position.

I continue Craig’s passion for finding a cure for all cancers, which is why I have become a Partner in the Cure. The researchers and medical professionals working at ACRF are equally passionate about finding cures in the hope that people like Craig get to live a fulfilling life with their families. I’m proud to do my small part by regularly donating to the ACRF so that they can continue to fund breakthroughs in cancer research.

Cures for cancer can only come from research and if we all contribute a small amount this means that cancer research can continue in Australia,” Regular Giver of the Month – Dianne King.

Learn more about becoming a regular giver.

Share your story

New discovery a sign of hope for melanoma patients

melanoma, cancer research, cancer types, give to charity, cancer charity, charity foundation, fighting cancer, medical research, breakthroughs, current cancer research, donate to charity,

After four years of dedicated research, PhD student Mitchell Stark has made a remarkable discovery at the QIMR Berghofer Medical Research Institute, a facility which has been awarded three grants from the ACRF. He has uncovered new markers which will help increase the speed, accuracy and accessibility of tests that monitor the progression of Melanoma.

Mr. Stark’s study has revealed that elevated levels of microRNA’s, which are tiny molecules that regulate the amount of protein in a gene, can indicate that the cancer is at risk of spreading.

“They are highly sensitive and specific, and are significantly better than markers currently being used,” says Mr. Stark. “In specimens from stage IV patients, the new biomarkers confirmed tumour progression in 100% of cases.”

Mr. Stark said this is significant because it will allow patients to start treatment before metastatic disease is clinically evident, which could greatly improve a patient’s chance of survival.

“Patients with stage III melanoma, with spread confined to regional lymph nodes, have a five-year survival rate of about 50%, compared to less than 15% if metastases are widespread.”

In addition to the accuracy, another positive is the method in which the testing is done. All that is required from a patient for the markers to be detected is a routine blood test. This will better identify the group of patients that require additional expensive and stressful tests such as CT scans.

Queensland Science Minister Leeanne Enoch said the research represents a significant advance for melanoma patients.

“This is an excellent example of the world-leading research at QIMR Berghofer which has the potential to make a real difference to the lives of patients in Queensland and around the world.”

QIMR Berghofer Medical Research Institute has received $6.65 million in grants from the ACRF which has funded technology to progress research in colon, breast, ovarian, prostate, leukaemia, lymphoma and melanoma.

The original article was published on the AIMR Berghofer Medical Research website.

Where one daughter leads, her mother follows – an inspiring distance runner shares her story

Professor Anne Boyd, marathon runner, fun runs, run for cancer research, cancer charity, charity foundation, fighting cancer, online fundraising, charity volunteer, city2surf, chairity challenge, cancer, fitness

“I truly believe we will beat cancer, possibly in my lifetime.” – Professor Anne Boyd.

Professor Boyd is 69 years young and discovered her passion for distance running only a few short years ago. This has led her to not only become a great advocate for cancer research, raising both funds and awareness, but it has also led her to win the Sydney Striders F65-69 Marathon trophy and become the Southern Highlands Challenge poster girl!

Her love affair with running began back in 2013, when she decided that, in celebration of her 67th Birthday, she would compete in her first 5K run at the Australian Running Festival in Canberra.

Two years later, she has become a dedicated running enthusiast and has completed a number of challenging races including City2Surf, four Half Marathons, the Melbourne Marathon and numerous other competitive10Ks.

“I’ve loved every step, even the more painful ones. I enjoy mid-race conversations with other runners and play up photo opportunities! A camera is always worth a grin and a grin helps deal with any fatigue issues which might be building up. Although there is real pleasure in achieving a personal best, my only important aim in a run is to finish,” says Anne.

Anne sees the sport as a really great way to raise funds for a cause that touches all our lives.

“I am personally so grateful for advances in cancer research. I’ve had tests detect precancerous polyps, which I had removed, and a recent breast scan that detected a small lump which was quickly determined not to be of any danger. These advances, of course, are bought about through the research that has made such great strides in my lifetime. But it needs everyone’s support, so I’m really happy that I can do my part and run for this cause.”

Anne’s daughter, Helen Louise is a huge supporter of her mum’s new found hobby and has been a great source of inspiration and encouragement to her since the beginning. As a distance runner herself, she became her mum’s go-to for knowledge on all things running and even ran alongside Anne in her very first race, helping her to achieve third place in her age division.

“My darling daughter ran with me as a warm-up for her serious event the next day and was rewarded with considerable grumpiness from her hot and bothered mother during the final kilometres! But to finish was a joy! She has played a key role in my new found passion, so now, where she leads, I follow.”

To support Anne at this year’s City to Surf, click here.

Share your story

Using your talent to raise funds for cancer research

Every one of us has a unique set of talents, and our mission at the ACRF is to support Australia’s top cancer researchers to do what they do best.

It’s not easy to find the motivation to explore your strengths and creativity, but raising funds to help the experts find new treatments and cures for cancer might be just the inspiration you need! To help get your started, see what some of our supporters are doing.

MusicMusic icon

May Carrick is a police officer by day and a musician who records his albums by night, dedicating all proceeds to cancer research in honour of his father whom he lost to cancer two years ago. May first began writing music to help him cope. Check out his latest album here.

ArtPaint icon

Mikaela Designs is an amazingly talented sketch artist who recently showcased her work in honour of her late friend Casey. Her artwork was auctioned off to the highest bidder at an exhibition that she organised for cancer research.

JewelleryJewellery icon

Kirin Matthews is the founder of Jewellery for a Cause – a jewellery company with a passion for supporting charitable organisations and important causes. She donates 20% of each piece to charities such as the ACRF. View one of her latest creations here.

If you’re still not sure what type of charity fundraising you want to do, you can visit our A-Z fundraising page for more fun ideas on how you can make the most of your own unique talents.

Alone, on foot, across the Simpson Desert, Ian Vickers is pushing himself to the limit for cancer research

fighting cancer, cancer charity, charity foundation, cancer research, funding research, online fundraising, adventure, walk the simpson, ian vickers, give to charity, donate to charity, charity donation

In the next few days, Ian Vickers will be venturing out into the Australian outback to start his journey across the harsh terrain of the Simpson Desert. He will be travelling over 400 kms by foot – hauling his food and water supplies on a custom built cart.

“I’ve been flat out the past week with last minute preparations, all is going well, feeling fit, strong and confident with a healthy dash of nervousness,” says Ian.

He has chosen to dedicate this challenge to raise awareness and funds for cancer research.

“There are many worthy charities whose name I could have chosen to support, however I lost both my parents to cancer far too early in their life, so it felt right to pick a charity that is dedicated to finding cures for this terrible disease. In fact, I believe that the success of my adventure will not only be measured by the completion of my walk but also in my ability to raise funds and awareness for cancer research.”

Ian says he’s enjoyed every step of the journey so far. He has already invested an incredible amount of time and effort leading up to his quest, with the initial planning and preparations starting back in May of last year.

“I literally walked the soles off a pair of old boots during one of my training sessions earlier in the year! I had a good friend of mine build a training rig consisting of scaffold poles and car tires that I could hook up to my new harness to drag up and down the beach.”

And with all the hard miles put in he could not be more ready to embark on this remarkable adventure.

“I’m relishing the new skills I’ve acquired along the way. I have a plan B, C or D for almost every eventuality should I run in to trouble along the way. But I have to credit all the support from friends, family and strangers alike, there’s no way I could have done this without them.”

We are all very excited (not to mention a little bit anxious) for Ian, and wish the best of luck as he sets out to accomplish this extraordinary feat.

To support Ian’s journey, visit his Everyday Hero Page here.

Share your story

Researchers expose how ‘James Bond’ cells are made to boost our immune system against cancer.

Our determination to understand how our bodies operate continues to reveal fascinating intricacies.

New research published in the journal of Nature Immunology exemplifies this. In the study, researchers from the ACRF funded Walter and Eliza Hall Institute reveal how immune cell ‘spies’ are created.

These dendritic cells, or ‘James Bond’ cells gather information on disease-causing agents to aid our bodies in fighting them.

“Dendritic cells are the intelligence-gathering cells that educate the immune system,” said Dr Naik from the Walter and Eliza Hall Institute.

“They tell the infection-fighting T cells and NK cells what a virus, bacterium, fungus or cancer looks like so they know what they’re looking for when fighting disease”.

Prior to this discovery, it was thought that dendritic cells shared one ‘parent’. But researchers have found that we actually have an army of unique ‘parent’ cells that decide whether or not to multiply or generate new dendritic cells to help identify and fight disease.

What this new knowledge provides us with are clues on how the immune system could be manipulated to better fight disease. In examining and understanding at a molecular level how our body naturally fights diseases, we can then single out the cells that are doing the right thing and suppress any ‘James Bond’ cells that are aiming at the wrong target.

This discovery could not have been achieved without cutting-edge technology that allows scientists to single out individual immune cells, rather than try to examine thousands at once.

“We and others have been following this family tree from one daughter cell to the next to discover how each cell type is created and how the parent cell ‘decides’ if it should make more of itself or create the next cell type. By dissecting the heritage of these cells, we can find new targets to tackle a range of conditions including infectious diseases, cancers and immune disorders, and even make vaccines more effective,” says Dr Shalin Naik.

Walter and Eliza Hall Institute has received $5.5 million in grants from the ACRF which has funded technology to progress research in lymphoma, breast, lung and genomics.

The original article was published the Walter and Eliza Hall Institute for Medical Research website. To read the original article, please click here.

Genetic sequencing in Australia could revolutionise cancer diagnostics

It is being called ‘the frontier of medical science”’.

Cancer research, genetic research, research, discoveries, fighting cancer, funding research, types of cancer, progress, genetic research, cancer scientists

The potential to pre-empt cancer diagnosis with genetic testing has taken a major step forward following the first Australian NATA* accreditation for ‘whole exome sequencing’.

SA Pathology’s Genetics and Molecular Pathology laboratory, in collaboration with the Centre for Cancer Biology’s ACRF genomic research facility, have received this important stamp of approval to test the complete set of human genes in a single assay, using cutting-edge Next-Generation Sequencing (NGS) Technology.

Professor Hamish Scott, Director of the ACRF Cancer Genome Facility at SA Pathology’s Centre for Cancer Biology explains: “In human DNA there are six billion data points, 2% of them are our genes, which can be sequenced in an ‘exome’. We’re searching through over a hundred million bases to try and find an anomaly or a mutation that may be causing disease.”

This landmark accreditation rewards many years of research dedication and collaboration between research and funding bodies, including the Australian Cancer Research Foundation.

Dr Karin Kassahn, Head of Technology Advancement says, “With this new approach, genetic tests will take months, not years, and see an end to some of the uncertainty – there will be definitive results for more patients.”

“These technologies weren’t available a decade ago, but now genomics is set to play a major role in medical treatment. If we get this right, genetic testing will become an integral part of health care, available to everyone in need.”

Professor Scott has said that unfortunately many rare genetic conditions still don’t have an effective treatment or cure.

“But if we can pick these things up, we may be able to alleviate symptoms with new therapies and help patients and families manage their disorders,” he said.

“This is the future of healthcare, what’s known as ‘personalised’ or ‘precision’ medicine.”

The ACRF is proud to have supported the world-class research teams at SA Pathology, Centre for Cancer Biology. We thank our donors and fundraisers for their dedication to cancer research, without which, this important progress would not have been possible.

This information was originally published by SA Pathology and can be viewed here.

*NATA is the National Association of Testing Authorities in Australia. It ensures facilities, testing and measurement methods comply with relevant international and Australian standards.

No hair don’t care – brave supporters lose their locks for cancer research

This inspiring group of individuals won’t have to worry about hat hair under their beanies this winter. They’ve faced the scissors in honour of those who have had to face cancer and in doing so have helped shave years off of cancer research.

The O’Neil family raised an incredible $10,000 and lopped off an equally impressive amount of hair at an event that honoured their mum. We all owe a big thank you to this family of legends for their most generous act of support.

head shave, cancer research, cancer charity, fundraising, donate to charity, give to charity, online fundraising, cancer fundraising, campaign for cancer, fight cancer, shave for the cure

Joining them, Angela from Bowral in the Southern highlands made the decision to shave her hair off on her grandpa’s birthday. “My grandfather was the most amazing kind hearted man. He lost the love of his life to this disease and had to then face it on his own so this was my way of honour them both.”

Meanwhile in Melbourne the ReachLocal team embarked on a race like no other. They were let loose on the town to carry out a mission that would prove themselves against their in-house rivals and raise money and awareness for cancer research.

No hair don’t care - brave supporters lose their locks for cancer research This inspiring group of individuals won’t have to worry about hat hair under their beanies this winter. They’ve faced the scissors in honour of those who have had to face cancer and in doing so have helped shave years off of cancer research. The O’Neil family raised an incredible ,000 and lopped off an equally impressive amount of hair at an event that honoured their mum. We all owe a big thank you to this family of legends for their most generous act of support. Joining them, Angela from Bowral in the Southern highlands made the decision to shave her hair off on her grandpa’s birthday. “My grandfather was the most amazing kind hearted man. He lost the love of his life to this disease and had to then face it on his own so this was my way of honour them both.” Meanwhile in Melbourne the ReachLocal team embarked on a race like no other. They were let loose on the town to carry out a mission that would prove themselves against their in-house rivals and raise money and awareness for cancer research. The winning team had the honour of cutting the Learning Program Manager’s gorgeous long locks and were pretty excited about it (as you can see!). Everyone came out feeling like champions in the end when they discovered that they smashed their fundraising target. Well done all! We are humbled by your efforts. If these superstars have inspired you and you want go bare under your beanie this winter find out more by clicking here. https://acrf.com.au/head-shaves-for-cancer-research/

The winning team had the honour of cutting the Learning Program Manager’s gorgeous long locks and were pretty excited about it (as you can see!). Everyone came out feeling like champions in the end when they discovered that they smashed their fundraising target.

Well done all! We are humbled by your efforts. If these superstars have inspired you and you want go bare under your beanie this winter find out more by clicking here.[/vc_column_text][/vc_column][/vc_row]

Share your story

Tracking ovarian cancers’ evolution to change approaches to treatment

David Bowtell, Peter Mac, cancer research, charity foundation, cancer research, cancer scientists, research discoveries, give to charity, progress, science, treatments, ovarian cancer, DNA, genetic mutations

We often think of evolution as a positive thing, associating it with progress, growth and development. But because evolution exists in all living things, including cancer cells, it also presents one of the greatest challenges for researchers as they seek out new ways to outsmart an ever moving target.

But thanks to the team of world-leading researchers at the ACRF funded Peter MacCallum Cancer Centre at least four evolutionary processes have now been identified that enable ovarian cancer cells to resist chemotherapy treatments.

In collaboration with two other key ACRF-funded research institutes, University of Queensland’s Institute of Molecular Biosciences and Westmead’s Millennium Institute, the research team used whole genome sequencing to analyse tumour DNA samples from 91 patients with high-grade serous ovarian cancer.

Their new insights into how these cells genetically change to become resilient will allow researchers to investigate more effective treatments – treatments that are tailored to break through each defensive barrier.

The defence mechanisms identified in these cancer cells included everything from “hijacking” genetic switches that enable them to pump chemotherapy drugs out of their way to reshaping and accumulating “scar tissue” which appears to block the chemotherapy drugs.

‘In this research we saw stark reminders of how evolution presents us with incredible challenges – to fight an insidious enemy, you need to understand them, and we’ve made a great leap forward thanks to a truly international collaborative effort ,’ says Peter Mac researcher Professor David Bowtell.

Before this clinicians would watch as initially effective treatment became ineffective and cancer cells made an aggressive comeback in their patients. For decades they had little information to guide them when selecting treatment for women whose cancer has returned.

‘The research is a turning-point in the global fight against ovarian cancer it offers great hope to patients world-wide,’ says Professor Bowtell.

To date this has been the largest complete DNA analysis of ovarian cancer in the world and it would not have been possible without the outstanding support of ACRF donors.

This information was originally published by the Peter MacCallum Cancer Foundation.

World-first research centre signifies a new era for cancer research

Cancer charity, fundraising, new facility, research, cancer research, children's hospital, discoveries, types of cancer, genetic research

The Australian Cancer Research Foundation Telomere Analysis Centre officially opened its doors this week to become the world’s first facility to specialise in Telomere research.

Recent findings argued a strong case for the development of this cutting-edge facility, indicating Telomeres could hold the answers to significant advancements in the treatment of some of the most aggressive types of cancer.
Telomeres are structures that cap the ends of our chromosomes. They serve a critical role in the cell renewal process and under normal conditions, gradually shorten as we age.

But studies at the Children’s Medical Research Institute have shown that cancer cells develop ways to disrupt this natural process. They re-program cells to prevent their telomeres from shortening, causing the DNA to “short-circuit” and cells to multiply out of control.

Furthermore, researchers have found ‘lock’ mechanisms on normal cancer cells which prevent this process. The ‘lock’ on cancer cells, however, is damaged, providing researchers with a new target for treatment.

CMRI Director, Professor Roger Reddel, who was involved in the research, said “We think that losing this lock makes cancer cells vulnerable to treatments that normal cells are protected against. So we may have found an Achilles heel for certain types of aggressive cancer.”

“The ACRF’s Medical Research Advisory Committee assessed this research initiative as both nationally ground-breaking and internationally competitive. The ACRF and our supporters are very proud to fund this life-saving work at CMRI,” said ACRF Chief Executive, Professor Ian Brown.

The new ATAC facility was funded with a $2 million ACRF grant and is outfitted with some of the most advanced technology and cutting-edge equipment that exist in this field. These microscopes and computer analysis stations provide speed and accuracy on unparalleled levels, helping to propel telomere-related cancer research to new heights and accelerate the race toward new treatments, and ultimately, cures for cancer.

A man honours his hero, best friend and father

Regular giving, cancer research, cancer charity, fathers, sons, types of cancer, donate to charity, give to charity

“I have chosen to become a Partner in the Cure due to the recent passing of my father, Stan Phillips, at age 76. My father was a major influence on me and truly was a great man. He lived his life to the fullest and touched the hearts of many. He lived a long life, but for me his passing still came too soon, I was hoping he would be around longer to see his two grandchildren grow up.

He was very fit and I think he would have had years left if it wasn’t for cancer. It was a shock when he had to be rushed to hospital and we discovered he had bowel cancer. He fought a hard battle for three years right up until he passed, and through it all he was positive, smiling and enjoying life.

He was a real family man who put us first and was more concerned with my family than his own struggle. He worked hard to give us every opportunity in life and rarely treated himself. He was my mentor, training partner and best friend. The way he lived his life and fought cancer is why he is my role model; I will be happy if I can live up to just half of his standards and I hope I can pass this attitude to life onto my children. It’s amazing what a perfect father he was especially when he lost his own in the 2nd World War at the age of four.

His determination in life led him to be successful in several different careers, starting out as a carpenter, then serving in the Elite Parachute Regiment, and finally becoming a construction site manager. He was also wonderful husband to my mother Margret. Today would have been their 50th Wedding Anniversary.

Karate was one of his favourite hobbies. He trained for eight years earning his black belt in 1983 and only stopping a few months prior to his passing when he became too ill. The club he belonged to now awards a trophy in his name.

He requested that people make donations to cancer research in lieu of bringing flowers to his funeral. He believed, as I do, that if we can contribute to the advancement for a cure it will one day save my children or grandchildren from this terrible disease,” Nathan Phillips.

Share your story

No wrapping required for gifts that keep on giving – Heather & Craig share their wedding story

Heather and Craig

With many modern couples now living together and making a home before they tie the knot, some are starting to think creatively about wedding gift ideas. If you are one of these couples who are newly engaged (congratulations!) and wondering whether you really need another toaster, we have a story to share with you that might inspire you to do something a little different at your wedding.

Heather and Craig met each other a lifetime ago. They both had families and were living happily, separately, in rural NSW.

When cancer claimed the lives of Craig’s late wife and Heather’s mother, they didn’t yet have each other to lean on. But a stroke of fate brought the two together, and they discovered an unmistakable connection.

It was at a food and wine ball in their hometown that they started a conversation that would turn into something completely unexpected. Their budding relationship brought two families together and challenged the grief that cancer left behind with new love.

Craig’s timing was perfect. He took Heather up in a helicopter and as they flew over a stunning view of Hillgrove, he proposed.

Memory Well

They were married at their house in Glenn Innes and started a new chapter in both their lives. To remember the loved ones they had lost, Heather and Craig created a Memory Well at the wedding where guests could donate to cancer research.

Heather and Craig’s wedding donations idea was a celebration of not just their love, but for the love of those who surround them and those who have shaped their lives.

“We would love other people to do the same thing. We have lost family members to cancer so to us there is no greater gift than a world without cancer.”

If you want to invest in the future of your loved ones at your wedding by funding cancer research – either in lieu of gifts, or wedding favours (bonbonniere) – you can find more information here: https://acrf.com.au/wedding-donations

Share your story

It’s Volunteer week!

As the great Mahatma Gandhi once said, “The best way to find yourself is to lose yourself in the service of others.”

Here at the ACRF we are lucky to meet so many wonderful people who live this mantra. From marathon runners, to head shavers, to gala dinners and everything in between, we get to watch people’s own strength and creativity shine in all their efforts towards raising funds for cancer research.

Our most dedicated volunteer groups are known as Cancerians Committees. Together these event-based charity volunteers have raised millions of dollars for world-class cancer research by organising annual events in their local area. Click here to take a look at our amazingly dedicated Cancerians.

We are also incredibly fortunate to have a number of volunteers who give their time to help end cancer, by helping out in our office.

We wanted to take a moment to share some of their stories with you.

IMG_6358

Lisa Sliteris: “It is an easy task to acknowledge the need for change, but it is more the action taken after this that determines the outcome. By volunteering, it gives you the chance to take such action for a cause that you are passionate about. I chose to volunteer for the ACRF as I wanted to be part of a positive goal directed and committed team. Their ambitious and hard work has had a major influence for cancer research, and I hope that through my volunteer work, I can contribute to future their accomplishments.”

 

 

IMG_0555

Duncan Innes: “Why volunteer for ACRF? Well, apart from the fact that cancer is likely to affect one in two men personally during their lifetime, my Mum, my favourite boss and my mother-in-law have all been cancer patients. My grandad died of stomach cancer 50 years ago, too.

When I started my career as a hospital administrator, bone marrow transplant was experimental: four out of five leukaemia patients didn’t survive. Now, four out of five kids do survive. So that tells you how important cancer research is, and how it is a long-term game. Contributing my time and my skills to that is definitely a worthwhile thing to do!”

 

Volunteer week - Sayako & her nephewV2

Sayako Inoue: “My sister found out she had thyroid cancer when she became pregnant with her first child. Thanks to the latest treatments she was able to receive, she has been well and my nephew is turning five this year. I thank ACRF for giving me the opportunity to invest my time in the cause I believe in.”

A big thank you again to all the volunteers out there, we get closer every day to ending cancer because of you.

If you would like to find out more about how you can volunteer with the ACRF, click here.

 

 

Why do so many people run for a cause? One runner tells his story.

running for charity, cancer research, brain cancer, types of cancer, funding research, running for cancer, online fundraising, marathons, city2surf, fighting cancer

Today it seems that everyone (and their dog) is running a fun run, half or full marathon. But what the growing numbers don’t say is how hard it actually is to finish a race. They don’t tell you that there is something special you need, right out of the gate, in order to have a shot at finishing what you’ve started.

You need something that will keep you going when your body is pleading with you to give up.

For most, this will be a cause that is bigger than they are. For Jonathan Weiner it’s the thought of his cousin. Having lost Michelle to cancer, Jonathan became determined to do something to honour her memory and make a difference. It’s fuelled his fire to run in this year’s City2Surf in August.

Jonathan says “I am going to keep a promise that I made her. I promised Michelle that I would do everything in my power to find a cure for this devastating disease, and this is my first step in keeping that promise.”

“Although my cousin died of brain cancer, many different types of cancers have affected my family, which is why I chose to raise funds for the ACRF. It is a way for me to help fund research in all types of cancer,” says Jonathan.

People from all over the world are joining forces to help Jonathan reach his goal of raising $18,000 for cancer research and support him in his journey to honour his cousin.

To get behind Jonathan in his cancer fun run please click here.

To see how you can embark on your own running challenge here.

Share your story

New screening technique developed to detect ‘silent’ ovarian cancers early.

Cancer scientists, UNSW, cancer research, discoveries, current cancer research, ovarian cancer, funding research, detection, diagnosis, advancement
University of NSW Vice-Chancellor Ian Jacobs. Image source: UNSW Newsroom

 

Ovarian cancer is often referred to as a ‘silent killer’, with around one hundred thousand women succumbing to the disease globally each year. Symptoms can be very vague, and the disease often spreads before the cancer can be found.

But there is new hope for early detection. The latest results from a clinical trial led by UNSW Vice-Chancellor, Prof. Ian Jacobs, in collaboration with University College London, have shown a novel new screening method can identify twice as many women with ovarian cancer as existing strategies.

The new screening programme allows researchers to better interpret the changing levels of a specific protein called CA125 (which has been linked to ovarian cancer) through a blood test, giving a highly accurate prediction of a woman’s individual risk.

“The sensitivity is very, very high – much higher than people thought would be possible,” said Professor Jacobs. The new method detected cancer in 86% of women with invasive epithelial ovarian cancer (iEOC).

Previous methods, which detected just 41%, would only raise concern once the concentration of this protein had passed a fixed threshold. The problem with this was that certain women with high levels didn’t actually have cancer, while others with levels below the threshold did.

Professor Jacobs says, “What’s normal for one woman may not be so for another. It is the change in levels of this protein that’s important.”

The trial involved over two-hundred thousand post-menopausal women aged 50 or over and was the largest of its kind to date in the world.

“My hope is that when the results of UK Collaborative Trial of Ovarian Cancer Screening are available, this approach will prove capable of detecting ovarian cancer early enough to save lives.”

Prof. Jacobs’ team are awaiting further test results later this year before the method has proved capable of detecting ovarian cancer early enough to save lives. If these results are positive, Prof. Jacobs says the method will likely be adopted in an annual screening program.

This article was originally published on UNSW Newsroom, to read the full article click here.

Running season is upon us!

city2surf, running, marathons, teams, charity, cancer research, running for the cure, cancer fundraising, It’s time to tie up those laces and get into a rhythm. There are four great running events coming up in locations across Australia.

If you’re a seasoned runner we hope that you’ll consider running for the ACRF in your next event because it’s runners like you that help fund critical cancer research. And if you’re brand new we want to encourage you to become not just any athlete, but the one that will end cancer.

When you join the ACRF running team you join an amazing group of individuals, some that have run over 10 marathons in a year! The ACRF will also be there to encourage you along the way, providing you with a wealth of resources to help you reach your goals.

If you have any questions or would like more information please contact run@acrf.com.au or click here.

Best of luck!

Mother’s Day gift ideas: 3 simple ways to show your mum how special she is

mothers day, charity, donation, cancer research, donations in lieu of gifts, cancer fundraising

Behind every wonderful human being is an even more amazing mother. May 10th is a special day for recognising them and it’s just around the corner!

It can be tough to find a way to thank our mums for standing tall and showing us that it is possible to be strong and gentle at the same time. They inspire us, ground us and support us endlessly. So how can we show them they are appreciated in more ways than they will ever know?

At the ACRF, we believe that the best gift you can give to your mum for Mother’s Day is your time. So here are some simple yet unique ideas of things you can do:

  1. Volunteer with her doing something she loves. She’ll get an extra dose of appreciation from the people she is helping.
  2. Get her an Entertainment Book! It’s full of deals on things you could do together.
  3. Or make an in-celebration donation to cancer research, a gift that will help protect her health and yours through world class research in prevention, diagnosis and cure. The ACRF can provide you with a selection of cards and cancer research ribbons, as a way of honouring and acknowledging your generous contribution to cancer research.

Whatever you decide to do, make sure she feels the love – she showered you with it all your life after all!

Cancer Scientists make a protein discovery that could improve new and existing treatments

cancer research, cancer, discoveries, treatments, progress, types of cancer, fighting cancer, cancer scientists

Researchers at the ACRF funded MIMR-PHI Institute of Medical Research have discovered a specific protein that may hold the key to controlling cancer-causing inflammation.

“Inflammation is a normal reaction to injury or exposure to an infectious agent — a little bit is good, but a lot is very bad,” says Professor Williams the institute’s director and one of the paper’s lead authors.

Cancer scientists have learned that a particular protein, called PLZF, plays a critical role in balancing the body’s inflammation response, and that when it is absent, our bodies have an exaggerated reaction to infections.

According to Professor Williams, the drugs presently being used to control inflammation are often imprecise and either have significant side effects or work only in a select group of patients. So once this protein was identified, cancer scientists at MIMR-PHI investigated PLZF further, to map its pathway and learn exactly how it is able to limit inflammation.

“By understanding the details of the regulatory processes that limit inflammation, we can begin to design more targeted therapeutic approaches,” says Williams.

Now that the pathways have been mapped, researchers are taking the next step in identifying ways to use this protein to increase the precision of treatments and control inflammation.

“Because this research focuses on inflammation, our results will not only inform the application of immune therapy, a new treatment showing promise for cancer, but also provide targets for tackling other inflammatory conditions, such as diabetes and heart disease,” says Williams.

The next generation sequencing technology used in this research was funded by ACRF supporters.

A Soldier Saved

Simon Toovey_and sonV2

“I support the ACRF because my son is alive and well today thanks to the great strides being made in cancer research around diagnosis and treatment.

My 23 year old son was diagnosed with testicular cancer during his final year of training to become an Officer in the Australian Army. Within days of hearing the news he had to go in for surgery and had an orchiectomy. Unfortunately though, at that point, the cancer had already spread to his lymph nodes and he was told that he would have to undergo chemotherapy treatments.

He began his chemo immediately following his graduation from the Royal Military College in December 2013. But as bad luck would have it, he didn’t get an all clear, even after four rounds of chemo. So the next step was an extensive open abdominal surgical procedure, known as a retroperitoneal lymph node dissection (RPLND) which was followed by a lengthy recovery. Fortunately, he’s now in remission and has embarked on what will be a proud military career.

Becoming a Partner in the Cure was a small way for me to help others become cancer survivors like my son.”

Simon Toovey, Regular Giver of the Month.

Share your story

15-year old Charlotte walks 56km in support of cancer research

cancer fundraising

Kingston local Charlotte Northam is busy nursing her weary feet after an incredible 12 hour walk to raise funds for cancer research.

Starting out on April 12th at 7:00am, Charlotte walked all the way from Robe to Kingston, SA with groups of supporters who met her throughout her journey, keeping her spirits soaring.

“I’m really happy with the amount of support,” Charlotte said. “More people than I would have thought turned up and I really appreciate it.”

Incredibly, having arrived at the finish line two hours earlier than expected, Charlotte continued on. She wanted to keep to her promise of reaching the 12 hour mark, and so continued walking around Maria Creek. In total she covered over 56kms!

Charlotte’s mum Maria-Rose said she couldn’t be more proud of her daughter. “She has absolutely exceeded all expectations,” she said. “I am very proud of what she has done.”

The local Lions club hosted a celebratory barbeque at Lions Park where Kingston Mayor Reg Lyon congratulated her on her achievement and presented her with a cheque. “For somebody so young to take on something like this, it’s just wonderful and I’m very proud,” he said.

Charlotte managed to raise $4,876 leading up to the event, smashing through her target of $2,000 for the ACRF. It’s thanks to supporters like Charlotte that researchers are making new discoveries towards better treatment and prevention of for cancer. We can’t thank her enough for her hard work and dedication.

Read about how Charlotte made headlines in the local newspaper Coastal Leader here. (Photo courtesy of the Coastal Leader).

Share your story

New melanoma treatment triggers 20-fold improvement

Cancer treatment, skin cancer, melanoma, cancer research, cancer scientists, discoveries,

Studies conducted by cancer scientists at The University of Queensland Diamantina Institute (UQDI) have found a new experimental drug called Anisina significantly increases the effectiveness of existing therapies used to treat melanoma.

Around 12,500 Australians are diagnosed each year with malignant melanoma and it is responsible for over 1,500 deaths. It is a notoriously difficult cancer to treat, due to the number of mutations that make the cancerous cells difficult to target.

Errors in the ‘BRAF’ gene have been identified as among the most prominent mutations, and two drugs that target ‘BRAF’ (vemurafenib and dabrafenib) have been developed and approved for use in recent years.

However no targeted therapy exists for the 50% of melanoma patients whose tumors do not have this most prominent mutation. As a result, developing a new drug that is effective across all mutations has become a focus in current cancer research.

Cancer scientists have found that when Anisina is partnered with existing drugs it helps destroy two key parts of the cancer cell’s skeleton, resulting in a 20-fold increase in the anti-cancer effect of the other drugs. This benefits all melanoma patients fighting cancer as the new drug targets melanoma cells regardless of their mutational status.

Nikolas Haass MD PhD conducted the research studies along with Brian Gabrielli PhD.

Dr. Haass said, “These findings from the preliminary screen with Anisina are exciting. Finding a compound that is equally effective against a wide panel of melanoma cell types irrespective of the genetic background has been a long-held goal.”

Justine Stehn PhD, Novogen Anti-Tropomyosin Program Director, said, ” The idea that we now have a means of making melanoma cells respond to potent anticancer drugs is an exciting development for patients with melanoma.”

Plans are now underway to bring Anisine into the clinic by early 2016.

The ACRF is proud to have provided $6.2 million to support the work of UQDI’s world-class researchers in recent years.

This information was originally published by Novogen website and can be found here.

Chris runs a marathon of marathons to support those fighting cancer

Marathons, running, cancer, cancer research, acrf, donations, charity

Cancer is one of the leading causes of death in Australia with an estimated 43,700 people succumbing to it each year.*

So what can one person do help so many who are fighting cancer?

Adelaide local, Chris Glacken answers with “anything and everything you can,” and has challenged himself to run 24 marathons in 24 months to help raise funds for cancer research.

Several of Chris’ close friends and family members, including his father, have been recently diagnosed with cancer. This motivated him to find a way to join in their battle against this terrible disease.

His mission now, for his 24 marathon conquest, is to have the “courage to start, strength to endure, and resolve to finish”.

“This may be a tough and expensive gig but the satisfaction gained from having a go at raising much needed funds for the ACRF makes it all worthwhile,” says Chris.

This adventure is just one of many fundraising efforts that he and his wife Grace have organised over the years, raising around $4,200. His target for marathon donations this year is $15,000. And if he reaches his target, Chris, his wife, and their incredible supporters will have contributed a whopping $20,000.00 in just a few years: fighting cancer through research.

Chris began his marathon of marathons last year at the Cadbury Hobart Marathon in January and will continue to participate in races across the country with his final race ending in Portland, Victoria in November 2015.

His every step is helping cancer scientists get closer to preventing, diagnosing and finding a cure for cancer, so we encourage anyone and everyone to cheer him on!

To follow him on his journey or to donate click here.

* https://acrf.com.au/on-cancer/cancer-statistics-australia/ (2015)

 

Share your story

Happy Easter from the ACRF!

charity gifts

It can be hard to believe there’s a great substitute for chocolate at Easter – but it’s true! It’s not too late to change things up this year and choose to give small donations in lieu of gifts. This kind of Easter gift truly is one that will make an amazing difference to the fight against cancer.

We’re not the only ones who will appreciate it, just take a look at the list of people who will thank you:

  • Your personal trainer
  • Your dentist (unless he likes to watch you squirm)
  • Cancer research teams across Australia (this is the best part)
  • Cancer patients of future generations
  • And of course, our team here at ACRF!

If you’re still not sure, just ask the lovely ladies of the Bexley North Cancerians who hosted their own Easter Parade last week. They’ve been helping raise funds for cancer research for the past 20 years and have raised an incredible $95,000 through small events. Proof that even the smallest of gestures add up in the end!

Our office will be closed on April 3rd for the long weekend, and we will be back in the office on April 7th. But fear not, if you are a last minute shopper you can make small charity gifts online during this time and a receipt will be sent to your email address automatically.

Thank you again for your ongoing support. Happy Easter, and special wishes to our Greek (Kaló Páscha) and Italian (Buona Pasqua) supporters!

Happy Easter from the ACRF!

charity giftsIt can be hard to believe there’s a great substitute for chocolate at Easter – but it’s true! It’s not too late to change things up this year and choose to give small donations in lieu of gifts. This kind of Easter gift truly is one that will make an amazing difference to the fight against cancer.

We’re not the only ones who will appreciate it, just take a look at the list of people who will thank you:

  • Your personal trainer
  • Your dentist (unless he likes to watch you squirm)
  • Cancer research teams across Australia (this is the best part)
  • Cancer patients of future generations
  • And of course, our team here at ACRF!

If you’re still not sure, just ask the lovely ladies of the Bexley North Cancerians who hosted their own Easter Parade last week. They’ve been helping raise funds for cancer research for the past 20 years and have raised an incredible $95,000 through small events. Proof that even the smallest of gestures add up in the end!

Our office will be closed on April 3rd for the long weekend, and we will be back in the office on April 7th. But fear not, if you are a last minute shopper you can make small charity gifts online during this time and a receipt will be sent to your email address automatically.

Thank you again for your ongoing support. Happy Easter, and special wishes to our Greek (Kaló Páscha) and Italian (Buona Pasqua) supporters!

Charity volunteer group celebrate Easter in style

Bexley_Nth_Cancerian_Lunch 133

Our Bexley North Cancerians Committee hosted another event last week – this time getting crafty for an Easter Hat Parade.

This amazing charity volunteer group has been hosting small events and afternoon teas for cancer research for the last 20 years, using special occasions such as Easter as a chance to get back in touch with each other, have a catch-up and a laugh.

After all, fundraising should be fun!

Our staff member Michael was delighted to attend, and to judge the hat parade. The cancer fundraising event also included an Easter themed word-search and a raffle, in total raising $1,600.

Since they started supporting the ACRF many years ago, the Bexley North charity volunteer group have presented to the ACRF an incredible $95,000 in funds raised for cancer research. They truly are the perfect example of how “every little bit counts” and we are so grateful for their support.

We’d like to thank all of the Bexley ladies, and send a special thank you to leaders of the Committee, Betty Holman and Carole Pont. We know we couldn’t continue to fund world-class cancer research without the support of these very special charity volunteer and fundraising groups.

Share your story

Alison’s Story

Regular charity donations

“I support the ACRF in honour of my Mum, Jean, who died from a brain tumour (Glioblastoma) in June 2011. I miss Mum every day.

I miss her even more after giving birth to twin daughters a couple of years ago. My mum was a wonderful grandmother – she would have been so excited at the thought of having twin grandchildren!

While I know it is a cliche, Mum was the glue that held my family together. Her loss was devastating.

She fought through two other cancers – breast cancer and melanoma – before passing from Glioblastoma. While Mum’s medical teams were skilled and dedicated, her treatment options for brain cancer were limited, and the very poor prognosis for this disease had not changed for a long time.

I work in health care, and know that more research is desperately needed and it is vitally important for medical researchers to be able to plan their work, with the security of regular financial input from donors. Every amount, no matter how modest, adds up to providing that security to researchers.

When I investigated various options for donating, the ACRF stood out – they seemed so dedicated to putting each dollar to the best possible use, and clearly had a great deal of respect for donations. After being a monthly giver for a short time, I decided to include the ACRF in my will.

The image I have included was taken on my wedding day in May 2010, 5 months before Mum became unwell.”

Share your story

One nutter takes on the Americas

cancer survivorFor many cancer survivors, fundraising to give back to cancer research is often about making the most of a challenge or adventure.

Testicular cancer survivor, David Melville, is using this very approach. Having shown cancer who’s boss, David is now grabbing life with a solo motorcycling adventure from Canada all the way to the southern-most tip of South America.

He set off on August 19,2014 from Vancouver, Canada, heading south to Tierra Del Fuego Argentina and planned to stop in to plenty of cities, fundraising as he went.

Starting a cheeky blog called One Nutter, David has documented his journey so far; telling tales of his epic adventure and how it all began.

David said, “Since [going into remission] I’ve done some basic social work talking to other guys who’d just been diagnosed, but I’ve always wanted to do a bit more to give back.”

David was only 22 years old when he was diagnosed with testicular cancer and after several operations and treatments was, thankfully, given the all clear.

David hopes that this ride will help raise some funds to help give back to all those people who helped him through his cancer journey – family, the medical professionals and the researchers behind the scenes.

David has already most generously raised over $1,700 for cancer research and, having just reached Costa Rica, is having the time of his life seeing some amazing sites and raising awareness along the way.

We’d like to thank David for taking on this epic challenge in support of cancer research in Australia and wish him the very best of luck for the remainder of his journey.

If you would like to keep up with David’s trip Down to Argentina, visit his blog or support him by donating here.

Share your story

ACRF announces special $10 million Anniversary Grant.

Westmead-LEUKAEMIA-LAB-300x154This year, Australia’s best cancers researchers will make exciting leaps forward in their work and we are excited to be contributing to this progress.

The first of our grant rounds for 2015 is now open, calling for applications for a special Anniversary Grant of $10 million.

This major grant is being offered to foster cutting-edge ideas in Australia’s cancer research circles. It commemorates the ACRF’s 30 year anniversary in keeping with the mission of the Foundation:  to promote bold and significant advances in the prevention, early detection, treatment and/or management of cancer.

It has been created to stimulate collaborative cancer research – bringing together expertise from around Australia and the world towards a shared and powerful research goal.

Detailed, written applications for the 2015 Anniversary Grant will be accepted up to COB on Friday 1 May, 2015.

A special expert panel, nominated by the ACRF’s Medical Research Advisory Committee (MRAC) will review the applications for scientific merit and select a shortlist to proceed to interview and, if deemed appropriate, a site visit.

We look forward to receiving outstanding applications from Australia’s best research teams, and will be sure to keep you informed on where your wonderful support will be making a difference this year.

For more information about our grants please click here.

Researchers develop antibody to target cancerous ovarian cells.

59910457_m1320934-pancreatic_cancer_-300x168Researchers from the Mater Research Institute-University of Queensland (MRI-UQ) have developed an antibody drug, in pre-clinical trials, which attacks cancerous ovarian cells.

The drug has been found to successfully target a specific protein which is present only on the surface of cancerous ovarian cells, not on normal ovarian cells.

Associate Professor John Hooper said, “One of the really interesting things is that while normal ovaries don’t produce this protein, the tumours of about 90 per cent of patients do.”

By targeting this protein, the drug will also help limit the serious side-effects of traditional treatments.

“We can attack the cancerous cells while having little impact on the normal ovarian cells, and that reduces the side-effects, which is obviously of great interest to patients” Associate Professor Hooper said.

“Another thing we found with this protein is that it sits on the surface of the cancerous cells so it’s much easier for the drug to target it.”

While the study is still in its early stages, the research team are taking leaps and bounds towards a better understanding of how to attack ovarian cancer, which is currently the second most commonly diagnosed gynaecological cancer in Australia.

In the project’s next phase, researchers will study how the antibody responds to patient samples to further determine its effectiveness.

More information about this discovery can be found here.

Discovery of four pancreatic cancer sub-types raises hope for future treatments.

Cancer ResearchACRF funding has enabled a new discovery which will improve pancreatic cancer treatments of the near future.

Sydney’s Garvan Institute of Medical Research, the University of Queensland’s Institute for Molecular Bioscience (IMB), and QIMR Berghofer Institute of Medical Research collaborated with researchers from the Wolfson Wohl Cancer Research Centre in Scotland, to analyse the complete genetic code of pancreatic tumours in 100 patients.

The team identified and mapped out the extensive and damaging genetic changes – finding four key subgroups which differentiate pancreatic tumours by their gene arrangements: ‘stable’, ‘locally rearranged’, ‘scattered’ and ‘unstable’.

Professor Sean Grimmond from IMB said, “Having access to these detailed genetic maps could help doctors in the future determine which chemotherapy drug a patient should get, based on their cancer’s genome.”

This discovery already promises to improve the treatment of at least one of these groups after the researchers noticed an existing class of chemotherapy drugs, used to treat some breast cancers, may also work on patients whose pancreatic tumours have the “unstable” genomes.

The team of researchers realised the significance of their discovery when they found four out of five study patients with this genetic signature responded to the DNA-damaging drugs.

“Two of them had an exceptional response, which happens very, very rarely in pancreatic cancer. Their tumours went away completely,” said the co-leader of the group, Andrew Biankin, who conducted the work at the Garvan Institute of Medical Research.

Dr Nicola Waddell from QIMR Berghofer (previously from IMB) said pancreatic cancer remained one of the most complex cancers to treat, with a survival rate that has not improved considerably in the last 50 years.

“Our study identified four major genomic subtypes in pancreatic cancer, revealed two new driver genes not previously associated with pancreatic cancer, and reaffirmed the importance of five key genes,” said Dr, Waddell.

The team at IMB plan to begin a clinical trial in the UK, selecting patients for targeted treatments based on their genomic testing.

The ACRF is proud to have supported each the Australian research centres involved in this study with funding over many years. 

Brave head shaves raise funds and honour loved ones.

charity challengeOver the past few months we’ve had some very brave supporters choose to lose their long locks in support and honour of loved ones.

Last year, Cristelle should have been happily celebrating her 26th birthday. Instead her family were rocked by the news that Cristelle’s mother had been diagnosed with breast and lung cancer.

Motivated by her mother’s strength and determination during her surgery and treatments, Cristelle grew her beautiful long hair even longer in order to cut it for charity in December.

Cristelle said, “I have been inspired to grow my hair to make a wig for someone who has lost their hair, just like my Mum did. She is such a strong woman, a fighter.”

On top of cutting and donating her hair, Cristelle also chose to fundraise for cancer research smashing her $2,500 target and raising a most generous $6,914!

Another recent head shave took place just after one of WA’s most famous swim events: the Rottnest Channel Swim.

Cabe Paparone and his three mates took on the challenging swim and, although they were met with some pretty rough conditions, managed to finish in seven hours and 41 minutes. What a fantastic effort!

Cabe’s (very excited) friends and family then took to the clippers to shave off that mane he had been growing for 3 years, in honour and memory of his father who sadly passed away in September.

Through a giant fundraising effort, which saw him organise fundraising events in the lead up to his swim, Cabe raised over $7,500 for cancer research! What a legend!

We’d like to thank Cristelle and Cabe for such an amazing effort. We are inspired and humbled by their dedication and generosity

If you are interested in fundraising for cancer research through shaving, cutting or colouring your hair please click here for more information.

Share your story

Boot scootin’ for Misty Molly Muffin raises funds to help end cancer.

47a4cc01b3127cce98548b87da4d00000015100RcNGzRq4aYSome boot scootin’ fun has led to a most generous fundraising event, in memory of a beloved pet.

Misty Molly Muffin, the Silkyhuahua, sadly passed away in 2014 and in her memory the owners of line-dancing studio, Bossy Boots Dancin’ Fun, raised a most generous $6,000 for cancer research in Australia.

Throughout 2014, David and Janene Lawson organised a series of fun line-dancing socials, with a portion of the door entry, and profits from the raffles helping to speed up cancer research discoveries.

But David and Janene didn’t stop there, they also organised fundraising at their annual Cruisin’ Country event, as well as at the Sydney Country Music Festival, and they also collected some extremely generous donations from their students.

Over the years, Bossy Boots Dancin’ Fun have danced up a storm in fundraising events, contributing a total of $9,320 to cancer research since 2010. We couldn’t be more grateful for their ongoing support.

We would like to extend our deepest sympathies for the loss of Misty Molly Muffin and also say thank you so very much to David, Janene, their most generous students and all those who attended their socials.

We’re very humbled by their generosity and thank them very much for their support.

To see photos from the Cruisin’ Country event please visit the Bossy Boots Dancin’ Fun website here.

Share your story

International study improves test for people at risk of bowel or endometrial cancers.

cancer researchA more accurate way to identify those at a high risk of bowel or endometrial cancer has been discovered by cancer scientists in Queensland.

Researchers at the QIMR Berghofer Medical Research Institute led a global effort to refine genetic information in an international database, meaning GPs will have the ability to access the publicly-available data and give patients a truer picture of their familial risk.

This global project arose from the issues many GPs and patients seemed to be having from inconclusive results when tested for Lynch Syndrome – an inherited condition that increases the risk of bowel and endometrial cancer.

Associate Professor Amanda Spurdle, who led the project, said, “The model – using the expertise of researchers and clinicians across the world with a particular knowledge of a rare disease – essentially turns indecipherable sequencing data into real knowledge that can have a clinical benefit.”

“As a result of this work, doctors can more conclusively say whether those patients have Lynch Syndrome, and therefore whether they are at a higher risk of getting another cancer.

“The reverse of that is that we may also ease the worry of some people who’ve had inconclusive results.”

The research team involved Professor Maurizio Genuardi from the University of Florence and Professor Finlay Macrae from the Royal Melbourne Hospital. The International Society for Gastrointestinal Tumours (InSiGHT) committee pooled data from across the world on thousands of different gene changes.

“Through this collaborative effort, we can be confident of our counselling advice to families, offer them testing for the gene fault, and, if they carry it, help them closely monitor their health and take preventative measures,” Associate Professor Spurdle said.

The findings of this project can be found in esteemed research journal Nature Genetics.

The ACRF is proud to have supported QIMR Berghofer Medial Research Institute, having provided more than $6 Million in research grant funding since 2002.

Possible cause of world’s most common childhood cancer, discovered

Cancer scientistsResearchers from the Peter MacCallum Cancer Centre have discovered a possible cause of medulloblastoma, one of the world’s most common childhood cancers.

Cancer scientists have found mature cells in the brain can revert to basic stem cells and initiate cancer – a process previously thought not to be possible.

Trials undertaken in the fruit fly, which shares around 70 per cent common cancer genes with humans, found mature cells, in the absence of a key gene, revert into rapidly dividing stem cells that can cause brain tumours.

Dr Louise Cheng, Head of the Stem Cell Growth Regulation Laboratory at Peter Mac and lead author on the study, said, ‘It was thought that, once matured, brain cells or neurons could not go backwards and become stem cells again — but we found this process is in fact reversible.

“In our fruit fly model, we found that once a gene called Nerfin-1, which keeps neurons locked in a mature, non-dividing state, is lost, the neurons revert to an out-of-control stem cell state, rapidly initiating cancer and quickly becoming brain tumours.”

These findings are significant as medulloblastoma patients often have a faulty version of the human equivalent of this Nerfin-1 gene, called INSM1.

“INSM1 is frequently mutated in people with medulloblastoma and we believe preserving the protective role of INSM1 could prevent the reversion of mature neurons into stem cells, and stop cancer initiation in the brain,” said Dr Cheng.

“This is particularly important in the current treatment context where chemotherapy is used to target rapidly dividing cells, but does not kill non-dividing, mature cells, which we now know can be a cause of medulloblastoma, potentially explaining why chemotherapy is not always successful in treating brain cancers in the long term.”

This discovery that non-dividing cells may also cause cancer now opens the door for cancer scientists to develop of new targeted therapies and drugs with the potential to block this reversion of non-dividing cells and eliminate cancer-causing stem cell populations altogether.

This information was originally published on the Peter MacCallum website and can be found here.

ACRF leads the way in digital innovation

World Cancer DayWednesday 4th February marks World Cancer Day and, in the next step towards putting an end to cancer, one of Australia’s leading cancer charities, the Australian Cancer Research Foundation (ACRF), will launch the world’s first charity-driven Top-Level Domain (TLD) .CancerResearch.

.CancerResearch is an internet domain enabling a new digital collective. It will be developed by the ACRF in collaboration with Australian cancer scientists and research centres, providing authoritative information, awareness movements, research news and important messages of hope for both Australian and global communities.

As the suite of .CancerResearch sites expands, international researchers, cancer sufferers, advocates and fundraisers will all have a powerful, unified voice on cancer research.

This effort towards ‘one’ voice will be highlighted in the Foundation’s introductory .CancerResearch awareness campaign, which can be seen at www.TheOne.CancerResearch.

TheOne.CancerResearch uses the latest in digital and social technology to provide an interactive experience for all supporters of cancer research, compiling their many thousands of faces into ‘The One’ entity that will enable new treatments and cures for cancer.

CEO of ACRF Professor Ian Brown said: “We have kick-started our launch with an incredible, community-based initiative – TheOne.CancerResearch. It has been developed through the support of M&C Saatchi and involves a powerful digital experience with the aim of mobilising our supporters in the fight against cancer.

“.CancerResearch is an internet domain with a collaborative vision. We have a long road ahead, but bringing the greatest minds and movements for cancer research together begins now.”

With the ACRF recently celebrating its 30th Anniversary, the launch of a new top-level domain marks a significant milestone for the Foundation. Since its inception, the ACRF has provided more than $100 million for cancer research, supporting major breakthroughs such as the early development of the cervical cancer vaccine.

For more information, please visit: www.theone.cancerresearch

Who is The One?

TheOne, ACRF, Fighting CancerNext week on February 4, people around the world will be getting involved in World Cancer Day, joining forces to show that cancer, its treatments and its cures are not beyond us.

A cancer free future is within our reach and we as a global community have the power to achieve this.

Fittingly, World Cancer Day’s 2015 tagline also ties in with some extremely exciting events happening at the ACRF. Next week is set to be a very momentous one.

Over many months, an incredible team of people – digital agencies, media outlets, Australian cancer researchers, and more – have been busily supporting the ACRF to produce a truly inspiring and original campaign.

It’s a campaign we hope will create a new movement towards increased support for cancer research.

While we can’t say too much to spoil the surprise, our campaign uses the latest in digital and social technology to give you – our supporters – a unique interactive experience.

We want to show you just how important you are in this fight against cancer.

The new campaign will feature alongside a series of websites that the ACRF has been developing in collaboration with Australian scientists, research centres, other not-for-profits, and like-minded organisations.

This community-based initiative is the next step towards putting an end to cancer. Its focus is to generate more awareness and funding for cancer research and we are so excited to get our supporters involved.

We look forward to staying in touch with you on new developments and for those on social, be sure to follow #WhoIsTheOne . Thank you for your ongoing and loyal support for cancer research.


Campaign supporters (what an amazing list of super generous organisations!):

ARI Registry Services
Australian Radio Network
Bang PR
Children’s Medical Research Institute
Commercial Radio Australia
Fairfax Media
Fairfax Radio
Foxtel
Hoyts Cinema
JC Decaux
King & Wood Mallesons
M&C Saatchi
Nine Network
Ooh! Media
Seven Network
Special Broadcasting Service (SBS)
Sticky Digital

Andrew bikes it around Tassie for cancer research

“Apparently riding a tour bike is harder than you think!”

ACRF supporter Andrew has pledged to ride a whopping 1100km around Tasmania and it seems the distance isn’t the only challenge he has vowed to tackle!

When discussing his bike challenge and how he’s planning to keep his supporters up to date with his hard work, Andrew jokes “You’ll be able to see my route and training, and of course any comical crashes that I might get into on the way.”

image-a66767bdaa6b89122a48b65797cce69bWhile we cross our fingers that Andrew, in fact, doesn’t have any crashes and completes his challenge injury free, we’re also extremely humbled by this selfless and extremely generous fundraising challenge and the story behind it.

In 2011 Andrew’s father was diagnosed with cancer, sadly passing away in June 2013. Andrew decided he wanted to do something to help prevent others going through what his dad, and his family, went through.

Andrew’s epic challenge starts in Launceston and makes its way to the west coast past Cradle Mountain, back to Hobart then up the scenic east coast, through Swansea and St Helens and back around to Launceston.

The trip will take just over 3 weeks and Andrew is aiming to raise $3,000 for cancer research in honour of his father. Andrew will be setting of on February 25 and he’s already surpassed the $1,000 mark.

We’d like to thank Andrew for taking on this massive physical challenge to help us end cancer – we couldn’t be more humbled by his dedication and training efforts.

If you’d like to find out more or help Andrew reach his target, you can visit his Everyday Hero page here.

Share your story

Promising step forward for triple negative breast cancer treatment

Triple Negative Breast CancerCancer researchers in the UK have linked an overactive gene to a particularly aggressive type of breast cancer called “triple negative” breast cancer.

The team, from the Wellcome Trust Sanger Institute and the University of Cambridge, identified the gene called BCL11A as especially active in triple negative breast cancer, raising hope for those affected by this cancer type.

Prognosis for triple negative cancers is generally poorer than for other forms as there is limited knowledge of the distinct genetic properties of the disease, making the development of new treatments difficult.

Generally, therapies used in treating other breast cancer types, like tamoxifen, do not work on this type of cancer because triple negative tumour cells lack three of the different ‘receptor’ molecules that are targeted by the treatments.

Most triple-negative breast cancer tumours are of a genetic type called ‘basal-like’. BCL11A was found to be overactive in tumour samples from around eight in 10 patients with the ‘basal-like’ disease.

Dr Pentao Liu, senior author on the study, said BCL11A activity stood out as being particularly active in samples from triple negative cancers.

Dr Walid Khaled, co-author on the study said, “Our studies in human cells clearly marked BCL11A as a novel driver for triple-negative breast cancers.”

This discovery builds on researchers’ work to develop a broader understanding of breast cancer which will inform clinical decisions, treatment choices and finding new therapies.

For more information, please click here.

Six more ovarian cancer risk genes found

Close-up of microscopeQIMR Berghofer and the University of Cambridge have led an international study, finding six new gene regions which increase a woman’s risk of ovarian cancer. The number of ovarian cancer risk susceptibility regions identified has therefore increased, from 12 to 18.

Although these risk gene variants, or “typos”, are much more subtle than the BRCA1 and BRCA2 mutations, incorporating them into tests which predict a woman’s ovarian cancer risk would be more precise.

Head of QIMR Berghofer’s Cancer Program, Professor Georgia Chenevix-Trench said “Individually, each of these ‘typos’ increases the risk of cancer by a very small amount.”

“However, if a woman carries a large number of these ‘typos’ her risk of developing ovarian cancer may be as high as that conferred by mutations in BRCA1 or 2.”

QIMR Berghofer scientists are now part of an even bigger study which is likely to double the number of gene regions known to increase ovarian cancer risk.

“Once we identify each of these genetic ‘typos’, the next challenge is to find out the way they work – both individually and together,” Professor Chenevix-Trench said.

“Understanding how each of these variants works will eventually lead to an understanding how ovarian cancer develops, and how to develop better reduction medications and treatments.”

The ACRF is proud to have provided over $6 million in grants funding to QIMR Berghofer since 2002, for technologies and infrastructure with the power to speed up lifesaving discoveries across many cancer types.

New Year. New Goals. Welcome to 2015.

Calendar with booksWe’re so excited to be starting off 2015 with some great opportunities for supporters to get involved in and help reach those New Year’s resolutions!

If you’re interested in bringing some positive karma to your 2015, read up on some of our great fundraising opportunities below:

Lose it

In 2014 we saw many brave, wonderful supporters shave or cut off their lovely long hair to help raise funds for cancer research. Many of our head-shave heroes did so in support of loved ones battling cancer, or in memory of those they have sadly lost.

They raised an incredible amount for cancer research in Australia and many, in addition to this most generous act of bravery, donated their lovely hair to the Beautiful Lengths program, which makes wigs for patients currently being treated for cancer.

So, if you feel like you’re due for a change in the hair department, why not make a fundraising goal out of it? You can read more about our head-shave program here.

Move it

Many people add at least one health and fitness goal to their New Year’s resolutions. Fitness fundraising doesn’t have to be about running a marathon – there are so many other ways you can be active while raising funds for cancer research!

This year we have a fantastic, and very exclusive, opportunity for 10 fundraisers to travel to France and take on one of the stages of the world famous Tour de France! The ACRF is the only Australian charity providing spots in L’Etape du Tour.

If cycling isn’t one of your strengths, that’s ok – we have so many fitness and endurance events coming up! Take a look at our events calendar to see what’s on.

Plan it

If you’re not much of a fitness event lover, but feel like you still want to do something, put your events planning skills to the test and organise a fundraising event for cancer research!

From local events such as a true-blue Aussie sausage sizzle, to big fancy gala balls, the sky is the limit when it comes to what you want to do to help put an end to cancer for future generations.

Our wonderful fundraising team is always available to talk through any ideas you may have and help you organise or sort through the nitty-gritty details. 

Work it

Many of us working full-time can find it hard to create time outside of work to help our favourite causes. But did you know that by simply opting to donate on a regular basis you’ll be providing our amazing cancer researchers with a stable future to continue their life-saving work?

If one of your New Year’s resolutions is to give back to the community in 2015 why not sign up to be a Workplace Giver?

And if work isn’t on the cards, but you still like the sound of regular gifts to cancer research, you can sign up as an ACRF Partner in the Cure. Our regular giving program is a great way to ensure you’re doing your part to help end cancer.

Whatever your goals for 2015 may be, we wish you a happy, peaceful and prosperous year and thank you very much for your dedication to helping us reach our goal – to end cancer for good.

New treatment options possible with bowel cancer discovery

090126_082-300x225Melbourne cancer scientists believe they have found a cause for the onset and acceleration of bowel cancer.

Being the third most common cancer in Australia, this exciting discovery opens up the possibility for new ways to treat bowel cancer, bringing hope to patients suffering from the disease.

Researchers from the prestigious Peter MacCallum Cancer Centre found a two-part failure in bowel cancer cells. Essentially, the mechanisms which stop a cell from multiplying uncontrollably, stop working in bowel cancer cells.

This failure causes the acceleration of the disease and, additionally, the development of resistance to cancer treatments. This two-part failure is known as “chromosomal instability” and is caused by a signalling network in the cell called the Wnt Pathway.

“Previously, in most bowel cancers, we thought this instability built up randomly over time as cancer cells evolved, while a signalling network, called the Wnt pathway, held cells back from chromosome chaos,” Professor Rob Ramsay said.

“Now we have proven this instability begins immediately with the breakdown of the Wnt pathway, which occurs in two steps and sets off an unstoppable acceleration of disease.

“Just as the loss of firstly the handbrake, followed by the secondary loss of a foot brake, both combine to allow a car to career down a hill.”

Chromosomal instability was found in 85 per cent of tumours in people with bowel cancer.

Professor Ramsay says the “double breakdown” in the Wnt pathway sparked complex evolution in the genetic make-up of bowel cancers.

“The dramatic genomic changes cells go through gives the cancer a breadth of opportunities to rapidly evolve, to deceive and outflank the cancer treatments.”

Professor Ramsay said the findings open up potential new treatment possibilities.

“This fundamental new information reaffirms why the Wnt pathway should be a high priority target of new treatment development, and the genetic clues uncovered by our research will help guide the selection of patients for different therapies, some of which are currently available,” he said.

Cabe to lose his locks after Rottnest fundraising swim.

Cabe imageThe Rottnest Channel Swim in WA is set to end its 25th event with a very close shave.

Cabe Paparone, at just 23 years old, has decided the February 2015 swim will be the day he loses his lovely locks that he has been growing for the last three years.

Cabe had originally decided to compete in the 2012 swim. However, when Cabe’s dad Claude was diagnosed with a rare form of lung cancer, he withdrew to help his dad instead.

Very sadly, Claude passed away aged 52 in September this year.

“On what will almost be three years to the day that dad was diagnosed, I will be swimming the 2015 Rottnest Swim in a team with three other mates and shaving my hair once we have completed the crossing,” said Cabe.

Once Cabe and his team of three other mates complete the 19.7km swim, he will have his head shaved on the beach.

“As soon as he got sick I decided to grow it,” Cabe said. “I was only going to grow it for a year, but thought no one would donate any money so I’d better keep on growing it.”

Cabe already has several eager volunteers putting their hands up to take part in the chop. Behind the clippers will be Cabe’s sister Romy, and brothers Marco and Jack.

Cabe told us his reason for supporting cancer research is because “we would like to contribute to research that assists people living with cancer to achieve the best care and treatment available.”

We’d like to extend our deepest sympathies to Cabe and his family for their loss, but also say a very big thank you taking on two amazing challenges in the New Year.

Thank you Cabe.

For more information you can see Cabe’s fundraising page here.

Wishing you a Merry Christmas

From all of us here at the ACRF, we wish you and your loved ones a very happy and safe holiday this Christmas. Whatever you may be doing we hope you are surrounded by lots of laughter and smiles.

Because of you, our amazing supporters, we surpassed $100 million in grants funding this year –   what a great way to end 2014! We’re looking forward to an even better 2015, helping cancer researchers in their mission to end cancer.

Please note we will be taking a short break over the Christmas holiday, with our office closing at COB Tuesday 23 December, 2014 and reopening on Monday 5 January, 2015.

If you would like to get a kick-start on those good 2015 vibes, please feel free to donate via our secure web portal where our online donation elves will be working hard to process your Christmas donations and issue your receipts ASAP.

As a final thank you for all your support this year we’ve put together this short video below. We look forward to staying in touch throughout 2015.

[/vc_column_text][/vc_column][/vc_row][/vc_column_text][/vc_column][/vc_row]

All I want for Christmas is…

ACR1320_mobilebanner_1200x627_01_AHave you seen our shiny, new Christmas campaign?

We are very excited here at the ACRF, having launched a series of Christmas videos that ask our supporters to change-up their wish-lists this year. Instead of that voucher, video game or fashion accessory, we hope you will ask for something we all need – a world without cancer.

We at the Australian Cancer Research Foundation are dedicated to ending cancer through the funding of cutting-edge and collaborative research projects. Our goal is to speed up discoveries in cancer prevention, diagnosis and cure.

About the Christmas Campaign:

Our Christmas ad campaign has been made possible thanks to the creative expertise at renowned advertising agency, M&C Saatchi. They have generously provided us with three 15 second commercials, which feature a mother, a son and a grandmother asking for a particular piece of technological research equipment for Christmas.

These gift requests are actual research tools and facilities that the ACRF is providing to Australian scientists.

Our ads are light-hearted and festive, but most importantly, they ensure our message is clear: only the funding of research will end cancer.

About the technologies:

The items our family members have requested in the commercial are not your everyday research items – like test-tubes or microscopes.

– The Electron Paramagnetic Resonance Spectrometer Machine
– Advanced Molecular Imaging Facility
– Flow Cytometer Analyser

They are cutting-edge machines and facilities, accessing the most detailed, complex information about the causes of cancer, potential diagnostic tests and treatments.

These technologies help researchers to speed up their work – ultimately saving lives by saving time. We hope you will join us to provide Australian cancer researchers with the very best in tools and technologies, so that we can end cancer sooner.

Our thanks…

We’d like to say thank you to the M&C Saatchi team for their amazing support with this campaign. They’ve been extremely dedicated to helping us get our message out about what we do in the best, most entertaining way possible!

If you would like to see our new TV ads you can view each one below and keep a look out for them on Foxtel and Facebook this Christmas![/vc_column_text][/vc_column][/vc_row][/vc_column_text][/vc_column][/vc_row][vc_separator color=”grey”][/vc_column][/vc_row][/vc_column_text][/vc_column][/vc_row][vc_separator color=”grey”][/vc_column][/vc_row][/vc_column_text][/vc_column][/vc_row]

Team CBA tackle 27kms to help end cancer.

image-c29750e56feccf46b8558398a3e9841427km of cliffs, oceans, waterfalls, steps, hills, rocky ascents, rivers, leeches, lots of mud, sweat was made all the more bearable for a team of CBA staff through the knowledge that together, they were doing something truly worthwhile.

Their hike for cancer research fell on one of the hottest days Sydney has had this Spring – exceeding 35 degrees! But the ‘CBA 27km Walk for ACRF’ kicked off bright and early at 6am, with the team determined to cover the coastline of the Royal National Park – from Otford to Bundeena – in just one day.

Finishing 8 hours later, at 2pm, the team were exhausted and relieved, but also very happy to have finished the trek raising much needed funds for cancer research.

The team were led by ACRF advocate, Mina Masoumian.  Incredibly, this will be her 5th year fundraising for cancer research in Australia. She has helped to raise over $40,000 by herself and we are so humbled to have someone like Mina, who continues to go above and beyond to support our work.

This year, Mina worked with her CBA team to smash their goal of $15,000, raising well over $17,000 to help end cancer! What an amazing achievement!

We are so grateful to the CBA team for their dedication and support in taking on such an epic challenge! Thank you; you’re all legends in our eyes.

World first brain cancer trial raises hopes for patients and families.

59910457_m1320934-pancreatic_cancer_-300x168A world-first trial will test an experimental brain cancer treatment which targets the surface of tumour cells expressing a cancer protein called EphA3.

The drug has already shown successful results in phase I clinical trials for leukaemia patients, and cancer scientists are now keen to test its effectiveness on solid tumours.

This world-first clinical trial on patients suffering from recurrent Glioblastoma (GBM) resulted from major discoveries by a team of scientists at the QIMR Berghofer Medical Research Institute, Ludwig Institute for Cancer Research (LICR) and Monash University.

Dr Bryan Day and Dr Brett Stringer, who led the research at QIMR Berghofer, said the study builds on work carried out by the collaborative research team for over more than a decade.

“The protein – EphA3 – was discovered by QIMR Berghofer scientist Professor Andrew Boyd in 1992,” said Dr Day.

Dr Stringer said the upcoming GBM trial would be the first test of the drug against solid tumours, as opposed to blood cancers.

“Unfortunately most new drugs tested for GBM have returned disappointing results and patients have very few treatment options,” he said.

“Once we begin recruiting, this study will have an immediate impact by giving patients access to an innovative treatment which has shown great potential in laboratory testing.”

GBM is the most common primary adult brain cancer and is almost always fatal, killing about 1,000 Australians every year.

Dr Day and Dr Stringer said this trial gives researchers an excellent start to developing a much-needed treatment for patients with aggressive GBM.

“The study will determine how patients tolerate the drug and how their tumours respond,” they said.

“There is also a very important imaging component with brain scans to be performed to detect the borders of the tumours and determine how much of the drug crosses from the blood into the brain to reach the tumour.”

#GivingTuesday – a day Tue give

GivingTuesdayAustralia-Heart

#GivingTuesday is a global charity challenge celebrating and providing opportunities for all of us to give. Charity giving can be equally as rewarding for the giver as it is for the recipient, so on #GivingTuesday we encourage you to jump on the band wagon. It’s like the world will be giving itself a big hug!

What can you do this #GivingTuesday?

Whether you give your Mum a call, give your pet a treat or give your boss a coffee, it doesn’t matter what you give it only matters that you give.

Give yourself a challenge

Why do so many people wait until January 1st to make resolutions? We want you to start early, on December 2nd, by registering for a 2015 charity challenge event. Not daring enough for you? Use #GivingTuesday as a chance to recruit a team to participate and raise money for cancer research with you. Search events here.

What can your workplace do?

Employees

Now is the time to let your employer know about the generous gifts you’ve made to charity this year and ask them to match your giving. With one email, you can double the impact you’ve had in 2014. If you haven’t given as much as you think you could, ask your employer about Workplace Giving. You can make a pre-tax monthly donation to charity through your payroll.

Employers

Share why your company supports Australian cancer research via the company LinkedIn page and intranet with a link to the ACRF donation page, ask your employees for matching submissions, organise a volunteering day or hold a #GivingTuesday party to thank everyone for their superb efforts this year. You could even challenge your employees to support charity by matching $2 for every $1 donated on #GivingTuesday.

[/vc_column_text][/vc_column][/vc_row][vc_video link=”https://www.youtube.com/watch?v=8zmt9AEFv1o”][/vc_column][/vc_row]

Existing drug for bone disease shows promising anti-cancer properties

imageAn existing drug, currently used to treat patients suffering from osteoporosis and some late-stage bone cancers, has now shown potential to treat other cancers outside of the skeletal system, such as breast cancer.

Several clinical trials, where women with early-stage breast cancer were given this drug, called ‘bisphosphonates’, alongside normal treatment for the disease, have resulted in a ‘survival advantage’ and, in some cases, stopped the cancer from spreading.

A new study by Professor Mike Rogers, Dr Tri Phan and Dr Simon Junankar from Sydney’s Garvan Institute of Medical Research found, using sophisticated imaging technologies, has revealed more information about how this advantage works.

They found the bisphosphonates attach to tiny calcifications within the tumours.

These calcium-drug combinations are then devoured by ‘macrophages’, immune cells that the cancer hijacks early in its development to conceal its existence.

“We do not yet fully understand how the macrophages revert from being ‘bad cops’ to being ‘good cops’, although it is clear that this immune cell interacts with tumours, and probably changes its function in the presence of bisphosphonates,” said Professor Rogers.

“Our next step will be to analyse the changes that take place in macrophages, so that we can understand their change in function, and effect on cancer cells.”

Professor Rogers explains cancer scientists already know that the drug is well-tolerated in people, providing a “survival advantage” for some patients with certain cancers when taken early in disease development.

“This now provides a rationale for using these drugs in a different, and potentially more effective, way in the clinic,” said Professor Rogers.[/vc_column_text][/vc_column][/vc_row]

ACRF surpasses $100 Million milestone with announcement of 2014 research grants!

cancer scientistWhat an amazing year!

Not only did we celebrate our 30th Anniversary this year, but we also reached the significant milestone of granting over $100 million to cancer research in Australia! This amazing achievement – made possible by all of our wonderful supporters – is a big step in our mission to fund cancer prevention, diagnosis and treatment to ultimately put an end to cancer.

Our $100 million milestone was officially reached yesterday, at the ACRF’s Annual Chairman’s Dinner, where we were thrilled to publicly announce four cancer research grant recipients for 2014. Collectively we awarded $9 million towards the newest innovations in Australian cancer research – bringing our total grants funding to $103.9 million!

We are extremely proud to announce the esteemed grant winners for 2014 are:

  • Children’s Cancer Institute, Sydney: $1.5 million granted to develop a national Precision Medicine Platform which aims to individualise the therapy for high-risk children that have relapsed from current treatments, and provide them with new treatment alternatives.
  • University of Queensland Centre for Advanced Imaging, Brisbane: $2.5 million in grants funding to purchase hybrid, digital imaging technology to enable best-quality treatment for humans and companion animals with cancer.
  • University of Sydney, Central Clinical School: $2.5 million granted to revolutionise radiotherapy. This project will increase cure-rates while decreasing the economic cost and the negative side effects of radiotherapy treatment.  It will make radiotherapy more affordable for the 135 countries around the world that don’t currently have access to appropriate radiotherapy treatment.
  • Walter and Eliza Hall Institute, Melbourne: Awarded $2.5 million to build a Breakthrough Technologies Laboratory to analyse genetic mutations that drive cancers at the individual cell-level.

A big thank you to all of our supporters and generous donors for helping us to reach this amazing achievement.[/vc_column_text][/vc_column][/vc_row]

Needle microscope pinpoints cancer cells, offering fresh hope to breast cancer patients

Researchers at the University of Western Australia have developed the world’s smallest hand-held microscope capable of detecting cancer cells often missed by surgeons during operations.

The microscope can be used to capture 3D images through a tiny lens, less than a third of a millimetre wide, which fits inside a needle.

Currently being tested on human tissue samples, Associate Professor Robert McLaughlin of UWA says it could help prevent the trauma of repeat surgery in breast cancer patients.

Continue reading “Needle microscope pinpoints cancer cells, offering fresh hope to breast cancer patients”

Blood test could predict risk of non-hereditary breast cancer

bloodtestA simple blood test could soon be made possible to predict those at risk of non-hereditary breast cancer.

Breast cancer can be caused by many factors, including gene mutations which are passed from parents onto their children. For example, the hereditary breast cancer gene, BRCA1, accounts for around 10% of breast cancer cases. The majority of cases however, are caused by factors not yet entirely understood.

But researchers are beginning to make headway. An epigenetic signature has been identified across all women who carry the mutated BRCA1 gene. Strikingly, researchers have found the same signature was discovered in the blood of women without the BRCA1 mutation but who went on to develop breast cancer, making it a potential early marker of women’s cancer in the general population.

Cancer scientists now understand that mutations within genes are not the only contributors to the development of disease. The arrangement and expression of our genes has a major impact, and this is overseen by the process of epigenetics.

One of the most studied epigenetic mechanisms is a process called DNA methylation, which was the focus of this particular study.

Researchers looked at the DNA methylation signature in the blood of women both with and without BRCA1 mutations. When the signature was applied to the samples from both of these groups, the women who had developed non-hereditary cancers were found to have the same DNA methylation signature as those with the hereditary gene.

Professor Martin Widschwendter, the study’s lead author and head of the UCL Department of Women’s Cancer, says: “We identified an epigenetic signature in women with a mutated BRCA1 gene that was linked to increased cancer risk and lower survival rates. Surprisingly, we found the same signature in large cohorts of women without the BRCA1 mutation and it was able to predict breast cancer risk several years before diagnosis.”

Further research is required to find out whether this epigenetic signature is just an indicator of breast cancer risk or is involved in the actual development of breast cancer. Work is now also being undertaken to use these findings in clinical trials.[/vc_column_text][/vc_column][/vc_row]

Potential early intervention for those susceptible to pancreatic cancer

Biankin-Andrew-3Australian clinical researchers have found that early detection may be possible for people who are genetically susceptible to pancreatic cancer.

Pancreatic cancer has been found to be a very slow growing disease in the early stages, taking between 10 and 20 years to develop. A very “broad window” therefore exists for intervention, provided certain genetic factors are detected early.

The Garvan Institute of Medical Research’s Dr Jeremy Humphris and Professor Andrew Biankin (Professor Biankin is also Regius Professor of Surgery at the University of Glasgow), analysed medical histories and tumour samples taken from 766 pancreatic cancer patients, operated on between 1994 and 2012. They found that roughly 9% of these patients had a first-degree relative (parent or sibling) with pancreatic cancer.

Patients with a close relative who developed pancreatic cancer were more likely to develop cancer in their life-time and 71 per cent of children whose parents had pancreatic cancer were found to have developed the same cancer but 10 years earlier than the parent’s own diagnosis age (known as ‘anticipation’).

These genetic factors, as well as the knowledge that the greatest known risk factors are cigarette smoking, diabetes, obesity and, to a lesser extent, alcohol consumption should make it possible for scientists and GPs to identify novel susceptibility genes, and at the same time design risk management and screening programs for the genetically susceptible group.

“Our findings suggest that when we’re assessing someone, it’s important to understand the family history – not just of pancreatic cancer, but other malignancies too,” said Dr Humphris.

“Smoking led to a much earlier onset of disease, so obviously you would counsel against smoking, especially in those who are genetically susceptible.”

Pancreatic cancer is a lethal disease with a 5-year survival rate of less than 5%. This very low survival rate is generally due to the fact that diagnosis comes only after the disease is advanced or has spread – making a case for early detection methods.

Professor Biankin said “a better understanding of the clinical features of genetically at-risk individuals will help us identify susceptibility genes as well as those who might benefit from genetic counselling and screening for detection of early disease”.[/vc_column_text][/vc_column][/vc_row]

Torch Publishing’s fourth annual golfing event a great success!

IMG_3753

An early 7am start saw 120 eager golfers take to the greens to kick off Torch Publishing’s fourth annual golf fundraising event.

The fantastic event, organised by father/son duo Trent and John Engisch and Helen Butler, gave businesses and supporters a chance to tee up a day of friendly competition for a great cause!

After a morning filled with buggies, bogies, birdies and maybe a few eagles too, the event headed in-doors for lunch where guests were treated to a key-note speech by NRL Bulldogs former team captain Andrew Ryan and an exciting fundraising auction.

All up the day has helped to raise almost $25,000 for world class cancer research in Australia.

We’d also like to say a massive thank you to Trent, John and Helen, along with the rest of the legendary Torch team for their dedicated support to us over the last 4 years.

Through the past four Torch Charity Golf Days they have raised over $72,000 for cancer research in total – such a fantastic and humbling effort![/vc_column_text][/vc_column][/vc_row][vc_images_carousel images=”23088,23089,23090,23091,23092,23093,23094,23095,23096,23097,23098,23099,23100,23101,23102,23103,23104,23105,23106,23107,23108,23109,23110,23111″ onclick=”link_image” custom_links_target=”_self” mode=”horizontal” speed=”5000″ slides_per_view=”1″ img_size=”full”][/vc_column][/vc_row]

Millions in private funding set for top cancer scientists in Australia

cancer scientistEvery year the Australian Cancer Research Foundation provides multi-million dollar grants to support research projects of the highest calibre in Australia.

Last week the ACRF Research Advisory Committee met with the six shortlisted applicants to hear more about their proposed projects for research funding. Chaired by Prof. Ian Fraser AC, the Committee is made up of 14 esteemed cancer scientists.

“There has been a particular interest this year in new technology for looking for molecules which fingerprint cancer cells, and for the genetic mistakes that fingerprint cancer cells,” said Prof. Frazer, following the grant interviews.

This year Committee member, A/Prof. Connie Trimble from John Hopkins Hospital in Baltimore, USA, travelled to Australia to join our panel of judges over the two day interview process.  Her experience and perspective on the international research stage will ensure that the successful ACRF grant recipients represent the cutting-edge of world research.

The shortlisted research groups, which were selected based on their significant potential to make an impact on cancer diagnosis, treatment and/or cure, represent a need for almost $25.M in funding.

The six shortlisted applicants are from all over Australia, covering research into all cancers. These are:

  1. Walter & Eliza Hall Institute, Melbourne, VIC
    Develop a purpose-built facility specialising in developing new targeted therapies for all types of cancer.
  2. Monash Institute of Medical Research – Prince Henry Hospital, Melbourne, VIC
    Expansion of an existing ACRF centre to tackle issues such as early detection, tumour diversity and drug resistance.
  3. University of Queensland Centre for Advanced Imaging, Brisbane, QLD
    A facility specialising in the development and validation of novel molecular imaging agents for cancer.
  4. Children’s Cancer Institute, Sydney, NSW
    Create an integrated and dedicated child cancer precision medicine centre, focused on delivering personalised therapies for Australian children at high risk of treatment failure.
  5. Garvan Institute of Medical Research, Sydney, NSW
    Build a space housing super-computer resources for a team of bioinformatics scientists, working towards the analysis of biological changes due to cancer treatment and disease progression.
  6. Sydney University Central Clinical School, Sydney, NSW
    Develop an ACRF imaging centre which will pioneer targeted radiotherapy and provide an opportunity for academia, medicine, industry and government to collaborate on the science and clinical practice of cancer treatment.

The recipients of the 2014 grants will be announced in November. If you would like to read more about our grants process or to find out our past grants recipients please click here.[/vc_column_text][/vc_column][/vc_row]

Will Ashley rides 3,200km in solo adventure for cancer research.

Will AshleyWe first met Will Ashley when, at the age of 16, he cycled from Coffs Harbour to Sydney with his best mate in tribute to a very special breast cancer survivor, Will’s mum.

The next year, Will rallied two other adventurers, including his brother Jo, to kayak over 2000Km down the Murray River and raise even more funds for world-class cancer research in Australia. We thought the amazing spirit and generosity of Will Ashley must have no end. And we were right:

Just last week, Will completed yet another epic fitness challenge in support of the ACRF.

At the beginning of September, he rode off on his bike from the Daly Waters Pub in the Northern Territory. In front of him stretched a four week solo journey, which would bring him back his home in Coffs Harbour, NSW.

The days were hot, long and often frustrating – juggling knee injuries, much-needed rest days, and stiflingly hot weather. But Will says the challenge was worth it.

“It was a wonderful ride,” he said.

“Especially North West Queensland where the country was so barren.

“There were a few hiccups. I injured my knee and had to hitch a ride to a physio, but all in all it was an awesome experience.”

At night Will would set up camp on park benches or on a beach and then as dawn broke he’d jump back on his bike and start all over again.

Each day Will pedalled for about 10 to 12 hours, and in the final stretch from Ballina to Coffs Harbour he also had traffic to dodge.

Will planned to raise $10,000 for cancer research in the lead up to, and during, his 3,200km trip. In addition to this most generous goal, Will also stopped in at schools along the way to talk to the students about goal-setting, and healthy lifestyles. Will wanted to show them anything is possible if they want to try and make a difference.

Will arrived back in Coffs Harbour last week, riding into his old school hall at Bishop Druitt College, packed full of students, teachers and family who were eager to congratulate him.

We’d like to thank Will for this amazing fundraiser. His dedication and generosity is truly humbling and his efforts in raising $10,000 by himself is truly an inspiration.

If you would like to find out more about Wills ride you can read about it here. Will also kept a video blog of each of his days – you can watch them here.[/vc_column_text][/vc_column][/vc_row]

Deb want’s to challenge you to Live A Little!

fight cancerWe have some pretty amazing supporters here at the Australian Cancer Research Foundation! Deb McNaughton, who has already raised $8,500 for cancer research, has begun a social challenge for 2014 called “Live a Little”.

After one week, Deb has already raised over $2,000 towards her $5,000 goal.

The basic idea around the “Live a Little” 2014 challenge is to do something you wouldn’t usually do; something out of the ordinary.

Deb explains that people who want to take part in the challenge can make it extreme or simple, crazy or kind, scary or funny, ridiculous or revolting. Most of all…they need to MAKE IT COUNT!

If you’re interested in living a little and getting involved in the “Live a Little 2014 Challenge” here’s what you can do:

  • Upload a photo/video of you (individual or group) ‘living a little’ to Facebook or Instagram.
  • Remember to tag with #livealittle
  • Donate to: http://give.everydayhero.com/au/live-a-little
  • Challenge/nominate as many friends as you like to make a difference and LIVE A LITTLE – because you can!

Get on board with the Live a Little challenge now and help fight cancer. A big thank you to Deb for creating this great fundraising challenge![/vc_column_text][/vc_column][/vc_row]

Norm “Bugs off” for the very last time.

1534775_722288464517659_156405772683906801_oThe Bug Off Cancer beetle that we’ve all come to love has, this week, set off on it’s very last Bug Off Cancer fundraising journey.

This time Norm and his support team have headed south to Tassy to take in the beautiful scenery of Australia’s apple isle, and for a whirlwind week of fundraising with the locals.

Before leaving home, Norm had already raised over $5,000 for cancer research in Australia and he hopes to reach $10,000 by the end of his journey. If he achieves his target, Norm’s total fundraising efforts will stand at almost $40,000!

Norm started his Bug Off Cancer fundraising mission five years ago when he decided he wanted to do something, anything, to help rid the world of this terrible disease.

Having lost both parents and other relatives to cancer over the years, and knowing others that have this insidious disease, Norm decided to combine his love of VW beetles with a fundraising idea and Bug Off Cancer was created.

As Norm travels back to Sydney we’d like to wish him all the best on this last leg of his journey and send out a massive congratulations for his efforts in fundraising such an incredible amount for cancer research in Australia.

The ACRF is always proud of, and very humbled by, our fundraisers and their dedication to support such a cause. To Norm, we thank you for everything you have done to help the ACRF fight cancer and wish the Bug Off Cancer Beetle a very happy retirement![/vc_column_text][/vc_column][/vc_row]

Team ACRF takes on Blackmores Sydney Running Festival

cancer fun runMore than 34,000 runners and walkers flooded over the iconic Sydney Harbour Bridge on Sunday 21 September to take on the Blackmores Sydney Running Festival events.

The ACRF was humbled that 400 of those people were participating in support of cancer research. They were running in memory or support of loved ones, and tackling the challenge of either the full or half marathons or enjoying the atmosphere and scenery of the shorter bridge and family funs.

Together, our amazing supporters have generated over $40,000 for cancer research in Australia at the Blackmores event and we are so very grateful for the dedication and massive support we have received!

Our highest fundraisers for the event included Nikki and Joey, who ran for cancer research in memory of a very close friend, Sarah. Sarah recently passed away from a rare type of bone cancer called Ewing’s Sarcoma .

The girls set themselves the gruelling challenge of running the half-marathon course in Sarah’s memory. Not only did they smash through the course but they also smashed their fundraising target, raising over an incredible $11,000!

Nikki and Joey represent so many wonderful runners, each of whom had an emotional reason to go the extra mile. We thank them so very much for their dedication and support. We’re incredibly humbled.

Along with our amazing runners we also had 15 volunteers who arrived at the crack of dawn to help the event run by setting-up and manning the drinks station.

We’d like to send a big thank you to our volunteers, including our teams from the UNSW Volunteer Army and corporate supporters Excelian, Makinson d’Apice and Leighton.

We hope you had a memorable and most enjoyable day![/vc_column_text][/vc_column][/vc_row]

Cancer scientists can now explain a third of the inherited risk of prostate cancer

tao-research-mainAn exciting discovery during a major international study has revealed cancer scientists can now identify men at a 6-fold increased risk of prostate cancer.

Cancer scientists at The Institute of Cancer Research, London, together with researchers in Cambridge, and California found 23 new genetic variants associated with increased risk of the disease.

The study means that scientists can now explain 33% of the inherited origins of prostate cancer in European men and will contribute to determining whether these genetic markers can improve on other tests for the disease.

Professor Ros Eeles, Professor of Oncogenetics at The Institute of Cancer Research, London, and Honorary Consultant in Clinical Oncology at The Royal Marsden NHS Foundation Trust, said, “Our study tells us more about the effect of the genetic hand that men are dealt on their risk of prostate cancer.

“We know that there are a few major genes that are rare and significantly affect prostate cancer risk, but what we are now learning is that there are many other common genetic variants that individually have only a small effect on risk, but collectively can be very important.”

They are now investigating whether genetic testing could help diagnose more men at risk of developing dangerous forms of prostate cancer that need urgent treatment – something that the current test is unable to determine.

“Building on previous research, this study gives a more complete list of these factors, bringing us closer to knowing who may need screening for prostate cancer and which men may benefit from early treatment. More work needs to be done, but identifying these genetic factors will allow us to better understand the disease and maybe even develop new treatments,” said Professor Eeles.

In Australia, 22,000 men die from cancer every year and one in two Australian men will get cancer in their lifetime – that’s 20% more men than women who will be touched by this terrible disease.

This September is Blue September, an annual campaign that encourages all Australians to face up to cancer in men and promotes research into men’s cancers.

If you are able to make a donation to men’s cancer research this September and help speed up research discoveries like this, we thank you so very much.[/vc_column_text][/vc_column][/vc_row]

New Hope for Sufferers of Ovarian Cancer

New_Hope_Ovarian_CancerAustralian experts say new drug developments and individualised treatments are bolstering efforts to improve the prognosis for patients with epithelial ovarian cancer.

Professor Martin Oehler, Director of the Department of Gynaecological Oncology at Royal Adelaide Hospital, said the past 20 years had seen little improvement in the detection and treatment of ovarian cancer, but there are now many advances in the pipeline and the research community is ‘very positive and hopeful’.

Epithelial ovarian cancer is the most common type of ovarian cancer and develops in the epithelium, which is the surface of the ovary. There are currently no tests effective enough for a population based screening program for ovarian cancer, and symptoms can often be vague making early diagnosis difficult.

International research efforts have been focused on early detection, and although technical limitations had so far prevented the development of a blood test to detect ovarian cancer researchers are now looking to the disease’s immune signature to aid early detection.

Oncologist Dr Anne Hamilton from the ACRF-funded research institute Peter MacCallum Cancer Centre said ‘the building blocks’ were now starting to fall into place and new drug therapies were showing promise. The Australian Ovarian Cancer Study, for which Dr Hamilton is a scientific advisor, is studying the genetic changes leading to the formation of cancers.

“The study has already identified subgroups of ovarian cancer and what that’s giving us now is an ability to try to tailor treatment to six different types of ovarian cancer rather than one.” Dr Hamilton said.

Researchers have realised that ovarian cancer is a very heterogeneous disease consisting of distinct subtypes of different origin that vary significantly with regard to molecular biology and clinical behaviour. With this increased knowledge, the hope is for the development of more innovative and targeted treatments.[/vc_column_text][/vc_column][/vc_row]

Tattoo for Cancer – Raising Money for Cancer Research

Thirroul tattoo artist Wayne Cartwright had long been keen to do something for charity, and after going over his own experiences with cancer he came up with a unique way to raise money for cancer research.

Tattoo for Cancer

His unconventional cancer fundraising event, Tattoo for Cancer, was held last Sunday at Soul Expression with Wayne and four fellow skin artists donating their time to ink courageous volunteers with a cancer inspired tattoo. Together, they raised an incredible $10,000 for the ACRF.

Wayne, the owner of Soul Expression, said interest leading up to the event had been immense with many people eager to get a permanent ode to their cancer experience.

“It’s a very emotional subject for a lot of people. I’ve done plenty of similar tattoos in the past and they always have so much meaning.” Wayne said.

“It could be someone who has been touched by cancer or a survivor and they get the tattoo to remind them of their journey; it’s often their first tattoo and the most important.”

The local community rallied behind the event with a local butcher donating 800 sausages for the day and, along with the skin artists working hard to get through as many tattoos as they could, many retailers donated prizes for the silent auction and raffle.

Wayne reassured all those that missed out not to worry as the massive turnout meant that hopefully they can do it again next year on an even bigger scale!

A huge thank you and congratulations to Wayne and everyone who contributed to the day! We’re so very grateful for your efforts and support.[/vc_column_text][/vc_column][/vc_row]

The Australian Cancer Research Foundation partners with SAHMRI in the fight against cancer

The Australian Cancer Research Foundation (ACRF) has awarded the South Australian Health and Medical Research Institute (SAHMRI) $1.8 million in funding, acknowledging the promising future of cancer research in Australia.

SAHMRI Research

The funding from the ACRF will be used to establish the ACRF Innovative Cancer Imaging and Therapeutics Facility housed at SAHMRI and within a new health and biomedical precinct in Adelaide that will enable the Institute’s researchers, and their collaborators, to rapidly translate basic biomedical research discoveries to novel cancer therapies.

This facility will provide cancer researchers with the tools necessary to perform cutting-edge research and will build cancer research capacity across South Australia.

SAHMRI’s Executive Director, Professor Steve Wesselingh said the Institute is thrilled with the announcement.

“We are so honoured to receive this generous award from the ACRF.  We have all been touched by cancer in some shape or form, and know its devastating effects. This award will enable us to seek better treatments, cures and even ways to prevent this disease in its many manifestations.

“The ACRF Innovative Cancer Imaging and Therapeutics Facility will facilitate groundbreaking cancer research by providing investigators with access to biomedical imaging technologies, such as advanced flow cytometry, magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET) and single photon emission computed tomography (SPECT).

“This facility will play a pivotal role in translating biomedical discoveries to therapies that will directly impact the health and survival of cancer patients, and we are extremely grateful to the ACRF for their support and fantastic work.”

The ACRF has been awarding major grants in excess of $1 million and up to $5 million, for building and updating research centres and laboratories, purchasing the latest technology and equipment and the establishment of national facilities in Australia, since its inception in 1984.[/vc_column_text][/vc_column][/vc_row]

‘Liquid’ cancer test to replace invasive biopsies

Peter MacCallum Cancer CentreA ‘liquid biopsy’ developed by Melbourne researchers has the potential to determine whether malignant tumours are shrinking, faster and more accurately than ever before. This simple new test would replace invasive tissue biopsies by analysing cancer tumour DNA in the blood.

Clinician researcher Dr Sarah-Jane Dawson from ACRF-funded research institute Peter MacCallum Cancer Centre said looking for this circulating tumour DNA in blood had been like ‘looking for a needle in a haystack’. However new-generation genetic sequencing allows a complete snapshot of the cancer to be captured as it evolves.

“As the cancer cells turn over they release their DNA into the bloodstream. While we’ve known this for some time, it’s only been recently with advances in genomic technologies that we now have sensitive techniques that allow us to very precisely identify this small fraction of tumour DNA in the blood.”

“We think this is a really exciting development and it does hold a lot of promise for making a big difference to the management of cancer patients.” Dr Dawson said.

A clinical trial testing the liquid biopsy in Victorian breast cancer patients is due to begin next year.

Dr Dawson said in an ideal world, regular biopsies would be taken during someone’s treatment. But often that’s not feasible, and it’s invasive.

“By repeating these blood tests regularly, they may give us a very accurate understanding of whether someone is responding to their treatment or not — which is very important for a woman to understand.”

“She doesn’t want to be on a treatment that’s not working, or be exposed unnecessarily to side-effects, when she could be switched to a therapy that could be more effective,” Dr Dawson said.[/vc_column_text][/vc_column][/vc_row]

Professor Haber wins NSW Cancer Researcher of the Year

Prof-M-Haber-WebThe annual Cancer Institute NSW’s Premier’s Awards for Outstanding Cancer Research were awarded last Friday evening at Sydney Town Hall and we are extremely proud to announce that ACRF Medical Research Advisory Committee member Professor Michelle Haber AM has been awarded the Outstanding Cancer Researcher Award for 2014. 

This prestigious award honours an individual who has made significant and fundamental contributions to any field of cancer research in NSW, and comes with a prize of $50,000 to further the recipient’s research endeavours.

Professor Haber is the Executive Director of the Children’s Cancer Institute Australia, and has previously been awarded the Excellence in Translational Research Award at the Premier’s Awards in 2012. She is internationally recognised for her world-class research into the treatment of neuroblastoma and acute lymphoblastic leukaemia in children.

We are very proud to count Professor Haber as a member of the ACRF Medical Research Advisory Committee. Committee members are cancer scientists of the highest national and, in many cases, global repute.

They are leaders in Australian cancer research and advise the ACRF on applications received for ACRF grants funding, making recommendations to the Board of Trustees of ACRF as to where grants should be awarded for maximum impact and innovation in cancer prevention, diagnosis and cure.

Excellence in children’s cancer research was further recognised on the night with the Premier’s Rising Star Award and the Outstanding Cancer Research Fellow of the Year going to members of the Kids Cancer Alliance.

Associate Professor Georgina Long from the Melanoma Institute Australia was awarded the Wildfire Award, and collaborations working in haematological clinical research and asbestos research were also acknowledged for their efforts in their fields.

Nikki and Joey – Fundraising for a Friend

Here at ACRF we are extremely humbled to have such fantastic and loyal supporters that continue to go above andNikki_Joey_Sarah_Web beyond in their efforts to raise money for cancer research. Sadly, many of our supporters have been touched by cancer personally, and their heartbreak and grief are what drives them to make a difference in the hope that nobody has to experience what they’ve gone through.

We’re incredibly humbled to share with you Nikki and Joey’s story – a story which has driven two ladies to fight cancer through research, in memory of their friend.

Last year Nikki and Joey met Sarah, a girl from America who was interning at Baseball Australia, where Nikki worked. The three girls hit it off instantly. Sarah was bubbly, happy and had a zest for life.

After returning home to Philadelphia, Sarah was diagnosed with Ewing’s Sarcoma – a rare type of bone cancer that usually occurs in children and young adults.

“It was such a shock when we found out and it made us want to make a difference, even if it was small,” Nikki and Joey wrote when they found out about Sarah’s cancer.

“Everyone knows someone who has been affected by cancer and there is still so much more research to be done. Sarah is a strong individual and we know she will kick cancers butt.”

The girls set themselves the challenge of running the half marathon in the Blackmores Sydney Running Festival in September, and they’ve already smashed their fundraising efforts by more than doubling their target so far. Feel free to click on the above link to view their fundraising page and add a message of support.

In the midst of their training, Nikki planned to visit Sarah in Philadelphia to boost her spirits while she was receiving treatment. However in a heartbreaking turn of events, Sarah’s condition deteriorated and she passed away a few days before Nikki arrived. At her funeral, Nikki met all of Sarah’s family and friends and through her grief decided that she wanted to plan another event to raise as much money as possible for cancer research.

Together with their Mum, Nikki and Joey are now busily organising their fundraising event for next month, so keep your eyes on our Events Calendar where we’ll bring you all the details of the night very soon. We’d like to thank Nikki and Joey for sharing this story with us, and send our condolences for their terrible loss.[/vc_column_text][/vc_column][/vc_row]

New method of treating solid tumours discovered from existing research

Prof Scott accepting ACRF grant 2011 - 1 A team of international scientists from ACRF-funded research institutes Monash University and Ludwig Institute of Cancer Research have uncovered that an antibody against the protein EphA3, could potentially be applied to treat a wide range of different cancers.

The protein EphA3 was discovered in 1992 by Professor Andrew Boyd for its role in promoting leukaemia cancer cells and an anti-body is now in clinical trials to treat this mutation in leukaemias.

Further discoveries showed aggressive brain tumours could also be targeted by this therapy, which you can read about here. EphA3 is present in normal organs only during embryonic development but is released in blood cancers and solid tumours, fuelling cancer growth and providing a target for anti-bodies.

The research team led jointly by the late Professor Martin Lackmann, from the School of Biomedical Studies at Monash; and Professor Andrew Scott, from Ludwig Institute for Cancer Research used laboratory models of prostate cancer to mimic disease progression in humans.

EphA3 was found in stromal cells and blood vessels surrounding the tumour and they observed that treatment with an antibody against EhpA3 (chIIIA4) significantly slowed tumour growth. The antibody damaged tumour blood vessels and disrupted the stromal micro-environment, and cancer cells died because their ‘life-support’ was restricted.

Professor Scott said, “in addition, we screened various tumours from patient biopsies – sarcomas, melanomas as well as prostate, colon, breast, brain and lung cancers – and confirmed EphA3 expression on stromal cells and newly forming blood vessels.”

“Our research findings indicate that the tumour micro-environment is important, and monoclonal antibodies against EphA3 are one way to target and kill a variety of solid tumours as well as blood cancer.”

[Pictured above: Professor Andrew Scott from Ludwig Institute for Cancer Research receiving a recent ACRF grant of $2 million.][/vc_column_text][/vc_column][/vc_row]

Help fight cancer this National Science Week by hosting a Schools Against Cancer event

FundraisingThis week is National Science Week and the perfect opportunity for your school to fundraise for cancer research!

Running until 24th September, National Science Week is an annual celebration of Australia’s ground-breaking work in science and technology, including breakthroughs in cancer diagnosis and treatment. Australian scientists are often at the forefront of cancer science discoveries, such as the development of the HPV vaccine, which has been proven to reduce the risk of cervical cancer.

The ACRF is dedicated to funding world-class research into treatments, diagnosis and cures for cancer. Your school or class can show support for the important work of researchers and scientists by holding a Schools Against Cancer event – and help fund the next big cancer breakthrough!

We have a number of great ideas for fundraising events. For example, you could conduct some fun science experiments in the classroom with ACRF-supplied props, or hold a Scientists & Superheroes mufti day. You could also combine fundraising with cancer education by holding a Mad Hat Day and promoting the importance of sun protection. Click here for more inspiration, or come up with your own ideas!

If you’re interested in holding a Schools Against Cancer event during National Science Week, please contact our Schools Against Cancer Coordinator, Kamille Araya.[/vc_column_text][/vc_column][/vc_row]

Charity Challenge supports cancer research

P8070001Last week, guests from leading beverage company and long-term ACRF supporter Lion Co. took part in a Hidden Door Charity Challenge, where they completed a series of challenges to earn funds for the ACRF while also working towards their annual corporate team building aims.

During the 3 hour event, the teams battled throughout Sydney in a fun and competitive afternoon that included a mystery brand food taste, testing their knowledge in with lateral thinking brain teasers and showing off their moves in an 80’s-inspired dance challenge!

Charity Challenges are a fun way for businesses to support cancer research as well as staff engagement and at the ACRF we have a number of challenge options. Regular team-building exercises have been proven to improve staff motivation and mood by promoting skills in leadership, negotiation and analysis. They also encourage staff bonding and create a positive atmosphere.

We have partnered with Hidden Door to provide ‘Amazing Race’ style Charity Challenges, where teams convert points into donations for cancer research, and the mouth-watering Wholefood Cook Off culinary experience. Click here to sign up or find out more about our Hidden Door Charity Challenges.

If you or your company are looking for something a little more adventurous, check out our International Charity Challenges or our Fitness Charity Challenges.[/vc_column_text][vc_gallery type=”flexslider_fade” interval=”0″ images=”22332,22337,22336,22335,22333,22334,22331,22330,22338″ onclick=”link_image” custom_links_target=”_self” img_size=”large”][/vc_column][/vc_row]

Why I Fly For Cancer Research

SDTB308240237161The Australian Cancer Research Foundation (ACRF) and the Australian Parachute Federation (APF) have joined forces to bring you our most exhilarating fundraising challenge yet!

‘Why I Fly’ has been developed as part of Blue September, an international campaign that actively promotes for research and awareness into men’s cancers.

With 1 in 2 men expected to be diagnosed with cancer in their lifetime, most of us will know someone affected by this terrible disease. ‘Why I Fly’ is the perfect opportunity to face your fears and skydive in tribute to a loved one.

When you sign up for our Blue September skydiving experience, you will be guaranteed a personal challenge with a difference as you raise vital funds for men’s cancer research.

‘Why I Fly’ is an extension of the ACRF’s successful ‘Jump’ programme where supporters skydive in tandem to raise money for cancer research in various locations around the country.

Our goal is to build ‘Why I fly’ into an annual national event that acts as an extended Father’s Day promotion. Through ‘Why I Fly’, we will celebrate and remember the men who are most important to all of us.

The APF exists to administer and represent the Australian sport of parachuting to encourage participation and excellence in performance. “We are delighted to partner the Australian Cancer Research Foundation to build what will become a unique promotion for both associations. At APF we are always looking for ways to promote the exhilaration of Skydiving and to join ACRF to promote cancer research for Why I Fly is a win for all,” said Brad Turner, CEO of APF.

Find out more about skydiving for cancer research or sign up to the challenge by contacting fundraising@acrf.com.au

ACRF runners raise over $115K at City2Surf 2014!

IMG_3283It’s one of our favourite events of the year: the Sun Herald City2Surf – and it took place on Sunday, with more than 80,000 runners hitting the streets of Sydney for this spirited community race.

Thanks to the amazing work of 270 runners, Team ACRF has had its most successful City2Surf ever, raising over $115,000 towards cutting-edge cancer research! We’re overwhelmed by the generosity of our supporters – and hope they’ll take the chance to grab a few final donations with fundraising pages open for another four weeks.

Many of team ACRF’s runners have been affected by cancer. One supporter in particular, Fi, ran in support of her best friend Glenno, who is battling advanced melanoma. Fi is a cancer survivor herself, having been diagnosed with colorectal cancer four years’ ago.

Fi told us that she ran for Glenno because the challenge of Heartbreak Hill was nothing compared to what Glenno faces and she wanted to support him in any way possible. Fi has so far raised over $3,500 for cancer search.

As well as many new runners, we were thrilled to welcome back The Shirl’s Girls running team and David Griffith’s Ann’s Angels.

After running the gruelling 14km, our top supporters were treated to a BBQ at the exclusive ACRF beach chalet, which was sponsored by Steggles. Complimentary massages were also on offer, perfect for post-race relaxation.

We would like to thank everyone who participated in the City2Surf or supported a friend, co-worker or family member, without you this incredible achievement would not have been possible!

We hope you all had a fun and enjoyable experience – check out our photos from the day![/vc_column_text][/vc_column][/vc_row][vc_gallery type=”flexslider_fade” interval=”0″ images=”22257,22258,22259,22260,22261,22262,22264,22265,22266,22267,22268,22269,22270,22271,22272,22273,22274,22275,22276,22277,22278,22279,22280,22281,22282″ onclick=”link_image” custom_links_target=”_self” img_size=”large”][/vc_column][/vc_row]

Australian researchers uncover a new gene in the battle against neuroblastoma

tao-research-mainResearchers at the ACRF-funded Children’s Cancer Institute Australia have made an important discovery in the battle against neuroblastoma – one of the most aggressive forms of childhood cancer.

The Institute’s work, published in the prestigious US Journal of the National Cancer Institute, has uncovered a gene linked to the cause of neuroblastoma that could lead to the development of new targeted therapy and change the way the cancer is treated.

It shows that a new long noncoding or ‘junk’ RNA (a type of molecule) plays a critical part in neuroblastoma tumour formation. This study, led by Dr Tao Liu, Group Leader for Histone Modification at CCI, is the first time that it have been discovered that a long noncoding RNA can impact the progression of neuroblastoma.

This discovery could help develop new treatments for the disease, which has a much smaller survival rate compared to other childhood cancers. Currently, neuroblastoma is often diagnosed once the cancer is already advanced and has a survival rate of only 50%.

“Dr Liu’s study has improved our understanding of what leads to the development of neuroblastoma, and uncovered another potential target for this rare but devastating disease,” said Children’s Cancer Institute’s Head of Translational Research, Prof Glenn Marshall AM.

“Side-effects associated with conventional chemotherapy used to treat kids with cancer are a significant clinical problem. Research results such as these will help us discover new treatments, specifically designed for children, to ensure they experience the highest possible quality of life – and support further work to uncover other junk DNA targets for cancer therapy.”

Watch the ABC News report on this important discovery.

[/vc_column_text][vc_video link=”http://www.youtube.com/watch?v=YSjs7Hn5Ov4&feature=youtu.be”][/vc_column][/vc_row]

Help fund new cancer research breakthroughs with workplace giving

James-Duncan-and-sisterNow that the new financial year has started why not set up regular donations with an immediate tax benefit?

Workplace giving is the perfect way to make a real difference to cancer research in Australia and as your regular donations are deducted from your payroll before tax is applied, you benefit too!

There are many benefits to workplace giving or corporate giving schemes for businesses, their employees and the charities they support. Workplace giving schemes provide an opportunity for employee engagement, with research conducted by the Charities Aid Foundation indicating that companies who offer these engagement opportunities experience higher staff retention. It also provides a common, shared goal between companies and their employees as staff work together towards an important goal – support for cancer research breakthroughs.

James Duncan, who is a current workplace giver for cancer research, explains how he made the decision to help his sister’s fight against cancer:

“My sister had stage 4 bowel cancer that spread to her liver. I cannot express the affect it had on her, her husband and our families in just a few sentences; suffice to say it was profound.

“The devastating events that occurred in the lead up to her diagnosis, her invasive surgery, treatment and lengthy recovery after diagnosis was an experience quite literally life changing for everyone – most of all my sister.

“She has won two battles so far, though the effects are ongoing. Her physical condition will never be the same and her three monthly check ups are a nail biting time. Despite the experience, my sister is resilient, strong and an inspiration to us all. She has made positive changes to her lifestyle and is a long way off meeting her quota of meltdowns.

“Workplace giving is an easy, simple way for me to make my stand against cancer.  It’s easy to opt in, opt out and control so is a no-brainer to me.”

If only 10% of working Australians made regular employee donations of $5 each week, their support would result in an incredible $260 million each year.

Find out more about workplace giving here, or talk to your HR department about your options for workplace giving.

New cancer research facility aims to accelerate personalised cancer medicine in Queensland

Diamantina_Opening_2The opening of a new cancer genomics centre at UQ Diamantina Institute at TRI means Queensland is now home to the largest and most sophisticated genome sequencing facility in the southern hemisphere.

Funded by the ACRF ($2 million), the Diamantina Individualised Oncology Care Centre (DIOCC) will be an innovative, world leading center of near-patient cancer genomics research.

“The way forward for cancer research is to really prioritise translational, patient-focused outcomes, and that is why the Australian Cancer Research Foundation is so proud to support this new centre at TRI,” said ACRF Chairman, Mr Tom Dery.

DIOCC will house state of the art genomics, proteomics and metabolomics technology. This technology will enable cutting edge research primarily into skin, blood and breast cancers.

The research to be undertaken within DIOCC will focus on understanding disease causes, improving diagnosis and treatment development. It will also allow for the development of protocols to implement the use of these new technologies in clinical practice.

As a collaboration of clinicians and scientists working in near patient cancer research, DIOCC offers a unique opportunity to foster translational research.

It brings together research and clinical groups across the Princess Alexandra Hospital (PAH) campus, including clinical services in Oncology, Haematology and Dermatology, The University of Queensland Schools of Medicine and Pharmacy and the Translational Research Institute (TRI).

The new facility was opened during an official ceremony on Thursday 31 July 2014.[/vc_column_text][/vc_column][/vc_row][vc_gallery type=”flexslider_fade” interval=”0″ images=”22170,22167,22172,22168,22171,22169″ onclick=”link_image” custom_links_target=”_self” img_size=”large”][/vc_column][/vc_row]

July News 2014

JulyNewsletterJuly 2014 Newsletter

In the July edition:

  • New targeted research could offer alternative treatment for Acute Myeloid Leukaemia
  • The search for early markers of brain cancer is supported with ACRF funding
  • James Robson takes on the Iron Man challenge in support of cancer research
  • ACRF golf day tees up fundraising success

ACRF Charity Golf Day tees up fundraising success!

golf_dayThe ACRF has held its annual Charity Golf Day, giving businesses and supporters a chance to tee up a day of friendly competition for a great cause! The event took place at the exclusive New South Wales Golf Club in La Perouse, which offered stunning views, undulating fairways and challenging greens.

The Charity Golf Day had a fantastic turnout – 65 people participated, with a great mix of individual fundraisers and corporate teams. A pod of dolphins even turned up off the coast! Competition was fierce but friendly, with over $16,000 raised from day in support of world-class cancer research.

Congratulations to David Archer’s team, which came first and have vowed to return in 2015 to defend their title. Individuals Michael Milakovic won the trophy for Nearest to Pin and Todd Archer for Longest Drive.

We would like to thank everyone who took part – to our long-term supporters such as David Archer, Goodman Group and Lion Co., and to our new friends whom we hope to see again in the very near future.

Our silent auction is open for another week. Please register and continue the bidding! http://galabid.com/auction/acrfgolf[/vc_column_text][vc_gallery type=”flexslider_fade” interval=”0″ images=”22133,22134,22138,22139,22140,22142,22143,22144,22145,22146,22147,22148″ onclick=”link_image” custom_links_target=”_self” img_size=”large”][/vc_column][/vc_row]

Olwen travels coast-to-coast in her 2014 Charity Challenge

Robin-Hood-BayOlwen Bradford Cowling, long-term ACRF supporter, is about to complete an incredible adventure, taking on the Charity Challenge of walking more than 320km across the UK countryside for cancer research.

Along with the support of her sister and friends, Olwen has been traveling the Wainwright’s Coast to Coast path, beginning at St Bees on the West Coast, and finishing at Robin Hood’s Bay on the East Coast of England.

Now a five-time charity challenger for the ACRF, Olwen has made an incredible impact on cancer research funding in Australia. For this event alone, her team have raised more than $10,000 – bringing her total fundraising for the ACRF to $37,384. We’re blown away by her efforts and the generosity of her family and friends!

Olwen’s trek is in memory of her mum, whom she lost to cancer in 2005.

“I decided from then on, I would do what I could to support cancer research in the hope of one day finding a cure,” Olwen said.

And for this trek specifically: “I would like to make this [online fundraising] page a Tribute Page, not only to those who have lost their battle against cancer but also to celebrate those who have kicked cancer’s butt!!”

International Charity Challenges are a fantastic, unique way to show support for cancer research while testing your strength both emotionally and physically.

If Olwen’s story has inspired you, we have a number of International Charity Challenges occurring in 2015:

Great Wall of China

Depart: 21 April 2015
Return: 30 April 2015

This 10 day adventure covers a classic section of the Great Wall in the Hebei Province including picturesque rural villages and camping in remote areas hosted by local families. Other highlights include visiting Tiananmen Square and the Forbidden City as well as a celebration dinner in Beijing at the end of the Challenge. 

Larapinta Trail

Depart: 5 May 2015
Return: 12 May 2015

Take in the beauty of central Australia and the West MacDonnell Ranges as you cross one of the country’s most iconic trails. The 8 day trip includes 6 days trekking, 5 nights in exclusive semi-permanent campsite accommodation and 2 nights in Alice Springs. 

Tiger Leaping Gorge, China

Depart: 15 May 2015
Return:
24 May 2015

Cycle along the length of dramatic Tiger Leaping Gorge, located in the Yunnan Province, and explore remote rural landscapes and villages of China. During the 12 day Challenge, you will also visit the ancient city Shaxi and discover World Heritage listed town Lijiang. 

Mt Everest Base Camp

Depart: 18 October 2015
Return: 6 November 2015

This once-in-a-lifetime adventure is our longest International Charity Challenge. During the trip you will experience the breathtaking views of Mt Everest and Nepal, climb Kala Pattar and visit Mt Everest base camp, take a step back in time at the Thyangboche Monastery and spend time sightseeing in Kathmandu. 

Search for early diagnostic markers of brain cancer supported with ACRF funding

014_Directors_MIMR_356911ACRF-funded cutting edge technology is helping researchers at Melbourne’s MIMR-PHI Institute move closer to early diagnosis and treatment of Glioblastoma multiforme, an aggressive form of brain cancer.

More than 1,000 Australians are affected by Glioblastoma each year and most are not expected to live more than two years after diagnosis. Although researchers have come a long way in understanding and managing the disease, diagnosis and treatment remain a challenge.

Continue reading “Search for early diagnostic markers of brain cancer supported with ACRF funding”

VCFG publishes first genome-wide screen

PeterMac_GenomeScreeningThe ACRF-funded Victorian Centre for Functional Genomics (VCFG) at the Peter MacCallum Cancer Centre has published its first genome-wide screen, in an open-access journal ‘Scientific Data’, allowing researchers around the world to benefit from the findings.

As the lead article in ‘Scientific Data’, which is produced by the prestigious Nature publishing group, the paper details how the VCFG performs genome screens, which help researchers understand the functional role of every gene in the genome in cancer cell growth and cancer cell death.

Continue reading “VCFG publishes first genome-wide screen”

New targeted research could offer alternative treatment for Acute Myeloid Leukaemia

Michael_ParkerACRF-funded research teams across Australia have collaborated to develop a remarkable new treatment option for Acute Myeloid Leukaemia (AML) and accelerate it into clinical trials.

AML is a particularly aggressive form of cancer with poor survival rates; although chemotherapy can induce remission there is often a high chance of relapse. However, this new research, published in major international journal Cell Reports, details how a newly developed therapeutic antibody (CSL362) binds to the cancer cells and then recruits the body’s immune system to kill the cancer cells.

Continue reading “New targeted research could offer alternative treatment for Acute Myeloid Leukaemia”

James Robson does the hard-yards for cancer research

JamesRobsonACRF super-fundraiser James Robson has completed another epic endurance event for cancer research – this time tackling a massive 226km Iron Man challenge.

James’ motivation for completing these events is very close to his heart.

Just over three years’ ago, James’ father was diagnosed with a brain tumour while he was visiting his son in Sydney. Despite extensive treatment including two major surgeries, radiotherapy and chemotherapy, James’s father has been told he will shortly lose his battle.

Continue reading “James Robson does the hard-yards for cancer research”

Millions in research funding applications received by the ACRF

493a4dc5fa0b7c39e8905bd0a3fb8a7dThe ACRF is very excited to have received 14 grant applications from research teams and collaborations all around Australia, applying for between $1.5 and $5 million in ACRF research funding.

Every year the ACRF provides major grants to help cutting-edge cancer research institutes develop state-of-the-art facilities, and purchase advanced equipment that speed up cancer discoveries.

No other private research funding body in Australia provides grants as large as these; grants which are designed to  fund research with the power to make significant breakthroughs in cancer diagnosis and treatment.

Continue reading “Millions in research funding applications received by the ACRF”

Advances in Leukaemia therapy bring hope to patients worldwide

Westmead - LEUKAEMIA LABTwo Australian research teams have made exciting progress into leukaemia treatments, raising hope for patients around the world suffering from the blood disease.

In a study led by the South Australian Health and Medical Research Institute (SAHMRI) and the University of Adelaide’s Centre for Personalised Cancer Medicine, researchers are testing a promising new approach to killing off leukaemia cancer cells.

They have found that cancer cells decide whether to live or die after a short period of intense exposure to a targeted therapy, reducing current treatment time, leading to reduced side effects in patients.

Continue reading “Advances in Leukaemia therapy bring hope to patients worldwide”

June Appeal: Tax donations making new progress possible

Danielle-and-David-panelIn Australia, almost 50% of the population are expected to be diagnosed with cancer during their lifetime. The road ahead needs to be one of research and discovery, and that’s why we’re here.

The Australian Cancer Research Foundation is the only private charity exclusively funding the tools and technologies capable of getting to the core of this disease.

This June tax-time, we asked our supporters to contribute a series of tributes to the parents, partners, friends and children they have loved and lost to cancer. We would like to share them with you, not to bring you pain or sorrow, but because we know that everyone has a story like this to tell. These stories represent us all – each of us living, in some way, with the pain and fear of cancer.

We have the power to rewrite these experiences for the next generation. By investing in research solutions with us, you can be part of the cures.

Your donation before June 30 will enable Australian scientists to speed-up discoveries, making new options for cancer patients available sooner.

PLEASE MAKE A TAX DONATION TODAY

Head shaving a big cancer fundraising trend this month!

Headshave

It’s definitely beanie weather! And it seems a lot of our cancer fundraising supporters are looking to add a little more room under those woolly hats by lopping off their lovely locks to raise funds for cancer research.

Nicole Sharrin from WA shaved off her hair on June 16. She decided to take on the cancer fundraising challenge because “Too often these days I’m finding myself surrounded by those suffering with cancer,” Nicole said.

Continue reading “Head shaving a big cancer fundraising trend this month!”

June Appeal: Tax donations making new progress possible

Danielle-and-David-panelIn Australia, almost 50% of the population are expected to be diagnosed with cancer during their lifetime. The road ahead needs to be one of research and discovery, and that’s why we’re here.

The Australian Cancer Research Foundation is the only private charity exclusively funding the tools and technologies capable of getting to the core of this disease.

This June tax-time, we asked our supporters to contribute a series of tributes to the parents, partners, friends and children they have loved and lost to cancer. We would like to share them with you, not to bring you pain or sorrow, but because we know that everyone has a story like this to tell. These stories represent us all – each of us living, in some way, with the pain and fear of cancer.

We have the power to rewrite these experiences for the next generation. By investing in research solutions with us, you can be part of the cures.

Your donation before June 30 will enable Australian scientists to speed-up discoveries, making new options for cancer patients available sooner.

PLEASE MAKE A TAX DONATION TODAY

Today we celebrate a milestone…

30-year-anniversary-webpicSuddenly 30! Or at least that’s how it feels to us here at the Australian Cancer Research Foundation – how time has flown. On this day, 30 years ago in 1984, prominent Australians Sir Peter Abeles and the Late Lady (Sonia) McMahon established a Foundation with the hopes of one day finding the cures for, and eradicating, cancer.

The ACRF has since become a leading cancer charity and not-for-profit organisation in Australia, leveraging of the immense power and support of the community to enable major breakthroughs in cancer research.

Continue reading “Today we celebrate a milestone…”

June Research News 2014

JUNE-RESEARCH-NEWSLETTER-2014In this edition:

  • 10-year trial of melanoma vaccine shows most promising outcomes to date
  • Gene discovery could stop spread of cancer through lymphatic system
  • Global clinical trial shows promising results for lung cancer patients
  • Newly-discovered gene linked to oesophageal cancer

 

Men’s Health Week

6a00e0097e4e68883301a3fd1c9334970b-300wiThis week is Men’s Health Week. It’s about celebrating the many wonderful contributions that men bring to the community, while also bringing a focus to the health challenges that are specific to men.

Men’s Health week is about focusing on and improving the mental, physical and social health of boys and men in Australia.

Men are more likely to be diagnosed with cancer than women – one in two are expected to be touched by the disease in their lifetime.  That’s why the Australian Cancer Research Foundation is proud to be a part of a men’s health awareness campaign which promotes awareness and research into the cancers which most affect men –  – not just prostate and testicular cancer, but also bowel, lung, liver, pancreatic and others.

Continue reading “Men’s Health Week”

Gene discovery could stop spread of cancer

Research-Image4_JLockLHammond1Scientists from The University of Queensland’s Institute of Molecular Bioscience (IMB) have discovered a gene called ccbe1 that could be targeted to help stop the spread of cancer.

Cancer scientist from IMB, Dr Ben Hogan, led a team that discovered how the gene works to.

“Lymphatic vessels carry lymph fluid around the body, transporting important substances like white blood cells, dietary fats and filtering excess fluid from our tissues back into our blood stream,” Dr Hogan said.

Continue reading “Gene discovery could stop spread of cancer”

Non-invasive laser technology could help bypass the need for biopsies

911561-melanomaEngineers and researchers from the University of Queensland have collaborated with the University of Leeds in England to create a new method of skin cancer detection that bypasses the need for biopsies.

Lead researcher, Dr Yah Leng Lim, from The University of Queensland’s School of Information Technology and Electrical Engineering, is a key member of the team that developed the ground-breaking laser imaging system that safely provides a different view of skin structure.

Continue reading “Non-invasive laser technology could help bypass the need for biopsies”

June is Workplace Giving Month!

Workplace Giving (also known as payroll donations) allow staff to work together towards an important common goal that is completely outside of the organisation, yet significant to each and every Australian.

With June being Workplace Giving Month, it’s a great time for organisations to get their employees involved in giving regular, pre-tax donations from their salary. Implementing such an important community-focused giving system will work wonders for your company reputation, and staff retention.

Continue reading “June is Workplace Giving Month!”

World No Tobacco Day

134128418-Quit-smoking_51ae76fa8dbbb-300x199Every 31st of May, The World Health Organisation (WHO) marks World No Tobacco Day, to highlight the health risks associated with tobacco use, and advocate for effective policies to reduce tobacco consumption.

Tobacco kills nearly six million people each year, of which more than 600 000 are non-smokers succumbing to second-hand smoke.

Lung cancer, which can be associated with smoking tobacco, is one of the most common causes of cancer death for men and women in Australia.

Continue reading “World No Tobacco Day”

ACRF supporters Run For A Reason and raise over $70,000!

From the serious runners to The Incredible Hulk, thousands of runners hit the pavement to take part in the fifth annual HBF Run For A Reason in Perth on Sunday.

A record number of people took part with nearly 30,000 runners – some in costume, others decked out in t-shirts displaying the faces or names of loved ones they were running for – taking on the 4km and 12km courses.

The ACRF was lucky enough to have 104 runners support cancer research in Australia, with team ACRF raising over $70,000! We would like to send a big thank you to all of our fundraisers for all their hard work and fundraising efforts!

Continue reading “ACRF supporters Run For A Reason and raise over $70,000!”

ACRF Canberra supporters tour the John Curtin School of Medical Research

Last week our valued supporters in Canberra attended an afternoon tour of the esteemed John Curtin School of Medical Research (JCSMR).

Our 27 guests were treated to a lovely afternoon tea, where they heard from respected ACRF board member, Air Chief Marshal Angus Houston AC AFC (ret’d) as well as head of the Cancer and Vascular Biology Group, at JCSMR, and 2014 Canberra Citizen of the Year, Professor Chris Parish.

Our supporters were then split into two groups and taken on a tour around the John Curtin School of Medical Research.

Continue reading “ACRF Canberra supporters tour the John Curtin School of Medical Research”

Skin Cancer Prevention – Promising Results

A study by researchers at Brisbane’s QIMR Berghofer Medical Research Institute has revealed some very promising statistics about one of Australia’s most deadly cancers – Melanoma.

With an estimated 12,000 people diagnosed with melanoma in 2012 it is Australia’s third most common cancer type.

The study, which analysed melanoma cases among 15 to 24 year olds in Queensland from 1982 to 2010, has shown there has been a five per cent a year decline among teenagers and young adults developing the disease from the mid-1990s to 2010.

Additionally, for people aged 20 to 24, the rate has fallen from 25 cases per 100,000 in 1996 to 14 per 100,000 in 2010.

Continue reading “Skin Cancer Prevention – Promising Results”

Half marathon runners raise over $83K for cancer research in Aus!

12,000 runners hit the pavement on Sunday for the 23rd annual Sydney Morning Herald Half Marathon

Competitors, geared up for their 21.1 km journey, were seen off by official event ambassador Stephanie Rice, who fired the starting gun.

Runners were presented with a beautiful morning in Sydney as they raced, jogged or walked their way from St Mary’s Cathedral, past some of Sydney’s most iconic landmarks including the Royal Botanic Gardens, Harbour Bridge and the Sydney Opera House.

The Australian Cancer Research Foundation was lucky enough to have 83 dedicated runners choose to be a part of the ACRF Half marathon team! And what a fantastic job they all did!

Continue reading “Half marathon runners raise over $83K for cancer research in Aus!”

ACRF welcomes distinguished scientist and businessman, Dr. Ian Brown, as new CEO

Today we are very excited to announce the appointment of distinguished scientist and businessman, Dr Ian Brown, as the new leader of the Australian Cancer Research Foundation.

Dr Brown will succeed long-serving CEO David Brettell who retires from ACRF on 10 July 2014.

Dr. Brown was the former CEO and Managing Director of the highly successful Clover Corporation, which focused on bio-delivery systems for nutritionally important ingredients and which is publicly listed on the Australian Stock Exchange.

Chairman of the ACRF, Mr. Tom Dery said, “Dr. Brown comes to us with considerable international experience.  His business acumen will help take ACRF to another level and we’re tremendously excited by the potential to further accelerate our contribution to world-class cancer research. We look forward to building on our crucial role in funding scientific breakthroughs of the future”

Continue reading “ACRF welcomes distinguished scientist and businessman, Dr. Ian Brown, as new CEO”

Newly-discovered gene linked to oesophageal cancer leads to potential new treatments

A newly-discovered gene linked to oesophageal cancer holds the promise of new treatments for this notoriously difficult-to-fight disease.

Researchers at Cambridge University in the UK have found a gene called TRIM44 which plays a key role in the development of oesophageal cancer. The discovery of this gene has also led to finding the disease’s key driver.

The new research has revealed that when multiple copies (called over-expressions) of the TRIM44 gene are found in a patient this leads to higher activity of the mTOR gene, which regulates cell growth and division – a process that, when uncontrolled, can lead to cancer.

Continue reading “Newly-discovered gene linked to oesophageal cancer leads to potential new treatments”

New leader for top Australian cancer research funding body

The Australian Cancer Research Foundation (ACRF) has appointed distinguished scientist and businessman Dr. Ian Brown as its new Chief Executive.

ACRF’s research grants, which will top the $100 million mark this year, have provided Australia’s best cancer scientists with the technologies, equipment and infrastructure needed to speed up discoveries and stay at the forefront of medical research.

ACRF Chairman Tom Dery said the foundation was thrilled to welcome Dr Brown who is currently an adjunct professor at Flinders University in Adelaide and special visiting professor at the University of Colorado in the US.

Continue reading “New leader for top Australian cancer research funding body”

ACRF hosts successful Corporate Social Responsibility breakfast event!

It’s all about creating shared value amongst stakeholders.

At least that was the topic of today’s successful Corporate Social Responsibility breakfast event with almost 50 corporate attendees looking forward to listening to this hot-topic discussion.

The ACRF was lucky enough to secure Deloitte’s Non-for-profit special group National Director, Tharani Jegatheeswaran, as the keynote speaker; as well as a panel discussion of leaders in the field of corporate philanthropy, including: Wendy Mason, Head of the Commonwealth Bank Foundation, Commonwealth Bank, Ro Coroneos, Manager, Community and Social Strategy, Barangaroo South, Lend Lease, Chris Drayton, Partner, Makinson & d’Apice Lawyers.

Continue reading “ACRF hosts successful Corporate Social Responsibility breakfast event!”

Saying thank you to our cancer charity volunteers during National Volunteer Week

This week we celebrate the power of volunteering with National Volunteer Week in Australia.

We would like to highlight the value our cancer charity volunteers bring to our communities and society. We are very thankful, humbled and honoured when members of our community, a group or a corporate partner chooses to dedicate their time and effort into volunteering for us.

Continue reading “Saying thank you to our cancer charity volunteers during National Volunteer Week”

Promising results in world-first trials for aggressive brain cancer treatment

A major breakthrough in the treatment of aggressive brain cancer called Glioblastoma Multiforme (GBM), using immunology has been made by scientists at the QIMR Berghofer Medical Research Institute.

Glioblastoma Multiforme (GBM) is the most common malignant brain cancer, diagnosed in about 800 Australians every year with, unfortunately very low five year survival rates.

The research used immunology to attack the cancer, and found that of the study participants lived much longer than the six-month prognosis normally given to a patient with recurrent GBM. Some patients showed no signs of disease progression at all.

Continue reading “Promising results in world-first trials for aggressive brain cancer treatment”

Have a Cuppa for Cancer and help fund research into prevention, diagnosis and cures!

This month, why not get a group together for a morning (or afternoon) tea party and support world-class cancer research?

With cancer being labelled the world’s number one killer – affecting people of all ages and backgrounds, the ACRF is often approached by community groups who wish to raise funds for cancer research.

We are humbled and motivated by this dedication and so we’ve thought of a fun and inspirational way you and your community group can join in the fight against all cancers – and the Cuppa for Cancer event was born!

Continue reading “Have a Cuppa for Cancer and help fund research into prevention, diagnosis and cures!”

Mother’s Day gift ideas for mum

We’ve got the perfect solution for those of you looking for Mother’s Day gift ideas that will make mum feel incredibly special!

With Mother’s Day coming up this Sunday, why not consider a Mother’s Day gift to cancer research? – It’s the perfect way to celebrate life and give new hope for the future.

This Mother’s Day gift is so simple – all you need to do is make a donation in lieu of gifts for your Mum. This way, your donation will go to research that has the power to beat all types of cancer, bringing new hope to cancer patients and their families around the world.

Continue reading “Mother’s Day gift ideas for mum”

Hidden Door challenges help cancer research through corporate charity donations!

It’s all about engaging businesses with their most valuable assets; their staff and their clients. And with the ACRF partnering with leadership and development company, Hidden Door, our corporate supporters can achieve this while delivering on their corporate social responsibility goals.

Hidden Door allows organisations to provide corporate charity donations to world-class class cancer research in Australia through a fun, engaging and beneficial program customised specifically for their staff.

The ACRF and Hidden Door have joined together to bring two great programs which, by raising corporate charity donations, will provide your team with a sense of pride while teaching them great leadership and team building skills.

Continue reading “Hidden Door challenges help cancer research through corporate charity donations!”

Streetsmart Marketing helps “Secure the future” for cancer research in Australia!

Strength in Numbers“Secure the Future” was a three day super-conference that took place in February in Sydney and Brisbane. In a massive act of generosity, the event organisers donated the cost of the base ticketing price to world-class cancer research in Australia!

Mal Emery, CEO of Streetsmart Marketing and Co-Founder of “StreetSmart Business School” chose the Australian Cancer Research Foundation as the beneficiary of this event and has raised an incredible $70,000 through ticket sales, to help in the fight against cancer.

Continue reading “Streetsmart Marketing helps “Secure the future” for cancer research in Australia!”

Community set to brew a world record for charity

Local beer lovers will be gathering together this Sunday as a potential world record is set to be brewed in Brunswick, Melbourne.

The Thunder Road Brewing Company will be holding its third community day this Sunday, May 4 and this time will have a charity brew to raise money for the Australian Cancer Research ­Foundation.

Anyone who wants to try their hand as a brewer, members of the community and all-round beer lovers can come along on the day and, for a $10 donation, help with tasks including grinding the malt, adding hops and temperature control.

Continue reading “Community set to brew a world record for charity”

Monster raffle and sausage sizzle brings community together for research

Natasha Tiedt has astounded us with what can only be achieved by the power of the community.

Together with her colleagues at Lynch’s Pub in Narooma, NSW, Natasha has organised a fantastic cancer fundraising raffle and sausage sizzle – rallying families and businesses within the community to contribute an incredibly generous $7,400+ for world-class cancer research!

Natasha instigated the monster raffle event to raise funds for world-class cancer research in Australia after seeing members of her own family and the Lynch’s Pub family and patrons fight various battles with cancer.

Continue reading “Monster raffle and sausage sizzle brings community together for research”

Powerful predictor discovered for aggressive breast cancers will ensure more effective treatment

A new, more powerful predictor for aggressive breast cancers, discovered by Dr Fares Al-Ejeh at QIMR Berghofer Medical Research Institute, will give women a more accurate prognosis and ensure they are receiving the most effective treatment for their breast-cancer type.

Every woman’s breast cancer has its own individual gene fingerprint – a specific combination of genes. Dr Al-Ejeh’s research has found new gene “signatures” which can predict likely survival across breast cancer cases.

Continue reading “Powerful predictor discovered for aggressive breast cancers will ensure more effective treatment”

10-year trial of melanoma vaccine shows most promising outcomes to date

Researchers at the University of Adelaide have discovered a new trial vaccine which offers the most promising treatment to date for advanced melanoma.

Known as ‘vaccinia melanoma cell lysate’ (VMCL), this new trial treatment was given regularly to 54 South Australian patients with advanced, inoperable melanoma over a 10-year period. The vaccine has been found to increase patient survival rates, with the ability to stop or reverse the cancer in some patients.

Continue reading “10-year trial of melanoma vaccine shows most promising outcomes to date”

International marathon season has kicked off!

We’ve just finished cheering on our group of amazing runners as they took on the streets of Paris and London for their epic marathon charity challenges. Together, they raised over $70,000 for world-class cancer research – incredible!!

Now, having witness some of the buzz, marathon runners all over the world are gearing up to secure a spot in next year’s international marathons.

Places for both the London and Paris Marathon are hard to come by. Last year the London Marathon ballot closed in record time, after 125,000 applications were received in less than 12 hours. Only 40,000 odd will get selected to take on the exciting course.

Continue reading “International marathon season has kicked off!”

Cancer patients could benefit from blood disorder treatment

Cancer scientists at the Walter and Eliza Hall Institute (WEHI) have recently discovered an existing treatment for a blood disorder could potentially also treat stomach and bowel cancer – two of the most common cancers worldwide.

Pre-clinical trials have found an existing class of medicines called ‘JAK inhibitors’ reduce the growth of inflammation often associated with stomach and bowel cancer.

JAK inhibitors are currently being used to treat myelofibrosis and are currently in clinical trials for the treatment of other conditions such as leukaemia, lymphoma, lupus and rheumatoid arthritis.

By understanding the way molecules are involved in promoting the survival and growth of cancer cells, researchers have been able to identify which of these molecules can be targeted with potential anti-cancer treatments.

The research team at WEHI discovered that certain types of bowel and stomach cancer were influenced by proteins, called JAKs, which helped with the cancer growth and formation.

Dr Emma Stuart, Dr Tracy Putoczki and Associate Professor Matthias Ernst from the WEHI made this discovery.

“It was exciting to discover that when JAKs were blocked with existing medications (JAK inhibitors), bowel and stomach cancer growth in experimental models was slowed, and many of the cancer cells were killed,” Dr Stuart said.

The discovery of JAK inhibitors has stemmed from research into the links between inflammation and cancers of the digestive tract.

“Recently we have begun to unravel the complex signalling that occurs in inflamed tissues, such as when a person has a stomach ulcer or suffers from inflammatory bowel disease, and how this drives cancer development,” said Dr Stuart.

This discovery of a treatment that already exists which can be safely and successfully inhibited in patients is very promising.

The Australian Cancer Research Foundation is dedicated to funding research which leads to better treatment outcomes for all types of cancer, and we are proud to have provided millions of dollars in funding to the team of researchers working at Melbourne’s WEHI.

These findings have been published in the journal Molecular Cancer Therapeutics.

ACRF Skydiving charity challenge opens again for 2014!

If a 60 second free fall from impossible heights sounds like your cup of tea, then it’s time to sign up for our most hair-raising fundraiser yet!

The ACRF is taking to the skies once again with our Jump! campaign, and we’re looking for fearless skydivers from all over Australia to help us raise vital funds for world-class cancer research.

This year we have four adrenaline fuelled days lined up across Aus and each skydiving charity challenge is bound to be filled with great memories. Fly solo or pull a team of friends together for any of the below dates. Either way, you know it’s going to be an experience you’ll never forget!

  • Byron Bay: June 14 (closest JUMP! location to Brisbane and Gold Coast)
  • Perth: August 24
  • Wollongong: September 7 (a special Father’s Day Jump!)
  • Melbourne: November 15

Continue reading “ACRF Skydiving charity challenge opens again for 2014!”

Global clinical trial shows promise for new lung cancer treatment

Young lung cancer patients in Victoria have become some of the first in the world to benefit from a new targeted therapy which has minimised tumours and improved symptoms in a Phase I clinical trial.

The global clinical trial tested 130 patients with a specific type of lung cancer, containing a change in a gene called ALK.

The ALK gene has been found to create “immortal” cells which never seem to switch off, meaning they are constantly in over-drive, growing and proliferating. A tablet therapy, called ceretinib works as an ALK inhibitor, shrinking tumours and resolving symptoms of the cancer.

Continue reading “Global clinical trial shows promise for new lung cancer treatment”

Claire loses her luscious red locks for cancer research

When your hair is almost long enough to sit on, it’s a big deal to trim an inch or two let alone shave it all off!

However, Claire Purio from Fremantle did just that. She took a number 2 razer to her long red hair at the Mt Claremont Famers Market on March 22, and through this brave gesture of support for her father, who is still grieving the loss of his mother, Claire raised almost $3,500 for cancer research.

Claire’s story into why she is shaving her head is incredibly touching.

Continue reading “Claire loses her luscious red locks for cancer research”

#NoMakeUpSelfie campaign for cancer research

In just a few days we were overwhelmed with support for the #NoMakeUpSelfie campaign for cancer research. The power of social media is incredible!

In just over a week the #NoMakeUpSelfie supporters helped raise over $25,000 for cancer research in Australia!

The #NoMakeUpSelfie campaign for cancer research was one of the biggest viral social media campaigns for 2014. Women all over the world are posting makeup-free selfies online with the hashtag #nomakeupselfie, before making a donation to cancer research, and spreading the word by nominating their friends to do the same.

The campaign started over in the UK with Cancer Research UK using the movement to raise vital dollars for cancer research – and now it has reached Australian shores!

Continue reading “#NoMakeUpSelfie campaign for cancer research”

Fighting cancer during NSW Seniors Week

Saturday 15 March to Sunday 23 March marks NSW Seniors Week, during which we are getting in touch with a very special group of people who are fighting cancer as volunteers, donors and supporters!

NSW Senior’s Week is an annual celebration featuring hundreds of events held across NSW by government, community and commercial organisations.

There’s something new for everyone to enjoy – art, technology, entertainment, health, wellbeing, sport and of course, giving to charity! One of the highlights of the week is the Seniors Week Expo held at the Qantas Credit Union Arena (The Entertainment Centre) which includes the Premier’s Gala Concerts and expo stalls.

Continue reading “Fighting cancer during NSW Seniors Week”

March Research News 2014

MARCH-RESEARCH-NEWSLETTER-2014March Research Newsletter 2014

In this edition:

  • New targeted therapy for adult leukaemia enters next trial phase
  • Australian study reinforces HPV vaccine is saving lives
  • Ovarian cancer markers to improve outlook for patients
  • Stomach and bowel cancers respond to existing medication

 

Birthday fundraiser sees Rob Kendall, 76, take the plunge for cancer research!

Free falling through the air at almost 200km per hour isn’t everybody’s cup of tea.

However, ACRF supporter and cancer survivor, Robert Kendall, on 15 March, will be conquering his fear of heights and skydiving for cancer research.

Robert will also be doing this in celebration of his 76th birthday!

Continue reading “Birthday fundraiser sees Rob Kendall, 76, take the plunge for cancer research!”

Help fund cancer research through an international charity challenge!

Achieve something you never thought possible, and help cancer scientists to fight cancer, by funding cancer research through an international charity challenge!

In 2015 The Australian Cancer Research Foundation has linked up with World Expeditions to bring you four amazing and life changing charity challenges that will test you physically, emotionally and of course, support the search for cancer cures.

We’ve got 3 trekking charity challenges and one cycling charity challenge located across the globe, with our first option located a little more close to home.

Continue reading “Help fund cancer research through an international charity challenge!”

International Women’s Day: celebrating the women who help bring us closer to the cancer cures!

Annually on 8 March, thousands of events are held throughout the world to inspire women and celebrate their achievements for International Women’s Day.

Here, at the ACRF, we want to acknowledge the amazing and inspirational women who are on our Board of Trustees and our world-class Medical Research Advisory Committee (MRAC) and showcase their fantastic work.

Each of these women is not only extremely successful in their field but are also helping us inch ever closer towards finding the cancer cures through their involvement with the ACRF.

Continue reading “International Women’s Day: celebrating the women who help bring us closer to the cancer cures!”

Study reinforces HPV vaccine is saving lives

Researchers at QIMR Berghofer Medical Research Institute and the University of Queensland have found young women who received the HPV vaccine are far less likely to develop high-risk abnormalities that can lead to cervical cancer.

They used Queensland Health datasets to show these women had a 46 % lower risk of developing high-grade changes in the cervix, compared with women who had not been vaccinated.

Cervical cancer is one of the most common causes of gynaecological cancer, killing more than 200 Australian women every year.

Continue reading “Study reinforces HPV vaccine is saving lives”

Starving cells could treat one of Australia’s deadliest diseases

Australia has the highest rate of melanoma, globally. It is the deadliest form of skin cancer, and is the third most common cancer type in Australia.

But Australian researchers at the Centenary Institute have bought hope to this statistic through the discovery that we could potentially treat, and even cure, melanoma by cutting off its food source.

Last year the same team of researchers, led by Professor Jeff Holst, showed they could starve prostate cancer cells. This discovery has opened up the prospect of a class of drugs that could treat a range of cancers, including melanoma, in the same way.

Continue reading “Starving cells could treat one of Australia’s deadliest diseases”

Australian Cancer Research Foundation secures support from internationally renowned researchers

With the World Health Organisation declaring cancer as the biggest cause of death globally, a leading national Australian charity has started paving the way towards greater global collaboration to help put an end to this disease.

The Australian Cancer Research Foundation today announces the addition of four world-class cancer researchers to their distinguished Medical Research Advisory Committee.  For the very first time, two researchers are based internationally.

Continue reading “Australian Cancer Research Foundation secures support from internationally renowned researchers”

Make the most of your City2Surf by setting up an Online Fundraising campaign!

Everything is going digital nowadays and that includes fundraising for your chosen cancer charity!

Online fundraising is a simple, easy and effective way to raise funds and engage with potential donors.

The Australian Cancer Research Foundation has partnered up with a number of online fundraising portals, such as Everyday Hero and GoFundraise, to make your online fundraising experience as easy as possible.

With the 2014 City2Surf general entries opening up today, why not make your run even more meaningful by opening up an online fundraising page and sharing it with your family and friends?

Continue reading “Make the most of your City2Surf by setting up an Online Fundraising campaign!”

Existing blood disorder medicine shows promise in treating certain stomach and bowel cancers

Cancer scientists at the Walter and Eliza Hall Institute (WEHI) have recently discovered an existing treatment for a blood disorder could potentially also treat stomach and bowel cancer – two of the most common cancers worldwide.

Pre-clinical trials have found an existing class of medicines called ‘JAK inhibitors’ reduce the growth of inflammation often associated with stomach and bowel cancer.

JAK inhibitors are currently being used to treat myelofibrosis and are currently in clinical trials for the treatment of other conditions such as leukaemia, lymphoma, lupus and rheumatoid arthritis.

Continue reading “Existing blood disorder medicine shows promise in treating certain stomach and bowel cancers”

David Blumenthal smashes the Melbourne Half-Ironman Challenge!

ACRF supporter, David Blumenthal, has tackled one of his biggest challenges yet – the Challenge Melbourne Half Ironman, on one of the hottest days in Melbourne this year – a scorching 41 degrees!

A far cry from the raining, cool weather of last year’s Paris Marathon, this fundraising challenge took place in summer heat so severe that the race organisers advised that there would be a good chance the race will be called off for those not finished by 12:30pm.

At this point David was faced with a decision: take an easier challenge due to the weather, or brave the scorching conditions and power through the full Half-Ironman Challenge of 1.9km swim, 90km bike ride and 21.1km run!

Continue reading “David Blumenthal smashes the Melbourne Half-Ironman Challenge!”

David Blumenthal smashes the Melbourne Half-Ironman Challenge!

ACRF supporter, David Blumenthal, has tackled one of his biggest challenges yet – the Challenge Melbourne Half Ironman, on one of the hottest days in Melbourne this year – a scorching 41 degrees!

A far cry from the raining, cool weather of last year’s Paris Marathon, this fundraising challenge took place in summer heat so severe that the race organisers advised that there would be a good chance the race will be called off for those not finished by 12:30pm.

At this point David was faced with a decision: take an easier challenge due to the weather, or brave the scorching conditions and power through the full Half-Ironman Challenge of 1.9km swim, 90km bike ride and 21.1km run!

Continue reading “David Blumenthal smashes the Melbourne Half-Ironman Challenge!”

Show how much you care with a Valentine’s Day donation

With Valentine’s Day coming up this Friday, we’re sure most of you have already wrapped up a lovely gift, organised a delivery of a roses, booked in a dinner or organised a special surprise for your Valentine.

After all, Valentine’s Day is a day to celebrate and cherish the special person you care about most, whether they know it or not!

However, if you’re still wracking your brain for a gift that has meaning but is also original, why not look into truly spreading the love and giving a gift that has the power to change the world?

Continue reading “Show how much you care with a Valentine’s Day donation”

Show how much you care with a Valentine’s Day donation

With Valentine’s Day coming up this Friday, we’re sure most of you have already wrapped up a lovely gift, organised a delivery of a roses, booked in a dinner or organised a special surprise for your Valentine.

After all, Valentine’s Day is a day to celebrate and cherish the special person you care about most, whether they know it or not!

However, if you’re still wracking your brain for a gift that has meaning but is also original, why not look into truly spreading the love and giving a gift that has the power to change the world?

Continue reading “Show how much you care with a Valentine’s Day donation”

Scott Eastburn sets an epic physical challenge for 2014!

Scott Eastburn is back on his cancer fundraising mission. Having set himself the challenge of competing in one of the most famous international marathons – the London Marathon – last year, Scott has again pledge to help fight cancer through a series of physical challenges.

In 2014, Scott will be participating in 20 endurance events – 14 of which will be marathons throughout Australia, New Zealand, France and England!

Scott is calling this his “20:14 in 2014 Challenge” and has already kicked it off by completing the Cadbury Marathon down in Hobart.

Continue reading “Scott Eastburn sets an epic physical challenge for 2014!”

Scott Eastburn sets an epic physical challenge for 2014!

Scott Eastburn is back on his cancer fundraising mission. Having set himself the challenge of competing in one of the most famous international marathons – the London Marathon – last year, Scott has again pledge to help fight cancer through a series of physical challenges.

In 2014, Scott will be participating in 20 endurance events – 14 of which will be marathons throughout Australia, New Zealand, France and England!

Scott is calling this his “20:14 in 2014 Challenge” and has already kicked it off by completing the Cadbury Marathon down in Hobart.

Continue reading “Scott Eastburn sets an epic physical challenge for 2014!”

Ovarian Cancer Awareness month kicks off with significant discovery

We begin Ovarian Cancer Awareness Month with news of fantastic progress by researchers at Queensland University of Technology (QUT), who have made significant headway into understanding one of the deadliest forms of the disease.

These Aussie cancer scientists have identified two enzymes that make serous ovarian cancer resistant to chemotherapy, and can be targeted to improve treatment results.

Serous ovarian cancer is generally an aggressive type of cancer. Due to its location it can move quickly from the ovaries to the abdominal cavity where it then spreads throughout the body quite rapidly.

Continue reading “Ovarian Cancer Awareness month kicks off with significant discovery”

Ovarian Cancer Awareness month kicks off with significant discovery

We begin Ovarian Cancer Awareness Month with news of fantastic progress by researchers at Queensland University of Technology (QUT), who have made significant headway into understanding one of the deadliest forms of the disease.

These Aussie cancer scientists have identified two enzymes that make serous ovarian cancer resistant to chemotherapy, and can be targeted to improve treatment results.

Serous ovarian cancer is generally an aggressive type of cancer. Due to its location it can move quickly from the ovaries to the abdominal cavity where it then spreads throughout the body quite rapidly.

Continue reading “Ovarian Cancer Awareness month kicks off with significant discovery”

This World Cancer Day we pledge to help debunk the myths!

February 4 is a day where we have the chance to raise our collective voices in the name of improving our understanding of cancer: of getting to know the risks and, importantly, overcoming misconceptions about this terrible disease.

World Cancer Day is an international movement held at the same time every year and is an opportunity for the entire world to join together in the fight against cancer.

Continue reading “This World Cancer Day we pledge to help debunk the myths!”

Brisbane Broncos legends hit the softball diamond to play for a cure

When it comes to raising funds for a good cause, NRL Broncos legends Allan Langer, Darren Lockyer, Kevin Walters, Gorden Tallis, Ben Ikin and Shane Webcke are ready to step off the footy field and into a whole new ball game.

An exciting softball event, hosted by the Play for a Cure Foundation, will see the Brisbane Broncos stars go head-to-head with a team of seasoned Softball stars.

Continue reading “Brisbane Broncos legends hit the softball diamond to play for a cure”

Streetsmart Marketing aims to raise 100K for cancer research in Australia

In a massive act of generosity, “Secure the Future”, a three day super-conference, is donating its base ticketing price to world-class cancer research in Australia!

Mal Emery, CEO of Streetsmart Marketing and Co-Founder “StreetSmart Business School” chose the Australian Cancer Research Foundation as the beneficiary of this event due to his very humbling experiences with cancer.

“Like most people, my company StreetSmart Business School has been touched by cancer – deeply,” Mal told us.

Continue reading “Streetsmart Marketing aims to raise 100K for cancer research in Australia”

Say thank you to Aussie cancer researchers this Australia Day!

On our national holiday, Australia Day, we come together to celebrate what’s great about Australia. It’s a day to reflect on what we have achieved as a nation and what we should be proud of in our great country.

Australia Day is the day where we re-commit to making Australia an even better place for the future! So why not take this day to celebrate all the amazing things our Aussie cancer researchers have helped to achieve over the years!

If you’re celebrating Australia Day at home with a group of mates and a BBQ why not make it a fundraising event? Ask everyone to chip in and donate to a cause that is helping cancer researchers in Australia take one step closer towards the cancer cures.

Continue reading “Say thank you to Aussie cancer researchers this Australia Day!”

The Fatman’s Great Aussie Trek from Geelong to Cairns comes to an end!

Brendon had always dreamt about walking around Australia.

After seeing a man and woman walking along the road in his home town for charity he was inspired to do the same. Five weeks later Brendon and his faithful dog, Jojo, set out on “The Fatman’s Great Aussie Trek”!

Weighing in at just over 145kgs, Brendon felt it was time to do something about his health – while also giving to a cause that would help the health of others.

Continue reading “The Fatman’s Great Aussie Trek from Geelong to Cairns comes to an end!”

Experience the rainbow with this cancer fun run!

Is one of your New Year’s resolutions to become more active, healthier or fitter? Why not kick start your 2014, and your resolution, with a cancer fun run with a difference?

Color Me Rad is a 5km cancer fun run where participants are showered in colour as they race towards the finish line!

Color Me Rad has announced its inaugural Australian race on February 23 at Sydney’s Motor Sport Park out at Eastern Creek. In this un-timed event, the focus is purely on fun, and the fitness is an added bonus! What better way to kick off a health and fitness goal?

Continue reading “Experience the rainbow with this cancer fun run!”

Tokyo to Osaka: A 36 hour fundraising cycle to bring in the New Year!

“It’s for my Great Aunt Lynn, and the thousands of other brave souls in the world facing their personal battle against cancer, that I am undertaking this challenge.”

This was ACRF supporter Andrew’s New Year’s Resolution for 2014. When he found out in December that his beloved Great Aunt Lynn had been diagnosed with terminal ovarian cancer, Andrew knew he had to do something to show his support and love for a woman who had been such an inspiration to him; a woman he described as “brave, pure and a kind-hearted fighter”.

Continue reading “Tokyo to Osaka: A 36 hour fundraising cycle to bring in the New Year!”

70% of cancer patients have new hope through WEHI discovery

A discovery led by Australian researchers at Melbourne’s Walter and Eliza Hall Institute (WEHI) has given new hope to those suffering from certain types of lymphomas as well as other types of blood cancers and some solid tumours.

For these types of cancers, which are driven by a cancer-causing protein, ‘MYC’, Dr Gemma Kelly, Dr Marco Herold, Professor Andreas Strasser and their research team at WEHI have uncovered a promising treatment strategy.

MYC affects up to 70 per cent of human cancers, including many leukaemias and lymphomas. It is responsible for cancerous changes in cells by forcing them into abnormally rapid growth. But the WEHI research team have discovered that MYC activity is co-dependent on another protein, called MCL-1.

Continue reading “70% of cancer patients have new hope through WEHI discovery”

What’s your New Year’s Resolution?

Have you made any New Year’s Resolutions yet?

Making New Year’s Resolutions is one of the best ways to get started  on your path towards self-improvement, transition and promise for the future.

Below we’ve put together a short list of some fun and creative resolutions you might want to adopt – or adapt! But don’t be distracted if you think you’ve seen them before because our little twist to these gems is that every single one of them can contribute to the fight against cancer!

Continue reading “What’s your New Year’s Resolution?”

Happy New Year – 2014

We wish all of our wonderful donors and supporters a very Happy New Year. After a quick break for Christmas, the ACRF office is once again humming with activity – we’re very excited for what 2014 will bring!

Of course, this year, our mission is to fund even more cancer research in Australia, helping our cancer scientists to take leaps and bounds in the lab, towards better treatments and cures for all types of cancer. The technologies and equipment we fund are designed to speed up this very important discovery process, and we are confident that we will be able to share many promising research developments with you this year.

Each of us has a role to play in the defeat of cancer, and at the Australian Cancer Research Foundation, we are always hoping to meet our passionate supporters. Please phone us at any time if you would like to make a donation, or get active in your community by taking part in a fundraising event. We’d love to hear from you – 1300 884 988; info@acrf.com.au.

Wishing you all the best for a positive start to 2014,

From the ACRF team.

Thank you and Merry Christmas

From all of us here at the ACRF, we wish you and your loved ones a very happy and safe holiday this Christmas. 2013 has been a terrific year with some truly exciting advances in cancer research. We thank you very much for your support!

Please note we will be taking a short break over the Christmas holiday, with our office closing at COB Friday 20 December, 2013 and reopening on Thursday 2 January, 2014.

If you would like to donate during this time (either in lieu of Christmas gifts or as a way of generating some positive karma for the New Year) please be sure to do so via our secure web portal where our online elves will be working hard to process your kind donations and issue your receipts.

As a final thank you for all your support this year we’ve put together this short video below. We look forward to staying in touch throughout 2014.

Unprecedented success in trialling new adult leukaemia therapy

A new, potentially life-saving drug has raised new hope for patients in advanced stages of chronic lymphocytic leukaemia – one of the most common types of adult leukaemia in Australia.

In many cases this cancer becomes resistant to traditional treatment methods such as chemotherapy. This is because of its high levels of a “pro-survival” protein called BCL-2 that render cancer cells, according to Walter and Eliza Hall Institute haematologist Prof. Andrew Roberts “basically indestructible”.

Continue reading “Unprecedented success in trialling new adult leukaemia therapy”

Pirates of the Cure-ibbean take on the Surf Swim Charity Challenge!

Pirates were spotted on Dee Why Beach a few weeks ago! However, it wasn’t Captain Jack Sparrow of the Black Pearl but Christine and her team of swash-buckling Pirates of the Cure-ibbean!

Located at the beautifully picturesque Dee Why Beach, the Sun Herald Surf Swim charity challenge attracts hundreds of swimmers, looking to take on  the 800m or 1.5km course for a charity of their choice.

Continue reading “Pirates of the Cure-ibbean take on the Surf Swim Charity Challenge!”

Why not make the most wonderful time of the year even more special?

It’s that time of the year again! All over Australia shopping strips are decked with Christmas wreaths, baubles and tinsel; Christmas trees glitter with lights, and carols ring through every store!

At the ACRF we are all excited about getting into the spirit of Christmas and looking forward to spending time with family and friends. But in the search for the perfect gifts, sometimes the Christmas retail rush can get intimidating, even overwhelming, especially are we get closer to the big day!

Continue reading “Why not make the most wonderful time of the year even more special?”

Michael Gunter climbs to beat cancer

Imagine clinging to a rock-face over 100m off the ground when all of a sudden it starts to snow…

This is just one of the challenges ACRF supporter, Michael Gunter, had to deal with while completing two big climbs in NSW’s Blue Mountains region.

Michael’s decision to do something extraordinary for cancer research is an inspirational story, showing true strength and determination throughout a harrowing cancer journey.

Only months ago, Michael completed chemotherapy treatment for Hodgkin lymphoma.

Continue reading “Michael Gunter climbs to beat cancer”

$8.4 Million in funding for some of the best cancer research innovations in Australia!

The Australian Cancer Research Foundation has acknowledged the promising future of cancer research in Australia, announcing $8.4million in grants to progress the work of four of the country’s most innovative research initiatives.

In an exciting first, the $8.4m will be shared between research teams from four separate Australian states. The funding will provide each research team with state-of-the-art technologies and facilities, the scope of which have the potential to make significant discoveries in the understanding and management of cancer.

CEO of the ACRF, David Brettell says “Never before have we so many such world-class proposals for cancer research, with applications for our grants this year totalling almost $50 million.”

Continue reading “$8.4 Million in funding for some of the best cancer research innovations in Australia!”

Lunching with our long-term and most loyal supporters

Every year, the ACRF Planned Giving team invites some of their most loyal and longest standing supporters to a special lunch event to say a big thank you.

This year, two events took place, with 34 ACRF supporters enjoying a lovely local lunch at Harboard Diggers, and 40 gathering at Parramatta Leagues Club the following day.

The Sydney north lunch consisted of a most informative and inspiring presentation by Dr Darren Saunders from the ACRF funded Kinghorn Cancer Centre at the Garvan Institute of Medical Research.

Continue reading “Lunching with our long-term and most loyal supporters”

Qantas team tackle 27km coastal trek in just one day!

Unpredictable weather in NSW this month was no match for the dedication and commitment of 30+ Qantas team members who tackled a 27km coastal trek this weekend.

Lead by ACRF advocate and Qantas employee, Mina Masoumian, the ‘4th Annual Qantas 27km Coastal Walk’ kicked off bright and early, at 6:30am. The team set out to cover the coastline of the Royal National Park – from Otford to Bundeena – in just one day.

After several hours of clambering up and down rocky spurs, making tracks along some picturesque beaches and hopping over bubbling creeks the team finished up their challenging trek at around 3pm at the lovely Bundeena Wharf.

Continue reading “Qantas team tackle 27km coastal trek in just one day!”

ACRF is the official Charity Partner for first ever Color Me Rad cancer fun run in Sydney!

Eastern Creek in Sydney’s west is soon to be filled with all the colours of the rainbow when the very first Color Me Rad cancer fun run takes place on February 23!

A blaze of colour bombs, colour cannons and colour-themed courses will fill the skies during this 5km race!

This will be the first Color Me Rad event in Australia, and the ACRF is thrilled to be named the 2014 Official Charity Partner! We’re proud to be involved in helping to spread joy and happiness through explosions of colour while, at the same time, raising funds for world-class cancer research in Australia!

Continue reading “ACRF is the official Charity Partner for first ever Color Me Rad cancer fun run in Sydney!”

The City2Sea fun run returns to Melbourne!

The third annual City2Sea was run in Melbourne yesterday, with almost 14,000 taking on the sister event to one of the world’s largest runs – the famous City2Surf!

Elite runners, joggers and walkers from around Australia were joined by characters in fancy dress costumes, all enjoying a beautiful spring day and entertained with live music along the route.

Many participants ran for a cause close to their heart or in honour or memory of a loved one. The Australian Cancer Research Foundation was lucky enough to have 15 runners fundraise for them with over $13,500 raised for cancer research in Australia!

Continue reading “The City2Sea fun run returns to Melbourne!”

Giving regular charity donations through workplace giving!

One in two men and one in three women in Australia will be diagnosed with cancer by the age of 85. Each of us is keen to do our part to prevent both our loved ones and ourselves from facing this terrible disease, but often life gets in the way of us sitting down to make a donation.

Workplace Giving is one way to get around this. It’s a simple way for working Australians to make a big difference to cancer research via regular charity donations that are deducted from your payroll, before tax.

Employees can therefore enjoy an immediate tax benefit, while their regular charity donations work hard to make an important difference to our ability to fund cancer research.

Continue reading “Giving regular charity donations through workplace giving!”

“Cutting out Cancer” Rodeo helps raise funds for cancer research

Gundagai recently hosted a most successful campdraft rodeo event called “Cutting out cancer”, organised by local, Toni Hart, who is currently battling HER2 Breast Cancer.

Competitors and spectators were invited to wear pink to support the event, with $2 from every entry fee generously donated by the Gundagai Rodeo Club.

Continue reading ““Cutting out Cancer” Rodeo helps raise funds for cancer research”

Unravelling ovarian cancer reveals potential new treatment

Researchers have taken another step towards understanding ovarian cancer, and in treating one of the most lethal forms of this elusive disease.

The findings by researchers from Melbourne’s Peter MacCallum Cancer Centre build on the understanding that some ovarian cancers are driven by the deactivation of the BRCA 1 gene, especially those with high-grade carcinomas.

‘We now know ovarian cancer is a very diverse disease, analogous to a Russian babushka doll,” said Professor Bowtell, senior author of the study, which was published this week in Proceedings of the National Academy of Sciences.

“It looks like one doll until you take it apart and find layer after layer — but we’re confident when we have finally separated this cancer into all its molecular groups, we will have a much better chance of improving survival for all women.”

Continue reading “Unravelling ovarian cancer reveals potential new treatment”

Millions in funding unveiled for Australia’s best cancer research innovations

The Australian Cancer Research Foundation (ACRF) has announced the recipients of their annual Cancer Research Grants, collectively awarding $8.4m towards the newest innovations in Australian cancer research.

In its quest to beat cancer, the ACRF has awarded almost $95m to Australian cancer research institutes, making it the largest private funding body for cancer research in Australia.

Continue reading “Millions in funding unveiled for Australia’s best cancer research innovations”

ACRF hosts successful Roadshow for PepsiCo

The ACRF hosted its second Roadshow at PepsiCo last week to acknowledge and thank them for such a valuable corporate partnership!

Hundreds of PepsiCo staff members attended the event to listen to an ACRF Ambassador panel of four inspirational Aussie personalities: respected sports broadcaster, Tracey Holmes; former NSW Liberal Leader, Kerry Chikarovski; television sport presenter and commentator Simon Hill and inspirational speaker and cancer survivor Michael Crossland.

Continue reading “ACRF hosts successful Roadshow for PepsiCo”

Affinity Construction celebrates annual George Veitch Memorial Bowls Day

A lovely, sunny day down in Canberra saw over 50 people turn up for a friendly round of bowls and a barbecue lunch at Canberra Bowling Club.

The George Veitch Memorial Lawn Bowls Day at Canberra Bowling Club is put on every year by Affinity Construction Management, and it honours the life of one of the founders of the company, George Veitch, who sadly passed away after a short battle with cancer in 2008.

The ACRF was delighted to attend this special event and get to know the staff over a barbeque lunch and a few games of bowls. Organisers also put on a few raffles and pulled together some great prizes to be auctioned off.

Continue reading “Affinity Construction celebrates annual George Veitch Memorial Bowls Day”

Torch charity golf day a great success!

The amazing team at Torch Publishing have held their third annual Charity Golf event, in partnership with the Australian Cancer Research Foundation.

The 4 Ball Ambrose tournament, held on Friday 25 October at the Georges River Golf Course, brought together local community, business and sporting personalities to raise much needed funds for world-class cancer research.

Players of all golf handicaps produced a wonderful spectacle, putting on show their eagles, chip shots, backspins, albatrosses, birdies, and bogies!

Continue reading “Torch charity golf day a great success!”

Cancer research foundation funds new treatment centre

The University of Queensland Diamantina Institute has secured a $2 million grant from the Australian Cancer Research Foundation for a new cancer treatment centre in Brisbane.

The agreement between ACRF and UQDI for the Diamantina Individualised Oncology Care Centre (DIOCC) will mean improved research opportunities and outcomes for cancer patients.

The centre will be based at the Princess Alexandra Hospital and the Translational Research Institute.

Continue reading “Cancer research foundation funds new treatment centre”

Avril takes on the Venice Marathon in memory of Silvana

On Sunday 27 October, ACRF supporter Avril Henry took on one of the most famous and scenic marathons, the Venice Marathon, in Italy.

Avril is an avid runner and this year alone has raced in several endurance events raising funds for cancer research in Australia. The Venice Marathon was to be her last, as well as her most significant, charity challenge for the year.

Avril was running in memory of several loved ones that she lost to cancer last year – including her good friend from South Africa, Blanche, as well as her beloved neighbour and good friend, Silvana.

Avril told us, “Having completed all of my local events, I’m now going to Italy – to where Silvana is from – to honour her memory, her enormous capacity to love and her generosity of spirit. If I am able to make a difference to another friend, mother, sister or daughter in Silvana’s memory, that is all that I can hope for.”

Continue reading “Avril takes on the Venice Marathon in memory of Silvana”

VIC sees out our running season with a bang

As our Aussie running season comes to an end, Victoria is celebrating a couple of their last big marathons with the Melbourne Marathon Festival and the City2Sea.

More than 34,000 runners and walkers flooded to Melbourne CBD on October 13 for the Melbourne Marathon Festival, either tackling the challenge of the full or half marathons or enjoying the atmosphere and scenery of the shorter 10km and family runs.

The Australian Cancer Research Foundation was humbled to have 17 supporters, running to raising money for cancer research. Together, these dedicated supporters raised over $12,000, every dollar of which will go to Australian researchers to help in their search for the cures.

Continue reading “VIC sees out our running season with a bang”

Fundraising ideas for schools

With term four just having kicked off we’ve got some great fundraising ideas for schools looking to donate to charity and help in the fight against cancer!

The ACRF Schools Against Cancer campaign is a call for Australian schools to take action in the search for the cures. We need your help in making our fundraising ideas for schools happen so we can continue funding great progress in cancer research!

Australian cancer scientists are among the best and brightest in the world, and we at the Australian Cancer Research Foundation (ACRF) are proud to support their vital work into new treatments and cures for cancer.

Continue reading “Fundraising ideas for schools”

New therapy in trial minimises side effects for leukaemia patients

Australian researchers are trialing a drug which could bring new hope to people fighting adult leukaemia.

This drug, known as KB004, targets a protein which is only found in cancerous stem cells. It is undetectable on normal cells, so when the therapy is administered, it targets only cancerous cells, minimising side effects.

A team of Australian collaborators from ACRF-funded research institutes, including Dr. Martin Lackmann of Monash University, Melbourne; Dr. Andrew Boyd of QIMR Berghofer Medical Research Institute, Brisbane, and Dr. Andrew Scott of Ludwig Institute for Cancer Research, Melbourne, realised the potential of this protein – called EphA3 – as a drug target some years ago and successfully tested an antibody in their laboratories.

The drug KB004 has since been developed from this antibody, and clinical trials have commenced.

Continue reading “New therapy in trial minimises side effects for leukaemia patients”

Cancer researchers find prostate cancer “Achilles Heel” and move closer to a new treatment

An international group of scientists from Australia and Canada are getting closer to a new treatment for prostate cancer that works by starving tumours of an essential nutrient.

Dr Jeff Holst from Sydney’s Centenary Institute, and his colleagues from Adelaide, Brisbane and Vancouver have shown they can slow the growth of prostate cancer by stopping the protein ‘leucine’ from being pumped into tumour cells.

Leucine is involved in cell division and making proteins. It ‘feeds’ cell growth by being pumped through ‘protein pumps’ on the surface of our cells.

In 2011, Dr Holst and his colleagues showed that prostate cancer cells have more ‘protein pumps’ on their surface compared with normal cells. These pumps are allowing the cancer cell to take in more leucine, thereby stimulating overactive cell division.

Continue reading “Cancer researchers find prostate cancer “Achilles Heel” and move closer to a new treatment”

Top Australian researchers bid for ACRF grants

Millions of dollars in ACRF funding will soon be awarded to Australia’s top cancer research teams, with this week heralding our final stage of assessments.

Today and tomorrow, lead researchers from five shortlisted institutes will meet with the ACRF’s esteemed Advisory Committee (which is chaired by Professor Ian Frazer AC) for the final interviews which will ultimately determine the successful research teams.

Shortlisted applicants include two institutes from Sydney: the Children’s Cancer Institute Australia, and the Children’s Medical Research Institute, as well as the QIMR Berghofer Cancer Research Institute in Brisbane, the South Australian Health and Medical Research Institute in Adelaide, and the Victorian Comprehensive Cancer Centre in Melbourne.

Continue reading “Top Australian researchers bid for ACRF grants”

Goodman Group thinks outside the box with a corporate charity challenge at Cradle Mountain!

Many organisations are starting to combine philanthropic work with leadership development charity challenges, ensuring their staff members achieve a personal sense of fulfillment as well as a physical and professional one.

These charity challenges often include a fundraising goal, asking teams to work together to fulfill their campaign for cancer research.

Global property experts, Goodman Group, are currently preparing their leadership team for a six day charity challenge to Cradle Mountain, TAS, which will include all the bells and whistles: leadership workshops, physical endurance, and a $10,000+ fundraising target for world-class cancer research in Australia.

Continue reading “Goodman Group thinks outside the box with a corporate charity challenge at Cradle Mountain!”

October Is Breast Cancer Awareness Month: How ACRF Is Outsmarting Women’s Cancers this October

October is known around the world as Breast Cancer Awareness Month. The aim of Breast Cancer Awareness Month is to increase awareness of breast cancer and the impact it has as well as to raise much needed funds. To celebrate breast cancer awareness month, people engage in fundraising activities and purchase pink merchandise to raise money for this fantastic cause.

At ACRF however, we refer to October as our “Women’s Cancer Month” – a time where we raise awareness and much needed funds for all types of cancer that affect Australian women, as cancer statistics show 1 in 4 Australian women will be diagnosed with cancer before the age of 75.

Why we are determined to find better prevention, detection and treatment methods for women’s cancers

At ACRF, we are committed to improving prevention, diagnosis and treatment of all types of cancer. That is why, this October we are focusing on all cancers that affect women, not just breast cancer.

Every day up to 50 women in Australia are diagnosed with breast or gynaecological cancer. These cancer types include uterine, cervical, vulva and ovarian – cancers which are sometimes forgotten and unfortunately under-funded. Then there are other common women’s cancers which we need to remember this October: these include; bowel, lung and skin cancers.

We are committed to funding research through our grants and research projects into these cancer types, bringing new hope to our mothers, daughters, sisters, cousins and friends around the world.

Continue reading “October Is Breast Cancer Awareness Month: How ACRF Is Outsmarting Women’s Cancers this October”

Make regular charity donations and become a Partner in the Cure!

Aussies are renowned for being very generous and those who decide to make regular charity donations to cancer research are part of a VIP group of ACRF supporters known as “Partners in the Cure”.

Their generous monthly donation allows us to plan for a stable and supportive future for some of the best cancer researchers in Australia. These regular charity donations are helping us to fight cancer for patients (and their families) of this generation and the next.

Our Partners in the Cure are part of the ACRF family and many have decided to join our cause by providing their monthly donations in memory of a loved one they have lost.

Continue reading “Make regular charity donations and become a Partner in the Cure!”

ACRF’s first Blackmores Sydney Running Festival a wonderful success!

More than 32,000 runners and walkers flooded to Bradfield Park on Sunday 22 September to take on the Blackmores Sydney Running Festival.

As one of thirty charity partners, the ACRF was humbled that 260 of those people were participating in support of cancer research. They were running in memory or support of loved ones, either tackling the challenge of the full or half marathons or enjoying the atmosphere and scenery of the shorter bridge and family funs.

Together, our amazing supporters have generated over $50,000 for cancer research in Australia and, as this was our first official experience at the Blackmores event, we are so very grateful for the dedication and massive support we have received!

Continue reading “ACRF’s first Blackmores Sydney Running Festival a wonderful success!”

Aussie researchers find genetic cause to the most common form of childhood cancer

Australian researchers have uncovered the first ever genetic marker specific to acute lymphoblastic leukaemia (ALL), the most common childhood cancer.

Cancer scientists at the Children’s Cancer Institute Australia (CCIA) and Sydney Children’s Hospital, along with a worldwide team of researchers, discovered the genetic link by studying families in which multiple cases of ALL have been diagnosed.

Dr David Ziegler, Clinical Research Fellow at CCIA, paediatric oncologist at Sydney Children’s Hospital and lead Australian author of the research paper said, “Leukaemia cells often contain many different genetic mutations, making it difficult to detect which ones actually cause the leukaemia.”

Continue reading “Aussie researchers find genetic cause to the most common form of childhood cancer”

Canberra Cancerians roll out the Red Carpet for cancer research

One of the most prestigious events on the Canberra social calendar, the Canberra Cancerians Gala Dinner, has dazzled guests with its most glamorous offering to date.

Renowned as one of the most successful fundraising groups for cancer research in Australia, the Canberra Cancerians are an incredible group of volunteers who have raised more than $3.2 million for the ACRF.

They launched their first ball in 1987 and, very quickly, the event blossomed into one of the most sought-after events on Canberra’s social calendar.

This year’s function was an elegant red carpet affair, with a black and white theme. The committee took a different approach, compared with previous years, limiting ticket numbers and raising the stakes. And the event certainly did not disappoint.

Continue reading “Canberra Cancerians roll out the Red Carpet for cancer research”

Research news: spring 2013

In the spring edition of the Research Review:

  • Research advances building precision tools for diagnosis and cancer surgery.
  • Breast cancer treatment could be enhanced with an existing anti-leukaemia compound.
  • ‘Junk’ DNA and its role in cell growth and development

 

 

Pancreatic cancer researchers find important molecular similarity between cancer types

High levels of the HER2 molecule have been identified in 2% of pancreatic cancer cases – indicating new treatment options could be possible via an existing therapy.

Pancreatic cancer is one of the most devastating cancer types, with a five year survival rate of less than 5%. It is also one of the most elusive cancers, with significant variability in molecular behaviour across cases, which dictates how the cancer behaves.

This means that each tumour will only respond to treatments that target its unique molecular blue-print.

But new research, supported with significant funding by the Australian Cancer Research Foundation and published in Genome Medicine, has suggested the treatment ‘Herceptin’ could bring new hope to these pancreatic cancer patients. Herceptin is currently available through the Pharmaceutical Benefits Scheme for breast and gastric cancers with high expressions of HER2, and clinical trials will show whether the drug is equally effective in pancreatic cancer patients.

The HER2 pancreatic cancer sub-group was identified following a series of modern genetics and traditional pathological assessments to estimate the prevalence of HER2- amplified pancreatic cancer. Continue reading “Pancreatic cancer researchers find important molecular similarity between cancer types”

PepsiCo ‘Can Do’ dinner a fantastic success!

PepsiCo staff recently came together again for their annual trivia fundraising night for cancer research – an event which was, this year, called the “Can Do Dinner”.

The trivia night marked the end of a whole month of fundraising, in which PepsiCo asked their staff: “What can you do to support cancer research”? They rallied around a number of internal activities, including a team effort in the fearsome Tough Bloke challenge.

Continue reading “PepsiCo ‘Can Do’ dinner a fantastic success!”

Rosebank College visits CCIA to learn how we are helping to fight cancer

In celebration of National Science Week, we recently welcomed the year 11 Rosebank Biology class to the ACRF Drug Discovery Lab at the Children’s Cancer Institute Australia (CCIA).

This educational tour allowed the students to get up-close with the cutting-edge technologies used inside a real laboratory, while meeting some of Australia’s best cancer scientists who are making amazing progress in the fight against children’s cancers.

The day started off with a very insightful presentation by Dr Eddy Pasquier who discussed his expertise and passion for cancer research, especially in the field of Neuroblastoma.

Continue reading “Rosebank College visits CCIA to learn how we are helping to fight cancer”

‘Can Do’ Corporate Roadshows Kick-off in Melbourne!

The very first ACRF ‘Can Do’ Roadshow took place at Lion last week with great success!

One hundred Lion staff members attended the special, inaugural event to listen to an ACRF Ambassador panel of four amazing Aussie personalities. Together, they inspired the room in discussions about their dreams, achievements, and their personal experiences with cancer.

The star studded panel consisted of NBL great, Andrew Gaze; former Olympian and Order of Australia Medallist, Nicole Livingstone; former Olympian and CEO of Basketball Australia, Larry Sengstock and Olympic bronze-medallist in rowing, Margot Foster.

Continue reading “‘Can Do’ Corporate Roadshows Kick-off in Melbourne!”

David takes 400 thousand steps for cancer research

It was a cold morning in Canberra when ACRF super-fundraiser departed on what would be one of the most gruelling journeys of his life.

His solo walk back to his home in the lower Blue Mountains brought back old injuries and painful memories, as he took step after step – some 400 thousand of them – in honour of his late wife Danielle.

But it also brought him hope.

Continue reading “David takes 400 thousand steps for cancer research”

Blue September starts this Father’s Day!

Blue September is a campaign in which we’re encouraging all Australians to face up to cancer in men.

Starting this Sunday, we’re asking you to get blue and help raise awareness about men’s cancers.

22,000 Australian men die from cancer every year, but at the ACRF we want to turn this statistic around. You can help by hosting a blue themed fundraiser, purchasing one of our limited edition Blue September  wristbands, or by donating to vital research into the cancers that affect men most!

Continue reading “Blue September starts this Father’s Day!”

Skyhigh fundraisers Jump! for the cures

Early in the morning on Saturday 24 August eleven extremely brave ACRF supporters took the biggest leap of faith – jumping out of a plane at 14,000ft for cancer research!

The skydive over the beautiful beach at North Wollongong was the climax of several months of fundraising (not to mention nerves!), with each ACRF supporter pledging to raise $1,700 for their jump.

Together, our 11 ‘Jump! for Cancer Research’ participants went above and beyond, raising more than $34,000 for world-class cancer research, a cause which is very close to their hearts.

Continue reading “Skyhigh fundraisers Jump! for the cures”

Painting the town Cobalt Blue for cancer research

Kristal Elliot’s world was turned upside-down when, at just 23 years old, she lost her mother Christine to oesophageal cancer. Christine was only 49, and Kristal a new mum herself to little Amy, when this devastating loss shook their family.

Christine’s favourite colour was cobalt blue – she wore it with everything, Kristal told us, even if it didn’t match – and so Kristal has carried on her mother’s passion for the colour, in a shave and colour fundraiser which was held on Sunday 18 August. Fittingly, in memory of her mother, she called the event ‘Cobalt Blue’.

Continue reading “Painting the town Cobalt Blue for cancer research”

Give the gift of cancer research this Father’s Day

It’s Father’s day this Sunday, and many of us are thinking about those meaningful yet creative Father’s Day gifts to show our dads how much we care.

If you’re feel a bit stumped we’ve got the perfect solution! Why not consider a Father’s Day gift to cancer research this year?

An in celebration donation to cancer research is a gift that truly gives back. Through the ACRF, you can make a direct donation in lieu of gifts for your Dad.

Continue reading “Give the gift of cancer research this Father’s Day”

Glenys' Appeal

Glenys’ Appeal: an excerpt

“Back in 1984, a wonderful group of people led by Lady Sonia McMahon (she was such a vibrant, and active ambassador for the ACRF) asked my husband John to help start up a charity that – free from government constraints – would fill a vital gap in cancer funding in Australia.

“They saw that great scientists were working in poor conditions with dated technologies, and by rectifying this situation, new treatments and cures would be discovered faster than ever before.

“Of course when we first came on-board we couldn’t have known John would one day be diagnosed with cancer. All we knew was that this organisation could make a difference. It could fight a disease which seemed to follow us around like a shadow…. Continue reading “Glenys' Appeal”

WEHI researchers identify an exciting new approach to the treatment of stomach and bowel cancers

Melbourne researchers from the Walter and Eliza Hall Institute (WEHI) have identified a potential new drug target (a molecule called interleukin-11) for the treatment of bowel and stomach cancer, which are two of the most common cancers worldwide.

When a tumour develops in the stomach or bowel region, the normal (non-cancerous) tissues around it often becomes inflamed producing many different molecules, including two particular (related) cytokine molecules: interleukin-11 and interleukin-6.

Interleukin-6 has long been in the spotlight in terms of cancer research, as it is known to promote the spread of cancer cells. In fact, anti-cancer agents that block interleukin-6 are already in clinical trials for ovarian, kidney, prostate and breast cancers.

However, interleukin-11 has only been thought to have a minor role in the growth and spread of cancers. Continue reading “WEHI researchers identify an exciting new approach to the treatment of stomach and bowel cancers”

ACRF City2Surfers raise $85,000+ and help make cancer history!

85,000 runners, joggers, walkers and super heroes gathered at Sydney’s Hyde Park from 8am on Sunday 11 August, ready for one of the world’s largest community running events: the famous City2Surf.

Our ACRF team was thrilled to be there, taking on the 14km course together with some amazing runners who had grabbed the opportunity to support cancer research throughout their City2Surf campaigns.

For many of our runners, this day was more about their reasons for participating, rather than trying to beat a time. They ran in support of loved ones, and Heartbreak Hill would be no match for their determination, passion and generosity.

Continue reading “ACRF City2Surfers raise $85,000+ and help make cancer history!”

From trash to treasure: Junk DNA and its role in Cell Development

97% of human DNA that was previously considered ‘Junk’ could hold the key to finding new therapies for cancer, according to new research published in the prestigious ‘Cell’ journal.

Junk DNA is characterised by genes which don’t encode proteins, and it has long been overlooked in medical research because of this reason (proteins have been considered the most important biochemical component of cells).

However, using the latest gene sequencing techniques and analysis, a team led by Royal Prince Alfred (RPA) Hospital’s Professor John Rasko AO, together with Centenary’s Head of Bioinformatics Dr William Ritchie, have shown that particular white blood cells do use Junk DNA to regulate a group of genes that controls cell shape and function.

Continue reading “From trash to treasure: Junk DNA and its role in Cell Development”

Great fundraising ideas for schools during National Science Week!

National Science Week is just around the corner (August 10-18) and we’ve got some great fundraising ideas for schools looking to help in the fight against cancer!

Australian scientists are among the best and brightest in the world, and we at the Australian Cancer Research Foundation (ACRF) are proud to support their vital work into new treatments and cures for cancer.

Your school can help us support these scientists by becoming involved in a Schools Against Cancer event! By holding a Schools Against Cancer event this National Science Week, your school community can help fund the next major breakthroughs in cancer science!

Continue reading “Great fundraising ideas for schools during National Science Week!”

Norm’s fourth trip sees him ‘bug off’ across the Nullarbor

Norman Elias has finished his fourth annual Bug Off Cancer Drive, this year taking on one of the biggest drives his vintage 1965 VW Beetle has ever tackled!

On June 29 in the early hours of the morning, Norm started his 16 day journey from his home in Mortdale, heading west across Australia to Perth and back again in a cancer fundraising ‘drive’ with a difference.

Norm told us, “I became determined to help raise funds for the ACRF so they can continue to fund research into finding better treatments and hopefully cures that will rid us of this disease that doesn’t discriminate and affects all ages.”

Continue reading “Norm’s fourth trip sees him ‘bug off’ across the Nullarbor”

New surgical tool to improve accuracy in both diagnosis and treatment!

In an exciting development towards more accurate cancer surgery and tumour diagnosis, a surgical knife that tells the difference between healthy and cancerous tissue is being trialled in the UK.

Surgeons from the Imperial College London have used this incredible piece of technology (called the iKnife) to analyse the vapour that is given off when electrical currents cut away tissue during surgery.

The tool uses mass spectrometry to identify chemicals present in the tissue and then it reports, within 3 seconds, what the target tissue contains.

Continue reading “New surgical tool to improve accuracy in both diagnosis and treatment!”

Couple take on tandem 1000km bike challenge for cancer research!

ACRF supporters Matt and An both know first-hand what it’s like when someone they love is diagnosed with cancer.

With Matt’s sister-in-law and An’s father both having received this devastating news, they decided they wanted to do something positive to support cancer research, and help their loved ones through this journey.

On 30 June, Matt and An set off from Perth on their “Tandem Tour for Cancer Cure”, riding a tandem push bike up north to the beautiful coastal town of Geraldton and back.

Continue reading “Couple take on tandem 1000km bike challenge for cancer research!”

When at Hadrian's Wall, do as the Romans did…

Ex-Victorian Policeman, Craig Harwood, made the decision several months ago to take on one of the most unique charity challenges we’ve ever seen.

Along with his wife, father-in-law, two children and some tour guides, Craig embarked on a 135km walk along Hadrian’s Wall in the UK in a complete replica of Roman armour – weighing in at 35kg!

Craig has a keen interest in Roman Military History and, although he doesn’t dress up in this attire usually, he thought it would be a great challenge and a unique way to fundraise for three charities very close to his heart, one of them being the ACRF.

Continue reading “When at Hadrian's Wall, do as the Romans did…”

All-female shearing team work the woolsheds for cancer research

The Ducks on the PondAfter more than a year of planning, fundraising, and physical training, Sam Westcott and Bec Flynn, and their team of 35 female shearers – the Ducks on the Pond – have reached their fundraising peak with a most generous donation of over $30,000 to the Australian Cancer Research Foundation!

“Ducks on the Pond” was a term traditionally used by male shearers when they saw a lady approaching the workmen’s shed. It was a warning for the gents to clean up their language and their appearance.

So when Sam and Bec devised their unique fundraising idea – they thought it would be only too appropriate to call their all-female event “Ducks on the Pond”. They wanted to show how times have changed, highlighting the important role of women in the wool harvesting industry.

Continue reading “All-female shearing team work the woolsheds for cancer research”

This is Why We Fight: A short film in tribute to our supporters

Over many years  we’ve been incredibly grateful to have the support of thousands of Australian fundraisers, donors and supporters, and we wanted to take this opportunity to say a very big: THANK YOU.

Some of our wonderful supporters have helped us to create a video in celebration of what we’ve achieved, and in tribute to the people who inspire us to continue fighting cancer.

We’d like to acknowledge each and every individual who contributed to our #ThisIsWhyWeFight video. They represent every Australian who has been touched by cancer and who, together, are helping the best researchers in Australia to make real progress in cancer prevention, diagnosis and cure.

Treatment for breast cancer enhanced with anti-Leukaemia compound

WEHI image Profs Visvader, Lindeman, and HuangMore than two decades of research at the Walter and Eliza Hall institute (WEHI) in Melbourne has culminated in a potentially life-saving discovery for women with the most common form of breast cancer.

In the late 1980s scientists at the WEHI identified a “pro-survival” protein called BCL-2 that helps cancer cells to become immortal and resist treatments such as chemotherapy. This work has contributed to the development of a compound which neutralises this vital cancer protein, and it is now in clinical trials to treat some types of leukaemia.

But latest news from the WEHI is that this compound has even more potential.

In 85% of women with oestrogen receptor-positive (or ER-positive) breast cancer, researchers have found very high levels of the very same BCL-2 protein.

Using the world-class facilities made possible through ACRF funding they were able to trial this ant-cancer compound in pre-clinical ER-positive breast cancer models, and found that it was successful when combined with an existing breast cancer drug, Tamoxifen. Continue reading “Treatment for breast cancer enhanced with anti-Leukaemia compound”

Our regular givers are making real progress possible!

“Cancer was certainly not part of who Danielle was as a person, but it was a part of the narrative of her life’s journey. Her legacy will always live on in our children Joshua, Grace and Caleb, who were 9, 8 and 5 respectively when Danielle passed away.

“To honour the memory of Danielle and to set an example for our children to follow in life – that together, we can all make a difference – I have made a life-time commitment to actively support Australian researchers in their search for the cures.

“It gives me hope for my children’s future that the Australian Cancer Research Foundation’s Partners in the Cure – a group I am proud to belong to – have raised more than $1.3 million.” Continue reading “Our regular givers are making real progress possible!”

ACRF SMH Half Marathon runners raise over $20,000 for world class cancer research

The SMH Half Marathon began in Sydney this year with a moment of silence in memory of the victims of the Boston Marathon bombing.

More than 10,000 runners assembled down College Street on May 19, 2013, waiting for their half marathon challenge to commence.

The starter’s pistol went off, and the serious runners were sent on their way.

We were thrilled to be able to attend the race this year, to meet with the runners who had taken the opportunity to support cancer research during their half marathon campaigns. Among the cancer fundraisers we had the privilege of meeting was super-fundraiser Martin Watters, who led the highest fundraiser board for weeks in the lead-up to the sporting event.

Martin generously raised more than $11,000 for the Australian Cancer Research Foundation, in support of his girlfriend, Sophie, who is currently being treated for Hodgkin’s lymphoma.

Continue reading “ACRF SMH Half Marathon runners raise over $20,000 for world class cancer research”

The Believers race a wheelbarrow towards an incredible cancer fundraising finish-line!

A team of ten amazing fundraisers have pushed a wheelbarrow for more than 140kms across far north Queensland as part of the 10th Great Wheelbarrow Race, and they’ve done so for a most worthy cause: world-class cancer research.

The Great Wheelbarrow Race takes participants along a historic road from Mareeba to Chillagoe, named Wheelbarrow Way in tribute to the miners of the 1800s that would travel between towns, using only a wheelbarrow to carry their possessions.

The race started early on the morning of Friday 17 May, but our wonderful fundraising team, called The Believers, commenced their campaign much sooner than that.

Continue reading “The Believers race a wheelbarrow towards an incredible cancer fundraising finish-line!”

July is Regular Giving Month!

Regular Giving Month is an opportunity for us to celebrate our regular givers, both new and long-standing, for their incredible commitment to world-class cancer research in Australia.

Through their regular charity donations, this amazing group of people have together raised more than $1.3 million!

For this, and for their ongoing support, we will be forever grateful:  they are a vital part of our work, ensuring we are able to fund the high-quality, world-class research grant applications we receive each and every year. Together, they are speeding up new treatments and cures for cancer.

One of our newest regular givers, Stephen Holyoak, joined our Partner in the Cure program because his life has been changed forever by this terrible disease.

“After losing my mum to cancer far too young, I felt it was time to try and help those who are suffering today and tomorrow.”

“I have been unfortunate to also see very close friends lose family members to this horrible disease.”

Continue reading “July is Regular Giving Month!”

This is why we fight.

At the Australian Cancer Research Foundation we rarely need a reminder, but every so often we speak at length to a supporter like Basia Andrews, who recently lost her husband to cancer, and a shock goes through our organisation. This is what we’re fighting for.

“Gary’s battle with cancer started on the 2nd July and lasted for twelve and a half weeks,” Basia said.

“I miss all the little things that made our lives so much fun. A thousand little things, the touch of his skin, a thousand gestures.”

“As the cancer ate away at Gary I thought he looked more beautiful. His spirit, grace and dignity shone through more with each passing day…”

YOU CAN READ BASIA’S STORY HERE

This is why we fight – to prevent tragedy, to give hope and, ultimately, to save lives through research. Please click below to read more.

Continue reading “This is why we fight.”

ACRF fundraisers take part in the inaugural Brisbane City2South

On Sunday 16 June, under a perfectly blue Brisbane sky, 25 runners for the ACRF joined a crowd of about 7,000 for Brisbane’s very first City2South.

The sister event for Sydney’s famous City2Surf, the City2South attracted runners from all over to take on the 14km challenge. Runners of all ages made their way from the Botanic Gardens, along Coronation Drive, through the University of Queensland and back through Highgate Hill.

We were lucky enough to be there on the day to meet with our runners and talk to them about the event and why they decided to turn this great event into a cancer fun run.

One of our fundraisers, James Shaw, raised an epic $1,715 for cancer research:

Continue reading “ACRF fundraisers take part in the inaugural Brisbane City2South”

Pancreatic cancer research enhanced through new access to advanced nanotechnology

Australian cancer researchers can now view never-before-seen images of how cancers respond to therapy, thanks to new access to an advanced imaging nanotechnology, based in the US.

Dr Paul Timpson of the Garvan Institute of Medical Research, in collaboration with a team from the UK, are using the Fluroescence Resonance Energy Transfer (FRET) technologies to map areas within pancreatic cancers, pin-pointing where drugs need to be delivered to significantly improve patient survival.

Continue reading “Pancreatic cancer research enhanced through new access to advanced nanotechnology”

Millions in private funding for top cancer research projects in Australia

Five of the best cancer research projects in the world stand to receive millions of dollars in funding,  following the Australian Cancer Research Foundation’s announcement today of its  shortlist for 2013 research grants.

From twelve research proposals, the Australian Cancer Research Foundation (ACRF) has shortlisted five for further assessment as a result of the world-class standard of proposed works, and the significant potential for this research to achieve major breakthroughs in cancer diagnosis, treatment and cure.

Continue reading “Millions in private funding for top cancer research projects in Australia”

Our shortlist of the most innovative cancer research projects in Australia

The ACRF is very excited with the quality of the five shortlisted applications for our grants in 2013. Some of the very best researchers in the world feature in these applications.

These final five applications represent a need for more than $20 million in advanced technologies and facilities. They cover many types of cancer, not just one or two.

Our highly esteemed Medical Research Advisory Committee selected these particular projects for further review on two grounds – the world-class standard of the proposed research, and the potential to achieve major breakthroughs in cancer diagnosis, treatment and cure.

That committee, led by Professor Ian Frazer, will now, through a detailed interview process,  recommend to our Board the best of the best for ACRF funding. The final awardees will be publicly announced on 13 November this year.

Every dollar we receive in donations this year will go to research that has the power to beat cancer. Please peruse the below, to find out where ACRF donations could be making a difference very soon.

Continue reading “Our shortlist of the most innovative cancer research projects in Australia”

Celebrating 29 years funding world-class research in Australia!

Today we celebrated the ACRF’s 29th birthday, with a beautifully decorated cake made by our own office Masterchef, the lovely Cheryl.

Since its inception in 1984, the ACRF has provided over $86 million to world class cancer research in Australia with more than 70% of the total being provided to Australian researchers in the last seven years.

This has been made possible thanks to our amazing and loyal donors who have helped cancer researchers achieve amazing outcomes and make incredible progress in the fight against cancer.

Continue reading “Celebrating 29 years funding world-class research in Australia!”

Cells involved in aggressive prostate cancer growth to be targeted in the disease’s early stages

A new sub-group of cells that influences prostate cancer recurrence has been identified by researchers at Monash University.

The previously unidentified cells are present in the disease’s early stages, opening up new doors to develop a therapy which targets these cells and prevents the disease from progressing to an aggressive stage.

Prostate cancer is the most common form of cancer in men, claiming more than 3000 Australian lives and affecting up to 20,000 annually.

For advanced cases, the best available treatment involves drugs that deprive the tumour of the male hormones which cause it to grow (androgen-deprivation therapy) . In many cases, the tumour can become resistant to this treatment leaving the patient with both debilitating side-effects and an aggressive new form of the prostate cancer.

The new sub-group of cells identified by Monash researchers is involved in this very treatment resistance. Continue reading “Cells involved in aggressive prostate cancer growth to be targeted in the disease’s early stages”

May 2013 Monthly News

In the May 2013 edition:

  • Skin cancer drug targets ‘growth’ gene with potential to treat other disease.
  • Your chance to run the International Marathon that’s closest to home: the Auckland Marathon.
  • We celebrate workplace giving month in June.
  • #ThisIsWhyWeFight social movement launch!

Workplace Giving Month

June is Workplace Giving Month – a time for working Australians to help make a big difference to cancer research.

Workplace giving is as simple as making a regular pre-tax donation from your pay which provides an immediate tax benefit. It also provides a focal point for employers to incorporate giving in the workplace: helping to achieve positive employee engagement, organisational culture and community impact goals.

If just 10% of working Australians made a regular employee donation of $5 each week, their contributions would amount to $260 million for the charitable sector each year. However, only 1% of Australian employees currently donate to charity through Workplace Giving, which is much lower than other developed economies.

That’s why, this Workplace Giving Month, we’d like to encourage you to either sign-up as a new ACRF workplace giver, or to increase your existing engagement with the Australian Cancer Research Foundation. Continue reading “Workplace Giving Month”

Childhood neuroblastoma treatment enhanced with high blood pressure ‘beta-blockers’

An ‘old’ drug which is normally used to treat high blood pressure in adults could bring new hope to children with Neuroblastoma, researchers from the Children’s Cancer Institute Australia have discovered.

Neuroblastoma is a cancer that develops from nerve cells left over from a baby’s development in the womb, predominantly affecting very young children – between 0 and 5 years old.

But researchers conducting pre-clinical trials at CCIA (a world-class facility that the ACRF is proud to have funded via a $3.1m grant) have combined standard chemotherapy with beta-blockers to successfully enhance the effectiveness of the chemotherapy – paving the way towards better treatment outcomes, and decreased treatment doses for these young children. Their study has been published in the prestigious British Journal of Cancer. Continue reading “Childhood neuroblastoma treatment enhanced with high blood pressure ‘beta-blockers’”

Two new ACRF facilities in Melbourne will help fast-track discoveries

The Australian Cancer Research Foundation has opened two new world-class cancer research facilities in Melbourne; the new ACRF Rational Drug Discovery Centre at St Vincent’s Institute (SVI) and a new Cancer Imaging Facility at the Ludwig Institute for Cancer Research.

These centres represent $4 million in Australian Cancer Research Foundation funding that would not have been made possible without the support of our amazing donors.

The potential for ground breaking discoveries within these world-class facilities is extremely exciting. Each of them houses the latest in advanced drug screening and imaging technologies, promising to find new treatment targets and therapeutic options faster than ever before.

Please find details about each cancer research facility below.

Continue reading “Two new ACRF facilities in Melbourne will help fast-track discoveries”

Australia’s best researchers request $49M from the Australian Cancer Research Foundation, as the government commits to a boost in cancer care.

The Australian Cancer Research Foundation is proud to have received 13 world-class cancer research grant applications after submissions for 2013 closed last Friday.

The applications represent a need for $49 million in seed-funding for cutting-edge technologies and facilities, supporting the development of collaborative, innovative cancer research initiatives.

Every year, the Australian Cancer Research Foundation awards up to $10 million in cancer research funding. But this response to our grants shows just how important it is for us to continue fundraising and building the profile of research in Australia.

We received five applications from researchers in NSW, four from Victoria, three from Queensland and one from South Australia – it’s fantastic to see the research expertise within so many States represented in this mix.

Continue reading “Australia’s best researchers request $49M from the Australian Cancer Research Foundation, as the government commits to a boost in cancer care.”

Tassie firies rally together to help fight cancer

After more than a year of planning, fundraising, and physical training, the Headin’ South for a Cure initiative has today reached its climax with a most generous donation of almost $48,000 to the Australian Cancer Research Foundation!

The team of 10 fire fighters from Tasmania, led by co-founders Emma Weitnauer and Tim McKay, campaigned for all of last year in the lead-up to a heroic 14 day cycle; starting in Brisbane and ‘headin south’ to Hobart.

They set out on January 1st, taking no rest days and battling extreme weather conditions (some days reaching 48 degrees with strong, head on winds and extreme – sometimes catastrophic – fire danger ratings). They averaged more than 160km a day, arriving home on Jan 14th!

Major sponsor Bendigo Bank were behind the team the whole way, supporting fundraising initiatives and collecting donations to help fight cancer along with the fire-fighters. Today, we have received the full fundraising amount, and we couldn’t be more proud of this incredible team!

Continue reading “Tassie firies rally together to help fight cancer”

Aussie researchers' ‘magic bullet’ gives new hope to children who relapse from blood cancer

Cancer scientists at the prestigious Children’s Cancer Institute Australia (CCIA) have discovered that an existing drug being trialled for adult cancer treatment also has the potential to treat children who relapse from acute lymphoblastic leukaemia (ALL), one of the most common types of paediatric blood cancers.

The current survival rate for children diagnosed with the ALL is 80 per cent, however if a child relapses this survival rate decreases to just 20 per cent.

“What is so exciting about this drug is it has the potential to not only improve the survival rate of children who have relapsed but, since it acts as a ‘magic bullet’, it only targets the cancer cells, leaving the healthy cells untouched!” explains Professor Lock, Head of the Leukaemia Biology Program at CCIA.

Dr David Ziegler, paediatric oncologist with the Sydney Children’s Hospital, said “Our patients and their parents can’t afford to wait years to have new treatments developed. We plan to start a clinical trial of this new therapy for children with leukaemia by the end of this year.”

Continue reading “Aussie researchers' ‘magic bullet’ gives new hope to children who relapse from blood cancer”

Local policeman is funding research through the adventure of a life-time

A Manly local area police commander, Supt David Darcy, took on an epic challenge last year, riding over 22,000KM from London all the way down to Sydney on his motorbike.

His goal: To help fund research by raising $20,000 for the ACRF.

David and fellow motor cycling enthusiast Darren Higginson left London on July 1, reaching Sydney four months later after experiencing a once-in-a-life-time journey.

David told us, “Both Darren and I have a number of close relatives and friends who have had their lives either affected or cut short by various forms of cancer and we would like to help this worthy cause.” Continue reading “Local policeman is funding research through the adventure of a life-time”

Run for Gold in next year’s London Marathon!

The Virgin London Marathon 2014 is one of the biggest marathons in the world, with around 35,000 competitors looking to complete the race each year. The ballot alone attracts more than 100,000 applications and generally is closed with-in 2 hours of being opened!

Anybody who applies will have to wait until October 2013 to find out if they have been successful in securing a place for the April 2014 race. And with not even half of the people entering being picked, chances might seem a bit slim…

This time last year Anouska “Noosh” Zerna was thinking exactly the same thing. She’d harboured the goal of running in the London Marathon for almost 7 years but had always put it off due to the feeling that a ballot entry ticket was too far out of reach. But then Noosh found an alternative. She applied for an ACRF Gold Charity fundraising spot– and in July 2012 her application was accepted.

As an official Gold Charity fundraiser Noosh was given a fundraising target of $9,000.

Noosh told us, “When I found out I had a place I was daunted, by both the amount of training and fundraising tasks ahead of me. However, once I started raising money and the momentum grew, it became apparent that the fundraising element would give my training extra focus – I couldn’t let down all the people who had supported me!”

Continue reading “Run for Gold in next year’s London Marathon!”

Mother's Day – gifts of hope for Mum

It’s nearly May, and many of us are starting to think about those meaningful Mother’s Day gift ideas that will show our Mums how much we truly care.

We’ve got the perfect solution! Why not consider a Mother’s day gift to cancer research this year? – It’s the perfect way to celebrate life and give new hope for the future.

Through the ACRF, you can make a direct donation in lieu of gifts for your Mum. This way, 100% of the donation dollars that we receive will go to research that has the power to beat all types of cancer, bringing new hope to cancer patients and their families around the world.

You can also browse some of our other Mother’s Day gift idea options here (including beautiful hampers, and access to our own ACRF shopping Mall through which a percentage of sales will go to cancer research!) Continue reading “Mother's Day – gifts of hope for Mum”

Discovery brings hope for new tailor-made anti-cancer agents

Researchers at the Walter and Eliza Hall Institute (WEHI) Melbourne have played a key role in developing a novel chemical compound which blocks a protein that has been linked to poor treatment responses in cancer patients.

The development of this compound is an important step towards designing a potential new anti-cancer agent, which will help to significantly reduce resistance to therapy.

The compound targets the function of a protein which prevents cells from dying.

Cell death is an important safeguard against cancer development, but once cancer cells start growing, they can produce high levels of this protein which prevents this natural process. This also reduces the effectiveness of chemotherapy and other anti-cancer treatments, and has been associated particularly with poorer outcomes in patients with lung, stomach, colon and pancreatic cancer.

Dr Guillaume Lessen (pictured) who co-led the study, together with Prof. Keith Watson and Prof. David Huang from the ACRF Chemical Biology Division at WEHI and colleagues Dr Peter Czabotar and Prof. Peter Colman, said:

“We were very excited to see the team’s work culminate in a compound that specifically inhibits the protein.” Continue reading “Discovery brings hope for new tailor-made anti-cancer agents”

Vaccine decreases pre-cancerous symptoms in Aussie women by 93%

Researchers have reported an incredible 93% drop in genital wart diagnoses (symptoms of the human papillomavirus) in young women who have received the HPV, or cervical cancer, vaccine.

The vaccine, co-created by Professor Ian Frazer AC (whose research was supported by an early ACRF seed-funding grant), became available for Australian girls in 2007.

The study, which was conducted by researchers at the University of NSW and the University of Melbourne together with both the Sydney and Melbourne Centres of Sexual Health, looked at the medical data of 85,770 patients during pre-vaccination period (2004-2007) compared to the vaccination period (2007-2011). Continue reading “Vaccine decreases pre-cancerous symptoms in Aussie women by 93%”

Triple-Negative Breast cancer stopped in its tracks with new treatment trial

Researchers at the Queensland Institute of Medical Research have run early studies of a new combination of treatments for breast cancer, with 100% success rate.

The treatment targets late-stage triple negative breast cancers, for which the average survival rate is only 12 months. This type of cancer is most common in young women and accounts for approximately 20% of breast cancer cases in Australia.

Unlike other cancer cells, triple negative breast cancers don’t have any of the three usual surface receptors, which would normally be the target of treatment.

But this latest treatment trial shows that targeting radiation specifically to an overload of proteins (known as EGFR) together with a dramatically reduced dose of chemotherapy is effective in stopping both the cancer growth, and its recurrence. Continue reading “Triple-Negative Breast cancer stopped in its tracks with new treatment trial”

London calling for cancer research

Believe it or not, Anouska Zerna (Noosh) really does like running! And next week she will be running 42.2km in support of the ACRF and world-class cancer research.

We wish Noosh the very best as she jets off to England on Monday to compete in the London Marathon – a goal she set for herself 7 years ago!

Noosh told us “There is definitely something in it and, aside from the post run highs and slender thighs, for me that something is a goal I have harboured for a long time – the London Marathon.” Continue reading “London calling for cancer research”

Prime Minister Julia Gillard recognises the vision and foresight of the ACRF

Fighting cancer by funding researchThe ACRF is proud to have played a key role in a world-class collaborative venture that will see Sydney’s next comprehensive cancer centre come to fruition; promising personalised, targeted treatment and care for cancer patients of the very near future.

The new Centenary Institute – Chris O’Brien Lifehouse Cancer Research Centre will be a land-mark development, kick-started by $5 million in ACRF funding (the equal largest ACRF grant ever awarded).

Prime Minister Julia Gillard has generously recognised the vision of the ACRF in seed-funding this state-of-the-art cancer facility. She states:

“… the Centenary Institute-Chris O’Brien Cancer Research Centre is so important as we seek to better understand and treat this insidious disease.

“But the Centre will only flourish through the generosity of its supporters, and so I warmly congratulate the Australian Cancer Research Foundation for its donation of $5 million, a remarkable act of philanthropy.”

Please click on the image right to view the full statement.

ACRF grant rounds open, funding research into all types of cancer

The ACRF is once again inviting world-class research teams and collaborations to apply for between $1.5 and $5 million in ACRF research funding.

Every year we provide major grants to help cutting-edge cancer research institutes develop state-of-the-art facilities, and purchase advanced technologies and equipment that speed up cancer discoveries.

No other private research funding body in Australia provides grants as large as these; and these grants help to fund research in Australia that has the power to make significant breakthroughs in cancer diagnosis and treatment.

Continue reading “ACRF grant rounds open, funding research into all types of cancer”

Up to $10 million in cancer research funding available through the Australian Cancer Research Foundation

The Australian Cancer Research Foundation (ACRF) has begun accepting applications for their 2013 annual Cancer Research Grant Round.

The ACRF provides major grants between $1.5 and $5 million to develop state-of-the-art, collaborative research centres and purchase advanced technologies and equipment. Grants of this magnitude are not available from any other private funding body in Australia.

Continue reading “Up to $10 million in cancer research funding available through the Australian Cancer Research Foundation”

Wishing you a Happy Easter!

From all of us at the Australian Cancer Research Foundation, we wish a Happy Easter to all of our supporters,  with special wishes to our Greek (Kaló Páscha) and Italian (Buona Pasqua) donors!

If you’re rushing to find those last minute Easter gifts, it’s not too late to make a small donation in lieu of easter eggs. Even though our office will be closed from Friday 6 April for the long weekend, if you make a donation online a receipt will be issued to your email address automatically.

Thank you again for your ongoing support of our work.

Aussie scientists lead the way in improving Leukaemia survival rates

A ten-year clinical trial has seen survival rates in children with the most common form of childhood cancer, acute lymphoblastic leukaemia (ALL), double to 70%.

The study gives new hope to children with a high-risk of relapse, based on the results of a novel test developed by scientists at the Children’s Cancer Institute Australia (CCIA) – a recipient of over $3.2 million in ACRF funding.

The test works by detecting Minimal Residual Disease (MRD) in the bone marrow of children with ALL. It identifies patients who (despite appearances) are not responding to treatment as well as others, allowing clinicians to reassess their treatment options and maximise the patient’s chance of a full recovery.

“The MRD test can detect one leukaemia cell among 100,000 healthy cells in the bone marrow, and this allows clinicians to tailor a child’s treatment,” said Professor Glenn Marshall, Head of Translational Research at CCIA (and Director of the Kids Cancer Centre, Sydney Children’s Hospital Randwick). Continue reading “Aussie scientists lead the way in improving Leukaemia survival rates”

‘A Million Footsteps for a Cure’ charity challenge

Charity Challenge

On 19th December 2010, Sydney local Sonia Longo’s life changed when her father was diagnosed with metastatic lung cancer.

At the point of his diagnosis the cancer had already spread to his spine making it very difficult for Sonia’s father to walk or even sit comfortably.

“Watching this strong, fiercely independent and jovial man fade away so rapidly broke my heart a million times over.  And it continues to do so.” Sonia told us.

“I would have done absolutely anything for this wonderful man, but there was just nothing I could do to lessen his pain.”

Unfortunately, less than 3 months after his diagnosis, Sonia’s father passed away in Sonia’s arms, surrounded by his loving family.

After watching what her father went through, Sonia is committed to raising awareness about the importance of cancer research.

On 23rd May, 2013, Sonia will be embarking on an epic charity challenge – walking 750km across France. Starting at Le Puy, Sonia will travel entirely on foot, taking over a million steps over 38 days until she reaches Saint Jean Pied de Port at the border of Spain.

Continue reading “‘A Million Footsteps for a Cure’ charity challenge”

Research news: autumn 2013 edition

In the Autumn 2013 edition of the Research Review:

  • The ACRF funds Australia’s first laser scanner cytometer, to be housed at St Vincent’s Institute in Melbourne.
  • Aggressive brain tumours to be newly targeted with leukaemia therapy.
  • Researchers look at ways to empower our immune systems to fight cancer from within.
  • New possibilities in blood testing will pave the way towards better treatment plans.

Fitting out St Vincent’s cutting-edge ACRF Rational Drug Discovery Centre

current cancer researchAustralia’s first laser scanner cytometer, to be housed at St Vincent’s Institute of Medical Research, Melbourne, is set to cut years off drug development and cancer treatment trials.

The $700,000 machine was purchased as part of the fit-out of the Institute’s ACRF Rational Drug Discovery Centre, a facility made possible thanks to a $2 million ACRF grant, awarded at the end of 2011.

Stem cell researcher Associate Prof Louise Purton (pictured)  has said the scanner will allow researchers to study “anything we want to know about a cell – this should be able to answer it.”

“This is the way the cancer field is moving forward into finding a cure, by understanding why that cancer is forming and designing drugs that specifically target those cancer cells, as opposed to the other cells around it.”

The scanner not only allows researchers to better profile, test and monitor cancer cells – it also will reduce the impact on animals at trial-level. Continue reading “Fitting out St Vincent’s cutting-edge ACRF Rational Drug Discovery Centre”

Bob Turner, sports personality, joins forces with ACRF

Fighting cancerThe ACRF is thrilled to welcome one of Australia’s most respected sports personalities to the team.

Bob Turner – best known for his coaching, marketing and management roles within Australia’s National Basketball League (NBL) – has taken up the reigns as General Manager, Marketing & Business Development of the cancer charity.

Bob is renowned throughout many sporting organisations for his incredible marketing ability – his work with the Canberra Cannons and Sydney Kings set the standard for the NBL during the early ‘90s.

Since 1979, Bob’s expertise has seen four NBL clubs (Newcastle Falcons, Canberra, Sydney and the Singapore Slingers) become highly competitive, successful teams, and over the years, Bob has combined his leadership and marketing skills to promote a variety of other sports including Baseball, Gymnastics, Lawn Bowls, and Speedway.

But in 2013, Bob will put his skills to the test in an entirely different, but not unfamiliar arena. Continue reading “Bob Turner, sports personality, joins forces with ACRF”

Australia loses a much-loved journalist to Pancreatic Cancer

Peter Harvey pancreatic cancerThis weekend, we farewelled one of Australia’s most esteemed journalists.

Peter Harvey was best known for his long-standing role as news reporter with the Nine Network – his baritone voice and well-known sign-off “Peter Harvey, Canberra” resonated throughout Australian homes for thirty-seven years.

Peter was overseas celebrating his 45th wedding anniversary last year when he fell ill. On returning home to Australia, he was diagnosed with pancreatic cancer.

Calling it the “Patrick Swayze disease”, Peter faced his diagnosis head-on.

“I’m not going to let fears and worries about tomorrow ruin my today. I’ll just take the most out of each day for as long as I possibly can,” he said

It was this determination and passion that Peter will be remembered for. Continue reading “Australia loses a much-loved journalist to Pancreatic Cancer”

Go for gold at this year’s City2Surf!

Cancer fun runCairns local Christine MacDonald had long considered herself one of the lucky ones; she survived childhood cancer despite a devastating prognosis and gives thanks to her incredibly supportive, specialised medical team which saw her through to recovery.

But last year, cancer struck in Christine’s life again. Her husband was diagnosed with bowel cancer which then spread to his liver. Despite a brave fight, Christine’s husband lost his life to this devastating disease.

“Before his diagnosis, we had planned to travel to Sydney to compete in the famous City2Surf together,” Christine told us.

“I now intend to compete on my own. 14kms of pain, and enduring Heartbreak Hill is nothing compared to losing your best friend.”

Rather than wait until the general City2Surf registrations open in March, Christine has decided to make fundraising her focus and sign up as an ACRF City2Surf Gold Charity runner.

Together with 20 other ACRF Gold Charity runners, Christine will rally behind the cause of cancer research, with every dollar raised going to the most promising, innovative research projects across the country. Continue reading “Go for gold at this year’s City2Surf!”

Simple blood test could revolutionise treatment plans for Hodgkin Lymphoma patients

Queensland researchers are paving the way towards less invasive and more personalised treatment plans for patients with the blood cancer type, Hodgkin Lymphoma.

Based at Queensland’s Institute of Medical Research (QIMR), the research team have developed a blood test which detects levels of a key protein – known as CD163 – during and after Chemotherapy.

Importantly, CD163 shows elevated levels in Hodgkin lymphoma patients’ serum, and it decreases when tumours shrink after treatment.

“Testing for these protein levels, using a simple blood test, could show doctors whether the treatment is working, whether they can reduce the doses, or, conversely, whether they need to increase the doses to beat the cancer,” said Ms Kimberly Jones, who co-led the research study together with Professor Maher Gandhi. Continue reading “Simple blood test could revolutionise treatment plans for Hodgkin Lymphoma patients”

Kayak 4 a Cure Charity Challenge Complete!

Kayak 4 a cureKayak 4 a Cure

On the 19th of December 2012, three inspirational teenagers from NSW’s mid-north coast embarked on a 2,200km journey from the Hume Weir to the Murray Mouth to raise vital funds for cancer research.

Brothers Will and Jo, and their friend Callum gave up their entire Christmas school holidays as they camped and kayaked along the world’s third longest navigable river – the Murray River.

By engaging their community, local school and family networks, the three boys had a wonderfully successful start to the campaign, exceeding their initial fundraising target of $10,000 before they’d even departed on their epic journey! Now at the end of the adventure, they’ve surpassed $16,000!

“Just a fabulous effort by you all,” said ACRF CEO, David Brettell.

“We at the ACRF are so touched and inspired, thank you, an amazing effort, we’re very proud of you.”

Their goals for the trip were twofold; to raise much needed funds for the ACRF as well as to spread a positive message about teenagers living life to the fullest. We think it’s certainly safe to say they have more than succeeded on both fronts. Continue reading “Kayak 4 a Cure Charity Challenge Complete!”

Aggressive brain tumours to be newly targeted with Leukaemia therapy

Current cancer researchA new target for treating aggressive brain tumours has been discovered by researchers at the Queensland Institute of Medical Research (QIMR), and better still, a therapy for this target is already in the advanced stages of development.

Originally, the protein EphA3 was discovered in 1992 for its role in promoting Leukaemia cancer cells. This finding was made by Professor Andrew Boyd at QIMR, and clinical trials have since commenced to test a treatment which targets that particular cancer cell activity.

Now, years later, Professor Andrew Boyd together with Dr Bryan Day have found the same protein is implicated in up to 50% of cases of glioblastoma multiforme (GBM), particularly in the most aggressive cases.

“This protein is something we can directly target with a treatment we’ve already developed,” said Dr Day.

“It’s early days, but we know cells which express the protein EphA3 can be eradicated in the laboratory with this treatment, so it’s very encouraging.” Continue reading “Aggressive brain tumours to be newly targeted with Leukaemia therapy”

World Cancer Day – Feb 4th

Have you found the cure for cancer yet?

Inevitably, when we meet new people who are interested in our work at the Australian Cancer Research Foundation, we get asked the same question.

“Have you found a cure yet?”

It’s the question on everyone’s lips. It’s what we’re all fighting for. But our response can often disappoint: “For which type of cancer?”

Cancer is an incredibly complex disease. It can be triggered by any number of environmental, behavioural and/or biological factors, and it can behave differently in each individual.

In 2013, World Cancer Day is about dispelling myths about cancer. Understanding your enemy is the first step to beating it, so on 4 February 2013 – World Cancer Day – we are being asked to seek the facts so that we can better understand this terrible disease.

The short answer to this common myth or question is that, unfortunately, we don’t have ‘a cure’. But we do have ‘cures’. Continue reading “World Cancer Day – Feb 4th”

Super fundraiser honoured as local hero

Cancer fundraisingThe Australian Cancer Research Foundation (ACRF) is delighted to congratulate one of our dedicated fundraisers, Chips Fearon, on receiving the ‘Local Hero’ award from Stawell Council for his tireless community and charity work. The ever humble man who himself says “I don’t think I do that much” was tricked into attending the Australia Day ceremony to receive his award.

Chips first came to the ACRF in 2011 with the crazy idea to shave off his 40 year old beard. With his connections throughout the community it wasn’t long before the much loved, “Unofficial Mayor of Marnoo” raised over $8000 through his cancer fundraising.

In 2012 Chips was back with a new fundraising idea and took on a drive all around Tasmania in his restored 1958 VW Beetle. Despite some car issues and setbacks, Chips and his friends scattered all over TAS & VIC helped raise $5000 and counting for cancer research.

The plans for his 2013 fundraising event are underway and we’re looking forward to seeing what happens this year.

Congratulations Chips from all of us here at the ACRF! We’re so glad to see all of your efforts for us and other causes honoured officially by your community and we are so grateful for your generous support of cancer research!

Charity challenges for leadership and personal development!

Charity Challenge | Corporate LeadershipFollowing the success of our inaugural Leadership Challenge which explored the Northern Territory’s Larapinta trail, we are thrilled to offer two new leadership development adventures for companies, as well as a ‘top 10’ international charity challenges for individuals and small groups!

Corporate charity challenges:

Rather than conduct your professional development workshops in an office space this year, why not give your staff the opportunity to really grow as individuals and a team with an ACRF Corporate Charity Challenge:

1) Kakadu and beyond: Spend 8 days exploring the wonders of Kakadu National Park, complete with 4WD, canoeing and trekking challenges. Departs June 1, 2013

2) Cradle Mountain and the Walls of Jerusalem: A 6 day challenge across two of Tasmania’s most spectacular and unique World Heritage National Parks. Departs October 20, 2013.

By registering in these leadership experiences, your staff will be helping the ACRF to fund world-class cancer research while, at the same time, participating in workshops which focus on overcoming workplace challenges and building leadership skills. Continue reading “Charity challenges for leadership and personal development!”

Manipulating molecules to enhance breast cancer treatment

funding research into breast cancerThe ACRF is proud to have funded a cutting-edge research discovery at Sydney’s Garvan Institute which revealed a known ‘transcription factor’ could be at the heart of many ineffective breast cancer treatments.

‘Transcription factors’ are molecules which act like a switch – turning genes on and off to change the behaviour and characteristics of our cells.

‘ELF5’ is one such transcription factor, best understood for its role in triggering oestrogen-receptor negative (ER-negative) cells for the development of breast milk during pregnancy.

But cancer researchers at the Garvan Institute of Medical Research have also shown that ELF5 can prevent breast cancer treatments from working.

In a preclinical study, Associate Professor Chris Ormandy and his team found that ELF5 can make an oestrogen-receptor positive (ER+) tumour cell behave like an ER- negative cell.  Continue reading “Manipulating molecules to enhance breast cancer treatment”

New Year’s Resolutions give hope to charity

New Year's Resolutions give hope to charityMaking New Year’s Resolutions is a wonderful tradition promoting self-improvement, transition and promise for the future.

We’ve put together a short list of some of the most popular Resolutions for the New Year, but don’t be distracted if you think you’ve seen them before. Our little twist to these gems is that every single one of them can contribute to the fight against cancer!

  1. Get fit: Community fun runs, marathons and ocean swims provide a fantastic fitness goal to work towards this year, and there’s so many to choose from! You could get a team together or take on the challenge yourself, and be sure to set a fundraising target to make your training efforts even more inspirational.
  2. See the sights: Are you planning an adventure abroad? Is the Great Wall of China, the Vietnamese countryside, or the mountain ranges of Nepal calling? Well in 2013, the ACRF would be thrilled to help you organise the trip of a lifetime in conjunction with a cancer fundraising target. We can also offer two Australian-based adventures that focus on professional development and work-place leadership!
    Continue reading “New Year’s Resolutions give hope to charity”

Wishing you a happy and safe Christmas!

2012 has been an incredible year with some truly exciting advances in cancer research. We thank you very much sharing for it with us.

Please note we will be taking a short break over the Christmas holiday, with our office closing on Friday 21 December, 2012 and reopening on Wednesday 2 January, 2013.

If you would like to make a kind donation during this time (either in place of Christmas gifts or as a way of kick-starting the new year with some positive karma) and you would like an immediate receipt, please be sure to donate via our secure online portal rather than via post.

Finally, we’ve put together a short video to thank you again for your support this year. We wish you a wonderful Christmas, and we look forward to staying in touch throughout 2013.

Wishing you a happy and safe Christmas!

2012 has been an incredible year with some truly exciting advances in cancer research. We thank you very much sharing for it with us.

Please note we will be taking a short break over the Christmas holiday, with our office closing on Friday 21 December, 2012 and reopening on Wednesday 2 January, 2013.

If you would like to make a kind donation during this time (either in place of Christmas gifts or as a way of kick-starting the new year with some positive karma) and you would like an immediate receipt, please be sure to donate via our secure online portal rather than via post.

Finally, we’ve put together a short video to thank you again for your support this year. We wish you a wonderful Christmas, and we look forward to staying in touch throughout 2013.

Cutting beautiful lengths for cancer research

Cancer fundraisingIt’s not everyday that 2 seven year old girls choose to chop off their hair in support of charity.

Ella Dries and Tylah Foley from Ocean Grove Primary School took part in the recent Pantene Beautiful Lengths campaign by cutting their hair to be donated for a wig for a cancer patient.

The story of these 2 girls have not only touched the hearts of the local community but touched the heart of a local mum Beth Williamson, also from Ocean Grove, and she decided to join the girls and cut for the cause too. For most little girls, hair is so precious, but these brave two knew they could help others and support cancer research in honour of their nanny who has just been through cancer. Continue reading “Cutting beautiful lengths for cancer research”

Dolina morning tea serves up generous support

Corporate Charity Donations, Cancer fundraisingThe Dolina Fashion Group hosted their second annual morning tea last month to great success. ACRF supporter, Douglas Strachan, was inspired to start the morning tea at his workplace after witnessing some of the fantastic research he had been contributing to over the years.

He explains “because I have gone through bowel cancer myself, since then I have been donating to give something back. I was recently invited to join the tour of the ACRF funded cancer research centre at Randwick, and was really impressed with at the amazing work they are doing there, so therefore I wanted to do something more”.

With rousing support of his idea from his colleagues the morning tea has been a hit the past 2 years. Loads of staff have been in attendance to enjoy an abundance of delicious sweets – generously baked by their colleagues. This year’s event raised $700, every dollar of which is going to world class cancer research throughout Australia. Continue reading “Dolina morning tea serves up generous support”

Lisa loses her locks

 Cancer fundraising Cancer fundraising

When a close friend started to undergo treatment for cancer, supporter Lisa Stoddart decided it was time to do something. It was Lisa’s long locks that were to be sacrificed in honour of a beautiful friend and to support cancer research.

In her own words, “I’m quite attached to my hair… so I was hoping I could raise some money as a by-product of cutting it off and it could go to a charity”

With just 2 weeks until her shave Lisa jumped into fundraising & the money started rolling in. As friends, family and colleagues rallied behind her – Lisa’s donation target of $2,500 was quickly surpassed. The generosity continued throughout the weeks leading up to the event showing great support of Lisa and her dear friend Amanda. Continue reading “Lisa loses her locks”

PepsiCo Charity Night brings in the big dollars for cancer research

Cancer fundraisingRecently PepsiCo staff came together again for their annual trivia fundraising night for cancer research.

The strong crowd of 130 took control of the auditorium at the Canada Bay Club for a night of fun and frivolity all for a good cause. This was the 3rd annual event, originally created to honour the memory of a much-loved team member Agnes Connell who lost her battle with cancer in August 2009.

Games, raffles, auctions and the all important trivia made for a fantastic night for the staff and their families and friends. A lot of new PepsiCo staff members were also in attendance this year making it the biggest event ever! Continue reading “PepsiCo Charity Night brings in the big dollars for cancer research”

From the City to the Sea in support of cancer research

Cancer fun run and cancer fundraisingThe streets of Melbourne were overtaken by more than 11,200 participants as part of the City2Sea last weekend. Among the elite runners, joggers and walkers were 20 individuals taking part in the fun run for cancer research, choosing to combine their 14km challenge with cancer fundraising at the same time.

For many of these fantastic supporters, their choice to contribute to the Australian Cancer Research Foundation (ACRF) was a personal one. Friends, family members, and colleagues had experienced cancer and they were taking part in their honour. Some had been inspired to take part by the strength and courage of their loved ones battling cancer, and others were honouring the memory and love of sport passed on to them by loved ones lost to cancer. Whether running for their parents, partner, grandparents or children they all wanted support a cause that will “benefit future generations” and allow their run to mean something more. Continue reading “From the City to the Sea in support of cancer research”

$7.5 million in funding to the most promising cancer research in the country!

Funding research - current cancer researchThe Australian Cancer Research Foundation is committed to fighting cancer by funding research, tonight investing a further $7.5 million into the search for the cures.

At the cancer charity’s annual Chairman’s Dinner in Sydney, donors, fundraisers and researchers came together to celebrate the incredible research outcomes made possible through ACRF funding.

They also acknowledged the promising future of cancer research in Australia, as the ACRF made multi-million dollar grants available to three visionary research projects.

The Peter MacCallum Cancer Centre in Melbourne, and Brisbane’s Diamantina Institute and Centre for Clinical Research all received a significant funding boost of $3.5 million and $2 million each, respectively. At these cancer research centres, the ACRF will be funding research into rare cancers, as well as facilitating world-class, targeted detection and treatment programmes.

Secret of deceptive cancer cells uncovered

Fighting cancerAustralian researchers have discovered a dangerous molecule which convinces the body that cancer cells aren’t a threat.

With this mystery uncovered, researchers can now test new treatments that interrupt this deadly deception.

The research was conducted primarily in the Cellular Immunology Laboratory at Melbourne’s Peter MacCallum Cancer Centre, with researchers working to investigate why the body is ‘fooled’ into ignoring cancer cells.

Typically, when a cell becomes infected or damaged, it loses its surface molecules which are our body’s marker for ‘safe’ or natural cells. When there are no surface molecules to bind to, our body’s biological security team identifies the cell as dangerous.

But the team at Peter Mac, led by Dr Dan Andrews and Professor Mark Smyth, found that cancer cells can imitate the expression of normal surface molecules with a molecule called H2-M3. Continue reading “Secret of deceptive cancer cells uncovered”

Stuck on what to buy your colleague this year for Kris Kringle?

When you have only $10 or $20 to spend, it can sometimes be difficult to find a gift which isn’t of questionable quality or taste.

This Christmas, instead of buying the usual box of chocolates or a bottle wine, why not make a contribution to world class cutting edge cancer research with a donation in lieu of gifts?

At the Australian Cancer Research Foundation (ACRF), we have the solution to all of your Kris Kringle worries. We’ve got a gift to suit every budget, with a range of ACRF gifts priced upwards from $10.

Check out our Christmas gift list here!

In buying your Kris Kringle gifts from the ACRF this Christmas, you will not only impress your colleagues with your thoughtful and creative gift idea,  but more importantly you will be contributing to fighting cancer. Continue reading “Stuck on what to buy your colleague this year for Kris Kringle?”

Mapping pancreatic cancer genes reveals hidden secrets for treatment

PancCurrent cancer researchreatic cancer has long been considered a mysterious, deadly disease. It has the highest mortality rate of all the major cancers, and it is one of the few cancer types for which survival has not substantially improved over the last 40 years.

But two Australian researchers can now tell us why. They know how to fix it, and ACRF funding will play a pivotal role in the realisation of their treatment plan.

Professors Sean Grimmond from Brisbane’s Institute for Molecular Biosciences (IMB), and Andrew Biankin from the newly opened Kinghorn Cancer Centre in Sydney (formerly of the Garvan Institute) led an international team of researchers towards this ground-breaking discovery.

They sequenced the genes of 100 pancreatic tumour cells and, in order to determine the genetic changes which lead to the cancer, they compared their results to normal tissue. Continue reading “Mapping pancreatic cancer genes reveals hidden secrets for treatment”

bridge2care – A fantastic celebration to start Carer's Week

Cancer fundraisingOctober 14th marked the start of the 2012 Carer’s Week, a week to raise awareness of carers and their importance in society.

In honour of this week, Bo Lukich-Yang had the idea to celebrate carers with a morning of adventure climbing the Sydney Harbour Bridge, and bridge2care was born. Immediately there were many people keen to take part in the challenge and support the chosen charity for the inagural event, the Australian Cancer Research Foundation (ACRF). The team chose to support cancer research because “people everywhere have been touched by this indiscriminate disease” with some participants climbing particularly in honour of loved ones that had been lost to cancer.

As a beautiful day dawned in Sydney, over 40 people took to the bridge as part of the event. The group was made up of all ages and included cancer survivors, care supporters, nurses, PhD students, and children and adults with disabilities. An amazing day was had by all involved and more than $9,000 has already been raised for cancer research. Continue reading “bridge2care – A fantastic celebration to start Carer's Week”

This week: site visits to finalise up to $10 million in cancer research funding!

The ACRF’s scientific advisory committee is on the road this week to assess five world-class cancer research initiatives for potential ACRF funding.

Three of the shortlisted research teams are based in Brisbane, with one in each of Sydney and Melbourne. You can click here to read about each proposed cancer research project.

This week, these research teams will host our scientific experts for site visits and final interviews. These in-depth assessments will ultimately determine the final funding recipients.

The scientific advisory committee is an independent board of 13 esteemed cancer scientists in Australia – it is chaired by Professor Ian Frazer AC, co-creator of the cervical cancer vaccine. The role of the Committee is to identify the most innovative cancer research initiatives in the country and recommend them for ACRF funding. Continue reading “This week: site visits to finalise up to $10 million in cancer research funding!”

Vale Professor Rob Sutherland

The ACRF was deeply saddened to learn of the passing this morning of one of the giants of cancer research in this country, Professor Rob Sutherland. The Board, staff and supporters of ACRF convey our deepest sympathies to Prof. Sutherland’s wife Cheryl and all members of their family.

Prof. Sutherland was a very long-serving member (20 years), in a totally honorary capacity, of our scientific advisory committee and was awarded Life Membership of the ACRF in 2009 for exemplary service.

At the time of his passing, he was Head of Research at the Garvan Institute of Medical Research, and also Director of the newly-created Kinghorn Cancer Centre in Sydney (which combines the Garvan and St Vincent’s Hospital). The Kinghorn Cancer Centre was officially opened by the Prime Minister in late August this year and only yesterday, ACRF was privileged to open the new ACRF-funded Molecular Genetics Facility within the centre. Professor Sutherland was one of a small number of visionaries behind the creation of this comprehensive cancer centre, and was undoubtedly well pleased that the initiative had become a reality during his lifetime.

Professor Sutherland has been a leader in Australian cancer research, and the research sector is much the poorer his passing.

Thank you Rob for your great service.

World-class Genetics Facility Now Open

Fighting cancerToday her excellency Prof. Marie Bashir AC CVO, Governor of NSW will officially open a world-class ACRF-funded facility at the Kinghorn Cancer Centre in Darlinghurst, NSW.

In line with the ACRF’s mission to fund only the best research initiatives in Australia, the ACRF Molecular Genetics Facility houses next-generation sequencing technology that has the power to carry out internationally competitive research in cancer genetics.

The facility was developed through a $5 million ACRF grant made in honour of the late Lady (Sonia) McMahon, life member and founding trustee of the ACRF. A plaque in Lady McMahon’s honour will be unveiled today at the official opening of the centre.

“Without doubt, and over a long period of time, the Garvan’s researchers, led by Professor Rob Sutherland, have been up there with the best in the world and we know this new facility will further strengthen their work,” said ACRF Chairman Tom Dery. Continue reading “World-class Genetics Facility Now Open”

ACRF Molecular Genomics Facility opened by the Governor of NSW

Fighting cancerToday Her Excellency Prof. Marie Bashir AC CVO, Governor of NSW will officially open a world-class ACRF-funded facility at the Kinghorn Cancer Centre, Sydney.

The facility houses next-generation sequencing technology with the power to carry out internationally competitive research in cancer genetics.

Continue reading “ACRF Molecular Genomics Facility opened by the Governor of NSW”

Supporting women's cancers in October!

October is a time when we go pink for a most important cause: Breast Cancer Awareness Month. It is a movement that has made a huge impact on breast cancer funding and research progress around the world.

At the ACRF however, we want to focus on all types of women’s cancers this October: breast AND gynaecological cancers – such as uterine, ovarian or vaginal.

We want to see equally significant progress made for patients with these lesser funded, though no less devastating cancer types.

These cancer types affect our mothers, daughters, sisters, wives or girlfriends and friends, and your donation will give these women hope in the fight against cancer.[/vc_column_text][/vc_column][vc_column width=”1/3″][vc_single_image image=”21690″ border_color=”grey” img_link_target=”_self” img_size=”medium”][/vc_column][/vc_row][vc_separator color=”grey”][/vc_column][/vc_row]A message from Helen Bathgate: Breast cancer survivor

“I was teaching at school when the GP phoned and said she wanted to see me. It was that dreaded news that I guess I’d half been expecting. My cousin had been diagnosed with breast cancer about two weeks earlier and I’d been able to feel a hard lump running down the side of my right breast.

“I had the operation eight days later. I had a mastectomy and they cut 14 lymph nodes out – 11 of them were cancerous.

“The doctors don’t tell you you’re ‘cured’ – but I certainly feel like one of the lucky ones. I’ve been in remission for nearly five years now. It can come back at any time though, and that’s what stays with me. My cousin’s breast cancer has returned. So far, fortunately, they’ve been able to control it.

“The women in our family have been tested for any known cancer-causing genes, but they came back negative. Research will be the only way to learn more about this terrible disease. It’ll be the only way we can find a cure.”[/vc_column_text][/vc_column][vc_column width=”1/3″][vc_single_image image=”19604″ border_color=”grey” img_link_target=”_self” img_size=”full”][/vc_column][/vc_row]

Thank you for helping us fund the treatments & cures for women's cancers

[/vc_column_text][/vc_column][vc_column width=”1/3″][/vc_column][/vc_row]

Classy for a Cause

Recently supporters Dianna Thompson and Samantha Fisher hosted ‘Classy for a Cause‘ – a delightful high tea for friends and family – all in support of a cause close to their hearts.

Cancer fundraising

The girls chose to support cancer research as they have both “been touched with cancer in our lives and wanted to create awareness, and in doing so raise some money for the research teams to continue their work”.

On the day a wonderful group of ladies turned out to support ‘Classy for a Cause’ and enjoy an array of delicious treats, and take part in raffles and games in aid of cancer research. The day was a great success with all attendees leaving with smiles, full belly’s and a great feeling of having contributed to a great cause, raising over $750. Continue reading “Classy for a Cause”

Workplace Giving: Make pre-tax donations from your payroll!

Workplace Giving allows employees to make charity donations regularly through their employer’s payroll system. Part of the appeal of Workplace Giving is that the donations are tax deductible and deducted from an employee’s pre-tax salary – so staff members receive an immediate tax-benefit and many hardly notice the difference in their pay!  Employers can also choose to match employee donations or to make one-off corporate charity donations, giving every employee contribution even more value in the fight against cancer.

The most exciting part of Workplace Giving to cancer research is the incredible potential to make a real difference. Your donations will provide ACRF with the long term, stable funding we need to plan effectively and maintain our funding to world-class cancer research.

Sign up today or click to learn more!

Adelaide University Mathematics Society gets quizzical for cancer research

Cancer fundraising

The Adelaide University Mathematics Society (AUMS) quiz night is major highlight in the university semester 2 calendar. The annual event provides support to a worthy cause each year, with the 2012 quiz night supporting the Australian Cancer Research Foundation (ACRF).

The sellout event brought together 14 tables of individuals keen to be part of the fun and competition, and to wow others with their fantastic knowledge. The night involved raffles, games, competitions as well as the much anticipated quiz questions which would determine the winner of the Parrot Shield. The quiz night was a battle amongst the many teams of students and staff from the mathematical sciences school.

The largely successful evening was attended by many teams of students and staff from the school of mathematical sciences, and the overall title was a tough battle. The winners of the evening, to be etched into history on the Parrot Shield were ‘BanAna Man’. The other winner on the night was cancer research thanks to the wonderful cancer fundraising throughout the night! Continue reading “Adelaide University Mathematics Society gets quizzical for cancer research”

ACRF $8 million, a catalyst for three new cancer research facilities!

ACRF funding research - Flinders Centre for Innovation in CancerThe coming week heralds the opening of three cutting-edge new cancer research facilities: one a national first; another, a world-class prevention unit; and the last, a specialist centre in bioinformatics.

These centres represent almost $8 million in ACRF funding – our donors should be so proud of this incredible outcome of their most generous support.

The potential for ground breaking discoveries within these laboratories is astounding and exciting.

Please find details about each cancer research program below.

The world-first ACRF Centre for Kinomics at the Children’s Medical Research Institute (CMRI), Westmead NSW

To be officially opened Thursday September 27, 2012

Kinomics, a combination study of genomics (genes) and proteomics (proteins) is a new discipline in the field of cancer research. Until now, there has been no concentrated effort that focuses on understanding “kinases” – a class of proteins within our cells which play a major role in cell regulation. Most importantly, when the function of kinases is stopped or blocked, they have been implicated in human cancers. Continue reading “ACRF $8 million, a catalyst for three new cancer research facilities!”

Milestone City Bay Fun Run brings in big dollars

Cancer fun run and cancer fundraisingThe 40th annual City Bay Fun Run brought out a record number of competitors with over 39,000 people taking part in the milestone event. The Australian Cancer Research Foundation (ACRF) is pleased to have had a fantastic group of supporters taking part on the day helping to make this the most successful year of City Bay yet!

The dreary (and at some times drenching) weather did nothing to dampen the spirit of the day with the community and atmosphere lifting the runners into completing great races. For some supporters, like the Red Robyns, it was a day to walk in honour of a loved one they had lost to cancer. Her battle with cancer was lost earlier in the year and the team formed to run in honour of their beautiful mum “to give something back; just as our beautiful Mum did towards everyone who knew her”. Continue reading “Milestone City Bay Fun Run brings in big dollars”

Research is winning the fight against cancer!

Call types of cancer, fighting cancerancer survival rates have increased by 19% in just a couple of decades, highlighting the fantastic success of great cancer research in Australia.

According to the latest report by the Australian Institute of Health and Welfare (AIHW) the average 5-year survival rate for all types of cancer increased from 47% in 1982 to 66% in 2010.

“Research is the key to beating cancer, and these statistics are evidence of how progress in the labs is being translated into positive health outcomes for Australians.” Said ACRF Chief Executive, David Brettell.

“The funding we award to cancer research teams across the country is used specifically to speed up discoveries – effectively working to save lives by saving time.

“Given continued investment in cancer research in Australia, we would very much expect and look forward to these survival rates improving even further in the very near future.” Continue reading “Research is winning the fight against cancer!”

Bug Off Cancer returns from the red centre

Bug Off Cancer Coober PedyFor the third year running, dedicated Australian Cancer Research Foundation (ACRF) fundraiser Norman Elias and his team of VW Beetle enthusiasts (co-driver Mario and Kombi drivers Joe and John) have taken a road trip for cancer research.

This time, the Bug Off Cancer crew put more than 7,500kms behind them on a round trip to Uluru and with the support of family and friends, corporate charity donations, and the general public they fundraised over $15,000 for the ACRF. Their overall fundraising total for the ACRF is now at an incredible $35,220!

Norman has very sadly lost both parents and other relatives to cancer and this is what motivates him to run his “cancer drive” every year, raising such a significant amount for cancer research.

“I am determined to help raise funds for Australian Cancer Research Foundation so they can continue to fund cancer research to find better treatments and hopefully a cure to rid us of this disease,” he said.

Continue reading “Bug Off Cancer returns from the red centre”

The ACRF welcomes Jennifer Hewett to its Board of Trustees

Fighting cancer through researchWe are delighted to welcome business and political journalist, Jennifer Hewett to the Board of Trustees.

Jennifer is a highly respect columnist, more recently and most notably in national affairs for the leading financial newspaper in the country, the Australian Financial Review. She has written on business and politics for over three decades for a variety of leading Australian papers, and is also well known and respected across radio and television networks.

“Jennifer is an outstanding person and we are thrilled that she will be joining us and making a wonderful contribution to our work of funding world-class research projects in Australia,” said Chairman of the ACRF Board, Mr Tom Dery. Continue reading “The ACRF welcomes Jennifer Hewett to its Board of Trustees”

Larapinta Challenge: corporate leadership making a difference

Corporate giving and cancer fundraisingThe inaugural Australian Cancer Research Foundation (ACRF) Larapinta Leadership Challenge set off last month, combining professional development, cancer fundraising and one of Australia’s most breathtaking landscapes.

The seven day company challenge was set up in consultation with 3BL Group, World Expeditions and Global Leadership consultants. With a fantastic format in place, all we needed was a forward-thinking company to sign up for this fantastic opportunity!

The challenge was embraced by Goodman Group. Goodman quickly registered four of their staff to experience the wonders of the Australian landscape and amazingly, they have now raised $30,000 for cancer research through individual and corporate charity donations.

We are so grateful for this incredible effort! Continue reading “Larapinta Challenge: corporate leadership making a difference”

Research news: spring 2012 edition

Current cancer researchIn the Spring edition of the Research Review:

  • Researchers have found a target for treating up to 50% of childhood cancer cases.
  • An ambitious Melanoma Genome Project has launched, with the aim of identifying all common mutations within melanoma cancers.
  • The Prime Minister, Julia Gillard has officially opened the world-class Kinghorn Cancer Centre in Sydney.

Perfect day for a fun run

Cancer fun run and cancer fundraisingA beautiful spring morning in Canberra provided the perfect conditions for the annual Canberra Times Fun Run. Almost 5000 participants took part in this great community event – with 13 individuals making this run a cancer fun run by fundraising for the Australian Cancer Research Foundation (ACRF).

This group of people represented cancer survivors, loved ones of cancer survivors, and sadly those who had lost family, friends and colleagues to cancer. For them it was a chance to remember their loved ones and honour them by contributing to a cause that may one day beat cancer. One supporter, Jill, said of her choice to fundraise for cancer research – “the more we know, the better equipped we are to fight something that sadly will affect pretty much everyone sometime in their life, either directly or through someone they love”.

The perfect day in Canberra meant a very successful run for our supporters – with lots of great times and personal bests made amongst the great atmosphere! Continue reading “Perfect day for a fun run”

Vale Mr John Boettcher OAM

Mr A John BoettcherThe Australian Cancer Research Foundation is saddened to report the passing, on 7 September 2012, of its long-serving and founding trustee Mr John Boettcher OAM.

John, who served on our Board of Trustees for 28 years, was much-loved, a friend to many, and a highly respected member of the ACRF team.

John was an enthusiast for the work of ACRF and so very positive in his outlook to life. A more modest man one would struggle to find.

The Board and staff of ACRF convey our deepest sympathies to his wife Glenys, their daughters Sue, Linda and Joanne, and their grandchildren.

We will all miss you enormously John.

Rest peacefully, dear friend.

Tom Dery
Chairman

Brisbane pounds the pavement for a good cause

Cancer fun run and cancer fundraising
Cancer fundraising in cancer fun run

As Father’s Day dawned in Brisbane, almost 40,000 people lined up in the chilly weather to take part in the annual Bridge to Brisbane race. In amongst the crowds of competitors were 28 supporters of the Australian Cancer Research Foundation (ACRF) who had their own personal reason for taking part in the race along with cancer fundraising.

The group of ACRF runners were a range of ages, abilities and people from different areas of life coming together with a common goal to support the future of cancer research. Team member Julia is a medical researcher at the Institute for Molecular Bioscience who has worked in cancer research in the past and has a passion for funding the talented scientists involved in medical research. Amber is a radiation therapist who helps to treat cancer everyday and wanted to use her love of running and training to help support those who she meets in her job. And for many others there were loved ones in their lives who had beaten cancer, were currently fighting cancer, or had sadly been lost to cancer – and this run was a way to acknowledge those wonderful people. Continue reading “Brisbane pounds the pavement for a good cause”

Two birthdays and a surprise engagement!

Donations in lieu of gifts for your birthdayOn the 18th August 2012, Nancy and Ian held their joint birthday celebrations at the Bankstown Sports Club. The invitations sent to guests requested that instead of giving gifts they make a donation to the Australian Cancer Research Foundation (ACRF). Nancy’s husband died of lung cancer six years ago and she decided that in his memory she would like the donations to go to a good cause.

Nancy celebrated her milestone 60th birthday while Ian’s celebrated his 61st. The evening featured a magician who entertained the guests with a variety of tricks including vanishing playing cards and bending spoons with an Australian buffet style meal filling everyone up for dinner. The speeches included a toast by Nancy’s stepson, Jack, and a speech by Nancy’s girlfriend, Victoria, who has known her for 29 years.

The highlight of the evening came when Nancy and Ian announced their engagement and Ian placed an engagement ring on Nancy’s finger. The guests then danced to lively music provided by the DJ for the remainder of the evening. Continue reading “Two birthdays and a surprise engagement!”

2012 City to Surf Perth – one for the record books!

Cancer fun run and cancer fundraisingThe 37th annual City to Surf in Perth was a record-breaker – over 45,000 participants got involved through the days 6 events. For the Australian Cancer Research Foundation (ACRF) it was also a record breaking event with our highest ever fundraising total coming in from the 2012 event – over $18,000!

The ACRF had a mammoth group of supporters in the event including a number of teams. As with any group of supporters there are so many stories about why cancer research is the chosen cause to support as part of the race, and for many it was the direct and indirect impact of cancer in the lives of those close to them, and in the hope that “we can find a cure for the future, so that maybe one day, [our] friends and family won’t have to suffer the pain and suffering caused by cancer in any way”.

Many of our teams formed in honour of someone they had lost to cancer – Team J-Rad were running in honour of former Labor State MP Jaye Radisich who passed away earlier in the year from a long battle with cancer and Team MG got together their mother’s group to run in memory of their friend Vickey who lost her battle with cancer last year. For other teams and individuals there were many stories of loss due to cancer, and their belief in “supporting the research to find a cure”. Continue reading “2012 City to Surf Perth – one for the record books!”

Inaugural Sunshine Coast Marathon a great success

Cancer fun runOn August 26th the Sunshine Coast came alive with the inaugural Sunshine Coast Marathon and Community Run Festival. More than 5000 runners turned out to take part in the variety of races throughout the on the day with a hoard of spectators also present to take in the new event. As part of this group, 5 participants added a little more meaning to their race by doing cancer fundraising at the same time.

Each of our supporters were contributing to the work of the Australian Cancer Research Foundation (ACRF) in honour of a loved one in their life that had been lost to cancer. For some it was a recent loss of a sister, family friend or uncle and for others it was a loss some time ago and the battle ahead for close friend’s that had been recently diagnosed. Many felt this was a way to remember their loved ones in a physical way, like Craig who said “I know [the marathon] is going to be very hard for me. But, nothing like the struggle that people with cancer go through every day”. Continue reading “Inaugural Sunshine Coast Marathon a great success”

ACRF and the Kinghorn Cancer Centre opening

current cancer researchThe ACRF is very excited to attend the opening of the world-class Kinghorn Cancer Centre in Darlinghurst, Sydney today.

The comprehensive cancer facility is a joint project of the Garvan Institute of Medical Research and St. Vincent’s Hospital, and it is modeled on revolutionary medical centres overseas which bring patients, clinicians and research scientists together under the one roof.

The Kinghorn Cancer Centre will play a major role in the future of Australian cancer care. It’s multidisciplinary approach covers the entire cancer journey, working to reduce the impact of cancer in the community through research, while providing holistic patient care from diagnosis, prognosis, treatment and quality of life.

The ACRF is proud to support this fantastic facility, having provided a significant $5 million towards its development. Continue reading “ACRF and the Kinghorn Cancer Centre opening”

Our City2Surf Success!

The training regimes have slowed down and our online fundraising pages are about to close, but for approximately 420 ACRF charity runners, the memories of our 2012 Sun Herald City2Surf are hopefully still fresh in everyone’s mind!

We’ve put together a cheerful selection of photos and video footage from the day which, though windswept and cloudy, was a huge success for cancer research, and a whole lot of fun.

You see, we didn’t just raise a sweat as we navigated the 14km course from the Sydney CBD to Bondi Beach. We also raised more than $85,000 – every dollar of which will go to research that has the power to beat cancer.

The City2Surf is the largest timed fun run in the world, and we are thrilled to have had such strong support from our charity runners. Thank you again and we hope to see you again next year!

Melanoma Genome Project will map out future for skin cancer cures

Melanoma cancer researchNSW Minister for Health and Medical Research, the Hon. Jillian Skinner has today officially launched the Australian Melanoma Genome Project, an ambitious cancer research program that aims to identify the common gene mutations that lead to melanoma.

The $5.5 million project could take 2-5 years and is being undertaken by a research coalition of teams from the Melanoma Institute Australia, the University of Sydney, Westmead Millennium Institute, Royal Prince Alfred Hospital, NSW Health Pathology and the Queensland Institute of Medical Research.

More than 500 melanoma tumour samples will be screened and analysed in order to determine common genetic characteristics for this most deadly and prevalent type of cancer. Continue reading “Melanoma Genome Project will map out future for skin cancer cures”

A big BBQ for a special little boy

Cancer fundraising to give to charity

On the 12th August, Rocks Riverside Park was overtaken with family and friends excited for a fun day supporting cancer research on behalf of a brave boy named Joshua. The Bates and Goodhew families decided to organise a BBQ fundraiser in their local park to support a cause close to their hearts with little Joshua suffering from a neuroblastoma that requires chemotherapy, radiation and surgery.

Many cancer charity foundations have touched the lives of this family during Joshua’s illness, but they chose to support cancer research knowing that funding research is the key to a cure.

In only a few days the family had already raised thousands of dollars in support of their cause and had people lining up to take part in the events on the day. It was decided that family members and friends would have the opportunity to shave their heads or colour their hair on the day to raise further funds. The local council even donated the park hire fee to allow more funds to be raised. Continue reading “A big BBQ for a special little boy”

New childhood cancer research could help prevent 50% of cases

A new discovery could lead to preventative treatments for embryonal cancer cells which are responsible for more than half of all childhood cancers.

Typically, only 20% of the embryonal cells created in the womb survive after birth to form nerve tissue in a baby’s body. The rest die off before the child is born.

However, sometimes excess cells survive and develop into cancers.

Under the leadership of Professor Glenn Marshall, Head of Translational Research and Molecular Carcinogenesis at the Children’s Cancer Institute Australia (CCIA), researchers have investigated this occurrence, focusing on the most common solid tumour cancer in early childhood – neuroblastoma. Continue reading “New childhood cancer research could help prevent 50% of cases”

Help us fight cancer this Father’s Day

Donations in lieu of giftsA donation to cancer research is a gift that truly gives back, with every dollar going to world-class research in Australia.

Many ACRF supporters choose to give donations in lieu of gifts on special days such as Father’s Day through our ‘In Celebration’ giving program. We are so grateful for their support.

If your Dad is your hero (and really, whose isn’t?) why not honour him this Father’s Day with a present that will bring hope to families around the world?

Please click here to donate

When you make your Father’s Day donation to the ACRF, we will gladly post a greeting card to your father, including your personal message of love and support. He will also receive a letter explaining the kind donation you have made in lieu of a gift at Father’s Day. Please note we will not disclose the amount you donated, as the donation receipt will be sent automatically to your email or postal address.

Thank you for your thoughtful gift at this most special time of year.

ACRF opens two new cancer research facilities in Melbourne

Cancer Research boost through ACRF fundingTwo new ACRF-funded cancer research facilities at the Walter and Eliza Hall Institute have today been officially opened by the Lord Mayor of Melbourne, Councillor Robert Doyle.

Thanks to a $2 million ACRF grant, these new divisions will expand the institute’s current cancer research into the causes and treatments for some of the most prevalent cancers in Australia.

In particular the ACRF Stem Cells and Cancer Division will study the biology of epithelial cancers – which account for 80% of human cancers – including breast, lung and ovarian cancers. Continue reading “ACRF opens two new cancer research facilities in Melbourne”

City2Surf: supporting our teams!

The world’s largest timed fun run, the Sun Herald City2Surf, is just around the corner and the ACRF is thrilled to have 350 runners registered to complete the 14km course for cancer research.

If you know of a friend, colleague or family member who is registered as an ACRF team member, please do support their efforts. 14km is no easy feat, and considering the approx. 80,000 other runners who will be joining us along the way, it’s certainly an event to get excited about.

Please also rest assured that ACRF staff members will also be putting out best feet forward for the cause, as we compete alongside alongside our dedicated supporters.

Support the ACRF City2Surf team here!

Last year we were thrilled to receive an incredible $75,000 from our City2Surf fundraiser’s efforts and every dollar we received went to world-class research with the power to beat cancer. Let’s see if we can reach an even higher fundraising total this year.

Thanks again to our fundraisers and very best of luck!

Gold Coast overrun by marathon festival

Cancer fun run & cancer fundraisingA record 28,000 runners turned out for the annual Gold Coast Airport Marathon event, encompassing the marathon, half marathon, 10km, 5km and junior dash races. As part of the event, 5 generous individuals chose to raise funds for cancer research as part of their race.

These supporters each had their own motivations for supporting cancer research, some were cancer survivors giving their all with their new found health, others had friends and family currently battling cancer, and others had sadly lost loved ones to cancer. Supporter Miles Thompson said it was the loss of his amazing papa, Keith Patching, a few years ago that inspired him to support cancer research, he was doing this run for his papa. Amongst all the worthy cancer charities, supporter Kylie King chose to support the Australian Cancer Research Foundation (ACRF) because she “decided [her] money would work the best, by going towards helping with research to find a cure.” Continue reading “Gold Coast overrun by marathon festival”

Great day to Run Melbourne

Cancer fundraising in Cancer fun runOn July a5, the city of Melbourne was taken over by runners, joggers and walkers as part of Run Melbourne. Amongst the 26,000 competitors on the day were 105 supporters who chose to combine their race with cancer fundraising for the Australian Cancer Research Foundation (ACRF).

This stellar group was made up of all ages and included first timers and seasoned runners. For some this cancer fun run was a chance to regain their fitness, have some fun, or to challenge themselves. But for all there was also a more personal motivation – in many cases that was to run in honour of a loved one that was fighting cancer or had been lost to cancer. In the words of one supporter, Meredith, “It’s my hope that in some small way this run will honour the memory of a wonderful man who was a great father, husband, grandfather and friend to everyone he met, but it will also give hope to the thousands of families who’s fight against cancer continues”. In many cases those watching their loved ones fighting cancer feel helpless and for another supporter, Coralie, fundraising for cancer research as part of her running challenge was “the only thing within my power to do and could help people in the future”. Continue reading “Great day to Run Melbourne”

Sharyn shares her Regular Giving story

Monthly donation
Sharyn and her family

This July we are celebrating the contributions of a VIP group of supporters known as Partners in the Cure. These Australians have made a long-term commitment to cancer research by making monthly donations to the ACRF, and we are so grateful for their support.

One Partner in the Cure and regular giver, Sharyn Hillas has also generously shared her story with us. Please take a moment to read about Sharyn, and her son’s brave fight against cancer:

“My son, Robert was diagnosed with a primary Central Nervous System Lymphoma in September 2011, but his battle began many months before that. Continue reading “Sharyn shares her Regular Giving story”

AGT winner Andrew De Silva shines a spotlight on cancer research

Cancer research ambassadorAndrew De Silva’s knowledge of the Australian music scene stems back further than most.

A taste of fame in the nineties as part of popular music group CDB has set the stage for what anyone can see is an exciting second chance for this amazing vocalist. His incredible success as the Seven Network’s ‘Australia’s Got Talent’ Winner has also allowed Andrew to tell his story to the world.

“Cancer research is so important to me. Not only has it affected me personally, but it has also affected my family and so many friends,” Andrew told us. “I’ve watched it take the lives of the young & old, and then it also changes the lives of the people that are left behind.”

Andrew has touched so many hearts as he has progressed through the reality television competition and shared his progressive soul/rock originals. We are delighted and humbled to be able to call him an Australian Cancer Research Foundation Ambassador, and to learn more about his journey through cancer: Continue reading “AGT winner Andrew De Silva shines a spotlight on cancer research”

ACRF grant recipients receive NSW Premier's praise

Researchers from three ACRF-funded cancer research centres have received accolades at the 2012 NSW Premier’s Awards for outstanding cancer research.

Hosted by the Cancer Institute NSW, the awards honour the work of the State’s most innovative and dynamic cancer researchers, and so we congratulate these esteemed scientists:

1. Excellence in Translational Research
Professors Michelle Haber, Glenn Marshall, and Murray Norris – Children’s Cancer Institute Australia (CCIA) for Medical Research

This team from CCIA (a recipient of two ACRF grants totaling $3.6m) have been acknowledged for their ground-breaking work in testing children with Acute Lymphoblastic Leukaemia (ALL) and improving survival rates. Their minimal residual disease testing (MRD) can predict which children suffering ALL are at the highest risk of relapse on standard therapy, triggering individualised treatment to commence at earlier stages.

Continue reading “ACRF grant recipients receive NSW Premier's praise”

A night of Glitz and Glamour in the nation’s capital

Wendy Newton Sonia and Robert Holgate and Lucy NesciThe Hellenic Club in Canberra recently played host to a cancer fundraising event organised by Australian Cancer Research Foundation (ACRF) supporters Wendy Newton and Lucia Nesci: a night of glitz, glamour, and giving.

This was the first fundraising event that the duo have hosted and they raised over $4,000 for cancer research – a great achievement! They also gave a charity donation to a local not-for-profit organisation in Canberra.

The night consisted of a three course meal, live band, and silent auction which included the sale of a NSW Blues State of Origin jersey signed by the entire squad and the coach.

The ACRF are very grateful for the cancer fundraising efforts of Wendy and Lucia and 100% of the funds we received from this event will be going to world-class cancer research into all types of cancer.

World-first HPV vaccination plan will protect young Australian men from cancer

current cancer researchYoung Australian males will receive the HPV vaccine (Gardasil) free of charge in a world-first public health measure that will help prevent a range of cancers.

Federal Health Minister Tanya Plibersek announced the plan yesterday at the Diamantina Institute in Queensland, where the vaccine was developed by Professor Ian Frazer and his team.

The HPV vaccine has already contributed to a decrease in pre-cancerous cervical lesions in young women.

When administered to males, it will help prevent cancers of the genital tract, some types of head and neck cancers, and it will also enhance the vaccine’s effectiveness in women.

Boys aged 12 – 13 will receive the vaccine through school-based programs under the National Immunisation Program, with Year 9 boys also included in a two-year catch-up plan. Continue reading “World-first HPV vaccination plan will protect young Australian men from cancer”

Kidney cancer therapy treats leukaemia patient into remission

current cancer research
Leukaemia patient, Dr Lukas Wartman. Source: the New York Times

After facing death just eight months ago, a leukaemia cancer patient is in remission following treatment with a drug tested and approved only for advanced kidney cancer.

This is thanks to the findings of a complete and complex genetic sequence undertaken by researchers at the University of Washington.

The research team used a type of analysis that had never been done before: the patient’s cancer cells, his healthy cells and his RNA (a close chemical cousin to DNA) were all sequenced in order to discover a rogue gene working to spur the cancer’s growth.

The patient, a cancer researcher himself – Dr Lukas Wartman – had been diagnosed with adult acute lymphoblastic leukaemia and was deteriorating quickly. But this study revealed a particular gene which was releasing large and unusual amounts of a protein that encourages cell growth. Continue reading “Kidney cancer therapy treats leukaemia patient into remission”

Give it up: Regular giving for cancer research

You can become a Partner in the Cure by making a regular gift to cancer research!

This month, we are celebrating the incredible Australians who make monthly donations to break-through cancer research. These individuals are called ‘Partners in the Cure’ and they are characterised by their long-term, passionate commitment towards finding the treatments and cures for cancer.

Every donation – large or small – received by the Australian Cancer Research Foundation goes to research with the power to beat cancer. That’s right – 100%. We don’t use any donation dollars to fund our administrative, marketing or operational costs, which means your monthly donation is able to work faster for the future of Australian lives.

What could you give up?

Use our gift chart below to work out how much you can afford to give! Continue reading “Give it up: Regular giving for cancer research”

Rising star, Andrew De Silva shines a spotlight on cancer research

Cancer research ambassadorAustralia’s Got Talent grand finalist, Andrew De Silva has shown his support for cancer research by becoming an ACRF Ambassador.

We were fortunate enough to catch up with Andrew just before his Australia’s Got Talent final to hear more about his journey through testicular cancer.

Continue reading “Rising star, Andrew De Silva shines a spotlight on cancer research”

Our Regular Givers are Partners in the Cure

Luke Hespanhol makes monthly donations to cancer researchJuly is Regular Giving month – a time when passionate supporters are encouraged to kick-start the new financial year by signing up to make monthly donations to cancer research.

These generous Australians who make regular charity donations to the ACRF are part of a VIP group of supporters known as Partners in the Cure. They are characterised by their ongoing commitment to our work and their belief that together, a group of dedicated donors can make a BIG difference to the lives of cancer patients and their families.

I would like to sign up as a Regular Giver today.

This July, we celebrate our Partners in the Cure.

We have gathered a number of stories for you, told to us first-hand by some of our Partners in the Cure. Luciano Hespanhol has been a regular giver since 2007 – and in his words “It is important to me that my donation is done regularly because at any given time I can remind myself that I am preventing other people from heading down the same no-through road.”

“When I was 17, my grandmother was diagnosed with cervical cancer, and in order for her to be looked after, my mother brought her to live with us.

“Although the prognosis seemed positive at the start, chemotherapy and radiotherapy quickly destroyed my once cheerful grandma. Continue reading “Our Regular Givers are Partners in the Cure”

An appeal for tax deductible donations to cancer research

Together we can fund cancer research innovations that will change the world.

This year, make a tax deductible donation to ACRF before June 30th and reduce your taxable income while supporting a cause you are passionate about. 100% of your tax donation to ACRF goes to cancer research.

Make a meaningful tax deductible donation this year

Please never doubt the impact that your tax deductible donation – however small or large – can have on our work. We are funding the innovations that matter together, and together we can beat this terrible disease.

It can be hard to imagine that one tax deductible donation – your donation – could make a difference, but it can, it does. The proof lies in what ACRF has been able to achieve thanks to generous Australians like you.

You see, when your donation combines with the single donations of thousands of Australian individuals, families, companies, community groups etc. ACRF is able to award up to $10 million to world-class cancer research initiatives every year.

This goes towards conducting ground-breaking research to outsmart cancer. An example of ACRF’s achievements is seed funding the development of the cervical cancer (HPV) vaccine, since this development, this vaccine has been delivered to over 150 million people worldwide.

Continue reading “An appeal for tax deductible donations to cancer research”

Top-Level Domain will strengthen our search for cancer cures

The Australian Cancer Research Foundation is embracing the next generation of online communication with an application for the Top-Level Domain “.cancerresearch”.

Top-Level Domain names are part of a new web-based program to expand the Internet’s address system, and we welcome the opportunity to occupy an authoritative and exclusive digital space that will support our commitment to helping find the cures, through research, for cancer.

At the ACRF, we’ve funded over $50.0 million in research in just the last six years – and we have a passion to fund more. Our donors and other supporters know that we fund research which produces results. They also know that we don’t waste money.

Zero donation dollars have been used to fund this application. We’ve been able, for some years now, to fund all our running costs with returns on responsibly invested funds. Every dollar we receive in donations goes to research.

Research is key to beating cancer, and cancer researchers are making great progress. Continued rapid progress is only limited by money.

By providing a dedicated domain for cancer research information, news and ways to support researchers’ vital work, we are confident this TLD will enhance our ability to provide more funds to support this incredible research into all types of cancer.

 

Top level domain will strengthen our search for cancer cures

The Australian Cancer Research Foundation is embracing the next generation of online communication with an application for the Top-Level Domain “.cancerresearch”.

Zero donation dollars have been used to fund this application, and we welcome the opportunity to occupy an authoritative digital space that will support our commitment to helping find the cures for cancer.

Continue reading “Top level domain will strengthen our search for cancer cures”

28 years funding fantastic cancer research!

Cancer research birthday cakeThe ACRF is today celebrating its 28th anniversary!

Established in 1984, the ACRF was created to fill a gap in cancer research funding. It pledged to provide significant private grants for progressive cancer research initiatives right across the country – specifically for cutting-edge technologies, facilities, and visionary collaborations.

The ACRF has since awarded almost $80 million in grants for world-class cancer research, a truly incredible feat. cancer research anniversary cakeFurthermore, thanks to our always careful financial management, the ACRF is proud to be able to say that every donation dollar we receive provides the funding for these grants. No donation dollars are used to fund our administrative, operational or marketing costs.

… Or the costs for this incredible anniversary cake. Thank you to Cheryl for your amazing handiwork in the kitchen. And thank you also to our guest cake-cutter Glenys (pictured) who, together with her husband John, has helped ACRF grow right from the very beginning. Happy birthday ACRF!

28 years funding cancer research in Australia

The ACRF is today celebrating its 28th anniversary!

Established in 1984, the ACRF was created to fill a gap in cancer research funding. It pledged to provide significant private grants for progressive cancer research initiatives across the country – specifically for cutting-edge technologies, facilities, and visionary collaborations. Continue reading “28 years funding cancer research in Australia”

Ruby cuts it for cancer research!

Ruby's cancer fundraising challenge!

She’s only 11 years old, and already Ruby Tilley is making headlines.

This incredible young lady pledged to shave her head amongst the cheers and support of thousands at the Roosters vs Broncos NRL match last Sunday, all in the name of charity.

Ruby has raised more than $13,000 for cancer research – and we at the Australian Cancer Research Foundation are so very grateful for such a fantastic fundraising effort.

Please click here to donate via Ruby’s fundraising page.

Cancer fundraising event head-shaveRuby was motivated to go above and beyond for the ACRF in this way having recently lost her grandfather to cancer. She has said she doesn’t want anyone else to go through the pain and suffering that her family did when her grandfather passed away.

The ACRF is committed to fighting cancer through research. Every donation dollar that we receive (100%)  goes to world-class research with the power to beat this terrible disease.

We thank Ruby very much for her brave actions last Sunday (in the pouring rain, we might add), and thank her again for choosing the ACRF to be part of this very special day.

Download an article about Ruby in the Wentworth Courier here.

 

Research news: winter 2012 edition

In the Winter edition of the Research Review:

  • June 2012 Research Review‘Breast cancer’ has been reclassified into approximately ten separate diseases after a landmark UK study.
  • A US trial for a new HER-2 positive breast cancer treatment, or medical ‘smart-bomb’, is shown to extend life expectancy with fewer side effects than traditional chemotherapy.
  • Brain tumours in nine out of ten patients with metastisised melanoma have shrunk in a clinical trial run by Westmead Millennium Institute for Cancer Research.

11 year old Ruby cuts it for cancer research

Ruby's cancer fundraising challenge!She’s only 11 years old, and already Ruby Tilley is making headlines.

This incredible young lady raised more than $13,000 for cancer research following her pledge to shave her head at the Roosters vs Broncos NRL match last Sunday. Continue reading “11 year old Ruby cuts it for cancer research”

Five of Australia’s best cancer research initiatives in the running for ACRF grants!

The ACRF was thrilled to recently receive 12 applications for our cancer research grants in 2012, representing a need for $41.7 million.

These applications have since been reviewed by our esteemed, independent Medical Research Advisory Committee and a shortlist of five fantastic initiatives has been identified for further assessment.

Each application presents an impressive, visionary project – three of which have been submitted by research centres in Brisbane with one more in each of Sydney and Melbourne.

Each research centre has been invited to submit a follow-up application containing further detail about their research projects, with site visits to be conducted by the Medical Research Advisory Committee in October. The final grant awardees will be announced at our annual Chairman’s Dinner in November 2012.

Centre for Clinical Research, University of Queensland, Brisbane

The UQ Centre for Clinical Research has applied for funding to purchase one of the first commercially available clinical (human) MRI/PET scanners. This application aims to establish a single site facility for clinical oncology imaging with hybrid molecular imaging technology. Continue reading “Five of Australia’s best cancer research initiatives in the running for ACRF grants!”

ACRF announces its cancer research grants shortlist

ACRF cancer research grantsFive of Australia’s best cancer research initiatives are in the running to receive a multi-million dollar grant from the Australian Cancer Research Foundation in 2012.

After an extensive review process, the final grant awardees will be announced at the ACRF’s annual Chairman’s Dinner in November. Continue reading “ACRF announces its cancer research grants shortlist”

Queen’s Birthday Honours List acknowledges four incredible Australians for their services to cancer research

Order of Australia AC Professor Ian Frazer
Professor Ian Frazer. Source: The Australian

 The Australian Cancer Research Foundation would like to congratulate the following four Australians on their appointment to the Order of Australia yesterday via the Queen’s Birthday Honours List. We are so proud and humbled to have the support of these incredible Australians in various aspects of our work:

Professor Ian Frazer, awarded Companion (AC) in the general division: Professor Frazer has been recognised for eminent service to medical research, particularly through leadership roles in the discovery of the human papilloma virus vaccine and its role in preventing cervical cancer. His services to higher education and charitable organisations (Professor Frazer is currently Chairman of the ACRF Medical Research Advisory Committee) have also been acknowledged with this award. Continue reading “Queen’s Birthday Honours List acknowledges four incredible Australians for their services to cancer research”

Running for a Reason

Cancer fun run and cancer fundraisingOn the 27th May 20,100 people ran, walked, jogged and strolled as part of the HBF Run for a Reason in Perth. For each and every person there would be a different reason for their run – perhaps for fun, fitness, as a dare, a challenge or just something to do, but for 31 individuals cancer research was a key part of their reason.

The group of supporters for the Australian Cancer Research Foundation (ACRF) were made up of long time contributors and some new faces all with a connection to cancer research and a reason for doing cancer fundraising alongside their run. For some they were running in support of their loved ones who had conquered cancer, for others they were competing in memory of those they had lost – mothers, fathers, cousins and friends. For Christine, the passion for supporting the ACRF came from the feeling that  “without the research, a cure, or at least more medications to help, would never be found” and for Cynthia it was a “want to do what I can to prevent anyone else in my family having to go through [cancer].” Continue reading “Running for a Reason”

The Mongol Rally charity fundraising challenge!

The Mongol Rally - Charity fundraising event “Imagine you’re lost in a massive desert, hundreds of miles from civilisation, driving a car your granny would be embarrassed by,” reads the website of epic charity fundraising event, the Mongol Rally.

“Then all of a sudden all your wheels fall off and the search for tools turns up a dirty sock and two dried apricots. That’s the Mongol Rally.”

The Mongol Rally is an annual charity fundraising event that puts teams behind the wheel of a 1.2L car, on an unspecified route from London to Mongolia. The ACRF is proud (not to mention a little nervous) for two very brave teams to be competing in this incredible cross-country race, all in the name of charity.

Both teams herald from Tweed Heads in NSW: ‘The Mongol Rally Roos’ (Ben Lockeridge and Rhys O’Sullivan) and ‘The Khangaroos’ (David and Peter Baker). Continue reading “The Mongol Rally charity fundraising challenge!”

Targeted breast cancer treatment prolongs life and reduces side effects!

A new treatment is being heralded as a ‘smart-bomb’ for breast cancer following very promising studies in a Phase III clinical trial based in the US.

Researchers at the Duke Cancer Institutes administered a new drug ‘T-DM1’ to almost 1000 women with the specific breast cancer type ‘HER-2 positive’, and found it prevented patients’ advanced tumours from progressing while delivering fewer side effects compared to conventional treatments.

“As a clinician who takes care of breast cancer patients, it’s important to have a treatment that is both effective and well tolerated,” said director of the Breast Cancer Clinical Program at the Duke Cancer Institute, Kimberley Blackwell.

“This is a drug that brings us another step closer to treating cancer without the side effects of chemotherapy.”

HER-2 breast cancer is distinguished by high levels of a protein known as ‘human epidermal growth factor’ which promotes cancer cell growth. It accounts for about 20% of invasive breast cancers. Continue reading “Targeted breast cancer treatment prolongs life and reduces side effects!”

Race day in memory of a much loved Grandma

Cancer Fundraising and donations in memoryAfter the loss of her Grandma to brain cancer, Kylie Lampard, wanted to do something to honour her memory. She chose to organise a Race Day for family and close friends to celebrate the life of her Grandma but also give to charity at the same time through a raffle.

On the day 100 people attended the event at Morphettville Racecourse. It was a beautiful day which honoured Kylie’s Grandma with a namesake race, the Joan McCulloch Fashion Handicap as Race 7. The CEO of Morphettville Racecourse sponsored the race which was a great success.

The raffle was conducted thanks to great sponsors who donated prizes – thanks to SAJC, ABS brakes, Angelakis, Groove Haircutters, Croydon Foodland, Alsco, Little Chez Pizza and Festival Theatre for your assistance in raising over $1,000 for cancer research. Continue reading “Race day in memory of a much loved Grandma”

Cheryl makes a comeback for the ACRF

Cheryl McGinnIn the 1970s and 1980s, Dayboro singer Cheryl McGinn toured the country as a popular cabaret singer.

She hasn’t returned to the stage for some time, but this month Cheryl has made her comeback to raise money for cancer research!

At a special fundraising concert for the Australian Cancer Research Foundation, Cheryl performed the hits of popular artists John Denver and Connie Frances. She sang in memory of several family members who have sadly passed away from cancer.

“There are so many families and so many people touched by it (cancer),” Cheryl said.

“This year the cabaret is our way of continuing to raise money for the cause, so that hopefully one day others won’t have to leave their families before their time.” Continue reading “Cheryl makes a comeback for the ACRF”

540km Cycle for cancer – target reached today!

Fundraising cycle for cancer researchA group of seven cyclists recently completed a cancer fundraising ride of 540km with money raised going to the Australian Cancer Research Foundation. They took three days to complete the ride, which went from Mudgee to Dubbo, Gilgandra, Warren, Nevertire and back to Mudgee.

All of the riders at some stage have been indirectly affected by cancer and have decided to use their passion for cycling to help find a cure.

Dave Berry, one of the cyclists raising funds for cancer research said “although the pain that we will go through pales in significance next to a cancer patient, we hope that our efforts will encourage people to donate generously to the Australian Cancer Research Foundation and help the dedicated researchers find a cure for cancer”. Continue reading “540km Cycle for cancer – target reached today!”

Miss Universe Australia 2008 signs up to support cancer research!

Laura Dundovic to run the City2Surf for cancer researchDating in the Dark host and 2008 Miss Universe Australia Laura Dundovic has pledged to support the fight against cancer as an Ambassador for the Australian Cancer Research Foundation.

Like so many thousands of Australians, Laura and her family have been directly affected by the pain and suffering of cancer.

“My grandfather died of bowel cancer at 73 and I saw how debilitating this disease is. I saw how important research and early detection are,” she said.

“Cancer is something which seems to sadly touch everyone in some way, and I want to be a part of the fight to find the cures.”

Laura has embraced her involvement with the organisation with open arms, having already secured a contribution from OK Magazine for her recent Mother’s Day photo shoot.

Her first official event as an ACRF Ambassador too, will be a family affair when Laura tackles the world’s largest fun-run, the 2012 Sun Herald City2Surf with her mother and father running by her side. Continue reading “Miss Universe Australia 2008 signs up to support cancer research!”

June is Workplace Giving Month

Workplace Giving for cancer researchJune is Workplace Giving month and the Australian Cancer Research Foundation (ACRF) is encouraging all companies and corporate organisations to take this opportunity and establish a Workplace Giving program in support of cancer research.

What is Workplace Giving?

Workplace Giving allows employees to make charity donations regularly through their employer’s payroll system. Part of the appeal of Workplace Giving is that the donations are deducted from an employee’s pre-tax salary – so staff members receive an immediate tax-benefit and many hardly notice the difference in their pay!  Employers can also choose to match employee donations or to make one-off corporate charity donations, giving every employee contribution even more value in the fight against cancer.

Sign up for workplace Giving today
Ask us a question about Workplace Giving!

Continue reading “June is Workplace Giving Month”

A picturesque setting for a marathon challenge

Cancer fundraising, Cancer Fun RunIn a “moment of madness” supporter Rob Turner signed up for the Great Ocean Road Marathon. This stunning place in Australia hosts a marathon festival each year with record entries flowing in for 2012, the spectacular course seems to spur people on to take up the challenge of a marathon. Along with Rob were team Lorne Long Strides featuring Gabby, Emma, Eliza, Stephanie and Jessica, fundraising for cancer research.

This group of supporters felt that doing cancer fundraising alongside their challenging run would “make it more worthwhile” and chose to support the Australian Cancer Research Foundation (ACRF) specifically because of the impact of cancer in their lives through their friends and family. In particular for Rob, the operations and treatment his father has received through his cancer battle are “purely a testament to organizations like [ACRF] who work tirelessly to find a cure to cancer”. Continue reading “A picturesque setting for a marathon challenge”

Half Marathon takes over Sydney

cancer fun run cancer fundraisingFor the 21st year, the Sydney Morning Herald Half Marathon flooded the streets of Sydney with over 16,000 runners taking part. Among these were a wonderful group of supporters fundraising for cancer research.

When asked why they chose to support cancer research in this way, many competitors were running in honour of their family members and friends who had been affected by cancer in their lives and in some cases lost to cancer. For others it was a focus on the importance of research in the hope that “the more money that is raised the closer we will get to finding a cure”.

As the challenge of the half marathon loomed some competitors were feeling confident to better their times from previous years, others were nervous of the task ahead in taking on their first half marathon, and sadly others were unable to compete due to injuries.

All in all the day was a great success for our wonderful supporters with many beating their target times, and some more than exceeding their fundraising targets as well. Continue reading “Half Marathon takes over Sydney”

New drug could boost brain cancer survival

Melanoma discovery at Westmead Institute for Cancer ResearchAustralian researchers have reported promising results from a new drug which could help prolong the life of people diagnosed with one of the most deadly forms of brain cancer.

Until now, patients with advanced melanoma that has spread to the brain have received a dire diagnosis. They survive only for an average of four months.

But cancer researchers at the University of Sydney, Melanoma Institute Australia, Sydney’s Westmead Hospital and the ACRF-funded Westmead Millennium Institute, have for the first time found a drug which shrinks brain tumours in these patients with advanced melanoma.

Dr Georgina Long of the University of Sydney said the drug, called Dabrafenib, works by targeting a gene mutation found in many melanoma cancers. The drug works by causing the cell to stop multiplying and in many cases it shrinks and disappears. Continue reading “New drug could boost brain cancer survival”

Corporate giving in QLD comes alive on the sporting field!

Company fundraising via the QLD Corporate GamesThe 13th annual QLD Corporate Games will finish with a bang this evening after a weekend of sporting enthusiasm, friendly competition, and of course, cancer fundraising for the ACRF.

As the Games’ official charity, the ACRF is delighted to be attending the Corporate Games Cocktail party tonight (and speaking more personally with the many staff and company representatives now that they’ve hung up their runners and football boots).

The QLD Corporate Games was a fantastic success! The ACRF would like to congratulate Walt Hiltner and Ellen Goff for such seamless organisation and for generating a fantastic community spirit. We also thank the Queensland government and the other major sponsors Canon, Marriot Brisbane, 4BC Radio, Scody and OKI.

It was a pleasure to visit the sporting grounds at the University of Queensland over the weekend (a location in which we are particularly proud to have two ACRF-funded cancer research facilities) and watch the 5000 staff from the finance, mining, retail, tourism and government sectors going head-to-head for their health, fitness, and a fantastic cause. Continue reading “Corporate giving in QLD comes alive on the sporting field!”

SHELLTER fashion house is fighting cancer!

Fighting cancer through fashion cancer fundraising!The ACRF would like to thank Shelley Pratt, director and designer of SHELLTER Maternity Wear, for fighting cancer through her Organic Thoughts and Action maternity clothing range.

SHELLTER is donating $10 from every Organic Thoughts t-shirt and $20 from every Organic Actions dress to world-class cancer research during the months of May and June.

Shelley’s involvement in cancer fundraising reflects a wider trend of corporate and company involvement in the cancer charity sector, and we’re thrilled to have her support.

“I believe the ACRF and their mission runs parallel with SHELLTER’s philosophy including sustainability, ethics and supporting small businesses hoping for big and positive changes for the future,” she told us. Continue reading “SHELLTER fashion house is fighting cancer!”

Funding research with the power to beat cancer!

ACRF cancer research grantsThe ACRF is thrilled to have received 12 applications for world-class cancer research after submissions for ACRF grants in 2012 closed last Friday.

Together, the applications represent a need for $41.7 million in cutting-edge technologies and/or capital works for the development of high-tech facilities and collaborative initiatives. It is a strong indication of how important it is for the ACRF and other bodies to continue funding research that has the potential to make significant break-throughs in cancer prevention, diagnosis and treatment.

Six applications have been received from Brisbane, with two each in Sydney and Melbourne, and then one more in each of Adelaide and Perth. The scope of works is truly impressive, and it’s fantastic to see the research expertise within so many Australian states represented in this mix. Continue reading “Funding research with the power to beat cancer!”

‘Brake gene’ turned off in pancreatic cancer

Pancreatic Cancer ResearchA new study has found that a particular gene is being switched off in the cancerous cells of up to 15% of pancreatic cancers.

New drugs are already being tested to turn the gene back on, thereby working to stop the spread of cancer.

Pancreatic cancer is one of the most aggressive and lethal types of cancer, and this discovery paves the way towards a new class of drugs which target this gene, thus treating some types of pancreatic cancer much more effectively.

The study was published in the journal ‘Nature’ following research which revealed that when the gene Usp9x was ‘switched off’ in mice, cells started to grow out of control. It has been called a ‘brake gene’ because it seems to have a key role in natural cell death.

Continue reading “‘Brake gene’ turned off in pancreatic cancer”

Metal for Cancer – funding research through music

Metal for Cancer - cancer fundraising initiativeLate last year, a group called Metal for Cancer released a new digital single called ‘Lets Unite in Rock’ featuring an all-star cast exclusively written and produced by Henrik Flyman to raise funds for cancer research.

Cancer is a disease that touches people from all walks of life and the heavy metal community is no exception. Many Hard Rock and Heavy Metal legends have sadly lost their battle to this devastating disease.

The song starts off with a riff which pays homage to the late Ronnie James Dio and lyrically uses typical heavy metal imagery describing the heavy metal community uniting to defeat cancer which in the song is portrayed as ‘the beast’.

Continue reading “Metal for Cancer – funding research through music”

A cancer research donation makes the perfect Mother’s Day gift

Mother’s Day is fast approaching, which means many of us are working overtime to think of creative but meaningful gift ideas.

Many ACRF supporters choose to give donations in lieu of gifts on special days such as Mother’s Day through the ACRF’s ‘In Celebration’ giving program, and we are truly grateful for their support.

Donations in lieu of gifts help to make an incredible difference to our work in cancer research. Every donation dollar we receive (100%) funds world-class research into all types of cancer.

Wouldn’t a world without cancer be the greatest gift of all this Mother’s Day?

Continue reading “A cancer research donation makes the perfect Mother’s Day gift”

2012 Australian Running Festival

cancer fun run cancer fundraisingThe country’s capital was out running on April 14th & 15th as part of the Australian Running Festival. Across the 5 events of the weekend ranging from 5km to the Ultra Marathon, 16 people were running for cancer research.

When asked why they chose to run for cancer research, many revealed personal motivations from the impact of cancer in their lives. From loved ones who had been lost, to supporting those currently fighting cancer they believed that the funds they raised “will truly help find a cure to this horrible disease”.

The weekend was “fresh” but produced great weather for the runs with a record number of 5,000 participants getting involved in the events for causes they were passionate about. Despite some feeling the pressure and struggling through their races, the runners for cancer research had great races, with many smashing their goals and that wonderful sense of personal achievement crossing the finish line. Continue reading “2012 Australian Running Festival”

Breast cancer study set to revolutionise diagnosis and treatment for patients

Researchers from the UK have “re-written the rulebook” * on breast cancer research with what is being called a ‘landmark’ study.

They have reclassified the disease into ten categories, where formerly it was understood there were four, based on the genetic fingerprints of breast cancer tumours from 2,000 women in the UK and Canada.

The implications of this study are significant: Women with breast cancer can now be identified as having a more specific disease – one of ten under the breast cancer “umbrella” – and their prognosis, and subsequent treatment options will be better defined as a result. Continue reading “Breast cancer study set to revolutionise diagnosis and treatment for patients”

Sean Wight and Jim Stynes – Remembering two AFL Legends

Melbourne's Irish recruits Jim Stynes and Sean Wight in 1988 Picture: Photo File Source: Herald Sun
Picture: New recruits, Jim Stynes and Sean Wight in 1988. Photo File Source: Herald Sun

When Sean Wight and Jim Stynes came to Australia as part of the “Irish Experiment” (Wight himself was Scotland-born) the legacy they would leave for AFL, for friendship, and for cancer patients around Australia could not have been guessed at.

Sean Wight was one of the first AFL players recruited to the Melbourne club as part of the “Irish Experiment”: a push to bring Gaelic footballers Down Under in the 1980s to try their hand at the Australian game. Jim Stynes, another budding young Gaelic Footballer also came to Australia as part of this program.

Wight and Stynes became two of the most famous players in this era of Australian football and even after retiring from the game, the pair made their lives in Australia.

Sadly however, both of these athletes followed the same path through a battle with cancer. They were both diagnosed in their 40s, and after a brave fight, they passed away within a few months of each other.

When Wight was undergoing treatment, family and friends held a cancer fundraising event last year. Part of the proceeds were dedicated to supporting Wight and his family through their medical expenses, but the ACRF was also humbled to recently receive the rest of the proceeds. A generous $10,000 from the money raised will thus go towards world-class cancer research and will leave a lasting legacy in Sean’s name.

Continue reading “Sean Wight and Jim Stynes – Remembering two AFL Legends”

The ACRF remembers Australian swimming legend, Murray Rose

ACRF is saddened to hear of the passing of swimmer and Leukaemia patient, Murray RoseThe ACRF is saddened to hear of the recent passing of Australian swimming legend, Murray Rose, following his battle with Leukaemia.

Rose is best known for winning back-to-back gold medals in the 1956 (Melbourne) and 1960 (Rome) Olympics 400m swim – an achievement replicated only by Ian Thorpe. He was an inspiration to Australian swimming, taking six Olympic medals (four Gold) in just these two Olympic games.

Rose’s in-the-pool performances inspired many modern-day Australian swimmers and their personal tributes to him have been heartwarming. He also was wonderfully community-minded and also inspired others out of the pool. We at the ACRF would like to take this opportunity to pass on our deepest sympathies to his family, peers and the Australian swimming community.

If you would like to make a memorial gift or donation in memory of Murray Rose, please click here.

$8.6 million from ACRF kick-starts leading Australian cancer research projects

Three world-class Australian cancer research projects, for which ACRF grants have previously been awarded, are underway following the start of our payments this week.

The total $8.6 million in funds will ensure Australian scientists are able to work in world-class conditions with the very best equipment, working to speed up the breakthroughs in cancer prevention, diagnosis and treatment.

1. $3.1 million to The ACRF Chemical Proteomics Centre for Kinomics, at the Children’s Medical Research Institute at Westmead in Sydney. Kinomics is a new discipline in Australia comprising a very simple, yet rapid, large scale, high-throughput screening process to study the entire kinome – that is, all of the protein kinases which are expressed in a cell at a given point in time. Continue reading “$8.6 million from ACRF kick-starts leading Australian cancer research projects”

Unbraid for a cure

For some people it is a big change to shave their head or colour their hair some outrageous colour, but for supporter Chakae D’Ellencourt that’s the norm in her circle of friends.

Starting out with brightly coloured braids in her hair she decided to do some cancer fundraising. Her chosen activity was to be brave and remove the unique colours from her hair in honour of friends who “have lost more than hair to cancer”.

After losing loved ones, and a close friend’s loss of her mother, Chakae decided to use her hair and love for performance art to create ‘Unbraid for a Cure’ in which she encouraged people to come along to local store, Voodoo Lulu, and alternative market to donate to charity and help undo a braid. With a number of generous friends and locals coming along and helping out after 9 days all the braids were gone (except one which was sponsored to be kept in)!

Chakae said “This project has made me feel better personally, as a concrete way of showing my friends I care about their losses”. This event helped to raise over $600 for cancer research, and also supported a local charity with the same amount. Continue reading “Unbraid for a cure”

Kick Cancer Fundraising Auction

Leanne Imber of NSW recently organised a cancer fundraising online auction. She was  inspired by a mother in America who had auctioned off signed celebrity merchandise to raise money. Leanne decided to bring the concept to Australia and received a very positive response from the people she approached for assistance.

Thanks to support from many Australian and International celebrities, including Actor Hugh Jackman, Surfing Champion Layne Beachley, and Singer Pete Murray, Leanne reached her cancer fundraising target of $1500 which she donated the Australian Cancer Research Foundation (ACRF).

Leanne encourages everyone to get involved and host their own cancer fundraising event “It’s a great way to contribute to helping find a cure for cancer. It’s my way of remembering those who have lost their battle with cancer and providing hope to those who are currently [fighting] this dreadful disease.” Continue reading “Kick Cancer Fundraising Auction”

ACRF-funded cancer research centre will speed up the fight against Leukaemia

ACRF provides  million to leukaemia research project in MelbourneA new research centre set to fast-track leukaemia discoveries and other types of blood cancer research from the lab to the hospital bedside was opened today by the Victorian Minister for Health, David Davis. Established through a $1 million grant from the ACRF, The Australian Cancer Research Foundation (ACRF) Centre for Translational Research will provide new hope to thousands of people with blood cancers. The facility is located at The Royal Melbourne Hospital, which sees more than 120 new leukaemia cases and performs some 80 bone marrow transplants each year. The Translational Research Centre will therefore provide a seamless link between the Hospital and collaborating research facilities, including the Walter and Eliza Hall Institute of Medical Research, the University of Melbourne and The Royal Melbourne’s Diagnostic Haematology Laboratory and clinical services. Executive Director of Research at The Royal Melbourne Hospital, Prof Ingrid Winship said such a centre was vital to improve outcomes for patients. Continue reading “ACRF-funded cancer research centre will speed up the fight against Leukaemia”

Breast cancer researcher elected to the Australian Academy of Science

Professor Visvader elected to the Australian Academy of ScienceThe ACRF would like to congratulate breast cancer researcher at the Walter and Eliza Hall Institute, Melbourne, Professor Jane Visvader for her recent election to the esteemed Australian Academy of Science.

The fellowship recognises Professor Visvader’s breakthrough research into defining the full genealogy of cells in the breast, and clarifying which of these cells gives rise to different types of breast cancer.

Professor Visvader, who jointly heads the institute’s ACRF Stem Cells and Cancer division with Professor Geoff Lindeman, said she was humbled to be one of 21 Australian scientists to join the Academy this year. “This recognition reflects a team effort between a wonderful group of scientists over many years,” she said.

Honouring the memory of Aussie sporting legend, Jim Stynes

The ACRF is humbled to have received memorial gifts in honour of Australian sporting hero Jim Stynes, who sadly passed away from cancer yesterday.

Since arriving in Australia more than 25 years ago, Jim Stynes has left a lasting legacy.  He is most well-known for his fantastic sporting achievements in the AFL and for his philanthropic work through the Reach Foundation, a youth organisation he founded in 1994.

The ACRF would like to take this opportunity to pass on our sympathies to Jim’s family and friends. We are truly grateful to have received donations for cancer research in his memory – donations which will fund world-class research into the prevention, diagnosis, treatment and ultimately cures for this terrible disease.

Click here to add a personal message or tribute to his memorial webpage, or make a memorial donation to cancer research here.

Man Eaters Devour Rotto Channel Crossing

An incredible foursome of women from the Claremont Masters Swimming Club – Elena Nesci, Nicola Corsbie, Lauren Thomas and Sally Bell took on the challenge of the Rottnest Channel Swim this year. Amongst stingers, swells, seasickness and other competitors they achieved amazing results in both the race and their fundraising for cancer research, raising over $10,000!

Congratulations to the Man Eaters and a huge thank you to you and all your supporters for your outstanding contribution to cancer research!

Check out their review of their experience:

“We came. We swam. We conquered! Continue reading “Man Eaters Devour Rotto Channel Crossing”

Net Effect: A charitable winner!

The much-anticipated netball ‘face-off’ between RailCorp and the Novo Rail Netters had everything a spectator could ask for: fierce competition, plenty of goals, a vocal crowd, and a fantastic charitable result, with almost $1500 raised for The Australian Cancer Research Foundation (ACRF).

RailCorp took an early lead in the match and despite a late challenge from Novo Rail, their netball prowess was not enough to claim back victory.

The winner’s trophy was presented to Nazha Dablan, the skipper of the RailCorp team; however the real winner for the night was charity. $1500 was raised through this company fundraising event and is already on its way to ACRF. Continue reading “Net Effect: A charitable winner!”

Teamwork pays off for Kiama Central Netball Team

The Australian Cancer Research Foundation (ACRF) would like to send a huge thank you to the Kiama Central Senior A’s Netball Team for their incredible support of cancer research.

Late last year, the team set themselves a goal to raise $30,000 for our cancer charity before the team captain Karen Appleby’s 30th birthday. Their efforts culminated in February with a grand ball (“A Bit-of-Bling Black Tie Ball”) which brought families, friends and local businesses together for a night of entertainment, dinner and dancing.

This dedicated group of women unfortunately have a very good reason to be so passionate about cancer research, as each member of the team has supported a parent through this terrible disease.

Some have been lucky and their parents have recovered, but others are still fighting cancer or have sadly lost their battles.

Karen, whose mother is now in remission after being diagnosed with breast cancer twice, said the heartbreaking statistic was not a team curse, but a mark of how common cancer has become. Continue reading “Teamwork pays off for Kiama Central Netball Team”

Research news: Autumn 2012 edition

In the Autumn edition of the Research Review:

  • Researchers are making leaps and bounds in leukaemia research with early clinical trials at the Walter and Eliza Hall Institute in Melbourne testing the safest dose of a new cancer therapy.
  • New QLD centre to target head and neck cancers.
  • Kinomics a new area of drug testing for researchers – specialist facility to open at the Children’s Medical Research Institute, Westmead.

Top Australian scientist takes another win for cancer research

John Mattick cancer researcher and Executive Director at the Garvan InstituteThe Australian Cancer Research Foundation would like to congratulate Professor John Mattick, Executive Director of the Garvan Institute of Medical Research in Sydney.

Professor Mattick has become the first Australian honoured with the esteemed Chen Award, an accolade awarded by the Human Genome Organisation to recognise academic achievement in human genetic and genomic research.

Professor Mattick is being commended for his pursuit of a then-radical theory regarding Human DNA. He has been described by the Award Reviewing Committee as a “true visionary in his field.”

Ever since DNA was found to be a double helix, scientists had believed that most genes comprised the written instructions for proteins, which were in turn the building blocks of all body processes.

Professor Mattick however, argued that the assumption was true for bacteria, but not for complex organisms like humans.

Continue reading “Top Australian scientist takes another win for cancer research”

Ladies Cancer Fundraising Night In

Melita Holden - Girls Night InHandbags, bubbles, and beauty packages combined at this recent cancer fundraising event to provide some much needed funds for the ACRF.

Queensland’s Melita Holden gathered her girlfriends together and hosted a ‘Ladies Night In’ in support of the Australian Cancer Research Foundation (ACRF). The group reasoned that they could donate to cancer research the money that they would normally spend on a night out!

To minimse the event costs, Melita managed to get all of the party essentials donated by generous local suppliers Dan Murphy, BWS, and Sam’s Warehouse.

She then invented a few games to spark the night’s entertainment. ‘Hand Bag Treasure Hunt’ and a novel balloon-popping game called ‘Pop and Spell’ were among the crowd-pleasers, as well as a a raffle through which a variety of beauty packages – which had been donated by salons from the local Mudgeeraba and Robina areas – were up for grabs. Continue reading “Ladies Cancer Fundraising Night In”

Vale Adam "Bear" Nicholson

This month the ACRF was saddened to hear of the passing of one of our loyal supporters Adam Nicholson. Last year Adam competed in Run Melbourne, whilst undergoing chemotherapy for bowel cancer. With only 2 weeks to prepare, Adam not only finished the race but was the ACRF’s top fundraiser and in the top 10 overall fundraisers in Run Melbourne.

Adam’s courage was truly inspirational and we would like to take this opportunity to thank Adam for his passionate support for cancer research. The ACRF is truly grateful for his commitment and passion in supporting cancer research over the past year.

We would like to extend our sympathies to the Nicholson family and all those who knew Adam and thank his friends, family and colleagues at I-Med who have generously donated to cancer research in his memory.

Solo kayak across Bass Strait is cancer fundraising at its bravest!

Journey Map

Adelaide’s Malcolm Blewett has embarked on an incredible cancer fundraising adventure. For the next 1-2 weeks, he will be at the mercy of wind and sea as he navigates 350 kilometres of treacherous Bass Strait waters in a one-man kayak.

“The aim of this trip is more than just personal achievement.” Mal told us.

“I have a good family friend who is a sea kayaking senior instructor and who is my mentor in this sport. His wife and family have endured great suffering for many years with him being in and out of remission from oesophageal cancer, and unfortunately his life span is now very limited.”

“Supporting those that are researching into a cure for cancer is my way of saying thanks to my good friend.”

Malcolm works for Lion, who are dedicated corporate and workplace giving supporters of ACRF and have contributed in excess of $200,000 toward cancer research.

Continue reading “Solo kayak across Bass Strait is cancer fundraising at its bravest!”

Colour & Shave for a good cause

A bright idea, generous donations, and a confident ACRF supporter made for a wonderfully successful recent fundraiser.

Tania Kriticos chose to fundraise for cancer research through her unique head shave because of her personal connection with cancer. “Having a number of family & friends who have succumbed and are currently battling with various forms of cancer, I wanted to pick an organisation that wasn’t cancer-specific”.

As an extra motivating factor to get her friends and family to donate, Tania included a hair colour auction as part of the process. When a donation was made a vote could be placed for which weird and wonderful hairstyle Tania would sport in the 2 weeks prior to her head shave – choices included bright blue, hot pink, zebra stripes and rainbow. In the end, blue won the day and along with the help of Miranda from Kurtz Hair by Design in Hawker, Tania was transformed! Much to Tania’s surprise, she received many amazing positive comments from strangers about her unique hairstyle! Continue reading “Colour & Shave for a good cause”

The importance of bequests in funding world-class cancer research

The Australian Cancer Research Foundation (ACRF) would like to take the opportunity to comment on recent stories in a number of news publications regarding Gifts in Wills.

The ACRF has long been a recipient of generous bequests from Australian individuals, some of which have entirely funded grants to world-class research centres. For example:

  • $2.4 million awarded to the Western Australian Institute of Medical Research, for the development of a world-class cancer imaging facility. Click here for more on this grant.
  • $3.1 million awarded to the Children’s Cancer Research Institute Australia, to create a comprehensive Drug Discovery Centre for Childhood Cancers. Read more about the CCIA grant here.

Without generous bequests such as these, progress in Australian cancer research would be significantly hindered. A bequest is an incredible legacy that many Australians like to leave behind. Any individual who pledges a bequest to the Australian Cancer Research Foundation is very important to us and, if they so wish, we keep in regular contact with them.

Continue reading “The importance of bequests in funding world-class cancer research”

Swimming Big for cancer research

ACRF supporter, Dave Fielding, recently competed in the Big Bay Swim. This 3.2km race from Port Melbourne to Williamstown is popular amongst swimmers ready for a challenge, with just 165 competitors taking on the race this year.

Like many people, Dave’s family had been affected by cancer, losing loved ones and supporting family and friends through the experience. He was also inspired by Lance Armstrong and his positive attitude to life despite having cancer. Dave himself summed up why he was fundraising for cancer research in saying – “I would like to see this thing gone”.

Dave took on the challenging swim despite some nerves prior to the race and completed in a great time of 1hour 13 minutes. With the weather creating some very choppy water, the race was hard work and made the participants thankful to hit the dry land in Williamstown. Continue reading “Swimming Big for cancer research”

Advanced Melanoma – New treatment has the potential to double survival time

One of the first new melanoma treatments to be released in over a decade could double the average survival time for melanoma patients.

The drug, Vemurafenib, was approved by regulators in the United States and Australia last year after studies showed that in a significant number of patients with advanced melanoma, the cancers either stopped growing or shrank after receiving the treatment.

The latest research now shows that in many cases, treatment with Vemurafenib has doubled cancer patients’ survival period from 6-10 months to approximately 16 months. Continue reading “Advanced Melanoma – New treatment has the potential to double survival time”

DeLia’s Jewellery Designs for cancer research

Corporate giving and cancer fundraisingAt the Australian Cancer Research Foundation (ACRF) we love having supporters doing things they love to support cancer research. That’s exactly what Deloraine Anderson is doing through her company DeLia’s Jewellery Designs. A percentage of her profits from exhibitions, as well as raffles at her sales are being contributed to the ACRF.

Deloraine’s choice do corporate giving to support ACRF came from the number of people she knows in both her immediate family and local area whose lives have been impacted, and in some cases lost, to cancer.

For Christmas, a collection of awareness bracelets were created in the various colours that have come to represent various types of cancer. And recently for Mother’s Day a special raffle was conducted of particularly unique pieces perfect for mums. Continue reading “DeLia’s Jewellery Designs for cancer research”

For a great cause, you can jump the queue – City2Surf charity spots are now open!

City2Surf Golden Charity places now open!The Australian Cancer Research is very excited to be a Gold Charity at this year’s City2Surf!

We have 50 places available to runners who want to register early and make some noise for the ACRF during their City2Surf campaign. City2Surf Gold Charity runners receive ongoing fundraising support from the team here at the ACRF, as well as a supporter’s kit, a unique gold City2Surf bib, and a start in front of the pack on the day (just after the timed runners).

The City2Surf will be held on Sunday August 12, 2012 and consists of a scenic 14km route from Sydney’s CBD to Bondi Beach.

This year, the ACRF aims to raise $100,000 through this incredible event, every dollar of which will go to world-class cancer research. We CAN do it with your help!

Your support will help Australian scientists better prevent, diagnose, treat and defeat cancer for Australians of this generation and the next.

Click here to register your interest!

Sun Run & Cole Classic

More than 4,500 participants turned out on the 4th of February 2012 to take on the 6.5km (approximate) Sydney Morning Herald Sun Run from Dee Why to Manly. The following day, Sydney put on one of its best days of the summer at Australia’s largest ocean swim, the Sydney Morning Herald Cole Classic. The event was a great success despite the choppy conditions at Manly Beach.

Amongst the competitors over the weekend were 15 enthusiastic ACRF supporters ready to run and swim in their events! A range of ages, abilities, and experience were represented in our supporter team this year – with many taking part in the races in honour of loved ones that had passed away from cancer.

Many of the supporters had a great time making personal bests in their challenge, and many far exceeding their targets for fundraising as well! Continue reading “Sun Run & Cole Classic”

Please vote today to help ACRF win a $5,000 charity donation!

Between February 13-29, 2012, Colonial First State will be selecting an Australian not-for-profit organisation to receive a $5,000 charity donation. The charity donation will be awarded based on votes from the Australian public – and we need your help to secure these vital funds for cancer research!

To enter, simply click on the relevant link below and fill out the brief online form, nominating Australian Cancer Research Foundation where it asks for ‘Your Answer’.

  • Sydney – click here
  • Melbourne – click here
  • Brisbane – click here

There are no Facebook pages to like, no minimum number of friends to forward the opportunity to – this is the simplest form of voting we’ve seen in a long time! Spreading the word is entirely optional, although we ask that you do tell your family and friends so that your vote is not in vein. You see, if the ACRF is successful in the competition, as someone who voted for us, you then go in the running to win $500! Continue reading “Please vote today to help ACRF win a $5,000 charity donation!”

Could common household drugs have anti-cancer properties?

For years doctors have observed the beneficial impact of Non-Steroidal Anti-Inflammatory drugs (NSAIDs, such as Aspirin) on cancer without fully understanding the biological processes involved.

But scientists from the Peter MacCallum Cancer Centre in Melbourne have just made a breakthrough that shows how lymphatic vessels respond to cancer – thus shedding light on the link between NSAIDs and the ability for tumours to spread in the body.

“We’ve known that tumours actively secrete a range of proteins and compounds called growth factors, to attract blood and lymphatic vessels from within their immediate vicinity, enabling them to flourish and metastasise, or spread,” explains Associate Professor Steven Stacker. Continue reading “Could common household drugs have anti-cancer properties?”

Cancer research partnership will improve treatments for patients

Cancer Research boost through ACRF fundingNew laboratories funded by ACRF are set to strengthen cancer research for some of the most prevalent cancers in Australia.

ACRF’s recent $2 million grant has allowed the Walter and Eliza Hall Institute in Melbourne to expand and enhance existing research programs into the causes of, and new treatments for breast cancer, ovarian cancer, lung cancer and leukaemia.

In order to do this, the ACRF funding will be directed into two particular cancer research divisions, known as ‘The ACRF Stem Cells and Cancer Division’ and ‘The ACRF Chemical Biology Division’.

“Lung cancer is the greatest cause of cancer-related death in Australians, while breast cancer is a leading cause of mortality in women,” said Professor Geoff Lindeman, joint head of the ACRF Stem Cells and Cancer Division (pictured, middle).

“These are diseases that are very prevalent, and patients need better treatments” he said. “Similarly, more research is needed into ovarian cancer, which is poorly understood and for which the outlook for patients is very poor. We need new treatment strategies, ACRF’s support will help us to do that.”

Continue reading “Cancer research partnership will improve treatments for patients”

ACRF joins World Cancer Day movement: Together it is possible!

World Cancer Day takes place on February 4th every year and is an opportunity for the entire world to join together in the fight against cancer.

The theme for World Cancer Day 2012 is ‘Together it is possible’. It refers to an international target to reduce premature death from cancer by 25% before 2025 – an ambitious but certainly possible goal, provided individuals, families, organisations, and government continue to invest in cutting-edge cancer research.

Research and more research is the key to beating cancer. Australian researchers are among the best in the world and have already made their mark with truly significant discoveries and treatments. Many of them have dedicated their lives to cancer research. Their work can only continue through our support: Together it is possible.

Cancer touches us all in some way – and it directly impacts on the lives of a third of Australians before the age of 75. But every day brings new light in the fight against cancer and there are many ways you can be involved:

Every dollar of every donation we receive (100%) goes to the fight against this terrible disease. To view the latest in cancer research discoveries, please visit our website.

New Year, New Opportunities for Regular Charity Donations

Juanita Stockwell partner in the cure giving regular charity donations to ACRFThe time for making New Year’s Resolutions is over – it’s now time to start thinking seriously about keeping them!

As the festive season winds down, we can start to think seriously about what we can do differently in 2012. We plan for new tasks, set new goals, and come up with new ideas. So this new year, why not commit to a resolution that could make a real difference, and consider regular charity donations to cancer research?

Regular charity donations are the most cost effective way for you to support the ACRF, and they enable us as a cancer research charity to plan for the future.

In 2012, you can have the satisfaction of being part of something big. Continue reading “New Year, New Opportunities for Regular Charity Donations”

February is Ovarian Cancer Awareness Month

05-womenFebruary is Ovarian Cancer Awareness month, and a very timely discovery has been made by Sydney’s Garvan Institute of Medical Research which has fantastic potential for early diagnosis of this terrible disease.

Ovarian cancer is currently the most lethal gynaecological cancer in Australia, with almost 850 women dying from the disease each year*.

It is very difficult to detect and is often only discovered once it has spread past the pelvis and into other organs (often the stomach, bowel and lungs). But Australian scientists from the Garvan have identified early biochemical changes which may help diagnose the cancer before it spreads. Continue reading “February is Ovarian Cancer Awareness Month”

Air Chief Marshal Angus Houston AC, AFC (Ret’d) joins Board of the Australian Cancer Research Foundation

The ACRF is proud to welcome Air Chief Marshal Angus Houston AC, AFC (Ret’d) to its Board of Trustees. Air Chief Marshal Houston became a board member of the Australian Cancer Research Foundation late in 2011. Air Chief Marshal Houston retired from the military last year after 41 years service. He served as Chief of Air Force for four years, and most recently as Chief of the Australian Defence Force from July 2005 – July 2011. “In both of those positions, Air Chief Marshal Houston had an extremely high public profile and was warmly regarded by the community for the manner in which he carried his responsibilities,” said ACRF Chairman, Mr Tom Dery. Continue reading “Air Chief Marshal Angus Houston AC, AFC (Ret’d) joins Board of the Australian Cancer Research Foundation”

Possible treatments for Acute Myeloid Leukaemia

ACRF is delighted to be associated with positive research findings leading to possible treatments for Acute Myeloid Leukaemia (AML).

Scientists from the Walter and Eliza Hall Institute (WEHI) in Melbourne, in collaboration with local and international scientists, have found a potential ‘achilles heel’ for this terrible disease which has such a poor prognosis.

They have found that AML cells may be susceptible to medications that target a protein called Mcl-1. Treatments removing that protein from AML cells can rapidly kill these aggressive cancer cells.

“Importantly, non-cancerous blood cells were much less susceptible to dying when Mcl-1 was depleted,” said lead researcher, Dr Stefan Glaser.

Continue reading “Possible treatments for Acute Myeloid Leukaemia”

Discovery motivates new cancer research into melanoma risk

 

Two ACRF-funded cancer research centres have worked in collaboration to discover a mutant gene that increases the risk of melanoma in approximately 200,000 Australians.

The gene, known as MITF, is known for regulating pigmentation – turning the skin brown after exposure to the sun, for example.

But cancer researchers at the Westmead Institute of Cancer Research (a 2011 ACRF grant awardee) together with the Queensland Institute of Medical Research have found that in many Australians, MITF is mutated, working abnormally to increase the risk that sunlight or other causes will cause malignant melanomas by 250%. Continue reading “Discovery motivates new cancer research into melanoma risk”

Thank you for your donations in memory

This month has seen the mourning of two highly regarded influential Australians, and the Australian Cancer Research Foundation (ACRF) would like to thank well-wishers for their generous donations in their memory.

The late Lady (Faye) Rowland, wife to the former Governor of NSW, Air Marshal Sir James Anthony Rowland, lost her fight with cancer on December 16, 2011. The family have requested that donations be made to the ACRF in lieu of flowers or gifts, a gesture for which ACRF is truly grateful. We send our thanks and best wishes to the family and friends of such a wonderful woman.

The ACRF is also humbled to receive donations in memory of the late V8 Supercar driver, Jason Richards. It was only a year ago that Jason was diagnosed with a particularly aggressive form of cancer. Despite the prognosis, Jason continued to be a force on the track, and his energy and determination has touched many Australians.

Christmas is a time that can be difficult for many thousands of Australians who have lost a loved one to this terrible disease in recent years. If you wish to make a memorial donation to the ACRF, please click here.

 

Running for cancer research

As summer begins the Australian 2011 fun run and marathon season draws to a close. The team here at ACRF are always astounded by how many fantastic supporters get out and get active for cancer research throughout the year. This year has been our most successful year yet with over $179,000 raised through the major running events across the country!

Each event has introduced us to some incredible supporters, each with their own story about why they chose to take on their running challenge while concurrently contributing to cancer research. Here are some of the highlights… Continue reading “Running for cancer research”

Golfers Against Cancer

The inaugural ACRF Charity Golf Day was held at Georges River Golf course on Friday 28th of October 2011. 70 passionate golf enthusiasts participated in the event, hosted by Torch Publishing. All the proceeds raised went to cancer research. Some amazing sporting personalities lent their support to cancer research, including former Canterbury Bulldogs great Garry Hughes and former Queensland State of Origin and Parramatta Eels Coach, Michael Hagan (a prostate cancer survivor).

Cr Khal Asfour and Cr Alan Winterbottom, Mayor and Deputy of Bankstown City Council respectively, were keen to be out there on the green. Amazingly many of the men at the event were cancer survivors or are very close to someone who died of cancer or is currently battling cancer. Continue reading “Golfers Against Cancer”

A miracle marathon in memory of her loved one

“The miracle is not that I finished, the miracle is that I had the courage to start.”

When we met Gill Thomas a few months ago, she told us her inspiration was simply to work towards the hardest thing she could ever conceive of doing. So in memory of her late husband, Ian, and for all the people she has known and loved who have fought cancer, Gill prepared herself for the epic New York marathon.

Gill left her home in Queensland for New York four days before the 42km run would be held on November 6th. Gill had not only trained hard in the lead-up to this marathon but she also managed to fundraise an incredible $13,000 for the Australian Cancer Research Foundation – donations in memory that will fight cancer for future generations.

Now that the race has been run, Gill has shared her story. She talks of the pre-dawn wintry congregation at the starting line, of the gospel singers surrounding the streets of Harlem motivating her on, and of finally reaching Central Park and finding amazing reserves of energy once again to run the last kilometre towards the finish line!

Experience the race through Gill’s eyes by clicking ‘read more’, below.

If you too would like to contribute to cancer research with a donation in memory of a loved one, or by participating in a sporting event, please speak to ACRF about your ideas. Continue reading “A miracle marathon in memory of her loved one”

CCIA Director and cancer scientist recognised for excellence in biomedical science

Professor Michelle HaberThe Australian Cancer Research Foundation would like to congratulate Professor Michelle Haber AM, Director of the Children’s Cancer Institute Australia, on her recent award at the NSW Science and Engineering Awards.

Professor Haber was recognised for excellence in biomedical science, having dedicated her career to drug discovery and biomedical therapeutics for children with cancer.

That same night, at a separate ceremony at Taronga Zoo, Professor Haber was also acknowledged as one of four NSW finalists for the 2012 Australian of the Year Award, lending further weight to her incredible commitment to ground-breaking cancer research in Australia. Continue reading “CCIA Director and cancer scientist recognised for excellence in biomedical science”

Cruising for cancer research

The sun was shining in Hervey Bay recently for the ‘Cruise into Summertime Show n Shine’. Organiser, Josh Theuerkauf, chose to make this car cruise a little different by supporting cancer research in amongst a great day out.

The esplanade and oval were flooded with over 30 cars for the afternoon cruise and show, the cars represented all eras with imports, Aussie cars and some American classics along for the ride. The day was a massive success with loads of people turning out to take part and do their bit for charity. Continue reading “Cruising for cancer research”

ACRF awards $9 million to world-class cancer research!

Last night the ACRF was proud to award $9 million in grants to three cutting-edge cancer research centres who are doing truly fantastic work here in Australia.

The awardees were selected after a thorough investigation by our Medical Research Advisory Committee (which consists of 13 esteemed Australian cancer researchers and is chaired by Professor Ian Frazer, co-creator of the cervical cancer vaccine).

In May of this year, ACRF received a total of 16 applicants for its cancer research grants. From these candidates, five were selected for further assessment , and yesterday, having conducted extensive site visits and interviews, the Committee made their final recommendations to the ACRF Board of Trustees.

The grants will be used exclusively to fund state-of-the-art technologies and facilities which speed up discoveries in our fight against cancer – ultimately working to save lives by saving time. Continue reading “ACRF awards $9 million to world-class cancer research!”

An Exhibition by Eleanor Lesley Hudson

Recently, ACRF supporter Eleanor Hudson held an exhibition of her oil paintings at Bar Nancy in Northcote. Eleanor chose to support cancer research by donating the revenue from ticket sales at her one night only event in honour of her Grandmother.

A few years ago, Eleanor’s Grandmother passed away from cancer. Eleanor was greatly affected by this and felt this was the worst experience of her life. She chose to support cancer research because “nothing changes the past, but I would love to help ACRF change the future.” Continue reading “An Exhibition by Eleanor Lesley Hudson”

Fighting for world-class cancer research

A great big welcome for the City2Sea

Rounding out the running events for the year was the inaugural City2Sea in Melbourne, the sister event to the Sydney City2Surf. And what a fantastic beginning for this new race!

A great team of 25 people turned out to support cancer research as part of their race challenge. The team was made up of cancer survivors, those who had lost loved ones and some who just wanted to do their bit knowing that “every dollar counts”.

On the day, many of our runners had great success, completing the race in personal best times. Continue reading “A great big welcome for the City2Sea”

2011 Run4Fun

The Sydney heat made for a tough race in the Run4Fun at Sydney Olympic Park.

Despite challenging conditions, our 18 supporters made it through in flying colours.

Some more than exceeded their goals in regards to both the race and fundraising. They chose cancer research as they wanted to make a contribution to a “future world where cancer no longer exists” and in the hope that other families would not have to experience the losses they had. Continue reading “2011 Run4Fun”

Polly's Lemonade Stand

When the people closest to her were diagnosed with cancer, six year old Polly rallied her troops.

Together with four families from her local area in Brisbane, Polly set up a fresh lemonade stall to raise money for cancer research.

“Polly’s grandmother has a brain tumour, so she has to have chemo every month for the rest of her life. And a couple of children at the school have been affected by cancer as well,” Polly’s Mum, Rebecca, told the local paper.

The level of support was such a surprise, she said, with Rocklea Markets donating 20 cases of lemons towards the effort! Polly also had a story in the local paper, and was on the radio twice in the lead up to the big day. Continue reading “Polly's Lemonade Stand”

HOW TO SUPPORT BREAST CANCER AWARENESS MONTH

Breast cancer is the most commonly diagnosed cancer in women worldwide. It has a devastating impact on those diagnosed and the people around them.

What is breast cancer awareness month?

Breast Cancer Awareness Month is held annually in October. It aims to raise awareness and generate support for breast cancer by raising much needed funds to improve it’s diagnosis, prevention and treatment.

This month also serves as a reminder to women to put their health first and get regular check ups for breast cancer.

How you can support breast cancer awareness month

There are a number of ways you can get involved and support breast cancer awareness month. Some ideas include;

  • Spreading awareness by adding a touch of pink to your wardrobe throughout the month to help start a conversation 
  • Using social media or engaging in conversations with your friends or family and using these platforms to talk about breast cancer, the impact of it and the importance of regular check ups 
  • Getting involved in a charity walk or run that raises money for breast cancer 
  • Making a donation to a cancer research charity such as ACRF, who are committed to improving the prevention, diagnosis and treatment of breast cancer

How ACRF is contributing to Breast Cancer research

“Research and more research is the key to defeating cancer,” says Chief Executive, Mr David Brettell.

“Since ACRF was established in 1984 we have given 16 multi-million dollar grants to research that is investigating preventative, diagnostic and/or treatment methods for breast cancer.” Continue reading “HOW TO SUPPORT BREAST CANCER AWARENESS MONTH”

Article lists ACRF at 7% fundraising cost ratio – a response from Chief Executive, David Brettell

This morning, a number of newspapers around the country ran a story about costs incurred by Australian charities.

The story heralded a new government initiative for charity reporting, to ensure transparency in financial accountability where donations are concerned.

The financial data published for ACRF relates to the year ending 31 December 2010, and all data is correct.

However the reported cost ratio of 7% could be misinterpreted, because ACRF fundraising costs are NOT funded through donation dollars. As our supporters know, every dollar of every donation we receive goes to cancer research, while we fund all operational costs through the returns from our investments. Continue reading “Article lists ACRF at 7% fundraising cost ratio – a response from Chief Executive, David Brettell”

Victor Harbor Boxing Club

Recently, ACRF supporters, Mark and Joachim took on the Australian Masters Games representing the Victor Harbor Boxing Club. Both men had been interested in boxing training for a while and made the decision in early 2011 to begin preparing for the Masters Games in October. As an extra incentive to keep up with the training they chose to raise funds for cancer research at the same time.

“I chose cancer research because there would not be many people who have not had a family member or close friend effected or lost to cancer” says Mark. Mark and Joachim also believe the challenge they were facing “is nothing compared to what a person with cancer has to go through”. Knowing they could make a difference, they reached out to family and friends to sponsor them and got on with their training. Continue reading “Victor Harbor Boxing Club”

Bank of Melbourne Marathon Festival

In early October, the crowds flocked to Melbourne for the Bank of Melbourne Marathon Festival.

The ACRF eight person contingent took part in different races amongst the four distances on offer.

Their family members had been affected by cancer, and the fact that every dollar of every donation received by ACRF goes to cancer research inspired our competitors to raise more than $5,000!

Thanks so much for your generous support and for helping in the fight against cancer.

Big thanks to Tracey, Tim, Laura & Dhiraj, Caroline, Mattius, Sarah, Lorraine & Russell!

Thanks for supporting Blue September

The ACRF sends a big thank you to everyone who took part in Blue September this year, by getting blue, by raising funds, by purchasing Blue September products and by helping to raise awareness about men’s cancers. We had a very successful campaign this year which wouldn’t have been possible without our wonderful supporters, here is a snapshot of some of their events…

Scarff Recruitment Solutions got out into the town at Bunnings Harbourside and put on a fabulous BBQ! Loads of people turned out to support the blue faced team & make a contribution to cancer research – raising over $1,800!!

Southside Malibu Club chose Blue September as their charity of choice for the 2011 Willett Johnston Spring Classic. The club supports a charity each year & helped Cronulla get blue this year, donating $1,500 to the cause as well. Continue reading “Thanks for supporting Blue September”

Congratulations to ACRF medical research advisor, Professor Doug Hilton

Director of the Walter and Eliza Hall Institute of Medical Research, Professor Douglas Hilton has been awarded the Milstein Award in Florence, Italy.

The Milstein Award is considered to be the pinnacle of scientific achievement in interferon and cytokine research, which involves the study of the immune system and cell communication.

We congratulate Professor Hilton on this most prestigious award and thank him for his contributions to cancer research. Continue reading “Congratulations to ACRF medical research advisor, Professor Doug Hilton”

A walk and BBQ in memory of Al

Carole Hill, her friends and family recently organised a walk & BBQ in honour of her father, Alistair Beange. Mr Beange lost his battle to oesophageal cancer earlier in this year and after his passing the family wanted to hold an event to pay tribute to his memory.

They also took the opportunity to honour him by contributing funds to cancer research to help in the fight against cancer.

On the day, the beautiful September sun was out as a great number of family & friends gathered to take part in a walk around the Sugarloaf Reservoir ending in a BBQ. A great day was had by all! Continue reading “A walk and BBQ in memory of Al”

YourShare services could raise thousands for cancer research

Register your current eligible policy with YourShare.com.au this month, and $50 will be donated in your name to the Australian Cancer Research Foundation. You will also go into the draw to win $1000!

YourShare, Australia’s leading cash-back service provider has donated over $22,000 to ACRF in the last four years. ACRF is delighted that this supportive organisation has developed yet another scheme by which they can pass-on donations to cancer research. Continue reading “YourShare services could raise thousands for cancer research”

Adelaide gets running in the City Bay Fun Run

The City Bay Fun Run in Adelaide produced our smallest marathon team, with just 6 competitors supporting cancer research.

They took on the race with great enthusiasm despite some pre-race injuries and some personal challenges to run the whole course!

Thanks to you all for your support and commitment to cancer research, raising more than $2,000 in the process 🙂

Thank you to Aaron, Megan, Alice, Southern Stompers, Sanja & Danni!

Six of the best in children’s cancer combine to bring new hope

A $6.5 million cancer research grant will strengthen expert collaboration between Australia’s top scientists and doctors in the fight against children’s cancer.

Every year more than 600 Australian children are newly diagnosed with cancer, and approximately 150 will not survive this ordeal.

But a promising new professional network will bring research breakthroughs made at the Children’s Cancer Institute Australia (CCIA), the Children’s Medical Research Institute (CMRI), and Kids’ Research Institute (KRI) directly to the hospital bedsides at Sydney’s Children’s Hospital Randwick, The Children’s Hospital at Westmead and John Hunter Children’s Hospital in Newcastle. Continue reading “Six of the best in children’s cancer combine to bring new hope”

Bridge to Brisbane

Brisbane’s big fun run event took place in September with over 40,000 people competing as part of Bridge to Brisbane.

Our 48 ACRF supporters took on the challenge to great results and having a fantastic time as part of the day.

Their generosity to cancer research was in many cases in honour of friends and family who were currently being treated for  cancer and most importantly, to shed some light during a difficult time.

One such fundraiser was Elisabetta who also took out the highest individual fundraiser title before the race, earning ACRF an extra $5,000 from sponsors, Suncorp. Also a big thanks to Ben & the boys from Villanova College raising over $1,000 from their community. Continue reading “Bridge to Brisbane”

Australian fashion houses unite to fight cancer

This September a high-end fashion show will bring the country’s most prestigious fashion labels together to raise $150,000+ for cancer research.

Where Couture Meets the Cure (WCMC) will be held at Dockside Darling Harbour on Wednesday, 28 September 2011, and with runway items by Alex Perry, Camilla Franks, Carla Zampatti, Fleur Wood, Rachel Gilbert and more, it promises to take the Sydney fashion scene by storm! Continue reading “Australian fashion houses unite to fight cancer”

Perth City to Surf

Perth had their City to Surf with a record numbers of competitors taking on the challenge, and 17 of them chose to support ACRF.

The weather was kind to the runners, producing a great day to be out running around the Swan River, with some taking motivation from those suffering through cancer to keep them running.

Many supporters chose to support cancer research because of their personal connection to cancer through family and friends, and feeling like they could contribute in a positive way. One supporter said “advances in cancer diagnosis and treatment don’t just benefit cancer sufferers, they benefit the whole community”. Continue reading “Perth City to Surf”

Bankstown Bulls Commando's lose their locks

The Bankstown Bulls Junior Rugby League Football Club Under 8 Div 3 “COMMANDO’s” team gave up their hair recently for a good cause.

The team wanted to do something for cancer research and decided to shave their heads as part of the July gala day. The gala day was a great success with the boys raising more than $1,150 for cancer research!

Big thanks to all the boys – Leon, Jihad, Charlie, Alaa, Rodney, Johnathon, Jaylen, Adham, Ali, Billy, Nicholas and Joey – for your commitment to cancer research and to all your generous supporters who contributed to our cause! Hope you keep your heads warm over winter!

Professor Frazer seeks vaccine for skin cancer

Professor Ian FrazerChair of the ACRF Medical Research Advisory committee (and co-creator of the cervical cancer vaccine), Professor Ian Frazer is currently working on a world-first strategy to combat skin cancer.

“This group of cancers (skin cancers)…may be started off by a virus infection – which presents a great opportunity, because the idea of vaccinating to prevent a cancer is enormously appealing,” Professor Frazer said.

Professor Frazer believes some virus types, including the wart virus or HPV, are embedded in the layers of the skin, and they pose a skin cancer risk when people with damaged or weak immune systems are overexposed to the sun. Continue reading “Professor Frazer seeks vaccine for skin cancer”

Taking on the 2011 City2Surf

In August the Sydney CBD was overrun by 85,000 people and filled with a fantastic atmosphere for the annual City2Surf. Over 400 of the competitors were proudly supporting cancer research.

A group of ACRF staff were even out in force for the day taking on the 14km course. Many of our supporters were running for cancer research in honour of those who were fighting cancer and those who had sadly lost their battle with this disease.

Our top fundraising team, Ann’s Angels, were doing just that. Dave and his team were running for his terminally ill mother Ann. Dave said “It’s easy to sit around and mope, but while she’s alive I’d rather be positive.”, and their team of over 30 people raised more than $18,000! Continue reading “Taking on the 2011 City2Surf”

Remembering Mr and Mrs Pearse

Mr Ronald Osborne Pearse passed away on August 22, 1987, and Mrs Jean Margaret Pearse on May 20, 2010.

Their generous donation to the Australian Cancer Research Foundation has been applied to world-class cancer research right here in Australia. Such research will help others to survive the disease of cancer.

We remember and honour them.

Every dollar of every donation goes to cancer research.

Clinical trials reward 20 years of research into leukaemia

A new anti-cancer agent is entering clinical trials to treat the most common type of leukaemia.

The Walter and Eliza Hall Institute (WEHI) in Melbourne is implementing the phase Ia clinical trial that will demonstrate the safest dose of ABT-199, a drug designed to block the function of the Bcl-2 protein which allows leukaemia cells to live longer. Continue reading “Clinical trials reward 20 years of research into leukaemia”

ACRF Cancer Discovery Centre at CCIA opens for National Science Week

The Lowy Cancer Research Centre at the University of New South Wales, will kick off National Science Week with an exclusive tour of  their ACRF Drug Discovery Centre for Childhood Cancer on Friday August 12, 2011.

The centre, which is part of the Children’s Cancer Research Institute Australia, was developed through a $3.1 million in ACRF funding.

It features Ham and Milton, two robots which work to dramatically accelerate the search for a cure for childhood cancer. These robots are the only two of their kind in Australia dedicated to childhood cancer research, and tomorrow high school students from Sydney will witness the wonders of this technology at a tour led by CCIA’s world-class researchers. Continue reading “ACRF Cancer Discovery Centre at CCIA opens for National Science Week”

International collaboration sheds light on cancer therapies

“We have identified new compounds that offer a starting point for the development of novel therapeutic approaches for serious diseases that currently have no cure.

“This opens up the possibility of desigining much more effective, targeted treatments for disease such as cancer,” said Professor Phil Robinson of the Children’s Medical Research Institute (CMRI), Westmead.

It was a working collaboration between CMRI, the University of Newcastle and the University of Berlin which led to the discovery of small molecules known as “Pitstops”. Continue reading “International collaboration sheds light on cancer therapies”

City2Surf 2011: ACRF will see you there!

The ACRF City2Surf team might need a little more training in the lead up to the City2Surf but we’re certainly not lacking in spirit!

This Sunday 14 August, five eager ACRF staff will rise to the 14.2km challenge, joining millions of Australians in the biggest timed fun run in the world.

To support our efforts with a small donation please click here, or click ‘more’ (below) to meet the team. If you are one of the 450+ supporters who are running the course for ACRF and you see one of our staff members throughout the day, please come and say hello. We’d love the opportunity to thank you in person for competing in support of cancer research. Best of luck everybody! Continue reading “City2Surf 2011: ACRF will see you there!”

Trivia night puts 'Bug Off! Cancer' into gear

One bug and one driver – this is how the original ‘Bug Off! Cancer’ initiative started. It combined a classic Australian road trip with the desire to fund world-class innovation, and ACRF is very excited for the fantastic knock-on effect the event has seen.

Just one year after the Bug’s inaugural 7 day trip across rural NSW, organiser Norman Elias anticipates there will be VW’s of all descriptions driving off from Sydney towards Sawtell on August 19.

But before the main event, ‘Bug Off! Cancer’ hosted a preliminary celebration to get its fundraising for 2011  into gear. Continue reading “Trivia night puts 'Bug Off! Cancer' into gear”

Running Melbourne for cancer research

Over 20,000 people turned out in Melbourne on Sunday July 17th to take part in one of the biggest ‘Run Melbourne’ events ever. It was a grey morning, but that didn’t dampen the spirits of the 128 ACRF supporters taking part in the day’s events.

Amongst the ACRF team, there were some first time competitors and some seasoned racers ranging from 15 to 77 years of age. Each one of them chose to fundraise for cancer research in an effort to support a worthy cause in the knowledge that every dollar of their contribution will help make a difference in the fight against cancer.

This race was a chance for all participants to take part in a fun and challenging event for their own special reason. For some it was a challenge to show their strength and courage through their cancer treatment, or to show that strength and courage for a loved one battling cancer. For others it was a chance to run for their loved ones lost to cancer, to honour their memory. Continue reading “Running Melbourne for cancer research”

ACRF remembers The Late Lady McMahon on her birthday

The Australian Cancer Research Foundation remembers The Late Lady (Sonia) McMahon on this, her birthday, 1 August.

Lady McMahon was a co-founder of ACRF in 1984 and a vibrant and enthusiastic member of our Board right up to her passing in April 2010.

We wish her family well at this difficult time, and remember with them the joy and hope that she brought to our lives and the lives of so many cancer patients.

Music for cancer research goes international

Dee Handyside has recently launched the song ‘Ten’ – a song written about her days at Burwash Primary School in England. With the help of the school, for every CD sold 1 pound will go to UK Cancer Research and 1 pound to cancer research here in Australia.

Dee recently did a LIVE Skype interview from her home in Australia with Burwash Primary School, England to launch the song. Dee loved answering questions from the children about her days at the school, music and what it was like to live in Australia! Continue reading “Music for cancer research goes international”

The Happiest Refugee incites joy, laughter… and hope for cancer patients

“I want to give you 1% of the retail sale price of every book sold,” Anh Do wrote in a letter to the Australian Cancer Research Foundation (ACRF) in July 2010 – just 2 months before the book in question, The Happiest Refugee, would take the Australian book industry by storm.

He anticipated that the funds raised for cancer research would be anywhere between $300 and $30,000: “Even more,” he wrote, “if the book goes well.”

… A humble understatement in hindsight, as last night The Happiest Refugee made headlines yet again when it won ‘Book of the Year’, ‘Newcomer of the Year’ and ‘Biography of the Year’ (joint winner with Musician Paul Kelly’s How to Make Gravy) at the Australian Book Industry Awards in Melbourne. Continue reading “The Happiest Refugee incites joy, laughter… and hope for cancer patients”

Music that continues to give hope

The music and impact of ACRF supporter Rosie Lee continues to grow and inspire those who hear her story. Rosie started supporting cancer research with her initiative Rosie’s Cancer Fund, giving hope to cancer sufferers while honouring the life of a loved one through song. Through her website she has been able to share her cancer journey to support and inspire others going through the cancer experience.

Her song “One Day We’ll Meet Again” is dedicated to her dear friend, Marilyn, and was first written the night before she sadly passed away after a long battle with both breast cancer and cervical cancer. 90% of the sales of this song are donated to cancer research. Continue reading “Music that continues to give hope”

Promising news for treating aggressive breast cancers

Researchers at the Walter and Eliza Hall Institute (WEHI) have found a new anti-cancer agent called ABT-737 that targets and neutralises Bcl-2 “pro-survival” proteins in cancer cells.

The project was undertaken at WEHI’s world-class cancer centre, which has received significant ACRF funding over the last five years.

This funding allowed researchers to better study the characteristics of proteins from the Bcl-2 family which are found at high levels in up to 70% of breast cancers – including typically aggressive ‘triple negative’ breast cancers – and work to prevent cell death, even in cells that have been damaged by chemotherapy. Continue reading “Promising news for treating aggressive breast cancers”

Two world-class research centres to open in QLD

Mr Tom S DeryI’m thrilled to announce the official openings of two world-class cancer research laboratories in Queensland next Tuesday [19 July, 2011]:

It is a true mark of the superior research being undertaken in the Sunshine State that these laboratories are opening on the same day to guests from all over the country.

In 2007 ACRF provided $2.7 million and $3.2 million respectively in seed funding to establish both of these facilities. Less than four years later, the labs are operating, and more importantly, they are making significant breakthroughs in our understanding of cancer and the ways we can prevent, diagnose, treat and defeat this terrible disease. Continue reading “Two world-class research centres to open in QLD”

2011 Gold Coast Airport Marathon

On the first weekend in July more than 24,000 people turned out to take part in the Gold Coast Airport Marathon events. With 6 events over 2 days there was something for all ages and fitness levels!

Amongst the thousands were 6 ACRF supporters competing in various events over the weekend.

Each of our supporters had their own personal reason for competing for cancer research. A few were inspired by their family and friends who had been through cancer and remained positive and courageous throughout their treatment. Others were taking on this challenge in honour of lost family members in the hope that their fundraising might help spare other families from going through what they had been through. Regardless of their specific motivations, they all knew that every dollar of every donation raised would be going to cancer research and in the process hopefully bringing us closer to a cure. Continue reading “2011 Gold Coast Airport Marathon”

Carrington Girls a great success

Late last year the lovely ladies of Carrington Retirement Village launched their 2011 calendar to great success!

It all began at a BBQ lunch where organiser Shirley Curtis came up with the idea of putting together a calendar to sell at the local Village fair. Shirley was determined to raise funds for cancer research following the loss of her husband to cancer in August 2008. Another 11 ladies jumped on board with the idea and the Carrington Girls 2011 calendar was born.

The calendar would not have been possible without the help of two local photographers, Suzi & Jodi, from Gorgeous Photography & Design, whose lives had also been touched by cancer. Suzi lost her mum a few years ago from cancer. As a result, the duo kindly offered to do the photography and design for the calendar free of charge. Continue reading “Carrington Girls a great success”

Chips' beard shave

42 years in the making, Chips Fearon’s fundraiser for cancer research was a hair-razing affair.

“Lots of people do feats of endurance to raise money, but I couldn’t ride a bike across the Nullarbor and I can’t run a marathon,” Chips told the local newspaper. “All I have is a 42 year old beard.”

With some mates who are fighting cancer, Chips decided he needed to do something. With over 26 tins out in the local community, support from local newspapers and radio, and even the local bakery donating money from their vanilla slice sales, the momentum for the shave just kept growing. Continue reading “Chips' beard shave”

Will and Kale ride for cancer research

Last week, two teenagers from Coffs Harbour showed us what can be achieved with the right motivation and support.

With almost 600km of NSW coastline ahead of them, Will and Kale left Coffs Harbour on Friday June 24 to the cheers of their local community – their impending six-day cycle made smoother through the knowledge that they had already reached their $10,000 target for the Australian Cancer Research Foundation. Continue reading “Will and Kale ride for cancer research”

Headshave to mark a milestone birthday

Kay Webb recently turned the big 60 & decided to celebrate by shaving her head for cancer research. Kay had always wanted to shave her head, and thought this occasion was a great time to do it & mark the milestone by getting rid of the “big red head and going the full monty”!

Kay chose to support cancer research as “we all know someone who has been touched by cancer and how this impacts on their lives and also their families, friends and colleagues” and there is a constant need for research. When the big day arrived, the red locks came off, but Kay was brave and kept smiling throughout the entire process. Continue reading “Headshave to mark a milestone birthday”

Super Duo complete WA State Marathon for cancer research

Cancer research supporters Carlo & Steph, recently took on the challenge of the WA State Marathon. Now in its 33rd year, the marathon spans 42.6 km through a picturesque course following the beautiful Swan river.

The super duo chose to donate to cancer research “as it’s not in the media as much as some of the other support based charities” and were “very astonished” at how much support their family and friends had given them.

Carlo & Steph took on the race with a great sense of humour, determination and the wonderful support and generosity of their family and friends. They were also hugely motivated by the fact that both their respective mothers have had cancer. Continue reading “Super Duo complete WA State Marathon for cancer research”

Donate to the ACRF tax-time appeal and help make cancer history

ACRF has launched its tax-time appeal to raise funds for world-class cancer research. Making a donation to the ACRF tax-time appeal before June 30th is a great way to boost your tax return and give back to charity you are passionate about helping at the same time.

Why donate to ACRF this tax-time?

When you make a tax deductible donation to ACRF, 100% of your tax donation goes towards cancer research in order to help us achieve our mission of outsmarting cancer by improving prevention, diagnosis and treatment of all types of cancer. 

Since 1988, thanks to our generous supporters, ACRF has awarded 75 grants totalling almost $160 million to world-class Australian cancer research initiatives in order to support and change the lives and future of those impacted by cancer.

With your help, the next vaccine, screening technology, or gene therapy is only a few years away.

Why make a tax deductible donation to ACRF this tax-time

A tax deductible donation is a gift made to an organisation which has deductible gift recipient (DGR) status. These are charities that comply with the transparency and accountability standards of the ACNC Charity Register. 

ACRF holds DGR status, which means any donation, $2 or more made to ACRF will reduce your taxable income. 

Donating to a charity has many benefits during tax-time, learn more about how tax deductible donations work and the impact they can have here or speak with your financial adviser or accountant. 

Make a tax deductible donation to ACRF today and help us support people like Jo receive lifelines from world-class researchers.

Shave, colour and wax all for cancer research

Recently Janet & Ben Turner decided to change their look for cancer research through a variety of shaving, waxing & colouring.

In honour of those close to them that had battled cancer and those that had been lost to cancer, the mother and son team decided to do something different. Their excitement and enthusiasm quickly extended their event to include Jan & Julie, 2 other teachers at Janet’s school, shaving their heads and a special day for the students of South Australian School for Vision Impaired (SASVI).

With a huge amount of support from family, friends & colleagues – Janet, Jan & Julie shaved their heads at SASVI. This was marked by a day of celebration with both students and teachers showcasing their crazy hair! Ben then endured a leg waxing and beard shave that weekend! Continue reading “Shave, colour and wax all for cancer research”

The best cancer research in the country shortlisted for ACRF support!

The distinguished ACRF Medical Research Advisory Committee (MRAC) has revealed their short-list of world-class cancer research initiatives to receive up to $10 million in 2011.

With 16 applications to consider, members of the MRAC (led by Fellow of the Royal Society of London and co-creator of the cervical cancer vaccine, Professor Ian Frazer) had a considerable task ahead of them.  But they are very enthusiastic about five particular applicants whose vision for the future of cancer research is truly world-class and worthy of further investigation. Continue reading “The best cancer research in the country shortlisted for ACRF support!”

Professor Ian Frazer elected Fellow of The Royal Society

Chairman of the ACRF Medial Research Advisory Committee, Professor Ian Frazer, has been appointed a Fellow of the esteemed Royal Society of London for his ground-breaking research that resulted in a vaccine for cervical cancer.

The 350 year old scientific academy acknowledges some of the most distinguished scientists in the world, with current and previous Fellows including Michael Faraday, Stephen Hawking and Isaac Newton.

“Election to The Royal Society is a great and unexpected honor, providing an opportunity to interact with the world’s leading scientists,” Professor Frazer said. Continue reading “Professor Ian Frazer elected Fellow of The Royal Society”

Two milestone birthdays for one great cause

Pam Davies and Christine Cook recently celebrated their milestone birthdays with a great celebration requesting donations to cancer research instead of gifts.

Their 60th and 70th birthdays were celebrated in a line dance hoedown party amongst 100 of their family and friends. At the event there was a wishing well in which people could make a donation to cancer research – and their “wishes were granted” with many people contributing generous, raising over $860! Continue reading “Two milestone birthdays for one great cause”

2011 Sydney Morning Herald Half Marathon

Bright and early on May 15th, 34 fantastic cancer research supporters took to the streets of Sydney as part of the Sydney Morning Herald Half Marathon.

The Foundation’s supporters chose to raise funds for cancer research for a variety of reasons. With the prevalence of cancer in Australia it’s no surprise that our supporter’s lives have been impacted in some way through cancer. Sadly many have lost loved ones to cancer, and others have loved ones currently fighting cancer and wanted to do something to show their support. Their fundraising was seen as a chance to support a “worthy cause”, do something positive in a difficult time, honour the memory of loved ones and mentors, and in the hope that research will be able to stop “this killer disease”. Continue reading “2011 Sydney Morning Herald Half Marathon”

ACRF seed-funding drives support to new SA cancer research centre

Image sourced from AdelaideNow, photographer Brenton EdwardsThe South Australia Cancer Genome Facility at SA Pathology is set to specialise in tailored cancer treatments thanks to ACRF seed-funding.

A grant of $3.5 million from ACRF, combined with $1.05 from the State Government and $500,000 from the Cancer Council SA, will buy state-of-the-art technology, such as gene sequencers, for the investigation of small, defined areas of DNA.

“ACRF is thrilled that our seed-funding provided the catalyst for other organisations to jump on board and fund the remaining $1.55 million required to establish this world-class facility,” Chief Executive of ACRF, Mr David Brettell said.

Continue reading “ACRF seed-funding drives support to new SA cancer research centre”

50% increase in ACRF funding applications an endorsement of no budget cuts

The Australian Cancer Research Foundation (ACRF) is thrilled that funding to medical research through the NHMRC will be maintained in the 2011/2012 budget.

“It is wonderful to see the government recognise the vital need for continued investment in medical research in Australia,” said ACRF Chief Executive, David Brettell.

“It would have been a huge shame to interrupt the momentum of such vital research initiatives.”

To highlight the growing need for research dollars, ACRF has just received grant applications totaling $50 million. These grants provide seed funding to leading cancer research institutes across Australia. Continue reading “50% increase in ACRF funding applications an endorsement of no budget cuts”

Hair Raising for cancer research

Ongoing ACRF fundraiser, Carmel McMahon, recently held an impromptu ‘Hair Raising Party’. The event was in honour of her friend, Annie, who is currently undergoing cancer treatment and had recently lost her hair. As always Carmel put together a fabulous evening in her backyard for what she considered a “small gathering” of 50 people!

During the event a number of people shaved their heads in support of Annie, and even one 30 year old moustache was shaved off for the cause. Everyone “had a ball” and $1000 was raised for cancer research!

The Foundation would like to offer our best wishes to Annie in her ongoing treatment – our thoughts are with you. Also huge thanks to Carmel for all her outstanding events held for us over the years and for the generosity of all who attend these wild and wonderful events! Looking forward to the next one!!

 

Breakthrough in lung cancer research

Researchers at the Children’s Cancer Institute Australia (CCIA) are using the ACRF Drug Discovery Centre for Childhood Cancer to enhance a recent breakthrough in lung cancer research.

Every year more than 9,000 Australians are diagnosed with non-small cell lung cancer. It is one of the most lethal forms of cancer. But while looking for ways to treat childhood solid cancer tumours, CCIA found a promising new therapy technique for lung cancer patients in Australia and throughout the world.

Continue reading “Breakthrough in lung cancer research”

Research grant at WAIMR named in memory of the Late Kevin McCusker

The ACRF Board and staff would like to extend their heartfelt condolences to the family of the Late Mr Kevin McCusker, and thank them for supporting his most generous bequest to cancer research.

To honour Mr McCusker’s significant donation to ACRF, a research grant awarded in 2010 has been named in his memory.

Mr McCusker’s donation in his Will will leave a lasting legacy through the provision of a world-class imaging hub for cancer diagnosis and management at the Western Australian Institute for Medical Research (WAIMR). The Director of WAIMR, Professor Peter Klinken, is thrilled to support the naming of this $2.4 grant in memory of Mr McCusker.

Continue reading “Research grant at WAIMR named in memory of the Late Kevin McCusker”

Fathers and sons go fishing

Three years ago, Drew Maddison and a friend started up a Father Son fishing trip. Along with a few others friends and their dads they had a great weekend and this soon became a yearly occurrence. A great time for the fathers and sons to get away together and enjoy some fishing!

At the end of the 2010 trip the group looked at the costs involved in the trip and decided to increase their individual cost to $100 for the weekend and donate all the profits to charity. Each of the 23 attendees this year were more than happy to support the chosen three charities – Australian Cancer Research Foundation, Royal Children’s Hospital, and Beyond Blue. These three charities were chosen as they “relate to what affects us blokes and our families”.

Thanks so much to Drew & the entire fishing group for your generosity to cancer research, and we look forward to hearing about next years trip!

 

Discovery of biomarkers will aid pancreatic cancer patients

Cancer researchers at Sydney’s Garvan Institute of Medical Research have discovered two ‘biomarkers’ which can indicate the likelihood of patient survival after pancreatic cancer surgery.

Lead investigator of the research, Professor Andrew Biankin, has acknowledged the significant financial contribution of ACRF to the work of his team for this and other cancer research at the Garvan. ACRF has awarded $6.1 million in grants since 2004 to the Garvan Institute.

Continue reading “Discovery of biomarkers will aid pancreatic cancer patients”

Cara and Chey's special day

On March 5th 2011 Cara Hogan and Chey Fisher were married amongst 110 of their family and friends. As part of their special day they chose to support cancer research.

At just 15, Cara was diagnosed with cancer, and after 14 months of treatment she was in remission from the Ewing Sarcoma she had battled. To this day she remains cancer free but cancer research will always be a cause close to her heart.

In planning their wedding both Cara and Chey “felt guilty” about the amount of money being spent on one day and wanted to find a way to give back. Their personal connection to cancer and the fact that every dollar of every donation goes to cancer research led them to donate to cancer research in place of gifts for their guests. Both Cara and Chey preferred to offer guests something meaningful rather than chocolates or ornaments that may not be used. Continue reading “Cara and Chey's special day”

ACRF concerned over potential cuts to cancer funding

 

 

ACRF urges the government to re-think any planned cuts to medical research funding.

“We’re puzzled,” said the Australian Cancer Research Foundation (ACRF) Chief Executive, David Brettell, “Take away research funds and it’ll be no surprise when great science slows, researchers either change jobs or head overseas, and patients unnecessarily suffer when they can’t access fast, effective treatments.”

ACRF recognises the vital need for continued, strong investment in medical research, so much so that it has set out to double its own cancer research funding over the next five years. Continue reading “ACRF concerned over potential cuts to cancer funding”

Australian Running Festival

Our nations capital got active on April 9th for the inaugural Australian Running Festival. Seven ACRF supporters got involved in this community event with 5km, 10km, half, full and ultra marathon events.

Each supporter had their own personal motivations for taking on this challenge. For some it was their first time and they wanted to support a worthy cause, for others it was about improving their lifestyle and inspiring others. For many it was a personal loss of family and friends to cancer that led them to supporting cancer research, with some feeling that “running a marathon is nothing compared to what these people have been through”. They know that cancer affects 1 in 3 Australians and can affect anyone, and set about showing their support for those battling cancer and hoping to “do my little bit to help”. Continue reading “Australian Running Festival”

Vietnam adventure will get the wheels turning for cancer research

ACRF has teamed up with Inspired Adventures to bring you the travel opportunity of a lifetime.

This 13-day adventure commencing November 19, 2011 will take you across the countryside of Vietnam – through the bustling streets of Ho Chi Minh City to the heart of the Mekong, through tropical forests, past rice paddies and pastures, and into historical sites of wars and political regimes past.

And the most exciting part? You’ll be doing all the leg-work (or at least 413km worth of it). Yes, bikes will be provided, but you’ll need to BYO enthusiasm! Continue reading “Vietnam adventure will get the wheels turning for cancer research”

Jaylene chops her locks for cancer research

Jaylene Davey recently took the plunge and shaved off her long locks for cancer research!

At Christmas last year the extended Davey family donated to cancer research instead of Secret Santa gifts. This generous gesture was prompted by the loss of a dear family member after an eight month battle with cancer in his gall bladder. Jaylene also chose to honour the memory of her uncle and positively contribute towards cancer research in another way. Continue reading “Jaylene chops her locks for cancer research”

Professor Whitelaw: Fellow of Australian Academy of Science

The Australian Cancer Research Foundation (ACRF) would like to congratulate Professor Emma Whitelaw for her election into the Australian Academy of Science (AAS) last week.

Professor Whitelaw received this prestigious Fellowship in recognition of her work in epigenetics – including the study of complex diseases resulting from gene-environment interactions (such as cancer). Continue reading “Professor Whitelaw: Fellow of Australian Academy of Science”

Up to $10 million for cancer research

Applications for the Australian Cancer Research Foundation’s (ACRF) Research Grants are NOW OPEN.

Applicants may apply for grants between $1.5 million and $3 million.

Our Board of Trustees, advised by our distinguished Medical Research Advisory Committee, invites grant applications from leading cancer scientists and scientific teams in Australia for the funding of:

• Capital Works & Facilities

• National Enterprises Continue reading “Up to $10 million for cancer research”

Ache and Brake to Wallis Lake

Six Central Coast men came together recently for the inaugural ‘Ache and Brake to Wallis Lake’. The group of mates decided to cycle from their homes to team member Dom Lovatt’s holiday house in Forster and raise some funds for cancer research in the process. Each of the team has been affected in some way by cancer, and experienced loss of family & friends to this terrible illness.

Despite some pre-ride injuries the group were eager and enthusiastic to take on this challenge, and with a huge amount of support from family, friends and the local community they rode more than 230kms over 2 days taking them from Terrigal through Newcastle and Hawks Nest to their destination in Forster. Continue reading “Ache and Brake to Wallis Lake”

A big THANKS to Schiavello

ACRF thanks Schiavello for recent works completed on a pro bono basis to our office.  They certainly do create great workplaces.

To Bernardo, Alan, John and the team – We thank you.

For information on Schiavello’s services please visit www.schiavello.com

A special birthday supporting cancer research

Cancer survivor Patrick Tully recently celebrated his 70th birthday surrounded by family & friends. His surprise party organized by family members, including daughter Kim, involved a wishing well for cancer research where loved ones could donate instead of giving presents. Guests were also given cancer research awareness ribbons as a sign of their support.

Patrick was delighted by his celebration and especially by the donations to cancer research – giving an emotional speech about the importance of ensuring organisations like the Australian Cancer Research Foundation receive support even amongst all the tragedies in the world. Continue reading “A special birthday supporting cancer research”

100km for cancer research

Tony Barrett‘s life has been touched by cancer in many ways, and he decided to compete in the Otway Odyssey Mountain Bike Marathon and raise funds for cancer research. He chose to support both the Australian Cancer Research Foundation and Cancer Research UK for friends and family across both countries to contribute towards a cure for cancer.

Tony’s mother was battling a rare form of cancer and a few weeks before the race she fell quite ill. Tony returned to the UK to be with his mother and subsequently missed the race. Sadly his mother passed away at the end of February, and inspired to honour her and honour the generous sponsorship he had already received from family and friends to compete in the race, Tony chose to ride his own 100km ride and film it to show all his supporters! Continue reading “100km for cancer research”

Cell ‘glue’ opens new pathways to understanding cancer

Australian researchers at the Institute for Molecular Bioscience, University of Queensland (UQ) have found a novel way in which the proteins that ‘glue’ cells together to form healthy tissues can come unstuck, opening new avenues to understanding how these proteins are disturbed in diseases such as cancer.

Professor Alpha Yap and Sabine Mangold have been studying how cells stick together and the diseases that occur when cells detach when they shouldn’t. In particular, the progression of tumours to advanced stages commonly occurs when cancer cells separate from their tissue of origin. Continue reading “Cell ‘glue’ opens new pathways to understanding cancer”

Two Bucks Goes Fourth

Happy 4th birthday to Australian Cancer Research Foundation supporters Two Bucks Til Wednesday! Last weekend this amazing team held the Two Bucks Goes Fourth sale in celebration of their 4 years of supporting cancer research!

Despite a scorching Perth day the crowds turned out at Mt Hawthorn Lesser Hall to snap up some of the hand picked vintage goodies and support cancer research at the same time. Through the clothes, accessories and bags, all priced under $20, more than $2,300 was raised on Saturday. Continue reading “Two Bucks Goes Fourth”

ACRF grant recipient wins international award

A world-leading researcher and ACRF research grant recipient, Professor Emma Whitelaw, has been awarded top honours in the fields of biochemistry and molecular biology during an international scientific meeting.

In 2007, ACRF awarded $2.7 million to Professor Whitelaw and her research team at the Queensland Institute for Medical Research (QIMR) to establish the ACRF Centre for Cancer Epigenetics. Epigenetics is the study of mechanisms which modify DNA structure in subtle ways, and thus change gene expression, without influencing the DNA base sequence. Continue reading “ACRF grant recipient wins international award”

Blood stem cells discovery to boost cancer research progress

A study partially funded by the Australian Cancer Research Foundation (ACRF) creates opportunities in the way some cancer patients can be treated. The blood stem cell discovery has been made by scientists from the Walter and Eliza Hall Institute (WEHI) in Melbourne.

Led by Professor Doug Hilton, Dr Samir Taoudi and their research teams, the scientists discovered that the Erg gene is key to blood stem cells’ unique ability to self-renew. Research in blood stem cells allows scientists to develop new strategies to combat disease of the blood cells, like leukaemia. Continue reading “Blood stem cells discovery to boost cancer research progress”

ACRF Drug Discovery Centre update

Researchers at the ACRF Drug Discovery Centre, located in the Children’s Cancer Institute of Australia (CCIA), are now screening the most promising drugs in the treatment for childhood cancers with a one of a kind robot funded by the Australian Cancer Research Foundation (ACRF).

Coinciding with International Childhood Cancer Awareness Day, today’s announcement of the first drug screening at CCIA using this new technology is a huge step in personalised medicine and revolutionising the development of treatments for children’s cancers. Continue reading “ACRF Drug Discovery Centre update”

Getting active in the Cole Classic & Sun Run

Last weekend Sydney’s northern beaches were host to two widely attended events. The Cole Classic, now in its 28th year, and the brand new fun run, the Sun Run, making its debut. Thousands of people turned out across the two days to compete in these events, and among them were 13 ACRF supporters.

Some of these supporters were competing for the first time, others were veterans for these sort of events, and each had their own personal reason for choosing to fundraise for cancer research. Some are cancer survivors and some have experienced the devastating loss of family and friends to cancer. Some also chose to support the ACRF because they believe that in funding research into all types of cancer we will make our way towards a cure. Continue reading “Getting active in the Cole Classic & Sun Run”

Tattooing for cancer research

Recently a number of brave and committed family members and friends, led by ACRF supporter Kristi Willis, came together to raise funds for cancer research doing something a little different. The group of tattoo fans decided to get awareness ribbon tattoos as a permanent sign of their support of cancer research.

Kristi told us these wonderful supporters were spurred on to support cancer research as each of them has seen the effects of cancer in those around them, including Kristi’s mother who has had cervical cancer twice and the recent passing of her uncle from leukaemia. Continue reading “Tattooing for cancer research”

Give a boost to cancer research on World Cancer Day

Today the Australian Cancer Research Foundation (ACRF) is uniting with thousands of supporters fighting against cancer across the globe for World Cancer Day.

Cancer is a leading cause of death around the world. The World Health Organisation (WHO) estimates that 84 million people will die of cancer between 2005 and 2015 without intervention.

DONATE NOW this World Cancer Day Continue reading “Give a boost to cancer research on World Cancer Day”

ACRF thanks the Late Mrs Alma May Rash

A very significant donation by the Late Mrs Rash in her Will has enabled ACRF to fund new research facilities throughout Australia.

New research grants totalling $8.5 million, which were announced in November 2010, would not have been possible without her generosity.

Thank you Mrs Rash for this most generous donation.

Every dollar of the Late Mrs Rash’s donation is being used for research.

For more information on remembering cancer research in your Will, please visit our bequests page.

The Xpan book

It all started with a group of people on Flickr, united by their love of a panoramic film camera – the Hasselblad Xpan. The group administrator, Matthew Joseph, decided that it would be fantastic to produce a book featuring Xpan images. He suggested the idea to the group members and 28 photographers from across the world jumped at the chance to be part of a book showcasing their work with this unique camera.

It was agreed that the beautiful collection of 32 images would be made into a book with all profits going to charity. For Matthew, choosing to support cancer research was a “no-brainer” as he had lost his mother to cancer 11 years ago.

Continue reading “The Xpan book”

Hitting the water for cancer research

On Australia Day over 2000 competitors lined the Wollongong harbour for the annual Illawarra Aquathon. Affectionately known by locals as the ‘splash n dash’, and now in it’s 13th year, the day involves 3 different events for all ages & abilities – each including a swim & run of varying distances.

Amongst the crowd was ACRF supporter Bindi Adams. She chose to raise funds for cancer research as part of her aquathon attempt as she had numerous family and friends whose lives had been touched by cancer, and sadly some who had lost their battle. Bindi felt that cancer “seems to touch everyone” and knew that “every little bit” of fundraising helps get one step closer to a cure.

Continue reading “Hitting the water for cancer research”

Lance Armstrong supports unique cancer centre

Seven-time Tour de France champion and cancer survivor Lance Armstrong met with researchers this week in Adelaide during the construction of the Flinders Centre for Innovation in Cancer (FCIC).

Due for completion later this year, the unique centre will incorporate Armstrong’s LIVESTRONG Cancer Research Centre and the Australian Cancer Research Foundation (ACRF) Cancer Prevention Unit. Continue reading “Lance Armstrong supports unique cancer centre”

Aussie scientists unravel colorectal cancer mystery

A team of scientists at the Garvan Institute of Medical Research in Sydney has identified why some patients are able to respond to treatments better than others for colorectal cancer.

Continue reading “Aussie scientists unravel colorectal cancer mystery”

Conquering Mt Kilimanjaro for cancer research

Intrepid mother-daughter duo Deb and Karen Short conquered Mt Kilimanjaro on December 25 2010, all in the aid of cancer research. Inspired to attempt the adventure in memory of husband and father Robert Short who lost his battle with cancer just one year earlier, they began their climb on the first day of his anniversary.

Continue reading “Conquering Mt Kilimanjaro for cancer research”

ACRF awards $8.5 million to 4 world-class cancer research initiatives

Australia’s best scientists have been given a major boost in their fight against cancer, with the announcement of $8.5 million worth of grants from the ACRF to the nation’s finest research institutions.

The Foundation awarded a total of three grants – to $2million grant to The Walter and Eliza Hall Institute (Melbourne), $2.4million to Western Australian Institute for Medical Research and $1.6million to Monash Institute of Medical Research (Melbourne).  This is in addition to the ‘top-up’ grant of $2.5 million the ACRF pledged earlier to The Kinghorn Cancer Centre, a joint facility of the Garvan Institute of Medical Research and St. Vincent’s Hospital in Sydney.

Continue reading “ACRF awards $8.5 million to 4 world-class cancer research initiatives”

2010 ACRF grant recipients

The 2010 ACRF grants – totalling $8.5 million – will fund two new cancer divisions, a scanner for imaging tumour development and state-of-the-art genomic technologies. Since 1987 the Foundation has provided 41 grants totalling almost $71 million to Australian cancer research institutes ($48 million of which has been awarded in the last six years). This year four grants have been awarded to four cutting edge research projects around the country. Continue reading “2010 ACRF grant recipients”

Help fund the research of today that will help the cancer patients of tomorrow

The Australian Cancer Research Foundation (ACRF) wants to fund even more groundbreaking cancer research and is aiming to raise $750,000 in its 2010 Christmas Appeal, says the Foundation’s Chief Executive David Brettell.

Continue reading “Help fund the research of today that will help the cancer patients of tomorrow”

PepsiCo supports cancer research

One of our most active sponsors and fundraisers, our friends at PepsiCo Australia & New Zealand, visited the Australian Cancer Research Foundation (ACRF) recently to present a cheque for over $12,000 for cancer research.

This generous contribution represents donations collected at an event hosted by PepsiCo and The Smith’s Snackfood Company employees, in honour of much-loved team member Agnes Connell who lost her battle with cancer in August 2009.

Continue reading “PepsiCo supports cancer research”

'Biggest shave ever' for cancer research

Nine year-old Gabi Scott recently raised over $2000 for cancer research by asking supporters to donate to her ‘Biggest Shave Ever for a Good Cause’ held on 30 November 2010.

In her touching request for support, Gabi shared her motivation for the event: “I am shaving my hair to raise money for cancer research. I have a friend who is nine like me who has cancer and I know a lot of people who are trying to fight it off.”

Continue reading “'Biggest shave ever' for cancer research”

ACRF awards $5M cancer research grant for Kinghorn Cancer Centre and honours Lady (Sonia) McMahon

The Australian Cancer Research Foundation (ACRF) will tonight award its equal largest ever research grant of $5 million towards the construction of The Kinghorn Cancer Centre, a joint facility of the Garvan Institute of Medical Research and St. Vincent’s Hospital in Sydney.

The ACRF grant honours the late Lady (Sonia) McMahon, life member and one of two joint founders of the Foundation (the other being the late Sir Peter Abeles).

Continue reading “ACRF awards $5M cancer research grant for Kinghorn Cancer Centre and honours Lady (Sonia) McMahon”

“Elvis” rocks it at Club Central Menai for cancer research

In early 2010, a group of six Club Central Menai employees got together to organise a dinner for the sole purpose of raising funds for cancer research.

“The Australian Cancer Research Foundation was chosen because it conducts research into all cancers that affect men, women and children” said Judith Howard, Club Central Menai Fundraising Committee Member. Continue reading ““Elvis” rocks it at Club Central Menai for cancer research”

Carmel McMahon hosts toga party for cancer research

One of our most dedicated fundraisers, Carmel McMahon, certainly knows how to throw a party – recently dazzling around 80 guests at the 2010 toga party for cancer research.

With an abundance of entertainment on offer throughout the night, the event catered to guests of all ages from seven months to 81 years supporting cancer research.

A combination of three soft rock acoustic bands set the mood on a fantastic balmy starlit night, and around $3,000 was raised at the event through raffles, auctions and donations. Continue reading “Carmel McMahon hosts toga party for cancer research”

BBQ for cancer research

The team at Scarff Recruitment Solutions recently held a fundraising BBQ for cancer research at their local Bunnings store in Harbourtown, Queensland.

Director of Scarff Recruitment Solutions, Helene Scarff, wanted to support cancer research due to the number of people, both staff and families of staff that have been affected by cancer. They are hoping to make a difference whilst engaging with the local community.

The BBQ raised more than $1,700 which greatly exceeded their expectations and starts them on their way to the goal of $10,000 they are hoping to raise through various events over the next 12 months. Continue reading “BBQ for cancer research”

Fred Pham 500 launch new initiative supporting cancer research

Fred Pham 500 supporters are showing no sign of slowing down since the group’s inception in September 2010, recently rolling out their latest initiative Schools Against Cancer.

Both on and off the running track, the Fred Pham 500 team is continuing the legacy of the inspirational Fred Pham, who recently lost his battle with cancer, and helping the Australian Cancer Research Foundation (ACRF) raise much needed funds for cancer research.

Schools Against Cancer is an initiative inspired by the legacy of the late Fred Pham and his fight to raise $100,000 for the ACRF. Organisers are urging education providers across Australia to enrol their schools and hold an event to increase awareness and raise funds for cancer treatments and cures.

Thanks to dedicated staff, teachers, and students, numerous events are already being held across Australia for the Schools Against Cancer initiative. ACRF especially thanks Fairfield High School, Sydney Boys High School, and Cabramatta High School for their fantastic achievements with their recent events: Continue reading “Fred Pham 500 launch new initiative supporting cancer research”

Popular acts unite at Megafauna Charity Music Festival

Ten of Canberra’s most talented bands took to the stage recently to entertain crowds at the 2010 Megafauna Charity Music Festival.

With a diverse selection of musical genres including rock, cabaret, metal, and pop, this year’s Megafauna Festival held at The Basement venue in Canberra was a massive success and raised over $3000 for the Australian Cancer Research Foundation (ACRF).

Some of the stand out acts included Canberra five-piece band The Red Vest, and a funk fusion metal performance by three-member band Yeti. Click here to read a review of other bands from the night.

The Megafauna Music Festival is now in its fourth year, and organisers have raised over $16,000 for ACRF so far. Continue reading “Popular acts unite at Megafauna Charity Music Festival”

Sutherland Shire Council gets loud for cancer research

And the loudest shirt prize goes to…

With over 200 staff in attendance, plenty of food, and a wealth of prizes on offer it was hard to hide any excitement for the Sutherland Shire Council’s recent loud shirt staff fundraising event.

Now in its third year, the morning tea event hosted by the staff in the environmental services division commenced as a way of honouring one of their colleagues who sadly passed away following a long battle with cancer in 2008, and now is a tribute to all lives lost to this devastating disease.

“It’s unfortunate that a number of other staff and their families have also been affected by cancer,” said the loud shirt committee from the Sutherland Shire Council. Continue reading “Sutherland Shire Council gets loud for cancer research”

Alex Dodds Walk 4 A Cure – congratulations Blaise White & Zac Dodds!

Boys become men

Over eleven long days, cousins Blaise White and Zac Dodds, tested their physical and mental abilities as they walked a gruelling 400km from Drysdale, Victoria across the New South Wales border, in memory of their grandfather.

The Alex Dodds Walk 4 A Cure team recently held a special BBQ on the one year anniversary of the passing of their grandfather to congratulate the pair and to officially donate proceeds from their fundraising efforts to the Australian Cancer Research Foundation (ACRF).

Throughout the journey the pair stopped in local towns to raise awareness for cancer research – and according to their proudest supporter, Kerryn White – it was an incredible challenge that has turned the teenage boys into men. Continue reading “Alex Dodds Walk 4 A Cure – congratulations Blaise White & Zac Dodds!”

ACRF research grant recipient awarded medal for excellence – Professor Chris Goodnow

The Australian Cancer Research Foundation (ACRF) congratulates Professor Chris Goodnow on his award, announced on 4 November 2010, of the Ramaciotti Medal for Excellence in Biomedical Research.

Professor Goodnow receives this award for his recent work on understanding the immune system and the way in which it wards off bacteria and viruses without attacking the body’s own tissues and organs. This discovery will allow more effective drug treatment to be created for many conditions, including cancer.

Chris and his team at the John Curtin School of Medical Research in Canberra have now received two grants from the ACRF.

The most recent, a $1.13 million researh grant in late 2004 to develop the ACRF Biomolecular Resource Facility for investigating the molecular aspects of cancer biology and provide researchers with access to new technologies.

Continue reading “ACRF research grant recipient awarded medal for excellence – Professor Chris Goodnow”

Running, swimming and cycling for cancer research

On October 31, Australian Cancer Research Foundation (ACRF) supporter Lisa Neath competed in her first long course triathalon as part of the Port Macquarie Half Ironman Triathalon.

Lisa felt compelled to raise funds for cancer research as part of her challenge as “every week I am told of another person that has cancer or has passed away. Whether it be family, friends or work colleagues it just seems to be affecting so many people every day.” She also competed in memory of a colleague who recently passed away from brain cancer who was also into swimming, riding and running as a way to honour his memory doing something he loved.

Lisa conquered the gruelling 1.9km swim, 90km cycle and 21km run in just over six hours despite tough weather conditions. She made it through with a great deal of determination and sugar to keep her going! Continue reading “Running, swimming and cycling for cancer research”

VALE Fred Pham

The Australian Cancer Research Foundation (ACRF) is saddened to hear of the passing, on 30 October 2010, of Mr Fred Pham. Just three months ago, Mr Pham, whilst battling terminal cancer, was the largest individual fundraiser for a charity in the annual Sun-Herald City to Surf Fun Run (in Sydney). ACRF was privileged to be the beneficiary of Fred’s amazing effort.

Fred,  just 47, leaves his wife and five children. We grieve with them and hope that his strength gives them strength.

All at ACRF are thinking of the Pham family. He was a true inspiration.

David Brettell
CEO

ACRF funds landmark discovery

At the Australian Cancer Research Foundation (ACRF), we love to see results and that’s why we’re investing more than ever in world-class equipment and infrastructure for research into cancer.

Since 1987 we’ve provided 41 grants totalling almost $71 million to Australian cancer research institutes ($48 million of which has been awarded in the last six years). We profile some of the latest breakthroughs:

1) In a landmark discovery, scientists at the Walter & Eliza Hall Institute have discovered the links between breast cancer risk and exposure to female hormones. This breakthrough research project – partially funded by a $5million ACRF grant – found that breast stem cells, despite lacking receptors for the female hormones oestrogen and progesterone, are still extra sensitive to sustained exposure to these hormones.

2) ACRF funding means researchers at the Garvan Institute are now closer to ‘switching off’ the gene identified as causing prostate cancer, following a world-first detailed description of gene expression in prostate cancer cells. ACRF has now awarded two research grants to the Garvan, the latest of $5million in honour of Lady (Sonia) McMahon.

3) Researchers at the Queensland Brain Institute’s ACRF Brain Tumour Research Centre are saving patients’ lives by safely taking primary tissue samples directly from patients and separating tumour cells from contaminated normal tissue, blood cells and cellular debris – made possible with numerous scientific instruments funded by ACRF.

 

Africa night for cancer research a huge success

Family and friends of Deb & Karen Short were treated to a taste of Africa at their recent fundraising night. The mother-daughter duo are continuing their fundraising efforts for cancer research in the lead up to their Mt Kilimanjaro climb in December.

The night was a great success with around 250 people in attendance, all wearing their African-themed costumes. An African drumming group and photo booth provided fantastic entertainment and memories for all attendees.

Deb & Karen have been overwhelmed by the support they have received from family, friends and local businesses – raising $10,500 from the Africa night. This takes their fundraising total to over $20,000 – double their target! And they are not slowing down yet – there are still some more fundraising projects to come, including ‘Africa day’ at the school where Deb teaches. Continue reading “Africa night for cancer research a huge success”

Cocktails for cancer 2010

Australian Cancer Research Foundation (ACRF) supporter, Chantelle Smoor, has once more dazzled family and friends by hosting the second annual Cocktails for Cancer.

More than 150 guests gathered in Newman, Western Australia for the popular event in support of cancer research and to honour Chantelle’s brother, John Simpson, sadly lost to cancer in 2009.

The evening was a night to reflect on all the lives lost to cancer and to encourage the community to unite and donate to a worthy cause.

Guests dressed in their most cheerful summer outfits for the pool-party themed event, and together they enjoyed an evening filled with joy, hope, and opportunity to contribute to the fight against cancer. Continue reading “Cocktails for cancer 2010”

Riding for 24 hours

On October 9th, 400 enthusiastic mountain bikers arrived at Stromlo Forest Park in Canberra for the Australian 24 Hour Mountain Bike Championships. Two fantastic ACRF supporters, Jane and Mathew Keeley, were among the riders preparing for the gruelling 24 hours of riding through the park’s terrain.

The brother and sister team were taking part in the race for the second time, choosing to raise funds for cancer research this year as part of their challenge.

Cancer research is a cause close to both their hearts, with the pair sadly losing their mother to lung cancer in 2007. Continue reading “Riding for 24 hours”

Blue September – thank you for getting blue for cancer in men

A great big blue thank you for Blue September 2010

The Australian Cancer Research Foundation (ACRF) wishes to thank everyone who supported Blue September 2010.

We are especially grateful for the support from all our fabulous fundraisers who organised numerous events across Australia at their workplace, at school, and in their communities.

Ranging from blue morning teas and blue dress days, to blue BBQs and blue footy matches, our supporters were a driving force in promoting the health of the men in our lives throughout September.

Thank you also to all the Blue September corporate partners and ambassadors for their tremendous support and for making a vital contribution to the fight against cancer in men.

Blue September is a national awareness campaign promoting men’s health, encouraging prevention and early detection of the most common cancers in men, while raising funds for vital cancer research. Continue reading “Blue September – thank you for getting blue for cancer in men”

Touch down for the India trek challenge adventurers

Overseas adventure for cancer research

The exuberant India Trek Challenge crew visited Tibetan and Indian communities as part of the 2010 Inspired Adventures Charity Challenge trip to raise funds for the Australian Cancer Research Foundation (ACRF).

The crew is made up of six wonderful ladies, Olwen Bradford-Cowling, Bonnie Mulholland, Amy Fraser, Michelle McNamara, Lynda Klompmaker and Nikita Hodgson, who have over the past 12 months tirelessly dedicated their time and efforts to raise money for ACRF.

Over $20,000 has been raised by the fundraising team thus far! Continue reading “Touch down for the India trek challenge adventurers”

Melbourne Marathon

ACRF supporter Claire Atley was among a milestone group of runners at the Melbourne Marathon on Sunday October 10th 2010, the first Australian marathon to ever have more than 5000 people compete over the 42 km course.

Claire chose to support cancer research as part of her marathon challenge in memory of her aunt who sadly passed away from cancer, and in support of her father who recently had surgery for prostate cancer. She hoped friends and family would dig deep for a cause she feels very strongly about.

Despite some nerves before race day, Claire powered through the event, finishing in 4hrs, 1 minute & 33 seconds – a fantastic effort! No doubt motivated by surprise support from some family who drove more than 2 hours to be there to cheer her on!

Thank you Claire and all your supporters for raising more than $740 for cancer research! And our warmest congratulations on your amazing achievement in completing the marathon!

Read more on raising funds for cancer research in sporting events.

World cycling legend gets behind cancer research

World-renowned cyclist and seven-time winner of the Tour De France, Lance Armstrong, has come to the aid of the Australian Cancer Research Foundation (ACRF).

Recently, the champion who had his own health scare several years back when he battled testicular cancer, signed a t-shirt given to him by one of our awesome supporters, Adelaide nurse Mark Gibbens.

The signed t-shirt is to be auctioned by the ACRF to raise funds for vital cancer research.

Gibbens wore the shirt on his “Cure Cancer Challenge” trek last year and presented it for a signature by Armstrong when the champion cyclist was in Australia on his “Tour Down-under” in January and February 2010. Gibbens, a registered nurse, husband and father of one, walked a staggering 5300 KM from Perth to Sydney to raise funds for cancer research in 2009.

His marathon walk was a tribute to a close friend and mentor who died from cancer in 2007, as well as all of the cancer patients (and their loved ones) that he has encountered during his time as a nurse.

Gibbens, who was in Sydney last week to attend the Asia Pacific Conference on Tobacco or Health, dropped into the ACRF office to generously donate the t-shirt signed by Lance Armstrong and offer his encouragement for our work in raising funds for cancer research.Previously Gibbens had undertaken a 3000-kilometre walk in Japan where he raised major awareness in a campaign against the dangers of smoking.

The story and pictures of Mark’s ACRF walk were presented at the recent conference. Nice one Mark!

Keep checking our website for further details on the auction of the Gibbens “Cure for Cancer” t-shirt signed by legendary cyclist Lance Armstrong.

Read more about Mark and his Cure Cancer Challenge.

Stem cell breakthrough – great news for cancer patients

CI_logoSydney researchers this week revealed a stem cell research breakthrough that will have a massive impact for cancer sufferers requiring bone marrow transplants.

Publishing the results in the esteemed biotechnology journal Nature Biotechnology, lead author Professor John Rasko and his team from Centenary Institute have found, for the first time, a way of growing an increasing number of blood-forming stem cells outside the body.

Patients who receive stem cell transplants for various conditions or treatments, including leukaemia or chemotherapy, could soon expect significantly improved outcomes thanks to the landmark finding by the research team at the Centenary Institute, Royal Prince Alfred (RPA) Hospital and the University of Sydney.

Stem cell transplants are vital for treating cancer patients who have had their bone marrow destroyed by chemotherapy. Continue reading “Stem cell breakthrough – great news for cancer patients”

Wedding bonbonniere with a difference

The wedding of Josie Standing and Ashley Pobje was a perfect day of celebration with family and friends on October 3rd 2010. Both Josie and Ashley have a family history of cancer and chose to support cancer research as part of their big day.

Rather than giving the traditional lollies as gifts to their guests – they chose to donate to cancer research and give each guest a ribbon to represent their donation. Josie & Ashley were hoping this would make a small difference and encourage guests to think about donating themselves.

The ribbons made a bigger impact than anyone expected. For one groomsman they were particularly significant as his father is currently undergoing treatment for bowel cancer and appreciated the gesture of a donation to cancer research rather than a traditional guest gift.

Thank you Josie & Ashley for your generosity and for including cancer research on such a special occasion & we are delighted to hear about your wonderful day!

For more details on how to support cancer research at your upcoming celebration visit Gifts to Cancer Research in Celebration.

 

Fred Pham on 'Insight' 7:30pm tonight

Major Australian Cancer Research Foundation fundraiser and champion Fred Pham will take to the television air waves tonight to talk about his unique experience battling cancer.

Pham will appear on the popular SBSInsight’ program, hosted by Jenny Brockie, in a show that focuses on terminal illness.  Jenny will ask patients who might have just weeks or months to live the big question. ‘Should they fight on or accept the inevitable? Should their doctors hold out hope, however slim, or deliver the hard medical reality?’

These decisions are much tougher as medicine and medical technology becomes increasingly sophisticated.  Patients, families and doctors wrestle with these ethical and moral dilemmas at the end of life..

Fred Pham, 47, has been told that he has incurable cancer but is still fighting. He is currently on “fourth-line chemo”, which doctors tell him has a slim chance of working. Continue reading “Fred Pham on 'Insight' 7:30pm tonight”

Inherited cancer centre opening in Tasmania

Tasmanian Minister for Health, Michelle O’Byrne today – Tuesday September 28 – opened the $1.1 million ACRF Tasmanian Inherited Cancer Centre at the Menzies Research Institute Tasmania in Hobart.

“The ACRF Inherited Cancer Centre enables our researchers to fast track their crucial research into preventing or finding better treatments for inherited cancers,” said Menzies’ Director, Professor Simon Foote.

Inherited cancers are those in which family history is a high risk factor. These can include prostate cancer and leukaemia. Research at the new Centre focuses on further identification of the genes underlying the causes of these cancers as well as their environmental triggers. Continue reading “Inherited cancer centre opening in Tasmania”

Chloe's head shave for cancer research

One of ACRF’s youngest supporters, Chloe Gemmell, recently held a unique and very special fundraiser for cancer research.

Touched by the passing of her cherished pet cat from cancer, Chloe decided she wanted to shave her head in memory of her much loved pet and for all those people out there who are battling the disease.

On the big day Chloe’s school friends helped out by cutting off pieces of her hair, before mum Vicky finished it off with the clippers.

With support from her family and sponsorship from a great bunch of friends Chloe managed to raise a fabulous $650 for cancer research.

Thanks so much for your support Chloe & Victoria – we think the new haircut looks great. Perfect for the upcoming summer!

 

Continue reading “Chloe's head shave for cancer research”

ACRF’S FANTASTIC SUPPORTERS: ANH DO – THE HAPPIEST REFUGEE

The Happiest Refugee on hardship, optimism, and supporting cancer research

One of Australia’s best-known comedians, Anh Do, has just joined The Australian Cancer Research Foundation’s community and long list of fantastic supporters.

Part of the sales from The Happiest Refugee will be donated to ACRF to help outsmart cancer

Anh is currently promoting his honest and uplifting memoir, The Happiest Refugee, and will be donating part of the sales from the book to ACRF in support of cancer research.

The book is dedicated to fellow comedian and friend, Dave Grant, who sadly lost his battle to pancreatic cancer earlier this year.

The Happiest Refugee has already received plenty of praise from the literary community, and was the highest selling Australian book in the week it debuted!

Based on his family’s struggle out of war-torn Vietnam and their integration into Australian society, The Happiest Refugee is a sincere, open account of Anh’s life, offering a ray of sunshine and hope for all who read it.

We’ve read it, and can say it is a remarkable read – expect to laugh hysterically under his comedic spell, to be astonished by his optimism toward life, and to wipe away the tears as he recounts the most harrowing moments of life as a refugee.

We would like to thank Anh Do for his contribution to cancer research

ACRF wishes to congratulate Anh Do on his tremendously successful literary debut, and extend a big thank you for supporting us in the fight against cancer.

If you would like to follow in Anh’s footsteps to help us outsmart cancer, you can donate online today. Your donation will go towards providing technology, equipment and infrastructure Australian researchers need to continuously explore new and improved ways to prevent, detect and treat all types of cancer.

27km coastal walk for the ACRF

At ACRF our supporters continue to surprise us with their stellar fundraising efforts and the recent 27km Coastal Walk  is no different, with more than $5000 raised for cancer research.

Enjoying breathtaking sceneries and crystal clear weather, the team of colleagues and friends walked the 27km coastal track from Otford to Bundeena, through the iconic Royal National Park, 30km south of Sydney, in support of breakthrough cancer research.

Event organisers say the participants were full of energy, passion and humour for the enduring walk, and received plenty of support through donations to cancer research by family and friends. Continue reading “27km coastal walk for the ACRF”

Fred Pham 500 off to a great start

Wow, you have to admire the stamina of Fred Pham supporter Kimberley Ung who was one of the first of the Australian Cancer Research Foundation’s supporters across the finish line in the recent Blackmores Sydney Running Festival nine-kilometer Marathon presented by the Sunday Telegraph.

“Yes, my legs were sore the next day” said the bubbly 19 year old recently after the race on September 19.

Kimberley said she took 55 minutes to complete the nine-kilometer course.

“A group of about 15 of us Fred Pham 500 supporters took part. Actually Fred was even there and did the course pushed around in his wheelchair. He was accompanied by his three beautiful daughters.”

Kimberley was one of the four former students of teacher Fred Pham, who have instigated the recent campaign to raise $100,000 for their “inspirational friend.” Continue reading “Fred Pham 500 off to a great start”

Regular giving – ongoing support for an ultimate goal

Since 1984, The Australian Cancer Research Foundation (ACRF) has been continuously fighting against cancer by funding world-class research that makes a difference. This would not be possible without the ongoing support from our regular givers.

Regular giving to cancer research is a simple and meaningful way to honour the memory of a loved one, and make a real difference to fast-tracking the vital work of Australian cancer research scientists. We greatly value each of our regular givers who generously contribute to the ACRF’s ultimate goal for a world free from the devastating effects of cancer.

One of our more recent regular givers, Andrew Morine, tells us why he first chose to donate to cancer research and continues to do so to the Australian Cancer Research Foundation.

Awesome! ACRF website attracts regular giver

Full marks go to the team behind the Australian Cancer Research Foundation’s innovative website, according to regular giver Andrew Morine.

Morine, who is the co-owner and Principal IT Consultant for Orange Data at Oxley in Queensland, said he was attracted to the ACRF while exploring various Australian cancer groups and organisations on the internet.

“I was particularly interested in finding an organisation that focused on research and the ACRF seemed the most appropriate group after I looked around,’’ he said recently.

“I often go back to the website to see the latest developments that are coming through thanks to the ACRF. I find some of the research very interesting and it makes me want to continue on as a supporter for sure.’ Continue reading “Regular giving – ongoing support for an ultimate goal”

Rosie Lee – music that gives hope

In 2007 Rosie Lee was diagnosed with stomach cancer, but that didn’t stop her from doing what she loves and achieving big things.

Now in remission, Rosie has just launched her inspiring initiative Rosie’s Cancer Fund, giving hope to cancer sufferers while honouring the life of a loved one through song.

“One Day We’ll Meet Again” is dedicated to Rosie’s dear friend, Marilyn, and was first written the night before she sadly passed away after a long battle with both breast cancer and cervical cancer.

“One evening in 2008, the music to this song came to me.  Then, on June 1st,  2009, the words of the first verse ran through my mind.  I dearly wanted to ring the hospital where Mal was and play it to her.  But I couldn’t bring myself to do it.  It wasn’t finished.  It wasn’t ready.  She passed away the next morning,” reveals Rosie. Continue reading “Rosie Lee – music that gives hope”

Living with cancer: one man's story

Blue September encourages men to share their stories; stories about their own and their father’s, brother’s, cousin’s, uncle’s, grandfather’s and mate’s experience of cancer.

Jonty Este is a 48-year-old, Sydney-based journalist who is sharing his story.

From the dreaded diagnosis of rectal cancer to facing up to surgery, uncertainty and pain, to encountering hope and hilarity in the most unexpected of places, Jonty’s intimate diary is a raw and real account of one man’s life with cancer.

This Blue September the Australian Cancer Research Foundation (ACRF) invites you to face up to men’s cancer by reading and then sharing Jonty’s story with others.

A pain in the arse: A diary about living with cancer first appeared in the online news publication, Crikey.

Jonty Este’s diary about living with cancer, parts 1 to 5

Continue reading “Living with cancer: one man's story”

Dream of Sky sale – a flying success

47522_429581024145_29158774145_4759496_5840151_nThe lovers of all things vintage in Mount Hawthorn, Perth were once again treated to an amazing sale from the girls of Two Bucks ‘Til Wednesday last weekend.

Their Spring sale – Dream of Sky – featured a “smörgåsbord of vintage dresses, skirts, shorts, blouses, tees, belts, bags, shoes, scarves and menswear” with all profits coming to the ACRF.

As always, their impressive photo shoots featuring a sample of the clothing being sold created a buzz around Facebook in the lead up to the event – with people all over Australia hoping to get their hands on the fashion delights.

With crowds lining up hours before to be first to claim the prize pieces, the sale was a wonderful success – collecting more than $4000.

The ACRF would like to thank Sophia, Alicia, Hannah & Anna for their amazing ongoing support of cancer research & their great achievements – raising more than $25,000 to date! Continue reading “Dream of Sky sale – a flying success”

Dance for a Cure

Students of Deakin University’s Sri Lankan Indian Club celebrated dance and cultural diversity whilst supporting cancer research in their recent fundraising night, DISHA 2010 -Dance For A Cure.

Club President, Jazeer Nijamudeen, made the decision to support cancer research as his best friend and fellow host of the previous DISHA events, Rohan Kulkarni, had been diagnosed with bone cancer. “We decided to put all our spare time and effort into DISHA to motivate him and help him recover and thank him for his service to our organisation in 2009”. Rohan is currently receiving treatment at Peter Maccallum cancer institute. An interview with Rohan and another Deakin University student was shown on the night to remind attendees why they were there.

The event was attended by over 350 students from Deakin Univeristy and included a diverse number of dance and music performances, both cultural and contemporary. Other highlights of the night were the successful raffle and the henna tattoo artist to entertain patrons during the intermission.

Thanks to the whole Deakin Sri Lankan Indian Club for their fantastic efforts in putting this night together and raising ** for cancer research. The Foundation and the club would like to thank all the members, staff, performers, and local businesses who offered their support to make this night happen.

To see some highlights from the night, check out the trailer video, comedy video & interview with cancer patients.

[nggallery id=57]

 

Alex Dodds Walk 4 A Cure – 400km in 11 days

Would you walk 400km for $15,000?

Alex-Dodds-Blaise-WhiteIn just a few days time cousins Blaise White and Zac Dodds will do just that – raising money for cancer research by walking 400km from Drysdale, Victoria on 19 September in memory of their grandfather, “Bumpa”, sadly lost to cancer last year.

With the help of family and friends, the 16-year olds from Victoria have already smashed their $15,000 fundraising target – even receiving some local fame along the way.

The boys were recently interviewed on a Victorian radio show, following their first major fundraising event in Geelong.

Over 100 supporters joined the pair and their families at the fundraising event at the Geelong Trots, collecting donations through raffle ticket sales and charity auctions. Continue reading “Alex Dodds Walk 4 A Cure – 400km in 11 days”

Thank you Australia for getting behind Blue Friday!

From local schools, to sporting icons, and workplace champions, we thank all our supporters who unleashed their creativity for all things BLUE to support men facing up to cancer on BLUE FRIDAY.

Armed with blue paint and flyers, representatives from our corporate supporters, PepsiCo Australia & New Zealand and Ernst & Young, volunteered their time on Blue Friday to spread the word on the street. An amazing effort, for which we thank them very much

Blue Friday celebrations were also a highlight over the Father’s Day weekend at Officeworks – with team members across Australia busy hosting a variety of activities for children, including blue face painting, in return for a gold coin. Local shop owners also rallied behind the cause, proudly displaying Blue September flyers and raising awareness of cancers in men among patrons. Continue reading “Thank you Australia for getting behind Blue Friday!”

Blue September: men facing up to cancer

Blue September sees the Australian Cancer Research Foundation turning blue for a whole month to raise awareness for cancer in men. We’re asking everyone to please Get Blue and support BLUE SEPTEMBER.

Supporting the Australian Cancer Research Foundation and Bowel Cancer Australia, Blue September launches across the nation on 1st September, and it is about one thing: men facing up to cancer.

Why Blue? Its Simple – Blue is for boys!

Continue reading “Blue September: men facing up to cancer”

Working up a sweat for cancer research

Last weekend over 50 fantastic ACRF supporters took part in 2 separate marathon events on opposite sides of the country, all in aid of cancer research.

The Perth City2Surf saw more than 40,000 runners turn out to compete in Perth’s largest community sporting event. ACRF supporters were made up of cancer survivors, first time marathon runners, and many who have family, friends and colleagues who have been affected by cancer.

They chose to support cancer research because “cancer is real in their lives” and a “very worthy cause” that has, or may some day, save their life.

Bridge to Brisbane also took place over the weekend, drawing more than 50,000 participants to compete in this fun run. Cancer research is a cause close to the heart of all our supporters involved in the race. One of the Foundation’s ongoing supporters, Dee Handyside, took part in this race as her first physical challenge since finishing chemotherapy and wanted to take the opportunity to raise some funds and celebrate returning to an active life. Continue reading “Working up a sweat for cancer research”

The race that never ends

When we first met Fred Pham, we knew he was a winner.

Having already raised more than $30,000 for cancer research as part of the Australian Cancer Research Foundation (ACRF) “Dream Team” and taking out first place in the City2Surf individual fundraising competition, Fred is as determined as ever to fulfill the dream of a world free of cancer for future generations.

His supporters are now getting ready for the next big adventure in their massive fundraising campaign – the amazing FRED PHAM 500.

Read more about the Fred Pham 500 (Media Release).

Read more about Fred’s and his amazing journey – Cancer Research: Fred Pham a City2Surf winner Continue reading “The race that never ends”

Carrington girls calendar

The lovely ladies from Carrington Retirement Village in Camden NSW have recently shed their clothes for a good cause, featuring in their very own Carrington Girls 2011 Calendar in support of cancer research.

With some strategically positioned props, these incredibly brave eleven women grace the cover of the calendar to raise funds for their chosen charity – the Australian Cancer Research Foundation (ACRF).

Calendar organiser, Shirley Curtis, has been supporting ACRF since losing her husband to cancer two years ago, and says the ladies have all been all been touched by cancer personally or through loved ones. Continue reading “Carrington girls calendar”

Tour of Garvan Institute of Medical Research

Researchers and clinicians will soon be able to fast-track efforts to tailor cancer treatments for patients through personalised medicine with the imminent construction of a new $100million cancer centre in Sydney, also leading the way for world-class translational research in Australia.

A joint venture of the Garvan Institute of Medical Research and the St Vincent’s & Mater Health Sydney, the new cancer centre – due for completion in 2012 – is partially funded with a $2.5 million grant awarded in 2006 by the Australian Cancer Research Foundation (ACRF).

Recently visiting the building site, ACRF staff also met with Garvan scientists to explore the Institute’s existing laboratories, as well as discussing the importance of ongoing funding to support cancer research. Continue reading “Tour of Garvan Institute of Medical Research”

The wedding of Sally & Jeff

Sally & Jeff decided to celebrate their engagement and recent wedding a little differently to most; asking family and friends to donate to cancer research in place of receiving traditional gifts.

Both newlyweds have experienced the impact of cancer in their lives, with Sally sadly losing her mother in 2005, and Jeff his father in 2006 after an almost 20 year battle. Cancer is a cause they both feel “very strongly” about, and they are “interested in stopping people getting the disease in the first place” so they decided to support the Foundation on their special day.

Sally & Jeff felt gifts to cancer research were a way to acknowledge the memory of their parents as part of their wedding even though they were not able to be there. Continue reading “The wedding of Sally & Jeff”

New era of personalised medicine

Chairman of the Australian Cancer Research Foundation Tom Dery said findings from the recently opened $3.1 ACRF Drug Discovery Centre would lead to a new era of personalised medicine.

“Personalised medicine is the future of cancer therapy,” Mr Dery said.

“The days of the one-size-fits-all approach to medicine will soon be over, thanks to the work of researchers at facilities such as the ACRF Drug Discovery Centre.

“Targeted drug treatments can ensure fewer long term side effects and better results, and that’s the kind of outcome that motivates the people who so kindly donate to the Australian Cancer Research Foundation,” he said. Continue reading “New era of personalised medicine”

Childhood cancer on notice

Official opening of the new ACRF Drug Discovery Centre

iStock_000000735381XSmall_two-hands-clasping-in-hospital-300x235“Tonight, together, we have put childhood cancer on notice.

“Tonight, we have glimpsed a not to distant future where no child who has cancer need suffer,” declared Bob Muscat, chairman of the Children’s Cancer Institute Australia at the August 19 launch of the $3.1m ACRF Drug Discovery Centre.

Mr Muscat joined University of New South Wales chancellor David Gonski, Children’s Cancer Institute Australia executive director Michelle Haber, CCIA founder Jack Kassas, and Australian Cancer Research Foundation chairman Tom Dery to officially open the new ACRF-funded facilities at the CCIA, part of the Lowy Cancer Research Centre at UNSW.

The ACRF Drug Discovery Centre will develop new and improved treatments for childhood cancers.

It houses customised technology that enables one year’s medical research to be done in just a few days. Continue reading “Childhood cancer on notice”

ACRF medical adviser wins top science prize

ACRF congratulates Philip Hogg

247Studios_Eureka_Prizes_0048-300x215Philip Hogg, director of the Lowy Cancer Research Centre at UNSW, has won the 2010 Eureka Prize for Medical Research Translation.

The prestigious award, announced in Sydney on August 17, is for research leading to the development of a novel class of anti-cancer drugs. It also recognises Professor Hogg’s work in monitoring real-time cell death during chemotherapy.

“Professor Hogg has been a member of the ACRF Medical Research Advisory Committee since 2003,” said ACRF chairman, Tom Dery. Continue reading “ACRF medical adviser wins top science prize”

City2Surf: the $80,000 dream

A very B-I-G congratulations and thank you to everyone who supported the cancer research City2Surf dream team!

The ACRF dream team – led by staffers Claire, Mahsa and Natasha – is jubilant following a massive effort at last Sunday’s City2Surf which will see an extra $80,000 go directly to cancer research.

The early morning start and chilly weather couldn’t keep them and close to 800 other Australian Cancer Research Foundation entrants from lining up for this annual race from the Sydney business district to Bondi beach.

One of the most inspiring participants in the 80,000 strong field was Fred Pham.

Mr Pham, schoolteacher and father of five young children, has only a short time to live. This did not stop him walking the 14 kilometre course with two of his sons and becoming the event’s most successful individual fundraiser. Continue reading “City2Surf: the $80,000 dream”

Cancer Research: Fred Pham a City2Surf winner

 

Fred Pham’s Walk Of Life raises $40,000+ for cancer research

Fred Pham is an ACRF supporter. He has terminal cancer. And he is a winner!

The Foundation is more than pleased to announce that Mr Pham has taken first place as thetop individual fundraiser for the 2010 City2Surf.

As a participant in Australia’s biggest fun run, Mr Pham raised an amazing $30,000 for cancer research, and was then rewarded with an additional $10,000 donation by race organisers, the SunHerald. Continue reading “Cancer Research: Fred Pham a City2Surf winner”

Professors appointed

ACRF congratulates Geoff Lindeman and Andrew Roberts

The outstanding work and longstanding dedication of two medical researchers from the renowned Walter and Eliza Hall Institute of Medical Research has recently been rewarded with professorial appointments.

“The Australian Cancer Research Foundation congratulates Geoff Lindeman’s and Andrew Roberts’s appointments as honorary professors by the University of Melbourne,” said David Brettel, ACRF’s chief executive.

“It is a great honour and serves to emphasise the high regard in which the nation’s leading cancer researchers are held,” Mr Brettell said. Continue reading “Professors appointed”

'Genetic' CD launches for cancer research

Musician and cancer survivor Dee Handyside recently launched her long-anticipated album, ‘Genetic’ – an eclectic collection of melodies inspiring cancer sufferers and their families.

Proudly supporting the Australian Cancer Research Foundation (ACRF), Dee is contributing 10% of her album sales to the Foundation to continue funding vital cancer research across Australia.

Leaving behind a dream job on Fraser Island to battle breast cancer, Dee found solace in her music and began composing and recording songs for her album, ‘Genetic’, during cancer treatments in 2007 and 2008.

Dee says that although music has given her focus and optimism during her battle, the album does also reflect the realities of cancer. Continue reading “'Genetic' CD launches for cancer research”

City2Surf dream team: good luck everyone!

The Sydney City2Surf is this weekend and already over $60,000 has been raised for cancer research!

We’re so proud of everyone on the Cancer Research City2Surf Dream Team and really excited about Sunday.

Don’t forget, we’ll be tweeting all along the way, as well as posting pictures of our progress, so please follow us on www.twitter.com/cancer_research

Big thanks to our fabulous Dream Team fundraisers (all 95 of you!) and all of the team’s super supporters.

Good Luck for Sunday Everyone and Go Team!!!

Continue reading “City2Surf dream team: good luck everyone!”

ACRF's $3.1 million launch

A $3.1 million ACRF Drug Discovery Centre for Childhood Cancer opens on Thursday August 19.

The new facility at the Children’s Cancer Research Institute Australia – part of the recently opened Lowy Cancer Research Centre at University of New South Wales – houses the only drug screening robot in Australia. It’s innovative technology can do a year’s research in just one day and the Centre marks a new era in the development of personalised medicine. On average three children in Australia die every week from cancer.

The ACRF Drug Discovery Centre for Childhood Cancer aims to change this.

UNSW Chancellor, David Gonski, ACRF Chairman, Tom Dery, Children’s Cancer Institute of Australia Executive Director, Professor Michelle Haber and CCIA Chairman, Bob Muscat will speak at the launch.

Click Here for ACRF Drug Discovery Centre for Childhood Cancer Media Release.

Bug off cancer drive a great success

ACRF supporter, Norman Elias, and his smooth running 1965 Volkswagen drove into Sydney last night, marking the end of his tremendous fundraising effort involving a 4000km journey along Australia’s South-east coast.

Despite being the sole driver for the entire seven-day trip, Norman says there were very few hiccups along the way.

“The Beetle performed as expected, albeit with a slight engine problem, but it got me and my travel companion back to Sydney safe and sound, and never complained once or gave up hope,” he said. Continue reading “Bug off cancer drive a great success”

Castle Hill Art Society fundraiser

Throughout the month of July, the White House Gallery was home to an exhibition with a difference. Among the items on display were a very special collection of art and jewellery in support of cancer research, put together by four members of the Castle Hill Art Society. The special display included two beautiful artworks and a lovely Swarovski necklace, all to be raffled off at the end of the month for the Foundation.

Rosanna Spencer, the organiser of the exhibition, said the exhibition was a “great success” with many pieces of art and jewellery being sold. The event was even attended by the Castle Hill Mayor, Cr P. Dimbrowsky who was presented with a gift pastel portrait that Rosanna did the day the exhibition opened! A fantastic $460 was raised for cancer research from this wonderful event. Continue reading “Castle Hill Art Society fundraiser”

City2Surf: join the cancer research dream team

2010 City2Surf team off and running

The Australian Cancer Research Foundation’s own “Three Amigas” are in final preparations for the upcoming City2Surf marathon on August 8.

Staffers Claire McArthur, Natasha Khema and Mahsa Lotfizadeh say that rather than just encourage runners taking part in the event this year on behalf of the Australian Research Foundation, they wish to show solidarity by taking part themselves.

“We just don’t want to just talk the talk, we want to walk the walk,” said Claire who added that she had purchased some “lovely new runners” for the event.

Cancer research supporters can also expect a unique experience from the team as they provide real time updates along the 14km route through the Foundation’s Twitter account. Continue reading “City2Surf: join the cancer research dream team”

Run Melbourne 2010

Run Melbourne is a huge community fitness event drawing competitors from all across Victoria, and even some from other states, to take part in the 5km, 10km or half marathon through Melbourne.

A staggering 17,665 runners turned out on Sunday 18th July to a beautifully sunny day ready to race in the “fitness event for everyone”.

More than 400 of those competitors were taking part in support of cancer research, the biggest group we’ve ever had supporting the Foundation, and together they raised more than $34,000!

The participants supporting cancer research in the 2010 Run Melbourne came from a wide variety of ages, backgrounds & fitness levels, each with different stories about why they chose to run the event and support cancer research. Some were survivors of cancer themselves or currently fighting their cancer, while others wanted to celebrate the remission of those close to them or to show support for family/friends currently fighting the disease.  A number of participants work in the cancer support industry, while others just wanted to raise awareness and do their bit for a good cause. And, of course, there were a large number running to honour the memory of loved ones who had sadly lost their battle. Continue reading “Run Melbourne 2010”

Cancer research ambassador chosen for State of Origin

Jamie SimpsonCancer research ambassador and South Sydney Rabbitohs’ star Jamie Simpson recently added yet another honour to his impressive career, being selected for the NSW Residents team, who played against the Queensland Residents in the curtain-raiser to Game 3 of this year’s State of Origin series.

Jamie scored the equalising try to bring NSW back into the game, which they went on to win 28-20. The victory provided some comfort to the thousands of Blues fans disappointed by the Maroons fifth straight Origin series victory.

The NSW Residents team boasts some of the best young rugby league players in the country and represents a significant honour for emerging players. Many past NSW Residents’ players have gone on to play at the highest levels, a feat Jamie is not far from achieving. Despite originally hailing from Rockhampton in Queensland, Jamie is very excited to represent NSW and test himself against some of Queensland’s best. “I’ve worked hard to get to this point and am really looking forward to the opportunity. It’s a great honour.” Continue reading “Cancer research ambassador chosen for State of Origin”

Cancer research supporter conquers Great Wall marathon

She has exceeded her target to raise $15,000 for ACRF and has endured the pain that is the Great Wall of China Half Marathon, but Avril Henry – one of our highest individual fundraisers to date – is not taking all the credit for the successful fundraising event, and says she owes it all to perseverance and gratitude.

“Due to my supporters’ generosity, I was able to raise $16,516, and am truly humbled by everyone’s kindness and support,” says Avril.

As a corporate motivator, Avril reached out to her network of business associates, local community, family, and friends, and put all her efforts towards raising awareness for cancer research and the half marathon held on 15 May 2010.

And she did it all with good reason; embarking on the fundraising challenge to honour close friends that had sadly lost their battle with cancer, and the urgent need to find a cure. Continue reading “Cancer research supporter conquers Great Wall marathon”

Donkey and the mule – not returning home just yet

Sure, they’ve spent days without any clean clothes, survived a few hairy encounters and spent countless nights searching for a place to get a little shut eye – but the Donkey and the Mule have not lost an ounce of their adventurous spirit, and are still doing it all for a good cause as they motor bike across 27 countries and raise thousands of dollars for cancer research.

It’s been four months since Dean and Paul Martinello, the brothers that make up this adventurous duo, left Australia to embark on a worldwide biking tour that has already taken them through three continents and twenty countries, some more dangerous than others.

The pair is now on their last leg of the tour, having just arrived in Russia following a delightful encounter with what they describe as “three angels” from Uzbekistan. Continue reading “Donkey and the mule – not returning home just yet”

Gold Coast Marathon

Gavin-Lister-GC-Marathon-225x300On a very cold morning on Sunday 4th July more than 25000 runners arrived at the Broadwater foreshore to compete in the 2010 Gold Coast Marathon, among them a very special group of enthusiastic & dedicated participants running in support of cancer research. The Foundation had 9 fantastic fundraisers compete in both the marathon and the half marathon in this year’s event, between them raising an outstanding $12,797.19!

Gavin Lister chose to challenge himself in the 21km half marathon, which he himself admitted would be a “very taxing and exhausting” exercise. He decided to raise funds for cancer research in memory of his father Brian and mother in law Siri who both passed away from cancer “well before their time”, and set himself the personal challenge of completing the race in less than 2 hours. During the preparations for the race Gavin was touched hear the personal experiences and stories of how those supporting him had also been affected by cancer, further adding to his motivation. Thanks Gavin for your fantastic fundraising and congratulations on achieving your goal time inside 2 hrs! Continue reading “Gold Coast Marathon”

Bug off cancer drive

Determined to raise funds for cancer research and to help rid future generations of this disease, Norman Elias is getting ready to commence his eagerly awaited “Bug Off Cancer Drive” – a solo motor journey across Australia’s South-east coast in his beloved 1965 Volkswagen Beetle.

Norman’s journey will begin on 29 July from Sydney, and he plans to cover 3800km in one week, driving through iconic locations such as Broken Hill, Adelaide, the Great Ocean Road, and through snowy country to Canberra.

Norman has lost both parents and other relatives to cancer, and with the support of family and friends, decided he wanted to do his bit to help rid the world of cancer.

“Not everyone is affected by cancer, but everyone will at least know of someone that is affected by or has been taken by cancer,” he says. Continue reading “Bug off cancer drive”

Thank you for supporting our tax time appeal

Thank you all… our 2010 tax time appeal was a big success for cancer research that helps save lives

Last month we made an urgent call on behalf of Australian scientists and cancer sufferers for donations to support our ambitious 2010 cancer research grants program. And in response, we’ve been overwhelmed by your generosity.

The Australia Cancer Research Foundation wishes to thank the individuals, organisations and community groups who rallied support for cancer research in June.

When you join with us, you’re helping create an environment that allows Australia’s best researchers to dream big in the fight against cancer – to create a world where we can save lives through diagnosis, treatment and prevention of cancer.

Please accept our thanks for your dedication and support through your very generous donations, and, just as importantly, your help conveying our message to others in the community. Whether it was spreading the word to your friends, to your family, in your workplace, among your social networks, or even online, we felt your support and it has really made a big difference to this appeal.

We are all now a step closer to even more breakthroughs in cancer research, ensuring we are able to fund the vital equipment and infrastructure for which scientists seek our Foundation’s support year after year. Continue reading “Thank you for supporting our tax time appeal”

ACRF to announce 2010 grant recipients

With the final review of the shortlisted applicants for Australian Cancer Research Foundation’s (ACRF) multi-million dollar grant program, the Foundation is set to announce the 2010 grant recipients in just one week.

All grant applications received by the Foundation are reviewed by the ACRF’s Medical Research Advisory Committee (MRAC) whose members are scientists of the highest national and global repute.

This leading Australian scientific committee make recommendations to the ACRF Board of Trustees after a rigorous review process. Assessment of applications is made by independent expert assessors, as well as an inspection of sites where grants will be applied to fund laboratories and house equipment.

The ACRF will announce the 2010 grant recipients on Thursday 25 November. Continue reading “ACRF to announce 2010 grant recipients”

Help us end cancer this tax year by making a tax deductible donation

Australian Cancer Research Foundation (ACRF) Chief Executive, David Brettell, has urged supporters to get behind the Foundation’s 2010 mid-year appeal and our mission to fund the fight against cancer by improving prevention, diagnosis and treatment of all types of cancer.

“This is a time we reflect on the 1 in 3 Australians who will be affected by cancer and on our role in funding vital research that can treat and cure the various cancers”.

Help us fund ground-breaking cancer research

It is our call to all cancer research supporters to help fund the work of the brilliant scientists who seek grants from ACRF each year to overcome cancer.

By making a tax deductible donation this year, you will be able to boost your tax return by reducing your taxable income and support a cause you are passionate about.

This year we have shortlisted six from the 13 grant applicants who will now progress to the second stage of our 2010 multi-million dollar grant program. Click here to read about our grant recipients and research projects.

How your donations are helping us to fund research to end cancer

Collaboration and world-class competitive research are among the top priorities for funding this year. Continue reading “Help us end cancer this tax year by making a tax deductible donation”

Prime Minister opens Cancer Research Centre

Prime Minister Kevin Rudd and NSW Premier Kristina Keneally will today officially open the highly anticipated Lowy Cancer Research Centre at the University of New South Wales, bringing together adult and children cancer researchers for the first time in Australia.

The new facility opens with the help of a $3.1 million grant from ACRF and features the ACRF Drug Discovery Centre for Childhood Cancer, equipped with advanced cancer screening technologies essential to finding and confirming new cancer targets and pathways.

During the official tour of the new facility with the NSW Premier, the Prime Minister said that the Centre will greatly support cancer treatments and cure.

“The Lowy Cancer Research Centre is a critical step in supporting our world-leading cancer researchers, whose discoveries will directly translate into better patient care and carry the potential to save generations from cancer,” Mr Rudd said.

Researchers at the Centre will investigate ways to develop cancer-fighting drugs, with three of the drugs to commence clinical trials this year. Continue reading “Prime Minister opens Cancer Research Centre”

Join the cancer research City2Surf team

Yay! We’ve just put our team together for the 2010 Sydney City2Surf & we’d love you to join us!

The Sun Herald City2Surf, presented by Westpac, is the community fitness event for everyone. With the right training, anyone, at any age and any fitness level can participate. It’s also an opportunity to raise money for the charity you care about most.

If your thinking of taking part in this year’s event, or have already registered, why not add a bit of extra meaning & team spirit by joining the Australian Cancer Research Foundation City2Surf team?

To join us simply select Australian Cancer Research Foundation as your team when registering, we’re in the yellow category. Visit the City2Surf website to register. Continue reading “Join the cancer research City2Surf team”

'Two Bucks 'Til Wednesday' vintage fashion fundraiser

Vintage shoppers warm up with winter fashion fundraiser

 

The latest Winter collection, The Tale of Two Bucks in Wednesday Wood, from the creators of Two Bucks ‘Til Wednesday went on sale recently in Mount Lawley, Perth, with organisers showcasing vintage clothing and accessories whilst raising funds for the Australian Cancer Research Foundation (ACRF).

The sale attracted hundreds of shoppers, with co-creators Sophia Brown, Alicia Clements, Anna Brown and Hannah McGrath raising much appreciated funds for cancer research from the event.

Bargain shoppers dashed through stormy weather for the fashion sale, picking up vintage clothing, accessories and jewellery from the 1920’s to 1980’s in the latest trend to sweep fashion lovers in Perth.

Also on sale were special edition sweet treat, Cakiepops, in strawberry and marshmallow flavours, sold on the day to increase funding for cancer research.

With all profits going to ACRF, the organisers work tirelessly each season to string together a unique collection of bargain-priced vintage clothing purchased from local op shops, and then preview the items to the public with a beautifully-themed photo shoot.

Since its inception in 2007, the girls have been dedicated to the event – translating their love of vintage fashion into a fundraiser in honour of loved ones lost to cancer. Continue reading “'Two Bucks 'Til Wednesday' vintage fashion fundraiser”

Global cancer research leaders gather

The Lowy Symposium has revealed significant developments for cancer treatments and cure during what has been an eventful month for researchers leading up to the opening of the new state-of-the-art Lowy Cancer Research Centre.

Australian and international scientists came together to share real-time data on the latest studies, and to engage in discussion and debate for improving future research.

Advanced equipment and technologies, and recent breakthroughs in drug therapies were among the highlights from the symposium.

Associate Professor Ricky Johnstone from the Peter MacCallum Cancer Centre in Melbourne said: “Throughout the meeting there was an emphasis on the use of cutting-edge platform technologies such as high throughput chemical screening and molecular imaging.”

Researchers also discussed the emergence of sophisticated new methods for discovering cancer drugs. One of those is structural biology, where scientists analyse the structure of protein molecules at a three-dimensional level. Continue reading “Global cancer research leaders gather”

Lowy Symposium

Lowy Symposium

World Leaders in Cancer Research Gather for Lowy Symposium

Sydney, Australia: Leading international and Australian cancer researchers met in Sydney to explore new frontiers for cancer drug development in drug discovery, pre-clinical testing and the translation of these discoveries into the clinic.

The Lowy Symposium with the theme of “Discovering Cancer Therapeutics” was held at the John Niland Scientia Building at the University of New South Wales from May 16 to 18.  The meeting program included 9 invited international speakers and 10 national experts in cancer therapeutics research. Full Media Release here.

The 2010 Symposium was the first of what is planned to be a biennial cancer symposium series that will celebrate the establishment of the Lowy Cancer Research Centre in Sydney. The Lowy Cancer Research Centre, to be officially launched on 28 May, will be one of the leading cancer research centres in the world integrating childhood and adult cancer research and taking a holistic approach to cancer across the life spectrum.

Announced at the Lowy Symposium to the world’s leading cancer researchers, the Australian Cancer Research Foundation (ACRF) Drug Discovery Centre for Childhood Cancer was recognised as key to sharpening the blunt instruments currently being used to treat cancer and achieving better health outcomes for patients. Full Media Release here.

The Lowy Symposium will gather international speakers and specialists at the forefront of world-class cancer research, promoting the link between research and achieving better health outcomes for people with cancer.

  • When: 16 – 18 May 2010
  • Where: The University of New South Wales, Kensington Campus

Read more about ACRF’s recent grant to CCIA

Read about a previous ACRF grant to CCIA (2002)


The Australian Cancer Research Foundation is now in its 25th year of operation.

Individual ACRF grants exceed $1.5 million with no upper limit. This is unique funding for infrastructure, not available from any other private source in Australia. A grant from ACRF in 1999 kick-started 2006 Australian of the Year Professor Ian Frazer’s quest to develop a vaccine to prevent and treat cervical cancer.

In the last five years alone, the foundation has awarded grants worth $46 million, with recipients including St Vincent’s Institute, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Walter & Eliza Hall, and Ludwig Cancer Institute. This figure includes a major $5 million grant for the ACRF Centre for Therapeutic Target Discovery at the Parkville Comprehensive Cancer Centre. Read more about our cancer research grants.

ACRF staff were lucky enough to have a Sneak Preview of the amazing new Lowy Cancer Research Centre recently. Read all about the visit at Sneak Preview of New Research Centre.

Great Ocean Road Marathon

The Great Ocean Road is recognised as one of the most scenic drives in the world – with a beautiful stretch of coastline and stunning views that captivate thousands of tourists each year. For one weekend a year, a large section of the road is closed down to accommodate more than 3,500 runners and 10,000 spectators for the world renowned Great Ocean Road Marathon.

Workmates Sam Zalin and Chris Ricketts chose to challenge themselves in this gruelling 42km race and raise funds for cancer research at the same time. When asked why they chose to support the ACRF specifically, they said they both had friends and family whose lives had been impacted by cancer, and wanted to direct their money to an organisation that was “committed to research”. Registered nurse,  Kate White also competed in the race in support of cancer research. A staff member at the Oncology Department of Royal Adelaide Hospital, Kate has a personal connection to this very special cause.

Our three incredible supporters were overjoyed by the generosity of their families, friends and colleagues in sponsoring them for the race, and raised a fantastic $6,560 for cancer research. They all finished the race, some quicker than others, but all enjoyed the run.

The ACRF thanks Sam, Chris & Kate for their fabulous support and congratulates them on their huge achievement completing the marathon.

Read more on raising funds for cancer research in sporting events.

Celebrating surfing, farewelling a mate, and helping to cure cancer

Mark Cummings was a good mate and an avid surfer who sadly lost his battle to cancer with a brain tumour on May 13th 2009. On the one year anniversary of his passing, good friend Warren Broadhurst decided to honour his mate with a fitting farewell by raising funds for cancer research through a surfing event called Paddle Out For Mark.

Fellow surfers and friends were invited to Mackay Harbour to collectively paddle out in the ocean and form a circle to pay tribute to Mark. Participants each donated $35 for cancer research in order to help find a cure, and continued the tribute with a group lunch and a screening of “4740” – filmed by local surfer Health Sneddon – at the Mackay Surf Lifesaving in celebration of surfing.

This event raised $1150 for cancer research, and the ACRF would like to thank Warren for organising a fabulous event that celebrates and honours the life of Mark Cummings in this unique and meaningful way. Big thanks also to all who took part in, and supported, the ‘paddle’.

Sneak preview of new research centre

ACRF staff visit amazing new Lowy Cancer Research Centre

Excited ACRF staff, accompanied by CEO David Brettell, were given a sneak preview of the new state-of-the-art children’s cancer research facility set to open soon at the Lowy Cancer Research Centre at the UNSW.

The new facility, opening on the 19th August 2010, is the first centre in Australia to bring together childhood and adult cancer research at the one site and was built with the help of a $3.1 million grant from the ACRF.

Shown the new complex by Dr Moira Clay, from Children’s Cancer Institute Australia, ACRF staff toured three floors of the $100 million-plus facility which will house up to 400 researchers from UNSW and which is set to be one of the largest dedicated cancer research centres in the Southern Hemisphere.

The first impression was that the innovative designers of the building had been more successful in creating “a very green building”.

Designed by Lahz Nimmo Architects in association with Wilson Architects, the building boasts lime green-cladding, precast concrete panels and a five-star environmental rating in accordance with the new Green Building Council of Australia method of evaluation.

Dr Clay was most welcoming of ACRF staff and full of praise for the Foundation.

“The ACRF does very important work and we are pleased to sing your praises and promote the work that you do,” she said. Continue reading “Sneak preview of new research centre”

Cancer research grant applications increase in 2010

Cancer research grant applications hit new heights

Proving once again its vital role in providing much needed funding for cancer research comes news of an increase in applications for the ACRF’s annual round of grants.

This year 13 of Australia’s leading medical research facilities have sought support from the ACRF for planned future operations, requesting millions of dollars each for new laboratories and equipment to further progress their cancer research.

This year’s intake included five applications from Queensland, four from Victoria, three from News South Wales, and one from Western Australia, totalling $38 million. Continue reading “Cancer research grant applications increase in 2010”

One dollar and one mighty mountain…

WATCH this space as one unstoppable young lady shows how $1 really has the power to change the world!

Amanda Ghirardello, 27, is setting out to trek through the mighty Himalayas in March 2011 and hopes to encourage one million individuals to support her fundraising efforts by donating just $1 each to The Australian Cancer Research Foundation.

Despite having no previous mountaineering experience, Amanda will climb first to Mount Everest Base Camp at an elevation of 5400 metres above sea level and then go on to ascend Island Peak which stands at 6190 metres.
Continue reading “One dollar and one mighty mountain…”

Kempsey Cancerians annual ball

Supporting cancer research more than just a fairytale for Kempsey Cancerians

Kempsey is home to big names like Slim Dusty and Thomas Keneally, but it’s the Kempsey Cancerians Annual Ball held every year in May that residents say is the one “signature” event in their town.

Complete with a castle backdrop and Cinderella-esque ushers, more than 300 guests flurried into the fairytale-themed ball this year at the Kempsey Macleay RSL to show their support for cancer sufferers and raise funds for the Australian Cancer Research Foundation. Continue reading “Kempsey Cancerians annual ball”

Rabbitohs star Jamie Simpson new cancer research ambassador

Jamie SimpsonTo the public, ACRF ambassador Jamie Simpson appears much like the other super-fit athletes that make up his team at the South Sydney Rabbitohs of the National Rugby League competition. We all know professional athletes sacrifice and overcome barriers to reach the pinnacle of their sport. But very few have overcome obstacles as daunting as Jamie’s in his bid to fulfil his dream of playing in the world’s best rugby league competition.

As a 15 year-old growing up in Rockhampton, Queensland, Jamie was faced with the toughest challenge anyone can confront: Cancer. After finding lumps in his groin, Jamie consulted with his family GP. Following a series of tests he received the worst possible news. His GP informed him he had Hodgkin’s Lymphoma, a form of lymphoma common in teenagers which originates from white blood cells and is spread throughout the body through the lymph nodes. To a 15 year-old with dreams of sporting glory just years away it was the worst possible news.

Continue reading “Rabbitohs star Jamie Simpson new cancer research ambassador”

Climbing Kilimanjaro for cancer

Mother and daughter super team, Karen & Deb Short, are taking on the highest mountain in Africa, the massive 19,340 ft peak of Mt Kilimanjaro, in memory of their very special husband/dad. On December 21st 2010 Karen & Deb will begin their journey walking 5-8 hours every day, taking on the final ascent on December 25th.

The beginning of this journey marks one year since the loss of Robert (Bob) Short, a wonderful husband and father who fought a four year battle with cancer, maintaining his amazing sense of humour and his passion for life until the very end. Karen and Deb are taking on the huge journey in the memory of this man who inspired so many.

These fabulous two-some are hoping to raise $10,000 for cancer research in honour of Bob’s memory. And they are already well on their way to reaching their target, having been generously supported by family, friends, colleagues, and even some students from Deb’s class at Edithvale Primary School. With many more great fundraising ideas up their sleeves, including some African-themed parties, they are sure they will more than exceed their target.

Thanks so much Karen & Deb for your generous support of cancer research & we wish you all the best for your trip. To support Karen & Deb, visit their fundraising page.

 

A fabulous family fun day for cancer research

1-200x300Hosting an event for family and friends is a great way to fundraise for cancer research and to acknowledge those loved ones who have been affected by cancer. Sydney resident, Kerrie Martino, recently hosted a fabulous ‘Family Fun Day’ – an event to raise money for the Australian Cancer Research Foundation (ACRF) – inspired by a family member’s personal journey with cancer.

“My cousin is currently ill, and it’s not always possible to visit her and help out in-person, so I thought this would be a great way to contribute”, said Kerrie.

“I did some research and realised I wanted to fundraise for cancer research and came across your organisation [ACRF]”.

“I really like that every dollar to you guys goes directly to research”. Continue reading “A fabulous family fun day for cancer research”

Breast cancer stem cell discovery follows $5 million grant from ACRF

walter_eliza_building1Scientists at the Walter & Eliza Hall Institute (WEHI) are now able to explain the links between breast cancer risk and exposure to female hormones, paving the way for breast cancer preventions and treatments.

The research, led by Dr Jane Visvader and Dr Geoff Lindeman, was partially supported by a $5 million grant from the Australian Cancer Research Foundation (ACRF). The new discovery was published in the international journal Nature on 12 April 2010.

The research team at the Institute discovered that breast stem cells, despite lacking receptors for oestrogen and progesterone, are still extra sensitive to sustain exposure to the female hormones oestrogen and progesterone. Continue reading “Breast cancer stem cell discovery follows $5 million grant from ACRF”

Coral Burdette Rose Bowl Open Golf Day

Pine-Rivers-Golf-Course_11th_Hole1The wonderful staff, volunteers and members of Pine Rivers Golf Club in Kurwongbah, 30km north of Brisbane, raised $600 in their Annual Coral Burdette Rose Bowl Open Golf Day for cancer research recently. The fundraising event is dedicated to the members and supporters of the club who have lost their battle to cancer over the past years.

‘This year we had 55 players for the golf day, and all of them know of someone who has been affected by the effects of cancer in some way’, said Faye Volter, one of the organisers of the event.

Faye is a member and volunteer at Pine Rivers Golf Club and says that although the club has donated previously to ACRF, it was only recently that they decided to raise awareness and fundraise for cancer research through this annual event. ‘Coral’s day has been run for many years as a ladies event, but in the last few years men and those from other clubs have been invited to come along and have a fun day and help with a great cause, which has helped us raise more money for cancer research’, said Faye recently. Continue reading “Coral Burdette Rose Bowl Open Golf Day”

Ken & 'Cranky Clyde's' fundraising road trip for cancer research

There is no shortage of community spirit for Kenneth (Ken) Pillar as he prepares for a two-year horse and wagon ride across Victoria, South Australia & New South Wales to raise funds for cancer research. Ken has set a target to raise $50,000-$150,000 during his road trip, and thanks to donations of products and services from local automotive companies, media groups, and community clubs, he’s right on track.

Ken will be heading off on the 10th July from Mansfield Victoria, with his gypsy wagon and, of course, his moody mare ‘Cranky Clyde’. Ken and Cranky Clyde have already raised over $5,500 for cancer research from a smaller trip earlier this year, and now, public interest is quickly growing. Continue reading “Ken & 'Cranky Clyde's' fundraising road trip for cancer research”

Lady McMahon – a message from the Chairman

tomandrewsoniadoug2_web-300x1881Our hearts go out to the family of Lady Sonia McMahon.

The Australian Cancer Research Foundation (ACRF) would simply not exist without Lady (Sonia) McMahon.

Over 26 years ago Lady McMahon approached Sir Peter Abeles to head up a new charity for medical research, dealing specifically with cancer. With a small group of Sydney philanthropists, she co-opted Sir Peter to establish the Australian Cancer Research Foundation in 1984, following the closure of Sydney Hospital which the group had been supporting. Continue reading “Lady McMahon – a message from the Chairman”

Greek Easter 2010 – Kalo Pashcha!

Australia’s local Greek community are once again preparing for their country’s most sacred and celebrated religious festival – Greek Easter.

And it is at this special time, when the family gathers together, that the Australian Cancer Research Foundation (ACRF) asks the community to take a moment to think of those we may have lost, or who are suffering from the devastating effects of cancer.

As the incidence of cancer increases for all Australians, we need more than ever to continue our investment in breakthrough cancer research. Why? Because our results are making a difference to people’s lives, not just in Australia, but around the world.

Just two weeks ago we were privileged to open the ACRF Centre for Cancer Genomics at the Peter MacCallum Cancer Centre in Melbourne (the second largest Greek city in the world – after Athens!)

Continue reading “Greek Easter 2010 – Kalo Pashcha!”

VALE Lady (Sonia) McMahon

lady_sonia_mcmahon-300x1932The Board of Trustees, management, staff and supporters of the Australian Cancer Research Foundation convey to Lady McMahon’s family our sincerest condolences.

Lady McMahon was a Founding Trustee and Life Member of the Australian Cancer Research Foundation (ACRF), which last year celebrated its silver anniversary.

Chief Executive of the ACRF, David Brettell said this morning “We will miss Lady McMahon greatly. Not only was she a shining star, charming and generous with her time and energy, she was also a totally committed Trustee, always available to share her extensive experience.

“She participated consistently and with real commitment to the mission and growth of the Foundation, attending and playing a critical role on the Board. Her contribution helped to ensure the Foundation remained focused on its core purpose of funding infrastructure and capital works for projects at the forefront of medical science in this country.

Continue reading “VALE Lady (Sonia) McMahon”

Tans do it again

When it comes to supporting world-class research in the fight against cancer there is no stopping Catherine Tan and her fantastic supporters.

The 2nd Annual Unite and Fight Cancer fundraising benefit in Melbourne, hosted by the Tans Martial Arts Supplier raised over $16,000 in one night.

The benefit kicked off with an exciting performance by the Chinese Lion Dance group organised by the Chinese Cultural Centre of Victoria. The group collected donations during their performance, under the guise of supporting the Chinese Lion Dance group, and then announced all funds would be donated to The Australian Cancer Research Foundation (ACRF). Continue reading “Tans do it again”

An epic trek for a tender life lost

sunset over the mountainsKellee McDougall Walk for Cancer Cure

When Peta Hughes lost her daughter to cancer, her friend Linda Stanley suggested they do something remarkable in her honour.

At the tender age of 29, Kellee McDougall passed away on 1 May 2009 after a three-year battle with bowel cancer. The Kellee McDougall Walk for Cancer Cure is an inspiring challenge to walk the 965 kilometre Bibbulman Track in Western Australia to fundraise for cancer research.

Stanley says she will ‘walk the walk’ to raise funds, setting off on 4 April from Albany to the northern terminus in Kalamunda. She will be making the courageous journey with her dear friend Peta, Kellie’s mum, by her side. Continue reading “An epic trek for a tender life lost”

New Cancer Genomics Centre opens in Melbourne

Peter MacCallum Cancer CentreThis morning the Cabinet Secretary of the Parliament of Victoria, Mr Tony Lupton, opened the ACRF Victorian Centre for Functional Genomics (VCFG) at the Peter MacCallum Cancer Centre. Support for this cutting-edge resource is centred on $2.5 million in funding from the Australian Cancer Research Foundation (ACRF).

The ACRF is dedicated to helping find a cure for cancer through the continued support of world-class research in Australia. Fundamental to their vision is the leveraging of funding and resources for the benefit of the wider Australian research community. In supporting the VCFG in Cancer, the ACRF is building on initial funding from the Victorian Department for Innovation, Industry and Regional Development, the Australasian Microarray Associated Technologies Association and the Victorian Cancer Agency, and the support ensures Australia remains at the forefront of global cancer research. Continue reading “New Cancer Genomics Centre opens in Melbourne”

Ride On! Cycling around the world for cancer

It’s been five years in the planning, and now Rebecca Uleman and Milo Koper are finally ready to embark on an inspiring two-year cycling tour across the globe – raising money for cancer research along the way.

The Australian and Dutch couple will take off in May 2010 from The Netherlands, and cycle across Western Europe, through South-East Asia before eventually arriving in Australia and New Zealand in early 2012. An adventure dubbed by the couple “2 bikers, 1 world”, this is set to be an epic journey covering over 33,000km!

Besides having a passion for cycling, Rebecca and Milo are both personally motivated to raise money for cancer research – having close family affected by the disease. Rebecca’s father, John Uleman, was a Dutch national who immigrated to Australia after WW2. He passed away on 13 August 2008 from cancer of the oesophagus, only one year after remission from lung cancer.

“My father had a good life and passed away at the age of 82. Unlike many others, he lived what we would consider until a ripe old age,” says Rebecca.

At the age of 39 and with four young children, Milo’s sister is now fighting bone cancer. Just before Christmas 2007 she was diagnosed with an aggressive form of breast cancer, only to discover she has bone cancer after numerous operations and treatments.

“‘We hope by doing this action we can contribute towards cancer research and hopefully a cure can eventually be found which will save so many lives,” say Rebecca and Milo.

This determined couple will self-fund the entire trip, as they want to see 100 per cent of the donations go toward cancer research.

“To give ‘Cycling for Cancer’ a kick start and to inspire others to give a little, we have made ourselves an initial donation of 500 euros!” say Rebecca and Milo.

The couple want to save lives, and are donating funds raised from their journey to the Australian Cancer Research Foundation. To support them please visit our Online Donations page and follow the links.

To follow their journey and read more, visit their website.

Thank you Rebecca and Milo for your huge generosity and best of luck with the trip!

If you would like more information on organising a fundraising event that raises money for the ACRF, click here.

Up to $5 million for cancer research

Applications for the Australian Cancer Research Foundation’s (ACRF) Research Grants are now closed.

Applicants may apply for grants between $1.5 million and $5 million.

The Board of Trustees of the ACRF, advised by our distinguished Medical Research Advisory Committee, invites grant applications from leading scientists and scientific teams for cancer research in Australia in the areas of:

  • Capital Works & Facilities
  • National Enterprises

Continue reading “Up to $5 million for cancer research”

Senior's Week Premier’s gala concert

60 years and counting…and the party is just starting!

One of the highlights of NSW Senior’s Week kicked off on March 22nd, with a mighty Hurrah! The Premier’s Gala Concert series attracts more than 30,000 Seniors from all over NSW, with a key event being the annual Senior’s Week concert, this year themed ‘After Dark’.

Funded by the State Government the fabulous concerts are free for anyone aged over 60 in NSW – acknowledging and celebrating the contribution Seniors make to the community.

The Australian Cancer Research Foundation (ACRF) was privileged to be invited to be involved in the event for the second year running, by Workplace Giving supporters the NSW Department of Ageing, Disability & Home Care (ADHC). The ACRF had a presence at the Entertainment Centre for the two days the concerts were being held. And we had a ball! There was lively music and a buzz in the crowd. It was so lovely to be in the midst of all these wonderful seniors – and to share in their stories, experiences and lives.

ACRF also gave away a prize to of 4 rounds of golf at the Dunheved Golf Course in St Marys, generously donated to us in memory of a past member. Congratulations goes to Gerry McInerney, we hope you enjoy the prize – and make sure you have wear plenty of sunscreen for your golf bonanza!

On behalf of the team at ACRF, we want to say ‘A Big Thank you’ – to everyone we met at the Senior’s Week Premier’s Gala Concert, ADHC for allowing us the opportunity to be involved, and to the NSW Government for putting it all together!

Read about the 2009 Premier’s Gala Christmas Concert.

40,000km for cancer research

First there was movie star Ewan McGregor and partner Charley Boorman’s ‘Long Way Round’ UNICEF marathon bike ride that inspired the world, and now comes our own Aussie version ‘Donkey And Mule’ – featuring local adventurers Dean and Paul Martinello.

The two brothers are setting off on a marathon motorbike ride beginning in early March from Cape Town South Africa and then travelling for six months covering 40,000 km, across four continents, through 27 countries.

Brothers, Dean, 35, and Paul, 37, Martinello, who go by the fundraiser name of ‘Donkey And The Mule’, will ride two motorcycles up the west coast of Africa and across the Sahara. From there, the duo plan to head east across the Suez into the Middle East, Turkey and then on to Caucuses.

Continue reading “40,000km for cancer research”

Peter MacCallum Cancer Centre opens new facility

The Peter MacCallum Cancer Centre will open a new cancer screening facility on 16 March, courtesy of a $2.5 million grant from the Australian Cancer Research Foundation (ACRF).

The Australian Cancer Research Foundation has now awarded grants totalling more than $62 million since being established 25 years ago by Sir Peter Able.

The opening of the ‘Victorian Centre for Functional Genomics in Cancer’ (VFGC) continues the fruitful relationship between the ACRF and the Peter MacCallum Cancer Centre. The ACRF awarded a $1 million grant to ‘Peter Mac’ in 2004 to establish a Cell Biology Program.

Continue reading “Peter MacCallum Cancer Centre opens new facility”

Corporate motivator takes on the Great Wall

Avril Henry’s Great Wall run for cancer research

With a career in corporate motivation and inspiration, you would expect Avril Henry to be able to achieve just about anything! As she begins the count down to tackling more than 4,000 stairs and 21.1kms across the Great Wall of China, Henry says her greatest motivator for the challenge is running in the memory of her friends who have lost their fight to cancer – “Their names will be proudly displayed on the back of my running singlet on the day.”

Like many of us, Avril Henry is well aware that too many lives are touched by cancer across Australia every year, and she hopes to make a big difference by raising funds for cancer research.

“The Australian Cancer Research Foundation does amazing work, with NO government funding at all. Without these grants, some of the greatest cancer cures would not have been discovered,” said Henry when asked about her choice to support ACRF.

Continue reading “Corporate motivator takes on the Great Wall”

Anneka's head shave for cancer research

Cancer research supporter Anneka Skirrow recently raised over $1000 for the Australian Cancer Research Foundation (ACRF) by shaving off her beautiful long-locks at a ‘wacky-hair’ day held at Eden Hills Primary School in South Australia.

Anneka sadly lost her father to prostate cancer in 2006, and has friends who have previously or are currently battling the disease.

“In a humble attempt to identify with one side effect of cancer treatment, I will be shaving my head to raise money for research,” wrote Anneka on her fundraising page.

“I am full of admiration for my friends who have undergone treatment where hair loss was their experience,” she added.

Children, staff and parents arrived to school with colourful and way out hairdo’s, and attended a special assembly for the occasion.

“At the special assembly I spoke about my reason for the head shave and the first few cuts were taken before the children returned to classes”, said Anneka, “morning tea and nibbles were put on for parents to enjoy whilst the chop went ahead!”

“…the support and encouragement I received from the school community was quite something”.

ACRF wishes to thank Anneka and the staff, parents and children at Eden Hills Primary School for their wonderful support.

Tassie Safari For Cancer Research

Wagons ho!

In the true spirit of great adventure journeys comes news of the annual Australian Motor-home Charity Safari – which this year takes place across the top of the Apple Isle from March 2010.

Now in its 10th year, this unique Tasmanian safari will see more than 70 motor-homes and their occupants tour from Stanley on the north coast all the way to Longford in the centre of the island over 10 fun-filled days.

Originally coined as the Kidney Safari’, supporting kidney health, the touring event has since expanded to the Australian Motor-home Charity Safari – supporting a number of charities and causes including this year, the Australian Cancer Research Foundation.

Angela Hulme, 61, will make her debut at this year’s ‘safari’, supporting cancer research. A two-time cancer survivor herself, Hulme strongly supports the need for research into the disease.

“Yes I have had both breast and lip cancer. I also lost my husband Gordon to the disease when he was just 41. He was a Vietnam Vet and a 20-year active member of the Australian Army,” she said.

“I don’t try and let things get me down and I am always up for a challenge. You just have to make the best of things don’t you.

“I am looking forward to the safari particularly the challenge of some of those roads which are very hilly and windy in some places.

Angela said she had bought her “much loved” six-wheel motor home in 2002 and had now traveled more than 130,000kms in it!

“I just love it and have been all around Australia and have even driven up to Darwin three times” she laughed.

“I like the beauty and the colors and landscapes of this country so much.”

“The Tasmanian Motor Home Safari should be a lot of fun as we have an activity planned for every night along the way and we travel in different groups each day. Already I have a number of sponsors supporting me and the number is growing.”

Angela will be giving the Foundation regular updates throughout the ‘safari’, so watch this space!

Warmest thanks for your wonderful support of cancer research Angie and wishing you all the very best for the big safari.

If you would like more information on organising a fundraising event that raises money for the ACRF, click here.

Angie would like to congratulate the following raffle winners – John Hearn (TV), Jeni Miller (Navman), Lillian Gardam (Springers 12V $150 Voucher), Kit Hall-Jonstone ($150 Voucher), Irene Stevens (TV Antenna), and Pat Glazebrook (Fishing Reel).

[nggallery id=42]

This one is for 'Bumpa' – Alex Dodds Walk 4 A Cure

Two young Australian Cancer Research Foundation (ACRF) supporters Blaise White and Zac Dodds will soon head off on the challenge of a lifetime to honor their beloved late grandfather ‘Bumpa‘.

Alex Dodds (Bumpa), 72, sadly passed away from cancer late last year and now the two 16 year-olds have decided to embark on a marathon walk to honor not only him but in their own words, “everyone who has lost a loved one or is suffering through this terrible disease.”

With the initial support of his mother Kerryn, Blaise White figured a great fundraising idea would be to organise a 400km marathon walk – starting at his current home in Drysdale Victoria through to the location of his previous home at Tocumwal just across the NSW border.

“Originally Blaise wanted to do the walk while Dad was still alive but the sickness came on too fast. A week after Dad died Blaise said he would continue with his idea and complete the walk,” said mum Kerryn.

Upon hearing of the idea, Blaise’s cousin Zac decided he would also like to take up the challenge, and the two boys will now complete the walk together. They plan to start their walk on 19 September.

“The boys adored their grandfather who was a very loveable, caring type of guy who would do anything for his kids. Dad arrived from Newcastle on Tyne in England 50 years ago. Blaise used to love watching the cricket with him where he would still barrack for the English cricket team,” said daughter Kerryn.

The two young fundraisers have the full support of their family and are undertaking all sorts of great fundraising events leading up to the trip to raise money.

White’s parents will be along on the trip to offer support.

Apart from the Australian Cancer Research Foundation the boys will also raise money for ‘The Andrew Love Centre’ (the Cancer ward at The Geelong Hospital).

Wishing you all the very best of luck for your challenge Blaise & Zac, and thank you (& your family) very much for your support!

Anyone wishing to support the two boys on their big adventure can contact Kerryn on 0407 743 376, visit the Walk 4 a Cure” fundraising page or join the Alex Dodds Walk 4 A Cure Facebook Group.

If you would like more information on organising a fundraising event that raises money for the ACRF, click here.

A Real Five Star Performance at Tassie's 'Concert Under The Stars'

TOS-Musician-frenchhornOur dedicated Hobart Cancerians Committee members this year celebrated their Valentine’s Day with a difference, putting the champagne & chocolates aside to raise vital funds for cancer research.

Following much success in 2009, members of the Foundation’s Hobart Cancerian Committee again collected donations in support of cancer research at one of the most looked forward to events on the Hobart social calendar, the free outdoor concert performance by the Tasmanian Symphony Orchestra (TSO).

“It is just a wonderful night where families and friends gather, pack a picnic hamper and settle down for a night of great music in the great outdoors. Patrons enjoyed some wonderful music and contributed to cancer research all at the same time”, said committee president Gillian Groom, after the event.

“It was a fantastic night performance wise, and weather wise, and we collected more than $2500 for cancer research from the capacity crowd, which is double what we made last year!”

A versatile orchestra, the TSO is renowned for its expertise in music of the Classical and early Romantic periods. It is equally at home playing jazz, popular music and light classics, and is also recognized internationally as a champion of Australian music.

This year’s featured artists included Conductor Marc Taddei, Soprano Jacqueline Porter and host Tim Cox and the program featured Mozart’s “The Marriage of Figaro”, “Overture Borodin”, “Polovtsian Dances”, “Massenet Meditation” from “Thaïs”, “Sibelius Finlandia” as well as popular tunes “The Laughing Song”, “Vilja”, and “My Favorite Things”.

The Hobart Cancerians also catered for the supper needs of the 50 strong Tasmanian Symphony Orchestra after their performance.

When asked about the possibility of an encore appearance in 2011, Gillian responded “We are already writing a letter asking if we can do the same at next year’s show. It is a great night as many Tasmanians now agree summer just wouldn’t be summer without the annual B&E Symphony under the Stars.”

In the past the Hobart Cancerians have held a variety of successful events in support of cancer research including a highly successful Errol Flynn movie fundraiser, beautiful cruise along the Derwent River to Peppermint Bay, drinks at Tasmania’s Parliament House, as well as a number of cocktail parties (including one honouring 2006 Australian Of The Year Professor Ian Frazer) and scenic train trips.

The next big event to be hosted by the Hobart Cancerians will be a “Madhatter’s Tea Party.”

For more information regarding the Hobart Cancerians Committee, please contact Jeannie Taranto on 0407 876 713

Advances in Queensland Cancer Research thanks to ACRF

The Australian Cancer Research Foundation (ACRF) continues to build on its 25-year legacy by funding the opening of a new $2.5 million world leading cancer-imaging facility in Queensland.

Since being established in 1984 by the late Sir Peter Abeles, the Australian Cancer Research Foundation has now funded more than $62 million in cutting edge cancer research with the power to change the world.

The new ‘ACRF Cancer Biology Imaging Facility’, part of The Institute for Molecular Bioscience located at The University of Queensland in Brisbane, is now the most advanced facility of its kind in the Southern Hemisphere.

The Governor of Queensland, Her Excellency Ms Penelope Wensley AO officially opened it on the morning of February 10.

The Facility will allow IMB researchers to unravel the molecular reasons why healthy cells turn into cancerous cells and spread through the body. Continue reading “Advances in Queensland Cancer Research thanks to ACRF”

Sporting Events for Cancer Research

Australia’s leading cancer scientists will depend more than ever on the support of the Australian Cancer Research Foundation to keep the funding up for their vital work, to get results in the race to find a cure for cancer.

Participating in charity marathons or an organised fundraising sporting event is not only lots of fun, but a great way you can help raise much needed funds for cancer research.

Whether you’re competing as part of a team or taking part individually, it’s as simple as registering for the sporting event and then asking your family, friends and colleagues to sponsor you. Plus a bit of training of course!

Did you know that a partnership between the Australian Cancer Research Foundation and Everyday Hero means you can create your own online fundraising page in minutes?

  1. Simply select the event you’d like to take part in
  2. Set a fundraising target;
  3. Create a fundraising page at the Cancer Research Online Fundraising Page or by clicking on the relevant link below (Don’t forget to select Australian Cancer Research Foundation as your chosen charity!); and
  4. Get everyone you know to sponsor you or your team by sending your fundraising webpage link out via email or posting it on your social networking sites.

Once you create an online fundraising page, just watch the momentum build. Before you know it, you’ll have your own fans, supporters and sponsors – all for cancer research. It’s that easy!

Online fundraising not your thing? Visit our Fundraise for Cancer Research page for further details on fundraising options.

2011 Sporting Events links:

An ever higher level of achievement

How good it feels when we hear that important research initiatives you’ve helped fund are achieving major results:

Massive Exercise Project Right Round Australia for Cancer Research

balmain_fitness_logoNick Deverell of Balmain Fitness is determined to help find a cure for cancer and they’re not doing it by halves.

The staff and customers at the inner city health club ‘Balmain Fitness’, have teamed up with the Australian Cancer Research Foundation for a massive fitness fundraiser that will run throughout all of 2010.

Recently, Nick Deverell, the 33 year old health trainer said “Almost all of our staff here have had their own battles with cancer or have family members who are affected by cancer.”

“We even had one staff member who was forced to stop working about a month ago because he had cancer. So it is personal for all of us here. Getting behind the Australian Cancer Research Foundation seems very fitting.”

Deverell was drawn to the work of ACRF through a combination of “word of mouth” and “online research”.

“Our ‘Exercise Around Australia for Cancer Research‘ event runs for 12 months with each month featuring a stand-alone leg so we can still encourage new members who join throughout the year to take part.”

How the challenge works: Every time one of the members does a workout, they earn kilometres towards the destination for that month’s leg. “The basic idea is that our members keep track of their workouts, each of which translates into a distance and we chart their progress with winners at the end of each leg plus random prizes along the way,” he said.

“Leg One will be Sydney to Bundaberg, Leg Two Cairns to Alice Springs etc. etc.”

“Each person taking part will be given a fund-raising form and we will have prizes for most money raised for each leg and a grand prize for most funds raised over the year,” said Deverell.Balmain Fitness for Cancer Research_group

“Local businesses have got on board with prizes/sponsorship and local media have been helping to promoting our efforts.”

Deverall said “We have about 100 people taking part in our event so far but I would like to think by year’s end we have 10 times more people.”

“Our efforts are building in momentum and we are encouraging people to come and get fit and join our community event to help fund cancer research.”

“We will let people know of our progress throughout the year.’’

The Foundation thanks Balmain Fitness and all those participating in this awesome ‘Exercise Around Australia’ fundraiser for their support of our research. We wish everyone all the very best for their fitness challenge.

To find out more or to support the fundraiser contact Nick at Balmain Fitness on 02 9818 3555 or visit the ‘Exercise Around Australia for Cancer Research ‘ fundraising page.

Getting Funky & Fashionable for the ACRF

Proving that one person’s “throw outs” can be another person’s treasures are the fabulous, funky and fun “Two Bucks ‘Til Wednesday” vintage fashion fundraisers.

Organised by a hot, hip and happening group of young women in West Australia, Two Bucks ‘Til Wednesday’s infamous vintage sales just continue to grow in size and profits.

The unique Cancer Research fundraiser is the brainchild of Sophia Brown, Alicia Clements, Anna Brown and Hannah McGrath, who basically “love” Vintage Fashion, and now hold seasonal Vintage Fashion Sales supporting the Australian Cancer Research Foundation.

Months before the sales the girls trawl all the Op Shops, markets, garage sales and shop sales around Perth and pick up a collection of funky vintage clothing and accessories. Then they put together a beautiful photo shoot showcasing the items for sale, and hold a sale at a local venue.

From humble beginnings of only 15-20 people at their first sale in 2007, the Two Bucks ‘Til Wednesday 2009 Winter Wonderland sale saw hundreds of people lining up outside the door, selling out in an hour and raising over $5000!

The awesome foursome has now raised almost $18,000 for Cancer Research since they started supporting us in 2007.

Youth pastor Sophia Brown, 22, said she had been inspired to raise funds for the Foundation in honor of her father who died of cancer when she was nine.

“The girl who I started it with Hannah has a boyfriend whose father also died of cancer so it was a personal thing for us,’’ she said.

“Rather than just being upset by these deaths we wanted to do something to help prevent cancer, to get active and contribute, and after searching the Internet came across the Australian Cancer Research Foundation and the great work you do.’’

She said Perth had many “Op Shops’’ which the girls prowled searching for vintage clothes bargains.

“Our favorite ones are the shops run by little old ladies who when they hear what we are doing give us some very cheap bargains.”

“Our enterprise started when someone donated a ‘deceased estate’ to us and we got bags and bags of really great hand made clothes, particularly dresses, from the 1920s right through to the 1980s.’’

Sophia said their first sale had been held at her brother’s house but it proved so popular they had moved their events to a larger community hall.

“We were even invited over to Melbourne to stage a sale which went very well,’’ she said.

“I really would like to inspire other people to hold vintage clothes sales for the ACRF all over Australia because it is a lot of fun and a great way to raise money.”

“It shows that it really is possible to turn anything you like, and particularly anything you love and/or are passionate about, into something that can help cancer research.’’

The girls have now been featured for their efforts in trendsetting magazines such as Frankie, Russh and Jmag.

For more information, check out the Two Bucks ‘Til Wednesday BlogspotFacebook & Twitter pages or call Sophia Brown on 0401 305 315.

Many thanks for your wonderful fundraising Sophia, Alicia, Anna and Hannah. You go girls!

Stefan Crosses The Line For Cancer Research

StefanLong distance runner Stefan Quaid finally achieved his year-long goal of running a staggering 1600 km for the Australian Cancer Research Foundation, completing his one thousand six hundredth kilometre on December 9.

The 32 year old Western Australian, who works for a pharmaceutical company, joked recently he had run every day of the year apart from six days in “all kinds of weather scorching heat, pouring rain and gusty winds. I just kept chipping away on the 1600 km I set out to run and it was great to finally get there.”

Quaid who lives in Secret Harbor south of Perth said his initial inspiration for fundraising for Cancer Research had come about after his father was diagnosed with lung cancer in 1995.

“I wanted to do something to help in the fight against it and I heard about the great work of your organization. Touch wood Dad is still doing fine and has a very positive attitude,” he said.

Talking Cancer Research at the Premier's Gala Concerts

The Australian Cancer Research Foundation was one of a select number of lucky organisations to receive a generous offer from the NSW Department of Ageing, Disability & Home Care’s (ADHC) to host an information stand at the 2009 Premier’s Christmas Gala Concerts on December 8 and 9 at the Sydney Entertainment Centre.

The Premier of NSW stages six free gala concerts each year for local seniors, a thank you for their contribution to the state and community. The concert series closes with a spectacular Christmas concert each December, attracting over 30,000 seniors from all across NSW.

This year’s Christmas Gala Concert transformed the Entertainment Centre into a spectacular “Christmas in the Park” extravaganza, with many attendees hailing it “the best concert yet”!

Cancer Research staff member Gabrielle Dunn said she was “struck by the number of survival stories that the attending seniors were keen to share.”

“Upon being handed a Newsletter, a ribbon and an introduction to the Foundation, the attendees would enthusiastically share their stories with us. ‘Yes, I had Cancer. I am a survivor,’ was proudly stated numerous times during the event.”

“In the past, the big ‘C’ was a very scary word that meant doom, but now there is definitely a strong message of hope and survival.”

The Australian Cancer Research Foundation thank ADHC very much for the opportunity to meet so many members of the NSW Senior’s community, and plans to work closely with Australian Seniors in the future.

25 years of progress in Australian cancer research

This year marked a milestone for the Foundation. 2009 was our silver anniversary; 25 years since the vision of the late Sir Peter Abeles set the Australian Cancer Research Foundation on its path of providing unprecedented multimillion-dollar private funding to cancer research in this country.

ACRF’s board throughout its history – Lady (Sonia) McMahon, Sir Ian Turbott AO, CMG, CVO HonDLitt, and Mr John Boettcher AO – supported Sir Peter in his mission in the very early day’s of the Foundation.

The original Medical Research Advisory Committee (MRAC) who stringently assessed applications for funding included esteemed scientist Professor Ronald Penny AO.

Similarly, today’s experts on ACRF’s MRAC, headed by Professor Ian Frazer, continue to advise the ACRF’s Board of Trustees. The first grant given by ACRF was for $1 million for an Immunotherapy Centre at St Vincent’s Hospital in Sydney when Immunotherapy – now a key element of our cancer knowledge bank – was very much on the fringe of mainstream research.

Since that first year, the Foundation has granted over $60 million to Australian medical research teams at many of the country’s leading cancer research institutes. Those funds are used to purchase major equipment, construct research laboratories and equip cancer centres.

More than two-thirds of our grants have been awarded since 2004, a reflection of the rapid progress made since the human genome was decoded and the sequencing of human DNA advanced our understanding of the relationship between genes and disease. That increase is also a reflection of the increasing generosity of the many companies, individuals and community groups who support ACRF.

ACRF will continue its critical contribution to breakthrough projects; projects which increase our knowledge and result in ways to prevent cancer and in more effective treatments. Ultimately cancer will be overcome.

Professor Ian Frazer, who discovered the cervical cancer vaccine, recently said of the Foundation “The ACRF provides critical funding for infrastructure support that enables our research to be competitive on an international basis.’’ Watch a recent interview with Professor Ian Frazer.

In 2009 we received ten grant applications for projects that would make a difference to the lives of the one in three people who will be touched by cancer. Those applications totalled $34.8 million. As we go to press, we are working on a five-year plan to enable us to increase our income and research funding significantly over the next five years. Read about the winners of 2009 research grants

We trust you will stay with us and join us in our mission to create a world free of cancer. We depend on you and are deeply grateful for your support over the last twenty-five years.

Hunter Hall: High Tea Setting for Donations

As one of ACRF’s major corporate sponsors, Hunter Hall Investment Management Ltd generously donates part of its pre-tax profits to our Foundation each year. Once again, Hunter Hall has shown tremendous support for cancer research by presenting a cheque close to $20,000 to ACRF. On the 30th November, the company held its annual afternoon ‘High Tea’ event at the Vaucluse House Tea Rooms in Sydney to celebrate handing over the generous company donation.

Staff, stakeholders and charity representatives were among the attendees of the event – including guest speaker, Louise Burton, from Philanthropy Australia. Burton gave a great speech on the future of philanthropy and corporate support of charities.

Hunter Hall has a policy of donating 5% of its pre-tax profits for charitable purposes and activities – and to date, the company has donated over $165,000 to the Australian Cancer Research Foundation.

Hunter Hall is a publicly listed company and owner of Hunter Hall Investment Management Ltd, an ethical investment manager committed to the concept of responsible investing.

Once again much thanks to the generous folk at Hunter Hall for all of their amazing support.

Read more about our Corporate Supporters and Company Fundraising.

 

[nggallery id=44]

Having a Ball for the ACRF – Masquerade Ball

For what chief organizer Carmel McMahon describes as ”just a backyard affair”, her annual fundraising dinner for ACRF, is now a much looked forward to fixture on the Brisbane social calendar and continues to grow each year.

This year more than 90 people, aged seven months to eighty, year ld attended Carmel’s backyard “Masquerade Ball”, raising a much-appreciated $3500 for the ACRF.

“It was a great night and you were not allowed in if you did not have a mask on,” laughed Carmel recently.

“I myself was dressed as a ‘Satanic Cat Woman’ but we also had a Zorro and a baby that looked gorgeous in a little tiger suit.”

“I couldn’t have done it without my core group of six girlfriends who all bring a different dish. Everyone is invited and we had three generations of people there this year including my sons, girlfriends, neighbors and people’s parents.”

Carmel’s fundraiser had been taking place annually since 2005 and is a glamorous sit down dinner in her beautiful back yard.

A hairdresser in her 50s, she said her mum and sister passed away from cancer several years back and she herself had been diagnosed with asbestosis.

“Yes I do have it sadly but I refuse to let it get me down and try and stay positive,” she said.

“My Mum Beth Franklin did a lot of charity work which she got involved with right back after World War II.”

“She actually won a Queensland Premier’s award for her good work.”

“My Mum was a big fan of Lady (Sonia) McMahon so it was a real thrill to meet Sonia myself when I was invited down to Sydney last year for the annual ACRF Chairman’s dinner at the Opera House. Mum always thought she was such a snappy dresser.”

“Another highlight for me was meeting the ACRF’S Errik Hasim. I often talk to him on the phone and he has always been very supportive so it was great to put a name to a face.”

Carmel said plans were already formulating for next year’s ACRF fundraiser.

There's No Place Like Home

Not only was mother of three, Jodi-Ann Goulter’s recent family fun day a successful fundraiser for the Australian Cancer Research Foundation it also marked her celebration of a first stage win against cancer.

Recently, the brave hearted Jodi-Ann said that when she was diagnosed with cancer, while pregnant with her third child, her greatest fear had been she thought she wasn’t going to be able to see the kids grow up.”

An Australian expat living in Hong Kong with her children and pilot husband Matt, Jodi-Ann had been unable to travel to Australia for quite some time due to her ongoing treatment.

Recently she triumphantly reported that her tumors were gone and she had been able to head back to Australia to celebrate with those she cares about most – her family and friends.

“I was 34 weeks pregnant when I found a lump in my leg,” she said.

“I was angry when cancer was confirmed by the doctor because I have always lived such a healthy life. There was no reason for me to have cancer.”

After several months of successful chemotherapy the expat recently returned to her Sunshine Coast home where she staged a fundraising event for cancer research.

“I am having my own personal cancer experience presently involving chemo on a weekly basis,” said Jodi-Ann mother of Jake 4, Corey 2 and Tim 6 months.

“I was given the all clear to see my family on the coast for the first time in 12 months. I try to keep a positive attitude on life.”

“To celebrate my home-coming and to raise a little money for cancer research we held a brunch for my family and friends on the 21st of November which was a wonderful success and raised more than $4000 for the Australian Cancer Research Foundation. Everyone had a great time.”

Big thanks Jodi-Ann. We think you’re just awesome!

2009 Grant Recipients Announced

The winners of the ACRF latest research grants are:

Children’s Medical Research Institute (CMRI) & University of Newcastle NSW: $3.1 million

To build and equip two dedicated laboratories for the world’s first Chemical Proteomics Centre for Kinomics. This is a new discipline, merging genomics (genes) and proteomics (proteins) implicated in certain human cancers and is a priority area for new drug targets.

The Centre for Cancer Biology (CCB), South Australian Pathology and the University of Adelaide: $3.5 million

For equipment to establish a new Cancer Genomics Facility, enabling researchers to obtain insights into genetic modifications that underpin development of new tools for better diagnostics, disease prognosis, drug response, and resistance to chemotherapy.

Let's Get Loud for Cancer Research

There was a touch of irony about the recent “Loud Shirt Morning Tea” that staff at the Environmental Services Division of the Sutherland Shire Council organized for their late friend and work colleague John Newman.

“John was a real gentleman and a scholar and always wore a suit and tie to work. You never would have seen him in a loud shirt at all but I know he would have appreciated our efforts because he was such a loving man with a great sense of humor,’’ said the division’s administration supervisor Judy Thompson.

“He was a very popular member of staff and people from all levels of the council attended our event.”

“John, 60, died last year and we all decided we wanted to honor him so his wife suggested a fundraiser for cancer research. He had battled several forms of cancer and he was well aware of the wonderful work of the Australian Cancer Research Foundation,” said Judy.

“We all wanted to help find a cure as cancer has now affected many members of staff here.”

For the event staff at Sutherland Shire Council brought their own food and their own collection of `outrageous’ shirts.

Loud Shirt Morning Tea Organiser Judy“I made myself a vest for the occasion,” said Judy.

“There was an abundance of delicious food. Actually, the Mayor who attended our event said she wished we catered for all of the council’s events.”

The team at the Environmental Services Division held their annual Loud Shirt Morning Tea on November 4th raising a much appreciated $5334 for the Foundation, building on the $3000 collected last year.

Big thanks goes to John’s family, Judy, and all the team at Sutherland Shire Council for their wonderful fundraising and support.

A gift for the future of cancer research

Some of the ACRF’s largest research grants have been made possible by bequests from people who, during their lives, decide to contribute to a future without cancer.

ACRF’s Planned Giving Coordinator, Jennifer Coffey, visited a very special couple who have recently decided to leave a bequest to the Foundation in their will.

Claudia and Peter Fisk live in picturesque Leura in the Blue Mountains and their delightful garden has recently been featured as a highlighted attraction at the Leura Gardens Festival. Claudia told Jennifer she worked in the travel industry and in art galleries until the couple moved to their beautiful Blue Mountains retreat.

Continue reading “A gift for the future of cancer research”

From Little Things Big Things Grow – Workout A Cure

Work Out CureParticipants got hot, sweaty and had a lot of fun at the ‘Workout A Cure’ fundraising event for Cancer Research, held on the Gold Coast recently.

It was after doing a personal motivation course that new supporter Anthony Balsamo came up with the novel idea of a “a fun, family charity event designed to improve fitness and create a sense of community while raising awareness and much needed funds for cancer research.”

‘Workout A Cure’ held on November 15 in Surfers Paradise attracted 25 enthusiastic participants who certainly ended up a lot fitter by day’s end, and raised some great funds for the ACRF.

Even though this year’s charity workout started on quite a small scale, Balsamo said he wanted to make the day an annual event and build the numbers each year.

“It was so good to at least try to make a difference. You see something that needs action and then act to do something about it. That brings a lot of satisfaction for sure,” said the Gold Coast resident recently

“I have my personal reasons for doing this as I lost a very close cousin in her forties to cancer two years ago.”

“Cancer actually is very prevalent on my Mum’s side of the family. I wanted to do something to help in the fight against it and after reading that the ACRF did research into all types of cancer and not just the one, I decided you guys were the best place to assist.”

For his ‘Workout A Cure’ event, Balsamo managed to organize the services of 12 volunteer personal trainers, who conducted 2 x 30min workout sessions including a boxing class and a boot camp class.

Balsamo said ‘Workout A Cure’ would begin promoting its next event in January and that it would hopefully be held in June 2010.

Coogee Beach Golf Club Fundraiser for Cancer Research

Forget Tiger Woods. ACRF’s Golf Fundraisers Have A Lot More Fun!

Yes folks they’ve hit the fairways again! Those free swinging, big hitting, fun loving enthusiasts from the Coogee Beach Golf Club have held another successful annual fundraiser for the ACRF.

First staged in 2006, the club’s special day has raised close to $50,000 for cancer research.

The much-anticipated event involves 18 holes of golf at the picturesque Randwick Golf Club, followed by a massive lunch, auction and raffle at the Beach Palace Hotel in Coogee. This year 102 golfers took to the fairways.

The ACRF’s own Claire McArthur and Jonathan Russo attended the after party lunch, which Claire later declared “a really fun (and loud) affair. I may even try the golf next year myself’’ she said.

Garry Ennis said the fundraising event had now become an event many golfers looked forward to and when asked who won the event he replied “that’s not important it’s really all about the end result.

“In 2006, the Coogee Beach Golf Club (CBGC) held its first ever Charity Golf Day to commemorate the passing of several members of the club who had died from cancer. The Club president for over 20 years Mark O’Connor, Fritz Krall the club’s top handicapper for over 20 years, Arthur Mears, and Dave Griffith all fell victim to this terrible disease,” he said.

“Once again the highlight of the day was the Charity Auction led by the one and only Chris White. Chris always manages to get the punters wound up.”

“Everyone really got into the spirit of giving and friendly competition. More importantly, all present had a great time with lots of golf, appetizing food and cold beer – all in aid of innovative cancer research.”

Garry said special items up for auction this year included an accommodation package at Boambee Bay Resort Coffs Harbour, golf trip packages at Pacific Dunes Horizons and the magnificent Bonville Gold Resort, a 2009 English league team jumper as well as Wallabies, Souths and Easts rugby jumpers.

“We owe a lot of our success to the very generous support we get from key businesses, golf clubs and individuals. The Beach Palace Hotel Coogee, The Shoalhaven Heads Golf Club, The Heads Hotel Shoalhaven, The Coogee Legion Club & Salamander Shores Port Stephens deserve special mention for their unyielding backing of the event. These supportive businesses donate everything from accommodation to catering, as well as rounds of golf & gift vouchers for the Charity Auction and Raffle.

Additionally the ever-friendly Tim & Gary from The Coast Golf Club Pro-Shop and the Manager of Coogee Sands Hotel & Apartments, Jean-Claude Niederer and Brendon Lanigan proprietor of L&R Motors on Carrington Rd Coogee, and Pinocchio’s Restaurant at The Spot also need to be acknowledged for their continual help and commitment.

ACRF provides major funding of between $1.5 million and $10 million, not readily available from government or other sources, to outstanding world-class research projects. Our grants fund state-of-the-art laboratories and equipment to support prevention, diagnosis and treatment of cancer. Every dollar of every donation received goes to funding cancer research.

Read about the 2008 Coogee Beach Golf Club fundraiser.

The Kids are Alright

Cartia & Leela with their sweet treats

Proving that Australian Cancer Research Foundation supporters do span across all generations are our latest two young fundraisers Leela Bishop and Cartia Mallan, Year 6 students at Somerville House in South Brisbane.

Leela and Cartia wanted to help in the fight against the disease and chose The Australian Cancer Research Foundation after doing some fact finding about cancer on the internet.

Both girls have family members who have been affected by cancer and showing a lot of initiative they decided that they wanted to make a contribution.

With great enterprise, the two young students made some homemade treats and sold them from a trolley around their neighbourhood over a weekend recently. Lots of people bought the cakes, biscuits and slices and the duo raised $177.

No one was happier about the efforts of the two girls than their own parents.

“We were delighted that Leela and Cartia took the initiative to do this and are very proud of their efforts,” said Kylie & Peter Mallan and Greg & Kanchana Bishop.

A Wedding with a Difference

Loving newly weds Roz Luce and Ian Dick tied the knot with a difference when they married in Perth on October 31 2009.

Instead of traditional wedding presents the pair invited guests to donate to cancer research in their honor.

Roz said recently that guests had appreciated the couple’s gesture.

“We have been thrilled by the response and the letters informing us of the donations made on our behalf.”

“It is great knowing it will assist in something really important and is certainly more beneficial than receiving a hundred kitchen appliances that we don’t need” she laughed.

“My father passed away 3 years ago of a glyoblastoma (a brain cancer) and we decided this was the best way to remember Dad.”

Warmest thanks Roz and Ian, we greatly appreciate you choosing to support cancer research on your special day.

For more details on how to support cancer research at your upcoming celebration visit ACRF’s In Celebration page.

Megafauna – Let's Rock for ACRF

The BandThe nation’s capital Canberra rocked out to the sounds of a huge benefit concert on Saturday October 24 called Megafauna, all in aid of the Australian Cancer Research Foundation.

Megafauna ’09 carried on the “rock” tradition of the 2006 and 2008 Megafauna events, which raised in excess of $10,000 for the ACRF.

This action-packed concert, held at ‘The Basement’ in Belconnen Canberra, was the brainchild of young music promoters Ryan Malcolm and partner Lachlan Paine.

The duo presented a glowing array of young and old metal, rock, punk, surf and even flamenco musical acts to entertain a large crowd of Australian Capital Territory enthusiasts.

Ryan, 30, said he has been personally affected by cancer as he lost his mother, Kathy, to the disease in 2005.

Continue reading “Megafauna – Let's Rock for ACRF”

All in the Family – Tammy Waughman

It was a real family affair for ACRF supporter Tammy Waughman, who recently completed the St George Melbourne Marathon for cancer research with a bit of help and inspiration from her dad and uncle.

In talking about her reasons for taking part in the marathon Tammy told ACRF that “Cancer has hit my family pretty hard in the past few years, most recently my dad’s brother Andy. It was like a bomb had landed into our worlds.”

“He has been through so many tough times and so much pain, and treatment and his determination and zest for life is just phenomenal.

“His strength has given me drive to do this, along with my beautiful dad who has been my rock and who I have cheered on at so many marathons, so this charity is one that is very close to my heart.”

Waughman said both her father, a former marathon runner, and uncle had helped her with her training, offering her tips and encouragement. “I’m a very lucky girl”, she added.

Tammy also revealed why she is pictured with tears running down her face as she completed the marathon.

“No it was not that I was exhausted.” she laughed.

”It was because I listening to some music for some inspiration as I ran the marathon and as I entered the MCG a song that my Dad was involved in came on my iPod.”

Tammy explained her father John Waughman, known better in music circles as “Johnny Warman”, was a well-known musician in the UK and had recorded a song with international superstar Peter Gabriel on vocals 1983 which was a hit in around the world.

“You can say that Peter Gabriel helped me to help the ACRF,” laughed the marathon runner.

Tammy said she had discovered the “great work and progress” of the ACRF surfing the Internet.

“What was wonderful about getting involved with you guys was the support I got from ACRF staff,” she said.

“In particular Claire McArthur sent me some really positive messages encouraging during training and this kept me going.”

Waughman said the marathon ‘bug’ had now beaten her.

“For me it does not stop there, I am now entering the Great Australian Run, so I will be setting up another sponsor page and aiming for the stars. That race is on the 29th November,” she said.

“A friend suggested I donate my run to another organization but I am sticking with the ACRF. Why leave a good thing?”

Thank you Tammy for all of your hard work and continuous support of the ACRF.

Patrick Swayze Inspires Action for ACRF

The death of Hollywood star Patrick Swayze inspired one new cancer research supporter to get involved with fundraising for the organization.

Mother of five, Melanie Heathcoat, 33, said the actor’s death had mobilized her into action.

“I was a huge fan of Patrick Swayze and his death really saddened me. I can’t really single out which was of his movies is my favorite because I love them all,” she said.

“I was also inspired to support the Austrailan Cancer Research Foundation because many of my own family members have been affected by cancer. I have lost two close relatives in the past six months through the disease.”

“I myself had a scare myself recently but luckily I was given the all clear.”

Melanie held a BBQ at her Mandurah home near Perth on October 31 for Cancer Research and said she wished to thank her local Coles supermarket and green grocer for donating food and drink for the event.

“I hope Patrick Swayze is somewhere looking down on me and appreciating my efforts.” Thanks for your wonderful efforts Melanie, we really appreciate your support.

One Man’s Walk Against Cancer Resonates Around the World

Veteran marathon walker Dave Wilson has turned a personal battle against prostate cancer into a world wide fundraising campaign in aid of cancer research.

The very fit 72 year old Englishman, was diagnosed with prostate cancer about two years ago but was delighted to report recently that since then his PSA levels have continued to recede to a low level and that he now “feels great”.

“I was treated for my cancer in England as it’s where I live, although I usually spend much of the English winter in Melbourne with my daughter, son-in-law & grandchildren” he said recently.

Dave said after finding out he had developed cancer he decided he was going to attempt an exhausting five month, 2,400 mile sponsored walk across England for cancer research.

“I have a considerable number of friends and acquaintances in the UK, Australia, New Zealand, Malaysia and France as I spent time in these countries. So I decided to support cancer research charities in Australia, UK and NZ,” he said before the event.

He then urged his many supporters ‘downunder’ to ‘support the ACRF’.

Dave signDave’s Big Walk began at Brighton Pier on 3rd May. On the massive trek which finished on October 10, he was supported by his loyal and loving son Rob who sacrificed five months of his life to be his Dad’s support vehicle driver, cook and bottle washer

After finishing the event Wilson said “On the last day I walked 26.5 miles (42.7 Km) and was joined by around 40 supporters who accompanied me on the final 12 mile leg. It was a wonderful way to finish”.

During this period he said he received very positive radio, press and TV coverage in the UK.

Well-done Dave from your many fans at the ACRF “downunder”.

Tweeting about cancer

This year, increasingly, the Foundation has shared our news and connected to a new community of friends and supporters on Facebook, Twitter, Youtube and LinkedIn.

“Staying at the forefront of change and capitalising on innovation are underlying elements of ACRF’s culture,” says Suzie Graham, Exec. Manager of Philanthropy.

“We all feel we owe it to our brilliant researchers to be across the most effective techniques that will maximise funds for our annual grants program. And we’d love you to join us.”

Cancer patients are also taking to social media, to help deal with the tribulations of battling their devastating disease.

They’re documenting their ongoing treatments and the daily battles they face in an often light-hearted and amusing way to help cope, and forming online relationships with others in the same situation.

Continue reading “Tweeting about cancer”

ACRF Life Membership Nomination

The Australian Cancer Research Foundation board and staff is delighted to announce our newest Life Members. Life Membership is the highest honour we can offer to express gratitude for our life-long supporters.

Sir Ian Turbott, Professor Thomas Jack Martin, Professor Rob Sutherland, Lady Sonia McMahon and Mr John Boettcher as their newest life members.

Sir Ian Turbott

Sir Ian Turbott AO CMG CVO HonDLitt, University of Western Sydney. Has been ACRF Director since June 18, 1984. Chairman – Penrith Lakes Development Corporation Limited, I T Graham Investments Pty Limited, Australian Youth Trust. Director – Commonwealth Council, Ted Noff Foundation. Fellow – Institute of Directors Association of Australia. Emeritus Chancellor – University of Western Sydney.


Professor Jack Martin

Professor Martin was appointed to the MRAC in 1997 and was Chairman of that committee in 2008.

Professor Martin trained and obtained his Bachelor of Medicine and Bachelor of Surgery at the University of Melbourne. He was appointed as the third director of St Vincent’s Institute in Melbourne in mid-1988.

Jack is held in the highest regard within the research community in Australia and internationally.

These past forty eight years, Professor Jack Martin’s research work has been prolific. During his tenure, ACRF witnessed a period of accelerated growth in cancer research and the birth of comprehensive cancer centres in Australia. Jack continues in research at St Vincent’s Institute.

Professor Rob Sutherland

Professor Sutherland was nominated and appointed to the MRAC 1st June 1987 and resigned November 2007 – Twenty years of tireless service. The longest serving member of the MRAC.

Over the last 20 years Professor Sutherland has established one of Australia’s largest cancer research programs at the Garvan Institute. The output from this research includes more than 250 scientific publications and several patents covering new methods of detecting cancer and new treatment strategies.

His most recent discoveries have shown how estrogens stimulate breast cancer growth resulting in the identification of several new genes that are targets for potential new treatments and improved disease outcomes for patients with cancer.

Lady [Sonia] McMahon

Lady McMahon has been ACRF Director since June 18, 1984. She’s also a board member of National and NSW Branch of the Australian Brain Foundation, Microsearch Foundation; Director – Tinine Pty Ltd. Chairman – Private Investment Company. Patron – Australian Ladies Variety Association.



Mr A John Boettcher OAM

Mr A John Boettcher OAM has been ACRF Director since June 18, 1984. Former Honorary Governor – Science Foundation for Physics, University of Sydney. Former Director, Philips Electronics Australia Limited. Director – Canty Pty Ltd. John Boetcher

Cancer Research gets Sticky

A call for online cases studies has resulted in a burgeoning relationship between the Australian Cancer Research Foundation and Newcastle-based digital agency Sticky.

Craig Wilson and his team at Sticky met recently with the Australian Cancer Research Foundation (ACRF), who were selected by the agency to take part in a comprehensive search engine optimisation (SEO) case study.

“We recently called for applications for sites to conduct a case study on and were inundated with responses. It was difficult to select just one but ACRF stood out due to the philanthropic nature of their organisation and we felt it would be a great way for Sticky to help such an important cause,” said Craig.

The case study involves bench-marking the ACRF website’s current online search capabilities and then providing strategies and recommendations to improve results.

Continue reading “Cancer Research gets Sticky”

Game on for the ACRF

“No 11” Legs Eleven, “No 55” Snakes Alive, “No 88” Two Fat Ladies

The air was filled with familiar bingo shout outs and laughs when a series of games was held recently to raise much appreciated funds for the ACRF.

Proving the versatility of our supporters who use a variety of methods to raise funds for the ACRF, “Bingo Games & Afternoon Tea” was organized by supporters Neville & Marie Holmes in Rochedale of south Queensland.

Their creativity and hard work raised an impressive $3,700!

According to Marie, “More than 60 people attended to make the event an enjoyable and entertaining afternoon. There were lots of laughs and good times had by all those that attended”.

The “Bingo Games & Afternoon Tea” event in support of the ACRF was held to honor the memory of her son David, aged 37, who died from cancer in December 2008.

“As a family we wanted to give something back to others, so we decided we would like to have a fundraiser to support the ACRF to help find a cure for this disease.

We intend to have an annual event to support the ACRF and all agreed that Bingo Games was a fantastic first start”.

We couldn’t agree more and wish Neville and Marie continued success. Thank you for your creative support!

 

Cocktails for cancer research

Locals in the small Western Australian mining town of Newman gathered recently for a cocktail party to mark the passing of a “valued friend and brother” and at the same time also to aid cancer research.

“Cocktails for Cancer”, was organized by Chantelle ‘Channy’ Smoor and Sheree Clark to honour Chantelle’s brother John Simpson. Earlier this year John was diagnosed with a very rare and aggressive cancer in his neck called Rhabdomyosarcoma, He sadly passing away “peacefully” on June 22 with family by his side.

John was only 27 and according to his sister “fought hard to fight the cancer”. He left behind a young daughter Ally.

Determined to honour her brother, Channy organized the cocktail event in Newman, a town of 8000 residents in outback Western Australia, raising a staggering $25,443.95.

A feature of the night was Channy’s speech, which “inspired” many present.

She told the audience “The reason we are all here tonight is to help raise money for ACRF which funds research into ALL types of cancer out there”.

“Cancer is one of the highest killing illnesses effecting Australians today.”

She pointed out that many residents of Newman had been affected by the disease.

“We are all aware of why we are here tonight. Someone be it a family member, friend or yourselves has been affected by or has cancer in some form. I have been affected through a family member with cancer, my own brother, and that’s why I organized this event.”

“John was the oldest of three and was a fit, active and healthy person who in his spare time played drums for a band and worked hard for a living.

Sadly John passed away two and a half months ago, just four months after his rare cancer was diagnosed.

Channy said her brother’s legacy would live on.

“Not a day goes by where I don’t think about him or his baby girl, my beautiful niece Alyssia. We promised him that we would never let her forget how strong her daddy was and how much he loved her. John will always be a hero to my family and we will never forget how hard he fought for his young life.”

“For now all we can do is do our bit to try and stop this from happening to future generations to aid research to find a cure for ALL cancers.”

Channy ending her speech with these parting words to the crowd of over 100 people:

Channy & Keith”I would like to say thanks to everyone here for attending because without all of you there wouldn’t have been a Cocktails for Cancer.

I hope you all have a wonderful night and for helping me make this event a success.

Who knows this could become a yearly event. I know I would love to be a part of that!”

ACRF profoundly thanks Channy and all the lovely attendees to this fantastic event. Our research grants would not be possible without your wonderful support.

"Pink and yellow day" for cancer research

The small town of Grenfell (NSW) hosted a very colourful footy match recently, swapping their usual black and yellow colours, for pink and yellow in support of cancer research.

For the last match of the 09 season, the Grenfell Junior Rugby League Football Club held a “Pink & Yellow Day”, with all referees, players, coaching staff, parents, and supporters dying their hair and/or wearing pink and yellow in support of ACRF.

Members of the opposition teams from Canowindra also joined in the fun, dressing up to show their support for the cause. The football club raised over $1000 for cancer research via raffles and collections on the day, a truly mighty effort for the small country town, who only has 65 kids playing in their Under 7 to Under 16 teams.

“One of our referees had a kidney removed last year due to cancer and we also have a young mum going through treatment for breast cancer at the moment, so this is our way of trying to help with the much needed funds for the very important job the Australian Cancer Research Foundation are doing” said event organiser Kate Eppelstun.

“We had lots of fun on our special day and we intend on making this an annual event.

A very big thank you to the Grenfell Junior Rugby League Football Club members and supporters for their brilliant fundraising efforts.

We wish them all the very best of luck for the 2010 season and look forward to next year’s “Pink & Yellow Day”!

All Aboard for ACRF

On 13th September 2009, 34 Sydney bus drivers left the comfort zone of their usual means of transport to undertake a week long 643 kilometre trek to Canberra and back in support of the Australian Cancer Research Foundation and Canteen.

The “Bussies on Bikes” charity ride was re-established in 2009 following a request from one of the event’s original organisers, Narelle Sinclair.

“Narelle’s husband sadly died of cancer and his last request was that we run the Bussies on Bikes challenge again,” said this year’s event co-coordinator Bill Kusabs.

They did it in 2005, 2006 and 2007 now once again a group of energetic and compassionate Sydney bus drivers have mounted their pushbikes for a marathon ride in aid of charity.

“Bussies On Bikes 09” was initially established by three keen Willoughby drivers who wanted to make a difference and more importantly to contribute to the fight to find a cure for cancer.

Showing just how much the ACRF appreciate the efforts of the riders, staff member Claire McArthur met the group at the halfway point for a BBQ at the picturesque Marsden Weir and Waterworks Picnic Area in Goulburn, hosted by the local Rotary Club.

“It was so wonderful to be able to meet the whole Bussies on Bikes team while they were ‘on the road’.” said Claire from ACRF.

“The riders had just completed a particularly difficult leg of the journey that day and being there to say thank you and talk about how their hard work is making a real difference for cancer research, came at just the right time.”

“The enthusiasm and dedication of all the riders was really inspirational, not to mention the generosity of the same guys at the nightly auction. I was just so glad to be able to be there to support the team and cheer them on” she added.

The race later finished at Port Botany Bus Depot, on September 12th. Friends and family welcomed the riders. The welcome included a BBQ, World Music Band and presentation of trophies, along with an auction.

Claire from ACRF was there again at the finish line to welcome the riders home, thanking the team and their supporters on behalf of the Foundation.

“The ride was a fabulous affair and we raised more than $40,000,” added Kusabs.

“We had four different groups amongst our riders, The Lizards, The Goanna’s, The Turtle’s and The Echidna’s. Each night of the seven we were on the ride we also had entrainment provided so that was fantastic.”

“On the weekend of December 19 and 20 we all now plan to go to Newcastle where we will present some awards and also hand over our cheque to the ACRF. He will certainly be doing another ride in the future.”

Great job Bussies! You amaze us with your wonderful enthusiasm and overwhelming support.


Cancer Research wins City2Surf

The Australian Cancer Research Foundation was well represented at this year’s huge Sun-Herald City2Surf marathon.

82 dedicated supporters ran, jogged, walked and “crawled’’ on behalf of the Foundation in this year’s event, jointly raising over $25,000 for cancer research, made possible through the incredible generosity of more than 700 supporters.

ACRF supporters and their motivations

One of the larger contingents of runners included the Gatorade PepsiCo ACRF team who raised more than $1000. Their runners were greeted at the end of the race by a corporate team who provided lunch and a soothing massage for any aching limbs in a specially provided for tent.

PepsiCo said `We had more than 40 runners who took part in the event supporting six different charities, including the Australian Cancer Research Foundation.

“A lot of our runners, who were wearing our distinctive Gatorade t-shirts, ended up finishing high up in the field.

“Our company has been involved with the event for the past 11 years and this year’s event was a fantastic day for all concerned. We will certainly be interested in being involved next year.”

Some of PepsiCo employers have been regular supporters of the ACRF since 2008 through a workplace giving program.

Another ACRF supporter, Sue Sanossian said she took part in the event in honor of her brother Graeme Medo, 51, who recently passed away from cancer.

“Graeme, who died June 14 leaving behind a wife and four kids, developed cancer of the bowel and liver. At first they thought they had got rid of the bowel cancer but then problems with his liver set in,’’ she said.

“I was absolutely delighted to run on behalf of the ACRF because of the important research they are funding”

“I ran as “Team Cray’’ because my brother loved crayfish. I did have to train for the event but because I did this I pulled up ok. I injured my foot earlier this year and ran under a little pain but nothing like that which my brother faced at the end. I come from a large family who all supported my run. So far I have collected almost $1000.’’

Westpac banker Peter Stenvert who also participated on behalf of the ACRF, said he had trained with work mates before the big race.

“I completed the run in 65 minutes and 30 seconds. I was happy with that. I have to be honest though I did pull up a little sore after it.

I heard about you guys and looked up your site on the Internet and was very impressed with the work you do. Keep at it’’ added Peter.

Fitness trainer Kaz Muddell, 43, must be good at her job as she said several of her clients actually beat her to the finish line.

“Yes, they did which I laughed about but I did do it in a time I was happy with especially as I have a bit of trouble with my knees.

“I wanted to support the ACRF because I have a real fear of cancer as my Grandmother died of breast cancer. I think the work you guys put into cancer research is vital’’ said Kaz.

Other participants were the Getalife team who raised $225 for the ACRF and met at the historic Archibald Fountain before the start of the race.

Winners

The winner of this year’s event was 25-year-old Queenslander Michael Shelley, who was ecstatic as he crossed the finish line at a packed Bondi Beach, ahead of a huge field of more than 75,000 runners.

First woman across the line was Blue Mountains athlete and two-time fourth place-getter Melinda Vernon, who slashed a huge 1:43 off her best time to triumph in a day for breakthrough performances. It was an awesome performance.

A big thank you

Below are the names of all our supporters in the Sydney City2Surf, whom we thank so very much for such amazing efforts and results!

Your generous support will assist this Foundation in its mission to fund breakthrough cancer research in Australia.

Thanks to: Andrew Innes, Elinor Lascelles, Jonathan Palasty, Rachel Lewins, Andrew Steven, Elyssa Herd & Team “Running for Eliza,” Julia Puntoriero, Raynee Dewar, Anne Nguyen, Erin Chadwick & Team “Chadlink,” Justin Ree, Rebecca Stafford, Ben Watford, Fiona Turner, Kate Velevitch, Richard Bull, Bonnie Mulholland & Team “Global Medics,” Frankie Piper & Team “TuTufast4you,”  Katrina Henderson & Team “BodyShape,” Richard James (Running for Rachy), Brad Nardi, Grant Sundin, Kaz Muddell, Rob Armstrong & Team “DDM2,” Bradley Merrick, Harvey Stockbridge,  Kevin Mc Cabe, Roberta Kelly & Team “GetaLife,” Brian Shuttleworth & Team “Shuttleworth,” Hayley Kain, Kylie Jones & Team “Baz,” Rosemary Brett, Briony Stevenson, Hoang Mai, Lauren Walsh,   Sandra Carew & Team “Carew,”  Cherie Mabbott, Ian Nash, Leonie Katsillis, Sarah McCandless (Scatty & Waz), Christopher Anthony Ilinkovski, James Adams, Magda Sutch, Sarah McGill,  Christopher Carreck, James Kilpatrick, Marc Dorfmueller, Simon Halpin, Clariza Pearce & Team “Stompers,” Jamie Nelson, Mark Neatherway, Stephen Thomas, (Yoggers), Collette Wilson, Jayne Wordley, Mark Rosinski, Sue Sanassian & Team “Cray,” Daisy Donnelly, Jennifer Crowcombe, Meng Ly, Susan Christie, Daniel Corcoran, Jimmy Bullard, Monica Betancourt, Tanya Hart, David Cocker, Joanne Wynne, Mukund Guruji, Terryn Gaudry, David Hall, Jodi Sanders, My Chung & Team “RunRun,”  The Gatorade-PepsiCo ACRF Team, David Le Roy, Joe Lam, Peter Curran, Wilson Kung, David Ngaue, Joel Davies, Peter Stenvert, Dilek Akguen, John Grauer and Philippa Brown

A big greek party for the ACRF

The special bond that exists between the Australian Cancer Research Foundation (ACRF) and the country’s Greek community has once again come into play.

Following the organisation’s special appeal to the community during this year’s Greek Easter celebrations comes news of a very special dinner held in Adelaide recently.

More than $2500 was raised when Greek mother Mrs Helen Polymenas prepared a great “feast” for more than 120 people in aid of the ACRF.

A cook of great renown amongst her family and friends, Mrs Polymenas and her husband Christos, in their 60s and early 70s, have lost friends to cancer recently so they wanted to do something to support cancer research.

Proud daughter Maria Kambanaros said the lunch had been a “marathon feast.”

“Mum and I and a big team were on our feet for eight hours last Sunday at the Folk Centre in Adelaide preparing nibbles, main courses and lovely desserts,’’ she said.

“We had great support from the whole community because with Greeks it is one in, all in.”

“My Mum and dad have recently lost some close friends to cancer and so they wanted to contribute to the fight against it. People responded by attending our lunch with many making large personal donations.

Maria said her mother did not have one specialty dish.“Everything she cooks is just fantastic. She really throws herself into it.”

Earlier this year ACRF chief executive David Brettell heaped lavish praise on Australia’s Greeks for their long time support of the ACRF organisation.

“The Greek community are one of our most generous supporters and I take time out to specifically applaud their ongoing support,” he said at Greek Easter time early 2009.

“Given the fact that cancer affects so many Australians and there is a lot of people with Greek heritage in this country, this support is not that surprising.

“I urge our Greek friends to take time out to think of the many people in the community suffering from the devastating effects of cancer. As the incidence of cancer increases, we need more than ever to continue our investment in breakthrough cancer research.”

Brettell said the work of ACRF was making a difference to people’s lives not just in Australia but also around the world.

“Professor Ian Frazer’s cervical cancer vaccine, funded by the ACRF, is now available to girls and young women in Australia and in many other countries across the globe,” he said.

“Earlier this year, we were privileged to open the ACRF Centre for Therapeutic Target Discovery in Melbourne. Funded by a $5 million ACRF grant, this Centre is an Australian first – a fully collaborative integrated cancer research centre where doctors treating cancer patients will work closely with scientists researching the disease. It brings together a world-class team of people with enormous skill and experience to work together under one roof.”

“With the world in financial crisis, this is a difficult time for everybody, but cancer remains immune to economic downturn and its effects are no less devastating.”

Thank you so much to Mr Christos and Mrs Helen Polymenas, Maria and all your generous friends for your wonderful support.

Every dollar of every donation received by the ACRF goes to breakthrough cancer research that has the power to change the world.

Please help by making a donation online at acrf.com.au, or by phone on 1300 884 988.

“Trojan Horse” future hope for pancreatic cancer patients

Extract from a story at ScienceNetwork WA. Full story here

A molecule developed by a Western Australian Institute for Medical Research (WAIMR) team, targeting a type of pancreatic tumour, was assisted by a $1.2 million grant from the Australian Cancer Research Foundation (ACRF).

Pancreatic cancer is one of the most virulent and fast-growing cancers with a very poor prognosis for survival from the time of diagnosis.

Lead researcher Professor Ruth Ganss said her team, working in a lab funded by the ACRF eight years ago, created the molecule which binds specifically to pancreatic tumours.

The process, which avoids toxic side effects, is showing improved survival rates.

“With an inflammatory agent packed into the molecule, the body’s own immune system will attack and destroy the cancer from the inside” says Prof Ganss.

“That’s why we called it the Trojan Horse”, she added.

The research is published in the July edition of The Journal of Immunology.

Click here to read about the original $1.2m grant to WAIMR from ACRF.


Development of next-generation leukaemia treatment was kick-started by an ACRF grant

Extracts from St Vincent’s Institute Media Release, 26th of August 2009.

Recent work at St Vincent’s Institute (SVI) using the Australian Synchrotron may help in the development of next-generation drugs to treat major diseases such as leukaemia.

Professor Michael Parker’s team at SVI has used the Australian Synchrotron to visualize a protein called the GM-CSF receptor. Abnormal signalling through this family of receptors is thought to be involved in certain types of leukaemia.

“More detailed knowledge of the shape of the receptor and its function may help us to design new and potentially more effective drugs to target leukaemia,” said Professor Parker.

Continue reading “Development of next-generation leukaemia treatment was kick-started by an ACRF grant”

Bussies on Bikes hit the road for cancer research

“Bussies On Bikes” is a very successful event in aid of cancer research, which was initially established by three keen Willoughby drivers who wanted to make a difference about the ill effects of cancer and more importantly to contribute.

In September more than 35 drivers and their supporters will be riding to Canberra and back to aid the Australian Cancer Research Foundation (ACRF) and Canteen.”

“It is 643 kilometers round trip this year,” said event organizer Bill Kusabs recently.

“The first year the event took place in 2005 there were 28 riders who traveled the 11,000 course we set down to Melbourne.”

“The next two years after that first event we switched and started in Melbourne and then we held the Port Phillip Bay to Port Botany marathon ride events.

“This was a lot of fun for us because friends and relatives all gathered to meet us when the riders finally made it back to Sydney,” he said.

“These three initial rides where very successful and we collected more than $160,000.”

The bus driver turned marathon rider, said the event was not held last year.

“We recently decided to hold the event again and to this time send collected funds to the ACRF, following a request from one of our original organizers Narelle Sinclair.

“Her husband died of cancer and his last request was we ride again not only for Canteen but for the ACRF as well.’’

Mr Kusabs said bus drivers and many of their support crew used their much cherished two weeks of annual leave to ride their push bikes.”

Bill Kusabs made a special request call for marathon support staff.

“This doesn’t include cycling, but provides essential assistance to the riders on and off the road.

Volunteer support roles include ride marshals, guides, ride escort duties, cook’s assistants and jack-of-all trades as the trip enfolds. Escort and support vehicles drive along with the cyclists whenever they are on the road, qualified St John’s Ambulance officers travel with the group and experienced bicycle maintenance personnel are also in the group.”

He said he was currently in the final stages of designing the ride gear for the “Sydney2Canberra2Sydney, Charity Ride“.

Knox College Old Boys Tribute

Members of the Knox Old Boys Rugby Club showed their more sensitive side recently when they held a benefit game in honor of one of their biggest supporters.

The old boys, whose club is based in Wahroonga North Sydney, held a memorial for their Knox Grammer School friend and staunch supporter Mr. Po Mar at their oval on August 22. Five Knox Old Boys teams had matches on the day, playing against the Kings Old Boys Rugby Club. It was also the team’s annual Ladies Day.

The Knox Rugby Club boasts international players from most of rugby’s key nations England, Wales, Ireland, Scotland, New Zealand, Europe, and from the USA, Canada, Fiji, and, of course Japan.

“Mr. Po Mar originally arrived from Japan in the fifties,” said club spokesman Bryn Robertson.

“He was a huge supporter and often attended our games with his Old Boys scarf wrapped around his neck and cheered us on from the sidelines. His son Ben Mar is presently a member of one of our teams and so we thought it fitting to honour his Dad.”

“The players all wore black armbands and marched out onto the field with the bagpipes playing,” said Mr. Robertson.

“The tribute to Mr. Po Mar was done very well and the day went well, although we didn’t win all our games.

Mr. Robertson said that it was Ben Mar who had suggested raising money for the Australian Cancer Research Foundation.

“He knew of the organization’s work and supports the work ACRF does” he said.

“We managed to collect just over $1,000 for cancer research. In these times that isn’t too bad! I hope we can do it again next year.” added team secretary Marilynn Buchanan.

ACRF’s Claire McArthur at ACRF hopes they do too. “When community groups like Knox Old Boys join together to honour friends and relatives who have been lost to cancer, and contribute to a future without cancer, we and the scientists we fund are deeply grateful and inspired” she said.

Knox Old Boys Rugby Club’s First Grade team won their minor premiership this year and play off in the Grand Final of their competition tomorrow, Saturday September 19. Good luck to the team.

Pictures kindly supplied by Mark Wallace (Knox Old Boys Rugby Club). Thanks Mark.

Bernadette goes bald for cancer research

Western Australian Bernadette Johnstone pulled out all stops recently when deciding to shave her head to support a friend battling lung cancer and to raise funds for the ACRF.

The former Scot called on friends from as far a field as Bridgetown Western Australia, Hong Kong, Port Headland and England, to sponsor her head shaving and they really came to the party helping her to raise more than $1500.

“I decided to support my friend who lives nearby, straight after I heard the news that she had cancer,’’ said Bernadette.

“We also had a party in her honor and basically the whole community in Bridgetown rallied behind us, as well as friends I could call upon from around the world.

I actually had a Mohawk haircut as a youngster so I am getting used again to my new look,’’ laughed the 41 year old.

“I have left the corporate world two years ago and moved to Bridgetown about an hour and a half from Margaret River in Western Australia which is a beautiful area of the world. I now work at The Cidery in Bridgetown,’’ she said.

“Both my father and my Aunty were effected by cancer and in the past I have already raised money for cancer research.

What I respect and admire about the ACRF is you fund all kinds of cutting edge research into various cancer, not just one kind.’’ added Bernadette.

Thank you Bernadette for your bravery and generosity. And hey, you look great!

Every dollar of every donation received goes to cancer research.

ACRF contributes to breast cancer breakthrough

Two leading Australian scientists from Melbourne’s Walter & Eliza Hall Institute, have discovered new clues to treating an aggressive form of breast cancer .

The breakthrough has been announced in “Nature Medicine” by Walter & Eliza Hall Institute (WEHI) in Melbourne. The research was funded in part by the Australian Cancer Research Foundation (ACRF) grants program.

Associate Professors Geoff Lindeman and Jane Visvader discovered that a population of breast cells – in science-speak known as luminal progenitor cells – is likely to be responsible for breast cancers that develop in women carrying mutations of a specific gene called BRCA1. These cells are not stem cells but are cells lining the mammary ducts.

Professor Lindeman said “ACRF’s contribution to this work has been significant and our team is very grateful indeed. We’ve been working on this research program for some ten years and our recent research breakthrough is strongly linked to the $5.0m grant awarded by the ACRF three years ago to Melbourne’s Centre for Therapeutic Target Discovery. In particular, flow cytometry equipment purchased with ACRF funds, was used to sort human breast stem and progenitor cells and enabled our work.”

The BRCA1 gene mutation is found in between 10% and 20% of women who have the hereditary form of breast cancer and these women often develop a particularly aggressive form of the disease, known as a ‘basal breast cancer’.

“Women with BRCA1 mutations have a 65% lifetime chance of developing breast cancer” said Professor Lindeman.

This discovery opens a whole new way of thinking about how breast cancer develops. Previously it has been thought it was stem cells which were key culprits in tumours developed by these patients.

Professor Visvader expects that pathologists will increasingly use c-KIT – a key marker of these luminal progenitor cells as a diagnostic marker for BRCA1 cancer.

Professor Lindeman also said that this discovery “will lead the way to focus on the team’s priority, which is developing new target treatments and prevention strategies for the next generation of women.

“Identification of cell types in the breast is beginning to reveal a breast cancer roadmap, highlighting cancer-prone cell types and key genetic pathways.

The ACRF-funded equipment continues to be instrumental to our ongoing research efforts in breast cancer”, added Professor Lindeman.

Click here for the full story on Lindeman Breast Cancer Nature Medicine

For ABC story click here

Penny's pizzas raise big dollars for cancer research

Chef Penny Bucur recently turned her passion for making mouth-watering gourmet pizzas into a fundraiser for the Australian Cancer Research Foundation.

To celebrate the 10th birthday of her Canberra restaurant ‘Pizza Arte’, Penny held a benefit bash, serving up her famous pizzas and raising more than $1500 for the ACRF in the process.

“My house specialty pizza features tomato, bocconcini, shaved prosciutto and basil,” said Penny, whose restaurant is located just a stone’s throw from Parliament House.

Continue reading “Penny's pizzas raise big dollars for cancer research”

Pure Grind cafe opening – Monday, August 17th 2009

New Sydney CDB café “Pure Grind’’ opens its doors this Monday (August 17) with proceeds from the opening day to go to aid the Australian Cancer Research Foundation.

Owner Jonathan Tua said he decided on the donation to honour his cousin Liz, who passed away from cancer several years ago.

“She was a wonderful person to whom I was very close and I would not be in this country without her trail blazing ways as an example.

“I am from New Zealand but my family all hail from Samoa.

Liz was a real livewire and went against the grain and was brave enough to leave the comforts of her surrounds in our small town. I know the first hand about the ill-effects of cancer and I would like to help in the fight against it.’’

Continue reading “Pure Grind cafe opening – Monday, August 17th 2009”

2009 Martin Mahy RIP

RIP MARTY

Staff of the ACRF were saddened to learn of the recent passing of one of the Foundation’s most enthusiastic supporters, Melbourne musician and teacher Martin Mahy.

As many would recall – Marty had organized two successful fundraiser rock and roll concerts for the ACRF over the past 6 months.

Recently, the musician organised a benefit concert for the Australian Cancer Research Foundation attended by a large crowd of young music enthusiasts at the school hall of the De La Salle College in Malvern, Victoria.

Despite the fact that he was battling brain cancer as well as serious lung and liver tumours and regularly underwent chemotherapy, Mahy took to the stage to perform with a drummer and lead guitarist in his band Mayhem.

He did so once again April 24 at the Dan O’Connell Hotel in Carlton with a line up of acts including Simon Windley, Radiostar, Soft Vishnu and his own band Mayhem with two new singers.

Mahy, who was also a 13-year Physics teacher at the De La Salle School, said he wanted to raise funds for a credible institution and therefore chose the ACRF.

“I wanted the money to go to someone who would use it well and the ARCF was recommended to me.”

“I checked out its website and was suitably impressed, it seemed like the real deal for me.”

If there is a rock and roll heaven, then there is a new member in the band tonight.

Our thoughts are with Marty’s wife and family during this time.

Read more about Mahy’s concerts here

On the run for ACRF

Record numbers of Australian Cancer Research Foundation (ACRF) supporters have recently been raising much-needed funds for the organization and staying fit and healthy at the same time.

This year numbers were well up on ACRF sponsored participants in both the Sydney Morning Herald Half (SMH) Marathon and also the Run Melbourne Marathon.

SMH HALF MARATHON

This year five individuals and two large teams of ACRF supporters took part in the Sydney Morning Herald Half Marathon held in May.

Thanks to this added support more than $20,000 was raised at this year’s run.

Two teams on the run for the ACRF

One particular team running on behalf of the organization was “Team SMP’’ led by long time supporter Rebecca Patterson. Her squad had previously supported the ACRF in last year’s event

Rebecca contacted the organization in early 2008 following her husband’s passing from colon cancer, and said her friends and family had wanted to run the Sydney Half Marathon in honor of him that year.

In 2008 the 17 members of Team SMP finished the Sydney Half Marathon and together raised over $25,000 for the Australian Cancer Research Foundation.

Rebecca said “Team SMP’’ chose to support the ACRF again this year, with 22 members finishing the marathon and raising over $15,000.

Team “KM’s for cancer”, led by ACRF supporter Angela Introna, also took on the challenge on this year’s SMH marathon.

The team of 17 included a number of Angela’s colleagues from the paramedic team at the New South Wales Ambulance Service, as well as many of her friends. “We are all beginners at running but are going to give it a good go, and we are hoping to raise some money for a good cause.” said Angela before the race.

The individual ACRF supporters in this year’s run included Alex, Belinda, Linley, Nataliya and Ross. Thank you all so very much for your enthusiastic support.

This year’s marathon honored much-missed champion Australian runner Kerryn McCann. Her husband Greg McCann and children Benton, Josie and Cooper proudly watched on as more than 8,500 runners lined up – many wearing pink bandanas – to run 21.1km in honor of the four-time Half Marathon champion, who died of breast cancer in December last year aged 41.

RUN MELBOURNE

ACRF participant numbers were up in the recent Melbourne marathon as well with 45 runners taking part in this year’s event, a rise from 13 runners for the same event last year.

Their motivations…

For ACRF supporters, the reasons for participating in this year’s Run Melbourne were many. Some supporters were running in memory of family members that had sadly passed away from cancer, others in support of friends/family currently undergoing cancer treatment, and some in celebration of friends/family overcoming cancer and going into remission. There were even a number of lovely supporters that simply chose to support cancer research in an effort “do their bit” to help find a cure for the disease that affects so many around the world.

These runners raised more than $10,000 from their event.

The ACRF supporters in this year’s Run Melbourne included: Vladimir, Helen, Vanessa, Steve, Carly, Chris, Renny, Joe, Christopher, Lisa, Vanessa, Matthew, Julian, Cairin, Trevor, Duncan, Nicole, Alexis, John, Steve, Emma, Penny, Steve, Sonia, Emily, Evry, Amanda, Darren, Vanessa, Belinda, Stacey, Ebony, Nerida, Philip, Kristine, Cameron, Teresa, Fleur, Anna, Paul, Anne-Nicole, Dave, Johanna, Mary, Olivia and Team Suzlon (Suzlon Energy Australia). We thank each and every one of you so very much for your wonderful support.

Some 14,000 runners and walkers enjoyed running around many of Melbourne’s major landmarks in Run Melbourne, presented by The Age newspaper June 28, raising a record $485,729 for a variety of charities. This brings Run Melbourne’s fundraising total to a staggering $772,729 in its two years it has been held.

A big thank you

Thanks again to everyone that took part in this year’s SMH Half Marathon and Run Melbourne marathon, as well as to all of their supporters and sponsors.

The Foundation’s grants program would not be possible were it not for the support and commitment of people such as yourselves.

Links to the marathon websites can be accessed via the below pages on our website.

SMH HALF MARATHON (Sunday, May 17th 2009): click here

RUN MELBOURNE (Sunday, June 28th 2009): click here

Passion for Fashion for the ACRF – Muse 09

If a recent successful fashion fundraiser in aid of the Australian Cancer Research Foundation (ACRF) is any indication, you can expect to hear the name Mikaela Hiew in the fashion news in years to come.

The entrepreneurial young student organised MUSE 09 to celebrate the memory of her grandmother who sadly passed away from pancreatic cancer in 2007 and to raise money for cancer research.

This was Mikaela’s second fashion show and was on top of her Year 12 study workload. “I started making the garments in the 2008 Christmas holidays” she said.

Mikaela’s collection was inspired by the decades her grandmother lived, ie 1930’s to date. There were ‘ready to wear’ garments as well as 10 couture pieces. In total Mikaela designed and made approximately 100 garments with every spare moment in the last 6 months dedicated to the show.

MUSE 09 was held at the Southern Cross Club with makeup and hair girls, family and friends donating their services. Over 500 people attended the event and an amazing $10,000 was raised for the ACRF!!

All proceeds from Mikaela’s event go to breakthrough cancer research projects.

Researchers discover genes that increase melanoma risk

Queensland researchers believe they may have found an important factor in pinpointing who may be more susceptible to melanomas.

Scientists from the Queensland Institute for Medical Research, Brisbane (QIMR) have found two genes, which together, double a person’s risk of developing melanomas.

Professor Nick Hayward – who, with Professor Emma Whitelaw and her QIMR team, is among the Australian Cancer Research Foundation’s (ACRF)’s recent grant recipients – told ABC radio recently that Australia has the highest incidence of this most lethal form of skin cancer in the world, with more than 10,000 new cases rep

“We found two new genes that increased a person’s risk of melanoma. If you carry a variant of either one, you have about a 25 per cent increased risk of developing melanoma,” he said.

“If you have two variants at each of the two genes, then you have about a double, or twice the risk.”

Most people would associate melanoma with exposure to sunlight. But scientists have known that genes are involved in a person’s likelihood of developing the disease.

“What we found today are the first two gene variants that increase the person’s risk of melanoma, that actually act through increasing the number of moles on a person,” he said.

What is the impact of this discovery?

“It now gives us a sort of entree, if you like, into understanding the pathways that this regulated in melanoma development and also in mole formation, and how those two processes are related.

“With knowledge of the pathways that this regulated, hopefully at some stage in the future we might be able to determine possible new therapies that actually could counteract whatever is wrong in those pathways.”

But Professor Hayward says the new research doesn’t mean people should be rushing out to be genetically tested or screened if they are susceptible.

“The actual risk associated with either one of these gene variants is quite small,” he added.

“But what we’re hoping is that now giving us an extra two gene variants that we can put towards some kind of diagnostic or screening tests in the near future, let’s say, two to three years away where we might have a small collection of gene variants.

“There could be 10 or 20 different variants that we could look at simultaneously and together we can calculate a person’s susceptibility to melanoma.”

ACRF Chief Executive David Brettell said the breakthrough highlighted the Foundation’s focus on funding “ground breaking” work which will have a global impact on cancer.

“Last year we awarded The Queensland Institute for Medical Research $2.7 million in funding for the Australian Cancer Research Foundation Centre for Epigenetics. Our support reflects the brilliant work done by this team, who are considered to be world leaders in their field. QIMR is one of the best cancer research facilities in the world,” said Mr Brettell.

“This result is exciting and is one very important step on a road which could lead to further understanding and ultimately prevention of one of the most devastating of cancer types.”

orted every year.

Professor Hayward’s international research was published in the journal Nature Genetics recently.

Continue reading “Researchers discover genes that increase melanoma risk”

Art for ACRF

Recently, Melbourne based artist Claudio Mantuano used his artistic talent to help a really great cause – cancer research.

He said he had started creating visual art from a very early age, choosing to practice mainly within the disciplines of painting and sculpture.

Upon giving up his 9-5 job for a life of pure creativity, he found his niche as a freelance artist in Melbourne – a city he says has “much talent and artistic freedom”.

Whether he was being involved in solo or group shows, painting canvases for private collectors, creating large scale murals for big and small clients Claudio said he was “happy to be doing what he loves within the city he loves.’’

[nggallery id=21]

But he confessed he had recently felt his artistic endeavors made him feel self-centered.

He sought to rectify this by holding a solo art exhibition at Kingston Art Gallery in Victoria called “About Face’’. 50% of the proceeds were donated to ACRF from Claudio’s unique collection of paintings, photos and sculpture.

Claudio said “many friends of mine have been affected by cancer and I thought this is a way for me to use my art to do some good.”

The team at ACRF thanks Claudio very much for his wonderful support, and also for sharing his beautiful artwork with us.

We look forward to seeing more of your stunning work in the future Claudio!

Canberra Ball "South Pacific" – SOLD OUT

Canberra Cancerians Committee is renowned as being one of the most successful fundraising groups for cancer research in Australia having raised more than $2 million for the ACRF.

In addition, the Committee enjoys a n unprecedented reputation for staging THE most sought after and glamorous events on the Canberra social calendar, culminating in their annual Black & White Ball at the Great Hall of Parliament House.

Themed “South Pacific Ball 2009” the Canberra Cancerians Ball once again promises to be an outstanding event, with an amazing ‘tropical chic’ aura. This SOLD OUT event will be held at Parliament House this Saturday, the 22nd of August.

The “South Pacific ball 2009” invite:

“It’s a balmy tropical night with a sky glistening under a canopy of stars. Every breath of wind carries the unmistakable perfume of frangipani. Strands of coloured paper lanterns flicker to life and harried band members are finalising their numbers. Waiters in crisp jackets scurry from table to table, checking that every detail is perfect, that settings are placed with military precision. This Ball has been planned for months….nothing has been left to chance…the darkness of the conflict in the Pacific is fading and the world is looking forward. It’s a time of change, a time to reflect…a truly enchanted evening.

INVITED GUESTS  US sailors, naval nurses, French plantation proprietors, military officers and their elegant wives, beautiful Polynesian women, MP’s, eccentric islanders, entertainers, and a husky voiced songstress.

STYLE SYNOPSIS It’s the conclusion of World War II. Women wear their hair in waves (all wishing they were Veronica Lake) men are expected to bring a corsage for their guests. If not in uniform men can wear either white or black tuxedos, similarly women can wear gowns or tea dresses. Remember… it’s a warm night, a night of music, of colour… and of hope.”

To read about Canberra Cancerians previous years’ balls, click here

ACRF continues support for Melbourne's PeterMac

The Australian Cancer Research Foundation (ACRF) recently paid the third instalment of a significant financial grant to Melbourne’s Peter MacCallum Cancer Centre.

Of the recent $2.5 million grant the ACRF awarded to the institution it has now paid $1,795,996 and Peter Mac has purchased state of the art equipment for gene screening and analysis as part of the ACRF Cancer Genomic Program.

Cancer research at the Peter Mac facility involves over 400 laboratory-based scientists, clinician researchers and support staff, chemists, statisticians, physicists, research nurses and allied health professionals involved in basic, clinical and translational cancer research.

Continue reading “ACRF continues support for Melbourne's PeterMac”

ACRF funded scientist delivers a new way to hit leukemia

An Australian researcher funded by the Australian Cancer Research Foundation (ACRF) is part of the team which has developed a new approach to the treatment of acute leukemia.

The antibody used in the new research was first created by ACRF funded Professor Angel Lopez now at the Centre for Cancer Biology in Adelaide, South Australia.

The research targets myeloid leukemia (AML), one of the most aggressive forms of leukemia.

Quoted in the July 2 issue of prominent research journal, Stem Cell, Associate Professor Richard Lock, Head of the Leukemia Biology Program at Children’s Cancer Institute Australia for Medical Research (CCIA) and the University of New South Wales – who have also received major funding from ACRF – said the findings were an exciting development towards finding more effective treatments for this rare but deadly disease.

Continue reading “ACRF funded scientist delivers a new way to hit leukemia”

Runway success for fashion and cancer research

Edwina Hunter chose Manly’s International College of Management, as the stunning venue for Runway for Research, a glamorous fashion auction held to raise money for the Australian Cancer Research Foundation (ACRF) and the first event for ACRF’s newest committee in Sydney.

The night was themed ‘Christmas in July’, with over 90 guests attending, including guest speaker ACRF Chief Executive, David Brettell and ACRF Fundraising Program Coordinator, Cathy McGough.

[nggallery id=26]

Continue reading “Runway success for fashion and cancer research”

Inspiring Adventures for Cancer Research

Interested in travelling on the adventure of a lifetime with a group of like-minded friends, while helping your favourite charity at the same time?

If you are, the good news is the partnership between the Australian Cancer Research Foundation and charity challenge organisation “Inspired Adventures”, means supporters can now take part in wonderful adventures across the globe whilst raising funds for cancer research in the process.

YAY! We’re really excited about our Inspired Adventure in India!

[nggallery id=22]

Our latest group of enthusiastic adventurers headed off to vibrant India in October 2010, trekking to the home of the Dalai Lama!

We will soon be starting the planning for our next trip, so if 2011 is your year for adventure contacts us on 1300 884 988 or email info@acrf.com.au. Further details are also available on the Inspired Adventures website www.inspiredadventures.com.au.

Check out some of the exciting adventures cancer research supporters have taken in the past:


Last year ACRF supporters Olwen Bradford-Cowling, Carol Simpson and Maggie Neale headed off to beautiful Vietnam on an inspired cycling adventure in support of cancer research.

Before boarding on their adventure, Olwen wrote to ACRF about her motivations for the trip and for supporting Cancer Research. Read her story here.


In 2008 showing just how varied ACRF’s charity challenge program can be, three intrepid supporters took part in three very different, but equally exciting, adventures in support of cancer research: Robert Lundie conquered Mt Kilimanjaro, Lyndall Banks journeyed across the Himalayas, and Sharmaine Squire trekked China’s Great Wall. Read the full story here.


Previously on the 2007 Great Wall of China Trek a team of 19 adventurers, including corporate group “The China Dolls” from Allco Finance Group, headed off for six days of trekking together over the diverse terrain and unique scenery of China.

Together the group raised over $155,000 for cancer research, making this charity challenge one of the most successful charity treks ever! Read more about the 2007 Great Wall of China Trek.


On the Great Wall 2006 Adventure, five adventure challengers trekked across some of the most remote and breathtaking sections of the Great Wall of China, taking part in ACRF’s first ever charity challenge trip.

“The Great Wall of China charity challenge was an amazing experience that will stay with me forever.” Read more about the 2006 ACRF Great Wall of China charity challenge.

Spreading the load of cancer research

The influence and support of the Australian Cancer Research Foundation (ACRF) is set to spread further with the news that three of the four major cancer research centres in the running for support this year have made the cut for the first time.

All of the centres involved are on the list of qualifiers for ACRF’S multi-million dollar annual funding program which supports projects which will have a global impact on cancer research.

The three new finalists are The Children’s Medical Research Institute (CMRI) with University of Newcastle NSW, The Kolling Institute of Medical Research, Sydney and the Centre For Cancer Biology South Australian Pathology and the University of Adelaide.

A fourth organisation, the Walter and Eliza Hall Institute Melbourne (WEHI), which in the past has received more than $6 million in two successful grant applications in both 2002 and 2006, is also up for consideration.

Continue reading “Spreading the load of cancer research”

Nurse walks across 4 states from Perth to Sydney for cancer research

Mark Gibbens’ motivation to walk 5300KM from Perth to Sydney, raising funds for cancer research, is a tribute to his close friend and mentor who died from cancer in 2007. It is also to honour all of the cancer patients (and their loved ones) that he has cared for as a nurse.

In addition to raising much needed funds, Mark has dedicated each day of his walk to people who have experience with cancer.

[nggallery id=23]

Mark’s journey began in Perth on the 22nd February, and has finished in Sydney’s eastern suburbs.

As Mark walked across four Australian states, he chose a cancer charity in each state to be beneficiaries of his fundraising efforts.

The Australian Cancer Research Foundation (ACRF) was his chosen charity in New South Wales and Chief Executive, David Brettell, greeted Mark as he completed his journey at Sydney Children’s Hospital on Tuesday (May 19th).

The official finish was marked with a welcome morning tea at the nearby Children’s Cancer Instutute of Australia in Randwick (Sydney), attended by ACRF representatives and supporters, and cancer researcher Dr. Michelle Henderson.

Celebrating its 25th year, the ACRF has awarded $55 million in cancer research grants, two thirds ($37 million) in just the last five years.

Last year ACRF awarded a $3.1 million grant to the Children’s Cancer Institute Australia for a state-of-the-art drug discovery laboratory working on targeted cancer drugs to lessen the impact of chemotherapy on children and young adults.

Mark also raised funds in Western Australia for the Children’s Leukemia and Cancer Research Foundation, in South Australia for McGuinness McDermott Foundation and in Victoria for the Prostate Cancer Research Consortium.

Mark has undertaken a 3000km walk in Japan previously and raised awareness of the dangers of smoking.

Click here for Mark’s early insights on the WA/SA border.

ACRF benefit concert rocks Colac

Musicians from around the Victorian Western Districts town of Colac united forces to perform at a recent benefit concert in aid of the Australian Cancer Research Foundation (ACRF).

Held in the community Hall in the hamlet of Forrest the concert included interesting sounding acts like Phyllis And The Crab People, The Zig Zag Wanderers and The Stole My Cheque, as well as solo artists Bridie O’Sullivan and Katie Maxwell,

Local ACRF supporter and music lover Sheila Johnson said she had organized a young performers’ concert to “pay tribute’’ to her husband Antony who died from cancer eight years ago.

“My husband really loved his rock and roll. Particularly artists like Bob Dylan and Nick Cave, We actually named one of our sons Dylan because of this love,’’ she said.

“I thought a concert in his honor and to raise funds for the ACRF was highly appropriate.

“Everyone helped out and we got close to 100 kids’’, Ms Johnson said.

“David at *Sounds Magic* Colac set up the stage and Annabel Tellis compared the night for us,” she said.

“Because all these young people are so talented I wanted to give them a forum for their music.” Ms Johnson’s own sons Dylan and Toby performed on the night.

“The night went so well we are considering holding another but this time is summer when it is a lot warmer.’’

Warmest thanks to Sheila, Dylan, Toby and Katie, to all of the talented artists that performed at the event, and all of the lovely event sponsors and supporters.

We greatly appreciate your enthusiasm and support. Looking forward to the next big event!

Jorn Utzon's Sydney Opera House Photo Book To Aid The ACRF

Australia’s most iconic building, the masterpiece Sydney Opera House is to be depicted in a series of photos in a stunning new book, proceeds from which will aid the ACRF.

The highly anticipated publication ‘Jørn Utzon’s Sydney Opera House, A Tribute’ , is expected to be one of the bestselling illustrated titles of 2009. Its superb quality of production, incredible images and the co-operation of architect Jørn Utzon family’ sets it apart from any other book ever published on the world famous Sydney Opera House – which he never saw completed with his own eyes.

Both a personal illustrated memoir and a tribute to this great architect, the ART Book Project embodies the spirit of Jørn Utzon in a remarkable way as it includes a foreword and last word by the award winning architect himself, personal stories and anecdotes, unpublished photographs from the Utzon archive including photographs of Jørn at his home in Hellebaek, and unpublished sketches of the Sydney Opera House.

Continue reading “Jorn Utzon's Sydney Opera House Photo Book To Aid The ACRF”

Top cancer award to ACRF research expert

Congratulations Professor Philip Hogg, a member of the Foundation’s prestigious Medical Research Advisory Committee, who has been awarded this year’s top cancer science award.

At a black-tie dinner in Sydney on the 21st of May, the Commonwealth’s Chief Medical Officer, Professor Jim Bishop, AO, presented Prof Hogg with the NSW Premier’s Award for Outstanding Cancer Researcher. Professor Hogg received a $50,000 cheque honouring his breakthrough scientific achievements.

Professor Hogg, director of the University of NSW Cancer Research Centre, developed a dye that fastens onto dead or dying cancer cells and reveals whether cancer treatments are working just days into the course.

He also discovered a protein that stops cancerous tumours growing by targeting blood cell production, helping to extend the lives of cancer patients.

Continue reading “Top cancer award to ACRF research expert”

Prof Ian Frazer new research chair

Ian Frazer Gives Worlds First Cervical Cancer Vaccine Shot2006 Australian of the Year Professor Ian Frazer will be Chairman of the Australian Cancer Research Foundation’s (ACRF) Medical Research Advisory Committee (MRAC) from 2009. The announcement caps off an outstanding year for Professor Frazer, who with his late research partner Dr Jian Zhou, contributed to the development of a vaccine for cervical cancer.

In October, Frazer won the nation’s pre-eminent award for excellence in science – the 2008 Prime Minister’s Prize for Science – which acknowledges the contributions of Australian scientists to economic and social wellbeing in Australia and the world. He donated the $300,000 he won in the Prime Minister’s Prize to the University of QLD for a research program to develop further vaccines. In September he took out the Balzan Prize, a major international award recognising his lasting contribution to preventive medicine. Since the vaccine’s global application in 2006, more than 40 million doses have been administered to women and girls in more than 90 countries.

Continue reading “Prof Ian Frazer new research chair”

ACRF Garvan Unit for Molecular Genetics of Cancer

Dr Vanessa Hayes, Garvan Institute of Medical Research

Recent discoveries within this group utilising the technology within the ACRF Unit for Molecular Genetics of Cancer:

  1. The technology within the ACRF has greatly advanced our search for genetic markers of hormone receptor pathways that predispose men to prostate cancer.

In addition to the androgen receptor gene, six more genes have been assessed within our large Australian prostate cancer case-control study (nation-wide collaborative effort) and markers of predisposition have been identified.Both prostate cancer and male pattern balding are dependent on androgens (male hormones), thus implicating the androgen receptor gene in these male conditions.

  • Both prostate cancer and male pattern balding are dependent on androgens (male hormones), thus implicating the androgen receptor gene in these male conditions.
  • Male patterned balding (in particular the circular vertex pattern of balding) has previously been loosely associated with prostate cancer risk.
  • We found no overall association between genetic markers of this gene and prostate cancer risk (1,600 prostate cancer cases and controls), however we did observe a significant association with metastatic disease in 800 prostate cancer cases.
  • A highly significant association with male patterned balding was observed.
  1. We have identified a novel gene that is mutated within an Australian Family with early-onset (younger than 40 years of age) breast cancer and multiple infected cases within the family, providing a diagnostic tool for this family as well as a novel target gene for high-risk breast cancer families.

Contacts

Branwen Morgan T: 02 9295 8112 Email: b.morgan@garvan.org.au

David Brettell T: 02 9223 7833 Email: criddington@acrf.com.au

The show goes on for ACRF rocker

MUSIC means the world to Melbourne singer & songwriter Martin Mahy and he will not let the onset of cancer related illness and setbacks stop him one bit.

Following the success of his first rock and roll benefit for the ACRF, comes news that singer/songwriter Martin Mahy has staged a second successful concert to aid cancer research.

Recently, top Melbourne music venue The Dan O’Connell hotel in Carlton jumped to the sound of rock and roll in aid of the ACRF with a line up that included: Simon Windley, Radiostar, Soft Vishnu and Mahy’s own band Mahyem with two new singers.

Continue reading “The show goes on for ACRF rocker”

GreenLight Australia BRW Mini Triathlon

Gary, Conor and Dennis write about their motivations for taking part in the 2009 – BRW Mini Triathlon and for supporting the Australian Cancer Research Foundation:

On Christmas Eve 2008 in Sydney, a close friend’s little boy was diagnosed with leukaemia. Koby is a beautiful boy of 2 ½ years, and he is fighting hard to overcome this cancer.

The Australian Cancer Research Foundation is set up to fund research to find cures for cancer, so we are going to complete the BRW Mini Triathlon on April 5th, and all proceeds we receive will go directly to the ACRF.

Athletically, Conor and Gary are questionable! So hopefully Dennis will spur us on to get a respectable time on the day.

Training Update: Training is going well – Dennis is dusting off his 1978 vintage Raleigh racer and is doing cross country runs and some swimming. His daughter recently won gold at the junior Olympics so he is pretty fit.

Conor has just completed a 400m swim for the first time in his life at the local pool (remember the 400m swim in the triathlon is in the harbor!!). He runs to and from the pool and gets out on his bike fairly regularly.

Gary is getting up early and doing some cycling around the hills near his home before work – when he gets enough sleep the night before (he has a recent 3rd child that is 6 weeks old), and is also doing some soft sand running at Bondi and gets into the water when he can.

Gary, Conor and Dennis.

Green Light Australia Team

2009 Crossing for Cancer

SUCCESSFUL SPORTING HISTORIC FIRST FOR ACRF

It was a historic marathon and very dangerous sporting first that slipped under the radar of the mainstream media. For the first time two six-person 14-metre outrigger canoes have crossed treacherous Bass Strait in aid of the Australian Cancer Research Foundation (ACRF).

Taking 11 event-filled days, the crossing saw the two teams of six battle huge waves, wild seas and encounter startled sharks and giant albatross.

It was done to honor two men.

One of these was Peter Corbishley who has personally built more than 300 racing outrigger canoes in Australia over the past 20 years. Corbishley continues to make an enormous contribution to the sport here in Australia and his canoes have been exported to teams in Germany, Hong Kong, Japan, Tahiti, Samoa and New Zealand.

After making canoes for many years in his factory in the Whitsundays Peter moved his operation down to Tweed Heads and it was here he finally picked up a paddle and began training and competing in the sport he has contributed so much to.

Earlier last year Peter was diagnosed with Non Hodgkin’s T-Cell Lymphoma a rare and terminal form of skin cancer. Astonishingly he was part of one of the crews who wished to raise awareness for cancer and funds for the ACRF, and to also prove that there is life after diagnosis.

The trip was also being made in honor of Chris Robinson, a paddler and world-renowned Greenpeace skipper and activist who sadly lost his battle with cancer this year. Chris devoted his life to protect the oceans from whaling activities, nuclear testing and exploitation.

He learnt his skills in Bass Strait and participated in campaigns to give the Bass Strait Islands protected status. Chris was to be the skipper of the support vessel for the crossing.

The two outrigger canoe teams island-hopped from Port Welshpool in Victoria, the most southern tip on mainland Australia, to Musselroe on the North Eastern tip of Tasmania .

The largest stretch of open-ocean they crossed was 65km and the teams averaged distances of a back breaking 50 kilometers per day.

The two canoes used were Outrigger Connection’s Mirage OC6 with a crew of 6 paddlers each. A support boat escorted the two canoes carrying supplies and a spare paddler in case of injury.

Participants camped along the route on Bass Strait Islands. Making the trip for the ACRF was a team of dedicated rowers.

These include Brendan Condon, nicknamed “Brendo’’ who is 40 and the Managing Director of Australian Ecosystems, Cape Paterson Ecovillage.

He said after the crossing he had personal reasons for making the trip.

“Cancer is a perennial scourge of humanity and impacts on the lives of everyone. I am paddling in memory of my friend Chris Robinson – last year he skippered a support boat and shepherded us across Bass Strait in sea kayaks and then was diagnosed with cancer,’’ he said.

“He was with us in spirit across the voyage. We need to find a cure for cancer as soon as possible and this trip will help give our best scientific brains a bit more support to that end.”

The journey’s highlights…

“Our group gathered on Good Friday at Port Welshpool where we rigged the canoes and practiced safety drills, before loading up our gear on to our escort boat the Furneaux Explorer.”

“Although our group is comprised of very experienced paddlers from all around Australia, it was our first time together as crews. We left in the pre dawn, hitting out on a 60-kilometer leg to Refuge Cove. We stayed together at all times for safety and morale, and blended the two crews so they were a as even as possible and not spread apart over the hours.’’

Fellow paddler Jason Shepherd confirmed the crossing had been an ordeal.

” We battled 40-50 knot winds and huge seas,’’ he said.

“Luckily the caretakers on Deal Island in Bass Strait looked after us with some accommodation as we waited for the seas to calm.”

“The roughest we went out in was 2-metre waves and 25 knot winds, the longest day being when we covered between 65 and 70 kilometers,’’ he said.

“But apart from that it was plain sailing and very appropriately Peter was the first to land.’’

Other participants in the paddle include Peter John Corbishley, Colin Bartley, Lisa Spain, Marie Jane Pearson, Chris McKiernan, Terrence Russell,ert Herremnn Christensen, John Huber, Ian Newland, Alison Green, Marcel Mangelsdorf, and Stephanie Jaques.

The crew was welcomed by a crowd of enthusiastic supporters upon their landing in Tasmania, including a large turnout of eager youngsters from the local primary school. Peter’s parents also made a surprise visit from New Zealand for the landing, adding further to the emotion of the occasion.

To mark the start of the “Crossing for Cancer’’ challenge, a special fundraising evening was held at Breezes Restaurant in Melbourne’s Crown Casino Complex.

The Australian Cancer Research Foundation is humbled to have been chosen as beneficiary of the “Crossing for Cancer”, and offer our warmest thanks to all involved – the enthusiastic and committed event organizers, the courageous paddler team and support crew, the generous sponsors, and all of the team’s wonderful supporters. What an absolutely awe-inspiring achievement!

See Crossing for Cancer’s website here

Watch the adventure’s video here

ACRF to Benefit From Historic Sporting event

Two outrigger canoes soon plan to cross-treacherous Bass Strait to raise awareness and money for the Australian Cancer Research Foundation and in doing so will be the first canoes to ever attempt such a feat.

Manned by two crews of six the historic crossing, starting April 10, is also being made to honour two men.

One of these is Peter Corbishley who has personally built more than 300 racing outrigger canoes in Australia over the past 20 years. He has made an enormous contribution to the sport here in Australia and his canoes have even been exported to teams in Germany, Hong Kong, Japan, Tahiti, Samoa and New Zealand.

After making canoes for many years in his factory in the Whitsundays Peter moved his operation down to Tweed Heads and it was here he finally picked up a paddle and began training and competing in the sport he has contributed so much to.

Earlier last year Peter was diagnosed with Non Hodgkinsons T-Cell Lymphoma a rare and terminal form of skin cancer. As a sign of respect and to honour Peter’s contribution to the sport the plan is to paddle with Peter in one of the canoes he has made across Bass Strait. Peter will be part of the crew to raise awareness for cancer and to raise money in aid of Cancer research and to also prove that there is life after diagnosis.

Continue reading “ACRF to Benefit From Historic Sporting event”

Kalo Pashcha!

As we celebrate one of the most important dates on the Greek calendar the Australian Cancer Research Foundation (ACRF) would like to acknowledge the wonderful support it regularly receives from Australia’s Greek Community.

“The Greek community has always been one of our most generous supporter groups and individuals. Easter is a wonderful time to specifically applaud their ongoing support,”  said the ACRF chief executive David Brettell recently.

“Given the fact that cancer affects so many Australians and there are a lot of people with Greek heritage in this country, this support is not that surprising.”

“I urge our Greek friends to take some time out at this time of year to think of the many people in the community suffering from the devastating effects of cancer.”

“As the incidence of cancer increases, we need more than ever to continue our investment in breakthrough cancer research.”

Brettell said the work of the ACRF’S was making a difference to people’s lives not just in Australia but also around the world.

“Professor Ian Frazer’s cervical cancer vaccine, which received funding from the ACRF, is now available to girls and young women in Australia and in many other countries across the globe,” he said.

“A few weeks ago, we were privileged to open the ACRF Centre for Therapeutic Target Discovery in Melbourne. Funded by a $5 million ACRF grant, this Centre is an Australian first – a fully collaborative integrated cancer research centre where doctors treating cancer patients will work closely with scientists researching the disease. It brings together a world-class team of people with enormous skill and experience to work together under one roof.”

“With the world in financial crisis, this is a difficult time for everybody, but cancer remains immune to economic downturn and its effects are no less devastating” added Brettell

“Every dollar of every donation received by the ACRF goes to breakthrough cancer research which has an impact not just in Australia but across the world. So please enjoy and give thanks this Easter” said David Brettell. “On behalf of cancer patients present and future, we thank you.”

Please help by making a donation online at acrf.com.au, or by phone on +61292237833

Queensland takes the lead on cancer research

At a recent board meeting of the Australian Cancer Research Foundation (ACRF) both Professor Jennifer L. Stow and Professor Georgia Chenevix-Trench were confirmed as new members of the organization’s Medical Research Advisory Committee (MRAC).

Both said they were “honoured’’ by the announcement and agreed there was not a high proportion of women in the top echelons of the scientific medical community.

Professor Stow and I have both received great support over the years from the ACRF.” Professor Chenevix-Trench said. We know of each other from our work in Queensland but we will not have worked so closely together before. There are some very impressive scientists on the MRAC. It is great there are actually two of us involved on the committee and not just the regulation one woman’’ she added.

Since being formed by the late Sir Peter Abeles in 1987 the ACRF has provided more than $55 million in grants to Australian cancer research institutes. Last year the Foundation received 15 applications for more than $50 million to fund outstanding projects. Both women said they had decided to join the team at the ACRF because they had “seen first hand the great work” of the organization.

Continue reading “Queensland takes the lead on cancer research”

Cancer cure – serious side to a fun day

AN AFTERNOON of fun and fine food yesterday had a serious side, with patrons aiding research into a cure for cancer.

The Launceston Cancerians Committee hosted its fourth annual Wining And Dining For A Cure at Hadspen’s historic Entally Estate, with 180 people giving their support.

Committee secretary Trudi Johnston said all of the $6000 raised at this year’s event would go to the Australian Cancer Research Foundation.

“With all the charity fundraising that is going on at the moment we were expecting about 150 people, so we’re very happy with 180,” Mrs Johnston said.

Continue reading “Cancer cure – serious side to a fun day”

Big dollars for cancer research despite downturn

For twenty-five years the Australian Cancer Research Foundation has been funding world class cancer research right here in Australia. We have awarded, nationally, grants totalling $55 million for research into all forms of cancer. 2009 will be no different.

The Foundation’s Board of Trustees, advised by the ACRF’s distinguished Medical Research Advisory Committee (MRAC), is inviting grant applications from leading scientists for cancer research in Australia in the areas of:

  • Capital Works & Facilities
  • National Enterprises

Applications for seed funding for ambitious cancer research projects or programs involving multi-disciplinary teams or collaborations, together with evidence of the translational impacts of the research for patients, will be given favourable consideration. The research should meet a criteria of excellence by world class standards.

Click here for the New 2009 Cancer Research Grants media release and comment from Professor Ian Frazer, Chair of the Foundation’s MRAC.

First stage application closing date: Friday 8 May 2009

Book launch to raise funds for ACRF – Gems of a generation

A death bed promise made to a friend by renowned author and journalist Sue Trethowan-Jones will soon pay dividends for the Australian Cancer Research Foundation (ACRF).

The writer revealed recently that when she stood by the bedside of dear friend and former Victorian MP, Ann Henderson, she was asked to do something to aid the fight against cancer, which was soon to take the life of her long time and dear friend.

“Ann made me promise I would do something to raise funds for cancer research and every year since her death in 2002 I have organised an annual fundraiser in her memory,’’ she said from her Melbourne home recently.

“This year I decided to do something a little different and came up with the idea of doing a book about our Gems Of A Generation group.”

“The Gems is a group of fifteen well known Melbourne women who meet regularly at the house of fashion designer Adele Palmer to make jewellery’’ she said.

Continue reading “Book launch to raise funds for ACRF – Gems of a generation”

Congratulations to three brilliant adventurers!

Robert Lundie (ACT) conquered the difficult Mt Kilimanjaro climb, Lyndall Banks (NSW) completed a 16-day journey from Dharamasala through untouched areas like Ladakh in the Himalayas and Sharmaine Squire (VIC) has just returned from treking China’s challenging Great Wall. The Australian Cancer Research Foundation salutes these three courageous and committed fundraisers for their heartfelt efforts to help overcome cancer through funding critical research.

Upcoming Inspired Adventures. If next year is your year for the adventure of a lifetime, start planning now! Contact Gilbert at glorquet@acrf.com.au or call 1300 884 988 to find out more. Get inspired by the adventures of our record-breaking “China Dolls” right here.

Soda Baby Boutique – Supporting Cancer Research

Danielle Gill, founder of online designer baby clothing and baby gift store Soda Baby Boutique wrote to ACRF about her motivations for supporting cancer research via her small business:

“We respect that The Australian Cancer Research Foundation contributes every dollar of our donation to cancer research and we believe that this cutting edge research is saving more lives worldwide as every year passes. Our family has been touched by cancer, as I imagine many Australian families have, and it is my hope that my children and their children will not be faced with the fear of cancer in their lifetimes. I live in hope that the generous donations to charities such as the Australian Cancer Research Foundation and scientists such as those supported by ACRF will see the fruits of their labour and reduce the cancer rates and make the lives of cancer sufferers easier.

“Our store is not large but I know that ACRF appreciates our efforts to fundraise through our online store, and I hope that our support will help to raise awareness of the great work that they are doing, and also to inspire other small business to make donations.”

“Our store donates $1 for every purchase as well as prompting customers to make their own contributions.”


Danielle Gill

Soda Baby Boutique

Unite and fight cancer benefit for the ACRF – Huge success

The RECENT well attended martial arts demonstration hosted by Melbourne’s Chinese community in aid of the Australian Cancer Research Foundation (ACRF) has proved “a major success.’’

Organiser Catherine Tan said more $15,000 was raised at the event in Ascot Vale which attracted close to close to 400 people who joined the fundraising fight against cancer at a meet and greet and martial art demonstration, which was followed by with some fine dining. She said the night had gone off “without a hitch’’.

[nggallery id=25]

“I was not stressed at all and many people have rung me already expressing support saying they had a great time,’’ she said.

“It looks like we will be doing another one next year as people are already trying to book tables”.

“Not only were there significant funds raised for the ACRF bit it provided members of the martial arts community with an invaluable opportunity to do a bit of bonding and networking.’’

Earlier Tan had said she did not just want to “talk’’ about the fight against cancer but to “follow through as well.’’

“Last year I was suddenly struck by how many people around me, including my own family, personal friends and customers at our martial arts school, were all being affected by cancer,’’ she said.

“Rather than just talk about it I decided to act because I knew a lot of people would support me with a fund raiser. And this has indeed happened.’’

“Martial arts people are all very healthy but it does not mean that cancer cannot affect them and their families,’’ she said.

“There was not one specific cancer I wanted to target but all cancer.’’

Tan said she did extensive research before deciding that the ACRF would be the beneficiary of her martial arts evening.

She thanked the generosity of all who attended her event in particular the Chinese Lion Dance Company .

“Not only did this much in demand act perform for free but they also donated $2000,’’ she said.

“A huge thank you to them.’’

The evening also included several martial arts schools performing demonstrations and a speech by ACRF Board member Mr Greg Camm.

Click here to see the previous media release.

Unite & Fight Cancer – Martial Artists Benefit for Cancer

Proving just how widespread and varied the support for the Australian Cancer Research Foundation (ACRF) is, comes news of a huge martial arts demonstration and fundraising event at Ascot Vale tonight.

380 people will join in the fight against cancer with a meet and greet, martial arts demonstration and some fine dining at Happy Receptions.

[nggallery id=25]

Organiser of the ACRF-endorsed event Catherine Tan explained she did not just want to “talk’’ about the fight against cancer but to “follow through as well.’’

“Last year I was suddenly struck by how many people around me, including my own family, personal friends and customers at our martial arts school, were all being affected by cancer,’’ she said.

“Rather than just talk about it I decided to act because I knew a lot of people would support me with a fund raiser. And this has indeed happened.’’

“There was not one specific cancer I wanted to target but all cancer”, she said. Tan said she did extensive research before deciding that the ACRF would be the beneficiary of her martial arts evening.

“I like the fact that with the ACRF all money raised, I mean every cent, goes to cancer research. That was the clincher. For me,” said Tan. She promised patrons a great night.

“A family member will perform on the night with the Chinese Cultural Centre’s Chinese Lion Dance Company, who are in high demand and who regularly perform at big events in Melbourne”, she said.

The evening, which is hosted by Tans Martial Arts Suppliers (Ringwood and East Brunswick), will also include several martial arts schools performing demonstrations.

ACRF Board member Mr Greg Camm, who is also Chief Executive of Melbourne’s Superpartners Pty Ltd, will speak on the night.

“Cancer is immune to economics and, despite the economic downturn, the Foundation has called for applications for grants in access of $1.5 million to fund breakthrough projects,’’ said Mr Camm.

“ACRF is funding great research across Australia, but none better than right here in Victoria.’’

Last month a cheque for $5 million was presented to a consortium of Melbourne’s leading cancer research institutions, taking the amount the ACRF has awarded in Victoria to more than $16 million. Institutions like St Vincent’s, Peter MacCallum, Ludwig, WEHI, Austin, Murdoch Children’s Research Institute, The Royal Melbourne in the last few years,’’ he added.

Next week ACRF will give $800,000 will go to our most recent grant recipient – Peter MacCallum Cancer Centre. This is the first instalment of a $2.5 million grant to help establish the ACRF Cancer Genomics Program providing new, enhanced technologies in gene screening and analysis. The focus of the research will be on prostate and breast cancer.”

Ends

For more information on the Martial Arts night – contact Catherine Tan on 0413011166


2009 Charity Challenge Vietnam story

Olwen Bradford–Cowling writes about her motivations for joining the “2009 – Vietnam by Bike” fundraising trip and for supporting the Australian Cancer Research Foundation:

Back in Sept 2007, I joined a group of 19 individuals, just like myself, and took off on an adventure of a lifetime walking the Great Wall of China. Not only did I get to fulfil my passion for walking, and my dream to walk “The Great Wall”, but I also managed to raise $12,000 for ACRF.

What inspired me to undertake such a trip, and to choose ACRF as my charity, was my mother, who died herself of cancer in 2005. Having lived a reasonably long, and very fulfilling life, dedicating most of her years to helping the mentally ill, she passed away peacefully at home in 2005 having battled with Cancer for many years.

Even though my mother over the years was diagnosed with various forms of cancer, she never gave up, she always soldiered on, not only in her career but also in nursing my father to the end who had MS. She was an extraordinarily strong woman, and our family were so proud when back in 1991 she was awarded an MBE in recognition for her services and for the years she dedicated to the mentally ill.

There isn’t going to be a cure for cancer tomorrow, there is still a long way to go in the research field, so while I am still fit enough to undertake such challenges I will continue to support ACRF, and that’s why I have signed up next year for the 2009 Vietnam by Bike. I have always been fascinated with Vietnam, the war, the people, the places I have read about, so when I heard there was a bike ride through Vietnam, and raising funds for ACRF, I knew I had to be on it.

I am so pumped at the prospect of the trip, my enthusiasm even rubbed off on a couple of friends whom have also decided to undertake the challenge. I couldn’t think of a better way to soak up the beauty and history of Vietnam, and to raise funds for ACRF, bring it on!


Olwen

World's first stem cell screening facility to target brain tumours

More effective treatments for brain cancer will be developed at a tumour-cell testing facility opened today (Wednesday, March 5) at The University of Queensland’s Queensland Brain Institute (QBI).

Funded by a $1.14 million grant from the Australian Cancer Research Foundation (ACRF), the ACRF Brain Tumour Research Centre was officially opened by Queensland Minister for Health, The Hon. Stephen Robertson, MP.

University of Queensland’s Vice-Chancellor, Professor Paul Greenfield, AO, thanked the ACRF for its $1.14 million donation establishing the centre, acknowledging the Foundation’s almost $8 million in individual grants to University research since 1995.

“The QBI, formed as part of the Queensland Government’s Smart State Initiative and building on a long history of neuroscience at The University of Queensland, is the ideal location for this world-first centre” Professor Greenfield said.

Continue reading “World's first stem cell screening facility to target brain tumours”

Rock for the ACRF

MUSIC means the world to Melbourne singer & songwriter Martin Mahy and he will not let the onset of cancer related illness and setbacks stop him one bit.

Recently, the musician organised a benefit concert for the Australian Cancer Research Foundation attended by a large crowd of young music enthusiasts at the school hall of the De La Salle College in Malvern Victoria.

The De La Salle school community has had a number of people affected by cancer over the years and Martin had the full support of the schools’ teachers, parents and students behind him.

Despite the fact that he himself is battling serious lung and liver tumours and regularly undergoes chemotherapy, Mahy took to the stage to perform with a drummer and lead guitarist in his band Mayhem.

Other acts on the bill included RadioStar, Choice Cuts and young sensation Balthazar Twins.

Continue reading “Rock for the ACRF”

Endurance walk continues for the ACRF

Ringing in by mobile phone on his trek from near the Western Australian/South Australian border, the walker said he was 28 Kilometers west of the small town of Eucla.

“I am feeling fine. The feet are a little sore. I spend my time doing a lot of thinking about life, politics, religion, love, the universe, everything really,’’ he said. “I do miss my family but it is all worth it because funds raised will go to several “great institutions” including the Australian Cancer Research Foundation.

“I am eating a lot of baked beans and tuna and have covered about 1900 Kilometers pushing a converted baby buggy. I have just got mobile phone coverage back so that is greet news.’’Gibbens – a registered nurse, husband and father of one – said he was on track to venture a staggering 5300 KM from Perth to Sydney to raise funds for Cancer Research. He has named his fundraiser the “Cure Cancer Challenge”

Gibbens’ motivation is a tribute to his close friend and mentor who died from cancer in 2007, as well as all of the cancer patients (and their loved ones) that he has encountered during his time as a nurse.

[nggallery id=23]

“I get a lot of trucks honk their horns as they drive by and a lot of people are stopping to wish me well and offer me water,’’ he said.

“I have also collected more than $3000 in roadside donations which is just fantastic.’’He said he was proving regular radio updates for ABC Perth which was closely monitoring his walk.’’ Gibbens said he hoped to make it to Adelaide in about 18 days and then Sydney a month after that.

As Mark is walking across four Australian states, he has chosen a cancer charity in each state to be the beneficiaries of his fundraising. ACRF has been the chosen charity for NSW. Funds will be raised in Western Australia for the Children’s Leukemia and Cancer Research Foundation Inc, in South Australia to the McGuinness McDermott Foundation, in Victoria to the Prostate Cancer Research Consortium and in New South Wales to the Australian Cancer Research Foundation (ACRF).

Gibbens has decided to dedicate each day to a person or people with experience of cancer. You can nominate a person for his dedication walk either through this blog. At the start of his journey the Children’s Leukemia and Cancer Research Foundation organized a send off party from Princess Margaret Hospital Perth with notable patron ex-Australian cricket star Justin Langer, some Subiaco Footballers and several kids with cancer.

In Adelaide, Mark said he plans a walk through the city, a stop at the Children’s Hospital and then a walk around the Adelaide Crows Football stadium during the teams match there against fellow AFL side St Kilda. More promotions and events are being planned for both Melbourne and Sydney.

Further updates of Mark’s remarkable journey will be added on to the ACRF website during the walk.

To nominate someone for a dedication, click here

Opening of cancer research centre funded by major grant from ACRF

The vision of a maverick one-time refugee to Australia will once again pay dividends for those in the fight against cancer.

The Australian Cancer Research Foundation, set up by Sir Peter Abeles, was thrilled to be present at the opening of a brand new cutting-edge facility made possible by its largest ever grant of $5 million to a consortium of leading cancer research institutes to support work in Melbourne that will bring new hope to cancer sufferers.

The opening was announced in honour of Sir Peter Abeles. It is an alliance comprising the Royal Melbourne Hospital, the Royal Women’s Hospital, the Ludwig Institute for Cancer Research, The Walter and Eliza Hall Institute of Medical Research and The University of Melbourne (Faculty of Medicine, Dentistry and Health Sciences).

ACRF chairman Tom Dery made the presentation at the opening of the new facility to an audience at that included the Governor of Victoria Professor David de Kretser, Victorian Minister for Health David Andrews, Minister for Innovation Gavin Jennings, ACRF Trustees, Lady (Sonia) McMahon, Carrillo Gantner AO, Greg Camm. Dr Roby Abeles (daughter of Sir Peter Abeles), Sir Gustav Nossal and leading Cancer research scientists and workers.

Continue reading “Opening of cancer research centre funded by major grant from ACRF”

Opening of cancer research centre funded by major grant from ACRF

The vision of a maverick one-time refugee to Australia will once again pay dividends for those in the fight against cancer.

The Australian Cancer Research Foundation, set up by Sir Peter Abeles, was thrilled to be present at the opening of a brand new cutting-edge facility made possible by its largest ever grant of $5 million to a consortium of leading cancer research institutes to support work in Melbourne that will bring new hope to cancer sufferers.

The opening was announced in honour of Sir Peter Abeles. It is an alliance comprising the Royal Melbourne Hospital, the Royal Women’s Hospital, the Ludwig Institute for Cancer Research, The Walter and Eliza Hall Institute of Medical Research and The University of Melbourne (Faculty of Medicine, Dentistry and Health Sciences).

ACRF chairman Tom Dery made the presentation at the opening of the new facility to an audience at that included the Governor of Victoria Professor David de Kretser, Victorian Minister for Health David Andrews, Minister for Innovation Gavin Jennings, ACRF Trustees, Lady (Sonia) McMahon, Carrillo Gantner AO, Greg Camm. Dr Roby Abeles (daughter of Sir Peter Abeles), Sir Gustav Nossal and leading Cancer research scientists and workers.

Continue reading “Opening of cancer research centre funded by major grant from ACRF”

Major New Grant For Cancer Research Centre

The vision of a maverick one-time refugee to Australia will once again pay dividends for those in the fight against cancer.

The Australian Cancer Research Foundation, set up by Sir Peter Abeles, awarded its largest ever grant of $5 million to a consortium of leading cancer research institutes to support work in Melbourne that will bring new hope to cancer sufferers.

The grant was awarded in honour of Sir Peter to an alliance comprising the Royal Melbourne Hospital, the Royal Women’s Hospital, the Ludwig Institute for Cancer Research, The Walter and Eliza Hall Institute of Medical Research and The University of Melbourne (Faculty of Medicine, Dentistry and Health Sciences).

ACRF chairman Tom Dery made the presentation to an audience at that included the Governor of Victoria Professor David de Kretser, Victorian Minister for Health David Andrews, Minister for Innovation Gavin Jennings, ACRF Trustees, Lady (Sonia) McMahon, Carrillo Gantner AO, Greg Camm. Dr Roby Abeles (daughter of Sir Peter Abeles), Sir Gustav Nossal and leading Cancer research scientists and workers.

Continue reading “Major New Grant For Cancer Research Centre”

NEW $5 million grant

ACRF’s largest-ever grant awarded to world-class Melbourne consortium

The Australian Cancer Research Foundation has awarded its largest ever grant of $5 million to a consortium of leading cancer research institutes to support work that will bring new hope to cancer sufferers. The grant is in honour of Sir Peter Abeles,AC who founded ACRF.

The grant was awarded to an alliance comprising the Royal Melbourne Hospital, the Royal Women’s Hospital, the Ludwig Institute for Cancer Research, The Walter and Eliza Hall Institute of Medical Research and The University of Melbourne (Faculty of Medicine, Dentistry and Health Sciences).

“The consortium will apply the $5 million grant to establish the ACRF Centre for Therapeutic Target Discovery , potentially forming a scientific cornerstone of the first comprehensive cancer centre established in Australia. The Centre will create an innovative Australian-first collaborative and integrated cancer research centre, where clinicians, diagnosing and treating cancer patients, will work closely with scientists researching the disease, said ACRF chairman Tom Dery.

Continue reading “NEW $5 million grant”

Coogee Golf Club funds cancer research

Golf, charity and good ol’ time!

It doesn’t seem right that you can have so much fun with all your mates, and still do a good deed. But that’s exactly what the Coogee Beach Golf Club did. They organised a Charity Golf Day to raise money for cancer research. The efforts incredible – $15,128 raised on one day!

In 2007, the Coogee Beach Golf Club (CBGC) held its first ever Charity Golf Day to commemorate the passing of several members of the club who had died from cancer. The Club president for over 20 years, Mark O’Connor, Fritz Krall, the club handicapper for over 20 years, Arthur Mears and Dave Griffith are some of the tragic victims of this terrible disease.

Garry Ennis, Chris White and rest of the motley crew of golfers did it again in 2008. Last year they raised a massive $13,777.50. This year they have done themselves even prouder – an incredible $15,128 was raised at the 2008 Charity Golf Day. The event teed off at the picturesque Randwick Golf Club in aid of the Australian Cancer Research Foundation (ACRF). Every dollar received from this golf day by ACRF will go to cancer research. We even saw two representatives from the ACRF take a swing this year!

The CBGC infused a lot of energy and time into organizing a fun-filled Golf Day complete with a major raffle, auction and novelty events played on the course including a ‘Port Hole.’ There were also donations from the golf entrance fees paid by each golfer.

The piece de resistance was the Charity Auction led by Chris White at the Palace Hotel, Coogee. Everyone readily got into the spirit of giving and friendly competition. More importantly, all present had a great time with lots of golf, appetizing food and cold beer – all in aid of innovative cancer research.

“What a fabulous afternoon of fun and good spirit with a terrific group of people, a super gesture on their part, says CEO David Brettell. These fanatical golfers wear their hearts on their sleeve, all their great work and financial contribution to ACRF made in memory of former clubmates lost to cancer. We’re humbled by their commitment and and we guarantee them that 100% of the funds they have raised for us will be used for research”

Continue reading “Coogee Golf Club funds cancer research”

Trekking the Great Wall. Climbing Mt Kilimanjaro!

The Australian Cancer Research Foundation’s 2007 Great Wall of China Challenge was a sell-out. The 21 participants raised a record sum from friends, colleagues and sponsors, every cent of which will go directly to cancer research.

2008 Great Wall – we’re doing it again, and more! Join in 10 days of discovery and fun! The Great Wall of China is an incredible architectural feat, a world heritage site with a history of more than 2,000 years.

Like a gigantic dragon, the Great Wall traverses deserts, grasslands, mountains and plateaus stretching 6,700 kms from east to the west of China. This challenging trek, which takes off on Friday September 21 and returns on Wednesday October 1, 2008, will see you experiencing sections of the wall rarely visited, allowing you to gain a deeper understanding of China’s vast history and her people.

Continue reading “Trekking the Great Wall. Climbing Mt Kilimanjaro!”

Australian scientists unravel Leukaemia link

Scientists have unravelled the structure of a cell signalling receptor in the blood control system which when damaged is responsible for diseases such as leukaemia. Their discovery helps to explain, for the first time, how this receptor is activated and will form the springboard for the development of new treatments.

The findings, published on 8 August in the prestigious science journal, Cell, are the result of an inter- state collaboration between a team of scientists led by Professor Michael Parker, St Vincent’s Institute (SVI), Melbourne and Professor Angel Lopez, Hanson Institute at the Institute of Medical and Veterinary Science, Adelaide.

Using leading edge technology that allows scientists to view minute parts of cells, the scientists have developed the first 3D image of the receptor’s structure and will use the unique knowledge it provides to find drugs to modify its action and control diseases such as Leukaemia and asthma.

Professor Lopez said: “Leukaemia is a type of cancer where an excessive number of malfunctioning white blood cells are produced. We have established the structure of a receptor that controls the actions of a blood-forming regulator called GM-CSF.”

He continued: “GM-CSF has been of interest to researchers and clinicians for many years now because its ‘controller’ or ‘receptor’, found on the surface of blood cells, is critical in regulating their many functions. In leukaemia some of the signals coming from the “receptor” are abnormal causing the blood cells to grow uncontrollably, malfunction or dangerously persist past their use-by-date.”

Professor Parker said: “Because our discovery shows precisely what the receptor looks like and also how it works, we can now begin to design new drugs to rein in the deadly abnormal blood cells. At the moment many leukaemias are treated with chemotherapy that destroys the diseased blood cells and bone marrow as well as normal cells. We hope that this discovery will lead to targeted therapies, more specific to the malfunctioning cells seen in diseases such as leukaemia.”

“To maximise the drug development opportunities of this discovery both Institutes have recently signed an agreement with biopharmaceutical company CSL Limited. Under the agreement the Institutes will work with CSL to discover and develop new therapeutic antibodies”. he continued.

Professor Andrew Roberts from the Walter and Eliza Hall Institute and Royal Melbourne Hospital said: “This is a major step forward. Abnormal GM-CSF signalling is pivotal to a variety of serious and difficult-to-treat diseases. With this discovery, rational design of targeted therapies can now be accelerated greatly.”

SVI Director, Professor Tom Kay, said: “SVI’s Australian Cancer Research Foundation Rational Drug Discovery Facility, Michael Parker and his collaborators are world leaders in their field. In the past ten years the Unit has discovered the structure of more than 30 disease-causing proteins, forming the basis for ongoing research into potential therapies. This latest discovery is very exciting.”

Director, SA Pathology and Hanson Institute, Professor Ruth Salom said: “We are delighted with the resounding success of the collaboration between Professor Lopez and Professor Parker. Professor Lopez and his team lead the way in understanding how growth factor receptors signal. This is a wonderful recognition of the importance of the research and its implications for the development of new drugs.”

Co-first authors of the Cell report are Dr Guido Hansen from SVI and Dr Tim Hercus from the Hanson Institute. Senior and corresponding authors are Professors Michael Parker and Angel Lopez. Additional co-authors are: Barbara J. McClure, Frank C. Stomski, Mara Dottore, Jason Powell, Hayley Ramshaw, Joanna M. Woodcock, Yibin Xu, Mark Guthridge and William J. McKinstry. The study was supported by grants from: Australian Research Council, Australian Synchrotron Research Program, National Health and Medical Research Council of Australia and National Institutes of Health (U.S.). Michael Parker is an Australian Research Council Federation Fellow and a National Health and Medical Research Council Honorary Fellow.

See page 3 for illustrated explanation of the discovery

About SVI

St Vincent’s Institute is an independent medical research institute which conducts laboratory research into the cause, prevention and treatment of high-impact diseases such as cancer, diabetes, obesity, bone diseases, Alzheimer’s, cardiovascular disease and infectious diseases. SVI is affiliated with St. Vincent’s Hospital and the University of Melbourne.

About The Hanson Institute

The Hanson Institute is the research arm of the Institute of Medical & Veterinary Science and Royal Adelaide Hospital and is dedicated to excellence in basic and clinical research. Its innovative research ranges from the investigation of basic cell and molecular biology of cancer and the immune system to new therapies for their treatment.

Media Contacts:

SVI

Jo Crowston Tel: 03 9288 3265/0416 799 359 Email: jcrowston@svi.edu.au

Hanson Institute

David Walsh Tel: 0419 850 572 Email: Dwalsh@mail.rah.sa.gov.au

Cell

Cathleen Genova Tel: 1 617 397 2802 Email: cgenova@cell.com

Breakthrough invention will reduce chemo hit-and-miss

Four years ago ACRF awarded $500,000 to a University of NSW research team led by Professor Philip Hogg at Children’s Cancer Institute Australia. The funding established the CCIA Australian Cancer Research Foundation (ACRF) Drug Discovery Program.

In 2007, Professor Hogg, a member of ACRF’s Medical Research Advisory Committee, developed technology that can indicate whether chemotherapy treatment is working in solid tumour cancers such as colon, bowel, breast, prostate and lung cancer.

“The ACRF state-of-the-art laboratory played a critical role in the development of an imaging agent which will show whether chemotherapy treatment is effective,” Prof. Hogg explained.

In explaining the potential impact of this major breakthrough, Prof. Hogg noted that 11 million new cases of cancer are diagnosed globally each year, with standard treatments being chemotherapy and radiotherapy and, if discovered early enough, surgery. There is currently no non-invasive way to measure death of cancer cells, he said.

“A major challenge facing doctors is being able to assess – in real time and after one or two treatments – whether a course of chemotherapy or radiotherapy is working or not,” Prof. Hogg said.

“With this new agent cancer patients will not have to waste time and edure the side-effects of an ineffective treatment.”

PM's science award to Professor Ian Frazer

Professor Ian Frazer, co-creator of the cervical cancer vaccine, has won the 2008 Prime Minister¹s Prize for Science. Professor Frazer, recently appointed as the next Chairman of the Australian Cancer Research Foundation’s Medical Research Advisory Committee (MRAC) is a Director of the Diamantina Institute for Cancer, Immunology and Metabolic Medicine at the Unviersity of Queensland.

Professor Frazer was presented with his prize by Prime Minister, Kevin Rudd, at a special ceremony in the Great Hall, Parliament House Canberra.

The Prime Minister’s Prize for Science is the nation’s pre-eminent award for excellence in science and acknowledges the contributions of Australian scientists to economic and social wellbeing in Australia and the world. Awarded for an outstanding specific achievement in any area of science advancing human welfare or benefiting society, it can encompass the physical, chemical, biological and technological sciences, mathematics and/or engineering.

Continue reading “PM's science award to Professor Ian Frazer”

MEDIA ALERT for WED MAR 5

The Queensland Minister for Health, The Hon. Stephen Robertson, MP, will open a world-first tumour-cell testing facility at The University of Queensland’s Queensland Brain Institute (QBI) on Wednesday, March 5, at 11.15am for 11.30am.

The Australian Cancer Research Foundation (ACRF) Brain Tumour Research Centre, established thanks to a $1.14 million donation from the Foundation, may lead to more effective treatments for brain cancer.

Where: The opening ceremony will be held at the Queensland Brain Institute, Building #79, Upland Road, at The University of Queensland’s St Lucia Campus.

Speakers at the ceremony include ACRF chair, Mr Tom Dery, UQ Vice-Chancellor, Professor Paul Greenfield, AO, and QBI Director, Professor Perry Bartlett.

MEDIA: QBI Director, Professor Perry Bartlett (telephone 3346 9560). QBI Communications (0403 601 066). David Brettell at the ACRF 02 9223 7833 or Shirley Glaister at UQ Communications (3365 1931).

ACRF 'ups the ante'. Multi-million dollar grant brings hope for kids

The Australian Cancer Research Foundation’s $3.1 million grant, in the name of the late Mrs Berenice M McDonnell, to establish a dedicated childhood cancer drug discovery unit at the Children’s Cancer Institute Australia (CCIA) was formally acknowledged by CCIA’s board and major supporters at a recent cocktail party. In attendance were some of Australia’s most respected philanthropists.

The funding is to establish a dedicated childhood cancer drug discovery facility at the Children’s Cancer Institute of Australia, located at the University of NSW.

The world-class facliity will be dedicated to developing less toxic, more effective drugs for the treatment of a range of childhood cancers.

Continue reading “ACRF 'ups the ante'. Multi-million dollar grant brings hope for kids”

2007 Great Wall of China trek

China DollsChina Dolls take the challenge

A team of eleven Sydneysiders from Allco Finance Group weren’t toying about when they took on the Great Wall of China challenge to raise funds for ACRF.

Calling themselves the ‘China Dolls’ the group had already raised record funds for the Foundation in the lead up to the Challenge, through a variety of fundraising events, including a highly successful trivia night, hosted by Malleson’s.

The China Dolls were joined by eight more trekkers from Sydney, Melbourne, Coffs Harbour, Perth and Hong Kong for six days of trekking together over diverse terrain and taking in unique scenery with many unforgettable highlights.

On the first day the group discovered the incredibly steep Juyongguan Pass Wall with spectacular views from every vantage point. Then a trek through the Black Dragon Pool Park took the trekkers past fabulous gorges, ravines and waterfalls. Other highlights included the most beautiful section of the wall between China and Mongolia and a dawn start to see the sun rise on Simatai, The Wall’s highest point.

Each day’s trekking ended with a long, fabulous late lunch, and evenings were spent relaxing at hotels, enjoying leisurely dinners, and chatting with other trekkers, before collapsing into bed.

With the challenge accomplished, the group spent a couple of days in exciting Olympic city, Beijing, visited Tiananmen Square, the Forbidden City and Temple of Heaven, took a rickshaw ride and shared tea with a local resident. They all returned home fit and invigorated by their cultural experience, and, said China Doll Clare Salke, “keen to start raising more money for ACRF and participate in the next adventure!”

Thank you Allco and all our trekkers for celebrating life and raising over $155,000 for cancer research. Together you have made this one of the most successful charity treks ever.

Read about Anne-Louise (Lou) McWilliam – our 2007 highest individual fundraiser – here.

Check out the pics and stories from the original 2006 Great Wall ACRF trekkers here.

Email Gilbert now for upcoming inspired adventures at glorquet@acrf.com.au or call 1300 884 988

2007 Great Wall of China fundraising

Introducing Anne-Louise (Lou) McWilliam

Anne-Louise (Lou) McWilliam was the trek’s highest individual fundraiser. A young mother of two, Lou lives in Hong Kong and lost her sister to cancer in 2003. A British Australian, Lou has raised AUD $31,720.41. Since completing the trek she has continued fundraising tirelessly for cancer research, talking to businesses and community groups in Hong Kong and writing about ACRF’s work and cancer research on her own website.

Lou has had fantastic support from the Hong Kong community. We thank the individuals, family and friends who supported her and the companies who contributed to her challenge – Links Relocations and Commonwealth Bank of Australia; The Australian Association of Hong Kong and British Chamber of Commerce in Hong Kong, RTHK Radio 3 and The Royal Hong Kong Yacht Club. An extra special thanks to Australian International School whose Christmas Fair was Lou’s top-earning fundraiser.

To read more about ACRF’s Great Wall adventure go here.



Minister Brumby opens Advanced cancer research facility

The Hon. John Brumby MP has opened a new research facility funded by the Australian Cancer Research Foundation that will assist with the early detection of colon cancer, the most common internal cancer.

The new Ludwig Institute for Cancer Research (LICR) facility, situated at the Royal Melbourne Hospital, features a mass spectrometer that offers improved capability for the early detection, diagnosis and treatment of colon cancer.

The recently purchased mass spectrometer is the centre piece of the Australian Cancer Research Foundation (ACRF) Cancer Proteomics Program at the LICR, which was made possible with a $1 million grant from ACRF.

Colon cancer is among the three most common cancers in the Western world, affecting almost 1 in 20 Australians and leading to about 5,000 deaths per year.

Continue reading “Minister Brumby opens Advanced cancer research facility”

The Gardasil Vaccine

Gardasil vaccine is now globally recognised as an effective and safe vaccine against cervical cancer.

Like all vaccines, it was extensively tested and trialed for safety before release to approval by the National Health and Medical Research Council (NHMRC).

The vaccine is subject to ongoing safety surveillance by various authorities, at least one of which, the United States Food and Drug Administration (FDA), which monitors all data on adverse affects on an ongoing basis and also publishes such data which is available to the public.

Public statements by the Australian Federal Government Department of Health and Ageing (DHA), FDA, and the European Medicines Agency (EMEA) have all restated the safety and effectiveness of the vaccine.

Second ACRF funded cancer research facility to open in Melbourne

The Hon. John Brumby, MP, Minister for Innovation to open a new Proteomics facility at the Ludwig Institute for Cancer Research (LICR). The facility is funded by a major grant from the Australian Cancer Research Foundation (ACRF).

What: Official opening of the Cancer Proteomics Program – Ludwig Institute for Cancer Research and a brief tour of the facility

Where: The Royal Melbourne Hospital Function and Convention Centre, Seminar Room 2

Date: Thursday, 8 March 2007

Time: 10:30am

Continue reading “Second ACRF funded cancer research facility to open in Melbourne”

Congratulations Professor Frazer

A member of this Foundation’s Medical Research Advisory Committee, Professor Ian Frazer has been awarded the prestigious Florey Medal for Medical Research honouring his work in discovering the HPV vaccine to eradicate cervical cancer.

The prestigious Florey award is named in honour of Australia’s first Nobel Laureate in Medicine, Howard Florey, who invented penicillin.

Professor Frazer, last year’s Australian of the Year, said he was honoured to receive the award on behalf of the team of people involved in developing human papillomavirus (HPV) cervical cancer vaccines, especially his UQ colleague, the late Dr Jian Zhou.

His discovery, a result of 20 years of research, has the potential to eradicate a cancer that annually kills close to 300,000 women worldwide.

Continue reading “Congratulations Professor Frazer”

ACRF awards $5m grant for new era in cancer research

The consortium is creating an Australian-first collaborative and integrated cancer research centre where clinicians who diagnose and treat cancer patients will work closely with scientists researching the disease.

The institutions involved are the Royal Melbourne Hospital and Royal Women’s Hospital, the Ludwig Institute for Cancer Research, The Walter & Eliza Hall Institute of Medical Research and the University of Melbourne.

ACRF chairman Tom Dery said: “We were impressed with the proposed Melbourne Comprehensive Cancer Centre (MCCC) and the $5 million grant will help establish the ACRF Centre for Therapeutic Target Discovery as its scientific cornerstone.”

Continue reading “ACRF awards $5m grant for new era in cancer research”

Professor Ian Frazer appointed to MRAC

2006 Australian of the Year Professor Ian Frazer has been appointed to the ACRF’s Medical Research Advisory Committee (MRAC).

Frazer joins eight other highly established national scientists on the Committee, who are collectively charged with considering the Foundation’s research applications

Professor Ian Frazer, the founder and leader of the University of Queensland’s Centre for Immunology and Cancer Research, has proven the link between cervical cancers and the papilloma virus.

After almost 20 years of research, he has developed a vaccine with the potential to eradicate cervical cancer within a decade. The vaccine has been proven to prevent infection and reduces pap smear abnormalities by 90%. The preventive vaccine will revolutionise women’s health in Australia and across the globe.

Professor Frazer was helped in his quest to develop the vaccine by a $1million ACRF grant to the Centre for Immunology and Cancer Research in 1999.

Procedures of the MRAC include assessment of applications by referees and independent expert assessors, as well as site visits and interviews of selected short-listed candidates. Membership of the Committee is authorised by the Department of Health. Each member is appointed on a three yearly basis, after which they may either stand down or seek re-election.

World Record Pole Dancers…

The world record for the most pole dancers, dancing the same routine at the same time, was set in September with the proceeds being donated to cancer research. The four studio’s in Australia, co-ordinated by Jamilla, Kerrin and Kennetta, joined forces with studio’s worldwide to help set the record which will appear in the next published Guiness Book of Records.

We would like to say a huge thank you to Jamilla, Kerrin and Kennetta for their efforts, and also to all those who took part or sponsored someone involved. Over $6000 was raised for cancer research.

Ian Frazer Vaccine

Last year, Professor Ian Frazer (Australian of The Year) and his team were able to create a vaccine that prevents cervical cancer by up to an astonishing 70% . With a little more help, who knows what we can achieve this year.

There’s never been a better time to donate.

Contact us on 1300 884 988 or make a secure online donation now.

Gosford teenager sells chocolates to save lives

Brittany Tait (pictured) a Year 7 Henry Kendall High School student from Gosford, has presented a cheque to the Australian Cancer Research Foundation (ACRF) for the sum of $1,800 to assist in the battle to find a cure for cancer.

“As part of the ‘Leadership Program’ at school I had to complete a fundraising project, so I chose the ACRF as my charity of choice, as I want to help find a cure for cancer. I sold chocolate and people donated money. I raised $1,800 for ACRF”, said Brittany.

This donation marks a significant milestone for the Tait Family, and for ACRF – Brittany is the third member of the Family to donate funds to the Foundation in three years. In 2003 big brother Nathan raised $1,300 for the ACRF, and in 2004 her sister Amanda, pictured here with Brittany and Jane Daly from ACRF, raised $1,500 which she donated to the ACRF and Canteen.

Jane Daly, from the ACRF Sydney office, accepted the donation cheque from Brittany at Henry Kendall High School and presented Brittany with a certificate of appreciation from ACRF today.

Pics left to right below – 1. Jane Daly, Bob Lange, Deputy Principal, Henry Kendall, Amanda and Brittany Tait, 2. Bob Lange shows Jane Daly through Brittany’s Leadership Project, 3. Brittany presents $1800 cheque to Jane Daly.

IIR Informa "Walks 2 Change" for Cancer Research

As Informa and IIR are set to make change for the future, both Australian offices prepared to contribute to positive changes by embarking on the momentous Walk2Change.

The ‘Walk2Change’ took place in Sydney and saw staff from both Informa IIR’s city and North Sydney offices walking in opposite directions before meeting half way across the Sydney Harbour Bridge! All the walkers were sponsored, with Informa and IIR matching all donations dollar for dollar.

All for a good cause to lend support to the Australian Cancer Research Foundation – walkers were sponsored and Informa & IIR matched all donations dollar-for-dollar!

“Morale was high!” Michelle Tan, General Manager and Walk2Change organizer told us.

“Despite the little spit from the skies when nearing our destinations, we were blessed with crisp clean air and a more than occasional peek of sunshine. The Opera House looked magnificent with the slight blanket of clouds hovering above its jagged dome and the harbour sparkled,” she said.

The mission was a success! As the team descended on their destination with sweaty bodies, clanking bones and hungry bellies, “supplies were shared and we ate heartily, with most of our mission behind us, a challenge met,” said Michelle.

Of course, there were a few athletes amongst the group who achieved the feat without taking a second breather!

Spiro Anemogiannis (IIR Informa CEO) presents cheque to Suzie Graham (r) and Deborah Warner ACRFInforma & IIR Australia raised a grand total of A$9,412 for the Australian Cancer Research Foundation.

IIR Informa’s Chief Executive, Spiro Anemogiannis, presented the cheque to ACRF’s Deborah Warner and Suzie Graham at IIR’s city office, with many of the participants sharing their success.

ACRF thanks all the walkers, all who sponsored them and their supporters for their generosity.

Here’s what the participants had to say…

“I liked the experience…I normally don’t walk so it was a good exercise + it felt great to do something for charity beside the usual” Rozalb Jamshidi, IIR Australia

“What a great way to raise money for charity! The walk was a great opportunity to keep fit and raise money for a fantastic cause. I should have called the walk ‘Push to Change’ though as I pushed my sleeping one year old son, Leo, in his pram, weighing in at over 12 kilos, he certainly made the walk a challenge. However, thanks to the help of Deen and Nathan, we managed to get him to the final pit stop” Dawna L, Informa Australia

“It was a wonderful experience and highlight of the corporate calendar. It was a rare opportunity that many Sydneysiders have not experienced: that of walking across the Sydney Harbour Bridge. The beauty of the surrounds and the magnitude of the city and harbour were a humbling experience and the perfect reminder that there are many less fortunate people in our world who are suffering and in need of our help and support. Let’s hope that fundraisers like this grow in corporate importance and social value over the years to come” Grace Mason, IIR Australia

“Liked it so much, I walked back!” Mel C, Informa Australia

“…3 wraps, 2 beakers of coke, one of lemonade and about 8 sandwiches later…I could feel that the mission back would not be as easy as we expected. We gathered the remaining troops and started our journey back. It was a grueling mission walking back that day, the repercussions of overeating…I could feel the beginnings of a “food-coma” setting in. Still, I had an unexpected rush of adrenalin and I knew then, I was going to make it. I grasped my aching stomach with both hands and dragged my tired legs, I only just made it into the lift before the doors closed in… a relief I can’t describe, we’d done it, we’d really made it back” Catherine L, IIR Australia

“Good opportunity to walk for a case & interact with colleagues” Linzie B, Informa Australia.

“Great way to keep fit, socialise and raise money with food as a reward at the end!!” Simone C, Informa Australia

“What better way to raise money than to get fit & experience the most beautiful harbour in the world” Tammy W, Informa Australia

“What better way to spend 2 hours of your life than to bond with your fellow workers in a spirit of charity, community, love and fitness. Moments like these make me want to cry and sing!” Loic B, Informa Australia.

“Money talks, the Subscription Department walks… for Cancer Research.” Grant W, Sam B, Tina K & Kimmy B, Informa Australia

“It was a great chance to appreciate our beautiful city and raise money for a deserving cause. The free lunch was just an added bonus!” Tom D, Informa Australia

The Great Wall of China Challenge

It’s the experience of a lifetime! Trekking across some of the most remote and breathtaking sections of the Great Wall of China whilst raising vital funds for cancer research…

The Australian Cancer Research Foundation has launched its Great Wall of China Challenge and is inviting you to join in the 10 days of fun!

The Great Wall of China is an incredible architectural feat, a world heritage site with a history of more than 2,000 years and has to be experienced.

Like a gigantic dragon, the Great Wall traverses deserts, grasslands, mountains and plateaus stretching 6,700 kms from east to west of China. This challenging trek, which is scheduled for May 18-27, 2006, will see you experiencing sections of the wall rarely visited, allowing you to gain a deeper understanding of China’s vast history and her people. Finally, you will celebrate the end of your incredible journey in Beijing amidst the ancient splendours of the Forbidden City, the Summer Palace and the Temple of Heaven.

Continue reading “The Great Wall of China Challenge”

Australian of the Year Professor Ian Frazer visits Hobart

Professor Ian Fraze2006 Australian of the Year Professor Ian Frazer was the guest of honour at a special function in Hobart to raise funds for cancer research.

Professor Frazer, who developed a vaccine with the potential to eradicate cervical cancer within a decade, attended the ‘Hobart Cancerians‘ Cocktail Party at the Tasmanian Museum and Art Gallery.

He was joined by Hobart Lord Mayor Rob Valentine and a host of long time supporters of the ‘Hobart Cancerians Committee‘, including Jeannie Taranto, Pamela Archer and Gillian Groom. The dedicated Committee has been raising funds for the Australian Cancer Research Foundation (ACRF) since its inception in 1984.

The founder and leader of the University of Queensland’s Centre for Immunology and Cancer Research, Professor Frazer provided a special insight into his 20 year cervical cancer research project. The vaccine has been proven to prevent infection and reduces pap smear abnormalities by 90 per cent.

Continue reading “Australian of the Year Professor Ian Frazer visits Hobart”

Great Wall of China bound

Six adventurous Aussies have set off on the Australian Cancer Research Foundation’s Charity Challenge across the Great Wall of China.

The Challenge – which goes from May 18-27 – will see them trekking across some of the most remote and breathtaking sections of the Great Wall whilst raising vital funds for cancer research.

To be eligible for the trip, individuals were given the task of fundraising a minimum amount of money ($5500).

Sydney’s Daniele Pandolfo rose to the challenge, and raised almost $10,000 by hosting a variety of Italian functions, including a ‘Slice for Life’ pizza party and a cocktail party at Hugo’s.

Meanwhile Natasha Williams (also pictured – above far right) from Cairns ran a successful raffle, a football day, sold chocolate frogs and received generous donations from local businesses and her family. Ably assisted by her husband Sean, who helped sell raffle tickets and frogs, Natasha soon met her target.

Continue reading “Great Wall of China bound”

Back from the Great Wall

Great Wall of China Challenge – Just brilliant! (or scroll down for 2008 adventures)

The Charity Challenge Great Wall of China challenge was an amazing experience that will stay with me forever. The scenery, culture, and food were exceptional. The trek was challenging but I am no athlete and I got through it with just a few sore calf muscles, but the pain was well worth it. I have made some beautiful friends, had a wonderful trip and have supported a fabulous charity.”

Thanks a million to adventure challengers Annabelle Aland, Sharyn Bunt, Daniele Pandolfo, David Prickett, Natasha Williams, Justine Curtis (Charity Challenge tour leader) and tour guide, Peter for their marvellous support of ACRF’s vital research projects. What a great way to support cancer research!

The group, who left Sydney on May 18, travelled across some of the most remote and breathtaking sections of the Great Wall, returning to Sydney on May 27. To be eligible for the trip, all the challengers had raised a minimum of $5500, with Daniele topping the challenge raising close over $11,000. Read about Challengers’ fundraising initiatives here.

Continue reading “Back from the Great Wall”

Georgie shaves her head for cancer research


Georgie Nathan - Head ShaveGeorgie Nathan’s
mission has been accomplished! Georgie has shaved her head to raise funds for cancer research, donating all the proceeds to the ACRF.

Georgie chose to have her long locks chopped in front of friends and work colleagues who had supported her quest. The Melbourne-based advertising manager said she was inspired to embark on her ambitious fundraising challenge after a close friend was diagnosed with cancer earlier this year.

“A couple of months ago my friend Danielle found out she was pregnant with her first child. Unfortunately what was supposed to be the happiest time of her life turned out to be the worst, when she was told that her pregnancy was a ‘Molar Pregnancy’ which in basic terms is an abnormal development of the placenta,” said Georgie.

“Part of her treatment involves chemotherapy, and she has since learned that the cancer has spread to her lungs.”

When Georgie found out about her friend’s plight she knew that she wanted to do something to help, but was unsure as to what.

“I could’ve simply made a donation to an appropriate cancer prevention organisation, however for me it was necessary to take a step further and do something that would affect me more personally. That’s why I chose to raise money by shaving my head for the cause.”

“Danielle is now into the third week of her treatment and whilst the outlook is positive, it is going to have a massive impact on her life.”

ACRF research funds critical to keeping international edge: Frazer

The AProfessor Ian FrazerCRF extends its congratulations to Professor Ian FrazerAustralian of the Year 2006.

Professor Frazer, from Brisbane, was given the award for his outstanding medical research. The founder and leader of the University of Queensland’s Centre for Immunology and Cancer Research, Professor Frazer has proven the link between cervical cancers and the papilloma virus.

After almost 20 years of research, he has developed a vaccine with the potential to eradicate cervical cancer within a decade.

The vaccine is in the final stages of world-wide trials. It has been proven to prevent infection and reduces pap smear abnormalities by 90%. Expected to be on the market by the end of 2006, his preventive vaccine will revolutionise women’s health in Australia and across the globe. Currently, the disease affects 500,000 women each year.

Professor Frazer, guest speaker at the ACRF Chairman’s Dinner, was helped in his quest to develop the vaccine by a $1million ACRF grant to the Centre for Immunology and Cancer Research in 1999.

Continue reading “ACRF research funds critical to keeping international edge: Frazer”

New facility at ANU takes major step in cancer fight

A new state-of-the-art Biomolecular Resource Facility has opened at The Australian National University. The facility cements the leading role The John Curtin School of Medical Research (JCSMR) plays in the race against cancer, providing access for a wide spectrum of researchers to advanced technology that is not usually available to individual research groups.

The Australian Cancer Research Foundation Biomolecular Resource Facility (ACRF BRF), officially opened by ACT Health Minister Katy Gallagher, features $1.7 million worth of equipment purchased thanks to a $1.13 million grant from the Australian Cancer Research Foundation and funding from the University.

Vice-Chancellor Professor Ian Chubb said the ACRF BRF and the new equipment would provide greater opportunity for cross-fertilization of ideas and sharing of data between ANU researchers.

“The research carried out at JCSMR is among the world’s best, and is making a significant contribution in the race against cancer,” Professor Chubb said. “The facility offers our researchers the first rate laboratory space they need to continue their first rate work. We’re grateful for the support of the ACRF that has enabled us to equip the facility with top-of-the-line equipment.”

Continue reading “New facility at ANU takes major step in cancer fight”

Adelaide innovation sparks $1million cancer research grant

The Australia Cancer Research Foundation (ACRF) has announced a $1million grant to fund a specialised Cancer Prevention Research Facility at the Flinders Medical Centre, within the proposed new Flinders Centre for Innovation in Cancer (FCIC).

The grant (announced on March 10) was awarded following a Flinders University proposal focused on innovative research that seeks to target precancerous cells and treat them, well before cancer takes hold.

“This research will assess the preventative impact of nutritional and lifestyle factors, as well as developing methods of genetic and molecular targeting for new treatments,” said David Brettell, ACRF Chief Executive.

FCIC Director of Development, Flinders University’s Professor Graeme Young, said that the new centre would provide the people of South Australia with a facility unlike any other in Australia.

Continue reading “Adelaide innovation sparks $1million cancer research grant”

Canberra 06 Bollywood Launch

The spectacular 2006 Canberra Cancerians Gala Ball, hosted by Bollywood impresario “Indian Love”, featured a Bollywood Dance Show, dance music and a sumptuous menu of gourmet Indian delicacies prepared by Hyatt Hotel Canberra chefs.

Parliament House was dazzling with more than 600 generous guests raising more than $250,000 for the Australian Cancer Research Foundation. ACRF Chief Executive, David Brettell, presented a cheque for $1.13 million to Professor Frances Shannon of ANU’s John Curtin School of Medical Research.

Auction items to die for brought spirited bidding from guests and included a rare white and gold South Sea pearl necklace from Creation Jewellers, Manuka, a 12-day Indian adventure tour flying Qantas and staying in superb Hyatt Hotels and Resorts iin Goa, Mumbai, Delhi and Kolkata and a painting by one of Australia’s foremost Aboriginal artists, Barbara Weir. The sought-after raffle prize was a 2006 Volkswagen Beetle Cabriolet donated by Lennock.

The Cocktail Party

The Cancerians Canberra Committee has raised more than $1 million hosting Canberra’s must-attend annual Black & White Ball. The hardworking committee launched the 2006 “Welcome to Bollywood” Gala Ball at a glittering cocktail party at Canberra’s magnificent Hyatt Hotel. A fashion parade of spectacular, exotic Indian fashions, a Grange Hermitage lucky dip, cocktails and sumptuous Indian delicacies, courtesy of Committee member and supporter, the Hyatt’s Karl Diefenbach, made the evening a brilliant success.

Cancerians Committee President, Eric Koundouris welcomed guests and brave lung cancer fighter and committee member, Jill Sunderland spoke about the importance of research funding in providing access to the newest treatments to fight this most devastating disease. The Bollywood Gala Fundraising Ball is at Parliament House, Canberra on Saturday August 26.

Thank you to principal sponsor MacDonalds, Gold Sponsors: ActewAGL, Hyatt Hotel Canberra, Lennock, Michalis Holdings and NAB.

[nggallery id=13]


Biggest ever private grant the catalyst for leading edge cancer research in Adelaide

Adelaide scientists are well positioned to further cement their position as national and international leaders in cancer research, following today’s opening of the Adelaide Proteomics Centre at the University of Adelaide.

The world-class $3million Proteomics Centre in the University’s School of Molecular and Biomedical Science – the only one of its kind in South Australia – was opened by Jennifer Rankine, Parliamentary Secretary to South Australian Premier, Mike Rann.

The Centre was built and equipped with the support of a $1.5million grant from the Australian Cancer Research Foundation (ACRF) – the biggest ever private foundation research grant awarded in South Australia. It is also the largest individual grant awarded by the Foundation in its 21 year history. It is also the biggest ever private grant awarded by the foundation.

Dr Peter Hoffman, an internationally-renowned Proteomics specialist, has been recruited to Adelaide to direct the centre.

Continue reading “Biggest ever private grant the catalyst for leading edge cancer research in Adelaide”

Ashley gets ready for the ride of his life!

Hats off to Ashley Williams who in December 2005 will cycle from his home in Townsville to Yulara (Ayers Rock) to raise funds for the Australian Cancer Research Foundation (ACRF).

Ashley’s journey will span 17 days and 2566kms, taking him through towns like Mingela, Homestead, Hughenden, Julia Creek, Cloncurry, Mt Isa, Camooweal, Devils Marbles and Alice Springs. And it’ll be well worth the ride, according to the Qantas employee, who last year lost his father Sam after a long and courageous battle with lung cancer.

“I want to bring awareness to the cause of cancer research on a much broader scale,” says Ashley. “This is also a personal tribute to the memory of my dad.”

Ashley is aiming to raise a minimum of $2 per kilometre he rides, although he is confident of raising much more. Already his support crew (consisting of wife Sian and family) has secured the support of the Ayers Rock Resort who will provide accommodation in Alice Springs and Ayers Rock and assistance with fundraising along the way.

Continue reading “Ashley gets ready for the ride of his life!”

Ashley completes the ride of his life!

In December 2005, Ashley Williams, supported by his manager and wife, Sian, cycled from his home in Townsville to Yulara in the Red Centre of Australia to raise funds for the ACRF. The ride was a personal tribute to his late father Sam, who lost his battle with lung cancer in 2004.

Ashley’s incredible journey spanned 17 days and 2566kms and with the help of many sponsors and individual supporters, he well exceeded his target of $2 per km he rode.

Ashley and Sian received a warm welcome at all of their pit stops, with the hospitality in each town varying from complimentary accommodation and meals to BBQ raffles, auctions and bingo nights to help raise funds.

“We were completely overwhelmed by the kindness of strangers,” said Sian.

Continue reading “Ashley completes the ride of his life!”

ACRF rep heads breast cancer breakthrough

ACRF Medical Research Advisory Committee member Professor Geoff Lindeman is at the head of a research team that has moved one step closer to understanding the genesis of breast cancer.

The research project – at the Walter and Eliza Hall Institute (WEHI) in Melbourne – induced mice to grow new mammary glands, complete with milk ducts, from stem cells.

It opens the possibility that complex organs, such as lungs, intestines and breasts, could be grown for humans. It is also the first time a complex organ – other than the skin – has been grown from a single stem cell, prompting eminent WEHI cell biologist Doug Hilton to hail it “possibly the most significant medical research advance to come out of Melbourne in the past decade”.

As well as helping scientists to understand the development of other organs, the project has important ramifications for cancer research. Scientists will be able to investigate how gene mutations occur, disrupting normal mammary development and eventually causing breast cancer.

Continue reading “ACRF rep heads breast cancer breakthrough”

Million dollar 'movies' of cancer cells now showing

Australian Cancer Research Foundation’s $1 million boost for Peter MacCallum Cancer Centre

A brand new cancer research facility, made possible with a $1million grant from the Australian Cancer Research Foundation (ACRF), officially opened today, revealing new technology that will enable researchers to watch real-time digital ‘movies’ of cancer cells.

The ACRF Microscopy Facility at the Peter MacCallum Cancer Centre, Melbourne – the largest cancer research group in the country – was officially opened by Lady Southey, AM, Lieutenant Governor of Victoria.

The new facility gives researchers the ability to move closer to harnessing the power of people’s immune systems and understanding how to guard against cancer development. The technology for the facility includes a new transmission electron microscope, a confocal imaging system for live cells, and a digital imaging workstation with an immensely improved cell analysis capability.

“This is the kind of major advance in cancer research that the Australian Cancer Research Foundation is committed to funding,” said ACRF Chairman, Mr Tom Dery. “We are optimistic that our generation will be the last to be devastated by cancer and Peter Mac is at the forefront of the latest global advances in treatment and prevention.

Continue reading “Million dollar 'movies' of cancer cells now showing”

Life savers for cancer research

2004 Australian ironman champion Zane Holmes was the star attraction at the inaugural ‘Life Savers for Cancer Research Charity Ball’ at the Ballina RSL on Friday October 7.

23-year-old Holmes, who is based on the Gold Coast, joined a host of VIP guests on the night to raise funds for the Ballina Lighthouse & Lismore Surf Life Saving Club (SLSC) and the Australian Cancer Research Foundation (ACRF).

Also attending was the Chief Executive of the ACRF David Brettell, melanoma expert Dr Therese Becker from Westmead Institute for Cancer Research, Ian Causley MP, Don Page MP and Ballina Mayor Phillip Silver. Local radio personality Jackie Hinrichsen was the Master of Ceremonies.

Ballina Lighthouse & Lismore SLSC President Paul Kelly said the evening provided local residents and businesses with the opportunity to pay tribute to Ballina’s volunteer surf life savers and the dedicated work of Australia’s best cancer research institutions.

Continue reading “Life savers for cancer research”

Australian Cancer Research Foundation announces biggest ever private grant

The Australian Cancer Research Foundation (ACRF) is paving the way for the next wave of cancer research with the announcement today of the biggest private grant ever of $5 million to help make cancer history.

The $5 million grant recipient will be decided by a panel of internationally recognised scientists, chaired by Professor Mathew Vadas and including Professor Sir David Lane. It will be awarded to an Australian researcher who provides the most compelling proposal for cancer research including potential cures for cancer, cancer prevention and the treatment of cancer patients.

“This is an exciting announcement for not only the scientific community but everybody who has been touched by cancer. The $5 million grant will be awarded to help fund what we hope will be a quantum leap in the field of cancer research. The ACRF grant will not exclude big picture, far-reaching proposals for seed funding if that’s what it’s going to take to move into the next wave of cancer research and innovations that matter. Anything is possible,” ACRF Chairman Tom Dery said.

Continue reading “Australian Cancer Research Foundation announces biggest ever private grant”

IMB ACRF Dynamic Imaging Facility

Researchers: Luke Hammond & John Lock

About the research:

Our research is focused on visualising dynamic events in cancer and neuronal cells in 4-dimensions (3-dimensions over time). This work includes how proteins are delivered to the cell surface and how the carriers they travel in form detach from the Golgi. We have been using the ACRF Dynamic Imaging Facility to do high-speed 4-dimensional imaging in multiple colours (fluorophores). The technique we are using to do this has not yet been attempted in Australia, and as far as we currently know, in the world.

Continue reading “IMB ACRF Dynamic Imaging Facility”

Australian first cancer research facility opens at UQ

A ‘state-of-the-art’ cancer facility funded by a $1.2 million grant from the Australian Cancer Research Foundation (ACRF) was officially opened at the University of Queensland (UQ) today.

The ACRF Dynamic Imaging Facility for Cancer Biology– the only one of its kind in Australia – was launched by Parliamentary Secretary to the Queensland Minister for Health, Jo-Ann Miller MP.

The $1.2 million laboratory at UQ’s Institute for Molecular Bioscience (IMB) houses two technologically advanced microscope systems which will enable cutting-edge research into cancer biology.

The IMB, is at the forefront of the latest global advances in cancer research” said ACRF Trustee Mr Tim Crommelin in Brisbane today. “The work underway at this new facility is laying the groundwork for the kind of major advances in cancer research that the Australian Cancer Research Foundation is committed to funding,” he said.

Continue reading “Australian first cancer research facility opens at UQ”

Funky fashion label 'cottons on' to cancer research

National retail brand Cotton On Clothing Pty Ltd is donating all the proceeds from the sale of its groovy ‘Enviro’ bags to the Australian Cancer Research Foundation (ACRF).

The Victorian company have made a $100,000 commitment to the ACRF this year.

Cotton On’s Financial Controller Ross Burrage said the decision to donate the Enviro Bag proceeds to the ACRF was an easy one.

“We did a lot of research into cancer-related charities in Australia. We wanted to make sure our contribution was reaching the source,” said Mr Burrage.

“In the ACRF we found a charity that was making a real impact on the cancer issue, because their administration costs are a tiny percentage of their overall budget, compared to other charities. We know that our money is being used to fund cancer research.

Continue reading “Funky fashion label 'cottons on' to cancer research”

PM launches ACRF Unit for Molecular Genetics of Cancer

A $1.1 million grant provided by the Australian Cancer Research Foundation (ACRF) has helped one of Australia’s leading research institutes to package eight months of cancer research into one day.

The Hon John Howard MP, Prime Minister of Australia, today officially opened the ACRF Unit for Molecular Genetics of Cancer at Garvan Institute of Medical Research, Sydney.

Mr Howard also toured the new state-of-the-art, world class facility, which was established using the $1.1 million ACRF grant awarded last year. Grant funds were also directed towards the purchase of major research equipment including the Mass Array Sequenom analyser, which can test 768 DNA samples at once, allowing eight months of cancer research to now be completed in one day.

Continue reading “PM launches ACRF Unit for Molecular Genetics of Cancer”

ACRF Drug Discovery Laboratory operational

The new ACRF Drug Discovery Laboratory was officially opened at a ceremony on Wednesday 27 April. Representatives of ACRF including Board Chairman Tom Dery and Children’s Cancer Institute Australia (CCIA) toured the lab formally following official proceedings.

The laboratory is now fully operational at CCIA for Medical Research in Randwick.

An announcement that a chemistry lab would be established at 64 High Street under the direction of highly accomplished cancer researcher Prof Philip Hogg was made in late 2003.

The establishment of the lab and the drug discovery program was made possible by a $500,000 grant from the ACRF.

Continue reading “ACRF Drug Discovery Laboratory operational”

Exclusive pics – Royal couple at ACRF fundraiser

HRH Crown Princess Mary of Denmark and husband Crown Prince Frederik were the guests of honour at the Australian Cancer Research Foundation’s recent fundraiser at one of Sydney’s most famous waterfront mansions, the historic Boomerang.

Dubbed the ‘most intimate event on their official schedule’ the modern day supper dance played host to just 100 couples, who met and mingled with the young royals throughout the evening.

Guests sipped on Dom Perignon on arrival, before indulging in a lavish supper prepared by celebrity chef Peter Evans (Hugos and Lifestyle Channel).

Money raised will be distributed to Australia’s leading scientists who are searching for a cure for the disease.



Exclusive pics – Crown Princess Mary at Westmead Millennium Institute

HRH Crown Princess Mary visited the Westmead Millennium Institute (WMI) in Sydney on Saturday (March 5) where she learned more about some of Australia’s world-leading melanoma research.

At the WMI, the Crown Princess met with the Institute’s Director, Professor Richard Kefford and some of his team of young award-winning researchers. The visit was initiated by the Australian Cancer Research Foundation (ACRF), Australia’s leading cancer research funding body, and one of the key charities the Crown Princess is lending her support to during her visit Down Under. The ACRF provided the Westmead Millennium Institute with $1.1million seed funding in 2000 to assist in the establishment of the integrated research centre.

ACRF Chairman, Tom Dery, today announced three new grants – to The Murdoch Children’s Research Institute, Melbourne ($1 million), The John Curtin School of Medical Research, Canberra ($1.13 million) and St Vincent’s (Melbourne) Institute of Medical Research ($900,000). The Foundation will also call for applications for a major new one-off grant of more than $3 million.

[nggallery id=28]

Interesting Facts About Skin Cancer and Melanoma | ACRF

As a country, Australia has one of the highest rates of skin cancer and melanoma in the world. The majority of those with skin cancer or melanoma is due the exposure to UV radiation in the form of sunlight.

Skin Cancer is a disease in which cancer cells form in the tissues of the skin. While Melanoma is a cancer that begins in the melanocytes.

Skin Cancer and Melanoma interesting facts

With these cancers so prominent in Australia, it is important you know all the facts. To help, here are some interesting facts on skin cancer and melanoma:

Skin Cancer interesting facts:

  • There are three main types of skin cancer, all strongly related to sun exposure, and all extremely common in Australia.
  • The first two, are the most common forms of skin cancer, squamous cell carcinomas and basal cell carcinomas
  • Each year more than 374,000 people in Australia are diagnosed with the: basal cell carcinoma and squamous cell carcinoma.
  • These two diseases are the least life-threatening and fortunately are very slow to spread. There are ways to prevent most non-melanoma skin cancers and to detect them early when they do arise before they have a chance to threaten function and life. When treated early, the vast majority of these cancers are curable.
  • Most people who are diagnosed with non-melanoma skin cancers are age 50 or older, but because these diseases often are a result of too much exposure to the sun, everyone — even the youngest toddlers — should take precautions against them.
  • In Denmark each year, there are approximately 13,000 new cases of skin cancer diagnosed: 12,000 are non-melanoma basal cell carcinoma and squamous cell carcinoma cancers, seen mostly in elderly people. The remainder are melanomas, and most often this cancer strikes young people between 20 and 30 years old
  • Over 90% of all cases of skin cancer in Denmark sun responsible for all cases of skin cancer, perhaps because of the impact of exposure to ultraviolet light in people with the northern hemisphere fair skin type.

Melanoma interesting facts:

  • Melanoma, which arises in the same cells in the skin that give rise to moles, is the most aggressive form of skin cancer, and one of the most aggressive of all types of human cancer. It is now the second most common cancer in men and women in NSW.
  • Melanoma – is more common in Australia than any other country. The melanoma incidence rates in Australia and New Zealand are around four times higher than those found in Canada, the UK and the US and up to ten times higher than in other countries.
  • Melanoma causes more productive years of life lost than most cancers because there are a large number of people affected in earlier life.
  • Melanoma risk is highest in the lower latitude areas where there are high levels of ambient UV.
  • Excluding melanoma, Tasmania has the highest incidence rate for all cancers combined and the highest mortality rates for both males and females while NSW has the lowest mortality rates.
  • Most melanomas are treatable if detected early However, mortality rates for melamona in Australia are quite low compared to other countries.

Causes of Skin Cancer and Melanoma

  • Australia has an incidence many times higher than most other Western countries, and this is thought mainly to be due to very high levels of environmental ultraviolet light exposure in people with northern fair skins.
  • Ultraviolet (UV) radiation is the single most important cause of skin cancer, especially when the overexposure resulted in sunburn and blistering. Other, less common causes of skin cancer include repeated exposure to x-rays and exposure to coal tar, arsenic, and other industrial compounds.

Facts about people who are at high-risks of Skin Cancer and Melanoma

  • The lifetime melanoma risk for the average Australian is about one in 25. However, a combination of genetics, environment, and lifestyle can make the development of melanoma much more common in some people.
  • The main risk for getting melanoma seems to be episodic severe sunburning in childhood and teenage years
  • People who sunburn easily and tan poorly, people with a family or personal history of melanoma, and those with weakened immune systems are at higher-than-average risk for developing melanoma
  • Sunlight provides much that is beneficial and even necessary to life and good health. Tanning and burning, however, are not among those benefits — there is no such thing as a “healthy tan.”
  • Although it’s clear that UV radiation can damage DNA, and that high levels of sun exposure are associated with melanoma risk, the exact relationship between UV exposure and melanoma remains unclear.
  • Over the past decade, researchers have discovered that the tanning response begins only after DNA in skin cells has been damaged by exposure to sunlight.
  • Other, less common causes of skin cancer include repeated exposure to x-rays and exposure to coal tar, arsenic, and other industrial compounds.
  • Although the exact wavelengths and timing of the solar radiation associated with different types of skin cancer are under investigation, the basic preventive lesson remains the same: protect your skin from the sun.

Skin Types

  • It is interesting to note that human beings almost certainly all started off with black skins, but as they migrated to areas with low sunlight, they evolved to have fairer skins because this gave them the advantage of being able to make vitamin D under conditions of lower sunlight exposure. Vitamin D is activated in the skin under the influence of sunlight and is essential for bone health.
  • Such changes in skin colour take place over millions of years, and the descendants of the Caucasian people who migrated to Australia in the 18th and 19th centuries obviously still have the fair skin of their ancestors which means that they generally tan poorly, and burn easily.

Treatment of Melanoma

  • Melanoma is usually treated with surgical removal of the primary tumor.
  • Melanoma cells tend to invade the bloodstream, migrate, and lodge in distant organs such as the liver, lung and brain, where they form secondary tumours that are often untreatable.
  • Treatment of more advanced melanoma could involve radiation therapy, chemotherapy, and immunotherapy.
  • Secondary or “metastatic” melanoma occurs commonly in young adults, and fewer than 5% of people with metastatic melanoma survive two years.
  • As yet we have no effective drug treatments and most medical care is directed towards comfort and palliation.

Facts about basal cell carcinoma

  • The most common cancer in humans worldwide.
  • Basal cell carcinomas are most often found on the face, neck, hands, or other parts of the body that have been exposed to the sun.
  • Overexposure to ultraviolet (UV) radiation is the single most important cause of skin cancer, especially when the exposure resulted in sunburn and blistering.
  • This type of cancer can have many different appearances: a red patch or irritated area; a small, pink pearly bump; a white or yellow scar-like area; a smooth growth with a dent in the center; or an open sore that bleeds or oozes.
  • Basal cell carcinomas rarely spread throughout the body and deaths from them are very rare; however, because they often occur on the face, their locally destructive effects can result in serious cosmetic deformity if not diagnosed and treated early.
  • Basal cell carcinomas are highly curable with both surgical and non-surgical therapy. Treatment options may include curettage and electrodesiccation, radiation therapy, standard excision, and other individualized approaches.

Facts about squamous cell carcinomas

  • Squamous cell carcinomas account for about 20 percent of skin cancers in Australia and have an excellent cure rate when detected early.
  • They arise from the upper levels of the epidermis, usually in places that have been exposed to the sun.
  • Squamous cell carcinomas are most commonly found on the ears, the face, and the mouth. They tend to occur in people who are slightly older than those who get basal cell tumors.
  • Often it comes from a precancerous lesion known as keratosis (sometimes called solar keratosis), which appears as a rough, flat pink spot. If the lesion becomes cancerous, it is raised above the normal skin surface.
  • Squamous cell tumors tend to be more aggressive than basal cell tumors, and are slightly more likely to spread to other parts of the bod
  • Most squamous cell carcinomas can be cured with minor surgery. Treatment options may include curettage and electrodesiccation, radiation therapy or standard excision.
  • Overexposure to UV radiation (UVB radiation in particular) is the most common risk factor associated with squamous cell carcinoma.
  • Exposure to ultraviolet (UV) radiation is the single most important cause of skin cancer, especially when the exposure resulted in sunburn and blistering.

Sources

Professor Richard Kefford, Westmead Millenium Institute

Memorial Sloan-Kettering Cancer Centre website at http://www.mskcc.org/mskcc/html/390.cfm

HRH Crown Princess Mary to visit Westmead Millennium Institute

HRH Crown Princess Mary will visit the Westmead Millennium Institute (WMI) in Sydney this Saturday morning (March 5), where she will learn more about some of Australia’s world-leading melanoma research.

At the WMI, the Crown Princess will meet with the Institute’s Director, Professor Richard Kefford and some of his team of young award-winning researchers.

The visit, which is scheduled from 11am-midday, was initiated by the Australian Cancer Research Foundation (ACRF), Australia’s leading cancer research funding body, and one of the key charities the Crown Princess is lending her support to during her visit Down Under.

The ACRF (which is chaired by M&C Saatchi Asia-Pacific chief, Tom Dery provided the Westmead Millennium Institute with $1.1million seed funding in 2000 to assist in the establishment of the integrated research centre.

Continue reading “HRH Crown Princess Mary to visit Westmead Millennium Institute”

HRH Crown Princess Mary to lend her support

HRH Crown Princess Mary of Denmark will assist the ACRF to raise funds for cancer research when she and husband HRH Crown Prince Frederik touch down for their first official visit to Australia this week.

The royal couple will be the guests of honour at the ACRF black-tie affair at historic Boomerang, the magnificent Sydney home of Juliana Schaeffer. Dubbed the ‘most intimate event on their official schedule’ the function will play host to just 100 couples who will meet and mingle with the young royals throughout the evening.

Crown Princess Mary’s attendance at the event was instigated by Tom Dery, the current Foundation Chairman. Mr Dery contacted the princess just after her May 2004 wedding and was overwhelmed by her support. “Mary was always very generous and keen to help and we’re obviously very grateful for her support now,” said Dery, who first employed Crown Princess Mary in 1994, as a graduate trainee at Melbourne ad agency DDB Needham.

Money raised will be distributed to Australia’s leading scientists who are searching for a cure for the disease. Tickets to the event are $3000/couple. F

News in brief

LUNG CANCER

Anti-tumor drug extends lung cancer patients’ lives

A cancer therapy that was approved last year to treat colon tumors, called Avastin, is also effective in prolonging life in lung cancer patients, according to the National Cancer Institute. Avastin, made by Genentech, belongs to a class of drugs called angiogenesis inhibitors. It starves tumors by cutting off the blood supply they need to grow and spread. Doctors say that since lung cancer is so common, Avastin has the potential to help tens of thousands of patients. Source: USA Today

BREAST CANCER

Second hand smoke causes breast cancer, study says

A study by the Air Resources Board, found that second hand smoke causes breast cancer, especially in younger women. The study was based on long-term exposure and concluded that women who are exposed to second hand smoke are at a 90 per cent higher risk of getting the disease. The risk though was not based on doses of second hand smoke. The implications of this study on tobacco control and breast cancer control could be powerful. Source: USA Today

Continue reading “News in brief”

Oncogene plays a critical role in tumor formation

NEW YORK, January 20, 2005 – Scientists at the Memorial Sloan-Kettering Cancer Centre (MSKCC) have identified a new cellular oncogene essential for the development of cancer. Oncogenes are genes that, when mutated or dysfunctional, lead normal cells to become cancerous. The investigators have named the gene POKEMON (for POK Erythroid Myeloid Ontogenic factor). The work has been published in the January 20, 2005, issue of Nature.

“There are a number of genes that can cause cancer, the so-called oncogenes, but Pokemon is unique in that it is needed for other oncogenes to cause cancer.” said MSKCC cancer geneticist Pier Paolo Pandolfi, MD, PhD, the senior author of the study. “More important, because the Pokemon protein plays such a crucial role in the formation of cancer, it could prove to be an effective target for new drug therapies.”

Pokemon works by controlling the pathways that are required to transform normal cells to cancerous ones. The researchers found that when they “knocked out” the Pokemon gene in mice, that transformation was blocked and cells do not become cancerous. (Knocking out a gene means inactivating it through genetic engineering.) A drug that could block the protein’s function in the same way could be a powerful anticancer agent.

Continue reading “Oncogene plays a critical role in tumor formation”

Research sheds light on how cancer cells become resistant to treatment

NEW YORK, January 14, 2005 – A new study by researchers at Memorial Sloan-Kettering Cancer Centre and The Johns Hopkins University provides new insight into how tumor cells can become resistant to anti-cancer therapy.

The scientists observed that a protein called P-glycoprotein (P-gp), which causes resistance to chemotherapy in many tumor types, is able to physically “jump” or transfer between tumor cells and retain its functional properties, protecting otherwise sensitive cells from the effects of anti-cancer treatment in vivo and in vitro. According to the authors, the research is the first to demonstrate that a protein transferred between cells retains its function long enough to allow the recipient cells to survive potentially toxic drug concentrations and ultimately develop intrinsic resistance.

In other words, cells that would normally be sensitive to treatment can develop resistance to it by receiving P-glycoprotein from other cells, making chemotherapy much less efficient. Uncovering the mechanism of this unusual “jumping” of the protein between the cells can potentially improve treatment success.

Continue reading “Research sheds light on how cancer cells become resistant to treatment”

News in brief

Aging: How grey hair may save skin

Researchers are studying the mechanism that kills hair-pigmenting cells to see if they can be used to kill the cells that cause skin cancer. Most cells are programmed to turn themselves off when they are exposed to harmful stresses, but the cells in the skin and in the hair are tougher. This study, published in the journal Science, found that hair turns grey when the stem cells that give hair colouring lose the hardiness and shut down. Doctors from the Dana-Farber Cancer Institute think that if the gene is blocked and a signal is sent to a melanoma cell, maybe the cell’s death could be emulated, and cancer growth stopped. Source: The Associated Press.

Genetics may play a role in lung cancer

While smoking is still the main cause of lung cancer, some people may be more genetically inclined to get the disease. A study published in the Journal of the American Medical Association found that people with a family history of lung cancer were at a higher risk than the general population. The relatives of those who developed lung cancer at 60 years old or younger had the strongest genetic connection to the disease. Source: Los Angeles Times

Continue reading “News in brief”

Latest research

Professor John Mattick believes this is the last generation that will be devastated by cancer. Speaking at the ACRF’s ‘Chairman’s Dinner’, in December 2004, Mattick, the Director of the Institute for Molecular Bioscience (IMB) at the University of Queensland, outlined a number of key developments that could relegate cancer to an historical disease.

“There is every reason to be optimistic that we will be the last generation to be devastated by cancer,” said Mattick, attributing the rapid progress in knowledge about the disease to advanced research in the post-clinical era.

Mattick labelled cancer “the disease of the second half of the 20th century”, adding that we are only now beginning to understand its underlying genetic and molecular causes.

“A generation ago most cancer research was empirical, because the disease was not understood,” he said, describing the chemotherapies and radiation therapies developed at this time as “blunderbuss approaches aimed at killing growing cells, which retarded tumour growth but had many negative side effects.”

Continue reading “Latest research”

2004 Life Members announced

ACRF Chairman Tom Dery recently presented ACRF Life Memberships to Evan Cameron, Gilles Kryger, Helen Kerr, and Professor Ron Penny.

About our new life members…

A founding member and trustee of the ACRF, Mr Evan Cameron played an invaluable role during the formative stages of the Foundation. He assisted the ACRF’s legal team in the drafting of their Memorandum and Articles, compiled the applications that led to the ACRF being granted approval to act as a Charity under the Act, and established the accounting and financial reporting systems for the Foundation. During his 20 years of service as a Trustee, he oversaw all system changes and approved all final reports before their submission to the board and the regulatory authorities. He acted as Deputy for Sir Peter Abeles on many occasions and was instrumental in introducing a number of corporate sponsorships that assisted the ACRF to establish a firm financial footing. Evan dedicated a tremendous amount of time to the Foundation, and richly deserves this life membership.

Mr Gilles Kryger was a founding member and trustee of the Foundation, and the ‘backbone’ of the ACRF’s finance and investments for two decades. He helped establish the Foundation’s income investment policy, and was a member of the original Finance and Investment Committee, alongside Sir Peter Abeles and Evan Cameron. He accepted the role as chairman of the Finance and Investment Committee, a position he held for the next 20 years until retirement as a trustee. Gilles also plated a crucial role in attracting corporate sponsors to the Foundation. He always gave freely of his time and the ACRF benefited greatly from his finance ability and wisdom.

Continue reading “2004 Life Members announced”

Chairman's dinner a success

The ACRF’s Chairman’s Dinner – held at the Taronga Centre, Mosman in early December 2004 – acknowledged the many individuals and organisations that helped the Foundation throughout the year.

In attendance were representatives from the various ACRF Cancerians Committees and corporate support groups, together with members of the Foundation’s Medical Research Advisory Committee, ACRF trustees, life members and research grant recipients.

Chairman Tom Dery personally thanked the many contributors, whilst reflecting on the success of 2004 – including new grant awards to centres in Melbourne, Sydney and Brisbane (a total of $3.3 million) and further investment with the Universities of Adelaide and NSW. Mr Dery also praised the Foundation’s key fundraising campaign with the catch cry ‘The cure for cancer is in your hands’, adding that the campaign won an advertising industry award.

Mr Dery outlined the ACRF’s plans for 2005, which included raising community awareness of the Foundation via the establishment of new Cancerians Committees, substantially boosting the ACRF’s investment in research, and the staging of an exclusive evening with Crown Princess Mary and Crown Prince Frederik of Denmark in March 2005.

He then presented ACRF Life Memberships to Mr Evan Cameron, Mr Gilles Kryger, Mrs Helen Kerr, and Professor Ron Penny.

Click here to read about our new life members.

ACRF gives $1.13 million to John Curtin School of Medical Research

The ACRF has directed a $1.13 million grant to the John Curtin School of Medical Research at the Australian National University.

ACRF Chief Executive David Brettell handed over the cheque during an official presentation at the Canberra Cancerians Cocktail Party at the Hyatt Hotel, Canberra on May 30. The cheque was accepted by Director Professor Judith Whitworth, and Head of Division of Molecular Bioscience, Professor Frances Shannon.

The grant has been used to fund state-of-the-art equipment in the ACRF Biomolecular Research Facility at The John Curtin School of Medical Research. The equipment will provide immediate access to recent technological advances that will aid in addressing many unanswered questions in cancer biology.

Continue reading “ACRF gives $1.13 million to John Curtin School of Medical Research”

QIMR scientists combating Asian cancer

The Queensland Institute of Medical Research (QIMR) is undertaking a major project to defeat one of the most common cancer killers in people of Chinese and Taiwanese descent. Nasopharyngeal Carcinoma (NPC) – also known as Guangdong Cancer – is a virulent cancer of the nose and throat and one which is often difficult to treat effectively. One in ten people in Southern China, Hong Kong and Taiwan will develop NPC – more than 100,000 people develop NPC each year.

NPC is linked to Epstein-Barr Virus (EBV), genetics, smoking, a diet high in salted fish, and exposure to wood dust and chemicals. QIMR scientists have undertaken extensive computer analysis and gene sequencing from blood taken from people in China, Africa, PNG and Australia, and have identified a genetic defect. They are now developing an “immunotherapy” treatment for NPC – which works in a similar way to a vaccine because it stimulates the body’s own immune system to recognise and kill the cancer cells. This is a world-first development and QIMR scientists are the only ones in Australia researching NPC and developing a treatment for this cancer.

“Earlier this year QIMR has received a preliminary funding grant from the NIH (National Institutes of Health) in the USA to develop such a treatment and I understand that this is the first research grant awarded to any group in the world. Preliminary results for this “immunotherapy” treatment, which was the basis for the research grant, have been published in a leading Cancer Research journal,” said Dr Rajiv Khanna from the Tumour Immunology Laboratory at QIMR.

Continue reading “QIMR scientists combating Asian cancer”

Obituary – Marie Tehan

Marie TehanA Sad Loss for Melbourne Cancerians

Melbourne Cancerians have expressed their extreme sadness at the loss of their inaugural chairman and ACRF trustee, The Hon Marie Tehan, following a short illness, aged 64.

Marie was the champion behind the development of the Melbourne Cancerians Committee, which she took on board from her close friend and former parliamentary colleague, the Hon Ann Henderson. Ann had the vision for the Committee and it was Marie who made it all a reality following Ann’s untimely death.

Tributes have flowed from all over Victoria for Marie, remembering a strong, articulate and brilliant woman, who, above all, placed her family at the top of her priority list.

A graduate of Melbourne University, finishing in the top three in her law/arts degree, Marie married Jim in 1963 and settled in regional Victoria. Being a mother of six children was no barrier to Marie to opening a legal practice in Mansfield, which quickly grew into a flourishing entity. With an enormous capacity, Marie also involved herself in a number of humanitarian plights during the 1970s, partly inspired by her compassion and commitment to Catholicism which carried through more recent involvements with the plight of asylum seekers in Australia and participation on the boards of the St Vincent de Paul Society, the Refugee and Immigration Legal Centre and the Catholic Commission for Justice Development.

Continue reading “Obituary – Marie Tehan”

Embryonic stem cells correct congenital heart defect in mouse embryos

NEW YORK, October 7, 2004 – A study published in the October 8 issue of Science describes a previously unsuspected capacity of embryonic stem cells to influence neighboring defective cells and restore their capacity to function normally. [PubMed Abstract]

Researchers at Memorial Sloan-Kettering Cancer Centre report that 15 embryonic stem cells injected into early embryos of mice whose hearts were genetically predisposed to develop a lethal defect, rescued the heart from developing the disorder by not only producing normal daughter cells that were incorporated into the defective embryonic heart but also by releasing biological factors into the nearby vicinity. This prevented neighboring heart cells from developing into defective tissue.

“In other words, stem cells act like nurses, restoring ‘sick’ cells to health” said Robert Benezra, PhD, a Member in the Cancer Biology and Genetics Program at Memorial Sloan-Kettering Cancer Centre and the study’s senior author. “The result was that fifty-percent of the mice fated to die in the womb were born with healthy hearts.”

Continue reading “Embryonic stem cells correct congenital heart defect in mouse embryos”

Melbourne Cancerians pay tribute to supporters

The Melbourne Cancerians’ end-of-year cocktail party honoured the many generous individuals and organisations that helped them raise money for the ACRF in 2004.

Over 100 people attended the party at the Grand Hyatt Melbourne, which also paid tribute to Melbourne Cancerians’ inaugural Chairman — the Hon Marie Tehan, who passed away after a short illness in November 2004.

During the evening, the ACRF presented a $1 million cheque to the Peter MacCallum Cancer Centre, as part of its 2004 annual grant allocation. The event was sponsored by the Grand Hyatt Melbourne. The hotel’s General Manager, Michel Koopman, is a long standing supporter of the ACRF, through his association with the Canberra and Melbourne Cancerians.

Medical Research Stats

Medical Research Statistics:

  • Australia spent $1.7bn on health Research & Development (R&D) in 2000-01.
  • Cancer was the leading area of research $160m (or 9% of the total).
  • Public sector investment in R&D is declining while the private sector investment grew rapidly.
  • Capital expenditure is 16% of total health R&D, mainly land and buildings (10%) while current expenditure (mainly labour) is 8%.
  • Australia ranks at the lower end of the OECD spectrum for health R&D spending related to GDP and trending in the wrong direction over the late 1990s (i.e. declining from a low base).
  • Australia, however, benefits substantially from global investments in health R&D with the fourth highest lifespan in the world. The gains are derived from reduced death rates in cardio and infections diseases, and reductions in morbidity and mortality from cancer.
  • Australia has contributed significantly to these global advances including development of vaccines against cervical cancer (an ACRF Initiative – see Centre for Immunology and Cancer Research, University of Queensland, Brisbane, which was built with $1 million funding from the ACRF in 2001).
  • Living standards improve as much due to health gains as to consumption gains.
  • In Australia, improved healthspan over 1960-1999 is valued at $5.4 trillion – 46% of Australian consumption ($2.9 trillion from longer life and $2.5 trillion from greater wellness).
  • Future R&D gains have potentially stunning impacts – reduced deaths from cancer by one-fifth as a result of R&D would be worth $184bn. To Australians, more than total forecast Commonwealth spending in the 2003-4 fiscal year.

Reference

Moira A Clay, PhD: independent analysis by Access Economics commissioned by the Australian Society for Medical Research, 2003